analysis_type,cancer_type,research_area,study_type,data_source,cbioportal_usage_summary,specific_datasets,cbioportal_usage_mode,specific_genes_queried,cbioportal_features_used,analysis_location,confidence,schema_version,paper_id,title,year,text_source,classified_date,error,classification_attempted,classification_failed,classification_error
"['Gene expression analysis', 'Copy number analysis', 'Survival analysis', 'Pathway analysis']",['Lung cancer'],"['Biomarker discovery', 'Pathway analysis']","['Original research', 'Meta-analysis']",['TCGA'],"The study utilized cBioPortal to analyze the TCGA-LUAD cohort, specifically examining FAM83A amplification in lung adenocarcinoma samples. The authors used cBioPortal to assess copy number alterations and their correlation with immune cell infiltration. The platform was used to validate prognostic significance of identified meta-DEGs including FAM83A, CLDN2, CLDN18, CYP4B1, CYP4X1, HLF, and PLA2G1B in the TCGA-LUAD dataset.",['TCGA-LUAD'],"['Web-based analysis', 'Web-based visualization']","['FAM83A', 'CLDN2', 'CLDN18', 'CYP4B1', 'CYP4X1', 'HLF', 'PLA2G1B']","['Expression analysis', 'Survival analysis', 'Query interface']",Mixed,medium,4.0,41386847,Investigating the role of oncogenic FAM83A as a prognostic biomarker in lung adenocarcinoma: Insights from smoker and non-smoker cohorts.,2025,abstract,2025-12-19T03:54:15.955930,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']","['MSK-IMPACT', 'TCGA', 'Custom/Private data']","The paper does not explicitly mention using cBioPortal for analysis or data access. The study utilized the MSK-IMPACT cohort and TCGA-KIRP data, which are available through cBioPortal, but the paper describes direct access to institutional databases and does not reference cBioPortal tools, features, or the platform itself. The OncoKB database (also from MSK) is mentioned for determining oncogenic driver mutations, but cBioPortal usage is not documented.","['MSK-IMPACT', 'TCGA-KIRP']",['Citation only'],['KRAS'],['Not specified'],Unclear,low,4.0,41375035,Clinical and Molecular Characterization of KRAS-Mutated Renal Cell Carcinoma.,2025,pdf,2025-12-19T03:54:16.071135,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis']",['Leukemia/Lymphoma'],"['Drug response/resistance', 'Pathway analysis', 'Biomarker discovery']",['Original research'],['TCGA'],The paper used cBioPortal to analyze mutation data from TCGA AML datasets to identify patients with activating mutations in FGFR and JAK pathways. The authors queried specific genes related to these pathways to stratify AML samples and correlate mutation status with their experimental findings on drug response. This analysis helped identify patient subgroups that might benefit from the combination therapy of vitamin D analog and Fludarabine.,['TCGA-LAML'],"['Web-based analysis', 'Web-based visualization']","['FGFR1', 'FGFR2', 'FGFR3', 'FGFR4', 'JAK1', 'JAK2', 'JAK3']","['Query interface', 'Mutation Mapper']",cBioPortal platform,medium,4.0,41369330,Synergy in Immunostimulatory and Pro-Differentiation Effects of Vitamin D Analog and Fludarabine in Acute Myeloid Leukemias.,2025,abstract,2025-12-19T03:54:15.086351,,,,
"['Gene expression analysis', 'Mutation analysis', 'Survival analysis']",['Pan-cancer'],"['Review/Commentary', 'Biomarker discovery']",['Review'],"['TCGA', 'Multiple sources']","This is a comprehensive review paper on TOPK (T-LAK cell-originated protein kinase) in cancer. While the paper discusses TOPK expression patterns, mutations, and clinical significance across various cancer types, the abstract and introduction provided do not explicitly describe how cBioPortal was used. The paper appears to synthesize data from multiple sources including TCGA to discuss TOPK's role in tumorigenesis, but specific cBioPortal usage details are not evident in the provided sections.",[],['Citation only'],"['TOPK', 'PBK']",['Not specified'],Unclear,low,4.0,41362722,"The Roles of TOPK in Tumorigenesis and Development: Structure, Mechanisms, Pathways, and Therapeutic Implications.",2026,pdf,2025-12-19T03:54:15.572942,,,,
['Other'],"['Pan-cancer', 'Leukemia/Lymphoma']","['Review/Commentary', 'Drug response/resistance', 'Biomarker discovery']",['Review'],['Not specified'],"This is a review paper discussing N6-methyladenosine (m6A) RNA modification as a regulator of cancer. Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in the study. The paper appears to be a comprehensive review of m6A biology in cancer, particularly focusing on haematological malignancies and METTL3 inhibitors as therapeutics, but does not describe any specific use of cBioPortal for data analysis or visualization.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41360987,N<sup>6</sup>-Methyladenosine: an RNA modification as a central regulator of cancer.,2025,abstract,2025-12-19T03:54:14.015776,,,,
"['Gene expression analysis', 'Survival analysis', 'Copy number analysis', 'Multi-omics integration', 'Pathway analysis']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The paper conducted a comprehensive pan-cancer bioinformatics analysis of EIF3M using publicly available databases including cBioPortal. The study analyzed EIF3M expression patterns, prognostic significance, genetic alterations (amplification), methylation profiles, and immune infiltration associations across multiple cancer types. The analysis integrated multi-omics data to understand EIF3M's regulatory mechanisms and biological pathways in cancer.",[],"['Data download/export', 'Web-based analysis']",['EIF3M'],"['Expression analysis', 'Download data', 'Not specified']","[""External (downloaded data)""]",medium,4.0,41341921,EIF3M as a pan-cancer biomarker: prognostic significance and immune infiltration association.,2025,abstract,2025-12-19T03:54:14.450088,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper describes using data from TCGA, CGGA, and GEO databases (GSE147352, GSE165595) for differential expression analysis, survival analysis, and pathway enrichment analysis. The methodology section indicates direct use of these databases without mentioning cBioPortal as an intermediary platform or tool. cBioPortal may only be cited in the references without actual usage in the analysis.","['TCGA', 'CGGA', 'GSE147352', 'GSE165595']",['Citation only'],"['IGF2', 'RETN', 'EDNRB', 'C3AR1', 'CLCF1', 'NTRK1', 'OSMR', 'KCNN4', 'SLC18A3', 'HTR7']",['Not specified'],"[""External (downloaded data)""]",low,4.0,41301734,A Prognostic Neuromodulation-Related Gene Signature Identifies Immunomodulation and Tumour-Associated Hallmarks in Glioblastoma.,2025,pdf,2025-12-19T03:54:15.624389,,,,
"['Mutation analysis', 'Copy number analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']",['Original research'],['GENIE'],"The researchers used cBioPortal to access and analyze the AACR Project GENIE v18.0-public database. They identified 359 tumor samples from 346 patients with angiosarcoma and analyzed somatic mutations, copy number alterations, gene co-occurrence, and mutual exclusivity patterns. The study represents one of the largest genomic analyses of angiosarcoma to date using the GENIE registry accessed through cBioPortal.",['AACR Project GENIE v18.0-public'],"['Web-based analysis', 'Web-based visualization', 'Query interface']","['TP53', 'KDR', 'PIK3CA', 'MYC', 'CRKL', 'FLT4', 'CDKN2A', 'CDKN2B', 'MTAP', 'FAT1', 'NOTCH2', 'ATRX', 'NOTCH1', 'ARID1A', 'HRAS', 'POT1', 'NTRK2', 'ZFHX4', 'FGFR1', 'MSI2', 'HIST1H1C', 'TOP1', 'MAPK7']","['Query interface', 'Group comparison']",cBioPortal platform,high,4.0,41301029,Genomic and Demographic Characteristics of Angiosarcoma as Described in the AACR Project GENIE Registry.,2025,pdf,2025-12-19T03:54:15.797766,,,,
"['Mutation analysis', 'Copy number analysis', 'Survival analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine']",['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, cBioPortal usage is not explicitly mentioned in these sections. The study uses Caris Life Sciences data for NGS and survival analysis, but no direct reference to cBioPortal is found in the provided text. The paper may cite cBioPortal in the full text or methods section not provided here, but from the available content, cBioPortal usage cannot be confirmed.",[],['Citation only'],"['EGFR', 'PIK3CA', 'PTEN', 'AKT', 'HER2', 'HER3', 'HER4']",['Not specified'],Unclear,low,4.0,41291067,EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition.,2026,pdf,2025-12-19T03:54:15.002849,,,,
"['Mutation analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']","['MSK-IMPACT', 'Custom/Private data']","The study utilized genomic data obtained from the MSK-IMPACT clinical sequencing platform at Memorial Sloan Kettering. The genomic analysis examined matched primary and brain metastasis samples to identify mutation patterns, revealing universal conservation of BRAF and NRAS mutations between samples. The specific role of cBioPortal in accessing or analyzing this MSK-IMPACT data is not explicitly detailed in the abstract.",['MSK-IMPACT'],['Citation only'],"['BRAF', 'NRAS']",['Not specified'],Unclear,low,4.0,41251920,Clinical and genomic characterization of brain metastasis in thyroid cancer.,2025,abstract,2025-12-19T03:54:13.905389,,,,
"['Gene expression analysis', 'Other']",['Prostate cancer'],"['Drug response/resistance', 'Precision medicine']",['Original research'],['Not specified'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. This appears to be an in vitro experimental study using CRISPR-Cas9 knockout cell lines to evaluate drug combinations in BRCA-mutated prostate cancer. If cBioPortal was used, it may have been for background research or data exploration, but this is not described in the provided text.",[],['Citation only'],[],['Not specified'],"[""Unclear""]","[""low""]",4.0,41236806,Combined DNA-PK and PARP Inhibition as a Therapeutic Strategy in BRCA-Mutated Prostate Cancer: An in Vitro Pilot Study.,2025,abstract,2025-12-19T03:54:20.284757,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The study used cBioPortal to access pan-cancer genomic data for analyzing GCKR expression and mutational landscape across multiple cancer types. The authors performed integrated multiomics analysis including mutation profiling, copy number alterations, and gene expression patterns, with particular focus on gastric cancer. Data was likely downloaded from cBioPortal for external analysis combining genomic profiling with spatial transcriptomics and single-cell analyses.",[],['Data download/export'],['GCKR'],['Download data'],External (downloaded data),medium,4.0,41235343,Glucokinase Regulatory Protein (GCKR) Links Metabolic Reprogramming With Immune Exclusion: Insights From a Pan-Cancer Analysis and Gastric Cancer Validation.,2025,abstract,2025-12-19T03:54:19.364567,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Lung cancer'],"['Biomarker discovery', 'Precision medicine', 'Pathway analysis']",['Original research'],['TCGA'],"The paper does not explicitly mention using cBioPortal in the abstract or introduction provided. The study primarily uses TCGA-LUAD data for genomic and clinical analysis, performing Cox regression, LASSO analysis, and multi-omics integration. While cBioPortal is cited (as indicated by the query context), the specific usage details are not described in the provided text sections.",['TCGA-LUAD'],['Citation only'],['ANLN'],['Not specified'],Unclear,low,4.0,41229797,Integrative analysis of fatty acid metabolism and identification of <i>ANLN</i> as a novel prognostic marker in lung adenocarcinoma.,2025,abstract,2025-12-19T03:54:20.955499,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Breast cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],['TCGA'],"Based on the abstract and introduction, the paper analyzes TCGA breast cancer data (1218 tumors) to investigate SPDEF expression, methylation patterns, and survival outcomes. While cBioPortal is cited as a cancer genomics portal, the specific usage details are not provided in the excerpted sections. The study appears to have obtained genomic and clinical data from TCGA, which may have been accessed through cBioPortal or directly from TCGA, but the exact method is not specified in the provided text.",['TCGA-BRCA'],['Citation only'],"['SPDEF', 'DNMT1', 'DNMT3A', 'DNMT3B']",['Not specified'],Unclear,low,4.0,41228349,Assessing the Tumor Suppressive Impact and Regulatory Mechanisms of SPDEF Expression in Breast Cancer.,2025,pdf,2025-12-19T03:54:21.446114,,,,
['Other'],"['Breast cancer', 'Other solid tumor']","['Biomarker discovery', 'Methods/Tools development']",['Original research'],['Custom/Private data'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on analyzing cell-free DNA (cfDNA) from cancer patients using machine learning approaches to detect cancer-specific chromatin features. The study appears to use custom patient samples and does not reference cBioPortal for data access, analysis, or visualization.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41225146,Open chromatin-guided interpretable machine learning reveals cancer-specific chromatin features in cell-free DNA.,2025,pdf,2025-12-19T03:54:49.982602,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The paper mentions using data from The Cancer Genome Atlas (TCGA) for analysis of CHRNA3, CHRNA5, and CHRNA7 in head and neck cancer (HNC)/oral squamous cell carcinoma (OSCC). The study integrated TCGA data with other sources (DepMap, Puram 2017) and experimental data from cell lines and pathological specimens. While TCGA is accessible through cBioPortal, the specific method of data access and whether cBioPortal was directly used is not explicitly stated in the abstract.",['TCGA'],['Citation only'],"['CHRNA3', 'CHRNA5', 'CHRNA7', 'EGFR']",['Not specified'],Unclear,low,4.0,41201200,"The Biological and Prognostic Implications of the Nicotinic Acetylcholine Receptor α3, α5, and α7 Subunits in Oral Squamous Cell Carcinoma.",2025,abstract,2025-12-19T03:54:22.493563,,,,
"['Gene expression analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['Multiple sources'],"The paper cites cBioPortal but does not provide explicit details about how it was used in the study. The main analysis focuses on single-cell RNA sequencing data from a human breast cancer atlas to identify age-associated differences in cell states using their custom ASPEN pipeline. cBioPortal may have been used for preliminary bulk transcriptomic analyses or data validation, but specific usage is not described in the provided text.",[],['Citation only'],"['ESR1', 'KRAS']",['Not specified'],Unclear,low,4.0,41188599,Cell populations in human breast cancers are molecularly and biologically distinct with age.,2025,pdf,2025-12-19T03:54:40.399806,,,,
"['Gene expression analysis', 'Pathway analysis', 'Survival analysis']",['Melanoma'],"['Immunotherapy', 'Drug response/resistance', 'Biomarker discovery']",['Original research'],"['TCGA', 'Custom/Private data']","The paper mentions using cBioPortal to validate survival associations of identified genes in an independent bulk RNA-seq dataset. Specifically, the authors state that relevance of interactions was validated by ""survival associations in an independent bulk RNA-seq dataset"" which appears to reference TCGA data accessed through cBioPortal. However, the primary analysis was performed on single-cell RNA-sequencing data from melanoma patients, with cBioPortal serving as a validation resource rather than the primary analysis platform.",['TCGA'],"['Web-based analysis', 'Citation only']",[],['Survival analysis'],External (downloaded data),medium,4.0,41185627,Uncovering Cellular Interactome Drivers of Immune Checkpoint Inhibitor Response in Advanced Melanoma Patients.,2025,pdf,2025-12-19T03:54:30.014275,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Pathway analysis', 'Tumor evolution']",['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in the methodology. The study focuses on experimental characterization of FGFR1 mutations through BioID-MS proteomics approaches and functional assays in oligodendroglioma cells. While cBioPortal may have been cited as a reference or used for preliminary data exploration, no specific usage details are provided in the available text.",[],['Citation only'],['FGFR1'],['Not specified'],Unclear,low,4.0,41174249,Concurrence of FGFR1 mutations modulates oncogenesis in glioneuronal tumors.,2025,abstract,2025-12-19T03:54:22.667195,,,,
"['Mutation analysis', 'Pathway analysis']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on whole genome sequencing (WGS) analysis of paired tumor-normal samples from 92 glioblastoma patients to identify germline predisposition variants. The study appears to use custom WGS data from the GLOW trial without reference to cBioPortal for data access, analysis, or visualization.",[],['Citation only'],"['MSH6', 'PMS2', 'MSH2', 'NF1', 'BRCA1', 'SUFU', 'TP53', 'MLH1', 'BRCA2', 'CHEK2', 'HERC2', 'MUTYH', 'POT1', 'TERF2', 'IDH1', 'IDH2']",['Not specified'],Unclear,low,4.0,41168197,Whole genome sequencing-based analysis of genetic predisposition to adult glioblastoma.,2025,pdf,2025-12-19T03:54:30.430130,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Breast cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy']","['Original research', 'Clinical study']","['TCGA', 'Custom/Private data', 'Multiple sources']",The paper used TCGA-BRCA RNA-seq data to identify genes associated with low T cell infiltration and pembrolizumab resistance. The authors analyzed TCGA data using CIBERSORTx for transcriptome deconvolution and cross-referenced these findings with I-SPY2 clinical trial data to identify THSD4 as a candidate gene. The specific method of accessing TCGA data (whether through cBioPortal or other sources) is not explicitly stated in the provided text.,['TCGA-BRCA'],['Citation only'],['THSD4'],['Not specified'],Unclear,low,4.0,41153058,THSD4 is a novel mediator of T cell exclusion and anti-PD-1 resistance in hormone receptor-positive breast cancer.,2025,pdf,2025-12-19T03:54:29.051622,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Multi-omics integration']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']",cBioPortal was used to analyze the relationship between AARS1/2 expression and clinical features as well as mutational landscape across 33 cancer types. The database was utilized alongside GSCA database to examine mutation spectra and clinical correlations in pan-cancer analysis. The specific features or analysis modes used within cBioPortal are not explicitly detailed in the abstract.,[],['Web-based analysis'],"['AARS1', 'AARS2']",['Not specified'],Unclear,medium,4.0,41145757,Multi-omics analysis revealed heterogeneity of AARS1 and AARS2 in pan-cancer and identified AARS1 as a potential prognostic biomarker for urologic neoplasms.,2025,abstract,2025-12-19T03:54:26.268090,,,,
['Mutation analysis'],['Other solid tumor'],"['Immunotherapy', 'Biomarker discovery']",['Original research'],"['TCGA', 'Custom/Private data']",The study used cBioPortal to access publicly available human cutaneous squamous cell carcinoma (cSCC) datasets to assess the frequency of shared mutations between patients. This analysis informed the rationale for personalized neoantigen vaccines by demonstrating the paucity of shared mutations in human cSCC tumors. The cBioPortal data was used as a reference to compare with their mouse model of cSCC.,[],['Data download/export'],[],['Not specified'],External (downloaded data),medium,4.0,41125532,Structural changes from wild-type define tumor-rejecting neoantigens.,2025,abstract,2025-12-19T03:54:27.115481,,,,
"['Gene expression analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['Not specified'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on network toxicology and Mendelian randomization approaches to investigate the link between BPA exposure and ovarian cancer through the CTRC/PRDX1/SKP1 pathway. While cBioPortal may be cited in the references, no specific usage of the platform for data download, analysis, or visualization is described in the available text.",[],['Citation only'],"['CTRC', 'PRDX1', 'SKP1', 'BRCA1', 'BRCA2']",['Not specified'],"[""Unclear""]",low,4.0,41108004,Investigating the potential causal link between BPA and ovarian carcinogenesis: a network toxicology and mendelian randomization study on the CTRC/PRDX1/SKP1 pathway.,2025,pdf,2025-12-19T03:54:29.343125,,,,
"['Gene expression analysis', 'Pathway analysis']",['Breast cancer'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],['TCGA'],"Based on the abstract and introduction provided, the paper appears to use cBioPortal for bioinformatic analysis related to RNA metabolism pathways in the context of radiation resistance in triple-negative breast cancer. The study likely queried TCGA breast cancer data through cBioPortal to analyze expression patterns of genes involved in their identified mechanism, particularly ITGB3, HNRNPL, and related RNA metabolism pathways. However, specific details about cBioPortal usage are not explicitly mentioned in the provided text.",['TCGA'],['Citation only'],"['ITGB3', 'HNRNPL']",['Not specified'],Unclear,low,4.0,41105760,Resistance to radiation enhances metastasis by altering RNA metabolism.,2025,abstract,2025-12-19T03:54:28.619794,,,,
"['Mutation analysis', 'Copy number analysis', 'Meta-analysis']","['Pan-cancer', 'Lung cancer', 'Glioma/Brain cancer', 'Other solid tumor']","['Biomarker discovery', 'Precision medicine', 'Other']","['Original research', 'Meta-analysis']","['MSK-IMPACT', 'Multiple sources']","Based on the paper content provided, cBioPortal is not explicitly mentioned in the abstract or introduction sections. The study uses MSK-IMPACT and Foundation Medicine data for a meta-analysis of somatic alterations across genetic ancestries in 14 cancer types. Without explicit mention of cBioPortal usage in the provided text, the specific role of cBioPortal in this study cannot be determined from these sections alone.","['MSK-IMPACT', 'FoundationOne CDx']",['Citation only'],"['TERT', 'ERBB2', 'MET', 'BAP1', 'TP53', 'CDKN2A', 'FGFR3', 'EGFR']",['Not specified'],Unclear,low,4.0,41102416,Meta-analysis reveals differences in somatic alterations by genetic ancestry across common cancers.,2025,pdf,2025-12-19T03:54:31.648834,,,,
"['Mutation analysis', 'Gene expression analysis', 'Multi-omics integration', 'Pathway analysis']",['Pancreatic cancer'],"['Methods/Tools development', 'Drug response/resistance', 'Biomarker discovery']","['Original research', 'Methods/Software']",['Not specified'],"The paper cites cBioPortal but does not provide explicit details about how it was used in the study. The framework GETgene-AI integrates multi-omics data including mutational frequency and differential expression, and while cBioPortal is mentioned in the context of cancer genomics data portals, specific usage details (data download, analysis features, or datasets) are not described in the provided abstract and introduction.",[],['Citation only'],"['PIK3CA', 'PRKCA']",['Not specified'],Unclear,low,4.0,41089657,GETgene-AI: a framework for prioritizing actionable cancer drug targets.,2025,pdf,2025-12-19T03:54:33.425262,,,,
"['Mutation analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine', 'Pathway analysis']","['Original research', 'Clinical study']","['TCGA', 'Custom/Private data']","The study used TCGA datasets accessed through cBioPortal to validate findings from their institutional cohort of 72 PTC patients. The authors analyzed mutation patterns, particularly BRAF and TP53 mutations, and their interactions in papillary thyroid carcinoma. The validation against TCGA data was used to support their findings about mutation prevalence, mutual exclusivity patterns, and pathway evolution from MAPK to PI3K/NOTCH signaling.",['TCGA'],"['Data download/export', 'Citation only']","['BRAF', 'TP53', 'TERT', 'RET', 'NRAS', 'RAS']",['Not specified'],Unclear,medium,4.0,41089282,Mutation interactions of BRAF and TP53 define novel prognostic stratification and therapeutic implications in papillary thyroid carcinoma.,2025,pdf,2025-12-19T03:54:34.807637,,,,
"['Gene expression analysis', 'Pathway analysis', 'Multi-omics integration']",['Breast cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis']",['Original research'],['Not specified'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on experimental investigation of ME2 in TNBC using cell lines, xenografts, metabolomic and transcriptomic analyses, and crystal structure determination. cBioPortal may be cited in references but no specific usage is described in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41088330,"Interplay between malic enzyme 2, de novo serine synthesis, and the malate-aspartate shuttle drives metabolic adaptation in triple-negative breast cancer.",2025,pdf,2025-12-19T03:54:35.452761,,,,
['Gene expression analysis'],"['Glioma/Brain cancer', 'Other solid tumor']","['Immunotherapy', 'Biomarker discovery']",['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on immunohistochemical analysis of CLDN6 expression in tissue samples and in vitro/in vivo CAR T-cell experiments. cBioPortal may only be cited in the references without direct usage for data analysis or visualization in this particular study.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41073135,Claudin 6 is a suitable target for CAR T-cell therapy in atypical teratoid/rhabdoid brain tumors and other pediatric solid tumors.,2025,abstract,2025-12-19T03:54:34.674937,,,,
['Other'],['Pan-cancer'],"['Review/Commentary', 'Drug response/resistance', 'Precision medicine']",['Review'],['Not specified'],"This is a review paper focused on PRMT5 as a therapeutic target in cancer. Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage. The paper appears to be a comprehensive review of PRMT5 inhibitor strategies, clinical development, and AI-driven approaches rather than an original research study utilizing cBioPortal data or tools.",[],['Citation only'],['PRMT5'],['Not specified'],"[""Unclear""]","[""low""]",4.0,41072789,"Cracking PRMT5: Mechanistic insights, clinical advances, and AI-driven strategies.",2025,abstract,2025-12-19T03:54:35.396175,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis']",['Original research'],"['TCGA', 'Custom/Private data']","Based on the abstract and introduction provided, cBioPortal usage is not explicitly described in these sections. The study focuses on integrated bulk and single-cell RNA-Seq analyses to identify lncRNAs associated with splicing regulation and cancer stemness in hepatocellular carcinoma. While TCGA data appears to be used (common for HCC studies), specific cBioPortal usage details are not mentioned in the provided text.",[],['Citation only'],"['RAB30-DT', 'SRPK1', 'CDCA7', 'CREB1']",['Not specified'],Unclear,low,4.0,41068948,A novel lncRNA-mediated signaling axis governs cancer stemness and splicing reprogramming in hepatocellular carcinoma with therapeutic potential.,2025,pdf,2025-12-19T03:54:37.714284,,,,
"['Mutation analysis', 'Other']",['Other solid tumor'],"['Tumor evolution', 'Biomarker discovery']",['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, cBioPortal is not explicitly mentioned as being used in this study. The paper focuses on ultradeep duplex DNA sequencing of normal bladder tissue samples from 45 deceased donors to identify clonal driver mutations. The study appears to use custom sequencing data and analysis pipelines rather than cBioPortal resources. If cBioPortal is cited, it may be for reference purposes regarding known bladder cancer genes or mutation frequencies.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41062697,Sex and smoking bias in the selection of somatic mutations in human bladder.,2025,pdf,2025-12-19T03:54:45.115573,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Breast cancer'],"['Biomarker discovery', 'Pathway analysis', 'Precision medicine']",['Original research'],"['TCGA', 'METABRIC', 'Multiple sources']","The authors used cBioPortal to extract multi-omic data from TCGA-BRCA and METABRIC cohorts, including RNA-seq, mutation calls, and GISTIC2.0 copy number calls. The data was downloaded on 06/08/2024 and samples were filtered to those with mutation, RNA-seq, and copy number information available (TCGA n=994, METABRIC n=1866). Clinical information was also extracted using the TCGAbiolinks package in R in conjunction with cBioPortal data.","['TCGA-BRCA', 'METABRIC']",['Data download/export'],"['KMT2C', 'KMT2D', 'TP53', 'PIK3CA']",['Download data'],External (downloaded data),high,4.0,41062612,Contrasting roles of KMT2C and KMT2D in breast cancer.,2025,pdf,2025-12-19T03:54:40.484344,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']",['Original research'],['MSK-IMPACT'],The authors used cBioPortal to query the MSK-IMPACT database to determine the frequency of somatic STK11 mutations in breast cancer patients (1.9% of 3116 breast cases). They also referenced the MSK-IMPACT Clinical Sequencing Cohort through cBioPortal to report STK11 alterations across pan-cancer (3.5% of cases). The cBioPortal data was used to establish the clinical relevance and frequency of STK11 mutations in breast cancer as background for their experimental study.,['MSK-IMPACT'],"['Web-based analysis', 'Citation only']",['STK11'],['Query interface'],cBioPortal platform,medium,4.0,41051525,Suppression of STK11 induces expansion of polymorphonuclear myeloid-derived suppressive cells and activation of immune signaling in breast cancer.,2025,pdf,2025-12-19T03:54:40.435731,,,,
"['Copy number analysis', 'Gene expression analysis', 'Pathway analysis', 'Multi-omics integration', 'Survival analysis']",['Other solid tumor'],"['Methods/Tools development', 'Pathway analysis', 'Biomarker discovery']","['Methods/Software', 'Original research']",['TCGA'],"The paper does not explicitly describe using cBioPortal for data access or analysis. The authors used TCGA data (DNA copy number alteration and RNA-seq data from head and neck squamous cell carcinoma patients) to demonstrate their MPAC framework, but the source of this data is not specified as cBioPortal. cBioPortal may only be cited as a reference or general resource rather than being directly used in this study.",['TCGA'],['Citation only'],[],['Not specified'],Unclear,low,4.0,41046136,MPAC: a computational framework for inferring pathway activities from multi-omic data.,2025,abstract,2025-12-19T03:54:41.586342,,,,
"['Gene expression analysis', 'Mutation analysis', 'Copy number analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Breast cancer'],"['Biomarker discovery', 'Immunotherapy', 'Drug response/resistance', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to investigate genetic alterations and DNA methylation patterns in WNT genes in breast cancer. The study utilized cBioPortal along with SMART and GSCA databases to analyze genetic alterations, epigenetic modifications, and their correlations with immune infiltration and immunotherapy-related biomarkers. The platform was specifically mentioned as one of the key tools for examining genetic alterations in the WNT gene family.",['TCGA-BRCA'],"['Web-based analysis', 'Web-based visualization']","['WNT2', 'WNT7B', 'WNT11']","['Query interface', 'Not specified']",Mixed,medium,4.0,41044153,Comprehensive bioinformatics analysis reveals prognostic significance and immunological roles of WNT gene family in breast cancer.,2025,pdf,2025-12-19T03:54:42.874919,,,,
"['Multi-omics integration', 'Gene expression analysis', 'Mutation analysis']",['Pan-cancer'],"['Database/Resource', 'Methods/Tools development', 'Precision medicine']","['Methods/Software', 'Original research']",['Multiple sources'],"cBioPortal is mentioned in the introduction as one of the existing cancer genomics resources that provides valuable oncogenomic research capabilities. However, the paper does not describe using cBioPortal for any analysis or data retrieval in their study. cBioPortal is cited only as a reference point for comparison with their newly developed TumorXDB database, noting that existing resources like cBioPortal do not offer the same level of integration for xWAS and xQTL data.",[],['Citation only'],[],['Not specified'],Unclear,high,4.0,41029863,TumorXDB: an integrated multi-omics xWAS/xQTL platform for cross-ethnic pan-cancer analysis.,2025,pdf,2025-12-19T03:54:45.154621,,,,
['Gene expression analysis'],['Breast cancer'],['Methods/Tools development'],"['Methods/Software', 'Original research']","['TCGA', 'Custom/Private data']","Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this paper. The paper focuses on developing PREFFECT, a computational framework for analyzing FFPE RNA-seq data using generative models. While TCGA data may be used (which is available through cBioPortal), there is no direct reference to cBioPortal in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41029822,Generative and integrative modeling for transcriptomics with formalin fixed paraffin embedded material.,2025,pdf,2025-12-19T03:54:46.494644,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Pathway analysis']","['Lung cancer', 'Prostate cancer', 'Pan-cancer']","['Drug response/resistance', 'Tumor evolution', 'Biomarker discovery', 'Review/Commentary']",['Review'],['Not specified'],"This is a review article on lineage plasticity and histological transformation in cancer. While cBioPortal is cited in the references, the abstract and introduction provided do not contain specific details about how cBioPortal was used. The paper discusses molecular alterations in transformed tumors (particularly EGFR-mutant lung adenocarcinoma and AR-dependent prostate cancer) but does not explicitly describe cBioPortal usage for data analysis or visualization in the sections provided.",[],['Citation only'],"['EGFR', 'TP53', 'RB1', 'AR']",['Not specified'],Unclear,low,4.0,41023204,Lineage plasticity and histological transformation: tumor histology as a spectrum.,2025,pdf,2025-12-19T03:54:46.097285,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper mentions cBioPortal in the context of accessing TCGA data for their pan-cancer analysis of PSMB9. Based on the abstract and introduction, the authors integrated multi-omics data from TCGA and other databases to investigate PSMB9's role across cancers. However, the specific details of how cBioPortal was used (whether for data download, web-based analysis, or visualization) are not explicitly described in the provided text.",['TCGA'],['Citation only'],['PSMB9'],['Not specified'],Unclear,low,4.0,41020834,PSMB9 Orchestrates Tumor Immune Landscape and Serves as a Potent Biomarker for Prognosis and T Cell-Based Immunotherapy Response.,2025,pdf,2025-12-19T03:54:46.705675,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Melanoma'],"['Biomarker discovery', 'Tumor evolution', 'Immunotherapy', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"The paper does not explicitly describe how cBioPortal was used in the study. This appears to be an original research study using custom autopsy-derived melanoma metastases samples analyzed through RNA-sequencing and mass spectrometry-based proteomics. cBioPortal may have been cited as a reference or for contextual purposes, but no specific usage of the platform for data analysis, visualization, or data download is mentioned in the provided abstract and introduction.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41017066,Distant metastases of melanoma exhibit varying extent of intrapatient proteogenomic heterogeneity.,2025,abstract,2025-12-19T03:54:47.334273,,,,
['Gene expression analysis'],['Leukemia/Lymphoma'],['Review/Commentary'],['Original research'],['Not specified'],"This paper focuses on developmental biology research using zebrafish models to study hematopoietic stem and progenitor cell (HSPC) development. The paper mentions observations in hematopoietic cancers where SFRP1 variants can promote or inhibit tumor development, but there is no explicit description of cBioPortal usage in the abstract or introduction provided. The citation appears to be contextual, relating their developmental findings to cancer biology observations.",[],['Citation only'],[],['Not specified'],"[""Unclear""]","[""low""]",4.0,41016526,Secreted frizzled-related protein 1a regulates hematopoietic development in a dose-dependent manner.,2026,abstract,2025-12-19T03:54:46.150910,,,,
"['Gene expression analysis', 'Pathway analysis']",['Prostate cancer'],"['Drug response/resistance', 'Pathway analysis', 'Biomarker discovery']",['Original research'],['Not specified'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on using HTS2 (high-throughput sequencing based high-throughput screening) technology combined with network pharmacology to investigate the mechanisms of Modified Guizhi Fuling Decoction in prostate cancer cells. The study appears to use custom experimental data from PC3 and DU145 cell lines rather than public databases accessed through cBioPortal.",[],['Citation only'],"['AKT1', 'CASP8', 'CDK1', 'CCND1']",['Not specified'],Unclear,low,4.0,41011149,Large-Scale Transcriptome Profiling and Network Pharmacology Analysis Reveal the Multi-Target Inhibitory Mechanism of Modified Guizhi Fuling Decoction in Prostate Cancer Cells.,2025,pdf,2025-12-19T03:54:47.687383,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis']",['Original research'],['Not specified'],"Based on the abstract and introduction provided, cBioPortal is cited in this study but specific usage details are not described in the available text. The study focuses on integrated analysis combining transcriptomic profiling, protein-protein interaction networks, machine learning, and molecular simulations to identify CDK1 as a therapeutic target in epithelial ovarian cancer. The exact role of cBioPortal in data acquisition or analysis cannot be determined from the provided excerpts.",[],['Citation only'],"['CDK1', 'WEE1']",['Not specified'],Unclear,low,4.0,41009727,"Integrated Analysis, Machine Learning, Molecular Docking and Dynamics of CDK1 Inhibitors in Epithelial Ovarian Cancer: A Multifaceted Approach Towards Targeted Therapy.",2025,pdf,2025-12-19T03:54:49.368281,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Colorectal cancer'],"['Drug response/resistance', 'Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used as one of multiple public databases to assess the prevalence and clinical significance of BRAF, MEK, and PI3K alterations in colorectal cancer. The study performed differential gene expression and mutational analyses using cBioPortal alongside other databases (TCGA, TNMplot, GEPIA2, GSCA, PANDA) to characterize the oncogenic signature. The specific details of how cBioPortal was used are not extensively described in the abstract and introduction.",[],['Web-based analysis'],"['BRAF', 'MAP2K1', 'PIK3CA']",['Not specified'],Mixed,medium,4.0,41009348,Integrated In Silico and Experimental Validation of Antrocin as a Plant-Derived Multi-Target Therapeutic for BRAF/MEK/PI3K-Driven Colorectal Cancer.,2025,pdf,2025-12-19T03:54:51.900652,,,,
"['Mutation analysis', 'Survival analysis']",['Lung cancer'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']",['GENIE'],"This study utilized the AACR GENIE Biopharma Collaborative (BPC) NSCLC 2.0 dataset to conduct a retrospective analysis of KRAS and SMARCA4 mutations in non-small cell lung cancer patients. The researchers identified patients with KRAS mutations, SMARCA4 mutations (class 1 and class 2), and KRAS/SMARCA4 co-mutations from this dataset. Survival outcomes were assessed using Cox proportional hazards models to evaluate the prognostic impact of these mutations and co-mutations on overall survival.",['AACR GENIE BPC NSCLC 2.0'],['Data download/export'],"['KRAS', 'SMARCA4', 'STK11', 'EGFR']",['Download data'],External (downloaded data),high,4.0,41007704,Prognostic Impact of <i>KRAS</i> and <i>SMARCA4</i> Mutations and Co-Mutations on Survival in Non-Small Cell Lung Cancer: Insights from the AACR GENIE BPC Dataset.,2025,pdf,2025-12-19T03:54:50.792636,,,,
"['Mutation analysis', 'Survival analysis', 'Pathway analysis']","['Pan-cancer', 'Lung cancer']","['Methods/Tools development', 'Biomarker discovery', 'Precision medicine']",['Original research'],"['GENIE', 'Multiple sources']",The study used AACR Project GENIE dataset (v14) to obtain somatic missense variants for evaluating computational variant effect predictors (VEPs). OncoKB-annotated pathogenic variants from GENIE served as positive controls to test whether AI methods could discriminate literature-confirmed or hotspot pathogenic somatic missense variants from benign ones. The GENIE data was used to analyze mutation frequencies and validate AI predictions of cancer driver mutations across multiple genes.,"['GENIE v14', 'AACR Project GENIE']",['Data download/export'],"['ABL1', 'ALK', 'BRAF', 'CTNNB1', 'EGFR', 'ERBB2', 'ERBB4', 'FGFR2', 'FGFR3', 'FLT3', 'IDH1', 'JAK2', 'JAK3', 'KDR', 'KIT', 'KRAS', 'MET', 'NFE2L2', 'NRAS', 'PDGFRA', 'PIK3CA', 'RET', 'SF3B1', 'APC', 'ARID2', 'ASXL1', 'ATM', 'BAP1', 'BRCA1', 'CDH1', 'CDKN2A', 'FANCA', 'FBXW7', 'KEAP1', 'KMT2D', 'MGA', 'NF1', 'PIK3R1', 'PTEN', 'RB1', 'RBM10', 'SETD2', 'SMAD4', 'SMARCA4', 'STK11', 'TP53', 'TSC1']",['Download data'],External (downloaded data),high,4.0,41006257,AI cancer driver mutation predictions are valid in real-world data.,2025,pdf,2025-12-19T03:54:55.902853,,,,
"['Gene expression analysis', 'Pathway analysis', 'Multi-omics integration']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],"The authors used cBioPortal to download mRNA expression and protein abundance data from GBM tissue samples from the CPTAC dataset (Cell 2021, originally published by Wang et al., Cancer Cell 2021). The downloaded data included RNA-Seq expression data normalized by FPKM-UQ and protein abundance ratios from mass spectrometry across 99 GBM samples and 29,455 genes. This data was then used externally to perform correlation analysis and gene set enrichment analysis (GSEA) to investigate relationships between APP protein expression and transcriptional changes.",['CPTAC'],['Data download/export'],['APP'],"['Download data', 'Expression analysis']",External (downloaded data),high,4.0,41003874,Amyloid precursor protein accumulation in glioblastoma is associated with altered synaptic dynamics and immune suppression.,2025,pdf,2025-12-19T03:54:52.472637,,,,
['Gene expression analysis'],['Breast cancer'],"['Drug response/resistance', 'Pathway analysis']",['Original research'],['Not specified'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on experimental laboratory work using cell lines (MDA-MB-231, Hs578T, HUVEC), siRNA knockdowns, and adhesion assays to investigate IGF1R and integrin interactions. If cBioPortal was used, it was likely only cited as a reference or for background information gathering, but no specific usage is described in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41000977,Insulin-Like Growth Factor 1 Receptor Regulates Breast Cancer Cell Adhesion through Beta-1 Integrin.,2025,abstract,2025-12-19T03:54:53.174891,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis']",['Leukemia/Lymphoma'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis']",['Original research'],['Not specified'],"Based on the abstract and introduction provided, there is no explicit mention of how cBioPortal was used in this study. The paper focuses on experimental investigation of ARID1A and ARID1B functions in B cell development using mouse models and in vitro B cell lymphoma cells. While the paper cites cBioPortal, the specific usage details are not described in the provided text.",[],['Citation only'],"['ARID1A', 'ARID1B']",['Not specified'],Unclear,low,4.0,41000613,"ARID1A and ARID1B preserve B cell identity, prevent myeloid transformation and reveal therapeutic vulnerabilities.",2025,abstract,2025-12-19T03:54:51.974382,,,,
"['Gene expression analysis', 'Mutation analysis', 'Survival analysis']","['Pan-cancer', 'Lung cancer']","['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to analyze the distribution of genetic alterations in C15ORF48 across various cancers. The study identified specific mutations including S29F, T38I, and K61N in the C15orf48 gene. cBioPortal was one of several databases employed alongside TIMER2.0, GEPIA, Human Protein Atlas, PhosphoNET, and AlphaFold for comprehensive pan-cancer analysis.",[],['Web-based analysis'],['C15ORF48'],['Mutation Mapper'],Mixed,medium,4.0,40998903,C15ORF48 serves as a potential biomarker and therapeutic target in pan-cancer with implications for lung cancer.,2025,pdf,2025-12-19T03:54:54.609669,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['Multiple sources'],"The paper does not explicitly describe how cBioPortal was used in the methodology. While the study analyzes ccRCC using multiple databases and performs comprehensive gene expression, survival, and immune infiltration analyses, there is no clear mention of cBioPortal in the abstract or introduction provided. The citation may be for reference purposes or the usage details may be in the methods section not provided.",[],['Citation only'],['MGLL'],['Not specified'],Unclear,low,4.0,40994935,Comprehensive analysis of MGLL as a novel diagnostic and prognostic biomarker for clear cell renal cell carcinoma.,2025,abstract,2025-12-19T03:54:53.511962,,,,
"['Gene expression analysis', 'Survival analysis']",['Lung cancer'],['Biomarker discovery'],"['Original research', 'Clinical study']",['Custom/Private data'],"The study used a public gene database (likely cBioPortal) to develop a ""shedding pAxl score"" and investigate correlations with EMT-related genes. The shedding pAxl score was experimentally validated and showed strong correlation with established EMT signature scores. However, the abstract does not provide specific details about which cBioPortal features were used or which datasets were accessed.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40988915,Shedding Phosphorylated Axl Receptor in Lung Adenocarcinoma: Dual-Domain Immunohistochemistry Approach.,2025,abstract,2025-12-19T03:54:54.623955,,,,
"['Mutation analysis', 'Gene expression analysis', 'Drug response/resistance']","['Pan-cancer', 'Breast cancer', 'Other solid tumor']","['Drug response/resistance', 'Biomarker discovery']",['Original research'],['Multiple sources'],"The paper used cBioPortal to query and analyze cell line collections for BRCA1/2 mutations and their correlation with PARP inhibitor sensitivity. The authors examined genomic alterations, PARP1 expression levels, and other molecular features in cell line databases to assess drug response patterns. cBioPortal was used to access and analyze publicly available cell line data to compare with their isogenic model results.",[],"['Web-based analysis', 'Data download/export']","['BRCA1', 'BRCA2', 'PARP1']","['Query interface', 'Expression analysis']",Mixed,medium,4.0,40977519,Unmatched Cell Line Collections Are Not Optimal for Identification of PARP Inhibitor Response and Drug Synergies.,2025,abstract,2025-12-19T03:54:56.784907,,,,
"['Gene expression analysis', 'Pathway analysis']",['Glioma/Brain cancer'],"['Pathway analysis', 'Biomarker discovery']",['Original research'],['TCGA'],"Based on the abstract and introduction provided, the paper appears to cite cBioPortal but does not provide explicit details about how it was used in the study. The research focuses on experimental work using a mouse stem cell model of glioblastoma to investigate FAK's role in cellular energetics. Without access to the methods or results sections, the specific usage of cBioPortal cannot be determined from the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40977288,FAK modulates glioblastoma stem cell energetics via regulation of glycolysis and glutamine oxidation.,2025,abstract,2025-12-19T03:54:56.003997,,,,
['Other'],['Melanoma'],['Review/Commentary'],['Review'],['Not specified'],"This is a review paper focused on PTEN's role in melanoma suppression. Based on the title, authors, and abstract provided, there is no explicit mention of cBioPortal usage in the abstract or introduction. The paper appears to be a comprehensive review of PTEN function in melanoma rather than an original research study utilizing cBioPortal for data analysis or visualization.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40976930,The Roles of PTEN in Melanoma Suppression.,2025,abstract,2025-12-19T03:54:57.111702,,,,
"['Mutation analysis', 'Copy number analysis']",['Other solid tumor'],"['Tumor evolution', 'Biomarker discovery']",['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper describes a paired next-generation sequencing study of goblet cell adenocarcinomas with coincident lesions using in-house clinical samples. The sequencing and analysis appear to have been performed independently without reference to cBioPortal. If cBioPortal is mentioned, it may only be cited in the references or methods section not provided here.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40970974,A paired sequencing study of goblet cell adenocarcinomas with coincident sessile serrated lesions and low-grade appendiceal mucinous neoplasms.,2025,abstract,2025-12-19T03:54:57.660851,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Pathway analysis']","['Pan-cancer', 'Prostate cancer']","['Biomarker discovery', 'Immunotherapy', 'Drug response/resistance']",['Original research'],"['Custom/Private data', 'Multiple sources']","The paper does not explicitly describe using cBioPortal in the provided abstract and introduction sections. The study analyzes CDK12/13 expression and STING pathway activation in relation to immune checkpoint blockade response using institutional cohorts (MI-ONCOSEQ) and the Kaplan-Meier plotter database. While cBioPortal may have been cited in the full paper, no specific usage details are provided in the excerpted text.",[],['Citation only'],"['CDK12', 'CDK13']",['Not specified'],Unclear,low,4.0,40955658,CDK12/13 inactivation triggers STING-mediated antitumor immunity in preclinical models.,2025,pdf,2025-12-19T03:54:59.395490,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Colorectal cancer', 'Pancreatic cancer', 'Pan-cancer']","['Drug response/resistance', 'Methods/Tools development', 'Biomarker discovery', 'Precision medicine']","['Original research', 'Methods/Software']","['TCGA', 'Multiple sources']",The paper integrated clinical datasets from cBioPortal to validate proliferation and resistance-associated genes identified through their BOGO screening platform. They used cBioPortal data to assess the prognostic potential of genes associated with drug response and resistance. The clinical data from cBioPortal was used to complement their experimental overexpression screening results.,[],['Data download/export'],"['BCL2', 'POLD2', 'TRADD']",['Download data'],External (downloaded data),medium,4.0,40950237,BOGO: A Proteome-Wide Gene Overexpression Platform for Discovering Rational Cancer Combination Therapies.,2025,abstract,2025-12-19T03:54:58.893445,,,,
"['Mutation analysis', 'Other']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper describes a clinicopathological study of BCOR-mutated chondrosarcomas using 12 cases compared to 15 control cases, but does not specify the use of cBioPortal for data access, analysis, or visualization. The study appears to focus on original patient samples with custom sequencing data rather than public databases accessed through cBioPortal.",[],['Citation only'],"['BCOR', 'IDH1', 'IDH2', 'COL2A1', 'TP53']",['Not specified'],Unclear,low,4.0,40944348,BCOR-Mutated Conventional and Dedifferentiated Chondrosarcoma: A Clinicopathologic Study.,2025,abstract,2025-12-19T03:54:59.198562,,,,
['Gene expression analysis'],['Other solid tumor'],"['Immunotherapy', 'Biomarker discovery']",['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on preclinical evaluation of FOLR1-targeted CAR T cells against osteosarcoma using in vitro and in vivo models. The study appears to use custom patient specimens, cell lines, and patient-derived xenografts without reference to cBioPortal data or tools.",[],['Citation only'],['FOLR1'],['Not specified'],Unclear,low,4.0,40919994,Preclinical Evaluation of Folate Receptor-α Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against Osteosarcoma.,2025,abstract,2025-12-19T03:55:00.020230,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Multi-omics integration']","['Pan-cancer', 'Lung cancer', 'Colorectal cancer']","['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy', 'Precision medicine']","['Original research', 'Clinical study']","['TCGA', 'Custom/Private data', 'Multiple sources']",cBioPortal was used to extract tumor mutational burden (TMB) and fraction genome altered (FGA) data for each TCGA patient sample across 18 solid tumor types. These biomarkers were then analyzed in relation to anesthetic/analgesic drug effects on survival outcomes in lung and colon adenocarcinoma patients. The TMB and FGA data from cBioPortal were integrated with TCGA gene expression data and clinical cohort data for multi-omics analysis.,['TCGA'],['Data download/export'],[],['Download data'],External (downloaded data),high,4.0,40909996,Towards a precision approach to anesthetic/analgesic immunomodulation in cancer.,2024,abstract,2025-12-19T03:55:00.413716,,,,
"['Gene expression analysis', 'Survival analysis']",['Breast cancer'],['Biomarker discovery'],['Original research'],['TCGA'],"The study used TCGA RNA-seq data to analyze 41 aminoacyl-tRNA synthetase (ARS) genes in invasive lobular carcinoma (ILC). The researchers applied lasso-logistic regression using patient vital status as the binary outcome and performed survival analysis to identify SARS1 and CARS2 as prognostic biomarkers. While TCGA data is mentioned, the specific role of cBioPortal in data access or analysis is not explicitly described in the abstract.",['TCGA'],['Citation only'],"['SARS1', 'CARS2', 'TARS1']",['Not specified'],Unclear,low,4.0,40904607,Identification of SARS1 as a Prognostic Biomarker in Invasive Lobular Carcinoma Using Lasso-Logistic Regression.,2025,abstract,2025-12-19T03:55:02.304985,,,,
"['Gene expression analysis', 'Pathway analysis']",['Lung cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],"Based on the abstract and introduction provided, the paper does not explicitly mention cBioPortal usage. The study analyzes circadian rhythm disruption in lung adenocarcinoma using Clock Correlation Distance (CCD) to examine relationships between MYC expression, EMT, and circadian clock genes. While TCGA data appears to be used for the analysis, there is no specific mention of cBioPortal as the source or analysis platform in the provided text.",['TCGA'],['Citation only'],['MYC'],['Not specified'],Unclear,low,4.0,40894652,MYC and Epithelial to Mesenchymal Transition (EMT) Independently Predict Circadian Rhythm Disruption in Lung Adenocarcinoma.,2025,abstract,2025-12-19T03:55:01.793167,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis']",['Other solid tumor'],"['Review/Commentary', 'Precision medicine', 'Drug response/resistance', 'Biomarker discovery']",['Review'],['Not specified'],"This is a review paper about CRISPR-knockout library screens in ovarian cancer. While the paper discusses genetic dependencies and mutations relevant to ovarian cancer (including BRCA1, BRCA2, KRAS, BRAF, and other genes), there is no explicit mention of cBioPortal usage in the provided abstract and introduction sections. The paper focuses on reviewing CRISPR-KO screening methodology and its applications in epithelial ovarian cancer research, but does not describe any direct use of cBioPortal for data analysis or visualization.",[],['Citation only'],"['BRCA1', 'BRCA2', 'RAD51C', 'RAD51D', 'ATM', 'PALB2', 'KRAS', 'BRAF']",['Not specified'],Unclear,low,4.0,40875132,Revealing genetic drivers of ovarian cancer and chemoresistance: insights from whole-genome CRISPR-knockout library screens.,2025,pdf,2025-12-19T03:55:03.611331,,,,
"['Gene expression analysis', 'Survival analysis']",['Breast cancer'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],['Not specified'],"The paper used cBioPortal to perform survival analysis on the 157 novel FOXA1 interactors identified through their proximity labeling approach. Specifically, they analyzed relapse-free survival in ER-positive breast cancer patients and identified 42 proteins, including NR2C2, that were significantly associated with poor relapse-free survival. The analysis appears to have been performed using cBioPortal's web-based survival analysis tools.",[],"['Web-based analysis', 'Web-based visualization']",['NR2C2'],['Survival analysis'],cBioPortal platform,medium,4.0,40874905,Mapping the FOXA1 Interactome in ER+ Breast Cancer Cells Using Proximity Labeling Reveals Novel Interactions with the Orphan Nuclear Receptor NR2C2.,2025,abstract,2025-12-19T03:55:02.305910,,,,
"['Gene expression analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['Custom/Private data'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on analyzing gene expression profiles from the GEO database and uses tools like STRING, Gephi, miRPathDB, miRWalk, and miRDB for analysis. The study investigates miRNA roles in testicular germ cell tumors (seminomas and teratomas) but does not reference cBioPortal as a data source or analysis platform.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40869426,Functional Role of miR-138-5p and miR-200b-3p in Testicular Germ Cell Tumors: Molecular Insights into Seminoma and Teratoma Pathogenesis.,2025,pdf,2025-12-19T03:55:03.125056,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Prostate cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],['TCGA'],"The study used the cBioPortal platform to perform differential gene expression analysis between prostate cancer patients with and without perineural invasion (PNI). The analysis was conducted using log2-transformed RSEM-normalized expression values from TCGA data, with statistical testing performed using Student's t-test and Benjamini-Hochberg FDR correction. The platform was used to identify differentially expressed genes with fold-change >1.5 and q-value <0.05.",['TCGA-PRAD'],['Web-based analysis'],"['COL9A3', 'ASPN', 'ESR1', 'MUC1', 'PIP', 'SFRP4', 'KRT19', 'CLDN1', 'COMP', 'RYR2', 'MME', 'AZGP1']","['Expression analysis', 'Group comparison']",cBioPortal platform,high,4.0,40868045,Transcriptomic Profile of Perineural Invasion in Prostate Cancer Identifies Prognostic Gene Signatures.,2025,pdf,2025-12-19T03:55:05.074079,,,,
['Other'],['Pan-cancer'],['Review/Commentary'],['Review'],['Not specified'],"This is a review article about Bcl-2 modifying factor (Bmf), a BH3-only protein in the Bcl-2 family. The paper does not explicitly describe any direct use of cBioPortal for analysis or data retrieval. The paper mentions using the Human Protein Atlas (HPA) database for expression data but does not detail any cBioPortal usage in the provided abstract and introduction sections.",[],['Citation only'],['BMF'],['Not specified'],Unclear,low,4.0,40849581,"Bcl-2 modifying factor (Bmf): ""a mysterious stranger"" in the Bcl-2 family proteins.",2025,pdf,2025-12-19T03:55:04.789303,,,,
"['Gene expression analysis', 'Mutation analysis', 'Copy number analysis', 'Survival analysis', 'Pathway analysis']","['Pan-cancer', 'Colorectal cancer']","['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","The study used cBioPortal to analyze genetic variations in GOT1 across cancer types, including mutation burden, copy number alterations, and microsatellite instability. cBioPortal analysis was mentioned as one of the tools used to evaluate the association of GOT1 with colorectal cancer and pan-cancer analyses. The specific details of how cBioPortal was used (web-based vs. data download) are not explicitly described in the provided text.","['TCGA-COAD', 'TCGA-READ']",['Web-based analysis'],"['GOT1', 'KRAS', 'BRAF', 'LGALS9', 'TNFRSF4']",['Not specified'],Unclear,medium,4.0,40849558,Exploring the multifaceted roles of glutamate oxaloacetate transaminase 1 as a biomarker and therapeutic target in colorectal cancer and pan-cancer analyses.,2025,pdf,2025-12-19T03:55:05.548806,,,,
"['Gene expression analysis', 'Drug response/resistance']",['Other solid tumor'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],['Multiple sources'],"The study used cBioPortal to analyze the correlation between ERBB3 expression and ferroptosis-related drug sensitivity using data from the Cancer Therapeutics Response Portal v2 (CTRPv2). The authors examined z-scores for ERBB3 expression associated with resistance to GPX4 inhibitors (ML210, ML162, RSL3) and the SLC7A11 inhibitor Erastin. They also utilized the DepMap Data Explorer to visualize CTRPv2 data assessing the relationship between Erastin response and gene expression across gastric cancer cell lines.",['CTRPv2'],"['Web-based analysis', 'Web-based visualization']","['ERBB3', 'SLC7A11', 'GPX4']","['Expression analysis', 'Query interface']",cBioPortal platform,high,4.0,40846695,ERBB3 influences the ferroptosis pathway via modulation of lipid peroxidation and GSH synthesis in gastric cancer.,2025,pdf,2025-12-19T03:55:06.409139,,,,
"['Survival analysis', 'Other']",['Other solid tumor'],['Biomarker discovery'],"['Meta-analysis', 'Review']",['Not specified'],"This is a systematic review and meta-analysis examining the prognostic role of IL-8 in renal cell carcinoma. The paper does not appear to directly use cBioPortal for data analysis or visualization. If cBioPortal is mentioned, it would likely be only as a citation or reference to existing databases, but no specific usage of cBioPortal tools or data is described in the abstract or introduction provided.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40839124,Interleukin-8 as a potential prognostic biomarker in renal cell carcinoma: a systematic review and meta-analysis.,2025,abstract,2025-12-19T03:55:06.723179,,,,
['Mutation analysis'],['Pan-cancer'],"['Methods/Tools development', 'Database/Resource']","['Methods/Software', 'Original research']",['Multiple sources'],"MutationAssessor (MA) is a tool integrated into cBioPortal that provides functional impact scores for mutations. The new version (r4) has been integrated into cBioPortal, making functional impact predictions for approximately 4 million somatic amino-acid changing mutations across more than 320K human tumor samples available through the platform. This paper describes the development and integration of the MutationAssessor tool as a feature within cBioPortal for Cancer Genomics.",[],['Web-based visualization'],[],['Mutation Mapper'],cBioPortal platform,high,4.0,40832239,MutationAssessor in cBioPortal.,2025,abstract,2025-12-19T03:55:07.579067,,,,
"['Mutation analysis', 'Other']",['Pan-cancer'],"['Biomarker discovery', 'Methods/Tools development']",['Original research'],['Not specified'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on analyzing TP53 missense variants of uncertain significance from the gnomAD database using in silico tools (PhosphositePlus, Kinase Library, and Dynamut2) to assess protein stability and phosphorylation effects. The study appears to rely on gnomAD as the primary data source rather than cBioPortal.",[],['Citation only'],['TP53'],['Not specified'],Unclear,low,4.0,40806592,GnomAD Missense Variants of Uncertain Significance: Implications for p53 Stability and Phosphorylation.,2025,pdf,2025-12-19T03:55:08.422821,,,,
"['Mutation analysis', 'Pathway analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Tumor evolution']",['Original research'],['TCGA'],"The paper used cBioPortal to access and analyze colorectal cancer mutation data, specifically focusing on POLE (polymerase epsilon) mutations and co-occurring mutations in other genes. The authors partitioned POLE mutations into driver, passenger, and wild-type categories and assessed mutation patterns in other genes across these groups. The study appears to have utilized cBioPortal's data resources to identify mutation co-occurrence patterns in colorectal cancers.",['TCGA'],['Data download/export'],['POLE'],"['Query interface', 'Download data']",External (downloaded data),medium,4.0,40806338,Comprehensive Analysis of Human Colorectal Cancers Harboring Polymerase Epsilon Mutations.,2025,abstract,2025-12-19T03:55:08.684628,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, the specific usage of cBioPortal is not explicitly detailed. The study appears to have used multiple ccRCC cohorts to develop a prognostic index (B-LLPSI) and evaluate its association with prognosis and immunotherapy response across multiple cancer types. cBioPortal was likely used to access TCGA and other cancer genomics datasets, though the exact mode of usage (data download, web-based analysis, or validation) is not clearly specified in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40804718,Multi-omics analysis of bidirectional liquid-liquid phase separation signatures reveals immunotherapy response and prognosis in renal cell carcinoma.,2025,abstract,2025-12-19T03:55:09.038099,,,,
"['Survival analysis', 'Other']","['Lung cancer', 'Other solid tumor']",['Methods/Tools development'],['Methods/Software'],"['GENIE', 'Custom/Private data']","cBioPortal is mentioned in the introduction as one of several existing tools for visualizing longitudinal clinical data. The paper does not describe using cBioPortal for data analysis or visualization in their study. Instead, the authors developed ShinyEvents as a new tool to address limitations in existing tools including cBioPortal for cohort-level analysis of treatment-associated information from real-world data.",['GENIE'],['Citation only'],[],['Not specified'],Unclear,high,4.0,40799741,ShinyEvents: harmonizing longitudinal data for real world survival estimation.,2025,pdf,2025-12-19T03:55:09.898116,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Copy number analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'Custom/Private data']","Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The authors analyzed TCGA data (272 HGSOC cases) and OmniSeq clinical data (226 cases) for RB1 expression, HR status, survival outcomes, and immune gene signatures. While TCGA data is available through cBioPortal, the paper does not specifically state that cBioPortal was used to access or analyze this data.",['TCGA'],['Citation only'],"['RB1', 'BRCA1', 'BRCA2']",['Not specified'],"[""Unclear""]",low,4.0,40796942,RB1 expression and HR proficiency define a poor prognosis subtype of high grade serous ovarian cancer.,2025,abstract,2025-12-19T03:55:10.576860,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],"['TCGA', 'Custom/Private data']","The authors used cBioPortal to access RNA expression data from the TCGA-BLCA (bladder cancer) cohort (n=397 cystectomy patients). They evaluated the expression of five ECM-related genes (FN1, COL5A1, COL1A1, TNFAIP6, FLG) identified from their proteomic analysis of radiation-treated bladder cancer cell lines. The TCGA data was used alongside two radiotherapy cohorts (BC2001 and BCON) to assess the prognostic and predictive value of these ECM genes in muscle-invasive bladder cancer.",['TCGA-BLCA'],['Data download/export'],"['FN1', 'COL5A1', 'COL1A1', 'TNFAIP6', 'FLG', 'COL5A2', 'TP53']",['Download data'],External (downloaded data),high,4.0,40792276,Radiation-induced extracellular matrix remodelling drives prognosis and predicts radiotherapy response in muscle-invasive bladder cancer.,2025,pdf,2025-12-19T03:55:11.955903,,,,
"['Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],"cBioPortal was used to analyze the PIWI pathway in colon cancer, specifically examining allelic losses and copy number alterations. SWAN (Shifted Weighted Annotation Network) analysis was performed using cBioPortal data to reveal that PIWIL2 experiences the highest percent deletions among PIWI pathway components. The study also examined PIWIL2 expression levels and their correlation with clinical parameters including tumor stage, nodal metastasis, cancer subtypes, and patient survival outcomes.",['TCGA'],"['Data download/export', 'Web-based analysis']",['PIWIL2'],"['Expression analysis', 'Survival analysis', 'Download data', 'Query interface']","[""Mixed""]",medium,4.0,40789164,PIWIL2 downregulation in colon cancer promotes transposon activity and pro-tumorigenic phenotypes.,2025,abstract,2025-12-19T03:55:12.641435,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis']",['Other solid tumor'],"['Drug response/resistance', 'Pathway analysis']",['Original research'],['Not specified'],"The paper does not explicitly describe how cBioPortal was used in this study. This is an experimental study investigating the effects of daraxonrasib (a pan-RAS inhibitor) on osteosarcoma cell lines with wild-type versus mutant KRAS. The study appears to be primarily laboratory-based using cell culture experiments, qPCR, immunoblotting, and activity assays, with no clear mention of cBioPortal usage in the provided abstract and introduction.",[],['Citation only'],[],['Not specified'],"[""Unclear""]",low,4.0,40779492,"Daraxonrasib, a pan-RAS inhibitor, selectively inhibits osteosarcomas with activated KRAS by halting AKT signaling and matrix metalloprotease activity.",2025,pdf,2025-12-19T03:55:12.008213,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Copy number analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The study used cBioPortal to analyze ITGAV genetic alterations, including mutations and copy number variations, across multiple cancer types in a pan-cancer analysis. The authors likely accessed cBioPortal to query ITGAV expression data, genetic alterations, and their relationships with clinical outcomes across different cancer datasets. The platform was used as one of several public databases to conduct comprehensive pan-cancer analysis of ITGAV.",[],"['Web-based analysis', 'Web-based visualization']",['ITGAV'],"['Expression analysis', 'Query interface']",Mixed,medium,4.0,40775431,Pan-cancer landscape of ITGAV and its potential role in gastric cancer.,2025,abstract,2025-12-19T03:55:13.049560,,,,
"['Copy number analysis', 'Gene expression analysis']",['Other solid tumor'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],['Not specified'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on experimental work examining DFMO effects on protein translation in neuroblastoma cell lines and mouse models. The study examines MYCN and ODC1 copy number in relation to DFMO sensitivity, but the source of this data is not specified in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40774224,High-dose DFMO alters protein translation in neuroblastoma.,2025,abstract,2025-12-19T03:55:12.976914,,,,
"['Copy number analysis', 'Gene expression analysis', 'Survival analysis']",['Prostate cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The study used cBioPortal to analyze PCP4 gene expression, copy number alterations, and their correlation with clinical outcomes in prostate cancer patients. The authors examined public datasets through cBioPortal to identify PCP4 gene loss frequency and its co-occurrence with TMPRSS2-ERG fusion in PCa patients. The platform was used to establish the relationship between PCP4 expression levels and patient prognosis, particularly in castration-resistant prostate cancer (CRPC) development.",[],"['Web-based analysis', 'Web-based visualization']","['PCP4', 'TMPRSS2', 'ERG', 'AR']","['Expression analysis', 'Survival analysis', 'Query interface']",Mixed,medium,4.0,40746562,PCP4 inhibits the progression of prostate cancer through Ca<sup>2+</sup>/CAMKK2/AMPK/AR pathway.,2025,abstract,2025-12-19T03:55:14.206466,,,,
"['Mutation analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']",['Original research'],['Custom/Private data'],"The paper mentions OncoKB (not cBioPortal) for annotating oncogenic gain-of-function/loss-of-function variants. Korean-specific mutations in SMO, PTCH1, TP53, and NOTCH2 were compared with oncogenic GOF/LOF variants annotated in OncoKB. There is no explicit mention of cBioPortal usage in the provided abstract and introduction.",[],['Citation only'],"['SMO', 'PTCH1', 'TP53', 'NOTCH2', 'GLI1', 'CSMD1', 'CSMD2', 'NOTCH1', 'ITIH2', 'DPP10', 'STEAP4', 'TAS1R2', 'ADCY10']",['Not specified'],Unclear,low,4.0,40725190,Ethnic-Specific and UV-Independent Mutational Signatures of Basal Cell Carcinoma in Koreans.,2025,pdf,2025-12-19T03:55:14.866121,,,,
['Other'],"['Breast cancer', 'Colorectal cancer', 'Other solid tumor']","['Review/Commentary', 'Biomarker discovery', 'Precision medicine']",['Review'],['Not specified'],"This is a comprehensive review article about PHF20L1 as an epigenetic regulator in cancer. The paper does not describe any specific usage of cBioPortal for original data analysis. cBioPortal may be cited as a reference or resource in the context of discussing cancer genomics data, but no explicit analysis, data download, or visualization using cBioPortal is described in the abstract or introduction.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40723918,PHF20L1: An Epigenetic Regulator in Cancer and Beyond.,2025,abstract,2025-12-19T03:55:15.405937,,,,
"['Gene expression analysis', 'Pathway analysis', 'Survival analysis']",['Lung cancer'],"['Biomarker discovery', 'Pathway analysis', 'Tumor evolution']",['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal being used in this study. The paper focuses on single-cell RNA sequencing (scRNA-seq) analysis of lung adenocarcinoma patient cohorts to investigate cell-type-specific transcriptomic changes. The methodology described involves clustering, lineage trajectory analysis, transcriptional regulatory network reconstruction, and intercellular communication network analysis, but cBioPortal is not mentioned in the provided text.",[],['Citation only'],"['ATF3', 'ATF4', 'HSF1', 'KLF4', 'NFIC', 'EGFR', 'BRAF', 'ALK', 'ROS1']",['Not specified'],Unclear,low,4.0,40722679,Single-Cell Transcriptomic Analysis Unveils Key Regulators and Signaling Pathways in Lung Adenocarcinoma Progression.,2025,pdf,2025-12-19T03:55:16.492905,,,,
"['Gene expression analysis', 'Other']",['Breast cancer'],"['Drug response/resistance', 'Other']",['Original research'],['Not specified'],"The paper does not explicitly describe using cBioPortal for any analysis. Based on the abstract and introduction provided, this appears to be a mechanistic study investigating how HDAC6 inhibition affects fumarate hydratase (FH) activity and mitochondrial structure in triple-negative breast cancer cells. The study uses experimental techniques including super-resolution microscopy, mass spectrometry, and metabolic labeling, but no mention of cBioPortal usage is evident in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40721560,Inhibition of HDAC6 alters fumarate hydratase activity and mitochondrial structure.,2025,pdf,2025-12-19T03:55:18.283218,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis']",['Leukemia/Lymphoma'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Custom/Private data']","Based on the abstract and introduction provided, the paper appears to cite cBioPortal as a reference or potential data source for analyzing mutations in PHF6 and PHIP in AML patients. The study focuses on experimental characterization of PHF6 and PHIP function using mouse models and cell lines, with cBioPortal likely used to access mutation data or validate clinical relevance of these genes in AML cohorts. Specific details about cBioPortal usage are not provided in the abstract/introduction sections.",[],['Citation only'],"['PHF6', 'PHIP', 'FLT3']",['Not specified'],Unclear,low,4.0,40721297,Leukemia mutated proteins PHF6 and PHIP form a chromatin complex that represses acute myeloid leukemia stemness.,2025,abstract,2025-12-19T03:55:19.099147,,,,
"['Gene expression analysis', 'Other']",['Prostate cancer'],"['Drug response/resistance', 'Precision medicine']",['Original research'],['Not specified'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on a high-throughput drug screen to identify synergistic combinations targeting Bcl-xL and Mcl-1 in AR-V7-expressing CRPC models using cell lines and patient-derived organoids. If cBioPortal was used, it may have been for background research or data mining, but this is not stated in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40704654,Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7-Expressing CRPC Models.,2025,abstract,2025-12-19T03:55:17.332311,,,,
['Other'],['Pan-cancer'],"['Review/Commentary', 'Methods/Tools development', 'Precision medicine']",['Review'],['Not specified'],"This is a review paper about multiplexed assays of variant effect (MAVEs) for clinical variant interpretation. Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in the study. The paper appears to cite cBioPortal as a reference resource in the context of discussing cancer genomics and variant classification, but does not describe any specific analysis or data retrieval from the platform.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40691352,Multiplexed assays of variant effect for clinical variant interpretation.,2025,abstract,2025-12-19T03:55:18.148741,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration', 'Pathway analysis']",['Lung cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract, this study utilized multi-omics data from lung adenocarcinoma (LUAD) to develop a prognostic risk score model. While cBioPortal is cited, the abstract does not provide explicit details about how cBioPortal was used, though it likely served as a source for accessing TCGA or other cancer genomics data. The study appears to have downloaded data for external analysis using machine learning algorithms and multi-omics integration approaches.",[],['Data download/export'],[],['Download data'],External (downloaded data),low,4.0,40681687,Integrative multi-omics and machine learning reveal critical functions of proliferating cells in prognosis and personalized treatment of lung adenocarcinoma.,2025,abstract,2025-12-19T03:55:19.371210,,,,
"['Mutation analysis', 'Tumor evolution']",['Other solid tumor'],"['Tumor evolution', 'Methods/Tools development']",['Original research'],['Multiple sources'],"The paper analyzed sequence data from 2171 samples to study somatic mutations in esophageal squamous-cell carcinoma development. The study employed evolutionary modeling to quantify selection pressures on somatic variants across different stages of esophageal tissue development, from organogenesis to clonal normal epithelium to carcinoma. The specific role of cBioPortal in data acquisition or analysis is not explicitly detailed in the provided abstract and introduction.",[],['Citation only'],"['NOTCH1', 'NOTCH2', 'FAT1', 'TP53', 'RB1']",['Not specified'],Unclear,low,4.0,40667321,Early <i>NOTCH1</i> mutation is positively selected but epistatically suppresses evolution of later esophageal squamous-cell carcinoma drivers.,2025,abstract,2025-12-19T03:55:22.379797,,,,
"['Gene expression analysis', 'Survival analysis']",['Glioma/Brain cancer'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],['TCGA'],"Based on the abstract and introduction provided, the paper appears to cite cBioPortal as a data source for glioblastoma genomic and clinical data, likely from TCGA. The authors probably used cBioPortal to access gene expression data and survival information for GBM patients to support their findings about PGE2 signaling and drug resistance mechanisms. However, specific details about how cBioPortal was used are not provided in the abstract/introduction sections given.",['TCGA-GBM'],['Citation only'],[],['Not specified'],Unclear,low,4.0,40658067,Contribution of Prostaglandin E2-Induced Neuronal Excitation to Drug Resistance in Glioblastoma Countered by a Novel Blood-Brain Barrier Crossing Celecoxib Derivative.,2025,abstract,2025-12-19T03:55:20.112847,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']","['Pan-cancer', 'Breast cancer', 'Gastric cancer']","['Biomarker discovery', 'Immunotherapy', 'Drug response/resistance']",['Original research'],"['TCGA', 'Multiple sources']","The cBioPortal database was used to explore potential MZF1 mutations across different cancer types in this pan-cancer analysis. The study examined MZF1 expression, prognostic value, and its role in the tumor immune microenvironment across multiple cancers. cBioPortal served as one of several databases used to characterize MZF1's molecular alterations in cancer.",[],['Web-based analysis'],['MZF1'],['Query interface'],Mixed,medium,4.0,40655141,"<i>Myeloid Zinc Finger 1</i>: insights into its oncogenic potential, prognostic value, and impact on immune microenvironment across cancers.",2025,pdf,2025-12-19T03:55:20.444744,,,,
"['Gene expression analysis', 'Pathway analysis', 'Survival analysis', 'Multi-omics integration']",['Other solid tumor'],"['Drug response/resistance', 'Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],"The study retrieved primary clinical data from patients from the TCGA database and analyzed it using cBioPortal along with other tools (stitch, string, R, and Python). cBioPortal was used as one of the analysis platforms for examining transcriptomic profiles of different renal cell carcinoma subtypes (tRCC, pRCC, and ccRCC) in the context of curcumin and conventional therapies. The specific features or extent of cBioPortal usage beyond data retrieval and analysis are not detailed in the provided abstract and introduction.","['TCGA-KIRC', 'TCGA-KIRP', 'TCGA-KICH']","['Data download/export', 'Web-based analysis']","['VHL', 'VEGF', 'HIF', 'MET', 'SETD2', 'CDKN2A', 'EGFR', 'NF2', 'TERT', 'TP53', 'SMARCB1', 'FH', 'BAP1', 'ARIDIA', 'TFE3', 'TFEB', 'ADAMTS18']",['Not specified'],Mixed,medium,4.0,40649942,"Comparative Transcriptomics Study of Curcumin and Conventional Therapies in Translocation, Clear Cell, and Papillary Renal Cell Carcinoma Subtypes.",2025,pdf,2025-12-19T03:55:22.383171,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis']",['Lung cancer'],"['Drug response/resistance', 'Biomarker discovery', 'Precision medicine']",['Original research'],['Not specified'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on experimental validation of ARAF p.S214C mutation using engineered cell lines, in vitro and in vivo models, followed by transcriptomics and proteomics analyses. While the paper cites cBioPortal (as indicated by the task description), the specific usage details are not described in the provided text sections.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40647542,Oncogenic Activity and Sorafenib Sensitivity of <i>ARAF</i> p.S214C Mutation in Lung Cancer.,2025,pdf,2025-12-19T03:55:23.158924,,,,
"['Mutation analysis', 'Copy number analysis', 'Survival analysis']","['Breast cancer', 'Lung cancer', 'Prostate cancer', 'Other solid tumor']","['Biomarker discovery', 'Precision medicine', 'Methods/Tools development']","['Original research', 'Clinical study']","['MSK-IMPACT', 'Custom/Private data']",cBioPortal was utilized to access and analyze MSK-IMPACT sequencing data from spinal metastases samples collected at Memorial Sloan Kettering Cancer Center. The platform was used to identify consecutive tumor samples from patients with spine metastatic disease that had been profiled by MSK-IMPACT next generation sequencing. The genomic data obtained through cBioPortal was then used to characterize the mutational landscape of spinal metastases and train a machine learning algorithm to stratify patients into high- and low-risk prognostic groups.,['MSK-IMPACT'],"['Data download/export', 'Web-based analysis']","['TP53', 'KEAP1', 'ESR1', 'MET', 'EGFR', 'CDK4']","['Query interface', 'Download data']",Mixed,high,4.0,40647516,Integration of Next Generation Sequencing Data to Inform Survival Prediction of Patients with Spine Metastasis.,2025,pdf,2025-12-19T03:55:23.676926,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],"Based on the abstract and introduction, this paper does not explicitly mention using cBioPortal. The study analyzed TCGA mRNA and miRNA data for pancreatic adenocarcinoma using various tools including TIMER2.0, survival packages, enrichr, multiMiR, CIBERSORT, and ImmuCellAI. While cBioPortal is cited (as indicated by the task context), there is no clear description of how it was used in the methodology described in the provided text.",['TCGA-PAAD'],['Citation only'],"['ENHO', 'PDCD1', 'LAG3', 'CD70', 'NT5E']",['Not specified'],Unclear,low,4.0,40647442,The Role of ENHO in Pancreatic Adenocarcinoma: A Bioinformatics Approach.,2025,pdf,2025-12-19T03:55:24.771958,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],"The study integrated data from the TCGA-LIHC cohort to identify translatable lncRNAs associated with hepatocellular carcinoma (HCC). The authors used TCGA data to analyze the expression patterns and clinical associations of ASH1L-AS1, including its relationship with disease progression, prognosis, immunosuppressive tumor microenvironment, and RAS mutation status. The analysis appears to have been performed using downloaded TCGA data rather than directly on the cBioPortal platform.",['TCGA-LIHC'],['Data download/export'],"['ASH1L-AS1', 'MAPK3', 'MAPK1', 'RAS']",['Download data'],External (downloaded data),medium,4.0,40646641,Non-canonical activation of MAPK signaling by the lncRNA ASH1L-AS1-encoded microprotein APPLE through inhibition of PP1/PP2A-mediated ERK1/2 dephosphorylation in hepatocellular carcinoma.,2025,pdf,2025-12-19T03:55:25.734850,,,,
"['Mutation analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Melanoma'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine', 'Methods/Tools development']","['Original research', 'Methods/Software']","['Multiple sources', 'Custom/Private data']","The paper does not explicitly describe using cBioPortal for data access or analysis. The study collected data from four independent cohorts of melanoma patients with pre-treatment whole or partial tumor exome sequencing data into their own database (MelanoDB). While cBioPortal is cited, there is no clear indication in the provided text that the authors directly used cBioPortal's platform, downloaded data from it, or accessed it via API for their machine learning analysis.",[],['Citation only'],"['BRAF', 'TERT', 'PTEN']",['Not specified'],Unclear,low,4.0,40634697,Improved prediction of MAPKi response duration in melanoma patients using genomic data and machine learning.,2025,pdf,2025-12-19T03:55:26.829675,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Leukemia/Lymphoma'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal being used in this study. The paper focuses on analyzing multiomic data from ETV6::RUNX1 leukemia patients using whole genome sequencing, targeted DNA sequencing, transcriptome sequencing, and array-based copy number analysis. The citation of cBioPortal may be in the references for context or comparison purposes, but no specific usage is described in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40634509,Genomic determinants of therapy response in ETV6::RUNX1 leukemia.,2025,pdf,2025-12-19T03:55:26.634607,,,,
['Mutation analysis'],"['Lung cancer', 'Colorectal cancer', 'Pan-cancer']","['Drug response/resistance', 'Precision medicine']",['Original research'],['Not specified'],"The paper mentions K-Ras(G13C) mutations being particularly abundant in lung, colorectal, and pancreatic cancer, which suggests potential use of cBioPortal or similar databases for mutation frequency information. However, the abstract and introduction do not explicitly describe how cBioPortal was used in this study. The paper appears to be primarily focused on drug development and testing of covalent inhibitors targeting K-Ras(G13C) in cancer cell lines.",[],['Citation only'],['KRAS'],['Not specified'],"[""Unclear""]",low,4.0,40629868,Distal Covalent Targeting Suppresses Signaling of Oncogenic K-Ras(G13C) in Cancer Cells.,2025,abstract,2025-12-19T03:55:26.364251,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis']",['Other solid tumor'],"['Drug response/resistance', 'Precision medicine', 'Biomarker discovery']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, the paper appears to use cBioPortal for accessing genomic data related to ovarian cancer, likely including mutation and expression data from TCGA or other databases. The functional modeling approach integrating drug screening with signaling assessment suggests they may have queried genomic alterations in ovarian tumors. However, specific details about cBioPortal usage are not explicitly mentioned in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40628262,Unlocking the therapeutic potential of rigosertib as a selective therapy for ovarian cancer.,2025,abstract,2025-12-19T03:55:27.027589,,,,
['Mutation analysis'],['Colorectal cancer'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"The paper cites cBioPortal but does not provide explicit details about how it was used in the study. Based on the abstract and introduction, the study focuses on whole exome sequencing of indigenous African patients with early-onset colorectal cancer, but specific cBioPortal usage for data comparison or analysis is not described in the provided text. The citation appears to be for reference purposes or potentially for comparative analysis with public datasets, but the exact usage is not specified.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40627234,High burden of variants of uncertain significance in early-onset colorectal cancer among indigenous African patients: a call for global research equity in cancer genetics.,2025,abstract,2025-12-19T03:55:28.081069,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis']",['Other solid tumor'],['Biomarker discovery'],['Original research'],['Custom/Private data'],"The paper does not explicitly describe using cBioPortal in their methodology. The study focuses on immunohistochemistry analysis of KDM6A expression in a tissue microarray of over 2,500 bladder tumors, with sequencing performed on 78 cases. While the paper mentions that KDM6A mutations occur in 30-52% of pTa and 23-25% of pT2-4 cancers based on literature, there is no clear indication that cBioPortal was directly used for data analysis or visualization in this study.",[],['Citation only'],['KDM6A'],['Not specified'],Unclear,low,4.0,40626673,KDM6A expression loss is frequent in low grade non-invasive urothelial carcinomas of the urinary bladder.,2025,pdf,2025-12-19T03:55:29.957356,,,,
"['Gene expression analysis', 'Mutation analysis']","['Lung cancer', 'Other solid tumor']","['Biomarker discovery', 'Other']",['Original research'],['TCGA'],cBioPortal was used to query TCGA datasets to examine the expression and mutation status of RNPC3 and other minor spliceosome components across different cancer types. The authors likely used cBioPortal to access TCGA data to support their hypothesis that minor splicing components represent a vulnerability in cancer cells. The specific usage details are limited in the abstract/introduction provided.,[],['Citation only'],"['RNPC3', 'TP53']",['Not specified'],Unclear,low,4.0,40624356,Inhibition of the minor spliceosome restricts the growth of a broad spectrum of cancers.,2025,abstract,2025-12-19T03:55:28.693250,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Melanoma'],"['Drug response/resistance', 'Database/Resource', 'Biomarker discovery']","['Methods/Software', 'Original research']","['TCGA', 'Multiple sources', 'Custom/Private data']","This paper mentions TCGA_SKCM (The Cancer Genome Atlas skin cutaneous melanoma cohort) as a reference dataset that includes genomic, epigenomic, transcriptomic and proteomic data from treatment-naive samples. However, the authors note that TCGA_SKCM lacks detailed treatment information and does not allow selecting patients who received MAPK inhibitors, which motivated the creation of their MelanoDB dataset. cBioPortal is not explicitly mentioned as being used for data access or analysis in this study.",['TCGA_SKCM'],['Citation only'],['BRAF'],['Not specified'],Unclear,low,4.0,40615439,MelanoDB: A dataset of clinical and molecular features of patients with advanced melanoma treated with MAPK inhibitors.,2025,pdf,2025-12-19T03:55:31.208237,,,,
"['Gene expression analysis', 'Other']",['Breast cancer'],"['Biomarker discovery', 'Other']",['Original research'],"['TCGA', 'Not specified']","Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in the paper. The study focuses on biochemical validation of NSUN6-mediated m5C modification on mRNAs and its role in breast cancer cell migration. If cBioPortal was used, it was likely for accessing TCGA data or validating gene expression patterns, but this is not clearly stated in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40615396,A cohort of mRNAs undergo high-stoichiometry NSUN6-mediated site-specific m<sup>5</sup>C modification.,2025,pdf,2025-12-19T03:55:30.470477,,,,
"['Mutation analysis', 'Gene expression analysis']",['Glioma/Brain cancer'],"['Review/Commentary', 'Biomarker discovery']",['Review'],"['TCGA', 'MSK-IMPACT']","The authors used cBioPortal to perform a comprehensive analysis of structural alterations in small GTPase genes in glioma patients. They queried data from two specific datasets: ""Glioma (MSK, Clin Cancer Res 2019)"" and ""Merged Cohort of LGG and GBM (TCGA, Cell 2016)"" to investigate the incidence of changes in small GTPase gene structure. The results demonstrated that structural alterations in small GTPase genes are relatively rare in glioma, supporting their focus on epigenetic regulation rather than genetic mutations.","['Glioma (MSK, Clin Cancer Res 2019)', 'Merged Cohort of LGG and GBM (TCGA, Cell 2016)']","['Web-based analysis', 'Web-based visualization']",[],['Query interface'],cBioPortal platform,high,4.0,40613212,The role of abnormal epigenetic regulation of small GTPases in glioma (Review).,2025,pdf,2025-12-19T03:55:31.979596,,,,
"['Mutation analysis', 'Copy number analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],['Custom/Private data'],"The study used cBioPortal to assess samples from the Guardant360 database (17,622 samples collected between October 2020 and December 2022). The platform was used to analyze demographics (sex and age) and to assess PIK3CA mutation frequency and distribution in advanced colorectal cancer patients using plasma-based ctDNA profiling.",['Guardant360'],['Web-based analysis'],"['PIK3CA', 'APC', 'BRAF', 'EGFR', 'ERBB2', 'KRAS']",['Query interface'],cBioPortal platform,high,4.0,40610594,Comprehensive analysis of PIK3CA mutations in advanced colorectal cancer using circulating tumor DNA profiling.,2025,pdf,2025-12-19T03:55:33.945882,,,,
['Mutation analysis'],['Colorectal cancer'],['Biomarker discovery'],['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper describes a retrospective analysis of 159 colon resection cases where DNA mutations were analyzed by next-generation sequencing (NGS) at their own institution between 2019 and 2023. The study compares somatic mutations and clinicopathologic features between micropapillary and non-micropapillary colorectal carcinomas using their own institutional data. cBioPortal may only be cited in the references without actual usage in the methodology.",[],['Citation only'],"['TP53', 'KRAS', 'PIK3CA', 'BRCA2', 'ERBB2', 'BRAF', 'MAP2K1']",['Not specified'],Unclear,low,4.0,40598036,Comparison of somatic mutations and clinicopathologic features of micropapillary and non-micropapillary colorectal carcinomas.,2025,pdf,2025-12-19T03:55:34.797083,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Lung cancer']","['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The study conducted a comprehensive pan-cancer analysis of ASCC1/2/3 genes across 10,967 tumor samples from 30 cancer types. cBioPortal was likely used to query mutation frequencies, copy number alterations, and expression data for the ASCC family genes across multiple TCGA cancer types. The analysis identified that alterations in ASCC1/2/3 occurred in 754 cases (7% of patients), with ASCC3 being most frequently altered at 4%.",['TCGA'],"['Web-based analysis', 'Web-based visualization', 'Data download/export']","['ASCC1', 'ASCC2', 'ASCC3', 'TRIP4']","['Query interface', 'Expression analysis', 'Download data']",Mixed,medium,4.0,40594069,Pan-cancer analysis reveals ASCC family promotes the cancer progression of lung adenocarcinoma.,2025,pdf,2025-12-19T03:55:34.986849,,,,
"['Gene expression analysis', 'Survival analysis']",['Pan-cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['Not specified'],"The paper examined FOXK1 and FOXK2 mRNA expression levels in normal and cancer tissues, noting higher expression trends in tumors. The authors analyzed the correlation between high FOXK1 expression and patient survival outcomes across different cancer types, finding that high FOXK1 levels were associated with poor survival. The specific platform or method used to access this data is not explicitly mentioned in the provided text.",[],['Citation only'],"['FOXK1', 'FOXK2']",['Not specified'],Unclear,low,4.0,40593803,O-GlcNAcylation of FOXK1 co-opts BAP1 to orchestrate the E2F pathway and promotes oncogenesis.,2025,pdf,2025-12-19T03:55:34.272560,,,,
"['Gene expression analysis', 'Pathway analysis']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],"Based on the abstract and introduction provided, the paper does not explicitly describe how cBioPortal was used. The study focuses on experimental work using mouse astrocytoma cell lines (CT2A, KR158, DBT, DBT-Erp-29) to investigate Connexin43's role in glioblastoma. cBioPortal appears to be cited but specific usage details are not mentioned in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40591997,Connexin43 functions as a non-canonical phenotypic stability factor in promoting hybrid Epithelial/Mesenchymal phenotype in glioblastoma cells.,2025,abstract,2025-12-19T03:55:33.232183,,,,
['Mutation analysis'],['Other solid tumor'],"['Drug response/resistance', 'Methods/Tools development']",['Original research'],['Not specified'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. This appears to be a chemical biology/drug discovery paper focused on developing covalent inhibitors targeting K-Ras(G12D) mutations in pancreatic cancer. The paper describes the synthesis and testing of α-diazoacetamide compounds and their effects on KRAS-mutant cancer cell lines, but does not reference cBioPortal for data analysis or visualization.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40587607,Denitrogenative Alkylation of K-Ras(G12D) Inhibits Oncogenic Signaling in Cancer Cells.,2025,abstract,2025-12-19T03:55:33.870519,,,,
['Mutation analysis'],['Colorectal cancer'],['Biomarker discovery'],['Original research'],['Custom/Private data'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper describes a retrospective analysis of 159 colon resection cases where DNA mutations were analyzed by next-generation sequencing (NGS), comparing serrated adenocarcinomas (SACs) with non-serrated adenocarcinomas. The study appears to use institutional/custom data analyzed with NGS. cBioPortal may only be cited in references or used minimally without clear description in the provided text.",[],['Citation only'],"['TP53', 'KRAS', 'PIK3CA', 'BRAF']",['Not specified'],Unclear,low,4.0,40572720,Do Colorectal Serrated and Non-Serrated Adenocarcinomas Differ in Somatic Mutations and Clinicopathologic Features?,2025,pdf,2025-12-19T03:55:36.243944,,,,
"['Gene expression analysis', 'Other']",['Other solid tumor'],"['Biomarker discovery', 'Other']",['Original research'],['Not specified'],"This paper does not appear to directly use cBioPortal for any analysis. The study focuses on Drosophila eye development and the role of miR-137 in regulating Myc expression using genetic screens and model organisms. While the paper discusses Myc as an oncogene and mentions a tumor model (RasV12;scribRNAi), there is no explicit mention of cBioPortal usage, data download, or analysis in the provided abstract and introduction.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40554764,miR-137 targets Myc to regulate growth during eye development.,2025,abstract,2025-12-19T03:55:36.945576,,,,
"['Copy number analysis', 'Gene expression analysis', 'Survival analysis']",['Prostate cancer'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The research appears to be based on a large tissue microarray analysis (17,747 samples) using immunohistochemistry and fluorescence in situ hybridization performed by the authors. If cBioPortal was cited in the full paper, it was likely for reference purposes only or for validation/comparison of findings, but this is not evident from the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40554389,Prognostic role of high MTAP expression is reversed by the ERG status in prostate cancer treated by radical prostatectomy.,2025,abstract,2025-12-19T03:55:37.355517,,,,
"['Gene expression analysis', 'Survival analysis']",['Leukemia/Lymphoma'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],['TCGA'],The study used cBioPortal to analyze SLFN11 expression levels and their correlation with overall survival in AML patients. The authors accessed TCGA-LAML (acute myeloid leukemia) data through cBioPortal to examine the prognostic significance of SLFN11 expression. This analysis demonstrated that low SLFN11 expression correlates with poor overall survival and worse prognosis in AML patients.,['TCGA-LAML'],"['Web-based analysis', 'Web-based visualization']",['SLFN11'],"['Expression analysis', 'Survival analysis']",cBioPortal platform,high,4.0,40552140,Targeting SLFN11-regulated pathways restores chemotherapy sensitivity in AML.,2024,abstract,2025-12-19T03:55:37.320832,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Pathway analysis', 'Immunotherapy']",['Original research'],['Multiple sources'],"The paper mentions using multiple bioinformatics databases including Kaplan-Meier plotter and TIMER2.0 to assess RSU1 expression and prognosis in colorectal cancer. While cBioPortal is cited, the abstract and introduction do not explicitly describe specific cBioPortal usage, features, or datasets. The primary analyses appear to have been conducted using other named databases (Kaplan-Meier plotter, TIMER2.0) along with in vitro experiments.",[],['Citation only'],['RSU1'],['Not specified'],Unclear,low,4.0,40544194,RSU1 Mediates Caco-2 Colorectal Cancer Cells Proliferation and Migration via PI3K/AKT Signaling Pathway.,2025,abstract,2025-12-19T03:55:39.048755,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis', 'Precision medicine']",['Original research'],['Multiple sources'],"The authors queried cBioPortal to analyze the DNA landscape of CIC::DUX4 sarcomas (CDS) in the largest cohort to date, including 39 unique CDS patients out of 28,636 total sarcoma patients. They identified pathogenic secondary genomic variants and compared the frequency of secondary variants in CDS to other small blue round cell tumors and translocation-associated sarcomas. The study also performed transcriptomic analysis across multiple datasets to identify CDS-specific gene expression signatures.",[],"['Data download/export', 'Web-based analysis']","['ARID1A', 'POLE', 'ETV1', 'ETV4', 'ETV5', 'DUSP4', 'IGF2', 'DKK1', 'MKI67', 'BCL2']","['Query interface', 'Download data', 'Group comparison']",Mixed,high,4.0,40542203,Upregulation of POLE and proficient DNA repair are features of CIC::DUX4 sarcomas.,2025,pdf,2025-12-19T03:55:40.435958,,,,
"['Mutation analysis', 'Pathway analysis']",['Colorectal cancer'],"['Review/Commentary', 'Biomarker discovery', 'Precision medicine']",['Review'],['Not specified'],"This is a review paper focusing on p53 in colorectal cancer. The paper mentions that TP53 mutations are detected in approximately 74% of CRC cases, but does not explicitly describe any direct usage of cBioPortal for data analysis or visualization. cBioPortal appears to be cited only as a reference or general resource rather than being actively used for analysis in this review.",[],['Citation only'],"['TP53', 'KRAS', 'APC']",['Not specified'],Unclear,low,4.0,40537809,p53 in colorectal cancer: from a master player to a privileged therapy target.,2025,pdf,2025-12-19T03:55:39.887393,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Multi-omics integration']","['Pan-cancer', 'Liver cancer']","['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this paper. The study uses publicly available databases including TCGA, GTEx, TIMER2.0, HPA, and TISIDB to analyze DBF4B expression, prognosis, immune infiltration, methylation, and drug sensitivity across pan-cancer. While cBioPortal may be cited in the references, the specific usage is not described in the provided text.",['TCGA'],['Citation only'],"['DBF4B', 'CDC7', 'SRSF1', 'DBF4']",['Not specified'],Unclear,low,4.0,40535802,Pan-cancer analysis identifies DBF4B as an immunologic and prognostic biomarker.,2025,pdf,2025-12-19T03:55:40.442441,,,,
"['Gene expression analysis', 'Other']",['Pan-cancer'],['Other'],['Original research'],['TCGA'],"Based on the abstract and introduction provided, the paper focuses on ZC3H4's role in maintaining genome integrity through suppression of noncoding RNA production and prevention of transcription-replication conflicts. While the paper appears to use bioinformatic analysis, the specific usage of cBioPortal is not explicitly described in the provided text. The paper likely used cBioPortal for accessing cancer genomics data, potentially for expression analysis or genomic feature analysis, but the exact usage mode and features cannot be determined from the abstract and introduction alone.",[],['Citation only'],['ZC3H4'],['Not specified'],Unclear,low,4.0,40531993,ZC3H4 safeguards genome integrity by preventing transcription-replication conflicts at noncoding RNA loci.,2025,abstract,2025-12-19T03:55:40.646310,,,,
['Other'],['Pan-cancer'],"['Methods/Tools development', 'Precision medicine']","['Methods/Software', 'Original research']",['Not specified'],"Based on the provided abstract and introduction, cBioPortal is not explicitly mentioned or described as being used in this study. The paper focuses on developing MONOCLE, a web application for molecular tumor board (MTB) documentation and workflow optimization at the University Medical Center Hamburg-Eppendorf. The paper appears to cite cBioPortal in references but does not describe specific usage of the platform for data analysis or visualization.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40526350,Streamlining and Accelerating the Molecular Tumor Board Process at the University Medical Center Hamburg-Eppendorf.,2025,pdf,2025-12-19T03:55:40.255095,,,,
"['Gene expression analysis', 'Survival analysis', 'Copy number analysis', 'Mutation analysis']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']",The paper used cBioPortal to analyze genetic alterations in the DCAF5 gene across multiple cancer types. The analysis identified gene amplification as the predominant form of genetic aberration affecting DCAF5. The specific methodology and extent of cBioPortal usage beyond genetic alteration analysis is not detailed in the provided abstract and introduction.,[],"['Web-based analysis', 'Web-based visualization']","['DCAF5', 'SMARCB1']",['Not specified'],Unclear,low,4.0,40522583,Identification of DCAF5 as a novel cancer prognostic and immunotherapy biomarker through pan-cancer analysis and renal clear cell carcinoma clinical data validation.,2025,pdf,2025-12-19T03:55:42.034931,,,,
['Other'],['Not specified'],['Other'],['Original research'],['Not specified'],"This paper does not appear to use cBioPortal. The study focuses on investigating the transmembrane domain of oxidized low-density lipoprotein receptor 1 (OLR1) through in vitro experiments using cell culture models, site-directed mutagenesis, and immunoprecipitation-mass spectrometry. The research is focused on signal transduction mechanisms related to oxidized LDL and its receptor, not cancer genomics analysis.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40518921,Mutation within the transmembrane domain of oxidized low-density lipoprotein receptor 1 influences oxidized low-density lipoprotein-induced signal transduction.,2025,abstract,2025-12-19T03:55:43.218430,,,,
"['Gene expression analysis', 'Survival analysis']",['Pan-cancer'],['Biomarker discovery'],['Original research'],['Custom/Private data'],"This paper does not appear to use cBioPortal at all. The study is based entirely on immunohistochemistry (IHC) analysis of tissue microarrays (TMAs) containing over 18,000 samples from 154 tumor types to evaluate HMGA2 protein expression. No mention of cBioPortal is found in the provided abstract and introduction sections.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40518465,High mobility group protein 2 (HMGA2) is highly expressed in a broad range of benign and malignant tumors.,2025,pdf,2025-12-19T03:55:43.556921,,,,
['Mutation analysis'],['Pan-cancer'],"['Review/Commentary', 'Drug response/resistance', 'Pathway analysis']",['Review'],['MSK-IMPACT'],cBioPortal was used to generate a lollipop plot visualization showing p53 mutation distribution across the protein structure using the MSK-CHORD dataset. The visualization demonstrates that p53 mutations primarily occur in the DNA binding domain and are enriched at specific hotspots (such as arginine 175 and arginine 273). This figure was used to illustrate the distribution and frequency of p53 mutations in cancer as part of the review's discussion of p53-mutant cancers.,['MSK-CHORD'],['Web-based visualization'],['TP53'],['Mutation Mapper'],cBioPortal platform,high,4.0,40517236,Bypassing the guardian: regulated cell death pathways in p53-mutant cancers.,2025,pdf,2025-12-19T03:55:43.452692,,,,
['Gene expression analysis'],['Prostate cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],"Based on the abstract and introduction provided, the paper appears to cite cBioPortal but does not provide explicit details about how it was used in the study. The research focuses on experimental investigation of the NF-κB-PLAC8-BCL-xL axis in cadmium-induced prostate carcinogenesis using cell lines and xenograft models. If cBioPortal was used, it was likely for querying gene expression data from TCGA prostate cancer datasets to validate findings, but specific usage details are not mentioned in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40512859,Interaction between NF-κB and PLAC8 impairs autophagy providing a survival advantage to prostate cells transformed by cadmium.,2025,abstract,2025-12-19T03:55:45.018507,,,,
"['Mutation analysis', 'Other']",['Other solid tumor'],"['Biomarker discovery', 'Methods/Tools development']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on comparing tumor-informed (mutation tracking via WES) and tumor-type informed (DNA methylation) approaches for ctDNA detection in epithelial ovarian cancer patients. The study appears to use custom patient samples and does not reference cBioPortal data or tools in the sections provided.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40506726,Improved tumor-type informed compared to tumor-informed mutation tracking for ctDNA detection and microscopic residual disease assessment in epithelial ovarian cancer.,2025,pdf,2025-12-19T03:55:45.780356,,,,
"['Mutation analysis', 'Copy number analysis', 'Survival analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis', 'Precision medicine']",['Original research'],"['TCGA', 'GENIE', 'METABRIC', 'Multiple sources']","The authors used cBioPortal to query and analyze EGFR amplification and PI3K pathway mutations across multiple breast cancer datasets including TCGA, METABRIC, and GENIE. They identified the frequency of EGFR amplification (1-5% of breast cancer patients) and co-occurrence with PI3K pathway mutations (up to 71% of EGFR amplified tumors). Survival analysis was performed to demonstrate that EGFR amplified patients have shorter overall survival compared to unamplified patients.","['TCGA', 'METABRIC', 'GENIE']","['Web-based analysis', 'Web-based visualization']","['EGFR', 'PIK3CA', 'PTEN', 'AKT']","['Query interface', 'Survival analysis', 'OncoPrint']",cBioPortal platform,high,4.0,40501689,EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition.,2025,abstract,2025-12-19T03:55:47.076891,,,,
"['Survival analysis', 'Other']",['Other solid tumor'],"['Clinical study', 'Other']","['Original research', 'Clinical study']",['Not specified'],"This paper does not appear to use cBioPortal at all. It is a clinical study examining the use and utility of an Endocrine Multidisciplinary Tumour Board (EMTB) at a tertiary care center in Florence, Italy. The study retrospectively analyzed 1038 cases discussed at the EMTB from 2021-2023, focusing on thyroid, adrenal, and rare endocrine neoplasms, and evaluated outcomes including survival for anaplastic thyroid carcinoma and adrenocortical carcinoma. There is no mention of cBioPortal in the abstract or introduction provided.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40496560,Use and utility of endocrine multidisciplinary tumour board: an appraisal from a tertiary centre.,2025,pdf,2025-12-19T03:55:46.711415,,,,
"['Gene expression analysis', 'Other']",['Lung cancer'],"['Drug response/resistance', 'Methods/Tools development']",['Original research'],['TCGA'],"Based on the abstract and introduction provided, the paper appears to focus on developing a novel CMA inhibitor (CIM7) for NSCLC treatment. While cBioPortal is cited, the specific usage details are not explicitly described in the provided text. The study likely used cBioPortal to access TCGA data for gene expression analysis related to RARα, NCoR1, or CMA-related genes in lung cancer, but the exact methodology is not detailed in the excerpts provided.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40490560,Small molecule disruption of RARα/NCoR1 interaction inhibits chaperone-mediated autophagy in cancer.,2025,abstract,2025-12-19T03:55:46.020179,,,,
"['Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],"The study used cBioPortal to analyze the PIWI pathway in colon cancer through Shifted Weighted Annotation Network (SWAN) analysis, which revealed significant allelic losses in the pathway. The analysis showed that PIWIL2 experiences the highest percent deletions among PIWI pathway components. The authors also examined PIWIL2 expression levels and their correlation with clinical parameters including tumor stage, nodal metastasis, cancer subtypes, and patient survival outcomes in colon cancer.",['TCGA'],"['Web-based analysis', 'Web-based visualization']",['PIWIL2'],"['Expression analysis', 'Survival analysis', 'Query interface']","[""cBioPortal platform""]",medium,4.0,40475606,PIWIL2 downregulation in colon cancer promotes transposon activity and pro-tumorigenic phenotypes.,2025,abstract,2025-12-19T03:55:47.622839,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],"The study used cBioPortal to perform bioinformatic analysis of The Cancer Genome Atlas (TCGA) dataset to examine YAP1 alterations in head and neck squamous cell carcinoma (HNSCC). The analysis confirmed that YAP1 is frequently altered in HNSCC, supporting the experimental findings about YAP1's role in oral squamous cell carcinoma carcinogenesis. The specific details of how cBioPortal was used (web-based analysis, data download, or specific features) are not explicitly described in the abstract.",['TCGA-HNSCC'],['Web-based analysis'],['YAP1'],['Not specified'],Unclear,medium,4.0,40464850,Waterpipe smoke condensate activates the oncogenes and promotes epithelial-mesenchymal transition to cause oral cancer.,2025,abstract,2025-12-19T03:55:48.073146,,,,
"['Mutation analysis', 'Survival analysis', 'Gene expression analysis', 'Pathway analysis']",['Lung cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine']","['Original research', 'Clinical study']","['MSK-IMPACT', 'GENIE', 'Multiple sources', 'Custom/Private data']","The authors used cBioPortal to analyze genomic data from 12,862 LUAD patients across four large studies (MSK-CHORD, MSK-IMPACT Clinical Sequencing Cohort, and others mentioned in the abstract). They identified ARID1A mutation as a potential prognostic marker in EGFR-mutant LUAD by analyzing mutation and survival data from cBioPortal. The analysis revealed that ARID1A mutation was associated with poor overall survival in EGFR-mutant LUAD patients, with greater prognostic influence than concurrent mutations in TP53, KRAS, CDKN2A, PIK3CA, RB1, or PTEN.","['MSK-CHORD', 'MSK-IMPACT Clinical Sequencing Cohort']","['Web-based analysis', 'Web-based visualization']","['ARID1A', 'EGFR', 'TP53', 'KRAS', 'CDKN2A', 'PIK3CA', 'RB1', 'PTEN']","['Survival analysis', 'Query interface']",cBioPortal platform,high,4.0,40463905,ARID1A deficiency attenuates the response to EGFR-TKI treatment in lung adenocarcinoma.,2025,pdf,2025-12-19T03:55:51.049261,,,,
"['Copy number analysis', 'Mutation analysis']",['Prostate cancer'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],['Multiple sources'],"cBioPortal was used to analyze copy number alterations in DNA prereplication complex genes in castration-resistant prostate cancer (CRPC) tumors. The authors found that approximately 50% of CRPC tumors have copy number loss of pre-RC complex genes, particularly CDT1. This analysis provided clinical context for their experimental findings on PARP inhibitor resistance mechanisms.",[],['Web-based analysis'],"['CDT1', 'CDC6', 'DBF4']",['Query interface'],cBioPortal platform,medium,4.0,40460119,BRCA2 reversion mutation-independent resistance to PARP inhibition through impaired DNA prereplication complex function.,2025,abstract,2025-12-19T03:55:49.440997,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']","['Pan-cancer', 'Glioma/Brain cancer', 'Breast cancer', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used as part of a pan-cancer bioinformatics analysis to assess GABRP expression patterns, survival associations, and immune infiltration across 33 cancer types. The platform was mentioned alongside TCGA and GEPIA2 as one of the data sources/tools used for the comprehensive genomic and clinical analysis. The specific features used and whether data was downloaded or analyzed on the platform are not explicitly detailed in the abstract.",[],['Web-based analysis'],['GABRP'],"['Expression analysis', 'Survival analysis']",Unclear,medium,4.0,40459297,GABRP Mediates GABA-A Receptor to Shape Tumor Immunosuppressive Microenvironment and Promote Tumor Immune Escape and Corresponding Targeted Therapy.,2025,abstract,2025-12-19T03:55:50.094165,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The paper mentions using cBioPortal as one of the data sources for obtaining RNA sequencing data from TCGA database for 33 cancer types, with primary focus on bladder cancer (BLCA). However, the abstract and introduction do not provide specific details about how cBioPortal was used for analysis or visualization. The usage appears to be primarily for data access from TCGA rather than using cBioPortal's analytical features.",['TCGA'],['Citation only'],['CXCL12'],['Not specified'],Unclear,low,4.0,40447619,CXCL12 links bladder cancer and diabetes as a potential biomarker.,2025,pdf,2025-12-19T03:55:50.932706,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['Multiple sources'],"cBioPortal was used to retrieve information about genetic variants in the HECW1 gene in gastric cancer. The study mentions that ""The cBioPortal retrieved information about genetic variants in HECW1 gene"" as part of their bioinformatics analysis approach. However, the abstract and introduction do not provide detailed information about specific datasets queried, analysis features used, or whether data was downloaded for external analysis.",[],['Web-based analysis'],['HECW1'],['Query interface'],Unclear,medium,4.0,40442732,High expression of HECW1 is associated with the poor prognosis and cancer progression of gastric cancer.,2025,pdf,2025-12-19T03:55:51.829582,,,,
"['Mutation analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the abstract or introduction provided. However, given that the study extracted data from public databases and analyzed TCGA data for immune infiltration analysis, cBioPortal may have been used as one of the data sources for accessing cancer genomics data. The specific usage details, if any, would need to be confirmed from the methods section of the full paper.",['TCGA'],['Citation only'],"['TP53', 'ATM']",['Not specified'],Unclear,low,4.0,40440584,Synthetic Lethal Co-Mutations in DNA Damage Response Pathways Predict Response to Immunotherapy in Pan-Cancer.,2025,abstract,2025-12-19T03:55:51.628660,,,,
['Gene expression analysis'],['Other solid tumor'],"['Biomarker discovery', 'Other']",['Original research'],['Custom/Private data'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on single cell RNA sequencing of mesenchymal stem/stromal cells isolated from papillary thyroid cancer and normal thyroid tissue. The study appears to use custom patient-derived samples and does not describe accessing or analyzing data through cBioPortal. If cBioPortal is mentioned, it may only be in the references or methods section not provided here.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40430098,Single Cell RNA Sequencing of Papillary Cancer Mesenchymal Stem/Stromal Cells Reveals a Transcriptional Profile That Supports a Role for These Cells in Cancer Progression.,2025,pdf,2025-12-19T03:55:52.673013,,,,
['Other'],['Other solid tumor'],['Methods/Tools development'],"['Methods/Software', 'Original research']",['Custom/Private data'],"This paper does not actually use cBioPortal for any analysis. The paper focuses on developing a large language model (LLM) pipeline for extracting structured information from pathology reports, specifically kidney tumor reports. cBioPortal is only mentioned in passing as a potential downstream application or data source, but is not utilized in the methodology or analysis presented in this study.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40410408,Iterative refinement and goal articulation to optimize large language models for clinical information extraction.,2025,pdf,2025-12-19T03:55:53.260743,,,,
"['Gene expression analysis', 'Survival analysis']",['Breast cancer'],"['Biomarker discovery', 'Other']",['Original research'],"['TCGA', 'METABRIC']",The paper used cBioPortal to analyze clinical data and examine correlations between gene expression and patient outcomes in breast cancer. Bioinformatics analysis of clinical data was mentioned as part of their methods to explore LMTK3-dependent effects on the tumor immune microenvironment. The specific details of cBioPortal usage are not extensively described in the provided abstract and introduction sections.,"['TCGA', 'METABRIC']",['Web-based analysis'],"['LMTK3', 'PSAT1', 'PHGDH']","['Expression analysis', 'Survival analysis']",Unclear,medium,4.0,40405280,LMTK3 regulation of EV biogenesis and cargo sorting promotes tumour growth by reducing monocyte infiltration and driving pro-tumourigenic macrophage polarisation in breast cancer.,2025,pdf,2025-12-19T03:55:54.003556,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Lung cancer'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal. The study utilized TCGA, GEO, CPTAC, and HPA databases to analyze HDAC6 expression, prognosis, and immune microenvironment in lung adenocarcinoma. While TCGA data was used extensively, there is no specific mention of accessing this data through cBioPortal or using any cBioPortal-specific features or tools.","['TCGA-LUAD', 'GSE27262', 'GSE75027', 'GSE19188', 'GSE68465', 'GSE31210']",['Citation only'],['HDAC6'],['Not specified'],Unclear,low,4.0,40404897,HDAC6 facilitates LUAD progression by inducing EMT and enhancing macrophage polarization towards the M2 phenotype.,2025,pdf,2025-12-19T03:55:54.575988,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis']",['Prostate cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine']","['Clinical study', 'Original research']",['Custom/Private data'],"This case report does not explicitly describe using cBioPortal for any analysis. The paper focuses on a single patient case with metastatic castration-resistant prostate cancer who developed resistance to PARP inhibition. Next-generation sequencing was performed using the Tempus platform (xG, xT, and xF+ panels) to identify germline and somatic mutations, including PPM1D as a potential resistance mechanism. No mention of cBioPortal usage is found in the abstract, introduction, or methods sections provided.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40400994,"Next-generation sequencing identifies the presence of protein phosphatase 1D, PPM1D, as a potential biomarker of resistance to PARP inhibition in metastatic castration-resistant prostate cancer.",2025,pdf,2025-12-19T03:55:55.752090,,,,
['Mutation analysis'],['Breast cancer'],"['Biomarker discovery', 'Methods/Tools development']",['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The research focuses on extracting and testing genomic DNA from FFPE breast cancer tissue samples from Trinidad and Tobago for the BRCA1-185delAG mutation using PCR and Sanger sequencing. If cBioPortal is cited in this paper, it appears to be a reference citation only without direct usage in the methodology or analysis.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40395657,Genetic screening of FFPE breast cancer biopsies for the <i>BRCA1</i>-185delAG mutation in Trinidad and Tobago.,2025,abstract,2025-12-19T03:55:56.628245,,,,
"['Gene expression analysis', 'Survival analysis']",['Breast cancer'],"['Biomarker discovery', 'Immunotherapy', 'Drug response/resistance']",['Original research'],"['TCGA', 'Custom/Private data']",The paper used cBioPortal to analyze MerTK expression and PD-L1 expression in TCGA breast cancer datasets. The authors queried gene expression data to examine the relationship between MerTK and PD-L1 expression levels in triple-negative breast cancer samples. This analysis was used to support their in vivo findings that tumor-bound MerTK expression is independent of PD-L1 expression in TNBC.,['TCGA'],"['Web-based analysis', 'Web-based visualization']","['MERTK', 'CD274']","['Expression analysis', 'Query interface']",cBioPortal platform,medium,4.0,40391157,Tumor-associated MerTK promotes a pro-inflammatory microenvironment and enhances immune checkpoint inhibitor response in triple-negative breast cancer.,2025,pdf,2025-12-19T03:55:57.383869,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],"cBioPortal was used to obtain GBM subtype classification data for samples from the TCGA-GBM project. The database was accessed to retrieve subtype information that complemented the RNA-Seq data downloaded from TCGA through the GDC Data Portal. This represents a limited, data retrieval use of cBioPortal rather than extensive analysis on the platform.","['TCGA-GBM', 'TCGA-LGG']",['Data download/export'],[],['Download data'],External (downloaded data),high,4.0,40389618,Human endogenous retroviruses (HERVs) associated with glioblastoma risk and prognosis.,2025,pdf,2025-12-19T03:55:57.206036,,,,
"['Multi-omics integration', 'Other']",['Lung cancer'],"['Methods/Tools development', 'Database/Resource']",['Methods/Software'],['TCGA'],"cBioPortal is mentioned in the introduction as a valuable platform that facilitates the visualization of TCGA studies and additional cancer genomic data. However, the paper does not describe any actual use of cBioPortal in their methodology or analysis. The paper focuses on developing a tool (TCGADownloadHelper) to simplify downloading and preprocessing TCGA data directly from the GDC portal, not from cBioPortal.","['TCGA-LUAD', 'TCGA-LUSC']",['Citation only'],[],['Not specified'],Unclear,high,4.0,40385985,TCGADownloadHelper: simplifying TCGA data extraction and preprocessing.,2025,pdf,2025-12-19T03:55:57.192418,,,,
"['Mutation analysis', 'Survival analysis', 'Gene expression analysis', 'Pathway analysis']",['Prostate cancer'],"['Biomarker discovery', 'Pathway analysis', 'Immunotherapy', 'Precision medicine']",['Original research'],['Not specified'],"The study used cBioPortal to analyze TP53 mutation prevalence in prostate cancer patients, finding that TP53 mutations were present in 27% of PCa patients. The authors performed survival analysis showing that TP53 mutations were significantly correlated with reduced overall survival (p < 0.001, HR = 1.97) and recurrence-free survival (p = 0.02, HR = 1.62), with the p.R248Q mutation being most prevalent. The analysis also identified immune subtypes and the distribution of TP53 p.R248Q mutations across these subtypes.",[],"['Web-based analysis', 'Web-based visualization']",['TP53'],"['Survival analysis', 'Query interface']",cBioPortal platform,medium,4.0,40384867,Modulating the Immunosuppressive Tumor Microenvironment and Inhibiting Growth in Mutp53-Driven CRPC via STAT3 Pathway Blockade.,2025,pdf,2025-12-19T03:55:57.942705,,,,
"['Gene expression analysis', 'Survival analysis']",['Breast cancer'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],"['TCGA', 'METABRIC']","Based on the abstract and introduction provided, the paper appears to use cBioPortal to access TCGA and/or METABRIC breast cancer datasets for analyzing PAFAH1B1 expression and potentially survival outcomes in triple-negative breast cancer. The specific details of cBioPortal usage are not explicitly described in the provided text, suggesting it was likely used for data access and preliminary analysis of gene expression patterns. The main experimental work appears to be laboratory-based functional studies of PAFAH1B1 in TNBC cell lines.",[],['Citation only'],['PAFAH1B1'],['Not specified'],Unclear,low,4.0,40378956,"The neural stem cell gene PAFAH1B1 controls cell cycle progression, DNA integrity, and paclitaxel sensitivity of triple-negative breast cancer cells.",2025,abstract,2025-12-19T03:55:58.908762,,,,
"['Gene expression analysis', 'Survival analysis']",['Leukemia/Lymphoma'],['Biomarker discovery'],['Original research'],"['TCGA', 'Custom/Private data']","Based on the abstract and introduction provided, the paper appears to focus on GTSF1 expression in cutaneous T-cell lymphoma (CTCL) and its role as a prognostic biomarker. While cBioPortal is cited, the specific usage details are not explicitly described in the provided text. The study likely used cBioPortal to access TCGA data for gene expression and survival analysis related to GTSF1 in lymphoma patients, but the exact methodology is not clear from the abstract alone.",[],['Citation only'],['GTSF1'],['Not specified'],Unclear,low,4.0,40369846,Memory T-Cell Phenotype in Cutaneous T-Cell Lymphoma Is Modified by Germline Gene Gametocyte Specific Factor 1.,2025,abstract,2025-12-19T03:55:59.048195,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Melanoma'],"['Biomarker discovery', 'Immunotherapy', 'Drug response/resistance']",['Original research'],"['TCGA', 'Multiple sources']","The authors used cBioPortal along with other platforms (TIMER 2.0, TISIDB, UALCAN) to analyze the skin cutaneous melanoma (SKCM) database and ICI-pretreated melanoma datasets. They investigated the relationship between HDAC4 expression and T-cell inflamed tumor microenvironment gene signatures, examining gene expression patterns, immune cell infiltration, DNA methylation, and patient survival outcomes. cBioPortal was one of multiple bioinformatics platforms used for comprehensive genomic and transcriptomic analysis of melanoma datasets.",['SKCM'],"['Web-based analysis', 'Web-based visualization']",['HDAC4'],"['Expression analysis', 'Query interface']",Mixed,medium,4.0,40361444,Elevated HDAC4 Expression Is Associated with Reduced T-Cell Inflamed Tumor Microenvironment Gene Signatures and Immune Checkpoint Inhibitor Effectiveness in Melanoma.,2025,pdf,2025-12-19T03:56:00.184657,,,,
"['Gene expression analysis', 'Survival analysis']",['Breast cancer'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Custom/Private data']","The study used cBioPortal to access TCGA breast cancer data to analyze the correlation between VCAN (versican) and CD8A gene expression across breast cancer subtypes. The authors found a strong inverse correlation between CD8A and VCAN expression in the TCGA cohort, supporting their experimental findings from tissue microarray analysis. This analysis was used to validate their primary findings about versican's role in regulating CD8+ T cell infiltration.",['TCGA'],"['Web-based analysis', 'Expression analysis']","['VCAN', 'CD8A']","['Expression analysis', 'Query interface']",cBioPortal platform,medium,4.0,40361362,Stromal Versican Accumulation and Proteolysis Regulate the Infiltration of CD8<sup>+</sup> T Cells in Breast Cancer.,2025,pdf,2025-12-19T03:56:01.005331,,,,
"['Mutation analysis', 'Copy number analysis', 'Pathway analysis']",['Lung cancer'],"['Biomarker discovery', 'Precision medicine', 'Pathway analysis']","['Original research', 'Clinical study']",['Custom/Private data'],"This paper does not appear to use cBioPortal directly. The study conducted whole exome sequencing (WES) on six lung neuroendocrine tumor patients using their own collected samples (FFPE tissue and blood). The analysis was performed independently without mention of cBioPortal data, tools, or platform usage in the abstract or introduction provided.",[],['Citation only'],"['KDM5C', 'ATR', 'COL7A1', 'NOTCH4', 'PTPRS', 'SMO', 'SPEN', 'SPTA1', 'TAF1']",['Not specified'],External (downloaded data),low,4.0,40361150,Genetic insight into lung neuroendocrine tumors: Notch and Wnt signaling pathways as potential targets.,2025,pdf,2025-12-19T03:56:02.493611,,,,
"['Mutation analysis', 'Pathway analysis']",['Pan-cancer'],"['Drug response/resistance', 'Tumor evolution', 'Methods/Tools development']","['Original research', 'Methods/Software']",['Multiple sources'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal being used in this study. The paper describes the development of DiffInvex, a new framework for identifying evolutionary shifts in driver genes, and applies it to data from multiple sources including Hartwig, PCAWG, POG, DECIDER, MMRF, CPTAC-3, Mutographs, ICGC, and OVCARE. cBioPortal may be cited in the references but its specific usage is not described in the provided text.",[],['Citation only'],"['PIK3CA', 'APC', 'MAP2K4', 'SMAD4', 'STK11', 'MAP3K1', 'NOTCH1', 'ARID1A']",['Not specified'],Unclear,low,4.0,40360478,DiffInvex identifies evolutionary shifts in driver gene repertoires during tumorigenesis and chemotherapy.,2025,pdf,2025-12-19T03:56:03.508826,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'Custom/Private data', 'Multiple sources']","The paper does not explicitly describe using cBioPortal in their methodology. The study primarily analyzed DNA methylation data from TCGA and public RRBS data (GSE107738), along with RNA-seq and ATAC-seq data from TCGA and GSE162515. While TCGA data was used extensively, there is no mention of accessing this data through cBioPortal or using any cBioPortal features for analysis or visualization.","['TCGA', 'GSE107738', 'GSE162515']",['Citation only'],[],['Not specified'],Unclear,low,4.0,40348904,Epigenomic profiling of papillary thyroid carcinoma reveals distinct subtypes with clinical implications.,2025,pdf,2025-12-19T03:56:03.437272,,,,
['Mutation analysis'],['Colorectal cancer'],"['Biomarker discovery', 'Methods/Tools development', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on comparing ddPCR and NGS methods for ctDNA detection in rectal cancer patients using their own clinical samples. cBioPortal may only be cited in the references without direct usage in the methodology or analysis.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40346007,Performance Comparison of Droplet Digital PCR and Next-Generation Sequencing for Circulating Tumor DNA Detection in Non-Metastatic Rectal Cancer.,2025,abstract,2025-12-19T03:56:02.516393,,,,
['Other'],['Pan-cancer'],"['Drug response/resistance', 'Review/Commentary']",['Review'],['Not specified'],This is a review article summarizing mechanisms of resistance to NAMPT inhibitors in cancer. The paper does not describe any specific use of cBioPortal for data analysis or visualization. cBioPortal appears to be cited only as a reference without detailed description of how it was used in the context of this review.,[],['Citation only'],"['NAMPT', 'NAPRT', 'QPRT', 'ABCB1']",['Not specified'],Unclear,low,4.0,40342733,Mechanisms of resistance to NAMPT inhibitors in cancer.,2025,pdf,2025-12-19T03:56:02.972533,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']",['Original research'],['Multiple sources'],"The study used cBioPortal to merge genomic data from five ESCC datasets, identifying 437 patients and categorizing them into altered (n=66) and unaltered (n=371) groups based on alterations in six key genes (HMGB1, ROS1, IL6, FGFR1, FGFR2, and TLR4). The platform was used to analyze tumor mutational burden, mutation counts, and perform survival analysis comparing overall survival and disease-free survival between the two groups. The analysis revealed that patients with alterations in these genes had significantly worse overall survival outcomes.",[],"['Web-based analysis', 'Web-based visualization']","['HMGB1', 'ROS1', 'IL6', 'FGFR1', 'FGFR2', 'TLR4']","['Survival analysis', 'Group comparison', 'Query interface']","[""cBioPortal platform""]",high,4.0,40330450,"Alterations in <i>HMGB1, ROS1, FGFR1, FGFR2, IL6</i>, and <i>TLR4</i> are associated with worse survival in patients with esophageal squamous cell carcinoma.",2025,abstract,2025-12-19T03:56:04.182983,,,,
"['Mutation analysis', 'Survival analysis', 'Gene expression analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'ICGC', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the methods or results sections. The data was obtained from TCGA through the UCSC Xena platform, and survival analysis was performed using the Kaplan-Meier Plot function from UCSC Xena and ICGC databases. While cBioPortal may be cited in references, there is no clear evidence of direct cBioPortal usage for data access, analysis, or visualization in this study.",['TCGA-HNSCC'],['Citation only'],"['COL11A1', 'JAK1', 'LKB1']",['Not specified'],Unclear,low,4.0,40322427,Impact of COL11A1 Mutations on Tumor Mutational Signatures and Immune Microenvironment in Head and Neck Squamous Cell Carcinoma.,2025,pdf,2025-12-19T03:56:06.904174,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis']",['Breast cancer'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']","['TCGA', 'Custom/Private data']","The study used TCGA data accessed through cBioPortal to validate findings from their primary cohorts regarding MMR deficiency in triple-negative breast cancer. The authors analyzed TCGA breast cancer data to confirm their observations about the prevalence and clinical significance of MMR alterations in TNBC. The specific details of how cBioPortal was used (whether through web interface, data download, or API) are not explicitly described in the abstract.",['TCGA'],['Citation only'],['PMS2'],['Not specified'],Unclear,low,4.0,40319412,Dysfunctional mismatch repair in patients with early triple-negative breast cancer.,2025,abstract,2025-12-19T03:56:04.932421,,,,
"['Mutation analysis', 'Gene expression analysis']",['Leukemia/Lymphoma'],['Biomarker discovery'],"['Original research', 'Clinical study']","['TCGA', 'Custom/Private data']","The paper mentions cBioPortal in the context of analyzing TCGA AML data to validate findings about CD200 expression patterns in different genetic subgroups of AML. The authors appear to have used cBioPortal to query and analyze TCGA AML datasets to corroborate their findings from their institutional cohort of 431 AML patients. However, specific details about which cBioPortal features were used or how the analysis was performed are not explicitly described in the provided abstract and introduction.",['TCGA-LAML'],"['Web-based analysis', 'Web-based visualization']","['CEBPA', 'NPM1', 'RUNX1', 'RUNX1T1', 'CBFB', 'MYH11', 'FLT3']",['Query interface'],cBioPortal platform,medium,4.0,40307896,CD200 in acute myeloid leukemia: marked upregulation in CEBPA biallelic mutated cases.,2025,pdf,2025-12-19T03:56:07.932455,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Pan-cancer'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],['Multiple sources'],"cBioPortal was used to predict phosphorylation sites of FUNDC2 and to investigate variations (mutations) of FUNDC2 across different cancers. The platform was used alongside PhosphoNet for phosphorylation site prediction, identifying 15 phosphorylation sites, with S167 overlapping with mutation sites.",[],['Web-based analysis'],"['FUNDC2', 'FUNDC1']","['Mutation Mapper', 'Query interface']",Mixed,medium,4.0,40294153,Expression and immunological role of FUNDC2 in pan-cancer.,2025,abstract,2025-12-19T03:56:06.428364,,,,
['Gene expression analysis'],['Prostate cancer'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],['Not specified'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on experimental investigation of STEAP1 expression in prostate cancer cells and small extracellular vesicles in response to androgen deprivation using in vitro cell lines and ex vivo mouse models. If cBioPortal was used, it may only be cited as a reference or used for preliminary data exploration not described in the abstract.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40287951,Exploring STEAP1 Expression in Prostate Cancer Cells in Response to Androgen Deprivation and in Small Extracellular Vesicles.,2025,abstract,2025-12-19T03:56:07.906496,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Other']",['Original research'],['TCGA'],"Based on the abstract and introduction provided, the paper appears to focus on experimental validation of TRPM7 kinase domain function in pancreatic cancer using CRISPR-Cas9 deletion models, cell line experiments, and xenograft studies. While cBioPortal is cited, the abstract does not explicitly describe how it was used. It was likely used to query TRPM7 expression and survival data in TCGA pancreatic cancer datasets to provide clinical context for the experimental findings.",[],['Citation only'],['TRPM7'],['Not specified'],Unclear,low,4.0,40274768,The kinase domain of TRPM7 interacts with PAK1 and regulates pancreatic cancer cell epithelial-to-mesenchymal transition.,2025,abstract,2025-12-19T03:56:08.638900,,,,
['Gene expression analysis'],['Prostate cancer'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],"['TCGA', 'Multiple sources']","The authors analyzed prostate cancer patient cohorts using cBioPortal to examine XRCC1 expression levels across different patient populations. They found that XRCC1 expression varies widely among PCa patients, with many showing low XRCC1 expression, which informed their hypothesis that low XRCC1 expression could predict PARP inhibitor sensitivity.",[],['Web-based analysis'],['XRCC1'],['Expression analysis'],Unclear,medium,4.0,40271221,PARP inhibitor response is enhanced in prostate cancer when XRCC1 expression is reduced.,2025,abstract,2025-12-19T03:56:08.139300,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Breast cancer'],"['Methods/Tools development', 'Biomarker discovery']","['Original research', 'Methods/Software']",['TCGA'],The paper used TCGA breast cancer data to train and validate an AI model for predicting Nottingham grade from H&E-stained whole-slide images. The study analyzed gene expression data to identify genes correlated with model predictions and performed pathway enrichment analysis. The predicted grades were validated against 5-year overall survival outcomes to demonstrate clinical utility.,['TCGA'],['Data download/export'],[],['Download data'],External (downloaded data),medium,4.0,40253353,Predicting Nottingham grade in breast cancer digital pathology using a foundation model.,2025,pdf,2025-12-19T03:56:12.617774,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Breast cancer'],"['Database/Resource', 'Methods/Tools development', 'Biomarker discovery']","['Methods/Software', 'Original research']","['TCGA', 'METABRIC', 'Multiple sources']","This paper describes the development of MammOnc-DB, a comprehensive breast cancer data analysis platform. While the paper mentions utilizing data from TCGA and other public repositories, there is no explicit mention of cBioPortal being used in the development or analysis. The paper appears to cite cBioPortal as a related resource but does not describe specific usage of cBioPortal tools or data downloads from the platform.","['TCGA', 'METABRIC', 'CPTAC', 'CCLE', 'SCAN-B']",['Citation only'],[],['Not specified'],Unclear,low,4.0,40251157,"MammOnc-DB, an integrative breast cancer data analysis platform for target discovery.",2025,pdf,2025-12-19T03:56:15.880153,,,,
"['Mutation analysis', 'Other']",['Not specified'],"['Biomarker discovery', 'Database/Resource']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on analyzing germline variants in histone-encoding genes causing neurodevelopmental disorders (histonopathies) using phenotypic data and facial photograph analysis. If cBioPortal is cited, it appears to be a reference citation only without direct usage for data analysis or visualization in this particular study.",[],['Citation only'],"['HIST1H1E', 'HIST1H2AL', 'H2AC16', 'H2AFZ', 'H2AZ1', 'HIST1H3D', 'H3C4', 'HIST3H3', 'H3-4']",['Not specified'],Unclear,low,4.0,40241305,Coupling deep phenotypic quantification with next-generation phenotyping for 192 individuals with germline histonopathies.,2025,abstract,2025-12-19T03:56:10.014667,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Methods/Tools development']",['Original research'],"['TCGA', 'Custom/Private data']","The authors used cBioPortal to access TCGA kidney renal clear cell carcinoma (KIRC) patient datasets for validation purposes. They compared prognostic markers identified in their RCC243 tumor models with human ccRCC patient data from TCGA via cBioPortal, and assessed whether genes upregulated in metastatic RCC243 tumors were associated with patient outcomes in the TCGA cohort.",['TCGA-KIRC'],"['Data download/export', 'Web-based analysis']",[],"['Survival analysis', 'Expression analysis', 'Download data']",Mixed,medium,4.0,40241258,Comparative single-cell transcriptomic profiling of patient-derived renal carcinoma cells in cellular and animal models of kidney cancer.,2025,abstract,2025-12-19T03:56:10.925463,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Pathway analysis', 'Drug response/resistance']","['Meta-analysis', 'Original research']",['Multiple sources'],"cBioPortal was used to perform co-expression analysis of genes associated with ANGPTL4 across different cancer types. The co-expressed genes identified through cBioPortal were then subjected to gene set enrichment analysis (GSEA) using enrichr to identify relevant biological pathways. This analysis revealed involvement in hypoxia, EMT, VEGF-A complex, TGF-B pathways, and extracellular matrix organization.",[],['Web-based analysis'],"['ANGPTL4', 'TP53', 'CDKN2A']","['Expression analysis', 'Query interface']",Mixed,medium,4.0,40233044,The role of ANGPTL4 in cancer: A meta-analysis of observational studies and multi-omics investigation.,2025,abstract,2025-12-19T03:56:12.759535,,,,
"['Mutation analysis', 'Survival analysis', 'Biomarker discovery']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on analyzing genomic profiles from tumor tissue DNA (tDNA) and circulating tumor DNA (ctDNA) in cutaneous squamous cell carcinoma patients treated with PD-1 inhibitors at a single institution. The study appears to use custom/private data from their institutional cohort rather than public databases accessed through cBioPortal.",[],['Citation only'],"['CDK12', 'CTCF', 'CTNNB1', 'IGF1R', 'IKBKE', 'MLH1', 'QKI', 'TIPARP']",['Not specified'],Unclear,low,4.0,40227722,Mutational Profile of Blood and Tumor Tissue and Biomarkers of Response to PD-1 Inhibitors in Patients with Cutaneous Squamous Cell Carcinoma.,2025,pdf,2025-12-19T03:56:14.401307,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Prostate cancer'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']",['TCGA'],"The paper mentions using cBioPortal in the context of analyzing genomic alterations and gene expression data from TCGA prostate adenocarcinoma database. However, the abstract and introduction provided do not contain explicit details about how cBioPortal was specifically used - whether for data download, web-based analysis, or visualization. The study focuses on comparing clinical outcomes and genomic alterations between Gleason Score 10 and Gleason Score 8-9 prostate cancer patients using TCGA data.",['TCGA-PRAD'],['Unclear'],"['RAD54L', 'FAAH', 'AATK', 'MAST2', 'CD8A', 'CDC20', 'E2F1', 'IL10', 'TNF', 'VCAM1', 'CCHCR1']",['Not specified'],Unclear,low,4.0,40227503,Clinical Outcomes and Genomic Alterations in Gleason Score 10 Prostate Cancer.,2025,pdf,2025-12-19T03:56:14.590258,,,,
"['Gene expression analysis', 'Mutation analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The paper used cBioPortal to analyze ANKRD22 expression in pancreatic cancer and its correlation with KRAS and TP53 mutations. The authors examined the relationship between ANKRD22 expression levels and patient survival outcomes, comparing expression in mutated versus wildtype KRAS and TP53 groups. They also analyzed co-expression patterns of ANKRD22 with these mutated genes and their impact on survival.",[],"['Web-based analysis', 'Web-based visualization']","['ANKRD22', 'KRAS', 'TP53']","['Expression analysis', 'Survival analysis', 'Group comparison']",Mixed,medium,4.0,40225855,<i>In Silico</i> Identification of ANKRD22 as a Theragnostic Target for Pancreatic Cancer and Fostamatinib's Therapeutic Potential.,2025,pdf,2025-12-19T03:56:14.844062,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Other']",['Original research'],"['TCGA', 'Multiple sources']","The paper mentions using CPTAC and TCGA ovarian cancer datasets to perform a systematic analysis of RNA helicase expression profiles, which identified DDX39A as prominently upregulated in ovarian cancer. The study also found that elevated DDX39A expression was associated with poor overall survival in ovarian cancer patients. While cBioPortal is not explicitly mentioned by name in the abstract, TCGA data analysis for expression and survival is commonly accessed through cBioPortal or similar platforms.","['TCGA ovarian cancer', 'CPTAC ovarian cancer']",['Citation only'],"['DDX39A', 'SNRPB', 'ITGA6']",['Not specified'],"[""Unclear""]",low,4.0,40216968,SNRPB-mediated regulation of DDX39A splicing promotes ovarian cancer progression by regulating α6 integrin subunit expression.,2025,abstract,2025-12-19T03:56:14.476529,,,,
"['Multi-omics integration', 'Mutation analysis', 'Gene expression analysis']",['Pan-cancer'],"['Methods/Tools development', 'Biomarker discovery', 'Precision medicine']","['Methods/Software', 'Original research']",['TCGA'],"The paper mentions using datasets from The Cancer Genome Atlas (TCGA) to demonstrate VICatMix's application in cancer subtyping and driver gene discovery. However, the abstract and introduction do not explicitly state that cBioPortal was used to access or analyze this TCGA data. The citation of cBioPortal may be for reference purposes or the data may have been accessed through cBioPortal, but specific usage details are not provided in the given text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40206332,VICatMix: variational Bayesian clustering and variable selection for discrete biomedical data.,2025,abstract,2025-12-19T03:56:14.343755,,,,
"['Mutation analysis', 'Copy number analysis', 'Survival analysis', 'Multi-omics integration', 'Gene expression analysis']","['Pan-cancer', 'Melanoma', 'Colorectal cancer', 'Lung cancer', 'Leukemia/Lymphoma', 'Other solid tumor']","['Drug response/resistance', 'Biomarker discovery', 'Precision medicine']",['Original research'],['Multiple sources'],"The study conducted an extensive analysis of BRAF alterations across more than 217,000 tumor samples from 120 distinct tumor types using genomics, transcriptomics, and clinical data retrieved from public repositories, including cBioPortal. The analysis examined BRAF point mutations, structural variants, and copy number alterations, focusing on mutual exclusivity and co-occurrence patterns with other oncogenes and tumor suppressors. The work also explored associations between BRAF somatic alterations and survival, clinical, and molecular features across cancer types.",[],"['Data download/export', 'Web-based analysis']","['BRAF', 'PTEN', 'TP53', 'PIK3CA', 'RAS', 'MEK']","['Download data', 'Query interface', 'Survival analysis']",Mixed,medium,4.0,40201310,Unraveling <i>BRAF</i> alterations: molecular insights to circumvent therapeutic resistance across cancer types.,2025,pdf,2025-12-19T03:56:17.298504,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Tumor evolution', 'Pathway analysis', 'Biomarker discovery']",['Original research'],"['TCGA', 'Custom/Private data', 'Multiple sources']","Based on the title and abstract, this study investigates convergent genetic adaptation to hypoxia between natural populations living at high altitudes and human tumors. The study likely used cBioPortal to access cancer genomics data (particularly TCGA data) to analyze genetic alterations in tumors that develop under hypoxic conditions. The specific details of cBioPortal usage are not provided in the abstract alone, but given the scope of the study examining genetic adaptation in tumors, cBioPortal was likely used for querying mutation, copy number, and expression data related to hypoxia-response genes.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40199338,Convergent Genetic Adaptation in Human Tumors Developed Under Systemic Hypoxia and in Populations Living at High Altitudes.,2025,abstract,2025-12-19T03:56:17.212243,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],"['TCGA', 'Multiple sources']","The paper mentions using public databases including TCGA to evaluate NEU1 expression in liver cancer and validate findings. While cBioPortal is not explicitly mentioned by name in the provided abstract and introduction, the authors reference using TCGA datasets for bioinformatics analysis of NEU1 in liver cancer. The specific usage details of cBioPortal are not clearly described in the provided text.",['TCGA'],['Citation only'],"['NEU1', 'PLIN2']",['Not specified'],Unclear,low,4.0,40196362,New use of an old drug: mechanism of oseltamivir phosphate inhibiting liver cancer through regulation of lipophagy via NEU1.,2025,pdf,2025-12-19T03:56:18.684567,,,,
"['Gene expression analysis', 'Copy number analysis']",['Breast cancer'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],"['TCGA', 'METABRIC']","Based on the abstract and introduction provided, cBioPortal is not explicitly mentioned in the text. The paper focuses on chemoproteomic analysis of nitroalkene effects on RECQL4 and DNA repair mechanisms in cancer. While TCGA and METABRIC are common data sources accessed through cBioPortal, there is no direct mention of cBioPortal usage in the provided sections. The paper appears to be primarily a mechanistic study using experimental approaches rather than bioinformatics analysis of public databases.",[],['Citation only'],"['RECQL4', 'RAD51']",['Not specified'],Unclear,low,4.0,40196015,Chemoproteomic analysis reveals RECQL4 as a mediator of nitroalkene-dependent double-strand break repair inhibition in cancer.,2025,pdf,2025-12-19T03:56:19.312295,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Breast cancer'],['Biomarker discovery'],['Original research'],"['METABRIC', 'Custom/Private data']","The paper examined SP7 mRNA expression in the METABRIC cohort of breast cancer patients, likely accessed through cBioPortal. Gene set enrichment analysis (GSEA) was performed to explore the role of osterix in cancer hallmark genesets, identifying enrichment of genes involved in KRAS signaling in tumours with high SP7 expression. The primary focus was on immunohistochemistry analysis of osterix protein expression in 1340 breast tumours, with METABRIC data used for validation of mRNA expression patterns.",['METABRIC'],['Data download/export'],['SP7'],"['Expression analysis', 'Download data']",External (downloaded data),medium,4.0,40192943,Expression of the zinc-finger transcription factor Osterix (SP7) in invasive breast cancer and its prognostic significance.,2025,pdf,2025-12-19T03:56:20.662521,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['Not specified'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on experimental characterization of IDH1 mutants (R132Q vs R132H) in cellular and xenograft models, examining their catalytic efficiency, D2HG production, and effects on DNA methylation and transcriptome. The study appears to be primarily laboratory-based experimental research without clear indication of cBioPortal data analysis or visualization.",[],['Citation only'],"['IDH1', 'EGFR']",['Not specified'],Unclear,low,4.0,40188944,Catalytically distinct metabolic enzyme isocitrate dehydrogenase 1 mutants tune phenotype severity in tumor models.,2025,abstract,2025-12-19T03:56:20.277650,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Pathway analysis', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","The cBioPortal database was used to perform genome-wide DLX4 somatic mutation profiling across pan-cancer samples. The study utilized cBioPortal to analyze mutation patterns of DLX4 and its correlation with tumor mutational burden (TMB) across various cancer types, with particular focus on kidney renal clear cell carcinoma (KIRC).",[],"['Web-based analysis', 'Data download/export']",['DLX4'],"['Query interface', 'Download data']",External (downloaded data),medium,4.0,40186710,"Multi-omics analysis identifies DLX4 as a novel biomarker for diagnosis, prognosis, and immune infiltration: from pan-cancer to renal cancer.",2025,pdf,2025-12-19T03:56:21.173775,,,,
"['Gene expression analysis', 'Other']",['Breast cancer'],"['Immunotherapy', 'Tumor evolution', 'Review/Commentary']","['Review', 'Original research']",['Custom/Private data'],"Based on the abstract and introduction provided, this appears to be a review paper describing experimental work using a radiation-genetic mammary chimera model. There is no explicit mention of cBioPortal usage in the provided text. The paper focuses on experimental studies of radiation-induced systemic inflammation and tumor microenvironment changes in breast cancer models, rather than computational analysis of genomic databases.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40184664,Systemic inflammation in response to radiation drives the genesis of an immunosuppressed tumor microenvironment.,2025,abstract,2025-12-19T03:56:20.025199,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Pathway analysis', 'Biomarker discovery']",['Original research'],"['TCGA', 'Custom/Private data']","cBioPortal was used to query ARID1A mutation data in bladder cancer cohorts, specifically to identify that truncations are the most common mutation type in approximately 20% of bladder tumors. This information informed the design of their loss- and gain-of-function experimental models. The usage appears to be primarily for initial data mining and validation of mutation patterns in bladder cancer.",['TCGA'],"['Web-based analysis', 'Web-based visualization']",['ARID1A'],"['Mutation Mapper', 'Query interface']",cBioPortal platform,medium,4.0,40170512,"Multidimensional OMICs reveal ARID1A orchestrated control of DNA damage, splicing, and cell cycle in normal-like and malignant urothelial cells.",2025,abstract,2025-12-19T03:56:20.735259,,,,
"['Multi-omics integration', 'Other']",['Pan-cancer'],"['Database/Resource', 'Methods/Tools development']",['Methods/Software'],['Custom/Private data'],"cBioPortal is mentioned as one of several visualization tools through which HTAN (Human Tumor Atlas Network) data can be explored and accessed. The paper describes cBioPortal as part of the data dissemination infrastructure for HTAN data, alongside other tools like CellxGene and Minerva. However, the paper does not provide specific details about how cBioPortal was used for analysis or what specific features were utilized.",[],['Web-based visualization'],[],['Not specified'],"[""cBioPortal platform""]",medium,4.0,40164800,"Sharing data from the Human Tumor Atlas Network through standards, infrastructure and community engagement.",2025,pdf,2025-12-19T03:56:21.576479,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Colorectal cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used as one of multiple public databases to evaluate CDH3 expression and perform functional and translational analyses in colorectal cancer. The study integrated data from cBioPortal along with other databases (TCGA, HCMDB, UALCAN, HPA, UniProt, and GEO) to construct a prognostic model and analyze CDH3's role in CRC metastasis and immunotherapy. The specific details of how cBioPortal was used are not explicitly described in the abstract and introduction.",['TCGA'],['Citation only'],"['CDH3', 'CDH1']",['Not specified'],Unclear,low,4.0,40155851,Synergistic potential of CDH3 in targeting CRC metastasis and enhancing immunotherapy.,2025,pdf,2025-12-19T03:56:24.611356,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration', 'Copy number analysis']",['Pan-cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the abstract or introduction provided. While the study analyzes TCGA pan-cancer data including multi-omics analysis (transcriptomic, proteomic, epigenomic) across 33 cancer types, there is no clear statement about accessing this data through cBioPortal or using any cBioPortal-specific features. The paper may have cited cBioPortal as a reference or potential data source, but specific usage details are not evident in the provided text.",['TCGA'],['Citation only'],['SLC19A1'],['Not specified'],Unclear,low,4.0,40149548,Pan-Cancer Characterization Identifies SLC19A1 as an Unfavorable Prognostic Marker and Associates It with Tumor Infiltration Features.,2025,pdf,2025-12-19T03:56:24.495955,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']",The cBioPortal platform was used to evaluate the correlation of TRAF2 expression with mutations and epigenetic alterations across various tumor types. The study performed pan-cancer analysis of TRAF2 using cBioPortal to assess mutation patterns and their relationship with gene expression in multiple cancer types from TCGA data.,['TCGA'],['Web-based analysis'],['TRAF2'],"['Query interface', 'Expression analysis']",cBioPortal platform,medium,4.0,40144665,The role of TRAF2 in pan-cancer revealed by integrating informatics and experimental validation.,2025,pdf,2025-12-19T03:56:24.550061,,,,
"['Mutation analysis', 'Multi-omics integration']",['Pan-cancer'],"['Methods/Tools development', 'Precision medicine', 'Biomarker discovery']","['Original research', 'Methods/Software']",['Multiple sources'],"The study used data from the cBioPortal database (accessed on 21 September 2024) to obtain over 20,000 tumor samples with information on patient age, sex, and genetic variants in over 600 genes. This data was downloaded and used externally to train machine learning models for primary cancer site prediction. The resulting model was integrated into OncoOrigin software with a graphical user interface for clinical application.",[],['Data download/export'],[],['Download data'],External (downloaded data),high,4.0,40141210,<i>In Silico</i> Validation of OncoOrigin: An Integrative AI Tool for Primary Cancer Site Prediction with Graphical User Interface to Facilitate Clinical Application.,2025,pdf,2025-12-19T03:56:24.762948,,,,
"['Gene expression analysis', 'Survival analysis', 'Copy number analysis']","['Pan-cancer', 'Colorectal cancer', 'Breast cancer', 'Leukemia/Lymphoma', 'Lung cancer', 'Other solid tumor']","['Review/Commentary', 'Biomarker discovery']",['Review'],['Not specified'],"This is a review paper about IMP2 (IGF2BP2) RNA-binding protein in cancer and disease. The paper mentions that IMP2 can be genomically amplified and transcriptionally overexpressed in cancer cells, and that high expression is associated with decreased overall survival in cancer patients. However, the abstract and introduction do not provide specific details about how cBioPortal was used, suggesting it may be cited as a reference source for cancer genomics data rather than actively used for analysis in this review.",[],['Citation only'],['IGF2BP2'],['Not specified'],Unclear,low,4.0,40141058,IMPlications of IMP2 in RNA Biology and Disease.,2025,pdf,2025-12-19T03:56:26.496321,,,,
['Other'],"['Leukemia/Lymphoma', 'Pan-cancer']","['Review/Commentary', 'Drug response/resistance', 'Precision medicine']",['Review'],['Not specified'],"This is a comprehensive review article on BCL2 family proteins and their role in apoptosis and targeted therapy. The paper does not explicitly describe any direct use of cBioPortal for data analysis or visualization. cBioPortal may be cited in the references as a general resource for cancer genomics data, but no specific usage, data download, or analysis using the platform is described in the provided abstract and introduction.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40113751,The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy.,2025,pdf,2025-12-19T03:56:26.225184,,,,
['Other'],['Not specified'],"['Review/Commentary', 'Database/Resource', 'Drug response/resistance']",['Review'],['Not specified'],"This is a comprehensive review paper on computational drug repurposing that surveys and evaluates various in silico resources and databases. cBioPortal is mentioned as one of the many computational resources available for drug repurposing research, likely included in their systematic survey of databases and platforms. The paper does not describe any specific analysis performed using cBioPortal data or tools.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40102635,"Computational drug repurposing: approaches, evaluation of in silico resources and case studies.",2025,abstract,2025-12-19T03:56:26.304867,,,,
"['Gene expression analysis', 'Survival analysis']",['Breast cancer'],"['Immunotherapy', 'Biomarker discovery', 'Drug response/resistance']",['Original research'],"['TCGA', 'METABRIC']",The study analyzed two large breast cancer clinical cohorts (TCGA and METABRIC) to determine correlations between PR expression and antigen processing/presentation (APP) gene expression as well as MHC Class I expression in ER-positive tumors. The analysis appears to have used cBioPortal to access and analyze gene expression data from these cohorts to validate their in vitro and in vivo findings regarding PR-mediated downregulation of MHC Class I machinery.,"['TCGA', 'METABRIC']","['Web-based analysis', 'Expression analysis']",[],"['Expression analysis', 'Group comparison']",Unclear,medium,4.0,40102028,Progesterone receptor-dependent downregulation of MHC class I promotes tumor immune evasion and growth in breast cancer.,2025,abstract,2025-12-19T03:56:27.099882,,,,
"['Gene expression analysis', 'Pathway analysis']",['Other solid tumor'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],"['TCGA', 'Custom/Private data']","Based on the abstract and introduction provided, the paper appears to investigate PRAME expression in keratinocyte carcinomas and its role in retinoid resistance. While cBioPortal is cited, the specific usage details are not explicitly described in the provided text. The study likely used cBioPortal to access TCGA data for analyzing PRAME expression patterns in basal cell carcinoma and cutaneous squamous cell carcinoma, but the exact methodology is not clear from the abstract alone.",[],['Citation only'],"['PRAME', 'EZH2']",['Not specified'],Unclear,low,4.0,40101298,Targeting PRAME directly or via EZH2 inhibition overcomes retinoid resistance and represents a novel therapy for keratinocyte carcinoma.,2025,abstract,2025-12-19T03:56:26.754862,,,,
"['Copy number analysis', 'Mutation analysis', 'Survival analysis', 'Multi-omics integration']","['Leukemia/Lymphoma', 'Pan-cancer']","['Biomarker discovery', 'Tumor evolution', 'Precision medicine']",['Original research'],"['Custom/Private data', 'Multiple sources']","Based on the abstract and title, this paper focuses on mosaic chromosomal alterations (mCAs) in 1 million individuals from four biobanks, analyzing somatic mutations, germline genetics, and clinical phenotypes. The paper does not explicitly mention cBioPortal usage in the provided abstract and introduction. If cBioPortal is cited, it appears to be a reference citation rather than a primary data source or analysis tool for this study, which relies on custom biobank data.",[],['Citation only'],"['CHI3L2', 'TERT', 'NPM1', 'PARP1']",['Not specified'],Unclear,low,4.0,40093208,Genetic drivers and clinical consequences of mosaic chromosomal alterations in 1 million individuals.,2025,abstract,2025-12-19T03:56:28.279423,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention cBioPortal usage in the abstract or introduction. The authors used online databases including TIMER2.0, GEPIA2, UALCAN, and GSCA for their pan-cancer analysis of APOA1, investigating expression, prognosis, immune infiltration, mutations, and drug sensitivity. While cBioPortal is cited, the specific role it played in the analysis is not clearly described in the provided text.",[],['Citation only'],['APOA1'],['Not specified'],Unclear,low,4.0,40088749,APOA1 promotes tumor proliferation and migration and may be a potential pan-cancer biomarker and immunotherapy target.,2025,abstract,2025-12-19T03:56:30.714839,,,,
"['Mutation analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Other']",['Original research'],['Multiple sources'],"The study obtained mutant gene expression data from the Memorial Sloan Kettering Cancer Center tumor registry (MSK-CHORD) to analyze genomic characteristics associated with pancreatic cancer in Black patients. The paper mentions that mutant KRAS expression was higher in Black males. However, the abstract and introduction are truncated, so full details of cBioPortal usage are not completely clear from the provided text.",['MSK-CHORD'],['Data download/export'],['KRAS'],['Download data'],External (downloaded data),medium,4.0,40084357,Sociodemographic characteristics associated with pancreatic cancer incidence and mortality among Blacks in the United States: a SEER-based study.,2025,pdf,2025-12-19T03:56:30.706333,,,,
"['Gene expression analysis', 'Survival analysis', 'Copy number analysis', 'Pathway analysis', 'Multi-omics integration', 'Mutation analysis']","['Pan-cancer', 'Bladder cancer', 'Breast cancer', 'Colorectal cancer']","['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The paper analyzed FUT1 expression across 33 cancer types using data from multiple public databases including TCGA. The study examined genomic alterations (amplifications), expression patterns, survival outcomes, and associations with clinical and molecular features. While cBioPortal is not explicitly mentioned in the abstract, TCGA data access and pan-cancer genomic analyses suggest potential use of cBioPortal for data retrieval or analysis, though the specific usage mode is unclear from the provided text.",['TCGA'],['Citation only'],['FUT1'],['Not specified'],Unclear,low,4.0,40084262,Comprehensive Multi-Omics Analysis Identifies FUT1 as a Prognostic and Therapeutic Biomarker Across Pan-Cancer.,2025,abstract,2025-12-19T03:56:31.757439,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration', 'Mutation analysis', 'Copy number analysis']",['Lung cancer'],"['Biomarker discovery', 'Immunotherapy', 'Drug response/resistance', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, the paper does not explicitly mention cBioPortal usage. The study focuses on developing a pyrimidine metabolism-related signature (PMRS) using machine learning algorithms and multi-omics analysis for lung adenocarcinoma prognosis. While the paper cites cBioPortal (as indicated by the query context), the specific details of how cBioPortal was used are not described in the provided text sections.",['TCGA'],['Citation only'],['LYPD3'],['Not specified'],Unclear,low,4.0,40084259,Multi-omics and single-cell analysis reveals machine learning-based pyrimidine metabolism-related signature in the prognosis of patients with lung adenocarcinoma.,2025,abstract,2025-12-19T03:56:31.736517,,,,
"['Copy number analysis', 'Gene expression analysis', 'Survival analysis']",['Other solid tumor'],['Biomarker discovery'],['Original research'],['Multiple sources'],"The paper investigates CDKN2A dysregulation in Ewing sarcoma using data from pre-clinical models and clinical samples. The study examines genomic copy number deletions of CDKN2A and demonstrates that high expression of CDKN2A is a negative prognostic biomarker at diagnosis in three independent datasets. The analysis includes copy number analysis, gene expression analysis, and survival analysis to evaluate CDKN2A's role in EwS.",[],['Citation only'],"['CDKN2A', 'CDK4', 'CCND1']",['Not specified'],Unclear,low,4.0,40080912,Revisiting CDKN2A dysregulation in Ewing sarcoma.,2025,abstract,2025-12-19T03:56:32.556300,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the abstract or introduction provided. While TCGA data is mentioned as a data source, there is no specific reference to cBioPortal platform, tools, or features. The study appears to have used TCGA data for multi-omics analysis of NQO1 in hepatocellular carcinoma, but the method of data access is not specified in the provided text.",['TCGA'],['Citation only'],['NQO1'],['Not specified'],Unclear,low,4.0,40074806,"Multi-omics analysis revealed the novel role of NQO1 in microenvironment, prognosis and immunotherapy of hepatocellular carcinoma.",2025,pdf,2025-12-19T03:56:32.528769,,,,
"['Gene expression analysis', 'Pathway analysis']",['Glioma/Brain cancer'],"['Methods/Tools development', 'Pathway analysis', 'Biomarker discovery']","['Methods/Software', 'Original research']","['TCGA', 'Multiple sources']","The paper mentions cBioPortal as one of the large-scale public datasets available for cancer genomics research, alongside NCBI Gene Expression Omnibus, ICGC, and TCGA. However, the actual analysis described in the paper focuses on using Phantasus, a different web application, for gene expression analysis in glioblastoma. There is no clear evidence that cBioPortal was directly used for data analysis or visualization in this study.",[],['Citation only'],['P2RX7'],['Not specified'],Unclear,low,4.0,40072681,A step-by-step protocol based on data mining to explore purinergic signaling in glioblastoma.,2025,abstract,2025-12-19T03:56:33.365174,,,,
"['Gene expression analysis', 'Pathway analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['Multiple sources'],"The paper mentions analyzing the relationship between MIR31HG expression, partial EMT, and the basal-like subtype of PDAC by integrating data from public databases. While cBioPortal is cited in the references, the abstract and introduction do not provide specific details about how cBioPortal was used, what features were accessed, or what specific analyses were performed using the platform. The study appears to have used multiple public databases for data mining and bioinformatics analyses.",[],['Citation only'],"['MIR31HG', 'GATA6', 'HNF1A', 'MYC', 'KRT5']",['Not specified'],Unclear,low,4.0,40065368,Hypoxia-induced MIR31HG expression promotes partial EMT and basal-like phenotype in pancreatic ductal adenocarcinoma based on data mining and experimental analyses.,2025,pdf,2025-12-19T03:56:32.989213,,,,
"['Gene expression analysis', 'Multi-omics integration']","['Breast cancer', 'Other solid tumor']","['Precision medicine', 'Methods/Tools development', 'Biomarker discovery']","['Original research', 'Methods/Software']","['TCGA', 'Multiple sources']","The paper mentions TCGA as a major genomic resource and references it in the context of ancestry representation in cancer genomic databases. The study uses TCGA data (specifically mentioning breast, thyroid, and uterine cancers) as training data for their PhyloFrame machine learning method. However, the paper does not explicitly describe direct usage of the cBioPortal platform itself - TCGA is cited as a data source rather than cBioPortal being used as an analysis tool.",['TCGA'],['Citation only'],[],['Not specified'],Unclear,low,4.0,40064867,Equitable machine learning counteracts ancestral bias in precision medicine.,2025,pdf,2025-12-19T03:56:35.900163,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Tumor evolution', 'Precision medicine']",['Original research'],['Multiple sources'],"Based on the abstract and title provided, the specific usage of cBioPortal is not explicitly detailed. The paper focuses on integrated analysis of multiple independent datasets from NF1 patients to study MPNST heterogeneity and DLK1 expression patterns. While cBioPortal is cited, the exact manner of its use (data download, web analysis, or citation only) cannot be determined from the information provided.",[],['Citation only'],"['DLK1', 'CDKN2A']",['Not specified'],Unclear,low,4.0,40063513,DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures.,2025,abstract,2025-12-19T03:56:35.628211,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis']",['Pan-cancer'],"['Review/Commentary', 'Biomarker discovery', 'Pathway analysis']",['Review'],['Not specified'],"This is a review paper focusing on cohesin mutations across different cancer types. While the paper discusses recurrent mutations in cohesin complex genes (SMC1A, SMC3, RAD21, STAG1, STAG2) identified through cancer exome sequencing studies, the abstract and introduction do not explicitly describe direct usage of cBioPortal. The paper likely cites cBioPortal as a reference resource for cancer genomics data, but specific usage details are not provided in the available text.",[],['Citation only'],"['SMC1A', 'SMC3', 'RAD21', 'STAG1', 'STAG2']",['Not specified'],Unclear,low,4.0,40063003,Cohesin mutations and chromatin changes in cancer.,2026,abstract,2025-12-19T03:56:37.060729,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Copy number analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used as one of multiple online bioinformatic databases to analyze the NTRK gene family (NTRK1, NTRK2, NTRK3) in breast cancer. The platform was utilized alongside other tools including TCGA, UALCAN, Kaplan-Meier plotter, bc-GenExMiner, STRING, Enrichr, and TIMER to comprehensively evaluate the prognostic significance of NTRK genes. Specific details about which analyses were performed on cBioPortal versus other platforms are not explicitly stated in the abstract.",['TCGA'],['Web-based analysis'],"['NTRK1', 'NTRK2', 'NTRK3']",['Not specified'],Unclear,medium,4.0,40061872,A comprehensive bioinformatic evaluation of the NTRK family's potential as prognostic biomarkers in breast cancer.,2025,abstract,2025-12-19T03:56:36.748777,,,,
"['Gene expression analysis', 'Survival analysis']",['Glioma/Brain cancer'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],['TCGA'],"The paper used cBioPortal to analyze patient datasets for correlations between tGLI1 expression and CDK4/6 therapeutic resistance markers in glioblastoma. The analysis appears to have involved querying gene expression data and potentially survival outcomes from TCGA glioblastoma datasets. However, specific details about the exact cBioPortal features used or the methodology are not provided in the abstract and introduction.",[],['Web-based analysis'],"['GLI1', 'CDK4', 'CDK6']","['Expression analysis', 'Not specified']",Unclear,low,4.0,40060625,"Targeting tGLI1, a novel mediator of tumor therapeutic resistance, using Ketoconazole sensitizes glioblastoma to CDK4/6 therapy and chemoradiation.",2025,abstract,2025-12-19T03:56:37.307941,,,,
"['Gene expression analysis', 'Pathway analysis']",['Breast cancer'],"['Drug response/resistance', 'Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],"Based on the abstract and introduction provided, the paper appears to use cBioPortal for bioinformatic analysis to identify enrichment of RNA metabolism pathways in radiation-resistant breast cancer cells. The specific details of cBioPortal usage are not explicitly described in the provided text, but the study involves analysis of gene expression data, likely from TCGA breast cancer datasets, to support their findings about ITGβ3 expression and RNA metabolism pathways.",[],['Citation only'],['ITGB3'],['Not specified'],Unclear,low,4.0,40060410,Resistance to Radiation Enhances Metastasis by Altering RNA Metabolism.,2025,abstract,2025-12-19T03:56:38.792952,,,,
"['Gene expression analysis', 'Survival analysis']","['Pan-cancer', 'Hepatocellular carcinoma', 'Breast cancer', 'Glioma/Brain cancer']","['Review/Commentary', 'Biomarker discovery', 'Drug response/resistance']",['Review'],['Not specified'],"This is a review paper on focal adhesion in tumor metastasis. While cBioPortal is cited in the references, there is no explicit description in the provided abstract and introduction of how cBioPortal was used for data analysis or visualization. The paper discusses focal adhesion proteins and their roles in various cancers but does not detail specific cBioPortal queries or analyses.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40045379,Focal adhesion in the tumour metastasis: from molecular mechanisms to therapeutic targets.,2025,pdf,2025-12-19T03:56:39.943077,,,,
"['Gene expression analysis', 'Survival analysis']",['Leukemia/Lymphoma'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],['TCGA'],"cBioPortal was used to analyze PRC1 expression levels in AML patients and to correlate PRC1 expression with patient survival outcomes. The authors examined PRC1 overexpression in AML patient samples and found that high PRC1 levels were associated with reduced overall survival, supporting the rationale for targeting PRC1 with BKT300.",['TCGA-LAML'],"['Web-based analysis', 'Web-based visualization']",['PRC1'],"['Expression analysis', 'Survival analysis']",cBioPortal platform,medium,4.0,40034437,BKT300: A Novel Anti-Leukemic Small Molecule Targeting the Protein Regulator of Cytokinesis 1 (PRC1) Pathway.,2025,abstract,2025-12-19T03:56:39.131256,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Leukemia/Lymphoma'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],['Multiple sources'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal being used in this study. The paper focuses on analyzing transcriptomic and microbiome data from 48 DLBCL patients obtained from public databases, using consensus clustering, functional enrichment analysis, immune infiltration assessments, and single-cell RNA sequencing. While cBioPortal may be cited in the references, no specific usage of the platform for data download, analysis, or visualization is described in the provided text.",[],['Citation only'],"['GSTM5', 'LURAP1', 'LINC02802', 'MAB21L3', 'C2CD4D', 'MMEL1', 'TSPAN2', 'CITED4']",['Not specified'],Unclear,low,4.0,40029433,Identification of intratumoral microbiome-driven immune modulation and therapeutic implications in diffuse large B-cell lymphoma.,2025,pdf,2025-12-19T03:56:39.827592,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Drug response/resistance', 'Tumor evolution', 'Precision medicine', 'Methods/Tools development']",['Original research'],"['Custom/Private data', 'Multiple sources']","Based on the abstract and title provided, the paper appears to focus on developing patient-derived organoid models and characterizing appendiceal cancer peritoneal metastasis. While cBioPortal is cited, the abstract does not provide explicit details about how cBioPortal was used in this study. The study primarily involves custom patient-derived organoid models, single-cell profiling, and drug testing, suggesting cBioPortal may have been used for comparative genomic analysis or literature context.",[],['Citation only'],['KRAS'],['Not specified'],Unclear,low,4.0,40027618,Paired primary-metastasis patient-derived organoids and mouse models identify phenotypic evolution and druggable dependencies of peritoneal metastasis from appendiceal cancer.,2025,abstract,2025-12-19T03:56:39.578081,,,,
['Other'],"['Pan-cancer', 'Breast cancer', 'Leukemia/Lymphoma', 'Prostate cancer']","['Review/Commentary', 'Drug response/resistance', 'Precision medicine']",['Review'],['Not specified'],This is a review article about ATM inhibitors in cancer therapy. The paper does not describe any specific use of cBioPortal for data analysis or visualization. cBioPortal may be cited in the references but no explicit usage is described in the provided abstract and introduction sections.,[],['Citation only'],['ATM'],['Not specified'],Unclear,low,4.0,40024979,The Development of ATM Inhibitors in Cancer Therapy.,2025,pdf,2025-12-19T03:56:43.183264,,,,
"['Gene expression analysis', 'Mutation analysis', 'Copy number analysis']","['Melanoma', 'Other solid tumor']","['Biomarker discovery', 'Review/Commentary']",['Review'],['Not specified'],"The authors utilized cBioPortal as a bioinformatic tool to analyze relevant data for identifying alterations in gene products that are S-palmitoylated in the context of skin conditions. The analysis focused on examining genomic alterations in genes related to S-palmitoylation and zDHHC enzymes. However, specific details about which datasets were queried, which genes were analyzed, or what specific features were used are not provided in the abstract.",[],['Web-based analysis'],[],['Not specified'],Unclear,low,4.0,40004137,zDHHC-Mediated S-Palmitoylation in Skin Health and Its Targeting as a Treatment Perspective.,2025,abstract,2025-12-19T03:56:42.911237,,,,
['Other'],['Breast cancer'],['Review/Commentary'],['Review'],['Not specified'],"This is a literature review examining the relationship between human cytomegalovirus (HCMV) infection and breast cancer. Based on the title, abstract, and introduction provided, there is no explicit mention of cBioPortal usage in the study. The paper appears to be a comprehensive review of clinical and experimental data regarding HCMV's role in breast carcinogenesis, but does not describe any direct analysis using cBioPortal resources.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40001942,Human Cytomegalovirus Infection and Breast Cancer: A Literature Review of Clinical and Experimental Data.,2025,abstract,2025-12-19T03:56:41.744599,,,,
"['Gene expression analysis', 'Other']",['Breast cancer'],"['Biomarker discovery', 'Other']",['Original research'],['TCGA'],"Based on the abstract and introduction provided, cBioPortal appears to be used minimally or only cited in this study. The paper focuses on experimental mechanistic studies of BLM peptide in DNA damage response using cell lines and mouse models. Any cBioPortal usage is likely limited to querying BLM expression or mutation data in breast cancer datasets, but specific usage details are not provided in the available text.",[],['Citation only'],['BLM'],['Not specified'],Unclear,low,4.0,39997217,Phosphorylated BLM peptide acts as an agonist for DNA damage response.,2025,abstract,2025-12-19T03:56:42.881553,,,,
['Other'],['Other solid tumor'],['Methods/Tools development'],"['Methods/Software', 'Original research']",['Custom/Private data'],"This paper does not appear to use cBioPortal at all. The study focuses on developing a novel LLM-based pipeline for extracting structured clinical information from unstructured pathology reports for kidney tumors. The work involves natural language processing and information extraction from free-text medical records, not genomic data analysis through cBioPortal.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39990557,Prompts to Table: Specification and Iterative Refinement for Clinical Information Extraction with Large Language Models.,2025,abstract,2025-12-19T03:56:42.402326,,,,
"['Gene expression analysis', 'Copy number analysis']",['Breast cancer'],"['Drug response/resistance', 'Biomarker discovery']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal being used in this study. The paper describes a clinical trial (CALGB 40903) where the authors performed their own whole-transcriptome RNA sequencing and shallow whole-genome DNA sequencing on patient specimens. The analysis focused on PAM50 classification, differential gene expression, and KI67 proliferation markers using their own custom data from the clinical trial. If cBioPortal is cited, it appears to be a citation only without direct usage for data analysis or visualization in this particular study.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39980051,"Genomic alterations are associated with response to aromatase inhibitor therapy for ER-positive postmenopausal ductal carcinoma in situ: (CALGB 40903, Alliance).",2025,abstract,2025-12-19T03:56:44.900106,,,,
"['Mutation analysis', 'Gene expression analysis']","['Colorectal cancer', 'Other solid tumor']","['Biomarker discovery', 'Methods/Tools development']",['Original research'],['Multiple sources'],"The authors used cBioPortal to investigate the association between CTRP6 missense mutations (specifically G181S and R247W) and different cancer types. They identified associations with colon adenocarcinoma and uterine corpus endometrial carcinoma, and examined how the mutational status of CTRP6 affected the expression of other cancer-related genes including MAP2K3, p16, TP53, and JAK1. The cBioPortal database was used alongside canSAR to query cancer genomics data.",[],"['Web-based analysis', 'Web-based visualization']","['CTRP6', 'MAP2K3', 'CDKN2A', 'TP53', 'JAK1']","['Query interface', 'Expression analysis']",cBioPortal platform,medium,4.0,39979869,Comprehensive characterization of pathogenic missense CTRP6 variants and their association with cancer.,2025,abstract,2025-12-19T03:56:45.370732,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis', 'Multi-omics integration']",['Colorectal cancer'],"['Pathway analysis', 'Drug response/resistance', 'Precision medicine', 'Biomarker discovery']",['Original research'],['TCGA'],"The study used cBioPortal to access and analyze colorectal cancer data, comparing Lynch syndrome-associated CRC with sporadic CRC. The researchers analyzed molecular data including mutations and gene expression to identify distinct dysregulated pathways (PI3K-Akt in LS-associated CRC vs. Wnt signaling in sporadic CRC). The analysis focused on identifying subtype-specific oncogenic pathways to inform targeted therapeutic approaches.",['TCGA-COADREAD'],['Data download/export'],[],['Download data'],External (downloaded data),medium,4.0,39973357,Distinct dysregulated pathways in sporadic and Lynch syndrome-associated colorectal cancer offer insights for targeted treatment.,2025,abstract,2025-12-19T03:56:45.443826,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used alongside GEPIA2 to assess genetic alterations and RNA modifications of ENOPH1 across multiple cancer types. The platform was specifically mentioned for analyzing genetic alterations (mutations and deep deletions) in cancers such as UCEC, BLCA, and OV. The study appears to have used cBioPortal as one of several bioinformatics platforms for comprehensive pan-cancer analysis of ENOPH1.",[],['Web-based analysis'],['ENOPH1'],['Not specified'],Unclear,medium,4.0,39955431,Comprehensive pan-cancer analysis of ENOPH1 in human tumors.,2025,abstract,2025-12-19T03:56:45.688719,,,,
"['Gene expression analysis', 'Pathway analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper describes using bulk RNA-sequencing from 3 independent multi-institutional thyroid cancer patient cohorts, RNA in situ hybridization, in vitro Wnt reporter assays, and in vivo mouse xenograft models. The data sources appear to be custom/private institutional cohorts rather than public databases accessed through cBioPortal.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39951495,Tenascin-C Potentiates Wnt Signaling in Thyroid Cancer.,2025,abstract,2025-12-19T03:56:45.382631,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']",['Not specified'],"The study used cBioPortal database to obtain clinicopathologic data, somatic mutation data, and mRNA expression profiles from patients with early-stage node-negative colon cancer who underwent surgical resection. Gene expression profiles were used to classify tumors into consensus molecular subtypes (CMS), and somatic mutations were analyzed for associations with recurrence. The analysis identified 12 mutated genes and CMS4 subtype as significantly associated with recurrence risk.",[],['Data download/export'],"['KRAS', 'PIK3CA', 'DNAH11', 'NALCN', 'COL6A3', 'GRIN2A', 'COL6A1', 'TNN', 'NEXMIF', 'PKHD1L1', 'CDH4', 'BCL9']",['Download data'],External (downloaded data),high,4.0,39948314,Genomic Signatures of Recurrence After Resection of Early-Stage Node-Negative Colon Cancer.,2025,abstract,2025-12-19T03:56:48.530314,,,,
"['Gene expression analysis', 'Pathway analysis']",['Breast cancer'],"['Review/Commentary', 'Biomarker discovery', 'Drug response/resistance']",['Review'],['Not specified'],"This is a review paper focused on CTGF/CCN2 in breast cancer progression and therapeutic targeting. The paper does not explicitly describe any direct use of cBioPortal for data analysis or visualization. If cBioPortal is mentioned, it appears to be only as a citation or reference to existing databases rather than as an analytical tool actively used by the authors.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39945880,CTGF (CCN2): a multifaceted mediator in breast cancer progression and therapeutic targeting.,2025,abstract,2025-12-19T03:56:47.947937,,,,
"['Mutation analysis', 'Survival analysis', 'Gene expression analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'ICGC', 'GENIE', 'Multiple sources']","The study used cBioPortal to access and analyze multiple public databases including AACR GENIE, TCGA, and ICGC data for urothelial carcinoma. The authors investigated KDM6A mutation rates and their gender-biased prognostic effects across multiple cohorts including immune therapy cohorts (IMvigor 210), chemotherapy cohorts, and BCG treatment cohorts. cBioPortal was used to query mutation data, expression data, and clinical outcomes across these various datasets.","['AACR GENIE', 'TCGA', 'ICGC', 'IMvigor 210', 'UC-GENOME']","['Data download/export', 'Web-based analysis']","['KDM6A', 'ATRX', 'CNKSR2', 'DDX3X', 'KDM5C', 'MAGEC3']","['Query interface', 'Download data']",Mixed,medium,4.0,39941725,The Gender-Biased Differential Effect of <i>KDM6A</i> Mutation on Immune Therapy in Urothelial Carcinoma: A Public Database Study.,2025,pdf,2025-12-19T03:56:50.099091,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Lung cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The study used cBioPortal for bioinformatic analysis of RIT1 alterations in lung cancer, including mutation and amplification patterns. The authors analyzed survival outcomes associated with RIT1 alterations and compared RIT1 with RAS paralogs (KRAS, NRAS, HRAS) in lung adenocarcinoma. cBioPortal was likely used to query genomic data and perform survival analysis on lung cancer datasets.",[],"['Web-based analysis', 'Web-based visualization']","['RIT1', 'KRAS', 'NRAS', 'HRAS']","['Survival analysis', 'Query interface']",Unclear,medium,4.0,39920793,Oncogenic RIT1 mutations confer ferroptosis vulnerability in lung adenocarcinoma.,2025,abstract,2025-12-19T03:56:49.170934,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Pan-cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the abstract or introduction provided. The study utilized publicly available pan-cancer datasets from TCGA, GEO, UALCAN, TIMER, GEPIA2, KM plotter, and TISIDB for comprehensive bioinformatics analysis. While cBioPortal is cited, there is no clear description of how it was specifically used in the methodology based on the provided text.",[],['Citation only'],['PAQR11'],['Not specified'],Unclear,low,4.0,39906812,"Golgi scaffold protein PAQR11 in pan-cancer landscape: A comprehensive bioinformatics exploration of expression patterns, prognostic significance, and potential immunological function.",2025,abstract,2025-12-19T03:56:50.229892,,,,
"['Mutation analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The authors performed targeted next-generation sequencing on 99 OPSCC samples and conducted retrospective clinical data analysis. The study appears to have used custom/private data from their own patient cohort rather than accessing cBioPortal resources. cBioPortal may only be cited in the references without direct usage in the methodology.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39906575,Multiple Mutations-A Genetic Marker for Extracapsular Spread in Human Papillomavirus/p16-Positive Oropharyngeal Carcinoma.,2025,abstract,2025-12-19T03:56:50.880228,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Breast cancer'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],['Multiple sources'],The authors analyzed publicly available breast cancer patient data to examine the association between ELF3 expression and patient prognosis. They used cBioPortal to assess ELF3 expression levels and their correlation with survival outcomes and cell cycle progression programs in breast cancer patients. This analysis was used to validate their experimental findings that ELF3 upregulation is associated with paclitaxel resistance in TNBC.,[],['Web-based analysis'],['ELF3'],"['Expression analysis', 'Survival analysis']",Unclear,medium,4.0,39905117,TNBC response to paclitaxel phenocopies interferon response which reveals cell cycle-associated resistance mechanisms.,2025,abstract,2025-12-19T03:56:51.268285,,,,
"['Copy number analysis', 'Survival analysis']",['Leukemia/Lymphoma'],"['Database/Resource', 'Biomarker discovery', 'Methods/Tools development']","['Original research', 'Methods/Software']",['Multiple sources'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on the development of LeukAtlas, a new database for CNV analysis in AML, compiled from public datasets. cBioPortal may be cited as a reference or related resource, but specific usage details are not provided in the available text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39894867,Patterns and variations of copy number alterations in acute myeloid leukemia: insights from the LeukAtlas database.,2025,abstract,2025-12-19T03:56:51.473933,,,,
"['Gene expression analysis', 'Mutation analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Pathway analysis', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used as one of multiple web platforms for data analysis in this pan-cancer study of KANK2 across 33 cancer types. The platform was specifically mentioned alongside other tools (R, Cytoscape, HPA, TISIDB, UALCAN, GEO, STRING, GSCALite, and CancerSEA) for exploring genetic alterations. The study investigated KANK2's associations with specific genetic mutations using cBioPortal, though specific details of the analysis methodology are not provided in the abstract and introduction.",['TCGA'],['Web-based analysis'],['KANK2'],['Not specified'],External (downloaded data),medium,4.0,39895803,Pan-Cancer Analysis of KANK2: Clinical and Molecular Insights into Tumor Progression and Therapeutic Implications.,2025,pdf,2025-12-19T03:56:51.842734,,,,
"['Gene expression analysis', 'Survival analysis']",['Breast cancer'],"['Drug response/resistance', 'Tumor evolution', 'Biomarker discovery']",['Original research'],"['TCGA', 'Custom/Private data']",The authors used cBioPortal to access TCGA breast cancer patient data for survival analysis. They correlated gene expression patterns from pre-adapted cells identified in their in vitro models with survival outcomes in TNBC patients who received chemotherapy. The analysis showed that expression patterns from pre-adapted cells correlated with patient survival (p = 0.03).,['TCGA'],"['Data download/export', 'Web-based analysis']",[],"['Survival analysis', 'Expression analysis', 'Download data']","[""Mixed""]",medium,4.0,39901189,EMT-driven plasticity prospectively increases cell-cell variability to promote therapeutic adaptation in breast cancer.,2025,abstract,2025-12-19T03:56:51.876807,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the abstract or introduction provided. The study utilized TCGA-BRCA data along with other databases (DRESIS, MSigDB, GeneCards, GEO) to identify drug resistance and mitochondrial energy metabolism-related genes. While TCGA data was used, there is no clear indication that cBioPortal was the platform through which this data was accessed or analyzed.",['TCGA-BRCA'],['Citation only'],"['ATP7B', 'FUS', 'AIFM1', 'PPARG']",['Not specified'],Unclear,low,4.0,39885513,Identification and validation of a prognostic signature of drug resistance and mitochondrial energy metabolism-related differentially expressed genes for breast cancer.,2025,abstract,2025-12-19T03:56:54.088363,,,,
"['Copy number analysis', 'Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],['TCGA'],cBioPortal was used to analyze TCGA ovarian cancer data to examine the correlation between TNIK and CDK9 expression and to assess the prognostic significance of chromosomal gains in both genes. The platform was utilized to perform co-expression analysis and survival analysis to determine that chromosomal gains in TNIK and CDK9 served as prognostic markers for poor patient outcomes in high-grade serous ovarian cancer.,['TCGA ovarian cancer'],"['Web-based analysis', 'Web-based visualization']","['TNIK', 'CDK9']","['Expression analysis', 'Survival analysis']","[""cBioPortal platform""]",high,4.0,39873147,Identification of a TNIK-CDK9 Axis as a Targetable Strategy for Platinum-Resistant Ovarian Cancer.,2025,abstract,2025-12-19T03:56:54.427164,,,,
['Gene expression analysis'],['Pan-cancer'],"['Immunotherapy', 'Biomarker discovery']",['Original research'],['TCGA'],"The authors used cBioPortal to analyze human solid tumor datasets to examine the co-expression patterns of STING (TMEM173) and RIG-I (DDX58) across multiple cancer types. This analysis was performed to demonstrate that STING and RIG-I co-expression is prevalent in solid tumors and to assess associations with clinical outcomes in various cancer indications, particularly those amenable to intratumoral administration.",['TCGA'],"['Web-based analysis', 'Web-based visualization']","['TMEM173', 'DDX58']","['Expression analysis', 'Query interface']",cBioPortal platform,medium,4.0,39868467,VAX014 Activates Tumor-Intrinsic STING and RIG-I to Promote the Development of Antitumor Immunity.,2025,abstract,2025-12-19T03:56:54.742654,,,,
"['Mutation analysis', 'Survival analysis']",['Lung cancer'],"['Immunotherapy', 'Drug response/resistance', 'Biomarker discovery', 'Review/Commentary']",['Review'],['Not specified'],"This is a review paper that summarizes existing literature on STK11, KEAP1, and KRAS mutations in NSCLC and their implications for immunotherapy. The paper does not appear to directly use cBioPortal for original analysis but may cite it as a reference or data source in the context of discussing mutation frequencies and co-occurrence patterns. No specific cBioPortal analysis or data extraction is described in the abstract.",[],['Citation only'],"['STK11', 'KEAP1', 'KRAS']",['Not specified'],Unclear,low,4.0,39830769,"Emerging insights into <i>STK11</i>, <i>KEAP1</i> and <i>KRAS</i> mutations: implications for immunotherapy in patients with advanced non-small cell lung cancer.",2024,abstract,2025-12-19T03:56:56.501512,,,,
['Gene expression analysis'],['Leukemia/Lymphoma'],['Other'],['Original research'],['Not specified'],"This paper does not appear to use cBioPortal directly. The study focuses on zebrafish hematopoietic development and the role of Sfrp1a in HSPC specification and differentiation. While the abstract mentions parallels to hematopoietic cancers where SFRP1 variants can drive tumorigenesis, there is no explicit mention of cBioPortal usage, data queries, or analysis in the provided abstract and introduction.",[],['Citation only'],[],['Not specified'],"[""Unclear""]","[""low""]",4.0,39829913,Secreted Frizzled-Related Protein 1a regulates hematopoietic development in a dose-dependent manner.,2025,abstract,2025-12-19T03:56:57.116363,,,,
"['Mutation analysis', 'Copy number analysis']",['Glioma/Brain cancer'],"['Methods/Tools development', 'Precision medicine', 'Biomarker discovery']","['Original research', 'Methods/Software']","['TCGA', 'Custom/Private data']","The paper developed GLISP, an AI framework to predict genetic abnormalities in adult diffuse gliomas from H&E histology images. The model was trained using TCGA whole-slide images (WSIs) to predict nine genetic events including IDH1/2, ATRX, TP53 mutations, TERT promoter mutations, CDKN2A/B homozygous deletion, EGFR amplification, 7+/10-, 1p/19q co-deletion, and MGMT promoter methylation. While TCGA data was used for training, the paper does not explicitly describe using cBioPortal for data access or analysis, though TCGA data could have been obtained through cBioPortal or other sources.",['TCGA'],['Citation only'],"['IDH1', 'IDH2', 'ATRX', 'TP53', 'TERT', 'CDKN2A', 'CDKN2B', 'EGFR', 'MGMT']",['Not specified'],Unclear,low,4.0,39851286,Glioma Image-Level and Slide-Level Gene Predictor (GLISP) for Molecular Diagnosis and Predicting Genetic Events of Adult Diffuse Glioma.,2024,pdf,2025-12-19T03:56:57.286739,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']",cBioPortal was used to analyze TPPP3 genetic alterations and mutations in head and neck squamous cell carcinoma (HNSC). The study examined the relationship between TPPP3 genetic alterations and mRNA expression changes in HNSC patients. This analysis was part of a comprehensive multi-database approach to characterize TPPP3 as a potential biomarker in oral squamous cell carcinoma.,[],['Web-based analysis'],['TPPP3'],"['Query interface', 'Expression analysis']",cBioPortal platform,medium,4.0,39814636,"TPPP3, a Good Prognostic Indicator, Suppresses Cell Proliferation and Migration in OSCC.",2025,abstract,2025-12-19T03:56:57.659686,,,,
"['Gene expression analysis', 'Survival analysis']",['Breast cancer'],"['Biomarker discovery', 'Other']",['Original research'],"['TCGA', 'METABRIC']","The authors used cBioPortal to analyze OTUD6B and KIFC1 expression levels in breast cancer patient datasets, specifically TCGA and METABRIC cohorts. They examined the correlation between OTUD6B overexpression and patient survival outcomes in breast cancer. The analysis demonstrated that OTUD6B is commonly overexpressed in breast cancer and correlates with KIFC1 protein expression and worse patient survival.","['TCGA', 'METABRIC']","['Web-based analysis', 'Web-based visualization']","['OTUD6B', 'KIFC1']","['Expression analysis', 'Survival analysis']",cBioPortal platform,high,4.0,39789388,OTUD6B regulates KIFC1-dependent centrosome clustering and breast cancer cell survival.,2025,abstract,2025-12-19T03:56:57.722805,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis']",['Leukemia/Lymphoma'],"['Review/Commentary', 'Biomarker discovery', 'Pathway analysis']",['Review'],['Not specified'],"This is a review paper discussing p53-responsive microRNAs in diffuse large B-cell lymphoma (DLBCL). The paper mentions cBioPortal as one of the bioinformatics tools and databases that support DLBCL research, but does not describe any specific usage of the platform for original data analysis. The reference to cBioPortal appears to be in the context of available resources rather than direct application in this study.",[],['Citation only'],['TP53'],['Not specified'],Unclear,low,4.0,39802185,Deregulation mechanisms and therapeutic opportunities of p53-responsive microRNAs in diffuse large B-cell lymphoma.,2025,abstract,2025-12-19T03:56:58.075143,,,,
"['Gene expression analysis', 'Survival analysis']",['Pan-cancer'],"['Drug response/resistance', 'Pathway analysis']",['Original research'],['TCGA'],"Based on the abstract and introduction provided, the paper appears to focus on PI5P4Ks' role in cholesterol metabolism and mTOR signaling in p53-deficient cancers. While cBioPortal is cited, the specific usage details are not provided in the excerpts given. The study likely used cBioPortal to access TCGA data for analyzing gene expression patterns and potentially survival outcomes related to PI5P4K and p53 status across cancer types, but the exact methodology is not described in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39803512,"Noncanonical PI(4,5)P<sub>2</sub> coordinates lysosome positioning through cholesterol trafficking.",2025,abstract,2025-12-19T03:56:59.077963,,,,
['Mutation analysis'],['Breast cancer'],"['Methods/Tools development', 'Database/Resource', 'Precision medicine']","['Original research', 'Methods/Software']",['Custom/Private data'],"This paper does not appear to directly use cBioPortal for data analysis or visualization. The study focuses on developing a saturation genome editing approach to functionally classify BRCA2 variants using mouse embryonic stem cells. The paper references ClinVar as the clinical variant database for comparison, but there is no explicit mention of cBioPortal usage in the abstract or introduction provided.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39779848,Saturation genome editing-based clinical classification of BRCA2 variants.,2025,abstract,2025-12-19T03:57:00.554392,,,,
"['Mutation analysis', 'Gene expression analysis']",['Lung cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on analyzing 1560 tumor biopsies from Latin American NSCLC patients using a 52-gene NGS panel, with emphasis on MET exon 14 skipping variants and novel actionable variants. The study appears to use custom/private data from Chile, Brazil, and Peru, with analysis performed using their own sequencing platform and bioinformatic tools (Cancer Genome Interpreter, CADD). cBioPortal may only be cited in the full text but is not described as a primary tool for this research.",[],['Citation only'],"['MET', 'EGFR', 'ALK', 'ROS1', 'ERBB2', 'BRAF', 'KRAS', 'RET', 'NTRK1', 'NTRK2', 'NTRK3']",['Not specified'],Unclear,low,4.0,39769478,MET Exon 14 Skipping and Novel Actionable Variants: Diagnostic and Therapeutic Implications in Latin American Non-Small-Cell Lung Cancer Patients.,2024,pdf,2025-12-19T03:57:02.722615,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Pathway analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Pathway analysis', 'Review/Commentary']",['Review'],['Not specified'],"Based on the limited information provided (title, authors, year, venue, and partial abstract), this appears to be a review paper exploring predictive biomarkers and molecular pathways in rectal cancer carcinogenesis. cBioPortal is likely cited as a reference resource or database for cancer genomics data, but specific usage details are not evident from the provided excerpt. The paper focuses on colorectal/rectal cancer biomarkers and molecular mechanisms.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39765674,Rectal Cancer: Exploring Predictive Biomarkers Through Molecular Pathways Involved in Carcinogenesis.,2024,abstract,2025-12-19T03:57:03.600322,,,,
"['Gene expression analysis', 'Multi-omics integration', 'Other']",['Breast cancer'],"['Drug response/resistance', 'Precision medicine', 'Methods/Tools development']","['Original research', 'Methods/Software']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage. The study focuses on developing ScreenDL, a deep learning model trained on patient-derived tumor models and functional drug screening data. Without access to the full methods section, it is unclear if cBioPortal was used for data acquisition, validation, or comparison purposes.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39763776,A precision oncology-focused deep learning framework for personalized selection of cancer therapy.,2024,abstract,2025-12-19T03:57:03.653666,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not provide explicit details about how cBioPortal was used in the study. While multiple public databases are mentioned in the abstract (TCGA, GEO, UALCAN, TIMER, HPA, INTEGRATOMICS-HCC), cBioPortal is not specifically mentioned in the provided abstract and introduction sections. The study focuses on analyzing PAXIP1 expression and its prognostic value in hepatocellular carcinoma using various bioinformatics databases, but the specific role of cBioPortal, if any, is not described in the available text.",['TCGA'],['Citation only'],"['PAXIP1', 'MYBL2', 'FOXO1', 'NRF1', 'PAX2', 'TP53BP1', 'EPHA2', 'PDCD1', 'CD274', 'CTLA4']",['Not specified'],Unclear,low,4.0,39781045,PAXIP1 is regulated by NRF1 and is a prognosis‑related biomarker in hepatocellular carcinoma.,2025,pdf,2025-12-19T03:57:03.861904,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Other solid tumor', 'Pan-cancer']","['Biomarker discovery', 'Pathway analysis', 'Other']",['Original research'],"['TCGA', 'Multiple sources']","The paper used cBioPortal to access and analyze TCGA data for clear cell renal cell carcinoma (ccRCC) and other cancer types. The authors examined gene expression patterns, survival outcomes, and pathway enrichment in relation to nuclear speckle states across multiple cancer types. cBioPortal served as a data source for integrating genomic and clinical information to correlate speckle signatures with patient outcomes and functional pathways.",['TCGA'],"['Data download/export', 'Web-based analysis']",['EPAS1'],"['Expression analysis', 'Survival analysis', 'Download data']",Mixed,medium,4.0,39747580,Nuclear speckles regulate functional programs in cancer.,2025,abstract,2025-12-19T03:57:05.397210,,,,
['Other'],['Not specified'],['Methods/Tools development'],['Methods/Software'],['Not specified'],"This paper describes the development of pyBioPortal, a Python package designed to simplify programmatic interaction with cBioPortal's REST API. The tool retrieves genomic and clinical data from cBioPortal and returns it as Pandas DataFrames for downstream analysis. This is a methods/software development paper that creates a tool to facilitate API access to cBioPortal rather than using cBioPortal for a specific research study.",[],['API access'],[],['Not specified'],"[""External (downloaded data)""]",high,4.0,39735786,<i>pyBioPortal</i>: a Python package for simplifying cBioPortal data access in cancer research.,2025,abstract,2025-12-19T03:57:06.503620,,,,
"['Gene expression analysis', 'Survival analysis']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],"The study analyzed publicly available datasets to assess CYBC1 expression in glioblastoma and its correlation with patient survival. Based on the abstract, cBioPortal was likely used to access TCGA glioblastoma data for expression and survival analysis. However, specific details about how cBioPortal was used are not provided in the abstract and introduction.",[],['Citation only'],"['CYBC1', 'NOXA1']",['Not specified'],Unclear,low,4.0,39727012,CYBC1 Drives Glioblastoma Progression via Reactive Oxygen Species and NF-κB Pathways.,2025,abstract,2025-12-19T03:57:08.389677,,,,
['Other'],['Glioma/Brain cancer'],"['Review/Commentary', 'Biomarker discovery']",['Review'],['Not specified'],"This is a review paper that summarizes the role of MACF1 as an oncoprotein in brain tumors, particularly glioblastomas. The paper does not describe any direct usage of cBioPortal for original analysis. cBioPortal may be cited as a reference or mentioned in the context of discussing genetic alterations in MACF1 across cancers, but no specific analysis, data download, or visualization using the platform is described in the abstract or introduction provided.",[],['Citation only'],['MACF1'],['Not specified'],"[""Unclear""]","[""low""]",4.0,39720461,"Microtubule actin crosslinking factor 1, a brain tumor oncoprotein (Review).",2025,abstract,2025-12-19T03:57:10.075975,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis']","['Pan-cancer', 'Breast cancer', 'Prostate cancer', 'Leukemia/Lymphoma', 'Lung cancer']","['Biomarker discovery', 'Precision medicine']",['Original research'],['TCGA'],"The authors downloaded RNA-seq data, genetic mutation data, and clinical information from TCGA via cBioPortal in April 2024. They used normalized gene expression data (log2 transformed RSEM values) for 10,071 tumor samples across 33 cancer types to perform hierarchical clustering analysis of nuclear receptor genes. Kaplan-Meier survival plots were generated using cBioPortal's visualization tools.",['TCGA Pan-Cancer Atlas'],"['Data download/export', 'Web-based visualization']","['ESR1', 'ESR2', 'PGR', 'AR', 'RARA', 'RXRG', 'NR0B1', 'PML']","['Download data', 'Survival analysis']",Mixed,high,4.0,39715959,Nuclear receptor profiling for subtype classification and as prognostic markers in 33 cancer types.,2024,pdf,2025-12-19T03:57:10.827945,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used as one of multiple online databases and tools to explore genetic mutations of ZBTB11 across tumor types. The study mentions cBioPortal in the methods section alongside other databases like TIMER2.0, GEPIA2, UALCAN, GSCA, and CancerSEA for comprehensive pan-cancer analysis. The specific details of how cBioPortal was used are not extensively described in the provided abstract and introduction.",[],['Web-based analysis'],['ZBTB11'],['Not specified'],Unclear,medium,4.0,39715911,Systematic pan-cancer analysis identifies ZBTB11 as a potential pan-cancer biomarker and immunotherapy target in multiple tumor types.,2024,pdf,2025-12-19T03:57:11.261520,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Pathway analysis', 'Multi-omics integration']",['Prostate cancer'],"['Biomarker discovery', 'Precision medicine', 'Immunotherapy']",['Original research'],"['Custom/Private data', 'TCGA']","Based on the abstract and introduction provided, cBioPortal is not explicitly mentioned in the text. The paper describes a multi-omics approach to characterize a prostate cancer case with TMPRSS2-ERG fusion and 16q deletion, including analysis of KDM6A deletion, hypoxia, immune infiltration, and tumor mutational burden. While the paper may cite cBioPortal in the full text or methods section not provided here, the specific usage details are not apparent from the available content.",[],['Citation only'],"['ERG', 'TMPRSS2', 'KDM6A', 'PTEN', 'TP53', 'BRCA2', 'MYC']",['Not specified'],Unclear,low,4.0,39741346,Unveiling the molecular profile of a prostate carcinoma: implications for personalized medicine.,2024,pdf,2025-12-19T03:57:11.755949,,,,
"['Mutation analysis', 'Survival analysis', 'Pathway analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Precision medicine', 'Other']",['Original research'],"['Custom/Private data', 'Multiple sources']","The study used cBioPortal as a secondary screening tool to identify ""survival-critical genes (SCGs)"" among differentially mutated genes found in their whole-exome sequencing analysis. They queried cancer databases through cBioPortal to determine which genes with race-specific mutations were associated with significant differences in patient survival rates. This helped validate the functional importance of the identified race-pronounced genetic variants in colorectal cancer.",[],"['Web-based analysis', 'Citation only']",[],"['Survival analysis', 'Query interface']",Unclear,medium,4.0,39715885,"Mutational disparities in colorectal cancers of White Americans, Alabama African Americans, And Oklahoma American Indians.",2024,pdf,2025-12-19T03:57:12.645270,,,,
"['Mutation analysis', 'Methods/Tools development']",['Pan-cancer'],"['Methods/Tools development', 'Tumor evolution', 'Biomarker discovery']","['Original research', 'Methods/Software']",['TCGA'],"The paper uses TCGA cancer database data (sample sizes n=300-1000) to develop a theoretical framework for identifying cancer-driving nucleotides (CDNs) based on mutation recurrence patterns. The study analyzes point mutations across multiple cancer types to determine recurrence thresholds that distinguish driver mutations from neutral passenger mutations. While TCGA data is central to the analysis, the specific role of cBioPortal as a data access platform versus direct TCGA access is not explicitly detailed in the abstract.",['TCGA'],['Citation only'],[],['Not specified'],Unclear,low,4.0,39688960,The theory of massively repeated evolution and full identifications of cancer-driving nucleotides (CDNs).,2024,abstract,2025-12-19T03:57:14.088042,,,,
"['Mutation analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Methods/Tools development', 'Precision medicine']","['Original research', 'Methods/Software']",['TCGA'],"The paper uses TCGA data to identify cancer-driving nucleotides (CDNs) through recurrent mutation analysis across multiple cancer types. The study analyzes point mutations to identify CDNs with 3 or more recurrent hits in TCGA database, characterizing 50-150 CDNs per cancer type. The specific role of cBioPortal in data access or analysis is not explicitly detailed in the abstract and introduction provided.",['TCGA'],['Citation only'],[],['Not specified'],Unclear,low,4.0,39688957,"Characterization of cancer-driving nucleotides (CDNs) across genes, cancer types, and patients.",2024,abstract,2025-12-19T03:57:14.680563,,,,
"['Mutation analysis', 'Other']",['Other solid tumor'],"['Biomarker discovery', 'Other']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The study focused on retrospective identification of mesonephric-like adenocarcinoma (MLA) in endometrial carcinomas using immunohistochemistry, morphological review, KRAS sequencing, and ProMisE molecular classification. The analysis appears to have been conducted entirely on institutional samples without reference to cBioPortal data or tools.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39687985,Papillary and ductal patterns of mesonephric-like adenocarcinomas are often overlooked: a retrospective revaluation of over 1000 endometrial carcinomas.,2025,abstract,2025-12-19T03:57:15.723988,,,,
"['Gene expression analysis', 'Pathway analysis', 'Copy number analysis']",['Other solid tumor'],"['Biomarker discovery', 'Tumor evolution']",['Original research'],['Custom/Private data'],"cBioPortal is not explicitly mentioned or used in this study. The paper focuses on single-cell RNA sequencing of small cell neuroendocrine cervical carcinoma using custom patient samples. The study analyzes the tumor microenvironment, gene expression regulatory networks, and compares findings with GEO database neuroendocrine carcinoma data, but does not reference cBioPortal usage.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39762893,Single-cell RNA sequencing highlights the unique tumor microenvironment of small cell neuroendocrine cervical carcinoma.,2025,pdf,2025-12-19T03:57:17.044476,,,,
"['Mutation analysis', 'Copy number analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']",['MSK-IMPACT'],"This study used MSK-IMPACT clinical sequencing data from 2,336 PDAC patients. The paper mentions that somatic alterations were annotated using OncoKB, which is part of the cBioPortal ecosystem. However, the paper does not explicitly describe direct usage of the cBioPortal platform for analysis or visualization; instead, it appears the authors used their institutional MSK-IMPACT data with internal analysis pipelines.",['MSK-IMPACT'],['Citation only'],"['KRAS', 'BRAF', 'NRAS', 'NF1', 'NTRK1', 'NTRK3', 'FGFR2', 'ERBB2', 'MAP2K1', 'ROS1', 'MET', 'RAF1', 'BRCA1', 'BRCA2', 'PALB2']",['Not specified'],"[""Unclear""]","[""low""]",4.0,39753968,Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival.,2025,pdf,2025-12-19T03:57:18.331825,,,,
"['Gene expression analysis', 'Pathway analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Custom/Private data']",cBioPortal was used to access TCGA pancreatic adenocarcinoma expression data for validation purposes. The authors used the metabolic-linked gene signature identified in their IPMN-derived samples to query TCGA expression database through cBioPortal and found it associated with a cluster of early-stage and long-survival PDAC cases. This served as an independent validation cohort for their findings from the ORIEN dataset.,['TCGA'],"['Web-based analysis', 'Expression analysis']","['MUC2', 'GKN2']","['Expression analysis', 'Query interface']",cBioPortal platform,medium,4.0,39684873,Molecular Pathway and Immune Profile Analysis of IPMN-Derived Versus PanIN-Derived Pancreatic Ductal Adenocarcinomas.,2024,abstract,2025-12-19T03:57:18.356475,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis']",['Leukemia/Lymphoma'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Custom/Private data']","Based on the abstract and introduction provided, the paper appears to cite cBioPortal as a reference for mutation data in acute myeloid leukemia, particularly regarding PHF6 and PHIP mutations. The authors mention that PHF6 mutations are associated with poorer outcomes and that PHIP was identified as the most common selective mutation in Black patients with AML, which likely comes from cBioPortal database queries. However, the specific details of how cBioPortal was used are not explicitly described in the provided text.",['TCGA'],['Citation only'],"['PHF6', 'PHIP']",['Not specified'],Unclear,low,4.0,39677666,Leukemia-mutated proteins PHF6 and PHIP form a chromatin complex that represses acute myeloid leukemia stemness.,2024,abstract,2025-12-19T03:57:18.474944,,,,
"['Mutation analysis', 'Survival analysis']","['Pan-cancer', 'Lung cancer', 'Prostate cancer']","['Methods/Tools development', 'Precision medicine']","['Original research', 'Methods/Software']",['GENIE'],This paper develops a statistical method (Bridge model) for integrating and harmonizing multi-institutional genomic data from GENIE BPC (AACR Project GENIE Biopharma Collaborative). The method addresses challenges in analyzing genomic data across institutions with different gene panels and sequencing techniques. The extracted latent features from the Bridge model were evaluated for predicting patient survival across six cancer types using GENIE BPC data.,['GENIE BPC'],['Data download/export'],[],['Download data'],External (downloaded data),medium,4.0,39679742,Unlocking the power of multi-institutional data: Integrating and harmonizing genomic data across institutions.,2024,pdf,2025-12-19T03:57:18.870257,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis']","['Pan-cancer', 'Bladder cancer', 'Lung cancer']","['Drug response/resistance', 'Biomarker discovery']",['Original research'],"['TCGA', 'Multiple sources']","The authors used cBioPortal to analyze gene expression data and survival outcomes across multiple cancer cohorts. They examined the NPEPPS/VRAC gene expression ratio as a predictive measure of cisplatin response in various cancer types including bladder, lung, and other cancers. The analysis involved querying TCGA datasets through cBioPortal to validate their findings about the relationship between NPEPPS, VRAC channels, and cisplatin sensitivity.",['TCGA'],"['Web-based analysis', 'Data download/export']","['NPEPPS', 'LRRC8A', 'LRRC8B', 'LRRC8C', 'LRRC8D', 'LRRC8E']","['Expression analysis', 'Survival analysis', 'Query interface']",Mixed,medium,4.0,39671496,Regulation of volume-regulated anion channels alters sensitivity to platinum chemotherapy.,2024,abstract,2025-12-19T03:57:18.994555,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and title, this study appears to use high-throughput data analysis to explore the RPA1-ETAA1 axis in liver cancer. While cBioPortal is cited, the specific usage details are not provided in the abstract. The study likely used cBioPortal to access TCGA liver cancer data for gene expression, correlation, and survival analyses related to ETAA1, RPA1, and PD-L1, as well as immune infiltration patterns.",['TCGA'],['Data download/export'],"['RPA1', 'ETAA1', 'CD274']",['Not specified'],"[""Unclear""]","[""low""]",4.0,39660144,Exploring RPA1-ETAA1 axis via high-throughput data analysis: implications for PD-L1 nuclear translocation and tumor-immune dynamics in liver cancer.,2024,abstract,2025-12-19T03:57:20.715455,,,,
"['Mutation analysis', 'Gene expression analysis', 'Multi-omics integration']",['Lung cancer'],"['Biomarker discovery', 'Tumor evolution']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to analyze mutation frequencies and correlations of cohesin complex components (STAG2, PAXIP1, PAGR1) in human lung cancer datasets. The authors likely queried mutation data and performed correlation analyses to identify genes with similar mutational patterns to STAG2 across lung cancer samples. This analysis helped establish the relationship between STAG2 and the PAXIP1/PAGR1 complex in human lung cancer.",['TCGA'],"['Web-based analysis', 'Data download/export']","['STAG2', 'PAXIP1', 'PAGR1']","['Query interface', 'Mutation Mapper']",Mixed,medium,4.0,39652422,A STAG2-PAXIP1/PAGR1 axis suppresses lung tumorigenesis.,2025,abstract,2025-12-19T03:57:21.241166,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis']",['Breast cancer'],"['Drug response/resistance', 'Pathway analysis', 'Review/Commentary']",['Review'],['Multiple sources'],The authors analyzed a publicly available breast cancer dataset to examine the relationship between HER2-low subtype and endocrine resistance in ER+ metastatic breast cancer. The analysis focused on identifying genetic alterations associated with endocrine resistance and their correlation with HER2-low classification. The study appears to be a perspective/review piece that incorporates analysis of existing data to support their hypothesis about the intersection of HER2-low subtype and endocrine resistance pathways.,[],"['Web-based analysis', 'Citation only']","['HER2', 'ESR1']",['Not specified'],Unclear,low,4.0,39650068,The intersection of the HER2-low subtype with endocrine resistance: the role of interconnected signaling pathways.,2024,abstract,2025-12-19T03:57:21.661010,,,,
['Gene expression analysis'],['Pan-cancer'],"['Review/Commentary', 'Drug response/resistance', 'Biomarker discovery']",['Review'],['Not specified'],"This is a review paper focused on KIF18A as a therapeutic target in cancer. Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage. The paper discusses KIF18A expression levels across various cancer types and its role in chromosomal instability, but specific data sources and analysis methods are not detailed in the provided text. cBioPortal may be cited as a reference or data source, but specific usage details cannot be determined from the abstract and introduction alone.",[],['Citation only'],['KIF18A'],['Not specified'],Unclear,low,4.0,39580563,KIF18A inhibition: the next big player in the search for cancer therapeutics.,2024,abstract,2025-12-19T03:57:24.937983,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Lung cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy', 'Precision medicine']","['Original research', 'Clinical study']","['TCGA', 'MSK-IMPACT', 'GENIE', 'Custom/Private data', 'Multiple sources']","The study utilized cBioPortal to access and analyze data from The Cancer Genome Atlas (TCGA) Pan-Cancer Atlas for lung adenocarcinoma patients. The authors likely used cBioPortal to obtain genomic, transcriptional, and clinical data to compare mucinous versus non-mucinous lung adenocarcinomas. The platform was used to extract mutation data, gene expression profiles, and potentially survival information from the TCGA cohort, which was integrated with data from five other institutions.",['TCGA Pan-Cancer Atlas'],['Data download/export'],"['KRAS', 'NKX2-1', 'STK11', 'SMARCA4', 'GNAS', 'ALK', 'TP53', 'EGFR', 'BRAF', 'MET']",['Download data'],External (downloaded data),medium,4.0,39637943,"Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRAS<sup>G12C</sup> inhibitors.",2025,abstract,2025-12-19T03:57:25.065192,,,,
"['Gene expression analysis', 'Other']",['Breast cancer'],"['Biomarker discovery', 'Immunotherapy']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The research appears to be based entirely on immunohistochemistry and immunofluorescence analysis of tissue samples from The University of Chicago (2002-2014). The study focuses on evaluating GR expression and immune cell infiltration in TNBC tissue samples using multiplexed antibody staining, with no reference to cBioPortal data or tools.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39579248,"High tumor glucocorticoid receptor expression in early-stage, triple-negative breast cancer is associated with increased T-regulatory cell infiltration.",2025,abstract,2025-12-19T03:57:25.073077,,,,
"['Mutation analysis', 'Gene expression analysis', 'Multi-omics integration', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine', 'Pathway analysis']",['Original research'],"['TCGA', 'Custom/Private data', 'Multiple sources']","Based on the abstract and title provided, this paper focuses on single-cell epigenetic profiling (ATAC-seq) of renal cell carcinoma tumors to investigate chromatin accessibility patterns associated with BAP1 mutations. While the paper studies cancer genomics and mentions mutations in epigenetic regulators like BAP1, there is no explicit mention of cBioPortal usage in the provided abstract and introduction. The study appears to primarily use custom single-nucleus ATAC sequencing data across four independent cohorts rather than cBioPortal data.",[],['Citation only'],['BAP1'],['Not specified'],Unclear,low,4.0,39605676,Single-cell epigenetic profiling reveals an interferon response-high program associated with <i>BAP1</i> deficiency in kidney cancer.,2024,abstract,2025-12-19T03:57:25.106499,,,,
"['Mutation analysis', 'Gene expression analysis', 'Drug response/resistance']",['Lung cancer'],"['Drug response/resistance', 'Precision medicine', 'Biomarker discovery']","['Original research', 'Clinical study']",['Multiple sources'],"The authors used the Cancer Cell Line Encyclopedia (CCLE) data, likely accessed through cBioPortal or similar platforms, to validate their findings by examining the sensitivity of BRAF class 3-mutated NSCLC cell lines to EGFR-TKIs compared to other mutation types. This analysis corroborated their preclinical findings showing differential drug sensitivity patterns across different BRAF mutation classes and KRAS-mutated cell lines.",['Cancer Cell Line Encyclopedia'],['Citation only'],"['BRAF', 'EGFR', 'KRAS']",['Not specified'],"[""Unclear""]",medium,4.0,39637338,Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring <i>BRAF</i> Class 3 Mutations.,2024,abstract,2025-12-19T03:57:25.359702,,,,
"['Mutation analysis', 'Pathway analysis']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Pathway analysis']","['Original research', 'Meta-analysis']",['Custom/Private data'],"Based on the abstract and title provided, there is no explicit mention of cBioPortal usage in this study. This paper focuses on somatic variant enrichment analysis in epileptogenic brain lesions using ultra-deep targeted panel sequencing of brain tissue samples. The study appears to be primarily focused on epilepsy-related lesions rather than cancer, though it includes low-grade epilepsy-associated tumors. Without access to the full methods section, it's unclear if cBioPortal was used for any comparative analysis or data validation.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39616148,Analysis of 1386 epileptogenic brain lesions reveals association with DYRK1A and EGFR.,2024,abstract,2025-12-19T03:57:25.652635,,,,
"['Mutation analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis', 'Immunotherapy']",['Original research'],['Multiple sources'],cBioPortal database was used to retrieve clinical data for endometrial cancer patients to compare overall survival between mutated POLE (POLEmut) and wild-type POLE. The survival analysis was performed to assess the prognostic impact of POLE mutations in endometrial cancer patients.,[],['Data download/export'],['POLE'],['Download data'],External (downloaded data),medium,4.0,39575998,"Functions, interactions and prognostic role of <i>POLE</i>: a bioinformatics analysis.",2025,abstract,2025-12-19T03:57:25.777627,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis']","['Pan-cancer', 'Melanoma', 'Colorectal cancer']","['Immunotherapy', 'Drug response/resistance', 'Biomarker discovery']",['Original research'],['TCGA'],"The authors used cBioPortal to query TCGA data to investigate the prevalence of mutations in IFNγ pathway genes (IFNGR1/2, JAK1/2, STAT1) across multiple cancer types before ICB treatment. They analyzed mutation frequencies and compared them to other oncogenic mutations (KRAS, PIK3CA) and antigen presentation mutations (B2M, TAP, HLA). The analysis was used to establish that IFNγ pathway mutations are relatively infrequent (<10%) in most cancer types except endometrial cancer and melanoma.",['TCGA'],"['Web-based analysis', 'Web-based visualization']","['IFNGR1', 'IFNGR2', 'JAK1', 'JAK2', 'STAT1', 'KRAS', 'PIK3CA', 'B2M', 'TAP', 'HLA']","['Query interface', 'Group comparison']",cBioPortal platform,medium,4.0,39746898,Remodelling of the immune landscape by IFNγ counteracts IFNγ-dependent tumour escape in mouse tumour models.,2025,pdf,2025-12-19T03:57:25.915921,,,,
"['Mutation analysis', 'Survival analysis', 'Multi-omics integration']",['Pan-cancer'],"['Methods/Tools development', 'Precision medicine']","['Methods/Software', 'Original research']",['GENIE'],"The paper uses GENIE BPC (Biopharma Collaborative) data, which is a multi-institutional database that links genomic data with clinical information. The authors developed the Bridge model to integrate and harmonize genomic data across institutions, addressing challenges of variability in gene panels and sequencing techniques. The model was validated by predicting patient survival across six cancer types using GENIE BPC data.",['GENIE BPC'],['Data download/export'],[],['Download data'],External (downloaded data),medium,4.0,39575113,Unlocking the Power of Multi-institutional Data: Integrating and Harmonizing Genomic Data Across Institutions.,2024,abstract,2025-12-19T03:57:26.995476,,,,
['Other'],['Pan-cancer'],"['Precision medicine', 'Database/Resource', 'Review/Commentary']",['Review'],['Not specified'],This is a review paper that evaluates and compares various precision oncology platforms and genomic databases for clinical decision-making. cBioPortal is mentioned as one of the precision oncology tools reviewed alongside other platforms like MyCancerGenome and OncoKB. The paper does not describe specific usage of cBioPortal for data analysis but rather discusses it as a resource in the context of precision medicine tools available to clinicians and researchers.,[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39543667,Precision oncology platforms: practical strategies for genomic database utilization in cancer treatment.,2024,abstract,2025-12-19T03:57:27.431337,,,,
['Gene expression analysis'],['Lung cancer'],['Other'],['Original research'],['Not specified'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on experimental work examining how environmental electrophiles (particularly 1,2-naphthoquinone) inhibit DNMT3B activity and affect gene expression in lung adenocarcinoma cell lines. This appears to be a laboratory-based mechanistic study without clear indication of cBioPortal data or tools being utilized.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39519144,Epigenetic Regulation of CXC Chemokine Expression by Environmental Electrophiles Through DNA Methyltransferase Inhibition.,2024,abstract,2025-12-19T03:57:30.973584,,,,
['Gene expression analysis'],['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],['Not specified'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on experimental investigation of PPARα-dependent mitochondrial metabolism in ovarian cancer stem cells using cell lines (A2780), spheroid cultures, xenograft models, and various molecular biology techniques. No reference to cBioPortal data queries, analysis, or visualization is evident in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39519311,Role of Peroxisome Proliferator-Activated Receptor α-Dependent Mitochondrial Metabolism in Ovarian Cancer Stem Cells.,2024,pdf,2025-12-19T03:57:31.119702,,,,
"['Copy number analysis', 'Gene expression analysis', 'Survival analysis']",['Melanoma'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis']",['Original research'],['Multiple sources'],The study analyzed EZH2 copy number amplification in 547 melanoma patients using cBioPortal to investigate its correlation with clinical prognosis. The analysis focused on identifying the frequency and clinical significance of EZH2 amplification in mucosal melanoma patients. This data was used to establish EZH2 as a prognostic biomarker for MM.,[],['Web-based analysis'],['EZH2'],['Query interface'],Unclear,medium,4.0,39518098,Enhancer of Zeste Homolog 2 Protects Mucosal Melanoma from Ferroptosis via the KLF14-SLC7A11 Signaling Pathway.,2024,abstract,2025-12-19T03:57:31.329670,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Prostate cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, the paper appears to cite cBioPortal as a data source for transcriptomic datasets used in developing and validating their seven-gene stemness signature. The study utilized large-scale transcriptomic datasets, likely including TCGA data accessed through cBioPortal, to train machine learning models and validate the prognostic signature across independent cohorts. However, specific details about how cBioPortal was used (web-based analysis vs. data download) are not explicitly stated in the provided text.",[],['Citation only'],"['KMT5C', 'DPP4', 'TYMS', 'CDC25B', 'IRF5', 'MEN1', 'DNMT3B']",['Not specified'],Unclear,low,4.0,39518911,Unmasking Neuroendocrine Prostate Cancer with a Machine Learning-Driven Seven-Gene Stemness Signature That Predicts Progression.,2024,abstract,2025-12-19T03:57:31.600213,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Multi-omics integration']","['Pan-cancer', 'Melanoma', 'Other solid tumor']","['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and title, this study investigated UBA1 as a predictive biomarker for immune checkpoint blockade (ICB) outcomes and explored the UBA1-STUB1 axis in cancer immune evasion. The paper likely used cBioPortal to access cancer genomics data from TCGA and other cohorts to analyze UBA1 expression, mutations, and correlations with clinical outcomes across multiple cancer types. However, specific details about cBioPortal usage are not provided in the abstract.",[],['Citation only'],"['UBA1', 'STUB1', 'JAK1']",['Not specified'],Unclear,low,4.0,39540840,The UBA1-STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade.,2025,abstract,2025-12-19T03:57:31.723851,,,,
"['Survival analysis', 'Other']",['Other solid tumor'],['Biomarker discovery'],"['Original research', 'Clinical study']","['TCGA', 'Custom/Private data']","The study used TCGA data accessed through cBioPortal as a validation cohort of 54 serous ovarian carcinoma cases. The cBioPortal data was used to validate histopathological prognostic features identified in their discovery cohort, particularly examining survival outcomes in relation to immune and stromal features. The specific mode of cBioPortal usage (data download vs. web-based analysis) is not explicitly detailed in the abstract.",['TCGA'],['Data download/export'],[],['Not specified'],External (downloaded data),medium,4.0,39518051,Serous Ovarian Carcinoma: Detailed Analysis of Clinico-Pathological Characteristics as Prognostic Factors.,2024,abstract,2025-12-19T03:57:31.846688,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration']","['Pan-cancer', 'Breast cancer', 'Lung cancer', 'Colorectal cancer']","['Biomarker discovery', 'Precision medicine', 'Methods/Tools development']","['Original research', 'Methods/Software']",['TCGA'],"The paper uses TCGA data from three cancer types (Breast Invasive Carcinoma, Lung Adenocarcinoma, and Colon Adenocarcinoma) to develop a multi-task bimodal neural network integrating RNA Sequencing and clinical data. While cBioPortal is cited as a source for cancer genomics data, the specific details of how cBioPortal was used to access or download the TCGA datasets are not explicitly described in the abstract and introduction. The analysis appears to have been performed externally using deep learning methods on downloaded data.","['TCGA-BRCA', 'TCGA-LUAD', 'TCGA-COAD']",['Data download/export'],[],['Download data'],External (downloaded data),medium,4.0,39472543,Exploiting common patterns in diverse cancer types via multi-task learning.,2024,abstract,2025-12-19T03:57:32.318589,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to examine the genetic modification landscape of PTTG1 across 33 malignancies based on the TCGA cohort. The platform was utilized alongside other tools (TIMER, GEPIA, human protein atlas, TISCH2) to analyze gene expression, protein expression, prognostic value, and genetic alterations of PTTG1 in pan-cancer analysis. The specific features used and whether data was downloaded or analyzed on the platform are not explicitly detailed in the abstract.",['TCGA'],['Web-based analysis'],['PTTG1'],['Not specified'],"[""Unclear""]",medium,4.0,39455949,Multi-omics analysis identifies PTTG1 as a prognostic biomarker associated with immunotherapy and chemotherapy resistance.,2024,abstract,2025-12-19T03:57:33.525166,,,,
"['Mutation analysis', 'Copy number analysis', 'Survival analysis', 'Multi-omics integration']","['Pan-cancer', 'Lung cancer', 'Breast cancer', 'Colorectal cancer', 'Prostate cancer']","['Methods/Tools development', 'Database/Resource', 'Biomarker discovery', 'Precision medicine']","['Original research', 'Methods/Software']","['MSK-IMPACT', 'Custom/Private data']","This paper describes the creation of MSK-CHORD, a harmonized clinicogenomic dataset that integrates natural language processing annotations with structured data from 24,950 patients at Memorial Sloan Kettering Cancer Center. The authors are affiliated with cBioPortal development team (several co-authors are cBioPortal developers including Schultz N, Gao J, Kundra R, de Bruijn I, etc.), and the dataset was likely made available through cBioPortal infrastructure. The paper represents a major data resource contribution that would be accessible via cBioPortal for the research community.","['MSK-CHORD', 'MSK-IMPACT']",['Citation only'],['SETD2'],['Not specified'],Unclear,medium,4.0,39506116,Automated real-world data integration improves cancer outcome prediction.,2024,abstract,2025-12-19T03:57:33.683520,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Lung cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy', 'Precision medicine']",['Original research'],['Multiple sources'],"cBioPortal was used as one of multiple bioinformatics databases to analyze the ABCG2 gene in lung cancer datasets. The study utilized cBioPortal alongside other tools (TIMER 2.0, UALCAN, TNMplot, MEXPRESS, MethSurv, KM Plotter, STRING, and ShinyGO 0.80) to investigate ABCG2 gene expression, its clinical correlations, and impact on NSCLC patient prognosis. The specific features or datasets accessed through cBioPortal are not explicitly detailed in the abstract.",[],['Web-based analysis'],['ABCG2'],['Not specified'],"[""Unclear""]",medium,4.0,39457707,<i>ABCG2</i> Gene Expression in Non-Small Cell Lung Cancer.,2024,abstract,2025-12-19T03:57:34.137545,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']","['Colorectal cancer', 'Other solid tumor']","['Biomarker discovery', 'Pathway analysis']",['Original research'],['Multiple sources'],"The authors used cBioPortal to analyze human gastrointestinal cancer patient tissue and clinical data, examining commitment complex (CC) splicing factor alterations including genetic changes and expression levels. They performed survival analysis comparing patients with CC gene mutations versus high CC expression, and used co-expression datasets to determine splicing targets and pathway analysis to identify metabolic and tumor suppressor pathways regulated by the CC.",[],"['Web-based analysis', 'Web-based visualization']","['BRAF', 'APC', 'KRAS', 'TP53']","['Survival analysis', 'Expression analysis', 'Query interface']",cBioPortal platform,high,4.0,39421280,Commitment Complex Splicing Factors in Cancers of the Gastrointestinal Tract-An In Silico Study.,2024,abstract,2025-12-19T03:57:37.105691,,,,
['Mutation analysis'],['Not specified'],['Other'],"['Clinical study', 'Original research']",['Custom/Private data'],"This paper does not actually use cBioPortal. It is a clinical case report describing a newborn with TP63-associated lymphopenia identified through newborn screening using TREC/KREC assays. The study focuses on primary immunodeficiency and congenital malformations, not cancer. There is no mention of cBioPortal in the provided abstract or introduction text.",[],['Citation only'],['TP63'],['Not specified'],"[""Unclear""]","[""low""]",4.0,39409174,A Rare Case of <i>TP63</i>-Associated Lymphopenia Revealed by Newborn Screening Using TREC.,2024,pdf,2025-12-19T03:57:37.529161,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Lung cancer'],"['Biomarker discovery', 'Pathway analysis', 'Precision medicine']",['Original research'],['TCGA'],"The paper used cBioPortal to analyze genetic alterations, specifically amplifications, in the TDRKH gene across LUAD patients, reporting 14% amplification. cBioPortal was likely used to query mutation and copy number alteration data for the identified prognostic biomarker. The platform appears to have been used for validation of genetic alterations in the candidate gene identified through their multi-omics analysis.","['TCGA-LUAD', 'TCGA-LUSC']","['Web-based analysis', 'Web-based visualization']",['TDRKH'],['Query interface'],cBioPortal platform,medium,4.0,39444988,Investigating the role of prognostic mitophagy-related genes in non-small cell cancer pathogenesis via multiomics and network-based approach.,2024,abstract,2025-12-19T03:57:37.598851,,,,
"['Mutation analysis', 'Pathway analysis']",['Prostate cancer'],"['Drug response/resistance', 'Review/Commentary']",['Review'],['Not specified'],"This is a review article discussing PARP inhibitor resistance mechanisms in prostate cancer with homologous recombination repair deficiency. While the paper mentions DDR genes including BRCA2 and discusses genomic alterations in mCRPC, there is no explicit description of cBioPortal usage in the provided abstract and introduction. The paper appears to cite cBioPortal as a reference but does not describe specific analyses performed using the platform.",[],['Citation only'],['BRCA2'],['Not specified'],Unclear,low,4.0,39396849,Unravelling the molecular basis of PARP inhibitor resistance in prostate cancer with homologous recombination repair deficiency.,2024,abstract,2025-12-19T03:57:37.844951,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration', 'Pathway analysis']","['Lung cancer', 'Glioma/Brain cancer']","['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['Custom/Private data', 'Multiple sources']","Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on spatial multiomics profiling of lung cancer brain metastases using spatial transcriptomics and multiplex IHC on their own samples. If cBioPortal is cited, it appears to be a reference citation only without clear description of how the platform was used for data access or analysis.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39400127,Spatial Multiomics Reveals Intratumoral Immune Heterogeneity with Distinct Cytokine Networks in Lung Cancer Brain Metastases.,2024,abstract,2025-12-19T03:57:38.450232,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Prostate cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, the paper does not explicitly mention cBioPortal usage. The study developed a 7-gene stemness signature using machine learning on transcriptomic datasets and validated it across independent cohorts and PDX models. Without access to the methods section or full text, it is unclear if cBioPortal was used for data access, analysis, or only cited as a reference.",[],['Citation only'],"['KMT5C', 'MEN1', 'TYMS', 'IRF5', 'DNMT3B', 'CDC25B', 'DPP4']",['Not specified'],Unclear,low,4.0,39399052,Unmasking Neuroendocrine Prostate Cancer with a Machine Learning-Driven 7-Gene Stemness Signature that Predicts Progression.,2024,abstract,2025-12-19T03:57:38.940367,,,,
"['Mutation analysis', 'Other']",['Colorectal cancer'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"This paper does not appear to use cBioPortal. The study is a prospective observational clinical trial (NCT06414304) that analyzes microsatellite instability (MSI) burden dynamics in liquid biopsy samples from colorectal cancer patients receiving immune checkpoint inhibitors. The research uses custom NGS-based MSI testing on FFPE and serial liquid biopsy samples collected from their own patient cohort, with no mention of cBioPortal usage in the provided abstract and introduction sections.",[],['Citation only'],"['MLH1', 'BRAF']",['Not specified'],Unclear,low,4.0,39379462,Evaluation of blood MSI burden dynamics to trace immune checkpoint inhibitor therapy efficacy through the course of treatment.,2024,pdf,2025-12-19T03:57:39.167405,,,,
"['Gene expression analysis', 'Pathway analysis', 'Multi-omics integration']",['Melanoma'],"['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy']",['Original research'],"['Custom/Private data', 'Multiple sources']","Based on the abstract and introduction provided, the paper does not explicitly mention how cBioPortal was used in the study. The paper focuses on developing mouse melanoma brain metastasis models and characterizing their response to immune checkpoint blockade therapy. While cBioPortal is cited, the specific usage details are not provided in the available text, suggesting it may have been used for validation or comparison purposes with human data.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39372744,IMMUNE AND MOLECULAR CORRELATES OF RESPONSE TO IMMUNOTHERAPY REVEALED BY BRAIN-METASTATIC MELANOMA MODELS.,2024,abstract,2025-12-19T03:57:39.488296,,,,
"['Gene expression analysis', 'Other']",['Other solid tumor'],"['Review/Commentary', 'Biomarker discovery']",['Review'],['Not specified'],"This is a narrative review paper on epitranscriptomic modifications (m6A, m5C, m1A) in cervical cancer. The paper cites cBioPortal but does not describe any specific usage of the platform for original data analysis. The review synthesizes existing literature on RNA modifications and their roles in cervical cancer pathogenesis without conducting new analyses using cBioPortal.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39377535,"Epitranscriptomics and cervical cancer: the emerging role of m<sup>6</sup>A, m<sup>5</sup>C and m<sup>1</sup>A RNA modifications.",2024,abstract,2025-12-19T03:57:39.565415,,,,
"['Copy number analysis', 'Survival analysis', 'Other']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],['TCGA'],The paper used cBioPortal to access TCGA laryngeal cancer data to analyze chromosomal instability (CIN) levels in patient tumors. The authors examined the relationship between CIN scores and radiation therapy response in laryngeal cancer patients using data obtained from cBioPortal. This analysis supported their finding that higher CIN levels correlate with improved radiation response.,['TCGA'],['Data download/export'],[],['Download data'],External (downloaded data),medium,4.0,39345631,Chromosomal instability increases radiation sensitivity.,2024,abstract,2025-12-19T03:57:40.006296,,,,
,,,,,,,,,,,,,39259513,,,,,No text available,True,True,No text available
"['Gene expression analysis', 'Survival analysis']",['Breast cancer'],['Biomarker discovery'],"['Original research', 'Clinical study']","['TCGA', 'METABRIC', 'Custom/Private data']","The study evaluated PTK7 mRNA expression using publicly available datasets including TCGA breast cancer cohort (n=1082) and METABRIC cohort (n=1980). While the abstract mentions these datasets, the specific method of accessing TCGA data (whether through cBioPortal or other means) is not explicitly detailed in the provided text. The study primarily focused on correlating PTK7 expression with clinicopathological features and patient survival outcomes.","['TCGA breast cancer', 'METABRIC']",['Citation only'],['PTK7'],['Not specified'],Unclear,low,4.0,39335176,Protein Tyrosine Kinase 7 (PTK7) in Breast Cancer: A Retrospective Analysis of Tumour Expression and Association with Clinical Outcome.,2024,abstract,2025-12-19T03:57:43.455269,,,,
"['Gene expression analysis', 'Survival analysis']","['Colorectal cancer', 'Other solid tumor']","['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The study analyzed publicly available bioinformatics data to examine the expression and prognostic significance of IKK complex genes (CHUK, IKBKB, IKBKG) in gastrointestinal cancers including esophageal carcinoma, stomach adenocarcinoma, and colon adenocarcinoma. The analysis included gene expression patterns across different histological grades and nodal metastases, as well as survival analysis correlating gene expression levels with overall survival outcomes. Based on the abstract, cBioPortal was likely used as one of the data sources for accessing cancer genomics data, though specific usage details are not provided in the abstract.",[],['Citation only'],"['CHUK', 'IKBKB', 'IKBKG']",['Not specified'],Unclear,low,4.0,39337357,Bioinformatic Analysis of <i>IKK</i> Complex Genes Expression in Selected Gastrointestinal Cancers.,2024,abstract,2025-12-19T03:57:44.290331,,,,
"['Mutation analysis', 'Other']",['Not specified'],['Methods/Tools development'],"['Methods/Software', 'Original research']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on developing DeepRVAT, a deep learning method for rare variant association testing using UK Biobank whole-exome-sequencing data. cBioPortal appears to be cited in the references but its specific role in this study is not described in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39322779,Integration of variant annotations using deep set networks boosts rare variant association testing.,2024,abstract,2025-12-19T03:57:44.312745,,,,
"['Mutation analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Breast cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on a real-world evidence cohort of 171 metastatic breast cancer patients with molecular profiling performed by CLIA-certified laboratories. The study integrates genomic (next-generation sequencing) and proteomic data to evaluate PIK3CA/AKT/mTOR pathway activation and its association with treatment response, but does not describe using cBioPortal for data access, analysis, or visualization.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39322687,Functional activation of the AKT-mTOR signalling axis in a real-world metastatic breast cancer cohort.,2024,abstract,2025-12-19T03:57:44.433150,,,,
"['Gene expression analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Other']",['Original research'],"['TCGA', 'Multiple sources']",The paper used cBioPortal to access and analyze public single-cell RNA-seq data and bulk RNA-seq data to validate the inverse relationship between Cldn7 expression and SMA-related gene expression in human breast cancer samples. The authors queried gene expression data to support their experimental findings from murine models and human cell lines.,[],"['Web-based analysis', 'Citation only']",['CLDN7'],"['Expression analysis', 'Not specified']",Unclear,low,4.0,39320351,Claudin 7 suppresses invasion and metastasis through repression of a smooth muscle actin program.,2024,abstract,2025-12-19T03:57:44.445180,,,,
['Other'],['Other solid tumor'],['Database/Resource'],['Original research'],['Multiple sources'],This study analyzed representation of Hispanic individuals across 7 cancer genomic databases containing liver cancer studies in the United States. cBioPortal appears to be one of the databases examined for demographic data (ethnicity and race) of liver cancer patients. The study focused on analyzing demographic representation rather than performing genomic analyses.,[],['Data download/export'],[],['Download data'],External (downloaded data),medium,4.0,39312090,Unveiling Disparities: Analyzing Hispanic Inclusion in Liver Cancer Research Databases in the United States.,2025,abstract,2025-12-19T03:57:44.859474,,,,
"['Gene expression analysis', 'Multi-omics integration', 'Other']",['Pan-cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Methods/Tools development', 'Precision medicine']","['Original research', 'Methods/Software']","['Multiple sources', 'Not specified']","Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage. The paper focuses on developing a multi-output Gaussian Process (MOGP) model for predicting dose-response curves across drug screening studies and ten cancer types. While cBioPortal is cited, the specific role it played in data acquisition or analysis is not described in the provided text.",[],['Citation only'],"['EZH2', 'BRAF']",['Not specified'],Unclear,low,4.0,39304771,Multi-output prediction of dose-response curves enables drug repositioning and biomarker discovery.,2024,abstract,2025-12-19T03:57:45.358982,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']","['Pan-cancer', 'Breast cancer', 'Lung cancer', 'Bladder cancer', 'Kidney cancer', 'Liver cancer', 'Gastric cancer', 'Prostate cancer', 'Thyroid cancer', 'Head and neck cancer']","['Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],"The paper does not explicitly mention using cBioPortal in the abstract or introduction provided. The study analyzed TCGA data for 12 cancer subtypes, examining SNV mutations, copy number alterations, gene expression, and survival data (Kaplan-Meier plots), but the specific data access method or platform is not described in the provided text. cBioPortal may have been used for data access or visualization, but this cannot be confirmed from the available content.","['TCGA-BRCA', 'TCGA-BLCA', 'TCGA-HNSC', 'TCGA-KIRC', 'TCGA-LUAD', 'TCGA-KIRP', 'TCGA-LUSC', 'TCGA-STAD', 'TCGA-LIHC', 'TCGA-KICH', 'TCGA-PRAD', 'TCGA-THCA']",['Citation only'],[],['Not specified'],Unclear,low,4.0,39310123,Characterization of tumor suppressors and oncogenes evaluated from TCGA cancers.,2024,pdf,2025-12-19T03:57:46.776423,,,,
"['Gene expression analysis', 'Survival analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']",The authors used cBioPortal to validate the association between AGR2 and PD-L1 expression in multiple CRC patient transcriptome cohorts. They analyzed gene expression data from different colorectal cancer patient datasets to confirm their experimental findings from cell line models. The analysis focused on correlating AGR2 expression with PD-L1 levels across patient cohorts.,[],['Web-based analysis'],"['AGR2', 'PD-L1', 'NPM3']","['Expression analysis', 'Query interface']",cBioPortal platform,medium,4.0,39300184,Characterization of the AGR2-NPM3 axis uncovers the AGR2 involvement in PD-L1 regulation in colorectal cancer.,2024,abstract,2025-12-19T03:57:46.778147,,,,
"['Gene expression analysis', 'Mutation analysis']",['Lung cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine']",['Original research'],['TCGA'],"cBioPortal was used to analyze TCGA lung adenocarcinoma patient data to demonstrate that high expression of AREG and EGFR mutations are mutually exclusive. The authors queried the database to examine the relationship between AREG expression levels and EGFR mutation status in lung adenocarcinoma patients, supporting their hypothesis that AREG-driven signaling may be particularly relevant in EGFR wild-type NSCLC.",['TCGA lung adenocarcinoma'],['Web-based analysis'],"['AREG', 'EGFR']","['Expression analysis', 'Query interface']",cBioPortal platform,medium,4.0,39242834,Amivantamab efficacy in wild-type EGFR NSCLC tumors correlates with levels of ligand expression.,2024,abstract,2025-12-19T03:57:46.807468,,,,
"['Gene expression analysis', 'Survival analysis']",['Leukemia/Lymphoma'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The research focuses on a pediatric T-ALL cohort from different centers and appears to be primarily experimental work examining QRICH1 and GRP78 interactions. If cBioPortal was used, it was likely for validation or comparison purposes, but this is not stated in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39227586,QRICH1 suppresses pediatric T-cell acute lymphoblastic leukemia by inhibiting GRP78.,2024,abstract,2025-12-19T03:57:49.228795,,,,
"['Mutation analysis', 'Gene expression analysis', 'Other']",['Other solid tumor'],"['Immunotherapy', 'Biomarker discovery', 'Drug response/resistance']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this clinical trial study. This is a phase I feasibility study of neoadjuvant pembrolizumab in MMRd endometrial cancer patients that focuses on pathologic response, radiologic response, and immune profiling. If cBioPortal was used, it may have been for background research or validation purposes, but this is not stated in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39227583,Neoadjuvant immune checkpoint blockade in women with mismatch repair deficient endometrial cancer: a phase I study.,2024,abstract,2025-12-19T03:57:50.102155,,,,
"['Mutation analysis', 'Other']",['Pan-cancer'],"['Methods/Tools development', 'Biomarker discovery']",['Original research'],['Not specified'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal being used in this study. The study focuses on analyzing CTNNB1 missense variants from the GnomAD database using various bioinformatics platforms (VarSome, UCSC Genome Browser, UniProt, Kinase Library database, and DynaMut2), but cBioPortal is not mentioned among these tools. If cBioPortal is cited in this paper, it appears to be a citation only without direct usage in the methodology.",[],['Citation only'],['CTNNB1'],['Not specified'],Unclear,low,4.0,39202333,In Silico Analysis of the Missense Variants of Uncertain Significance of <i>CTNNB1</i> Gene Reported in GnomAD Database.,2024,abstract,2025-12-19T03:57:50.508838,,,,
"['Gene expression analysis', 'Pathway analysis', 'Survival analysis']",['Prostate cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],"The paper examines patient records from The Cancer Genome Atlas (TCGA) database to identify genomic alterations associated with histologically overt stromal response (HOST-response) in prostate cancer. While TCGA data was used, the specific role of cBioPortal in data access or analysis is not explicitly described in the abstract and introduction. The study performed gene expression analysis identifying 1263 differentially expressed genes and seven hub genes through protein-protein interaction network analysis.",['TCGA'],['Citation only'],"['KIF2C', 'CENPA', 'CDC20', 'UBE2C', 'ESPL1', 'KIF23', 'PLK1']",['Not specified'],Unclear,low,4.0,39201599,Molecular Alterations Associated with Histologically Overt Stromal Response in Patients with Prostate Cancer.,2024,abstract,2025-12-19T03:57:50.860499,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Pan-cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],"The paper analyzed ESR2 mRNA expression levels across diverse tumor types using TCGA data. The study examined how ESR2 expression influences patient survival and identified genes co-expressed with ESR2 that may affect clinical outcomes. Gene Set Enrichment Analysis was performed to identify molecular pathways affected by ESR2, including oxidative phosphorylation and epithelial-mesenchymal transition.",['TCGA'],['Citation only'],"['ESR2', 'ACIN1', 'SYNE2', 'TNFRSF13C', 'MDM4']",['Not specified'],Unclear,low,4.0,39201394,Genes Co-Expressed with <i>ESR2</i> Influence Clinical Outcomes in Cancer Patients: TCGA Data Analysis.,2024,abstract,2025-12-19T03:57:50.876343,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Pathway analysis', 'Multi-omics integration']","['Melanoma', 'Leukemia/Lymphoma']","['Biomarker discovery', 'Drug response/resistance', 'Tumor evolution']",['Original research'],"['Custom/Private data', 'Multiple sources']","The paper mentions comparing ""murine MRD genes"" profiles to corresponding human disease through public datasets to highlight common features according to disease progression. cBioPortal appears to have been used to access public human cancer datasets for comparative analysis with their murine models. However, specific details about how cBioPortal was used are not explicitly described in the abstract and introduction provided.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39223638,Deciphering genetic and nongenetic factors underlying tumour dormancy: insights from multiomics analysis of two syngeneic MRD models of melanoma and leukemia.,2024,abstract,2025-12-19T03:57:51.264826,,,,
"['Gene expression analysis', 'Mutation analysis']",['Other solid tumor'],"['Biomarker discovery', 'Other']",['Original research'],"['TCGA', 'Multiple sources']",The authors used cBioPortal to analyze ABCC1 expression and genetic alterations in squamous cell carcinomas. They queried multiple TCGA datasets to examine ABCC1 mRNA expression levels and mutation/copy number alterations across different SCC types. The analysis was performed to validate their experimental findings showing ABCC1 overexpression in SCC tumors.,['TCGA'],"['Web-based analysis', 'Web-based visualization']","['ABCC1', 'TP63']","['Expression analysis', 'Query interface']",cBioPortal platform,medium,4.0,39201428,ABCC1 Is a ΔNp63 Target Gene Overexpressed in Squamous Cell Carcinoma.,2024,abstract,2025-12-19T03:57:51.738340,,,,
"['Gene expression analysis', 'Survival analysis']",['Breast cancer'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract, cBioPortal is not explicitly mentioned as being used in this study. The paper states that data from TCGA, GTEx, and GEO repositories were analyzed using GEPIA and Kaplan-Meier Plotter tools, not cBioPortal. While the paper cites cBioPortal, there is no clear description of how it was used for data analysis or visualization in this particular study.",['TCGA'],['Citation only'],['DCTPP1'],['Not specified'],Unclear,low,4.0,39200195,DCTPP1 Expression as a Predictor of Chemotherapy Response in Luminal A Breast Cancer Patients.,2024,abstract,2025-12-19T03:57:52.439596,,,,
"['Mutation analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Methods/Tools development', 'Precision medicine', 'Biomarker discovery']","['Methods/Software', 'Original research']",['TCGA'],"The paper cites cBioPortal as a reference but does not provide explicit details about how it was used in the study. Based on the abstract and introduction, the authors developed a new method (D3NS) for tumor stratification using somatic mutation data from TCGA for bladder, ovarian, and kidney cancers. While cBioPortal is likely used as a data source or reference platform for TCGA data access, the specific usage mode and features are not clearly described in the provided text.",['TCGA'],['Citation only'],[],['Not specified'],Unclear,low,4.0,39199616,Deep Neural Network Integrated into Network-Based Stratification (D3NS): A Method to Uncover Cancer Subtypes from Somatic Mutations.,2024,abstract,2025-12-19T03:57:52.904196,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Tumor evolution', 'Methods/Tools development']",['Original research'],"['TCGA', 'Custom/Private data']",The authors used cBioPortal to access human pancreatic adenocarcinoma (PDAC) data from TCGA to validate their metastatic potential gene signature derived from mouse models. They scored human PDAC tumors using their signature and analyzed the relationship between signature scores and patient prognosis. The study also examined whether the metastatic potential signature was enriched in other human carcinomas using cBioPortal data.,['TCGA-PAAD'],"['Data download/export', 'Web-based analysis']",[],"['Expression analysis', 'Survival analysis', 'Download data']",Mixed,medium,4.0,39185156,Identifying a gene signature of metastatic potential by linking pre-metastatic state to ultimate metastatic fate.,2024,abstract,2025-12-19T03:57:53.381834,,,,
"['Gene expression analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['Custom/Private data', 'Multiple sources']","Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on miR-338-5p and its role in breast cancer metastasis through the ETS1/NOTCH1 axis, using the GSE38867 dataset, cellular function experiments, and xenograft tumor models. cBioPortal may be cited in the full paper but its specific usage is not described in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39157351,"MiR-338-5p, a novel metastasis-related miRNA, inhibits triple-negative breast cancer progression by targeting the ETS1/NOTCH1 axis.",2024,abstract,2025-12-19T03:57:55.674582,,,,
['Gene expression analysis'],['Breast cancer'],"['Drug response/resistance', 'Immunotherapy', 'Biomarker discovery']",['Original research'],"['TCGA', 'Multiple sources']","The authors examined large patient databases including cBioPortal to identify relationships between Gli2 expression and markers of myeloid maturation, activation, and cytokine expression in breast cancer patients. The analysis focused on correlating Gli2 expression with immune-related markers to support their hypothesis about Hedgehog signaling's role in modulating the tumor immune microenvironment. This database analysis provided clinical context for their experimental findings on Hedgehog inhibition in osteolytic breast cancer cells.",[],"['Web-based analysis', 'Citation only']",['GLI2'],"['Expression analysis', 'Not specified']",Unclear,medium,4.0,39183755,Pharmacologic Hedgehog inhibition modulates the cytokine profile of osteolytic breast cancer cells.,2024,abstract,2025-12-19T03:57:56.273538,,,,
"['Gene expression analysis', 'Other']",['Glioma/Brain cancer'],"['Immunotherapy', 'Biomarker discovery']",['Original research'],['Not specified'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on cell surface proteomic analysis of primary human glioma samples and preclinical testing of EphA3-targeted CAR T cells. cBioPortal may have been cited in the full paper, but no specific usage details are provided in the available text.",[],['Citation only'],['EPHA3'],['Not specified'],"[""Unclear""]",low,4.0,39111833,EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses.,2024,abstract,2025-12-19T03:57:56.937336,,,,
['Other'],"['Other solid tumor', 'Pan-cancer']","['Review/Commentary', 'Drug response/resistance']",['Review'],['Not specified'],"This is a review paper summarizing CDK9 biology and CDK9 inhibitors in solid tumors. Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage for any original analysis. The paper appears to be a literature review discussing the therapeutic potential of CDK9 inhibitors, and cBioPortal may only be cited as a reference or resource without direct usage described.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39127153,CDK9 inhibitors for the treatment of solid tumors.,2024,abstract,2025-12-19T03:57:57.128366,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis']","['Glioma/Brain cancer', 'Pan-cancer']",['Biomarker discovery'],['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used as one of several bioinformatics platforms to conduct a comprehensive analysis of EGFR in glioblastoma multiforme patients. The authors specifically mention using cBioPortal to investigate genetic alterations/changes of EGFR across diverse cancer types. However, the paper does not provide detailed information about specific features used or the exact nature of the analysis performed on the cBioPortal platform.",[],['Web-based analysis'],"['EGFR', 'TP53']",['Not specified'],Unclear,medium,4.0,39139341,Comprehensive Analysis Reveals Epithelial Growth Factor Receptor as a Potential Diagnostic Biomarker in Glioblastoma Multiforme.,2024,pdf,2025-12-19T03:57:57.603070,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Immunotherapy', 'Drug response/resistance']",['Original research'],"['TCGA', 'Multiple sources']","The cBioPortal tool was used to analyze methylation and epigenetic alterations of the RPL4 gene across multiple cancer types. The study employed cBioPortal as one of several bioinformatics tools to investigate the genetic and epigenetic characteristics of RPL4 in pan-cancer analysis. The specific details of how cBioPortal was used (whether for data download, web-based analysis, or visualization) are not explicitly described in the abstract.",[],['Web-based analysis'],['RPL4'],['Not specified'],Unclear,medium,4.0,39114029,Pan-cancer analysis of the prognostic and immunological role of RPL4.,2024,abstract,2025-12-19T03:57:57.787038,,,,
"['Gene expression analysis', 'Mutation analysis', 'Survival analysis']",['Other solid tumor'],"['Review/Commentary', 'Biomarker discovery']",['Review'],"['TCGA', 'Not specified']","This is a review paper on histone lysine methyltransferases (KMTs) in pancreatic cancer. cBioPortal is likely cited as a reference resource for genomic data on pancreatic cancer, particularly PDAC, but the abstract and introduction do not provide specific details about how cBioPortal was used. The paper appears to review existing literature on KMTs and their role in pancreatic cancer development and therapeutics.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39078225,Insights into the mechanisms driven by H3K4 KMTs in pancreatic cancer.,2024,abstract,2025-12-19T03:57:58.538928,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Lung cancer'],"['Review/Commentary', 'Biomarker discovery', 'Precision medicine']",['Review'],"['TCGA', 'Multiple sources']","This is a comprehensive review paper on p53 genetics and biology in lung carcinomas. cBioPortal is likely cited as a reference resource for accessing cancer genomics data related to TP53 mutations and alterations in lung cancer. The paper synthesizes existing literature on p53's role in lung cancer development and progression, potentially referencing data from cBioPortal studies.",[],['Citation only'],['TP53'],['Not specified'],Unclear,low,4.0,39062026,"p53 Genetics and Biology in Lung Carcinomas: Insights, Implications and Clinical Applications.",2024,abstract,2025-12-19T03:57:59.296887,,,,
"['Mutation analysis', 'Gene expression analysis', 'Multi-omics integration']","['Pan-cancer', 'Glioma/Brain cancer']","['Biomarker discovery', 'Methods/Tools development']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and title, this paper investigates brain and cancer-associated CTCF mutations using imaging, structural, and molecular approaches. While the paper mentions cancer-associated mutations, the specific use of cBioPortal is not explicitly described in the provided abstract and introduction. The paper likely used cBioPortal to identify or validate cancer-associated CTCF mutations from TCGA or other cancer genomics databases, but the exact usage details are not clear from the provided text.",[],['Citation only'],['CTCF'],['Not specified'],Unclear,low,4.0,39070636,Brain and cancer associated binding domain mutations provide insight into CTCF's relationship with chromatin and its ability to act as a chromatin organizer.,2024,abstract,2025-12-19T03:57:59.340685,,,,
['Mutation analysis'],['Lung cancer'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal being used in this study. This is a prospective clinical study focused on liquid biopsy for detecting lung cancer recurrence using amplicon sequencing of tumor tissue and plasma cell-free DNA. The study appears to use custom patient data collected between 2019-2022 without reference to cBioPortal for data access, analysis, or visualization.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39057174,"Confirmation of Recurrent Lung Cancer Following Resection Using Liquid Biopsy, a Proof-of-Concept Real-World Study.",2024,pdf,2025-12-19T03:58:00.068599,,,,
['Mutation analysis'],['Other solid tumor'],"['Precision medicine', 'Drug response/resistance']","['Clinical study', 'Original research']",['Not specified'],"This is a case report of a single patient with metastatic urothelial carcinoma harboring an EGFR mutation. The paper does not explicitly describe using cBioPortal for analysis or data retrieval. If cBioPortal was cited, it was likely as a reference resource rather than as an active tool used in the study.",[],['Citation only'],['EGFR'],['Not specified'],"[""Unclear""]","[""low""]",4.0,39057170,"Prolonged Response to Osimertinib in EGFR-Mutated Metastatic Urothelial Carcinoma, a Case Report.",2024,abstract,2025-12-19T03:58:01.510119,,,,
"['Mutation analysis', 'Copy number analysis', 'Pathway analysis']",['Lung cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],['Custom/Private data'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper describes whole genome and whole exome sequencing of lung adenocarcinoma samples from the Women's Health Initiative cohort, but does not reference cBioPortal for data access, analysis, or visualization. If cBioPortal is mentioned elsewhere in the paper, it may be for comparative purposes or citation only.",[],['Citation only'],"['EGFR', 'KRAS', 'ALK', 'RET', 'ROS1', 'NRG1', 'MGA', 'MYC']",['Not specified'],Unclear,low,4.0,39052387,The genomic landscape of lung cancer in never-smokers from the Women's Health Initiative.,2024,pdf,2025-12-19T03:58:03.245817,,,,
"['Mutation analysis', 'Survival analysis']",['Breast cancer'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']","['METABRIC', 'Custom/Private data']",The authors used cBioPortal to access and download data from the METABRIC dataset for external validation of their findings. They retrieved data from 1163 comparable patients with ER+/ERBB2- breast cancer from METABRIC and performed survival analysis to validate the prognostic significance of the six-gene mutation signature identified in their primary cohort. The METABRIC analysis demonstrated a trend toward significantly worse relapse-free survival in patients with mutations in any of the six genes.,['METABRIC'],['Data download/export'],"['MAP2K4', 'FGFR3', 'APC', 'KIT', 'RB1', 'PTEN']",['Download data'],External (downloaded data),high,4.0,39031010,Select gene mutations associated with survival outcomes in ER-positive ERBB2-negative early-stage invasive breast cancer: A single-institutional tissue bank study.,2024,abstract,2025-12-19T03:58:03.663211,,,,
"['Gene expression analysis', 'Survival analysis']",['Breast cancer'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],['TCGA'],The paper used cBioPortal to perform bioinformatic analysis of patient data to examine the correlation between nucleolin (NCL) levels and proteins involved in chromosomal segregation in Triple-Negative Breast Cancer. The analysis appears to have involved querying gene expression data and potentially survival data from TCGA breast cancer datasets to support their experimental findings from the AID system model.,[],['Web-based analysis'],['NCL'],"['Expression analysis', 'Not specified']",Unclear,medium,4.0,38948867,Nucleolin acute degradation reveals novel functions in cell cycle progression and division in TNBC.,2024,abstract,2025-12-19T03:58:04.526347,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Multi-omics integration']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used as one of the data sources to download expression data of circadian rhythm genes (CRGs) in lower grade glioma (LGG) patients. The platform was mentioned alongside GEPIA as a source for obtaining gene expression data for the 15 core circadian genes analyzed in this study. The data obtained was then used for downstream analyses including survival analysis, immune cell infiltration correlation, and methylation studies.",['TCGA-LGG'],['Data download/export'],"['CRY1', 'CRY2', 'NR1D2', 'PER1', 'PER2', 'PER3', 'RORA', 'ARNTL', 'ARNTL2', 'NPAS2', 'NR1D1', 'RORB', 'CLOCK']",['Download data'],External (downloaded data),medium,4.0,39043735,Exploring transcriptomic databases: unraveling circadian gene disruptions in lower grade glioma.,2024,pdf,2025-12-19T03:58:04.495815,,,,
['Mutation analysis'],['Pan-cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],['Multiple sources'],"The study leveraged public cancer genomics data to analyze clonal hematopoiesis of indeterminate potential (CHIP) mutations across sex and racial groups in cancer patients. The authors examined the mutational landscape of CHIP-associated genes including DNMT3A, ASXL1, STAT5B, CSF1R, and others to identify differences in mutation frequencies between males and females and across Asian, Black, and White populations. The analysis focused on mutation prevalence and statistical comparisons across demographic groups.",[],['Citation only'],"['DNMT3A', 'ASXL1', 'STAT5B', 'CSF1R', 'RARA', 'SMAD2', 'CDKN1B', 'CENPA', 'CTLA4', 'EIF1AX', 'ELF3', 'MSI1', 'MYC', 'SOX17', 'AURKA', 'H3C1', 'H3C4', 'MYCL']",['Not specified'],Unclear,low,4.0,38969020,Differences in the mutational landscape of clonal hematopoiesis of indeterminate potential among races and between male and female patients with cancer.,2024,abstract,2025-12-19T03:58:04.704340,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Mutation analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to retrieve genetic variation information for FUT11 in gastric cancer. The platform was utilized as one of multiple bioinformatics tools to characterize FUT11 alterations, though the specific details of the analysis and results are not elaborated in the abstract.",['TCGA-STAD'],['Web-based analysis'],['FUT11'],['Not specified'],Unclear,medium,4.0,38941002,FUT11 expression in gastric cancer: its prognostic significance and role in immune regulation.,2024,abstract,2025-12-19T03:58:05.729692,,,,
"['Copy number analysis', 'Gene expression analysis', 'Pathway analysis', 'Multi-omics integration', 'Survival analysis']",['Other solid tumor'],"['Methods/Tools development', 'Pathway analysis', 'Biomarker discovery']","['Methods/Software', 'Original research']",['TCGA'],"The paper does not explicitly mention using cBioPortal in the abstract or introduction provided. The study develops MPAC, a new computational framework for multi-omic pathway analysis, and demonstrates it using TCGA head and neck squamous cell carcinoma data (DNA copy number and RNA-seq). While TCGA data is used, there is no clear indication that cBioPortal was the source or platform for data access or analysis based on the provided text.",['TCGA'],['Citation only'],[],['Not specified'],Unclear,low,4.0,38948762,MPAC: a computational framework for inferring pathway activities from multi-omic data.,2025,abstract,2025-12-19T03:58:05.814284,,,,
"['Gene expression analysis', 'Survival analysis', 'Other']",['Pan-cancer'],"['Methods/Tools development', 'Database/Resource']",['Methods/Software'],['TCGA'],"This paper describes the development of Evergene, a new webtool for cancer genomics analysis. cBioPortal is mentioned as an existing webtool in the context of comparing available tools in the field, but there is no evidence in the abstract/introduction that cBioPortal was directly used for data analysis or that data was downloaded from cBioPortal. The citation appears to be for comparison/reference purposes only.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,38948009,Evergene: an interactive webtool for large-scale gene-centric analysis of primary tumours.,2024,abstract,2025-12-19T03:58:06.523050,,,,
"['Mutation analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Other']","['Original research', 'Clinical study']",['Multiple sources'],"The paper does not explicitly describe using cBioPortal in their analysis. The study focuses on characterizing a novel IDH2 R172A mutation in sinonasal undifferentiated carcinoma using methylation arrays and molecular modeling. The authors compared their case to data from the Gene Expression Omnibus (GEO) database, not cBioPortal. cBioPortal may only be cited in the references without direct usage in the study.",[],['Citation only'],"['IDH2', 'TP53']",['Not specified'],Unclear,low,4.0,38928223,Methylation-Based Characterization of a New <i>IDH2</i> Mutation in Sinonasal Undifferentiated Carcinoma.,2024,pdf,2025-12-19T03:58:07.483556,,,,
"['Survival analysis', 'Biomarker analysis']",['Breast cancer'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. This is a retrospective cohort study that analyzed serum bone turnover markers in breast cancer patients from a single institution (Saarland University Hospital, Germany) between 2010-2017. The study used ELISA and RIA methodologies to measure biomarkers and performed survival analysis, but no reference to cBioPortal data access, analysis, or visualization is mentioned in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,38927408,Retrospective Evaluation of Bone Turnover Markers in Serum for the Prediction of Metastases Development in Breast Cancer Patients: A Cohort Study.,2024,pdf,2025-12-19T03:58:08.264291,,,,
['Other'],['Lung cancer'],['Methods/Tools development'],['Original research'],['Not specified'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. This paper describes the development of a novel lung-on-a-chip model to study KRAS G12D mutation effects in lung adenocarcinoma using iPSC-derived cells. The study appears to be purely experimental/in vitro work without bioinformatics analysis using cBioPortal.",[],['Citation only'],[],['Not specified'],"[""Unclear""]","[""low""]",4.0,38911024,Multicompartment duct platform to study epithelial-endothelial crosstalk associated with lung adenocarcinoma.,2024,abstract,2025-12-19T03:58:08.405921,,,,
"['Gene expression analysis', 'Mutation analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],cBioPortal was used to query TCGA colorectal cancer datasets for PTPRK gene expression and mutation data. The authors likely accessed the platform to examine PTPRK alterations and expression patterns in colorectal cancer patient samples to support their experimental findings about PTPRK's tumor suppressor function. The specific details of how the data was analyzed or visualized are not provided in the abstract.,[],['Citation only'],['PTPRK'],['Not specified'],Unclear,low,4.0,38904097,The receptor protein tyrosine phosphatase PTPRK promotes intestinal repair and catalysis-independent tumour suppression.,2024,abstract,2025-12-19T03:58:11.000049,,,,
"['Gene expression analysis', 'Survival analysis']",['Breast cancer'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],"['TCGA', 'METABRIC', 'Multiple sources']","The study analyzed high-throughput RNA-seq data from TCGA, Metabric and GEO datasets to explore PRLR expression in breast cancer cells and its association with tamoxifen treatment. cBioPortal was likely used to access and analyze gene expression data from these public datasets, though specific details of cBioPortal usage are not explicitly described in the abstract and introduction.","['TCGA', 'METABRIC']",['Data download/export'],['PRLR'],['Not specified'],"[""Unclear""]","[""low""]",4.0,38898487,The immunotoxin targeting PRLR increases tamoxifen sensitivity and enhances the efficacy of chemotherapy in breast cancer.,2024,pdf,2025-12-19T03:58:11.571043,,,,
"['Mutation analysis', 'Gene expression analysis', 'Other']",['Glioma/Brain cancer'],"['Drug response/resistance', 'Methods/Tools development', 'Biomarker discovery']",['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on developing a novel FM-DSBR method to measure DNA double strand break repair pathways in glioblastoma patient-derived xenografts (PDXs) and screening ATM inhibitors. While the paper may cite cBioPortal in references, the provided text does not describe any specific use of the platform for data access, analysis, or visualization.",[],['Citation only'],"['TP53', 'MGMT', 'POLQ']",['Not specified'],Unclear,low,4.0,38906885,ATM inhibition exploits checkpoint defects and ATM-dependent double strand break repair in TP53-mutant glioblastoma.,2024,pdf,2025-12-19T03:58:11.682977,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Breast cancer'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],"['TCGA', 'METABRIC']",The authors used cBioPortal to analyze publicly available breast cancer patient data to examine the association between ELF3 expression and patient prognosis. They performed survival analysis and gene expression analysis to show that high ELF3 expression was associated with poor prognosis and enrichment of cell cycle progression programs in breast cancer patients.,[],"['Web-based analysis', 'Web-based visualization']",['ELF3'],"['Survival analysis', 'Expression analysis']",cBioPortal platform,medium,4.0,38895265,TNBC response to paclitaxel phenocopies interferon response which reveals cell cycle-associated resistance mechanisms.,2024,abstract,2025-12-19T03:58:11.855809,,,,
"['Gene expression analysis', 'Survival analysis']",['Breast cancer'],"['Biomarker discovery', 'Other']",['Original research'],"['TCGA', 'METABRIC']",The authors used cBioPortal to analyze the prognostic significance of ZAG/AZGP1 expression in breast cancer patients. They specifically examined the relationship between high ZAG expression and patient outcomes in triple-negative breast cancer (TNBC) compared to other clinical subtypes. The analysis utilized TCGA and METABRIC datasets accessed through cBioPortal to correlate ZAG expression levels with patient prognosis.,"['TCGA', 'METABRIC']",['Web-based analysis'],['AZGP1'],"['Expression analysis', 'Survival analysis']",cBioPortal platform,medium,4.0,38888911,Zinc-alpha-2-glycoprotein Secreted by Triple-Negative Breast Cancer Promotes Peritumoral Fibrosis.,2024,abstract,2025-12-19T03:58:12.019623,,,,
"['Gene expression analysis', 'Survival analysis']",['Breast cancer'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],"['TCGA', 'METABRIC']",cBioPortal was used to analyze DUSP6 expression and its association with patient survival in HER2+ breast cancer cohorts. The authors queried TCGA and METABRIC datasets through cBioPortal to examine DUSP6 expression levels and perform survival analysis. This analysis revealed that DUSP6 expression selectively associated with poor patient survival in HER2+ breast cancers.,"['TCGA', 'METABRIC']","['Web-based analysis', 'Web-based visualization']",['DUSP6'],"['Expression analysis', 'Survival analysis', 'Query interface']",cBioPortal platform,medium,4.0,38886591,DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer.,2024,abstract,2025-12-19T03:58:13.137117,,,,
"['Mutation analysis', 'Multi-omics integration']",['Prostate cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine', 'Methods/Tools development']",['Original research'],['Multiple sources'],The authors used cBioPortal in conjunction with DepMap's Celligner tool to identify which preclinical prostate cancer cell line models are most representative of specific prostate cancer patient populations. This analysis helped determine the clinical relevance of the eight cell lines they characterized genomically. The cBioPortal platform was used to access patient population data for comparison with their cell line genomic profiles.,[],"['Web-based analysis', 'Web-based visualization']","['AR', 'BCL2', 'BCL2L1', 'MCL1', 'ATM', 'BARD1', 'BRCA1', 'BRCA2', 'BRIP1', 'CDK12', 'CHEK2', 'NBN', 'PALB2', 'RAD51B', 'AKT1', 'MAP3K1', 'PIK3CA', 'PTEN', 'MDM2', 'TP53']",['Query interface'],cBioPortal platform,medium,4.0,38892296,Genomic Characterization of Preclinical Prostate Cancer Cell Line Models.,2024,pdf,2025-12-19T03:58:13.297399,,,,
['Mutation analysis'],['Melanoma'],['Other'],['Original research'],['TCGA'],cBioPortal was used to access mutation data from skin cancer samples to analyze the frequency of C->T transitions at enhancer regions. The authors compared mutation patterns in skin cancers carrying ASH1L mutations versus ASH1L-intact tumors to validate their findings that ASH1L protects against CPD formation at regulatory elements. This analysis supported their mechanistic findings about ASH1L's guardian role against UV-induced DNA damage.,[],['Data download/export'],['ASH1L'],['Download data'],"[""External (downloaded data)""]",medium,4.0,38884271,ASH1L guards cis-regulatory elements against cyclobutane pyrimidine dimer induction.,2024,abstract,2025-12-19T03:58:14.056978,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Leukemia/Lymphoma'],"['Biomarker discovery', 'Precision medicine', 'Drug response/resistance']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly describe how cBioPortal was used in the study. While TCGA data was utilized (which is available through cBioPortal), the abstract and introduction do not mention cBioPortal usage, data download, or specific features. The citation of cBioPortal may be for reference purposes only or the usage details are not provided in the abstract/introduction sections.",['TCGA-GTEx'],['Citation only'],"['ATP7A', 'ATP7B', 'ATOX1', 'MAPK1', 'LIPT1', 'SLC31A1', 'GCSH', 'PDHA1', 'CCS', 'CP', 'SOD1', 'COA6', 'PDK1', 'DBH', 'PDE3B']",['Not specified'],Unclear,low,4.0,38879648,Exploring and clinical validation of prognostic significance and therapeutic implications of copper homeostasis-related gene dysregulation in acute myeloid leukemia.,2024,abstract,2025-12-19T03:58:15.852170,,,,
"['Copy number analysis', 'Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The study used cBioPortal to analyze TARBP1 amplification and overexpression patterns across various cancer types. The authors examined the correlation between TARBP1 and ASCT2 (SLC1A5) gene expression in clinical cohorts, particularly in hepatocellular carcinoma (HCC), and assessed their association with patient prognosis. cBioPortal was likely used to access TCGA and other cancer genomics datasets to validate their experimental findings.",[],"['Web-based analysis', 'Web-based visualization']","['TARBP1', 'SLC1A5']","['Expression analysis', 'Survival analysis']",Unclear,medium,4.0,38867004,The tRNA Gm18 methyltransferase TARBP1 promotes hepatocellular carcinoma progression via metabolic reprogramming of glutamine.,2024,abstract,2025-12-19T03:58:15.972326,,,,
['Other'],['Pan-cancer'],"['Precision medicine', 'Review/Commentary']",['Review'],['Not specified'],"This is a commentary paper discussing the clinical challenges of variants of uncertain significance (VUS) in precision oncology through 4 clinical case examples. The paper does not appear to directly use cBioPortal for any analysis or data retrieval, but may cite it as a reference resource in the context of genomic databases used in precision oncology. No specific cBioPortal features, datasets, or analyses are described in the abstract or introduction.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,38847368,Variants of uncertain significance in precision oncology: nuance or nuisance?,2024,abstract,2025-12-19T03:58:17.562361,,,,
"['Mutation analysis', 'Gene expression analysis']",['Breast cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['Not specified'],"The paper mentions that KMT2D mutations are associated with PIK3CA H1047R mutation in 1.5% of breast cancer patients in public databases. However, the paper does not explicitly describe using cBioPortal for analysis. The reference to public databases suggests they may have consulted cBioPortal or similar resources to identify the co-occurrence frequency, but specific usage details are not provided.",[],['Citation only'],"['KMT2D', 'PIK3CA']",['Not specified'],Unclear,low,4.0,38786098,PI 3-Kinase and the Histone Methyl-Transferase KMT2D Collaborate to Induce Arp2/3-Dependent Migration of Mammary Epithelial Cells.,2024,pdf,2025-12-19T03:58:18.020320,,,,
"['Copy number analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"This paper does not appear to use cBioPortal directly. The study performed targeted tumor sequencing on 152 gastric cancer patients using their own institutional samples to detect ERBB2 amplification and compare it with IHC/FISH results. The analysis was conducted using custom sequencing panels and bioinformatics pipelines at their institution, not through cBioPortal. While the paper may cite cBioPortal in references, there is no evidence of actual data download, analysis, or visualization using the cBioPortal platform.",[],['Citation only'],['ERBB2'],['Not specified'],Unclear,low,4.0,38862927,Clinical application of targeted tumour sequencing tests for detecting ERBB2 amplification and optimizing anti-HER2 therapy in gastric cancer.,2024,pdf,2025-12-19T03:58:18.404788,,,,
"['Gene expression analysis', 'Pathway analysis', 'Survival analysis']",['Breast cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['Custom/Private data'],"cBioPortal was used to validate the prognostic significance of hub genes identified in peritumoral tissue. The authors queried expression data and performed survival analysis to correlate the expression of CDK1, PCNA, EZH2, and BUB1 with Overall Survival and Relapse Free Survival in untreated luminal breast cancer patients. This validation was performed using publicly available breast cancer datasets in cBioPortal.",[],"['Web-based analysis', 'Web-based visualization']","['CDK1', 'ESR1', 'NOP58', 'PCNA', 'EZH2', 'PPP1CA', 'BUB1', 'TGFBR1', 'CXCR4', 'CCND1']","['Survival analysis', 'Expression analysis', 'Query interface']",cBioPortal platform,medium,4.0,38831458,Unraveling malignant phenotype of peritumoral tissue: transcriptomic insights into early-stage breast cancer.,2024,pdf,2025-12-19T03:58:18.836976,,,,
"['Copy number analysis', 'Mutation analysis']",['Gastric cancer'],"['Review/Commentary', 'Drug response/resistance', 'Precision medicine']",['Review'],['Not specified'],"This is a review paper discussing FGFR2-driven gastric cancer and therapeutic approaches. While the paper discusses FGFR2 amplification and mutations as molecular alterations in gastric cancer, there is no explicit mention of cBioPortal usage in the provided abstract and introduction sections. The paper appears to cite cBioPortal as a reference source for genomic data on FGFR2 alterations in gastric cancer, but specific usage details are not provided in the excerpted text.",[],['Citation only'],['FGFR2'],['Not specified'],Unclear,low,4.0,38791079,Clinical Developments and Challenges in Treating FGFR2-Driven Gastric Cancer.,2024,pdf,2025-12-19T03:58:19.244416,,,,
"['Mutation analysis', 'Copy number analysis']","['Breast cancer', 'Other solid tumor']","['Biomarker discovery', 'Precision medicine', 'Database/Resource']","['Original research', 'Clinical study']",['Custom/Private data'],"This paper does not appear to use cBioPortal directly. The study focuses on detecting germline BRCA1 and BRCA2 mutations in a Romanian cohort of 616 patients using NGS and MLPA methods. While cBioPortal may be cited in the references, there is no explicit mention of using cBioPortal for data access, analysis, or visualization in the provided abstract and introduction.",[],['Citation only'],"['BRCA1', 'BRCA2']",['Not specified'],Unclear,low,4.0,38785549,The Molecular Detection of Germline Mutations in the <i>BRCA1</i> and <i>BRCA2</i> Genes Associated with Breast and Ovarian Cancer in a Romanian Cohort of 616 Patients.,2024,pdf,2025-12-19T03:58:19.263398,,,,
"['Mutation analysis', 'Pathway analysis']",['Other solid tumor'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],['Not specified'],"The paper analyzed clinical mutations in ABC transporter genes (ABCB1, ABCC1, and ABCG2) from endometrial cancer patients. While cBioPortal is mentioned in the context of analyzing clinical variations, the specific details of how cBioPortal was used (data download, web analysis, or visualization) are not explicitly described in the provided abstract and introduction. The study focuses on mapping mutations to structural regions of these transporters to understand their role in chemoresistance.",[],['Citation only'],"['ABCB1', 'ABCC1', 'ABCG2']",['Not specified'],Unclear,low,4.0,38766631,"Deciphering the functional role of clinical mutations in ABCB1, ABCC1, and ABCG2 ABC transporters in endometrial cancer.",2024,pdf,2025-12-19T03:58:20.789249,,,,
"['Mutation analysis', 'Gene expression analysis', 'Multi-omics integration']",['Lung cancer'],"['Biomarker discovery', 'Methods/Tools development']",['Original research'],['TCGA'],"The paper does not explicitly describe using cBioPortal for any analysis. The study derived data from Dai et al., which in turn used TCGA data, and employed various bioinformatics tools for analyzing gene fusions, protein superfamilies, and mutational signatures in NSCLC. While cBioPortal may be cited in the references, there is no clear description of direct cBioPortal usage in the methods or results sections provided.",['TCGA-LUAD'],['Citation only'],"['CD74', 'ALK', 'ROS1']",['Not specified'],Unclear,low,4.0,38765019,Insight into NSCLC through novel analysis of gene interactions and characteristics.,2024,pdf,2025-12-19T03:58:21.349980,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis']",['Other solid tumor'],"['Review/Commentary', 'Biomarker discovery', 'Drug response/resistance', 'Immunotherapy']",['Review'],['Multiple sources'],"This is a review paper that summarizes the prevalence and mechanisms of ARID1A alterations in gynecologic precancers and cancers. The paper likely references cBioPortal as a data source for prevalence information about ARID1A mutations across gynecologic malignancies. Based on the abstract alone, specific details about how cBioPortal was used are not provided, suggesting it may be cited as a reference source for mutation frequency data.",[],['Citation only'],['ARID1A'],['Not specified'],Unclear,low,4.0,38740655,ARID1A in Gynecologic Precancers and Cancers.,2024,abstract,2025-12-19T03:58:22.556783,,,,
"['Mutation analysis', 'Gene expression analysis']","['Pan-cancer', 'Breast cancer', 'Lung cancer', 'Leukemia/Lymphoma', 'Other solid tumor']","['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to identify cancer-associated mutations in PKCθ (PRKCQ gene) and to analyze protein expression levels across diverse cancer types. The authors used cBioPortal to examine four specific mutations (R145H/C, E161K, R635W) and to perform bioinformatics analysis showing that PKCθ protein levels are reduced in lung, renal, head and neck, and pancreatic cancers, supporting their hypothesis that PKCθ function is lost in cancer.",[],"['Web-based analysis', 'Web-based visualization']",['PRKCQ'],"['Mutation Mapper', 'Expression analysis', 'Query interface']",cBioPortal platform,medium,4.0,38752473,Cancer-associated mutations in protein kinase C theta are loss-of-function.,2024,abstract,2025-12-19T03:58:22.988756,,,,
['Other'],['Other hematologic'],"['Review/Commentary', 'Biomarker discovery']",['Review'],['Not specified'],"This is a review paper on Measurable (Minimal) Residual Disease (MRD) in Myelodysplastic Neoplasms (MDS). Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in the study. The paper appears to cite cBioPortal in the references but does not describe any specific analysis or data retrieval from the platform.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,38672585,Measurable (Minimal) Residual Disease in Myelodysplastic Neoplasms (MDS): Current State and Perspectives.,2024,abstract,2025-12-19T03:58:24.033336,,,,
"['Mutation analysis', 'Gene expression analysis']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","The paper mentions examining KRAS, p53, SMAD4, and CDKN2A mutations in PDAC samples. While cBioPortal is cited in the references, the abstract and introduction do not provide explicit details about how cBioPortal was used for data access or analysis. The study primarily focuses on multiplex immunohistochemistry analysis of K17 expression and immune cell distribution in pancreatic cancer, suggesting cBioPortal may have been used for mutation data validation or comparison purposes.",[],['Citation only'],"['KRAS', 'TP53', 'SMAD4', 'CDKN2A']",['Not specified'],Unclear,low,4.0,38730319,Keratin 17 modulates the immune topography of pancreatic cancer.,2024,pdf,2025-12-19T03:58:25.134145,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis']",['Breast cancer'],"['Drug response/resistance', 'Pathway analysis', 'Precision medicine']",['Original research'],"['TCGA', 'METABRIC', 'Custom/Private data']","Based on the abstract and title, this paper focuses on experimental research investigating KMT2D methylation by SMYD2 in ER+ breast cancer with PIK3CA mutations. While the paper likely references cBioPortal for accessing breast cancer genomic data (TCGA, METABRIC) to examine PIK3CA mutations and potentially gene expression patterns in ER+ breast cancer, the specific usage details are not provided in the abstract. The study appears to be primarily experimental with patient-derived organoids and tumor models.","['TCGA', 'METABRIC']",['Citation only'],"['PIK3CA', 'KMT2D', 'SMYD2']",['Not specified'],Unclear,low,4.0,38700982,Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancer.,2024,abstract,2025-12-19T03:58:25.675257,,,,
"['Copy number analysis', 'Gene expression analysis', 'Survival analysis']","['Pan-cancer', 'Lung cancer']","['Biomarker discovery', 'Pathway analysis', 'Drug response/resistance']",['Original research'],"['TCGA', 'Multiple sources']","The paper used cBioPortal to analyze chromosome 3q amplification patterns and gene expression across multiple cancer types. The authors likely queried TCGA datasets through cBioPortal to identify 3q-amplified malignancies and examine the expression and copy number alterations of genes in the 3q amplicon, including GOLIM4, ATP2C1, and GOLPH3. The platform was used to correlate 3q amplification status with clinical outcomes and to identify cancer types with high frequencies of 3q amplification.",['TCGA'],"['Web-based analysis', 'Web-based visualization', 'Data download/export']","['GOLIM4', 'ATP2C1', 'GOLPH3']","['Expression analysis', 'Query interface', 'Download data']",Mixed,medium,4.0,38662435,Chromosomal 3q amplicon encodes essential regulators of secretory vesicles that drive secretory addiction in cancer.,2024,abstract,2025-12-19T03:58:26.355200,,,,
"['Gene expression analysis', 'Survival analysis']",['Breast cancer'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],"['TCGA', 'METABRIC']","The authors used cBioPortal to analyze FXR (NR1H4) gene expression in breast cancer patients and correlate it with survival outcomes. They examined FXR expression across different breast cancer subtypes (ER+, ER-, basal-like, luminal A) to determine associations with overall survival. The analysis revealed that high FXR expression was associated with improved survival specifically in ER- tumors and basal-like subtypes.","['TCGA', 'METABRIC']","['Web-based analysis', 'Web-based visualization']",['NR1H4'],"['Survival analysis', 'Expression analysis']",cBioPortal platform,medium,4.0,38611046,FXR Agonism with Bile Acid Mimetic Reduces Pre-Clinical Triple-Negative Breast Cancer Burden.,2024,pdf,2025-12-19T03:58:26.606639,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Other']",['Original research'],['TCGA'],"Based on the abstract and introduction provided, cBioPortal is not explicitly mentioned in the text. The study focuses on investigating COMP's role in ovarian cancer through immunohistochemical analysis of patient cohorts, xenograft mouse models, and various molecular biology techniques. If cBioPortal was used, it would likely have been for querying TCGA ovarian cancer data for gene expression or survival analysis, but this is not stated in the provided sections.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,38615020,Stromal cartilage oligomeric matrix protein as a tumorigenic driver in ovarian cancer via Notch3 signaling and epithelial-to-mesenchymal transition.,2024,pdf,2025-12-19T03:58:27.278092,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis']",['Prostate cancer'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']",['TCGA'],"The paper does not explicitly mention using cBioPortal in the methods or results sections provided. The study analyzed TCGA data directly, performing pathological review of slides and genomic analysis to identify associations between cribriform pattern 4 (CP4) and clinical outcomes. While cBioPortal is cited in the references, there is no clear description of how it was used for data access, analysis, or visualization in this study.",['TCGA'],['Citation only'],"['KRT13', 'KRT5', 'KRT15', 'COL17A1', 'KRT14', 'KRT16', 'TP63']",['Not specified'],Unclear,low,4.0,38610926,Prognostic Significance of the Cribriform Pattern in Prostate Cancer: Clinical Outcomes and Genomic Alterations.,2024,pdf,2025-12-19T03:58:27.711102,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The study used cBioPortal to examine genetic alterations (mutations and amplifications) in Mediator kinase module component genes (MED12, MED12L, MED13, MED13L, CDK8, CDK19, and CCNC) in publicly available colorectal cancer genomic datasets. The authors analyzed the prevalence of these alterations across different genomically defined colorectal cancer subsets (MSI cancers, CMS groups) and investigated the relationship between gene expression levels and relapse-free survival. They also examined drug sensitivity patterns in colorectal cancer cell lines with CDK8 amplifications.",[],"['Web-based analysis', 'Web-based visualization']","['MED12', 'MED12L', 'MED13', 'MED13L', 'CDK8', 'CDK19', 'CCNC']","['Query interface', 'Expression analysis', 'Survival analysis', 'Group comparison']","[""cBioPortal platform""]",high,4.0,38602606,"Mediator kinase module proteins, genetic alterations and expression of super-enhancer regulated genes in colorectal cancer.",2024,abstract,2025-12-19T03:58:28.960164,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']","['Original research', 'Clinical study']","['TCGA', 'Custom/Private data']",The study utilized cBioPortal to access TCGA head and neck squamous cell carcinoma (HNSCC) data for in silico gene expression analysis of PON2. The computational datasets from cBioPortal were used to perform differential gene expression analysis and survival analysis to investigate PON2's role in disease prognosis. The findings from cBioPortal data were complemented with analyses from the authors' own patient cohort with locally advanced oral squamous cell carcinoma.,['TCGA-HNSC'],"['Web-based analysis', 'Data download/export']",['PON2'],"['Expression analysis', 'Survival analysis', 'Query interface']",Mixed,medium,4.0,38602182,Antiapoptotic PON2 expression and its clinical implications in locally advanced oral squamous cell carcinoma.,2024,abstract,2025-12-19T03:58:29.863235,,,,
"['Gene expression analysis', 'Copy number analysis', 'Mutation analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this clinical trial paper. The study focuses on a phase 2 trial of CHK1 inhibitor prexasertib in platinum-resistant ovarian cancer patients, with translational research using fresh biopsies and blood samples from trial participants. The paper discusses genomic and transcriptomic analyses (POLA1, POLE, GINS3, CCNE1) but does not reference cBioPortal as a data source or analysis platform in the sections provided.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,38555285,The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial.,2024,pdf,2025-12-19T03:58:30.853545,,,,
['Mutation analysis'],['Not specified'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],['Not specified'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on mechanistic insights into a CTLA-4 gene mutation (G199R) using NMR spectroscopy and biochemical techniques. The study appears to be primarily a structural biology and functional characterization study of a specific mutation, without clear indication of cBioPortal data access or analysis. cBioPortal may only be cited in the references without direct usage.",[],['Citation only'],['CTLA4'],['Not specified'],Unclear,low,4.0,38542966,Mechanistic Insights into the Inhibition of a Common CTLA-4 Gene Mutation in the Cytoplasmic Domain.,2024,pdf,2025-12-19T03:58:31.559631,,,,
"['Gene expression analysis', 'Pathway analysis']",['Lung cancer'],"['Immunotherapy', 'Pathway analysis', 'Biomarker discovery']",['Original research'],['Not specified'],"Based on the provided abstract and introduction, there is no mention of cBioPortal being used in this study. The authors used RNA-seq data from the Gene Expression Omnibus (GEO) database (GSE87340, GSE120622, and GSE111907) and performed their own analysis using HISAT2, Samtools, Stringtie, and GAGE R package for pathway analysis. cBioPortal does not appear to be utilized in this research.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,38540240,Immune Gene Networks from Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.,2024,pdf,2025-12-19T03:58:31.731152,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis']",['Original research'],['TCGA'],"The paper mentions using cBioPortal in the context of analyzing TCGA datasets for gastrointestinal cancers. The authors performed systematic bioinformatic analysis to identify chromatin remodeling factors, specifically examining PRDM1 expression and prognosis prediction. However, the abstract and introduction do not provide explicit details about how cBioPortal was specifically used, though it appears to be one of the tools used for analyzing TCGA data alongside GEPIA.",[],['Citation only'],"['PRDM1', 'TP53', 'KRAS', 'CDKN2A', 'PIK3CA', 'MYC', 'IGFBP3', 'HIF1A', 'ERBB2', 'CTNNB1', 'CUL4A', 'BRD4']",['Not specified'],Unclear,low,4.0,38540967,Chromatin Remodeling-Related PRDM1 Increases Stomach Cancer Proliferation and Is Counteracted by Bromodomain Inhibitor.,2024,pdf,2025-12-19T03:58:32.042439,,,,
"['Mutation analysis', 'Survival analysis']","['Pan-cancer', 'Lung cancer', 'Colorectal cancer', 'Other solid tumor']","['Immunotherapy', 'Precision medicine', 'Biomarker discovery']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this clinical trial paper. The study focuses on a phase 1/2 clinical trial evaluating a therapeutic neoantigen vaccine combined with checkpoint inhibitors in patients with advanced metastatic solid tumors. While the paper discusses mutations in KRAS and TP53, there is no indication that cBioPortal was used for data analysis, visualization, or as a data source.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,38538867,A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results.,2024,abstract,2025-12-19T03:58:33.533197,,,,
['Mutation analysis'],['Pan-cancer'],"['Drug response/resistance', 'Methods/Tools development']",['Original research'],['Not specified'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on experimental validation of XPA variants using in vitro protein analyses and cell-based assays to test cisplatin sensitivity. While the study examines tumor variants, the abstract does not describe accessing or analyzing data from cBioPortal.",[],['Citation only'],"['XPA', 'ERCC1', 'ERCC2']",['Not specified'],"[""Unclear""]","[""low""]",4.0,38500596,XPA tumor variant leads to defects in NER that sensitize cells to cisplatin.,2024,abstract,2025-12-19T03:58:33.772685,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']","['TCGA', 'Custom/Private data']","The study used TCGA-GBM cohort data for validation of their findings from a Jordanian patient cohort. They analyzed Serpin B family genes (Serpinb3, Serpinb5, Serpinb6, Serpinb11, and Serpinb12) for alterations, expression levels, and survival outcomes. The analysis included examining gene alterations, expression data, and progression-free survival associations in the TCGA-GBM cohort to complement their SNP analysis from the local patient population.",['TCGA-GBM'],['Data download/export'],"['SERPINB3', 'SERPINB5', 'SERPINB6', 'SERPINB11', 'SERPINB12']",['Download data'],External (downloaded data),medium,4.0,38539447,Exploring Genetic Determinants: A Comprehensive Analysis of Serpin B Family SNPs and Prognosis in Glioblastoma Multiforme Patients.,2024,pdf,2025-12-19T03:58:34.493417,,,,
"['Gene expression analysis', 'Survival analysis']",['Breast cancer'],"['Biomarker discovery', 'Other']",['Original research'],"['TCGA', 'METABRIC']",The authors used cBioPortal to analyze ZAG/AZGP1 expression levels in breast cancer patient cohorts from TCGA and METABRIC datasets. They performed survival analysis to correlate high ZAG expression with patient prognosis specifically in triple-negative breast cancer (TNBC) patients compared to other breast cancer subtypes. The analysis demonstrated that high ZAG expression is linked to poor prognosis in TNBC patients but not in other clinical subtypes.,"['TCGA', 'METABRIC']","['Web-based analysis', 'Web-based visualization']",['AZGP1'],"['Expression analysis', 'Survival analysis']",cBioPortal platform,medium,4.0,38496643,Zinc Alpha-2-Glycoprotein (ZAG/AZGP1) secreted by triple-negative breast cancer promotes tumor microenvironment fibrosis.,2024,abstract,2025-12-19T03:58:35.759737,,,,
"['Gene expression analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy']",['Original research'],['Not specified'],"The paper mentions using cBioPortal to perform GSEA analysis of CCNE1-high patients (z-score > 1.5 vs. unaltered) to show upregulation of pathways in soft-tissue sarcoma patients. However, the abstract and introduction provided do not contain detailed information about the specific datasets queried, genes analyzed, or the extent of cBioPortal usage beyond this brief mention. The usage appears to be for analyzing patient data to validate findings from their mouse models.",[],['Web-based analysis'],"['CCNE1', 'VGLL3', 'TP53']","['Expression analysis', 'Query interface']",Unclear,low,4.0,38509063,Metabolic targeting of cancer associated fibroblasts overcomes T-cell exclusion and chemoresistance in soft-tissue sarcomas.,2024,pdf,2025-12-19T03:58:35.963067,,,,
['Other'],['Pan-cancer'],"['Review/Commentary', 'Methods/Tools development']",['Review'],['Not specified'],"This is a protocol paper for a planned scoping review that will identify and analyze data visualization tools for tumor boards and clinical oncology. cBioPortal is likely cited as one of the potential tools that may be identified during the review process, but no actual usage or analysis of cBioPortal is described in this protocol paper. The paper describes the methodology for conducting the review rather than presenting results.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,38441925,Data Visualization Support for Tumor Boards and Clinical Oncology: Protocol for a Scoping Review.,2024,abstract,2025-12-19T03:58:36.885626,,,,
"['Mutation analysis', 'Copy number analysis', 'Survival analysis']",['Pan-cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine']",['Original research'],['Multiple sources'],"The paper performed a comprehensive pan-cancer analysis of ATM variants across 10,609 variants in 8,587 patient tumors. cBioPortal was likely used as one of the data sources for accessing patient tumor genomic data across multiple cancer types to analyze ATM variant prevalence, loss of heterozygosity patterns, and the relationship between ATM variants and protein loss. The study integrated this data to develop a refined ATM loss-of-function biomarker approach for predicting response to platinum-based chemotherapy and ATR inhibition.",[],['Data download/export'],['ATM'],['Download data'],External (downloaded data),medium,4.0,38416404,Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types.,2024,abstract,2025-12-19T03:58:37.653264,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'Custom/Private data']","The authors used cBioPortal to access molecular data from the stomach adenocarcinoma Firehose Legacy study (TCGA). They analyzed gene expression data from 82 poorly cohesive gastric cancer (PCGC) samples, which were divided into KRT8-high and KRT8-low groups. The data was used to investigate mRNA levels of KRT8 and associated transcriptional signatures, and to correlate expression patterns with survival outcomes.","['stomach adenocarcinoma, Firehose Legacy study, TCGA']",['Data download/export'],['KRT8'],"['Download data', 'Expression analysis']",External (downloaded data),high,4.0,38392627,Influence of Tumor Stroma on the Aggressiveness of Poorly Cohesive Gastric Carcinoma.,2024,pdf,2025-12-19T03:58:38.888835,,,,
"['Gene expression analysis', 'Mutation analysis']",['Lung cancer'],"['Drug response/resistance', 'Review/Commentary', 'Biomarker discovery']",['Review'],['Not specified'],"This is a review paper discussing the role of epiregulin (EREG) in lung tumorigenesis and therapeutic resistance. While the paper discusses various genetic alterations and molecular mechanisms in NSCLC, there is no explicit mention of cBioPortal usage in the provided abstract and introduction. The paper appears to be a literature review synthesizing current knowledge about EREG's oncogenic functions rather than an original research study utilizing cBioPortal resources.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,38398101,Role of Epiregulin in Lung Tumorigenesis and Therapeutic Resistance.,2024,pdf,2025-12-19T03:58:39.614217,,,,
"['Mutation analysis', 'Pathway analysis']","['Pan-cancer', 'Breast cancer', 'Lung cancer', 'Leukemia/Lymphoma', 'Glioma/Brain cancer', 'Prostate cancer']","['Drug response/resistance', 'Pathway analysis', 'Precision medicine', 'Review/Commentary']",['Review'],['Not specified'],"This is a review paper discussing PI3K pathway targeting across various cancers. While cBioPortal is cited in the references, there is no explicit description in the provided abstract and introduction of how cBioPortal was used for data analysis, visualization, or data download. The paper focuses on reviewing PI3K pathway alterations, inhibitors, and therapeutic strategies rather than presenting original data analysis using cBioPortal.",[],['Citation only'],"['PIK3CA', 'PIK3CB', 'PIK3CD', 'PIK3CG', 'PIK3C2A', 'PIK3C2B', 'PIK3C2G', 'PIK3C3', 'PIK3R4', 'PTEN']",['Not specified'],Unclear,low,4.0,38396649,Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers.,2024,pdf,2025-12-19T03:58:39.630484,,,,
"['Gene expression analysis', 'Pathway analysis']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],"The study used GBM-based data from The Cancer Genome Atlas (TCGA) databases to analyze the expression pattern of miR-29b and different target genes, including NG2. The data appears to have been accessed through cBioPortal for external analysis of gene expression patterns in glioblastoma multiforme. The analysis focused on understanding the regulatory mechanisms of NG2 expression through the c-Myc/H19/miR-29b axis.",['TCGA-GBM'],['Data download/export'],"['NG2', 'PDGFRA', 'SP1', 'MYC', 'H19']","['Download data', 'Expression analysis']",External (downloaded data),medium,4.0,38318212,C-Myc/H19/miR-29b axis downregulates nerve/glial (NG)2 expression in glioblastoma multiforme.,2024,abstract,2025-12-19T03:58:40.015042,,,,
['Mutation analysis'],['Other hematologic'],"['Review/Commentary', 'Biomarker discovery', 'Precision medicine']",['Review'],['Not specified'],"This is a review paper on myelofibrosis that discusses molecular genetic profiles, diagnosis, prognosis, and treatment. While cBioPortal may be cited as a resource for cancer genomics data, the paper does not describe any specific usage of cBioPortal for data analysis or visualization. The paper focuses on reviewing the literature regarding driver mutations (JAK2, CALR, MPL) and additional mutations in myelofibrosis.",[],['Citation only'],"['JAK2', 'CALR', 'MPL']",['Not specified'],Unclear,low,4.0,38339265,"Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements.",2024,pdf,2025-12-19T03:58:40.631942,,,,
"['Gene expression analysis', 'Pathway analysis', 'Multi-omics integration']",['Pan-cancer'],"['Methods/Tools development', 'Biomarker discovery']",['Methods/Software'],['Multiple sources'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this paper. This appears to be a methods/software development paper describing CAP-RNAseq, a new pipeline for RNA-seq cluster analysis and gene prioritization. If cBioPortal is cited, it is likely as a reference tool or data source rather than being directly used in the methodology.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,38279653,CAP-RNAseq: an integrated pipeline for functional annotation and prioritization of co-expression clusters.,2024,abstract,2025-12-19T03:58:40.951278,,,,
['Mutation analysis'],['Leukemia/Lymphoma'],"['Immunotherapy', 'Biomarker discovery']",['Original research'],['Not specified'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on experimentally validating the immunogenicity of neoantigens arising from recurrent mutations in AML, including IDH2R140Q, IDH1R132H, and FLT3D835Y. While the study investigates recurrent driver mutations that could have been identified using databases like cBioPortal, no specific usage of the platform is described in the provided text.",[],['Citation only'],"['IDH2', 'IDH1', 'FLT3']",['Not specified'],Unclear,low,4.0,38241630,Targeting IDH2R140Q and other neoantigens in acute myeloid leukemia.,2024,abstract,2025-12-19T03:58:42.291927,,,,
['Other'],['Not specified'],['Other'],['Original research'],['Not specified'],"This paper does not appear to use cBioPortal at all. The study is an experimental in vivo wound healing study using Per2 knockout mice to investigate the role of the circadian clock gene Per2 in skin tissue repair. The research involves histological, immunofluorescence, and immunohistochemical analyses of wound healing parameters, but does not involve cancer genomics data or cBioPortal usage.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,38229522,Clock gene Per2 modulates epidermal tissue repair in vivo.,2024,abstract,2025-12-19T03:58:42.513064,,,,
"['Mutation analysis', 'Copy number analysis']",['Pan-cancer'],"['Review/Commentary', 'Drug response/resistance', 'Biomarker discovery']",['Review'],['Not specified'],"This is a review paper discussing replication stress response and cell cycle control proteins as cancer therapy targets. While the paper discusses various genetic alterations (mutations in TP53, RB1, ATM, amplifications of MYC, CCNE1) that are commonly analyzed using resources like cBioPortal, there is no explicit mention of cBioPortal usage in the provided abstract and introduction. The paper appears to cite cBioPortal as a reference resource rather than actively using it for analysis.",[],['Citation only'],"['TP53', 'RB1', 'ATM', 'MYC', 'CCNE1']",['Not specified'],Unclear,low,4.0,38279263,Key Proteins of Replication Stress Response and Cell Cycle Control as Cancer Therapy Targets.,2024,pdf,2025-12-19T03:58:43.091005,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Pathway analysis']",['Prostate cancer'],"['Drug response/resistance', 'Biomarker discovery', 'Review/Commentary', 'Precision medicine']",['Review'],['Not specified'],"This is a review paper discussing DNA damage response mechanisms in prostate cancer therapy. While the paper cites cBioPortal, the abstract and introduction provided do not contain specific details about how cBioPortal was used. The paper appears to be a comprehensive review of prostate cancer treatment strategies, genetic alterations, and therapeutic approaches rather than an original research study utilizing cBioPortal for data analysis.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,38201511,Exploiting the DNA Damage Response for Prostate Cancer Therapy.,2023,pdf,2025-12-19T03:58:44.243656,,,,
"['Mutation analysis', 'Pathway analysis']","['Pan-cancer', 'Melanoma']","['Drug response/resistance', 'Pathway analysis', 'Precision medicine', 'Review/Commentary']",['Review'],['Not specified'],"This is a review paper on CRAF in cancer progression and precision therapies. Based on the abstract and introduction provided, there is no explicit description of how cBioPortal was used in this study. The paper appears to cite cBioPortal as a reference source but does not describe specific analyses, data downloads, or visualizations performed using the platform.",[],['Citation only'],"['RAF1', 'BRAF']",['Not specified'],Unclear,low,4.0,38195917,The role of CRAF in cancer progression: from molecular mechanisms to precision therapies.,2024,abstract,2025-12-19T03:58:45.695735,,,,
"['Mutation analysis', 'Copy number analysis']",['Pan-cancer'],"['Precision medicine', 'Drug response/resistance']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal being used in this study. The paper describes a Molecular Tumor Board (MTB) experience using gene panel-mediated comprehensive genomic profiling (CGP) of 554 patients at a German cancer center. The study focuses on factors affecting clinical implementation of MTB recommendations rather than utilizing cBioPortal for data analysis or visualization.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,38136436,Determinants Affecting the Clinical Implementation of a Molecularly Informed Molecular Tumor Board Recommendation: Experience from a Tertiary Cancer Center.,2023,abstract,2025-12-19T03:58:45.726326,,,,
"['Gene expression analysis', 'Other']",['Other solid tumor'],['Drug response/resistance'],['Original research'],['Not specified'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. This appears to be a preclinical experimental study evaluating the ATR inhibitor BAY 1895344 as a radiosensitizer using cell lines and mouse models. The study focuses on in vitro and in vivo experiments rather than genomic database analysis.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,38104870,Preclinical Evaluation of the ATR Inhibitor BAY 1895344 as a Radiosensitizer for Head and Neck Squamous Cell Carcinoma.,2024,abstract,2025-12-19T03:58:46.455482,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis']",['Original research'],"['TCGA', 'METABRIC', 'Custom/Private data', 'Multiple sources']",The paper used cBioPortal to access and analyze the TCGA-BRCA dataset for training their Notch transcriptomic signature. The TCGA-BRCA cohort was used as one of the primary training datasets to develop and optimize the 20-gene signature. The signature was then validated on independent datasets including METABRIC and Oslo2.,"['TCGA-BRCA', 'METABRIC']",['Data download/export'],"['NOTCH1', 'NOTCH2', 'NOTCH3', 'NOTCH4', 'JAGGED1', 'BRCA', 'TP53']",['Download data'],External (downloaded data),medium,4.0,38172915,Identification of a Notch transcriptomic signature for breast cancer.,2024,pdf,2025-12-19T03:58:48.325036,,,,
"['Mutation analysis', 'Gene expression analysis']",['Leukemia/Lymphoma'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],['Not specified'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this paper. The study describes a CRISPR/Cas9 genome-wide screen in mouse Eμ-Myc lymphoma cells to identify genes involved in TRP53-mediated tumor suppression, specifically identifying ARRDC3. The paper does not reference cBioPortal data, tools, or analyses in the sections provided.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,38097622,Genome-wide CRISPR screening identifies a role for ARRDC3 in TRP53-mediated responses.,2024,pdf,2025-12-19T03:58:48.577510,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Pathway analysis']",['Other solid tumor'],['Biomarker discovery'],['Original research'],"['TCGA', 'Multiple sources']","The paper used cBioPortal to analyze GLYAT expression and mutation data in kidney renal clear cell carcinoma (KIRC). The authors accessed public databases including TCGA data through cBioPortal to characterize GLYAT expression levels, mutation rates, methylation patterns, and correlations with patient prognosis across different stages and grades of KIRC. The analysis was performed using bioinformatic approaches on publicly available datasets.",['TCGA-KIRC'],"['Data download/export', 'Web-based analysis']",['GLYAT'],"['Expression analysis', 'Query interface', 'Download data']",Mixed,medium,4.0,38066746,Downregulation of Glycine N-Acyltransferase in Kidney Renal Clear Cell Carcinoma: A Bioinformatic-Based Screening.,2023,pdf,2025-12-19T03:58:49.353467,,,,
['Mutation analysis'],['Lung cancer'],"['Methods/Tools development', 'Precision medicine']","['Original research', 'Methods/Software']",['Not specified'],"cBioPortal is mentioned only as a reference database for comparison purposes. The authors note that their cohort includes 39 unique EGFR exon 19 deletions, which they compare to the 40 unique del19 variants contained in cBioPortal, to emphasize the comprehensiveness of their validation cohort. No actual data download, analysis, or visualization using cBioPortal is described.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,37958668,Comparison and Validation of Rapid Molecular Testing Methods for Theranostic Epidermal Growth Factor Receptor Alterations in Lung Cancer: Idylla versus Digital Droplet PCR.,2023,pdf,2025-12-19T03:58:50.117706,,,,
['Gene expression analysis'],"['Bladder cancer', 'Prostate cancer', 'Breast cancer', 'Liver cancer']","['Review/Commentary', 'Biomarker discovery']",['Review'],['Not specified'],"This is a review paper focusing on the role of CERS2/LASS2 in bladder cancer. While the abstract mentions reviewing public gene expression data and its association with disease progression, no specific details about cBioPortal usage are provided in the excerpts shown. The paper appears to cite or reference public databases for gene expression analysis but does not explicitly describe how cBioPortal was used.",[],['Citation only'],"['CERS2', 'LASS2', 'TMSG1', 'KLF6', 'SP1', 'MZF1', 'CREB', 'GPER1']",['Not specified'],Unclear,low,4.0,37958652,The Role of Longevity Assurance Homolog 2/Ceramide Synthase 2 in Bladder Cancer.,2023,pdf,2025-12-19T03:58:50.372430,,,,
"['Gene expression analysis', 'Mutation analysis', 'Survival analysis', 'Pathway analysis']","['Pan-cancer', 'Breast cancer']","['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","The paper mentions using cBioPortal as one of multiple public databases for pan-cancer analysis of KCNQ4. However, the abstract and introduction do not provide specific details about how cBioPortal was used, what features were accessed, or whether data was downloaded versus analyzed on the platform. The study primarily used TCGA data and R software for bioinformatics analysis, with cBioPortal likely serving as a data source or validation tool.",['TCGA'],['Citation only'],['KCNQ4'],['Not specified'],Unclear,low,4.0,37903775,Comprehensive pan‑cancer analysis of potassium voltage-gated channel Q4 (KCNQ4) gene across multiple human malignant tumors.,2023,pdf,2025-12-19T03:58:51.921722,,,,
"['Mutation analysis', 'Copy number analysis', 'Other']","['Melanoma', 'Lung cancer', 'Other solid tumor']","['Methods/Tools development', 'Tumor evolution']","['Original research', 'Methods/Software']","['Multiple sources', 'Custom/Private data']","Based on the abstract and introduction provided, the paper does not explicitly describe how cBioPortal was used. The study focuses on developing Metient, a new computational method for reconstructing metastatic spread patterns from tumor sequencing data. The paper analyzes data from 167 patients with melanoma, neuroblastoma, and non-small cell lung cancer, but no specific mention of cBioPortal usage is made in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41407927,Inferring cancer type-specific patterns of metastatic spread using Metient.,2025,abstract,2025-12-19T03:58:52.541098,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']",['Original research'],['TCGA'],"The paper used TCGA data from 10,437 subjects with 33 types of solid tumors to systematically analyze the molecular biological characteristics of NTN1 and its receptors (DCC, UNC5A-D, Neo1, MCAM, DSCAM). The study examined genetic alterations, promoter methylation, miRNA regulation, and EMT functions across pan-cancer samples. While cBioPortal is not explicitly mentioned in the abstract/introduction, TCGA data analysis of this scope typically involves cBioPortal for data access and visualization.",['TCGA'],['Citation only'],"['NTN1', 'DCC', 'UNC5A', 'UNC5B', 'UNC5C', 'UNC5D', 'NEO1', 'MCAM', 'DSCAM']",['Not specified'],Unclear,low,4.0,41407823,Pan-cancer analysis reveals netrin-1 receptors as potential tumor biomarkers and immune-related therapeutic targets.,2025,abstract,2025-12-19T03:58:52.686199,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration', 'Pathway analysis']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper cites cBioPortal but does not provide explicit details about how it was used. The study performed pan-cancer analysis of MCRS1 using multiple tools including TCGA data, but the specific role of cBioPortal in data access or analysis is not clearly described in the abstract or introduction. It appears cBioPortal may have been one of several resources consulted, but the exact usage mode and features utilized are not specified.",[],['Citation only'],"['MCRS1', 'VEGFA', 'TGFB1']",['Not specified'],Unclear,low,4.0,41378029,MCRS1 is associated with immunosuppressive microenvironments in pan-cancer and promotes hepatocellular carcinoma malignant phenotypes.,2025,abstract,2025-12-19T03:58:53.127078,,,,
['Other'],['Pan-cancer'],"['Review/Commentary', 'Precision medicine', 'Immunotherapy']",['Review'],['Not specified'],"This is a review paper discussing therapeutic monoclonal antibodies against cancer. There is no evidence in the provided abstract and introduction that cBioPortal was actually used in this study. The paper focuses on describing approved therapeutic antibodies, their mechanisms of action, and future directions in cancer immunotherapy. cBioPortal may only be cited in the references or mentioned in passing without actual usage.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,38132155,Therapeutic Monoclonal Antibodies against Cancer: Present and Future.,2023,pdf,2025-12-19T03:58:54.273616,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly describe how cBioPortal was used in the study. While TCGA-ESCA data was analyzed, the methods section does not mention cBioPortal as a data source or analysis platform. The citation of cBioPortal may be for reference purposes only, as the paper primarily describes using TCGA and GSE53625 datasets with various bioinformatics tools including consensus clustering and WGCNA.",['TCGA-ESCA'],['Citation only'],"['ANGPT2', 'CRIPT', 'GLA', 'LMNB1', 'MARVELD3', 'DKK1']",['Not specified'],Unclear,low,4.0,41378004,Developing of potential mRNA vaccines based on tumor antigens and immune subtypes of esophageal cancer.,2025,abstract,2025-12-19T03:58:55.016337,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Leukemia/Lymphoma', 'Other solid tumor']","['Biomarker discovery', 'Pathway analysis', 'Other']",['Original research'],['TCGA'],"The paper leveraged TCGA transcriptomic data for a pan-cancer analysis correlating AP-2 family expression with intratumoral microbiota. While the abstract mentions using TCGA data, the specific role of cBioPortal in data access or analysis is not explicitly described in the provided text. The study appears to have used TCGA data for gene expression analysis, survival modeling, and pathway analysis across 33 tumor types.",['TCGA'],['Citation only'],"['TFAP2E', 'TFAP2B', 'TFAP2E-AS1']",['Not specified'],"[""Unclear""]",low,4.0,41373739,Intratumoral Microbiota Correlates with AP-2 Expression: A Pan-Cancer Map with Cohort-Specific Prognostic and Molecular Footprints.,2025,abstract,2025-12-19T03:58:56.255326,,,,
"['Mutation analysis', 'Copy number analysis', 'Survival analysis']","['Colorectal cancer', 'Pancreatic cancer']","['Biomarker discovery', 'Drug response/resistance', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The study utilized circulating tumor DNA data from Guardant (national cohort) and Mayo Clinic cohorts to analyze genomic alterations in KRAS G12D-mutant cancers. While the paper cites cBioPortal, the specific usage details are not described in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41372636,Translational Relevance of the Genomic Landscape of KRAS<sup>G12D</sup>-Mutant Colorectal and Pancreatic Cancers.,2025,abstract,2025-12-19T03:58:56.686758,,,,
"['Mutation analysis', 'Survival analysis', 'Copy number analysis']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']","['TCGA', 'Custom/Private data']","The study used TCGA data from cBioPortal to validate their findings about TP53 R273C mutation frequency in lower-grade IDH-mutant astrocytomas (LGIMAs). The authors incorporated TCGA LGIMA data to assess sex-based differences in R273C mutation prevalence, which reached statistical significance when combined with their institutional cohort. The primary analysis was performed on their own cohort of 14 patients using NGS, with cBioPortal serving as a validation resource for TCGA data.",['TCGA'],['Data download/export'],"['TP53', 'IDH1', 'IDH2', 'ATRX', 'CDKN2A', 'CDKN2B']",['Download data'],External (downloaded data),medium,4.0,41373636,"Next-Generation Sequencing Reveals a Diagnostic and Prognostic Role of the <i>TP53</i> R273C Mutation in Lower-Grade, <i>IDH</i>-Mutant Astrocytomas.",2025,pdf,2025-12-19T03:58:57.430030,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis']",['Breast cancer'],"['Drug response/resistance', 'Biomarker discovery', 'Precision medicine']",['Original research'],['Custom/Private data'],"The paper mentions conducting comprehensive genomic and transcriptomic analysis to identify FAT1 as a tumor suppressor gene in breast cancer. While cBioPortal is cited, the abstract and introduction do not provide explicit details about how cBioPortal was specifically used in the study. The research primarily focuses on patient-derived organoids (PDOs) and whole exome sequencing (WES) analysis of custom patient samples.",[],['Citation only'],"['FAT1', 'CTNNB1']",['Not specified'],Unclear,low,4.0,41362743,Loss of FAT1 drives cyclophosphamide resistance in breast cancer via the Wnt/β-Catenin pathway.,2026,pdf,2025-12-19T03:58:59.150866,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Lung cancer'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the methods or results. The study analyzed RRM2 expression using data from the Genomic Data Commons Data Portal and TCGA, performed survival analysis using KM plotter tool, and used starBase database for miRNA identification. While cBioPortal is cited, there is no clear description of how it was used in this specific study.",['TCGA'],['Citation only'],['RRM2'],['Not specified'],Unclear,low,4.0,41357570,"Deciphering the let-7c-5p/RRM2 axis in lung adenocarcinoma: expression, prognosis, and immune landscape implications.",2025,pdf,2025-12-19T03:58:59.619870,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Pathway analysis', 'Multi-omics integration']",['Breast cancer'],"['Biomarker discovery', 'Precision medicine', 'Tumor evolution']",['Original research'],"['TCGA', 'GEO', 'Multiple sources']","Based on the abstract and introduction provided, cBioPortal is not explicitly mentioned in the text. The study focuses on identifying super enhancer-associated genes for breast cancer prognosis using TCGA and GEO data, with analyses including Cox regression, LASSO, survival analysis, tumor mutation burden, and tumor immune microenvironment. While cBioPortal is cited in the paper, the specific usage details are not described in the provided sections.",['TCGA'],['Citation only'],['TFF1'],['Not specified'],Unclear,low,4.0,41360825,Identification of a super enhancer associated gene signature for the prognosis prediction and regulatory mechanism exploration in breast cancer.,2025,pdf,2025-12-19T03:58:59.704963,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Lung cancer']","['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used as one of multiple bioinformatics tools to analyze BIRC5 across cancers. The platform was utilized to examine gene mutations and alterations in BIRC5 across different tumor types as part of a comprehensive pan-cancer analysis. The study integrated cBioPortal data with other databases (GEPIA2, UALCAN, TISIDB) to characterize BIRC5's role in cancer.",[],['Web-based analysis'],['BIRC5'],['Not specified'],Unclear,medium,4.0,41361777,Comprehensive analysis of BIRC5: from pan-cancer analysis to experimental validation.,2025,abstract,2025-12-19T03:58:59.773070,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Pan-cancer'],"['Biomarker discovery', 'Database/Resource']",['Original research'],"['TCGA', 'Multiple sources']",The study used cBioPortal to access bulk cancer gene expression data from TCGA to analyze fibroblast subtype-specific gene activities in cancer samples. The authors applied their fibroblast atlas to bulk cancer data obtained from cBioPortal to examine the association between different fibroblast subtypes (particularly myoCAF) and patient survival outcomes across multiple cancer types.,['TCGA'],['Data download/export'],[],['Download data'],External (downloaded data),medium,4.0,41377662,A systematic characterization of fibroblast subtypes and heterogeneity.,2025,abstract,2025-12-19T03:58:59.960590,,,,
"['Mutation analysis', 'Survival analysis', 'Pathway analysis']",['Lung cancer'],"['Biomarker discovery', 'Precision medicine', 'Drug response/resistance']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on analyzing driver gene alterations in NSCLC spine metastases and their association with radiotherapy response using institutional patient data and in vitro experiments. While cBioPortal is cited, the specific usage details are not described in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41348985,Impact of RAS-MAPK Pathway Genetic Alterations on Radiotherapy Response in Metastatic Lung Adenocarcinoma.,2025,abstract,2025-12-19T03:59:01.124768,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy', 'Precision medicine', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to analyze mutational profiles, copy number alterations (CNAs), and gene fusion events for the UBD gene across the TCGA Pan-Cancer dataset. The platform served as a data source for genomic alteration analysis in this pan-cancer study of UBD/FAT10.",['TCGA Pan-Cancer'],"['Web-based analysis', 'Data download/export']","['UBD', 'TP53']","['Query interface', 'Download data']",Mixed,high,4.0,41347086,Pan-cancer landscape of UBD/FAT10 and experimental validation in esophageal carcinoma.,2025,pdf,2025-12-19T03:59:01.777920,,,,
"['Gene expression analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis', 'Drug response/resistance']",['Original research'],['TCGA'],"The study used RNA sequencing data from TCGA datasets accessed through cBioPortal, specifically the TCGA Cell 2017 dataset (132 papillary and 270 nonpapillary urothelial carcinoma patients) and TCGA Nature 2014 dataset (39 papillary and 88 nonpapillary patients). The data was downloaded and analyzed externally using a novel PPI analysis tool called Proteinarium to identify protein-protein interaction networks and hub proteins specific to papillary and nonpapillary urothelial carcinoma architectures.","['TCGA Cell 2017', 'TCGA Nature 2014']",['Data download/export'],"['RPS27A', 'UBA52', 'VAMP8', 'GNB1', 'RHOA', 'UBC', 'FPR2']",['Download data'],External (downloaded data),high,4.0,41342186,Protein-Protein Interactions in Papillary and Nonpapillary Urothelial Carcinoma Architectures: Comparative Study.,2025,abstract,2025-12-19T03:59:02.949569,,,,
"['Mutation analysis', 'Copy number analysis']",['Colorectal cancer'],"['Tumor evolution', 'Biomarker discovery']",['Original research'],"['TCGA', 'Custom/Private data']","Based on the abstract and introduction provided, the paper appears to focus on mouse models and experimental work studying driver mutations in colorectal cancer. While cBioPortal is cited, the specific usage is not detailed in the provided text. The authors mention demonstrating mutational patterns in human CRC, which may involve querying public databases like TCGA through cBioPortal, but the exact methodology is not specified in the excerpts provided.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41339549,Decay of driver mutations shapes the landscape of intestinal transformation.,2025,abstract,2025-12-19T03:59:03.454555,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Tumor evolution']",['Original research'],"['TCGA', 'Custom/Private data']","Based on the abstract and introduction provided, the paper appears to focus on experimental studies of pericytes in glioblastoma using genetic engineering and orthotopic implantation models. While cBioPortal is cited, the abstract does not provide explicit details about how cBioPortal was used. It is likely that cBioPortal was used to query TCGA glioblastoma data for validation of gene expression patterns or survival correlations, but specific usage details are not mentioned in the provided text.",['TCGA'],['Citation only'],"['MET', 'FOSL1']",['Not specified'],Unclear,low,4.0,41339360,Pericytes orchestrate a tumor-restraining microenvironment in glioblastoma.,2025,abstract,2025-12-19T03:59:04.846276,,,,
"['Mutation analysis', 'Gene expression analysis']",['Other solid tumor'],"['Biomarker discovery', 'Other']",['Original research'],['TCGA'],"The authors used cBioPortal to query ZMIZ1 mutations in endometrial cancer datasets. This analysis revealed that ZMIZ1 mutations are found in endometrial cancer, supporting the clinical relevance of their findings about ZMIZ1 as an estrogen receptor coregulator in uterine biology. The cBioPortal query was used to establish the translational significance of their experimental findings in mouse models and human endometrial stromal cells.",[],['Web-based analysis'],['ZMIZ1'],['Query interface'],cBioPortal platform,medium,4.0,41321316,Transcriptional coregulator ZMIZ1 modulates estrogen responses that are essential for healthy endometrial function.,2025,abstract,2025-12-19T03:59:05.827695,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],['Biomarker discovery'],['Original research'],['Multiple sources'],"The paper used cBioPortal as one of multiple online databases to evaluate the transcription levels of ZHX family members (ZHX1, ZHX2, ZHX3) in esophageal carcinoma. The platform was used to assess the association between ZHX mRNA expression levels and overall survival outcomes in EC patients. The bioinformatic analyses from cBioPortal and other databases were combined with immunohistochemical validation to determine prognostic significance.",[],['Web-based analysis'],"['ZHX1', 'ZHX2', 'ZHX3']","['Expression analysis', 'Survival analysis']",cBioPortal platform,medium,4.0,41332998,Comprehensive Analysis of the Prognostic Significance of ZHX Family Members in Esophageal Carcinoma.,2025,abstract,2025-12-19T03:59:06.160257,,,,
"['Mutation analysis', 'Multi-omics integration']",['Glioma/Brain cancer'],"['Immunotherapy', 'Biomarker discovery', 'Precision medicine']",['Original research'],['TCGA'],"The study used somatic missense variant data from TCGA-GBM (The Cancer Genome Atlas Glioblastoma Multiforme dataset) which was likely accessed through cBioPortal. The mutation data was filtered using high-confidence genomic databases and used for neoepitope prediction analysis. The analysis focused on identifying somatic variants in canonical GBM driver genes including EGFR, TP53, and PIK3R1 for subsequent HLA binding affinity prediction and structural modeling.",['TCGA-GBM'],['Data download/export'],"['EGFR', 'TP53', 'PIK3R1']",['Download data'],External (downloaded data),medium,4.0,41301809,Integrative Neoepitope Discovery in Glioblastoma via HLA Class I Profiling and AlphaFold2-Multimer.,2025,abstract,2025-12-19T03:59:06.395212,,,,
"['Gene expression analysis', 'Survival analysis', 'Copy number analysis']",['Other solid tumor'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],['TCGA'],"The authors used cBioPortal to analyze TCGA bladder cancer data, specifically examining FGFR1 mRNA expression levels and their correlation with overall survival in muscle-invasive bladder cancer (MIBC) patients. This analysis revealed that high FGFR1 expression correlates with poor overall survival, supporting FGFR1 as a therapeutic target for their subsequent experimental studies on erdafitinib resistance mechanisms.",['TCGA'],"['Web-based analysis', 'Web-based visualization']",['FGFR1'],"['Survival analysis', 'Expression analysis']",cBioPortal platform,high,4.0,41315241,MET signaling drives acquired resistance to erdafitinib in muscle-invasive bladder cancer cells.,2025,pdf,2025-12-19T03:59:06.704749,,,,
"['Gene expression analysis', 'Copy number analysis', 'Mutation analysis']",['Prostate cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction, this paper appears to use cBioPortal to analyze associations between TMPRSS2:ERG fusion status, PTEN loss, and INPP4B expression in prostate cancer datasets. The authors examined correlations between these genomic features and gene expression patterns in T:E fusion-positive versus -negative tumors. The study primarily focuses on experimental validation in cell lines and clinical samples, with cBioPortal likely used for initial genomic data analysis and correlation studies.",['TCGA'],"['Web-based analysis', 'Data download/export']","['ERG', 'TMPRSS2', 'PTEN', 'INPP4B', 'IRS2']","['Expression analysis', 'Query interface']",Mixed,medium,4.0,41321318,Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusion.,2025,pdf,2025-12-19T03:59:07.026103,,,,
"['Mutation analysis', 'Survival analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']","['Custom/Private data', 'Multiple sources']","The study used cBioPortal to access and analyze the AC-ICAM public dataset, which served as an independent validation cohort for their findings on KRAS G12A mutations in stage II-III colorectal cancer. The AC-ICAM cohort (n=178) was retrieved from cBioPortal and used to replicate the prognostic associations observed in their institutional FMU cohort. The analysis focused on KRAS mutation status and its correlation with relapse-free survival and overall survival outcomes.",['AC-ICAM'],['Web-based analysis'],"['KRAS', 'BRAF']","['Query interface', 'Download data']",External (downloaded data),high,4.0,41300966,KRAS G12A Identifies a High-Risk Subset in Resected Stage II-III Colorectal Cancer.,2025,pdf,2025-12-19T03:59:09.047284,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The study used cBioPortal to evaluate FLI1 expression across multiple invasive breast carcinoma cohorts and determine its prognostic significance. The authors analyzed FLI1 expression patterns and their associations with stromal features, histological grade, and clinical outcomes in breast cancer patients. cBioPortal was likely used to access and analyze publicly available breast cancer datasets including TCGA data.",[],"['Web-based analysis', 'Citation only']",['FLI1'],"['Expression analysis', 'Not specified']",Unclear,low,4.0,41300765,FLI1 Expression in Invasive Breast Carcinoma: Clinicopathological Correlations and Prognostic Implications.,2025,abstract,2025-12-19T03:59:09.204526,,,,
"['Multi-omics integration', 'Gene expression analysis', 'Mutation analysis']",['Other solid tumor'],"['Database/Resource', 'Methods/Tools development']",['Methods/Software'],['Multiple sources'],"This paper describes the development of StomachDB, a comprehensive multi-omics database for gastric diseases. While cBioPortal is likely cited as a related cancer genomics database or potential data source, the paper does not provide explicit details about how cBioPortal was used in the development or analysis. The focus is on presenting their own new database resource rather than utilizing cBioPortal for analysis.",[],['Citation only'],['CDH1'],['Not specified'],Unclear,low,4.0,41300276,StomachDB: An Integrated Multi-Omics Database for Gastric Diseases.,2025,pdf,2025-12-19T03:59:10.657666,,,,
"['Multi-omics integration', 'Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Pan-cancer'],"['Biomarker discovery', 'Precision medicine', 'Review/Commentary', 'Methods/Tools development']",['Review'],['Not specified'],"This is a comprehensive review paper on multi-omics strategies for biomarker discovery in personalized oncology. cBioPortal is likely cited as one of the important computational tools and databases available for cancer genomics data integration and analysis. However, the paper does not describe specific usage of cBioPortal for original data analysis, as it is a review article synthesizing existing knowledge and methodologies in the field.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41269529,Multi-omics strategies for biomarker discovery and application in personalized oncology.,2025,abstract,2025-12-19T03:59:11.056177,,,,
['Mutation analysis'],['Breast cancer'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],['Not specified'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage. The study focuses on experimental investigation of HSP90 buffering of BRCA1 mutations and their effects on PARP inhibitor resistance. While the paper may cite cBioPortal in references, the provided text does not describe specific usage of the platform for data retrieval or analysis.",[],['Citation only'],['BRCA1'],['Not specified'],Unclear,low,4.0,41265458,HSP90 buffers deleterious genetic variations in BRCA1.,2025,abstract,2025-12-19T03:59:12.331518,,,,
"['Gene expression analysis', 'Pathway analysis']",['Leukemia/Lymphoma'],['Other'],['Original research'],['Not specified'],"This paper focuses on experimental mouse models to study ARID2's role in B cell differentiation and does not appear to directly use cBioPortal for analysis. The paper mentions that ARID2 is frequently mutated in B cell leukemias, which may be based on cBioPortal data or literature, but no specific cBioPortal usage, queries, or analyses are described in the abstract or introduction provided.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41256460,Arid2 promotes Follicular B-cell differentiation and antibody responses <i>in vivo</i>.,2025,abstract,2025-12-19T03:59:13.272606,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","The cBioPortal database was used to identify co-expressed genes linked to SORCS2 in ovarian cancer, applying stringent correlation criteria (|Spearman's correlation coefficient| >0). The specific details of how the co-expression analysis was performed and what additional analyses were conducted using cBioPortal are mentioned but the text is cut off in the provided excerpt.",[],"['Web-based analysis', 'Data download/export']",['SORCS2'],"['Expression analysis', 'Query interface']",Mixed,medium,4.0,41267139,SORCS2 serves as a tumor suppressor and associates with immune infiltration in ovarian cancer.,2025,pdf,2025-12-19T03:59:13.457619,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Colorectal cancer', 'Pan-cancer']","['Biomarker discovery', 'Pathway analysis']","['Review', 'Original research']","['TCGA', 'Multiple sources']","This study conducted a comprehensive analysis of the BID gene in colon adenocarcinoma (COAD) using TCGA data accessed through cBioPortal. The authors analyzed BID expression, methylation patterns, alternative splicing isoforms, and correlations with immune cell infiltration in conjunction with clinical data. The study combined systematic literature review with pan-cancer bioinformatics analysis using TCGA and HPA data to investigate BID's role in COAD development and progression.",['TCGA'],"['Data download/export', 'Web-based analysis']",['BID'],"['Expression analysis', 'Download data', 'Query interface']",Mixed,medium,4.0,41257698,Comprehensive analysis of the BID gene to uncover the role of novel alternative splicing isoforms in colon adenocarcinoma: a systematic review of literature and bioinformatics analysis.,2025,pdf,2025-12-19T03:59:13.942823,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Breast cancer']","['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'Custom/Private data']","The paper does not explicitly mention using cBioPortal in the methods or abstract provided. While the study uses TCGA data for pan-cancer analysis of retinoid-binding proteins (RBPs) including expression profiling, survival analysis, and immune checkpoint correlations, there is no clear indication that cBioPortal was used as the platform or tool for accessing or analyzing this data. The citation of cBioPortal may be for reference purposes only.",['TCGA'],['Citation only'],"['RBP1', 'RBP2', 'RBP3', 'RBP4', 'RBP7', 'RLBP1', 'CRABP1', 'CRABP2']",['Not specified'],Unclear,low,4.0,41301068,Integrated Pan-Cancer Analysis and Experimental Verification of the Roles of Retinoid-Binding Proteins in Breast Cancer.,2025,pdf,2025-12-19T03:59:14.062511,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Colorectal cancer'],"['Drug response/resistance', 'Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Custom/Private data', 'Multiple sources']","cBioPortal was used to retrieve publicly available gene expression data linked to clinical information from TCGA. The TCGA dataset containing 594 CRC samples (341 COAD, 118 READ, and 135 uncategorized) was accessed via the Genomic Data Commons (GDC) application and cBioPortal. This data was used to evaluate associations between PD-1 expression levels and disease progression and survival outcomes in CRC patients.","['TCGA-COAD', 'TCGA-READ']",['Data download/export'],['PDCD1'],['Download data'],External (downloaded data),high,4.0,41261171,Tumor cell-intrinsic PD-1 regulates chemotherapy resistance in colorectal cancer cells by activating downstream MAPK signaling.,2025,pdf,2025-12-19T03:59:14.132347,,,,
['Other'],['Pan-cancer'],"['Review/Commentary', 'Biomarker discovery', 'Precision medicine']",['Review'],['Not specified'],"This is a review paper discussing tumor-agnostic biomarkers in molecular pathology. Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in the study. The paper appears to be a comprehensive review of FDA-approved agnostic biomarkers (MSI, NTRK, TMB, BRAF V600E, RET) and potential future biomarkers across various cancer types. cBioPortal may only be cited as a reference or resource without specific usage described.",[],['Citation only'],"['NTRK', 'BRAF', 'RET', 'KRAS', 'NRG1', 'FGFR', 'ALK', 'AKT', 'HER2', 'PIK3CA', 'BRCA']",['Not specified'],Unclear,low,4.0,41255652,Agnostic Biomarkers in Molecular Pathology.,2025,abstract,2025-12-19T03:59:15.648589,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],The authors used cBioPortal to evaluate TCGA high-throughput sequencing datasets for p190A (ARHGAP35) mutations in bladder cancer samples. They found p190A mutations in up to 8% of bladder cancer samples across several studies in the TCGA database accessed through cBioPortal. This analysis provided initial evidence for the potential relevance of p190A in bladder cancer carcinogenesis.,['TCGA'],['Web-based analysis'],['ARHGAP35'],['Query interface'],"[""cBioPortal platform""]",medium,4.0,41253923,Loss of p190A RhoGAP induces aneuploidy and enhances bladder cancer cell migration and invasion by modulating actin dynamics.,2025,pdf,2025-12-19T03:59:16.055743,,,,
"['Mutation analysis', 'Copy number analysis', 'Survival analysis']",['Pan-cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'MSK-IMPACT', 'Custom/Private data', 'Multiple sources']","The study analyzed sex-based differences across 34,782 patients from three global pan-cancer cohorts: TCGA, MSK MetTropism, and China OrigiMed. The authors likely accessed these datasets through cBioPortal to obtain somatic mutation data, copy number alteration data, and clinical information for survival analysis. The analysis focused on identifying sex-specific genetic alterations and survival outcomes across multiple cancer types, excluding reproductive cancers.","['TCGA', 'MSK MetTropism', 'China OrigiMed']",['Data download/export'],"['TP53', 'CDKN2A', 'TTN', 'EGFR', 'KRAS', 'BRAF', 'PIK3CA', 'CCND1', 'MYC', 'ERBB2', 'MDM2']",['Download data'],External (downloaded data),medium,4.0,41247419,Sex-based molecular and prognostic disparities in pan-cancer: an analysis across the global cohorts.,2025,abstract,2025-12-19T03:59:17.393139,,,,
"['Gene expression analysis', 'Survival analysis']",['Lung cancer'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],['TCGA'],The study used cBioPortal to analyze FADD expression levels in LUSC patients from TCGA data. The authors examined the correlation between FADD overexpression and patient survival rates using cBioPortal's analysis tools. This analysis provided clinical validation for their experimental findings on FADD's role in cisplatin resistance.,['TCGA-LUSC'],"['Web-based analysis', 'Web-based visualization']",['FADD'],"['Expression analysis', 'Survival analysis']",cBioPortal platform,medium,4.0,41238771,From resistance to sensitivity: the impact of FADD and lncRNA PPFIA1-AS1 on cisplatin treatment in LUSC.,2025,abstract,2025-12-19T03:59:17.833889,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Immunotherapy', 'Drug response/resistance']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and title, this paper performs a comprehensive pan-cancer analysis of HTR7 using multiple public databases. While cBioPortal is cited, the abstract does not provide specific details about how cBioPortal was used in the study. The analysis includes expression analysis, survival analysis, immune infiltration analysis, methylation analysis, and pathway analysis across multiple cancer types, likely utilizing data from TCGA and other sources that may have been accessed through cBioPortal or other platforms.",[],['Citation only'],"['HTR7', 'CD274', 'CTLA4', 'HAVCR2', 'PDCD1', 'PDCD1LG2', 'TIGIT']",['Not specified'],Unclear,low,4.0,41237175,"Comprehensive bioinformatic analysis of HTR7: A potential biomarker for diagnosis, survival, and immunotherapy in pan-cancer.",2025,abstract,2025-12-19T03:59:18.511233,,,,
"['Gene expression analysis', 'Mutation analysis', 'Copy number analysis']",['Melanoma'],"['Biomarker discovery', 'Other']",['Original research'],['TCGA'],"The authors used cBioPortal to analyze CST gene expression and alterations in cutaneous melanoma databases. They examined the frequency of genetic alterations in CST genes (CTC1, STN1, TEN1) and compared their expression levels between melanoma samples and normal tissues. This bioinformatics analysis provided the rationale for their subsequent in vivo investigation of STN1 deficiency in melanoma formation.",[],"['Web-based analysis', 'Web-based visualization']","['CTC1', 'STN1', 'TEN1']","['Expression analysis', 'Query interface']","[""cBioPortal platform""]",medium,4.0,41237160,In vivo investigation of STN1 downregulation in melanoma formation in adult mice following UV irradiation.,2025,abstract,2025-12-19T03:59:19.581403,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],['TCGA'],"The paper does not explicitly describe using cBioPortal for data access or analysis. The study used RNA-seq data from TCGA and performed analyses using Limma, WGCNA, CIBERSORT, and TIMER algorithms. cBioPortal may have been cited as a reference or potential data source, but no specific usage of the platform's features or tools is mentioned in the provided abstract and introduction.",['TCGA'],['Citation only'],[],['Not specified'],Unclear,low,4.0,41234433,Gene expression profile in colon cancer therapeutic resistance and its relationship with the tumor microenvironment.,2025,pdf,2025-12-19T03:59:20.310827,,,,
"['Multi-omics integration', 'Gene expression analysis', 'Mutation analysis', 'Copy number analysis']",['Pan-cancer'],"['Methods/Tools development', 'Review/Commentary', 'Precision medicine']",['Review'],"['TCGA', 'Multiple sources']","This is a review paper that discusses computational models for pan-cancer classification using multi-omics data. While the paper mentions public biomedical databases and references TCGA data, there is no explicit mention of cBioPortal being used in this study. The paper focuses on reviewing machine learning and deep learning approaches for pan-cancer classification rather than describing original analysis using cBioPortal.",['TCGA'],['Citation only'],[],['Not specified'],Unclear,low,4.0,41220429,Computational models for pan-cancer classification based on multi-omics data.,2025,pdf,2025-12-19T03:59:20.510823,,,,
"['Multi-omics integration', 'Gene expression analysis', 'Mutation analysis', 'Copy number analysis']",['Pan-cancer'],"['Methods/Tools development', 'Biomarker discovery']","['Methods/Software', 'Original research']","['TCGA', 'Multiple sources']","SynOmics is a new graph convolutional network framework for multi-omics integration that was evaluated using cancer genomics data. The paper likely used cBioPortal as a source for obtaining multi-omics datasets (mutation, copy number, gene expression) from TCGA and other cancer studies for benchmarking their method. The data was downloaded and analyzed externally using their novel SynOmics framework to demonstrate improved performance over existing multi-omics integration approaches.",[],['Data download/export'],[],['Download data'],External (downloaded data),medium,4.0,41231214,SynOmics: integrating multi-omics data through feature interaction networks.,2025,abstract,2025-12-19T03:59:21.549285,,,,
"['Gene expression analysis', 'Other']",['Breast cancer'],['Methods/Tools development'],"['Methods/Software', 'Original research']","['TCGA', 'Custom/Private data']","Based on the abstract, this paper develops IPScan, a computational pipeline for detecting intronic polyadenylation events using RNA-seq data. The paper mentions benchmarking against TCGA breast cancer datasets, but does not explicitly describe how cBioPortal was used. The citation of cBioPortal may be for data access or reference purposes only, as the focus is on developing a novel computational method for IPA event detection rather than using cBioPortal's analysis features.",['TCGA breast cancer'],['Citation only'],[],['Not specified'],Unclear,low,4.0,41218079,IPScan: Detecting novel intronic PolyAdenylation events with RNA-seq data.,2025,abstract,2025-12-19T03:59:22.180661,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Breast cancer'],['Biomarker discovery'],['Original research'],"['TCGA', 'Custom/Private data']","The study performed in silico bioinformatic analysis using methylation and expression data from The Cancer Genome Atlas (TCGA) TNBC cohort accessed through cBioPortal. The authors analyzed the relationships between ADIPOQ, GAS5, GATA4, and YAP1 methylation and expression patterns with various survival endpoints including overall survival (OS), disease-specific survival (DSS), disease-free interval (DFI), progression-free interval (PFI), and relapse-free survival (RFS). The TCGA data analysis complemented their experimental MSP analysis of 57 TNBC patient samples.",['TCGA-BRCA'],"['Data download/export', 'Web-based analysis']","['ADIPOQ', 'GAS5', 'GATA4', 'YAP1']","['Survival analysis', 'Expression analysis', 'Download data']",Mixed,medium,4.0,41226688,"Molecular Implications of <i>ADIPOQ, GAS5, GATA4</i>, and <i>YAP1</i> Methylation in Triple-Negative Breast Cancer Prognosis.",2025,pdf,2025-12-19T03:59:22.686761,,,,
"['Gene expression analysis', 'Survival analysis']",['Lung cancer'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],['TCGA'],"Based on the paper content provided, cBioPortal appears to be used for analyzing TMPRSS11B expression and potentially survival data in lung squamous cell carcinoma (LUSC) patients. The study focuses on TMPRSS11B as a therapeutic target in LUSC and likely utilized cBioPortal to access TCGA lung cancer datasets for validation of their findings. However, specific details about cBioPortal usage are not explicitly described in the abstract and introduction provided.",['TCGA'],['Web-based analysis'],"['TMPRSS11B', 'SOX2', 'NKX2-1', 'LKB1', 'KRT13']","['Expression analysis', 'Not specified']",Unclear,low,4.0,41214366,TMPRSS11B promotes an acidified microenvironment and immune suppression in squamous lung cancer.,2025,abstract,2025-12-19T03:59:22.727329,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the methods or results sections. The study primarily used TCGA-LIHC data obtained through the R package TCGAbiolinks and GEO datasets (GSE10143, GSE14520) for their analyses. While TCGA data was used, there is no clear indication that cBioPortal was the source or platform for data access or analysis.","['TCGA-LIHC', 'GSE10143', 'GSE14520']",['Citation only'],['FCGR2A'],['Not specified'],Unclear,low,4.0,41208969,FCGR2A defines prognostic immune subtypes and drives tumor progression in hepatocellular carcinoma.,2025,pdf,2025-12-19T03:59:23.901279,,,,
"['Gene expression analysis', 'Survival analysis']",['Breast cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'METABRIC']",The study used cBioPortal to analyze gene expression data and clinical outcomes in breast cancer patients. The authors queried ribosomal protein gene expression levels and their association with patient survival outcomes in TNBC and breast cancer cohorts. cBioPortal was used to access TCGA and METABRIC datasets for correlation analysis between ribosomal protein gene expression and clinical prognosis.,"['TCGA', 'METABRIC']","['Web-based analysis', 'Web-based visualization']","['RPL38', 'RPL39L', 'RPS14', 'PML', 'RONIN']","['Expression analysis', 'Survival analysis', 'Query interface']",cBioPortal platform,medium,4.0,41206371,Regulation of ribosomal gene expression and senescence by a PML-mTOR-RONIN nuclear complex in triple-negative breast cancer.,2025,abstract,2025-12-19T03:59:25.130650,,,,
"['Mutation analysis', 'Copy number analysis']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']","['Clinical study', 'Original research']",['Custom/Private data'],"The paper mentions ""Caris genomics study"" at the end of the introduction, indicating that genomic data from patient tumors were sent to Caris Life Sciences for next-generation sequencing. However, the abstract and introduction provided do not contain explicit details about how cBioPortal was specifically used in this case report. The paper appears to focus on a single patient case with PBRM1 and BAP1 mutations in a grade 2 meningioma responding to pembrolizumab immunotherapy.",[],['Citation only'],"['PBRM1', 'BAP1']",['Not specified'],Unclear,low,4.0,41199851,Case Report: Advanced grade 2 meningioma with <i>PBRM1</i> inactivation with prolonged response to immunotherapy.,2025,pdf,2025-12-19T03:59:26.296023,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis']",['Prostate cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Methods/Tools development']",['Original research'],['Multiple sources'],"The paper mentions ""analysis of PCa data"" demonstrating that PTGES3 expression is associated with AR-directed therapy resistance, but does not provide specific details about cBioPortal usage in the abstract or introduction. The reference to clinical PCa data analysis suggests potential use of public databases, but the exact role of cBioPortal, if any, is not explicitly described in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41193657,Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer.,2025,pdf,2025-12-19T03:59:27.412196,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']","['Breast cancer', 'Prostate cancer', 'Other solid tumor']","['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The study used cBioPortal to perform mutational profiling and expression survival analysis for radiation-sensitive genes in hormone-sensitive cancers. Specific hub genes (MYC, STAT3, CTNNB1, IL1B, ESR1, SRC, BRCA1, JUN, KRAS, PIK3CA, PTEN) were validated through cBioPortal for mutation frequencies and survival outcomes. The mutation frequencies were reported (e.g., MYC with 18%, STAT3 with 2.6%, and other genes with 4% mutation) based on cBioPortal data.",[],"['Web-based analysis', 'Web-based visualization']","['TNF', 'STAT3', 'CTNNB1', 'MYC', 'IL1B', 'ESR1', 'SRC', 'BRCA1', 'JUN', 'KRAS', 'PIK3CA', 'PTEN']","['Survival analysis', 'Expression analysis', 'Query interface']",cBioPortal platform,medium,4.0,41186627,Systems biology-driven identification of biomarkers and significant pathways in radiation-induced hormone-sensitive cancers.,2025,pdf,2025-12-19T03:59:27.616164,,,,
"['Multi-omics integration', 'Survival analysis', 'Gene expression analysis']",['Breast cancer'],"['Biomarker discovery', 'Methods/Tools development', 'Precision medicine']","['Original research', 'Methods/Software']",['TCGA'],"The paper does not explicitly describe using cBioPortal in their methodology. The study focuses on developing an adaptive multi-omics integration framework using genetic programming for breast cancer survival analysis with TCGA data. While cBioPortal is cited in the references, there is no clear description of how it was used to access or analyze the data in the provided abstract and introduction sections.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41184341,Adaptive multi-omics integration framework for breast cancer survival analysis.,2025,pdf,2025-12-19T03:59:30.051072,,,,
"['Gene expression analysis', 'Pathway analysis']",['Prostate cancer'],"['Immunotherapy', 'Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],The authors analyzed TCGA Firehose Legacy prostate cancer data to examine the relationship between CD274 (PD-L1) expression and IGF1/IGFBP5 levels. The analysis showed higher CD274 expression in tumors with elevated IGF1 and IGFBP5. This was used to validate their experimental findings from cell line studies regarding IGF-1's role in immune checkpoint regulation.,['TCGA Firehose Legacy PCa'],['Web-based analysis'],"['CD274', 'IGF1', 'IGFBP5']","['Expression analysis', 'Query interface']",cBioPortal platform,medium,4.0,41184420,IGF-1 regulates cancer cell immune evasion in prostate cancer.,2025,pdf,2025-12-19T03:59:30.170713,,,,
"['Gene expression analysis', 'Survival analysis']",['Breast cancer'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],"['TCGA', 'METABRIC']","The study analyzed gene expression and clinical data from METABRIC (n=2,509) and TCGA Pan-Cancer Atlas (n=1,084) datasets to investigate the relationship between PKCζ, CTNNBIP1, and ALDH1A3 expression in luminal A and B breast cancer. The researchers used Kaplan-Meier and Cox proportional hazards models to assess disease-specific survival in patients treated with hormone therapy. The data appears to have been downloaded from cBioPortal (which hosts both METABRIC and TCGA datasets) for external statistical analysis.","['METABRIC', 'TCGA Pan-Cancer Atlas']",['Data download/export'],"['PRKCI', 'CTNNBIP1', 'ALDH1A3']",['Download data'],External (downloaded data),medium,4.0,41179319,"<i>PKCζ, CTNNBIP1</i> and <i>ALDH1A3</i> Expression in Luminal B Breast Cancer Indicates Decreased Hormone Therapy Effectiveness.",2025,pdf,2025-12-19T03:59:30.321433,,,,
"['Gene expression analysis', 'Survival analysis']",['Breast cancer'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],"['TCGA', 'METABRIC']","The authors downloaded two datasets (METABRIC with n=2,509 and TCGA with n=1,084) from cBioPortal on August 1, 2024. These datasets contained gene expression and clinical data for patients with primary breast cancer. The downloaded data were then analyzed externally using R software to evaluate the association between p62 and ALDH1A3 expression levels and endocrine therapy effectiveness in luminal B breast cancer patients through Kaplan-Meier survival analysis and multivariate Cox regression analysis.","['METABRIC', 'TCGA']",['Data download/export'],"['SQSTM1', 'ALDH1A3', 'ESR1', 'PGR', 'ERBB2', 'MKI67']",['Download data'],External (downloaded data),high,4.0,41179310,High <i>p62</i> and <i>ALDH1A3</i> Reduce the Effectiveness of Endocrine Therapy in Luminal B Breast Cancer.,2025,pdf,2025-12-19T03:59:31.485248,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Copy number analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy', 'Precision medicine', 'Pathway analysis']",['Original research'],['Multiple sources'],"The paper does not explicitly describe how cBioPortal was used in the methodology. While the study analyzes mutation profiling and copy number alterations in osteosarcoma, there is no clear mention of cBioPortal in the abstract or introduction provided. The citation of cBioPortal may be for reference purposes or the actual usage details may be in the methods section not provided.","['TARGET', 'GSE162454']",['Citation only'],[],['Not specified'],Unclear,low,4.0,41172875,A Glycerophospholipid Metabolism-Based Prognostic Model Guides Osteosarcoma Therapy.,2026,abstract,2025-12-19T03:59:31.547466,,,,
"['Gene expression analysis', 'Multi-omics integration', 'Other']",['Glioma/Brain cancer'],"['Drug response/resistance', 'Pathway analysis']",['Original research'],['Custom/Private data'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on experimental work with patient-derived DIPG cell lines, metabolic assays, RNA-seq, LC-MS/MS metabolomics, and in vivo xenograft models. No reference to cBioPortal data queries, analysis, or visualization is evident in the text provided.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41163069,Metabolic reprogramming in diffuse intrinsic pontine gliomas (DIPG): dual inhibition of mitochondrial oxidative phosphorylation and lactate metabolism to enhance anti-tumor and radiosensitizing effects in DIPG cells.,2025,pdf,2025-12-19T03:59:32.165855,,,,
"['Gene expression analysis', 'Other']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy', 'Tumor evolution']",['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. This appears to be a preclinical mouse model study focusing on metastatic immunodormancy with gene expression and microRNA analysis. If cBioPortal is cited in the paper, it appears to be a reference citation only without direct usage for data analysis or visualization in this particular study.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41159143,Dormant Metastases Exhibit a Unique Phenotype Primarily Promoted by the Ch25h Gene and Are Maintained in Dormancy by T Lymphocytes.,2025,abstract,2025-12-19T03:59:33.800391,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis']","['Breast cancer', 'Ovarian cancer', 'Prostate cancer', 'Pancreatic cancer']","['Biomarker discovery', 'Tumor evolution', 'Drug response/resistance']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, cBioPortal appears to be used for clinical correlation analysis. The study mentions that ""low APE1 expression correlates with poor survival in patients with BRCA2-mutant tumors, with high APOBEC3 levels further worsening outcomes,"" suggesting survival analysis was performed using cBioPortal data. The study likely queried BRCA2-mutant tumor datasets to examine APE1 and APOBEC3 expression levels and their correlation with patient outcomes.",[],"['Web-based analysis', 'Citation only']","['BRCA2', 'APE1', 'APOBEC3B', 'BRCA1']","['Survival analysis', 'Expression analysis', 'Query interface']",Unclear,low,4.0,41162355,BRCA2 deficiency and replication stress drive APOBEC3-Mediated genomic instability.,2025,pdf,2025-12-19T03:59:37.747465,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Copy number analysis']",['Pan-cancer'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used as one of several bioinformatics tools to systematically analyze FAM72B in pan-cancer. The study examined correlations between FAM72B expression levels and genetic mutations, genomic heterogeneity, and other cancer-related parameters. cBioPortal was mentioned alongside other tools like SangerBox3.0, GEPIA2.0, and Kaplan-Meier Plotter for comprehensive pan-cancer analysis.",[],"['Web-based analysis', 'Citation only']",['FAM72B'],['Not specified'],"[""Unclear""]",medium,4.0,41153357,Spotlight on <i>FAM72B</i>: Pan-Cancer Expression Profiles and Its Potential as a Prognostic and Immunotherapeutic Biomarker.,2025,pdf,2025-12-19T03:59:38.070162,,,,
"['Gene expression analysis', 'Copy number analysis', 'Pathway analysis', 'Multi-omics integration']",['Colorectal cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis', 'Precision medicine']",['Original research'],"['TCGA', 'Not specified']","The paper does not explicitly describe how cBioPortal was used in the study. While the study analyzes NTRK gene expression, copy number alterations, methylation, and pathway enrichment in colorectal cancer cohorts, there is no clear mention of cBioPortal in the provided abstract and introduction sections. The citation of cBioPortal may be in the methods or references section not provided here.",[],['Citation only'],"['NTRK1', 'NTRK2', 'NTRK3']",['Not specified'],Unclear,low,4.0,41155675,Fusion-Negative NTRK Overexpression Exhibit Biological Relevance in Colorectal Cancer: Implications for Prediction of Responses to Kinase Inhibitors.,2025,pdf,2025-12-19T03:59:38.287688,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Breast cancer'],"['Biomarker discovery', 'Precision medicine', 'Review/Commentary']",['Review'],"['TCGA', 'METABRIC', 'Multiple sources']","This is a review paper discussing bioinformatics strategies in breast cancer research. While cBioPortal is likely mentioned as one of the important bioinformatics resources/databases available for breast cancer research, the abstract and introduction provided do not contain specific details about how cBioPortal was used in any original analysis. The paper appears to be a comprehensive review of bioinformatics methodologies including genomics, transcriptomics, proteomics, and metabolomics approaches for breast cancer biomarker discovery and therapeutic target identification.",[],['Citation only'],"['BRCA1', 'BRCA2', 'PALB2', 'PTEN', 'PIK3CA', 'ATM', 'BARD1', 'CHEK2', 'RAD51C', 'RAD51D', 'TP53']",['Not specified'],Unclear,low,4.0,41154638,Bioinformatics Strategies in Breast Cancer Research.,2025,pdf,2025-12-19T03:59:38.798841,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']","['Pan-cancer', 'Lung cancer', 'Other solid tumor']","['Biomarker discovery', 'Precision medicine', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used for mutational profiling of MAPK genes across nine cancer types. The platform was employed to analyze mutation patterns in the identified differentially expressed MAPKs (MAPK3, MAPK7, MAPK9, MAPK10, MAPK12, MAPK13 in LIHC and MAPK6 in LUAD). The mutational profiling results were integrated with differential expression and survival analysis to validate the prognostic significance of these genes.",['TCGA'],['Web-based analysis'],"['MAPK3', 'MAPK6', 'MAPK7', 'MAPK9', 'MAPK10', 'MAPK12', 'MAPK13']","['Query interface', 'Not specified']",Mixed,medium,4.0,41151853,Investigating the Roles of MAPKs as Precision Oncology Targets: A Multi-cancer Expression and Survival Study.,2025,pdf,2025-12-19T03:59:39.123432,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration', 'Pathway analysis']",['Pan-cancer'],"['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The paper conducted a comprehensive pan-cancer analysis of SKP2 using multi-omics data from public datasets including TCGA. While cBioPortal is likely used as a data source for accessing TCGA pan-cancer data and performing expression and survival analyses, the specific details of cBioPortal usage are not explicitly described in the abstract. The study integrated multi-omics data to analyze SKP2 expression characteristics and its relationship to tumor immunity across multiple cancer types.",[],['Citation only'],['SKP2'],['Not specified'],Unclear,low,4.0,41142634,A pan-cancer analysis revealed <i>SKP2</i> as an inhibitor of the tumor immune microenvironment and a promising therapeutic target for immunotherapy.,2025,abstract,2025-12-19T03:59:39.585636,,,,
"['Mutation analysis', 'Survival analysis', 'Pathway analysis']",['Lung cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine']","['Original research', 'Clinical study']","['Custom/Private data', 'Multiple sources']","The paper mentions using cBioPortal as part of their methodology to analyze BRAF mutations in NSCLC, though specific details of usage are not provided in the abstract and introduction sections. The study appears to have used cBioPortal to access an independent clinico-genomic database (n=342) to complement their multi-institutional cohort analysis. The exact features and analysis methods used on cBioPortal are not explicitly described in the provided text.",[],['Citation only'],"['BRAF', 'EGFR', 'NF1', 'RAS']",['Not specified'],Unclear,low,4.0,41152458,Diversity of BRAF mutations in non-small cell lung cancer and implications on treatment.,2025,pdf,2025-12-19T03:59:40.701260,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Mutation analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on analyzing 3'RNA sequencing data from uterine leiomyosarcomas and leiomyomas using differential gene expression analysis, machine learning, and immunohistochemistry validation. The study appears to use custom/private data from Helsinki University Hospital samples. If cBioPortal is mentioned, it may only be cited in the references or methods section not provided in this excerpt.",[],['Citation only'],"['TP53', 'RB1', 'PTEN', 'ATRX', 'MED12', 'HMGA2', 'FH', 'SRCAP', 'COL4A5', 'COL4A6', 'DEPDC5', 'TOP2A', 'CDK1']",['Not specified'],Unclear,low,4.0,41162745,Transcriptome profiling of uterine leiomyosarcomas identifies a leiomyoma-like expression pattern that indicates better survival.,2025,pdf,2025-12-19T03:59:41.327235,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Breast cancer']","['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, there is no explicit mention of cBioPortal being used in this study. The authors utilized UCSC XENA platform for TCGA data, GEO database for validation datasets, UALCAN for protein expression analysis, and The Human Protein Atlas for immunohistochemistry images. While TCGA data was used, the paper does not indicate that cBioPortal was the source or analysis platform for accessing this data.","['TCGA', 'GTEx', 'GSE7904', 'GSE83889', 'GSE121248', 'GSE19804', 'GSE26886', 'GSE54129', 'GSE15471', 'GSE65144']",['Citation only'],['CLIC6'],['Not specified'],Unclear,low,4.0,41142627,CLIC6's role in cancer: from broad analysis to breast cancer validation.,2025,pdf,2025-12-19T03:59:42.210554,,,,
"['Mutation analysis', 'Gene expression analysis', 'Multi-omics integration']",['Pan-cancer'],"['Drug response/resistance', 'Precision medicine', 'Biomarker discovery']",['Original research'],"['TCGA', 'GENIE', 'Multiple sources']","cBioPortal was used to analyze TP53 mutation prevalence across multiple cancer types and to estimate the proportion of cancer deaths associated with TP53-mutant cancers. The authors performed a pan-cancer analysis across cBioPortal to determine that TP53-mutant cancers are associated with approximately 46% of cancer deaths. The paper cites cBioPortal data showing that TP53 is mutated in 36% (PCAWG), 37% (TCGA), and 39% (GENIE) of cancers.","['TCGA', 'GENIE']","['Web-based analysis', 'Citation only']",['TP53'],['Query interface'],Unclear,medium,4.0,41184486,Mutant p53 protein accumulation is selectively targetable by proximity-inducing drugs.,2025,pdf,2025-12-19T03:59:45.311579,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Colorectal cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, the paper focuses on DLX4 as a prognostic biomarker in colorectal cancer using bulk, single-cell, and spatial transcriptomics along with proteomic analyses. While cBioPortal is cited, the specific usage details are not explicitly described in the provided text. The study likely used cBioPortal to access TCGA colorectal cancer data for validation of DLX4 expression and survival analysis, but the exact methodology is not clear from the abstract alone.",['TCGA'],['Citation only'],"['DLX4', 'ZC3HC1']",['Not specified'],Unclear,low,4.0,41126177,Cell-cycle-related transcriptional factor DLX4: a novel prognostic biomarker and potential therapeutic target in colorectal cancer.,2025,abstract,2025-12-19T03:59:46.414390,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration', 'Pathway analysis']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy', 'Drug response/resistance']",['Original research'],"['Multiple sources', 'Custom/Private data']","The paper does not explicitly mention using cBioPortal in the abstract or introduction provided. The study integrates 41 single-cell RNA sequencing datasets and pan-cancer transcriptomic data to develop a glycolytic signature for predicting immune checkpoint inhibitor response. While cBioPortal is cited, there is no clear description of how it was used for data access, analysis, or visualization in the provided text.",[],['Citation only'],"['FH', 'LDHA']",['Not specified'],Unclear,low,4.0,41112295,Integrated multi-omics analysis reveals a glycolytic signature that predicts pan-cancer immune checkpoint inhibitor response and LDHA as a combinatorial target in fumarate hydratase-deficient renal cell carcinoma.,2025,pdf,2025-12-19T03:59:46.868642,,,,
"['Mutation analysis', 'Survival analysis']",['Other solid tumor'],"['Precision medicine', 'Drug response/resistance', 'Biomarker discovery']","['Clinical study', 'Original research']",['Custom/Private data'],"This is a case report of a cholangiocarcinoma patient with PBRM1 mutation treated with tazemetostat. The paper does not explicitly describe using cBioPortal for data analysis or visualization. The mutation analysis was performed using FoundationOne sequencing on tumor tissue. While cBioPortal may be cited in the references, there is no clear description of how the platform was used in this study.",[],['Citation only'],"['PBRM1', 'EZH2', 'SMARCB1', 'SMARCA4']",['Not specified'],Unclear,low,4.0,41136536,Prolonged survival in a patient with pbrm1 mutated metastatic cholangiocarcinoma receiving tazemetostat.,2025,pdf,2025-12-19T03:59:47.184688,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Breast cancer']","['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal is not explicitly mentioned in the provided abstract and introduction sections of this paper. The study uses data from UCSC XENA platform (TCGA and GTEx) and KM Plotter for their pan-cancer analysis of CORO1A. While the paper cites cBioPortal (as indicated by the user stating it cites cBioPortal), the specific usage details are not described in the provided text sections.","['TCGA', 'GTEx']",['Citation only'],['CORO1A'],['Not specified'],Unclear,low,4.0,41122645,"CORO1A: a pan-cancer prognosis, diagnostic and immune biomarker based on breast cancer validation.",2025,pdf,2025-12-19T03:59:47.881175,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Glioma/Brain cancer'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],['Multiple sources'],"The paper mentions data-mining from the GLASS database to analyze survival outcomes in recurrent GBM patients. Specifically, they examined the relationship between EGR1 expression, MGMT promoter methylation status, and survival in females with recurrent GBM. The GLASS database analysis was used to validate findings from their PDX model experiments regarding EGR1 as a predictor of bevacizumab response.",['GLASS'],['Citation only'],"['EGR1', 'MGMT', 'PTEN', 'EGFR', 'CHRNA7']",['Not specified'],Unclear,low,4.0,41125665,Transcriptomic analysis identifies a potential target for bevacizumab resistant glioblastoma.,2025,pdf,2025-12-19T03:59:47.941204,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Drug response/resistance', 'Precision medicine']","['Clinical study', 'Original research']",['Custom/Private data'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this clinical trial paper. This is a phase 1/2 clinical trial evaluating VT3989, a YAP/TEAD inhibitor, in patients with solid tumors, particularly mesothelioma. The paper focuses on clinical outcomes including safety, response rates, and progression-free survival from the trial itself rather than utilizing cBioPortal for genomic data analysis.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41111090,YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial.,2025,abstract,2025-12-19T03:59:47.991194,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Breast cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The paper used cBioPortal to analyze DAPL1 in breast cancer, examining genetic alterations including mutation status and copy number variations of genes such as MAP3K1, NUP98, and CCDC59. The study utilized TCGA-BRCA data accessed through cBioPortal for comprehensive multi-omics analysis including DNA methylation, genetic alterations, and their correlation with DAPL1 expression. The analysis appears to have been conducted using cBioPortal's web-based tools for querying and analyzing the TCGA breast cancer dataset.",['TCGA-BRCA'],"['Web-based analysis', 'Web-based visualization']","['DAPL1', 'MAP3K1', 'NUP98', 'CCDC59']","['Expression analysis', 'Query interface']",Mixed,medium,4.0,41111983,DAPL1 Identified as a Novel Prognostic Biomarker in Breast Cancer: Insights from Comprehensive in Silico Analysis.,2025,abstract,2025-12-19T03:59:48.052615,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis']",['Melanoma'],"['Drug response/resistance', 'Pathway analysis']",['Original research'],['Not specified'],"Based on the provided abstract and introduction, the specific usage of cBioPortal in this study is not explicitly described. The paper focuses on investigating Rac1-driven melanoma cell resistance to MAPK pathway inhibitors through experimental approaches. While cBioPortal is cited, the abstract and introduction do not provide details about how the platform was used, what data was accessed, or what specific analyses were performed using cBioPortal.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41109929,A critical role of FAK signaling in Rac1-driven melanoma cell resistance to MAPK pathway inhibition.,2025,abstract,2025-12-19T03:59:48.928410,,,,
"['Mutation analysis', 'Copy number analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine', 'Pathway analysis']",['Original research'],['Multiple sources'],"The study interrogated publicly available genomic cohorts of biliary cancer from different primary locations (intrahepatic, extrahepatic, and gallbladder) through cBioPortal to analyze mutations and copy number alterations. The focus was on receptor tyrosine kinases and their signal transduction pathways, examining alterations in genes like FGFR2, HER2, BRAF, and IDH1 across the different biliary cancer subtypes. The analysis quantified RTK pathway alterations across biliary subtypes to identify therapeutic opportunities for targeted therapies.",[],"['Web-based analysis', 'Web-based visualization']","['FGFR2', 'ERBB2', 'BRAF', 'IDH1']",['Query interface'],cBioPortal platform,medium,4.0,41109905,The Landscape of Genomic Alterations in Receptor Tyrosine Kinase Pathways in Biliary Cancers: Implications for Targeted Therapies.,2025,pdf,2025-12-19T03:59:52.811559,,,,
"['Mutation analysis', 'Multi-omics integration']",['Colorectal cancer'],"['Biomarker discovery', 'Immunotherapy', 'Methods/Tools development', 'Precision medicine']","['Original research', 'Methods/Software']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on developing a machine learning-based scoring system using data from 188 CRC patients, analyzing MSI status, immune cell distributions, clinical features, and gene mutations. cBioPortal may be cited in the references but its specific role in data acquisition or analysis is not described in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41100766,A Machine Learning-Based Scoring System to Identify High Immunoactivity Microsatellite Stability Tumors by Quantifying Similarity to Microsatellite Instability-High Tumors in Colorectal Cancers: Development and Quantitative Study.,2025,abstract,2025-12-19T03:59:53.673529,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration', 'Mutation analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],"The paper does not explicitly mention using cBioPortal in the methods or results sections provided. The methods describe obtaining RNA-seq data directly from TCGA database and performing all analyses using R packages (survival, clusterProfiler, pROC, etc.). While the paper cites cBioPortal in the context of genomic alteration analysis (section 2.9 title visible but content cut off), there is no clear description of how cBioPortal was actually used in the study workflow.",['TCGA-PAAD'],['Citation only'],['TICRR'],['Not specified'],Unclear,low,4.0,41105363,Deciphering TICRR's oncogenic landscape in pancreatic adenocarcinoma: molecular insights and clinical implications.,2025,pdf,2025-12-19T03:59:54.051088,,,,
['Gene expression analysis'],['Glioma/Brain cancer'],['Methods/Tools development'],['Original research'],['Not specified'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. This paper describes the development of a novel serum-free triculture model system for studying glioblastoma with astrocytes and macrophages. The study uses patient-derived xenograft (PDX) lines and performs gene expression analysis using a custom 350-gene NanoString chip, but does not reference cBioPortal for data access, analysis, or visualization.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41096603,"A Novel Serum-Free Triculture Model of Glioblastoma, Astrocytes, and Macrophages.",2025,pdf,2025-12-19T03:59:55.363523,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Lung cancer']","['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used as one of multiple public databases to explore genetic and epigenetic characteristics of KRT6A across different cancers. The study specifically mentions that the main type of genetic variation in KRT6A is mutation, and cBioPortal was used to analyze genetic variation patterns. The platform was listed among the primary databases used for the pan-cancer analysis of KRT6A.",[],"['Web-based analysis', 'Web-based visualization']",['KRT6A'],['Not specified'],Mixed,medium,4.0,41083700,Comprehensive pan-cancer analysis of KRT6A as a prognostic and immune biomarker.,2025,pdf,2025-12-19T03:59:55.886988,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],"cBioPortal was used solely to download clinical data corresponding to the TCGA-HNSC cohort. The RNA sequence data was downloaded directly from the TCGA data portal, and all analyses (DESeq2, functional enrichment, GSEA, Kaplan-Meier survival analysis) were performed externally using R software and other tools. cBioPortal served as a data source for clinical information only.",['TCGA-HNSC'],['Data download/export'],"['HOXC6', 'NUCB2', 'IL12A-AS1', 'CAB39L', 'NOSTRIN', 'SLC8A1-AS1', 'PIK3CA', 'TP53', 'CDKN2A', 'CCND1']",['Download data'],External (downloaded data),high,4.0,41098933,Differentially Expressed Genes in Head and Neck Squamous Cell Carcinoma: Exploratory Research Using the Cancer Genome Atlas (TCGA) RNA Sequence Data and DESeq2 Package.,2025,pdf,2025-12-19T03:59:56.035669,,,,
"['Gene expression analysis', 'Mutation analysis', 'Copy number analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Liver cancer', 'Kidney cancer', 'Lung cancer', 'Bladder cancer', 'Pancreatic cancer', 'Esophageal cancer']","['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used as one of multiple public databases to evaluate EME1 genetic alterations and their association with clinical outcomes across multiple cancer types. The study integrated multi-omics data from cBioPortal along with TIMER2.0, GEPIA2, and TISIDB to conduct a comprehensive pan-cancer analysis of EME1 expression, mutations, and prognostic significance. cBioPortal specifically contributed to the analysis of genetic alterations in EME1 across various human cancers.",['TCGA'],"['Web-based analysis', 'Citation only']","['EME1', 'MUS81']",['Not specified'],Unclear,medium,4.0,41082058,Oncogenic EME1 promotes tumor progression and immune modulation in human cancers with therapeutic targeting potential.,2025,pdf,2025-12-19T03:59:56.143420,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Other']",['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper describes whole-genome sequencing and gene expression profiling of endometrial polyps using their own collected samples. cBioPortal may be cited in the references or methods section not provided, but no specific usage is described in the available text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41137179,Genomic landscape of endometrial polyps.,2025,pdf,2025-12-19T03:59:56.159573,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration', 'Mutation analysis']","['Pan-cancer', 'Breast cancer']","['Biomarker discovery', 'Immunotherapy', 'Drug response/resistance', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']",cBioPortal was used to obtain tumor mutational burden (TMB) and microsatellite instability (MSI) data for TCGA pan-cancer cohorts. The data was downloaded from cBioPortal database to investigate associations between UVR-related genes and immune suppression across 30 cancer types. This data was used alongside transcriptomic data from UCSC Xena for comprehensive multi-omics analysis.,['TCGA'],['Data download/export'],"['ENO2', 'ATP6V1F']",['Download data'],External (downloaded data),high,4.0,41080584,Multi-omics analysis reveals ultraviolet response insights for immunotherapy and prognosis.,2025,pdf,2025-12-19T03:59:56.299802,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Colorectal cancer'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper mentions TCGA as a data source for bulk RNA-sequencing samples to map PNI phenotypes and validate CAF subsets in colorectal cancer. The study integrated TCGA data with single-cell transcriptome datasets and independent cohorts (silu_2022, GSE39582, GSE17536) for clinical validation. However, the abstract and introduction do not explicitly describe how cBioPortal was used to access or analyze TCGA data, suggesting either external data download or citation only.","['TCGA', 'GSE39582', 'GSE17536']",['Citation only'],"['PRRX2', 'MMP2', 'TGFB1', 'NGF']",['Not specified'],"[""Unclear""]",low,4.0,41089673,Single-cell and bulk RNA-sequencing reveal PRRX2-driven cancer-associated fibroblast-mediated perineural invasion for predicting the immunotherapy outcome in colorectal cancer.,2025,pdf,2025-12-19T03:59:56.978420,,,,
"['Mutation analysis', 'Copy number analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Tumor evolution', 'Precision medicine']",['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper describes sequencing of 48 samples from 16 Guatemalan patients using a 127-gene panel to identify genetic drivers in preneoplastic and early gastric cancer. The study appears to have generated and analyzed custom data without clear indication of cBioPortal involvement. If cBioPortal was used, it may have been for comparative analysis with other studies, but this is not explicitly stated in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41079989,Genetic heterogeneity and key driver mutations in the preneoplastic and earliest stages of gastric cancer.,2025,abstract,2025-12-19T03:59:59.533089,,,,
"['Gene expression analysis', 'Pathway analysis']",['Colorectal cancer'],"['Drug response/resistance', 'Pathway analysis', 'Biomarker discovery']",['Original research'],['Not specified'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on network pharmacology analysis and experimental validation of DPP4 inhibitors in colorectal cancer cell lines. The study appears to be primarily laboratory-based experimental research without clear indication of cBioPortal data or tools being utilized.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41071836,DPP4 inhibitors as a novel therapeutic strategy in colorectal cancer: Integrating network biology and experimental insights.,2025,abstract,2025-12-19T04:00:00.082586,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the abstract or introduction provided. The study primarily used TCGA and GEO datasets to develop an M1 macrophage-related prognostic signature for gastric cancer. While cBioPortal is cited, there is no clear description of how it was used for data access, analysis, or visualization in the provided text.",['TCGA'],['Citation only'],['FN1'],['Not specified'],Unclear,low,4.0,41071812,Identification of an M1 Macrophages-Related Signature for Predicting the Survival and Therapeutic Response in Gastric Cancer.,2025,abstract,2025-12-19T04:00:01.140932,,,,
"['Mutation analysis', 'Pathway analysis']",['Pan-cancer'],"['Pathway analysis', 'Biomarker discovery', 'Drug response/resistance']",['Original research'],['Not specified'],"The paper does not explicitly mention using cBioPortal. The authors used data from the Catalogue of Somatic Mutations in Cancers (COSMIC) database to analyze genetic interactions between PRMT5 mutations and mutations in DNA double strand break repair genes. While cBioPortal is cited, the actual data source and analysis platform used was COSMIC, not cBioPortal.",[],['Citation only'],"['PRMT5', 'TIP60', 'RAD9', 'RAD1', 'HUS1']",['Not specified'],Unclear,low,4.0,41066315,PRMT5 genetic interactions with DNA double strand break repair genes.,2025,abstract,2025-12-19T04:00:01.529696,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Pathway analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The study performed pan-cancer analysis of CDK2 to evaluate its expression, prognostic behavior, genetic alterations, and immune infiltrations across multiple tumor types. cBioPortal was likely used to access and analyze multi-omics data including expression patterns, survival outcomes, and mutation data for CDK2 across various cancer types. The analysis revealed CDK2 overexpression in multiple tumors and its correlation with poor overall and disease-free survival in some cancers.",[],"['Web-based analysis', 'Web-based visualization']",['CDK2'],"['Expression analysis', 'Survival analysis', 'Not specified']",Unclear,medium,4.0,41058670,Multi-omics pan-cancer profiling of CDK2 and <i>in silico</i> identification of plant-derived inhibitors using machine learning approaches.,2025,pdf,2025-12-19T04:00:02.470555,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Custom/Private data']","Based on the abstract and title, this study analyzed 499 human HCC samples for FZD7 expression and stemness markers. The paper likely used cBioPortal to access TCGA liver cancer data for gene expression and survival analysis related to FZD7 and CD133 markers. The study combined public data analysis with experimental validation in cell lines and primary hepatocytes.",['TCGA'],"['Web-based analysis', 'Data download/export']","['FZD7', 'CD133', 'EPCAM', 'CD90', 'NANOG']","['Expression analysis', 'Survival analysis']",Mixed,medium,4.0,41056281,Frizzled 7 drives amplification of cancer stem-cell subpopulations and the aggressiveness and poor differentiation of human hepatocellular carcinoma.,2025,abstract,2025-12-19T04:00:02.489426,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Multi-omics integration']",['Pan-cancer'],"['Precision medicine', 'Biomarker discovery', 'Methods/Tools development']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, cBioPortal is cited in this paper but specific usage details are not described in the provided text. The study focuses on using whole genome and transcriptome sequencing (WGTS) to diagnose difficult-to-classify tumors at a quaternary oncology center. The paper appears to be primarily about their own sequencing approach rather than utilizing cBioPortal data or tools for the main analysis.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41053870,Pathologist-initiated whole genome and transcriptome sequencing demonstrates diagnostic utility in resolving difficult-to-diagnose tumors.,2025,pdf,2025-12-19T04:00:03.021284,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis']","['Other solid tumor', 'Glioma/Brain cancer']","['Biomarker discovery', 'Tumor evolution', 'Pathway analysis']",['Original research'],['Multiple sources'],"cBioPortal was used to access and analyze bulk RNA-seq data from 54 NF1-associated tumors (6 cNFs, 32 pNFs, 13 MPNSTs) to examine SPP1 expression across tumor types. Additionally, the authors downloaded bulk RNA-seq and clinical data from 632 low-grade glioma (LGG) patients from cBioPortal to perform survival analysis stratified by SPP1 expression levels and to analyze the relationship between NF1 mutations and SPP1 expression.",[],['Data download/export'],"['SPP1', 'NF1']","['Download data', 'Expression analysis']",External (downloaded data),high,4.0,41053414,Natural history of SPP1 signaling in NF1 tumors.,2025,pdf,2025-12-19T04:00:03.720402,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Breast cancer'],"['Biomarker discovery', 'Tumor evolution', 'Precision medicine']",['Original research'],"['TCGA', 'GENIE', 'METABRIC', 'Custom/Private data', 'Multiple sources']","The study used cBioPortal to analyze SF3B1 mutations in breast cancer clinical cohorts, identifying mutation frequencies, variant allele fractions, and survival outcomes in HR+ HER2- breast cancer patients. The authors queried multiple datasets through cBioPortal including TCGA, METABRIC, and GENIE to characterize SF3B1 mutations and their clinical associations. This analysis formed the basis for identifying SF3B1 as a driver mutation in approximately 2.5% of HR+ HER2- breast cancer cases with enrichment of K700E substitutions.","['TCGA', 'METABRIC', 'GENIE']","['Web-based analysis', 'Web-based visualization', 'Data download/export']",['SF3B1'],"['Query interface', 'Survival analysis', 'Mutation Mapper', 'Download data']",Mixed,high,4.0,41055979,Distinct and convergent effects of <i>SF3B1</i> mutations in human breast cancer.,2025,abstract,2025-12-19T04:00:03.812757,,,,
"['Mutation analysis', 'Gene expression analysis', 'Multi-omics integration', 'Pathway analysis']",['Lung cancer'],"['Biomarker discovery', 'Tumor evolution', 'Immunotherapy']",['Original research'],"['TCGA', 'Custom/Private data', 'Multiple sources']",The paper likely used cBioPortal to access TCGA lung adenocarcinoma data for validation and comparison of TP53 mutation patterns and associated gene expression programs. cBioPortal was probably used to query TP53 mutation frequencies and correlate them with clinical outcomes or gene expression patterns in publicly available LUAD cohorts. The primary analysis was performed on custom patient samples (23 treatment-naive tumors) with cBioPortal serving as a reference database for validation.,['TCGA-LUAD'],"['Data download/export', 'Web-based analysis']",['TP53'],['Not specified'],External (downloaded data),low,4.0,41057692,A cellular and spatial atlas of TP53-associated tissue remodeling defines a multicellular tumor ecosystem in lung adenocarcinoma.,2025,abstract,2025-12-19T04:00:03.883317,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis']",['Melanoma'],"['Drug response/resistance', 'Pathway analysis']",['Original research'],['Not specified'],"The paper does not explicitly describe using cBioPortal for any analysis. While the study investigates NRAS-mutant melanoma and performs RNA-sequencing and various molecular analyses, there is no mention of cBioPortal in the provided abstract and introduction sections. The citation appears to be a reference citation only without clear description of how the platform was utilized.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41053077,MEK5/ERK5 inhibition sensitizes NRAS-mutant melanoma to MAPK-targeted therapy by preventing Cyclin D/CDK4-mediated G1/S progression.,2025,pdf,2025-12-19T04:00:05.538855,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The cBioPortal platform was used to collect data on variant frequencies, variant types, and variant sites for CGB5 across all TCGA tumor datasets. This was part of a comprehensive pan-cancer analysis examining the genetic alterations of CGB5 including mutations and copy number variations across multiple cancer types.",[],['Data download/export'],['CGB5'],"['Download data', 'Query interface']",External (downloaded data),high,4.0,41048937,Comprehensive pan-cancer analysis reveals CGB5 is a potential promising predictive and immunotherapeutic biomarker.,2025,pdf,2025-12-19T04:00:05.563300,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Lung cancer'],"['Biomarker discovery', 'Tumor evolution']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, the paper appears to use cBioPortal to analyze LMNA expression levels and their correlation with survival outcomes in SCLC patients. The study likely accessed publicly available datasets through cBioPortal to validate their experimental findings regarding LMNA's clinical significance. However, specific details about cBioPortal usage are not explicitly mentioned in the provided text.",[],['Citation only'],"['LMNA', 'EZH2']",['Not specified'],Unclear,low,4.0,41030978,Lamin A/C Deficiency Drives Genomic Instability and Poor Survival in Small-Cell Lung Cancer through Increased R-loop Accumulation.,2025,abstract,2025-12-19T04:00:08.004743,,,,
"['Mutation analysis', 'Survival analysis']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"cBioPortal was used as a reference database during the design phase of a custom amplicon sequencing panel. The authors utilized cBioPortal, along with NCBI/Clinvar and COSMIC databases, to identify relevant genomic coordinates and mutations in neuro-oncology-related genes for their targeted sequencing approach. The actual genomic analysis was performed on their own Chilean patient cohort using the custom-designed panel.",[],['Citation only'],[],['Not specified'],External (downloaded data),medium,4.0,41044136,Characterization of the mutational status of glioblastoma and high-grade astrocytomas in a Latin American cohort.,2025,pdf,2025-12-19T04:00:08.375217,,,,
"['Mutation analysis', 'Multi-omics integration']",['Leukemia/Lymphoma'],"['Immunotherapy', 'Biomarker discovery']",['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper describes whole-exome sequencing of matched tumor-normal samples from pediatric ALL patients to identify neoantigens. If cBioPortal was used, it was likely for validation or comparison purposes, but this is not stated in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41011272,"Somatic Mutations in DNA Mismatch Repair Genes, Mutation Rate and Neoantigen Load in Acute Lymphoblastic Leukemia.",2025,abstract,2025-12-19T04:00:09.654667,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'METABRIC']","The authors used the cBio Cancer Genomic Portal to obtain tumor gene expression and clinical data from The Cancer Genome Atlas (TCGA) cohort. They accessed data for 584 patients with ER-positive/HER2-negative breast cancer (ILC and IDC) to analyze differences in gene expression, cell proliferation, immune cell infiltration, and clinical outcomes. The data was downloaded and analyzed externally using various bioinformatics approaches including gene set enrichment analysis.",['TCGA'],['Data download/export'],"['MKI67', 'ERBB2']",['Download data'],External (downloaded data),high,4.0,41030644,Invasive Lobular Carcinoma Has Higher Immune Response Than Invasive Ductal Carcinoma in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancers.,2025,pdf,2025-12-19T04:00:09.684858,,,,
['Gene expression analysis'],['Pan-cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],"Based on the abstract and introduction provided, the paper focuses on the biochemical and cellular mechanisms of PERK kinase regulation by copper, using purified proteins and C. elegans models. While cBioPortal is cited, the abstract does not provide specific details about how cBioPortal was used in this study. The paper appears to be primarily a mechanistic study of PERK-copper interactions rather than a cancer genomics analysis, though cBioPortal may have been used for preliminary data mining or validation purposes.",[],['Citation only'],['EIF2AK3'],['Not specified'],Unclear,low,4.0,41014556,ER stress tolerance is regulated by copper-dependent PERK kinase activity.,2025,abstract,2025-12-19T04:00:09.997694,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Glioma/Brain cancer', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used as one of multiple bioinformatics platforms to analyze HMOX1 across diverse tumor types from TCGA data. The platform was specifically mentioned for analyzing genetic alterations, where mutations were identified as the predominant alteration affecting HMOX1. The study integrated cBioPortal data with other platforms (TIMER2, UALCAN, GEPIA2, R, GSCA, LinkedOmics) for comprehensive pan-cancer analysis of HMOX1 expression, prognosis, and immune infiltration.",['TCGA'],"['Web-based analysis', 'Web-based visualization']",['HMOX1'],"['Query interface', 'Expression analysis']",Mixed,medium,4.0,41030312,Pan-cancer analysis reveals HMOX1 as a cancer prognosis and immune infiltration-related biomarker.,2025,abstract,2025-12-19T04:00:10.025742,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration', 'Mutation analysis', 'Copy number analysis']","['Pan-cancer', 'Hepatocellular carcinoma']","['Biomarker discovery', 'Precision medicine', 'Immunotherapy']",['Original research'],"['TCGA', 'GTEx', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the methods or results sections provided. The data sources mentioned are TCGA, GTEx, and the UCSC Xena platform, with analyses conducted using the Xiantao platform and R packages. While cBioPortal is cited, there is no clear description of how it was used for data access, analysis, or visualization in this study.",['TCGA'],['Citation only'],['ILF2'],['Not specified'],"[""External (downloaded data)""]",low,4.0,41021104,Multi-omics analysis of ILF2 reveals its prognostic value and functional roles across pan-cancer.,2025,pdf,2025-12-19T04:00:10.247095,,,,
"['Gene expression analysis', 'Survival analysis', 'Copy number analysis', 'Pathway analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, cBioPortal is not explicitly mentioned in the text. The study uses TCGA data and multiple other bioinformatics platforms (TIMER2.0, GEPIA2, UALCAN) for analysis. While cBioPortal is cited as a reference, there is no clear description of how it was specifically used in this study. The analysis appears to have been conducted using other platforms for gene expression, survival, and immune infiltration analysis.",['TCGA'],['Citation only'],"['ZNF703', 'CD274', 'ICAM1', 'CXCL3', 'DDHD2', 'LSM1', 'BAG4']",['Not specified'],Unclear,low,4.0,41023871,Pan-cancer analysis of the oncogenic role of ZNF703 in regulating tumor immunity.,2025,pdf,2025-12-19T04:00:10.509988,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Breast cancer']","['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']",cBioPortal was used to investigate mutations in the JCHAIN gene and their connection with methylation across multiple cancer types. The study mentions using the cBioPortal website along with UALCAN to analyze JCHAIN mutations and methylation patterns as part of their comprehensive pan-cancer analysis.,[],['Web-based analysis'],['JCHAIN'],['Not specified'],External (downloaded data),medium,4.0,41010015,<i>JCHAIN</i>: A Prognostic Marker Based on Pan-Cancer Analysis to Inhibit Breast Cancer Progression.,2025,pdf,2025-12-19T04:00:11.619865,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Pathway analysis', 'Multi-omics integration']",['Breast cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis', 'Precision medicine']","['Original research', 'Clinical study']","['TCGA', 'Multiple sources']","The study analyzed genomic and transcriptomic profiles from thousands of breast cancer samples, including the TCGA cohort, to identify FH mutations and copy number alterations. cBioPortal was likely used to access and query TCGA breast cancer data for FH alterations and associated genomic features. The analysis integrated mutation data, copy number alterations, and gene expression data to characterize FH-deficient tumors and their angiogenic signature.",['TCGA'],"['Data download/export', 'Web-based analysis']","['FH', 'CDH5', 'CLDN5', 'VWF', 'PECAM1']","['Query interface', 'Download data']","[""Mixed""]",medium,4.0,41008787,Revealing the Angiogenic Signature of <i>FH</i>-Deficient Breast Cancer: Genomic Profiling and Clinical Implications.,2025,abstract,2025-12-19T04:00:12.753187,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Pan-cancer'],"['Methods/Tools development', 'Biomarker discovery']","['Original research', 'Methods/Software']",['TCGA'],"The paper cites cBioPortal as a reference but does not provide explicit details about how it was used in the study. Based on the methodology involving multimodal fusion of genomic data and whole slide images for survival prediction across four cancer datasets, it is likely that cBioPortal was used to access TCGA data. However, the specific usage mode and features are not clearly described in the abstract and introduction.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41006935,Interpretable Cancer Survival Prediction by Fusing Semantic Labelling of Cell Types and Whole Slide Images.,2025,abstract,2025-12-19T04:00:15.224009,,,,
"['Gene expression analysis', 'Mutation analysis', 'Pathway analysis', 'Survival analysis']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis']",['Original research'],"['TCGA', 'Custom/Private data']","The paper does not explicitly mention using cBioPortal in the methods or results sections. The study analyzed TCGA lower-grade glioma (LGG) transcriptome data and GSE107850 dataset to identify differentially expressed genes and differentially co-expressed gene pairs between IDH mutation statuses. While TCGA data was used, there is no clear indication that cBioPortal was the source or platform for data access or analysis.","['TCGA-LGG', 'GSE107850']",['Citation only'],"['IDH1', 'IDH2', 'ACAA2', 'PLCG1', 'OLIG2']",['Not specified'],Unclear,low,4.0,41007824,Transcriptomic Profile of Isocitrate Dehydrogenase Mutant Type of Lower-Grade Glioma Reveals Molecular Changes for Prognosis.,2025,pdf,2025-12-19T04:00:15.481685,,,,
"['Gene expression analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Immunotherapy', 'Pathway analysis', 'Biomarker discovery']",['Original research'],['TCGA'],The paper used cBioPortal to analyze TCGA pancreatic adenocarcinoma (PAAD) data to examine the relationship between STK11 expression and macrophage markers. The analysis appears to have involved querying gene expression data from TCGA-PAAD dataset to correlate STK11 levels with M2 macrophage-associated markers in pancreatic cancer patients. This was likely used to validate their experimental findings in a clinical dataset.,['TCGA-PAAD'],"['Web-based analysis', 'Data download/export']",['STK11'],"['Expression analysis', 'Query interface']",Mixed,medium,4.0,41004572,STK11 coordinates IL-4 signaling with metabolic reprogramming to control M2 macrophage polarization and antitumor immunity.,2025,abstract,2025-12-19T04:00:15.765280,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']","['Pan-cancer', 'Breast cancer']","['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used as one of several online bioinformatics tools in this pan-cancer analysis of TRNT1. The platform was utilized to analyze genomic alterations (mutations and copy number changes) across multiple cancer types. The study combined cBioPortal analysis with other tools (GEPIA2, TIMER2, Metascape, UALCAN) and experimental validation to comprehensively characterize TRNT1's role in cancer, particularly breast cancer.",[],"['Web-based analysis', 'Web-based visualization']",['TRNT1'],['Not specified'],Unclear,medium,4.0,41001838,Comprehensive Pan-Cancer Analysis of TRNT1 as a Potential Biomarker for Breast Cancer.,2025,abstract,2025-12-19T04:00:16.286531,,,,
"['Gene expression analysis', 'Copy number analysis', 'Mutation analysis']",['Pan-cancer'],"['Review/Commentary', 'Biomarker discovery']",['Review'],['Not specified'],"This is a review paper focusing on microRNAs and cancer racial disparities. Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in the study. The paper appears to cite cBioPortal as a resource or reference but does not describe specific analyses or data downloads from the platform.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40998459,MicroRNAs and Cancer Racial Disparities.,2025,abstract,2025-12-19T04:00:16.616581,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance']","['Original research', 'Clinical study']","['TCGA', 'Custom/Private data']","Based on the abstract and introduction provided, cBioPortal is not explicitly mentioned in the text. The study focuses on RNA sequencing analysis of laryngeal cancer patient samples to identify KRT1 as a biomarker for recurrence and treatment response. The paper appears to use custom patient data from Chonnam National University Medical School and Hwasun Hospital. Without the full methods section visible, it's unclear if cBioPortal was used for validation or comparative analysis.",[],['Citation only'],['KRT1'],['Not specified'],Unclear,low,4.0,41002590,Expression of Keratin-1 Predicts Recurrence and Treatment Response in Advanced Laryngeal Cancer: A Potential Therapeutic Target.,2025,pdf,2025-12-19T04:00:16.786504,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Custom/Private data']","The researchers accessed 499 scanned histological slides (H&E-stained) from the TCGA-THCA (Thyroid Carcinoma) dataset via cBioPortal to assess the presence of tertiary lymphoid structures (TLSs) in papillary thyroid carcinoma. They stratified PTC cases with detected TLS according to BRAF and RAS mutation status and evaluated the expression of molecular markers including B and T cell markers and SLC5A5 (NIS) among patients with both TLSs and BRAF mutations. The analysis revealed TLSs in 8.4% of cases, with 62% harboring the BRAFV600E mutation along with upregulation of immune cell markers and SLC5A5 expression.",['TCGA-THCA'],"['Data download/export', 'Web-based analysis']","['BRAF', 'RAS', 'SLC5A5']","['Download data', 'Query interface']","[""Mixed""]",high,4.0,41004667,Tertiary lymphoid structures in thyroid cancer.,2025,pdf,2025-12-19T04:00:17.389152,,,,
"['Gene expression analysis', 'Copy number analysis', 'Mutation analysis', 'Survival analysis']",['Lung cancer'],"['Biomarker discovery', 'Methods/Tools development']",['Original research'],"['TCGA', 'Custom/Private data']",The paper used cBioPortal to analyze human lung adenocarcinoma data from TCGA to examine histone modification patterns and clinical associations. The authors queried cBioPortal to assess the relationship between epigenomic regulator expression levels and clinical features in human lung adenocarcinoma patients. This analysis complemented their primary functional genomics experiments in mouse models.,['TCGA-LUAD'],"['Web-based analysis', 'Web-based visualization']",[],"['Expression analysis', 'Query interface']","[""cBioPortal platform""]",medium,4.0,40997327,Functional Mapping of Epigenomic Regulators Uncovers Coordinated Tumor Suppression by the HBO1 and MLL1 Complexes.,2025,abstract,2025-12-19T04:00:18.359018,,,,
['Other'],['Not specified'],"['Methods/Tools development', 'Database/Resource', 'Review/Commentary']","['Review', 'Methods/Software']",['Not specified'],"This paper is a review/commentary article discussing integrated data-driven research environments in biotechnology. cBioPortal appears to be cited as an example of an interactive database platform in the life sciences, but no specific analysis, data download, or direct usage of cBioPortal is described. The paper focuses on conceptual frameworks for database design and data interrogation strategies rather than conducting original research using cBioPortal.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40996701,Integrated data-driven biotechnology research environments.,2025,abstract,2025-12-19T04:00:19.351827,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Other solid tumor'],"['Tumor evolution', 'Biomarker discovery']",['Original research'],['Custom/Private data'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper describes a genetically engineered mouse model (GEMM) of pancreatic ductal adenocarcinoma (PDAC) with reversible Smad4 inactivation. The study appears to use custom mouse model data with whole-genome sequencing, western blots, and histological analyses. cBioPortal may be cited in the references but is not described as being used for data analysis or visualization in the sections provided.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40999053,SMAD4 induces opposite effects on metastatic growth from pancreatic tumors depending on the organ of residence.,2025,pdf,2025-12-19T04:00:19.887235,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Breast cancer'],"['Biomarker discovery', 'Precision medicine', 'Immunotherapy']",['Original research'],"['TCGA', 'METABRIC', 'Multiple sources']","The authors used cBioPortal to obtain the METABRIC dataset for validation of their radiation-related gene signature in breast cancer. The METABRIC data was used as an independent validation cohort to confirm the prognostic performance of their risk model that was initially developed using TCGA-BRCA data. The paper explicitly states that ""The cBioPortal website (https://www.cbioportal.org/) provided the METABRIC"" dataset.",['METABRIC'],['Data download/export'],[],['Download data'],External (downloaded data),high,4.0,40983794,Novel radiation-derived gene blueprint stratifying patients with breast cancer.,2025,pdf,2025-12-19T04:00:22.431316,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper mentions using data from The Cancer Genome Atlas (TCGA) database for analyzing gene expression profiles in colorectal cancer. However, the abstract and introduction do not explicitly describe how cBioPortal was used or whether it was the primary access point for TCGA data. The study focused on developing a prognostic model using mRNA stemness index, hypoxia, and glycolysis-related genes through various computational analyses including LASSO regression and Cox regression.",['TCGA'],['Citation only'],"['ALDOB', 'AQP1', 'IL1A', 'PHGDH', 'PTGIS']",['Not specified'],Unclear,low,4.0,40989165,"A machine learning-based prognostic model integrating mRNA stemness index, hypoxia, and glycolysis‑related biomarkers for colorectal cancer.",2025,abstract,2025-12-19T04:00:22.654581,,,,
"['Gene expression analysis', 'Mutation analysis', 'Survival analysis', 'Pathway analysis']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The cBioPortal database was used to identify genomic alterations in PIEZO1 across pan-cancer patients. The analysis revealed that PIEZO1 genomic alterations were found in 4% of pan-cancer patients. The specific methodology of how cBioPortal was accessed (web interface, API, or data download) is not explicitly detailed in the abstract and introduction.",[],['Citation only'],['PIEZO1'],['Not specified'],Unclear,medium,4.0,40977743,"Pan-cancer analysis of PIEZO1: a promising biomarker for diagnosis, prognosis, and targeted therapies.",2025,pdf,2025-12-19T04:00:23.282173,,,,
"['Gene expression analysis', 'Survival analysis']","['Colorectal cancer', 'Pan-cancer']","['Immunotherapy', 'Biomarker discovery']",['Original research'],['TCGA'],The study used cBioPortal to analyze clinical data showing associations between ZEB2 expression and CD274/CCL2 expression in cancer patients. The authors also used cBioPortal data to assess the prognostic significance of ZEB2 and CD274 or CBX4 expression for predicting survival in colon cancer patients. The analysis appears to have involved querying gene expression data and performing survival analysis using TCGA datasets.,['TCGA'],"['Web-based analysis', 'Web-based visualization']","['ZEB2', 'CD274', 'CCL2', 'CBX4']","['Expression analysis', 'Survival analysis', 'Query interface']",cBioPortal platform,medium,4.0,40970322,Cooperation between ZEB2 and SP1 upregulates PD‑L1 and CCL2 to promote the immunosuppressive activity of tumor cells.,2025,abstract,2025-12-19T04:00:23.313040,,,,
"['Gene expression analysis', 'Mutation analysis', 'Survival analysis', 'Pathway analysis']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy']","['Original research', 'Clinical study']","['TCGA', 'Custom/Private data']","The paper performed a pan-cancer analysis using TCGA datasets to investigate SLC7A11 genetic alterations, expression patterns, and their impact on tumor microenvironment and therapy response. cBioPortal was likely used to access and analyze TCGA data for mutation analysis, expression profiling, and survival analysis across multiple cancer types. The study focused on hepatocellular carcinoma (HCC) but included pan-cancer perspectives using TCGA data accessed through cBioPortal or similar platforms.",['TCGA'],"['Data download/export', 'Citation only']",['SLC7A11'],['Not specified'],Unclear,low,4.0,40978058,A pan-cancer perspective analysis reveals the prognostic significance of SLC7A11 in hepatocellular carcinoma.,2025,pdf,2025-12-19T04:00:23.518407,,,,
['Other'],['Pan-cancer'],"['Review/Commentary', 'Drug response/resistance', 'Pathway analysis']",['Review'],['Not specified'],"This is a review paper on G protein-coupled receptors (GPCRs) in cancer biology and therapeutic development. Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in the study. The paper appears to cite cBioPortal as a reference resource but does not describe any specific data analysis, visualization, or data download from the platform.",[],['Citation only'],[],['Not specified'],"[""Unclear""]","[""low""]",4.0,40969301,G Protein-Coupled Receptor Signaling: Implications and Therapeutic Development Advances in Cancers.,2025,abstract,2025-12-19T04:00:24.005327,,,,
"['Copy number analysis', 'Gene expression analysis', 'Mutation analysis']",['Prostate cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']",The study used cBioPortal to analyze KBTBD11 genomic alterations (deletions) in prostate cancer patient samples. The authors queried cBioPortal databases to identify the frequency of KBTBD11 deletion in human prostate cancer specimens and to correlate KBTBD11 loss with AKT phosphorylation status in patient samples. This analysis provided clinical evidence supporting their experimental findings that KBTBD11 loss promotes AKT hyperactivation in prostate cancer.,[],"['Web-based analysis', 'Data download/export']","['KBTBD11', 'AKT1', 'PTEN', 'SPOP', 'PIK3CA']","['Query interface', 'Download data']",Mixed,medium,4.0,40983636,KBTBD11 loss promotes AKT hyperactivation and therapeutic vulnerability in prostate cancer.,2025,pdf,2025-12-19T04:00:24.914794,,,,
"['Gene expression analysis', 'Mutation analysis', 'Copy number analysis', 'Survival analysis', 'Pathway analysis']","['Melanoma', 'Pan-cancer']","['Biomarker discovery', 'Immunotherapy', 'Drug response/resistance', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to explore the genomic landscape of MCM4 in skin cutaneous melanoma, including analysis of mutations and copy number variations. The platform was also used to examine the relationship between mutation sites and protein structure of MCM4. The study utilized cBioPortal's visualization and analysis features to characterize genomic alterations of MCM4 across cancer samples.",['TCGA-SKCM'],"['Web-based analysis', 'Web-based visualization']",['MCM4'],"['Mutation Mapper', 'Query interface']",cBioPortal platform,high,4.0,40959096,Comprehensive analysis reveals MCM4 as a biomarker for guiding therapies and immunomodulatory role in skin cutaneous melanoma.,2025,pdf,2025-12-19T04:00:26.336459,,,,
['Copy number analysis'],"['Pan-cancer', 'Leukemia/Lymphoma', 'Other solid tumor']","['Review/Commentary', 'Biomarker discovery']",['Review'],['Not specified'],"cBioPortal was cited as a data source to support the observation that ZIC genes harbor copy number alterations in multiple cancer types, particularly homozygous deletions in pediatric leukemias and Wilms' tumor. The authors used this information to contextualize the role of ZIC genes in cancer pathogenesis. No specific analysis or data download from cBioPortal was described.",[],['Citation only'],"['ZIC1', 'ZIC2', 'ZIC3', 'ZIC4', 'ZIC5']",['Not specified'],Unclear,medium,4.0,40952541,The multifaceted roles of ZIC genes in cancer: from development regulators to cancer modulators.,2025,pdf,2025-12-19T04:00:26.353203,,,,
"['Gene expression analysis', 'Multi-omics integration']",['Pan-cancer'],"['Methods/Tools development', 'Database/Resource']",['Methods/Software'],"['TCGA', 'Multiple sources']","This paper describes the development of UALCAN Mobile, a mobile application for cancer proteogenomic data analysis. While the paper focuses on UALCAN as a comprehensive platform for cancer data analysis, there is no explicit mention of cBioPortal being used in this study. The paper appears to cite cBioPortal as a related resource in the field of cancer genomics data portals, but does not describe any specific usage of cBioPortal for data analysis, visualization, or data download in the development or validation of the UALCAN Mobile app.","['TCGA', 'CPTAC']",['Citation only'],[],['Not specified'],Unclear,low,4.0,40950112,"UALCAN Mobile, an app for cancer proteogenomic data analysis.",2025,abstract,2025-12-19T04:00:28.720813,,,,
"['Gene expression analysis', 'Mutation analysis']",['Other solid tumor'],"['Pathway analysis', 'Biomarker discovery']",['Original research'],['Not specified'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage. The paper describes an RNAi screen identifying CYLD as a regulator of mTOR, with mechanistic studies in cell lines, C. elegans, and patient skin biopsies from CYLD cutaneous syndrome. While the paper cites cBioPortal, the specific usage details are not described in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40950055,The tumor suppressor CYLD acts as a deubiquitinase for mTOR to constrain its activity.,2025,abstract,2025-12-19T04:00:29.268424,,,,
"['Gene expression analysis', 'Survival analysis']",['Breast cancer'],['Biomarker discovery'],"['Original research', 'Clinical study']","['TCGA', 'Custom/Private data']","The authors used cBioPortal to perform bioinformatics analyses examining the association of SDC2 and FN expression with breast cancer staging and prognosis. The study mentions that bioinformatics analyses confirmed the relationship between SDC2 and FN expression patterns and clinical outcomes in breast cancer patients. However, the abstract and introduction do not provide detailed information about specific cBioPortal features used or the exact nature of the analyses performed.",['TCGA'],['Web-based analysis'],"['SDC2', 'FN1']","['Expression analysis', 'Not specified']",Unclear,low,4.0,40940401,SDC2 and FN as cargo proteins in circulating extracellular vesicles in obese breast cancer patients with lymph node metastasis.,2025,pdf,2025-12-19T04:00:29.989024,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration', 'Mutation analysis', 'Copy number analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'ICGC', 'Multiple sources']","The paper does not explicitly describe how cBioPortal was used in the methodology. While multiple databases including TCGA, GTEx, ICGC, GEO, HPA, and CPTAC are mentioned as data sources for assessing expression patterns, prognostic implications, DNA methylation, genomic alterations, and tumor immune microenvironments, there is no specific mention of cBioPortal in the abstract or introduction provided. The usage appears to be citation only or the data may have been accessed through other means.",['TCGA'],['Citation only'],"['FAM50A', 'FAM83D', 'FAM104B', 'FAM220A', 'FAM222B']",['Not specified'],Unclear,low,4.0,40950660,Exploration of signature-related FAM genes and correlation between FAM50A expression and the pathogenesis and prognosis of hepatocellular carcinoma.,2025,abstract,2025-12-19T04:00:30.114898,,,,
"['Mutation analysis', 'Copy number analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']","['MSK-IMPACT', 'Custom/Private data']","The study used MSK-IMPACT targeted genomic sequencing panel data for 18 patients with metastatic clear-cell renal cell carcinoma. Genomic data including fraction of genome altered and CDKN2A copy number loss were correlated with disease-free survival outcomes. The analysis appears to have been performed using institutional data, likely accessed through cBioPortal infrastructure for MSK-IMPACT data.",['MSK-IMPACT'],['Citation only'],['CDKN2A'],['Not specified'],"[""Unclear""]",medium,4.0,40940250,Long-term oncologic outcomes of metastatic clear-cell renal cell carcinoma after local therapy alone.,2026,abstract,2025-12-19T04:00:30.495169,,,,
"['Mutation analysis', 'Multi-omics integration', 'Methods/Tools development']","['Pan-cancer', 'Lung cancer', 'Colorectal cancer', 'Prostate cancer', 'Other solid tumor']","['Methods/Tools development', 'Tumor evolution', 'Biomarker discovery']","['Original research', 'Methods/Software']","['TCGA', 'ICGC', 'Multiple sources']","Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on developing a machine learning method called SCOOP that combines whole genome sequencing data with single-cell chromatin accessibility data to predict cell of origin for 37 cancer types. The study uses WGS data from public sources (3,669 samples) and scATAC-seq data (559 cellular profiles), but cBioPortal is not mentioned as a data source or analysis platform in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40962882,Learning the cellular origins across cancers using single-cell chromatin landscapes.,2025,pdf,2025-12-19T04:00:30.946626,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Copy number analysis', 'Multi-omics integration']","['Pan-cancer', 'Lung cancer']","['Biomarker discovery', 'Immunotherapy', 'Drug response/resistance']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the abstract or introduction provided. While the study performs comprehensive pan-cancer analyses including expression patterns, clinical correlations, genetic alterations, and immunogenomic profiles of MDH1 across multiple cancer types, there is no clear statement about cBioPortal being used as a data source or analysis platform. The citation of cBioPortal may be in the references but specific usage details are not provided in the excerpts given.",[],['Citation only'],['MDH1'],['Not specified'],Unclear,low,4.0,40948768,Panoramic view of MDH1: driving cancer progression and shaping the tumor immune microenvironment.,2025,pdf,2025-12-19T04:00:31.197521,,,,
"['Gene expression analysis', 'Survival analysis']",['Breast cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'METABRIC', 'Custom/Private data']","The authors used cBioPortal to validate their findings by examining the expression levels of RICTOR, ZFX, and UGCG in publicly available breast cancer datasets. They specifically analyzed TCGA and METABRIC datasets through cBioPortal to confirm elevated expression of these genes in luminal breast cancer tissues, supporting their experimental observations from cell culture and mouse models.","['TCGA', 'METABRIC']","['Web-based analysis', 'Web-based visualization']","['RICTOR', 'ZFX', 'UGCG']","['Expression analysis', 'Query interface']",cBioPortal platform,medium,4.0,40934285,The mTORC2 subunit RICTOR drives breast cancer progression by promoting ganglioside biosynthesis through transcriptional and epigenetic mechanisms.,2025,abstract,2025-12-19T04:00:31.937447,,,,
"['Gene expression analysis', 'Survival analysis']",['Leukemia/Lymphoma'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],['TCGA'],"Based on the abstract and introduction provided, cBioPortal appears to have been used to analyze SR-B1 expression and its correlation with patient outcomes in AML. The study likely queried TCGA AML datasets through cBioPortal to examine SR-B1 expression levels and perform survival analysis to establish the clinical relevance of SR-B1 as a therapeutic target. However, specific details about cBioPortal usage are not explicitly mentioned in the provided text.",['TCGA'],['Citation only'],['SCARB1'],['Not specified'],Unclear,low,4.0,40932875,Targeting scavenger receptor class B type 1 with a bioinspired ligand induces apoptosis or ferroptosis in AML.,2025,abstract,2025-12-19T04:00:33.224093,,,,
"['Mutation analysis', 'Copy number analysis', 'Survival analysis']",['Lung cancer'],"['Biomarker discovery', 'Tumor evolution', 'Precision medicine']","['Original research', 'Clinical study']","['TCGA', 'Custom/Private data', 'Multiple sources']",The study used TCGA lung adenocarcinoma data from cBioPortal as a comparison cohort to analyze early-stage tumors. The authors compared their SAFIR02-Lung cohort (advanced/metastatic tumors) with TCGA early-stage tumors to identify molecular alterations specific to tumor progression and metastasis. cBioPortal served as the source for accessing TCGA data for comparative analysis of copy-number alterations and mutations.,['TCGA'],['Data download/export'],"['LAMB3', 'TNN', 'KIAA0040', 'TNR', 'KRAS', 'DAB2', 'MYC', 'EPHA3', 'VIPR2', 'AREG', 'ZNF503', 'PAX8', 'MMP13', 'JAM3', 'MTURN', 'CDKN2A', 'TP53', 'STK11', 'NKX2-1']",['Download data'],External (downloaded data),medium,4.0,40931129,Molecular analysis of lung adenocarcinomas from the SAFIR02-Lung cohort reveals new metastasis-associated copy-number alterations including frequent mutant-specific KRAS-allelic imbalance and identifies CDKN2A homozygous deletions as an independent biomarker of poor prognosis.,2025,abstract,2025-12-19T04:00:34.038452,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']","['TCGA', 'Multiple sources']",The study used cBioPortal to access and analyze the TCGA-BLCA cohort (n=412) as a validation cohort for muscle-invasive bladder cancer. The authors likely used cBioPortal to obtain METTL3 expression data and clinical information from TCGA-BLCA to validate their findings regarding the association between METTL3 expression loss and poor survival outcomes in MIBC patients.,['TCGA-BLCA'],['Data download/export'],['METTL3'],['Download data'],External (downloaded data),medium,4.0,40923330,Loss of METTL3 m6A methyltransferase results in short-term progression and poor treatment outcome of bladder cancer patients.,2026,abstract,2025-12-19T04:00:34.870750,,,,
"['Mutation analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"The paper mentions that tumor mutational analyses were collected for all available patients from a prospectively maintained pancreatic cancer database at Memorial Sloan Kettering Cancer Center. While cBioPortal is cited, the abstract does not provide explicit details about how cBioPortal was specifically used in the analysis. The study appears to have used institutional data with mutational profiling, but the specific role of cBioPortal in data access or analysis is not clearly described in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40928210,Influence of biologic sex and obesity on liver recurrence and survival in patients undergoing upfront surgery for pancreatic adenocarcinoma.,2025,abstract,2025-12-19T04:00:35.328880,,,,
['Other'],['Pan-cancer'],"['Review/Commentary', 'Pathway analysis']",['Review'],['Not specified'],This is a narrative review paper examining RAS genes and Ras proteins in housekeeping functions and tumorigenesis. The paper does not describe any specific use of cBioPortal for data analysis or visualization. cBioPortal appears to be cited only as a reference or resource in the context of discussing RAS-associated cancers.,[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40906088,RESEARCH CHALLENGES IN STAGE III AND IV RAS-ASSOCIATED CANCERS: A Narrative Review of the Complexities and Functions of the Family of <i>RAS</i> Genes and Ras Proteins in Housekeeping and Tumorigenesis.,2025,abstract,2025-12-19T04:00:36.092003,,,,
"['Mutation analysis', 'Copy number analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine']","['Original research', 'Clinical study']","['Custom/Private data', 'Multiple sources']","The cBioPortal database was used to explore molecular profiling data in ERBB2-amplified gastric cancer samples. The authors queried the database to identify common co-mutations associated with ERBB2 amplification, finding that TP53 missense mutations (51.1%) and CCNE1 amplifications (25.5%) were the most frequent alterations. This analysis complemented their primary NGS analysis of real-world patient data to understand resistance mechanisms to trastuzumab therapy.",[],"['Web-based analysis', 'Query interface']","['ERBB2', 'TP53', 'CCNE1']",['Query interface'],cBioPortal platform,medium,4.0,40922695,Next-generation sequencing identifies potential mechanisms of primary resistance to trastuzumab-containing therapies in HER2-positive gastric cancer: Analysis based on real-world data and online databases.,2025,abstract,2025-12-19T04:00:36.157805,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on evaluating the HER2DX ERBB2 mRNA assay in a retrospective cohort of 134 patients with advanced gastric cancer. The study appears to use custom patient data and does not describe accessing or utilizing cBioPortal resources, though cBioPortal may be cited in the references.",[],['Citation only'],['ERBB2'],['Not specified'],Unclear,low,4.0,40913834,HER2DX ERBB2 score in advanced HER2-positive gastric cancer treated with trastuzumab and chemotherapy.,2025,abstract,2025-12-19T04:00:36.850590,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Copy number analysis', 'Pathway analysis']",['Pan-cancer'],"['Biomarker discovery', 'Immunotherapy', 'Drug response/resistance']",['Original research'],"['TCGA', 'Multiple sources']","The paper mentions cBioPortal in the context of analyzing UBE2T gene variations across multiple cancer types. Gene variation analysis identified 'amplification' as the predominant alteration in the UBE2T gene, followed by mutations. However, the abstract and introduction do not provide specific details about how cBioPortal was used, what features were accessed, or whether data was downloaded or analyzed on the platform.",[],['Citation only'],['UBE2T'],['Not specified'],Unclear,low,4.0,40904601,Comprehensive pan-cancer analysis reveals ubiquitin-conjugating enzyme 2T as a potential biomarker for prognosis and cancer immunity.,2025,pdf,2025-12-19T04:00:37.565685,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Lung cancer'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to evaluate SMC2 mutations and gene alterations in lung adenocarcinoma (LUAD). The database was employed as one of several analytical tools to assess genetic alterations of SMC2 in LUAD samples. The specific details of how cBioPortal was used are limited in the abstract and introduction, but it appears to have been used for mutation analysis.",[],['Web-based analysis'],['SMC2'],['Not specified'],Unclear,medium,4.0,40900734,SMC2 as a potential prognostic biomarker in lung adenocarcinoma and its correlation with immune microenvironment.,2025,pdf,2025-12-19T04:00:38.355862,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Breast cancer']","['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, cBioPortal is not explicitly mentioned in the text. The study uses TCGA, GEO, and other databases (UALCAN, HPA, UCSC XENA) for pan-cancer analysis of BYSL gene. While TCGA data is used, there is no clear indication that cBioPortal was the platform used to access or analyze this data. The paper may cite cBioPortal in references but specific usage is not described in the provided sections.","['TCGA', 'GTEx', 'GSE45827', 'GSE83889', 'GSE6791', 'GSE121248', 'GSE31547', 'GSE29450', 'GSE46517', 'GSE54129']",['Citation only'],['BYSL'],['Not specified'],Unclear,low,4.0,40904351,Bystin is a Prognosis and Immune Biomarker: From Pan-Cancer Analysis to Validation in Breast Cancer.,2025,pdf,2025-12-19T04:00:39.511155,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction, this study performed a comprehensive pan-cancer bioinformatics analysis of YRDC examining expression, prognosis, genetic alterations, copy number variations, and methylation levels. The study likely used cBioPortal to access multi-omics data including mutation, copy number, and expression data across multiple cancer types. However, specific details about how cBioPortal was used are not provided in the abstract and introduction alone.",[],['Data download/export'],['YRDC'],['Not specified'],External (downloaded data),medium,4.0,40898423,YRDC is a Prognostic-Related Biomarker Correlated With Immune Infiltration and Drug Sensitivity in Pan-Cancer.,2025,abstract,2025-12-19T04:00:40.164933,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis']",['Prostate cancer'],"['Immunotherapy', 'Biomarker discovery', 'Drug response/resistance']",['Original research'],"['TCGA', 'Custom/Private data']","The paper appears to use cBioPortal to analyze human prostate cancer datasets, likely examining MYC amplification and p53 alterations in patient samples. The authors likely queried cBioPortal to validate their mouse model findings in human CRPC datasets and to examine the correlation between genetic alterations (MYC, p53) and immune-related features or clinical outcomes. Based on the abstract and introduction, cBioPortal was likely used to access TCGA prostate cancer data for comparative analysis with their experimental models.",['TCGA'],"['Web-based analysis', 'Web-based visualization']","['MYC', 'TP53']",['Not specified'],"[""Unclear""]","[""low""]",4.0,40899986,MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T-cell and Immunotherapy Responses in Prostate Cancer.,2025,abstract,2025-12-19T04:00:40.704343,,,,
"['Copy number analysis', 'Gene expression analysis', 'Survival analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine']",['Original research'],['TCGA'],"cBioPortal was used to analyze FBXO7 alterations in colorectal cancer patient samples, specifically examining shallow deletions and their association with gene expression levels. The platform was utilized to assess clinical outcomes and correlate FBXO7 copy number alterations with patient prognosis in CRC cohorts. The analysis helped establish that FBXO7 deficiency is present in approximately one-third of CRC cases and associates with adverse clinical outcomes.",['TCGA'],"['Web-based analysis', 'Web-based visualization']",['FBXO7'],"['Expression analysis', 'Survival analysis', 'Query interface']",Mixed,medium,4.0,40896366,<i>CHEK1</i> is a synthetic lethal interactor of <i>FBXO7</i> in colonic epithelial cells.,2025,abstract,2025-12-19T04:00:41.238276,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Copy number analysis', 'Pathway analysis']","['Pan-cancer', 'Melanoma']","['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used as one of six databases to assess ANGPT2 expression patterns across pan-cancer samples and to explore genetic alterations (mutations, amplifications, and deep deletions) in ANGPT2 across multiple tumor types. The study integrated data from cBioPortal along with UCSC Xena, TCGA, GTEx, TIMER2.0, GEPIA, and HPA databases to comprehensively analyze ANGPT2's role in cancer, with particular focus on skin cutaneous melanoma (SKCM).",[],"['Data download/export', 'Web-based analysis']",['ANGPT2'],"['Query interface', 'Download data']",Mixed,medium,4.0,40890493,"Integrated pan-cancer and melanoma-specific analysis of angiopoietin-2: prognostic value, immune microenvironment modulation, and ceRNA network regulation.",2025,pdf,2025-12-19T04:00:42.232473,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, the paper does not explicitly mention cBioPortal usage. The study uses TCGA-CESC data and GEO datasets (GSE29570, GSE63514) to construct a prognostic signature based on MHC-related genes. While cBioPortal is cited, there is no clear description in the provided text of how it was specifically used for data acquisition, analysis, or visualization.","['TCGA-CESC', 'GSE29570', 'GSE63514']",['Citation only'],"['CANX', 'HLA-DMB', 'HLA-DPB1', 'PSMB6', 'PSMB7']",['Not specified'],Unclear,low,4.0,40888998,Predictive value of MHC-related genes in cervical cancer: implications for immunotherapy and prognostic nomogram development.,2025,pdf,2025-12-19T04:00:42.719646,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Review/Commentary', 'Biomarker discovery', 'Drug response/resistance']",['Review'],['TCGA'],"This is a review paper focused on UBASH3B in head and neck squamous cell carcinoma (HNSCC). The paper mentions TCGA data in the context of discussing genetic alterations and mutation patterns in HPV+ and HPV- HNSCC tumors. cBioPortal is likely cited as a reference for accessing TCGA data, but specific usage details are not provided in the abstract and introduction sections.",['TCGA'],['Citation only'],"['UBASH3B', 'EGFR']",['Not specified'],Unclear,low,4.0,40885971,"Investigating the role of UBASH3B in cancer: structural relevance, physiological functions, and therapeutic possibilities.",2025,pdf,2025-12-19T04:00:42.850713,,,,
"['Copy number analysis', 'Multi-omics integration', 'Other']",['Pan-cancer'],"['Methods/Tools development', 'Biomarker discovery']","['Original research', 'Methods/Software']","['TCGA', 'ICGC', 'Multiple sources']","Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on developing a machine learning algorithm for detecting chromoanagenesis events using data from PCAWG and TCGA. cBioPortal may be cited as a reference or potential data source, but specific usage details are not provided in the available text.","['TCGA', 'PCAWG']",['Citation only'],[],['Not specified'],Unclear,low,4.0,40884651,Machine Learning for Detecting and Analyzing Chromoanagenesis Events.,2025,abstract,2025-12-19T04:00:43.124380,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis']",['Lung cancer'],"['Drug response/resistance', 'Immunotherapy', 'Precision medicine']","['Original research', 'Clinical study']",['Not specified'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on developing TNG260, a CoREST inhibitor, and testing it in preclinical models and clinical trials for STK11-mutant NSCLC. While the paper cites cBioPortal, the specific usage details are not described in the provided text.",[],['Citation only'],['STK11'],['Not specified'],Unclear,low,4.0,40882030,TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti-PD-1 Immunotherapy.,2025,abstract,2025-12-19T04:00:44.138866,,,,
"['Copy number analysis', 'Gene expression analysis', 'Survival analysis']","['Breast cancer', 'Leukemia/Lymphoma']","['Biomarker discovery', 'Immunotherapy', 'Methods/Tools development']",['Original research'],"['TCGA', 'Custom/Private data']","This paper does not appear to use cBioPortal at all. The authors accessed data directly from dbGaP (database of genotypes and phenotypes) and the Genomic Data Commons (GDC) portal, downloading WGS and WXS files for analysis on their own computing cluster. All analyses of copy number variation, gene expression, and survival were performed using their own bioinformatics pipelines and tools (SAMtools, custom scripts) rather than through cBioPortal.","['CGCI-BLGSP', 'TCGA-BRCA']",['Citation only'],"['FASLG', 'CD4', 'CD8A', 'PRRC2C']",['Not specified'],External (downloaded data),high,4.0,40883027,Programmatically Efficient Separation of Immune Infiltrate and Tumor Gene Expression Overlap Potentials in a Big Data Setting: FASLG Gene Expression-related Survival Distinctions.,2025,pdf,2025-12-19T04:00:44.705672,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Colorectal cancer', 'Pan-cancer']","['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction, the study used TCGA data for rectal cancer analysis (177 samples). While cBioPortal is cited as a cancer genomics portal, the specific usage details are not explicitly described in the provided text. The study appears to have accessed TCGA rectal cancer data, which may have been obtained through cBioPortal, but the exact method of data acquisition and analysis platform is not clearly specified in the abstract/introduction.",['TCGA'],['Citation only'],['PYGM'],['Not specified'],Unclear,low,4.0,40873584,Machine learning identifies PYGM as a macrophage polarization-linked metabolic biomarker in rectal cancer prognosis.,2025,abstract,2025-12-19T04:00:46.359327,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Prostate cancer'],"['Drug response/resistance', 'Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],"The paper mentions using cBioPortal in the context of analyzing prostate cancer data, likely for gene expression and survival analysis related to their identified target genes (TP53, EGFR, AR, AKT1, ESR1, TGFBR2, SRC, NQO1, ALDH2, ADH1B). The authors developed a prognostic model based on Pae-target genes and stratified patients into high- and low-risk groups with distinct survival outcomes. However, specific details about how cBioPortal was used are not provided in the abstract and introduction sections.",[],['Citation only'],"['TP53', 'EGFR', 'AR', 'AKT1', 'ESR1', 'TGFBR2', 'SRC', 'NQO1', 'ALDH2', 'ADH1B']",['Not specified'],Unclear,low,4.0,40872629,Network Pharmacology and Experimental Validation Identify Paeoniflorin as a Novel SRC-Targeted Therapy for Castration-Resistant Prostate Cancer.,2025,pdf,2025-12-19T04:00:46.550111,,,,
"['Gene expression analysis', 'Other']",['Breast cancer'],"['Pathway analysis', 'Biomarker discovery']",['Original research'],['Not specified'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper describes high-throughput RNAi-based kinome screens performed in TNBC cell lines to identify novel regulators of YAP/TAZ. cBioPortal may have been cited in the references but no specific usage is described in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40869130,"Integrative High-Throughput RNAi Screening Identifies BRSK1, STK32C and STK40 as Novel Activators of YAP/TAZ.",2025,abstract,2025-12-19T04:00:47.527395,,,,
['Gene expression analysis'],['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],['TCGA'],"The study analyzed RNA-seq data from the TCGA-THCA dataset comprising 355 papillary thyroid carcinoma samples and 58 normal thyroid tissue samples to examine MMP gene family expression patterns. The analysis focused on identifying overexpression of MMP-2, MMP-9, and MMP-14 in PTC samples compared to normal tissue. The data was used to correlate MMP-14 expression with disease status and recurrence risk in papillary thyroid carcinoma.",['TCGA-THCA'],['Data download/export'],"['MMP2', 'MMP9', 'MMP14']","['Expression analysis', 'Download data']","[""External (downloaded data)""]",medium,4.0,40869275,"Inhibition of Metalloproteinases-2, -9, and -14 Suppresses Papillary Thyroid Carcinoma Cell Migration and Invasion.",2025,pdf,2025-12-19T04:00:47.552249,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis', 'Survival analysis']","['Melanoma', 'Other solid tumor']","['Drug response/resistance', 'Pathway analysis', 'Biomarker discovery']",['Original research'],"['Custom/Private data', 'Multiple sources']","The hospital developed its own instance of cBioPortal to archive genomic data from clinical commercial labs, collecting data from nearly 6000 independent patient tumors. The authors used their internal cBioPortal database to perform retrospective analysis of melanoma and thyroid cancer samples from April 2019 to October 2023, comparing BRAF mutation frequencies with TCGA and AACR GENIE databases accessed through cBioPortal. The study integrated whole exome and transcriptome sequencing data with tumor registry outcomes data within their institutional cBioPortal instance.","['TCGA', 'AACR GENIE']","['Web-based analysis', 'Citation only']",['BRAF'],"['Query interface', 'Not specified']","[""Mixed""]",medium,4.0,40869231,<i>BRAF</i> V600E Mutation Has Variable Tumor-Specific Effects on Expression of MAPK Pathway Genes That Could Affect Patient Outcome.,2025,pdf,2025-12-19T04:00:47.946719,,,,
"['Gene expression analysis', 'Other']",['Lung cancer'],"['Immunotherapy', 'Biomarker discovery']",['Original research'],['Not specified'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. This appears to be a preclinical experimental study using murine models of NSCLC to investigate the role of EphA2 in tumor immunity through flow cytometry and transcriptomic profiling. The paper may cite cBioPortal in the references or methods section not provided, but no specific usage is described in the available text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40867322,Tumor-Specific EphA2 Receptor Tyrosine Kinase Inhibits Anti-Tumor Immunity by Recruiting Suppressive Myeloid Populations in Murine Models of Non-Small Cell Lung Cancer.,2025,pdf,2025-12-19T04:00:48.786190,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Precision medicine', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the methods or results. While TCGA data was used as one of the validation cohorts for analyzing IDH-mutant gliomas, there is no clear statement about accessing this data through cBioPortal or using any cBioPortal features. The study primarily used CGGA datasets (325 and 693) and GLASS dataset alongside TCGA data for their ECM-based molecular subtyping analysis.",['TCGA'],['Citation only'],"['TP53', 'CDKN2A', 'CDKN2B', 'CLCF1', 'COL11A1', 'CSPG5', 'SULF1']",['Not specified'],Unclear,low,4.0,40866630,"ECM-based molecular subtypes define prognostic, EMT status, and therapeutic diversity in IDH-mutant gliomas.",2025,pdf,2025-12-19T04:00:50.136251,,,,
"['Gene expression analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Breast cancer', 'Lung cancer', 'Prostate cancer', 'Other solid tumor']","['Biomarker discovery', 'Precision medicine', 'Review/Commentary']",['Review'],"['TCGA', 'Multiple sources']","This is a review paper that synthesizes advances from 2010-2024 on luminal and basal subtypes across epithelial tumors. The paper mentions that large-scale cancer genomics initiatives (including TCGA data accessible through platforms like cBioPortal) provide an unbiased framework to detect and compare luminal and basal molecular features across different cancer types. However, the abstract and introduction provided do not contain specific details about direct cBioPortal usage for original analysis.",['TCGA'],['Citation only'],"['KRT8', 'KRT18', 'KRT5', 'KRT6', 'KRT14']",['Not specified'],Unclear,low,4.0,40867349,Luminal and Basal Subtypes Across Carcinomas: Molecular Programs Beyond Tissue of Origin.,2025,pdf,2025-12-19T04:00:50.143881,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Breast cancer', 'Lung cancer']","['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention cBioPortal usage in the abstract or introduction provided. The study primarily references TCGA, GEPIA2, and HPA databases for their pan-cancer analysis of SGO1. While cBioPortal is cited (as indicated by the paper being identified as citing cBioPortal), the specific usage details are not described in the provided text.",[],['Citation only'],"['SGO1', 'BUB1']",['Not specified'],Unclear,low,4.0,40861810,Pan-cancer analysis reveals SGO1 as a potential cancer prognostic and immunological biomarker.,2025,abstract,2025-12-19T04:00:51.507843,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration', 'Mutation analysis']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],['Multiple sources'],"cBioPortal was used to evaluate the clinical relevance of 46 key genes identified through multi-omics integration. The platform was specifically employed to perform survival analyses (disease-free and overall survival) in papillary thyroid carcinoma (PTC) and anaplastic thyroid carcinoma (ATC) patients. Additionally, tumor mutation burden correlations with outcomes were assessed using cBioPortal data.",[],['Web-based analysis'],"['AK2', 'SUCLG2', 'NDUFV2', 'GLUD1', 'HADHA', 'ALDH1A1', 'NADSYN1']",['Survival analysis'],cBioPortal platform,medium,4.0,40861812,Integrative Multi-Omics Analysis Reveals Key Metabolic Regulators and Prognostic Biomarkers in Pediatric and Adult Thyroid Cancer.,2025,abstract,2025-12-19T04:00:51.916488,,,,
"['Mutation analysis', 'Survival analysis', 'Pathway analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],['Multiple sources'],"The study obtained clinical characteristics, mutational characteristics, and survival data of CRC patients from cBioPortal for RNF43-mutated analysis. They screened 11 datasets with 4028 patient data from cBioPortal and performed mutation analysis, survival analysis, and pathway analysis. The data were filtered by a 1021-panel and used to analyze the predictive value of RNF43 mutations and concomitant co-mutations for overall survival.",[],['Data download/export'],"['RNF43', 'BRAF', 'EGFR']","['Download data', 'Query interface']",External (downloaded data),high,4.0,40860811,Define a good prognosis of <i>RNF43</i> codon 659-mutated and concomitant genomic signatures in CRC: an analysis of the cBioPortal database.,2025,abstract,2025-12-19T04:00:52.224197,,,,
"['Gene expression analysis', 'Mutation analysis']",['Prostate cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, cBioPortal usage is not explicitly described in these sections. The paper focuses on identifying ASPN as a HER3 ligand in prostate cancer and testing ADC therapies. While the paper likely used cBioPortal to query genomic alterations in ErbB genes or expression data in prostate cancer cohorts (as suggested by the statement that ""genomic alterations in ErbB genes are uncommon in prostate cancer""), specific details about cBioPortal usage are not provided in the available text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40857406,Identification of asporin as a HER3 ligand exposes a therapeutic vulnerability in prostate cancer.,2025,pdf,2025-12-19T04:00:53.092167,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Custom/Private data']","The paper does not explicitly describe using cBioPortal for data access or analysis. The study used TCGA-LIHC data to identify migrasome-related lncRNAs and construct a prognostic signature, but the methods do not mention cBioPortal as the data source or analysis platform. cBioPortal may have been cited in references but no specific usage is described in the abstract or introduction provided.",['TCGA-LIHC'],['Citation only'],[],['Not specified'],Unclear,low,4.0,40843374,A migrasome-related lncRNA signature predicts prognosis and immune response in hepatocellular carcinoma: Implications for biomarker discovery and therapeutic targeting.,2025,pdf,2025-12-19T04:00:54.553311,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Pathway analysis', 'Multi-omics integration']",['Lung cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis', 'Precision medicine', 'Review/Commentary']",['Review'],['Not specified'],"This is a review article examining multi-omics studies in non-small cell lung cancer (NSCLC) lacking actionable mutations. The paper does not explicitly describe using cBioPortal for any original analysis. cBioPortal may be cited as a reference resource for genomic profiling data or mentioned in the context of discussing available cancer genomics databases, but no specific usage details are provided in the abstract and introduction sections.",[],['Citation only'],"['EGFR', 'ALK', 'ROS1', 'RET', 'NTRK', 'NRG1', 'MET', 'BRAF', 'KRAS', 'HER2', 'TP53', 'KEAP1', 'STK11', 'NF1']",['Not specified'],Unclear,low,4.0,40849356,Refining treatment strategies for non-small cell lung cancer lacking actionable mutations: insights from multi-omics studies.,2025,pdf,2025-12-19T04:00:55.130386,,,,
"['Pathway analysis', 'Mutation analysis']","['Colorectal cancer', 'Ovarian cancer', 'Melanoma', 'Other solid tumor']","['Drug response/resistance', 'Biomarker discovery']",['Original research'],['Not specified'],"This paper focuses on the synthesis and biological evaluation of novel nitrated quinolone derivatives as anticancer agents. While the paper mentions cancer-related pathways (MAPK/ERK, PI3K/PKB/mTOR, etc.) and discusses mutations in PI3Kα (H1047R mutant), there is no explicit mention of cBioPortal being used in this study. The paper appears to be primarily a medicinal chemistry study involving compound synthesis, in vitro testing, and computational docking studies. cBioPortal may only be cited in the references without actual usage in the research.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40846973,"Exploring the anticancer potential of nitrated N-substituted-4-hydroxy-2-quinolone-3-carboxamides: synthesis, biological assessment, and computational analysis.",2025,pdf,2025-12-19T04:00:55.742926,,,,
"['Mutation analysis', 'Other']",['Not specified'],"['Methods/Tools development', 'Other']","['Original research', 'Methods/Software']",['Not specified'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this paper. The study focuses on developing computational and experimental methods to study phospho-regulation of short linear motifs (SLiMs) in autophagy, specifically examining the Optineurin LIR motif and its interaction with LC3B. The paper describes using AlphaFold models, molecular dynamics simulations, microfluidic diffusional sizing, and surface plasmon resonance, but does not reference cBioPortal for data retrieval or analysis.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40835742,Decoding phospho-regulation and flanking regions in autophagy-associated short linear motifs.,2025,pdf,2025-12-19T04:00:56.343598,,,,
"['Gene expression analysis', 'Multi-omics integration', 'Mutation analysis']",['Other solid tumor'],"['Biomarker discovery', 'Other']",['Original research'],"['TCGA', 'Custom/Private data']","The paper does not explicitly describe how cBioPortal was used in the study. While the paper focuses on endometrial cancer and mentions TCGA data and various genomic analyses, there is no clear mention of cBioPortal usage in the provided abstract and introduction sections. The citation appears to be for reference purposes only.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40829174,A distinct mechanism of epigenetic reprogramming silences PAX2 and initiates endometrial carcinogenesis.,2025,pdf,2025-12-19T04:00:58.040923,,,,
"['Mutation analysis', 'Copy number analysis']",['Breast cancer'],"['Precision medicine', 'Methods/Tools development', 'Biomarker discovery']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on comparing two comprehensive genomic profiling (CGP) panels - Oncomine comprehensive panel (medium-sized) and TruSight Oncology 500 (large-sized) - for analyzing triple-negative breast cancer samples from Taiwanese patients. The study appears to use custom/private data from the Veterans General Hospital TAipei-Yung-Ling foundation sinO-canceR study without reference to cBioPortal.",[],['Citation only'],"['AKT1', 'BRCA1', 'BRCA2', 'PALB2', 'ERBB2', 'PIK3CA', 'PTEN', 'TP53']",['Not specified'],Unclear,low,4.0,40831628,Comprehensive genomic profiling of Taiwanese triple-negative breast cancer samples with medium- and large-sized sequencing panels: A comparative study implicating treatment allocations.,2025,pdf,2025-12-19T04:00:58.927215,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis']",['Other solid tumor'],"['Review/Commentary', 'Biomarker discovery']",['Review'],['Not specified'],"This is a review paper focused on ARID1A in endometrial cancer. The paper likely cites cBioPortal as a reference resource for cancer genomics data and ARID1A mutation frequencies across cancers, but does not appear to perform original analysis using the platform. The review discusses ARID1A mutation status and protein expression discordance in endometrial cancer, potentially referencing cBioPortal data to support these observations.",[],['Citation only'],['ARID1A'],['Not specified'],Unclear,low,4.0,40826172,"ARID1A: gene, protein, and function in endometrial cancer.",2025,abstract,2025-12-19T04:00:59.594524,,,,
"['Mutation analysis', 'Copy number analysis', 'Survival analysis']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'GENIE', 'MSK-IMPACT', 'Multiple sources']","The authors downloaded clinical and molecular data from four independent glioma datasets (GENIE-DFCI, GLASS Consortium, MSKCC, and TCGA) through the cBioPortal interface to create a combined cohort of 790 IDH-mutant astrocytomas. The downloaded data was then manually reviewed and analyzed externally to determine the impact of molecular alterations (EGFR, CDKN2A/B, TERTp, +7/-10) on progression-free survival and overall survival in IDH-mutant astrocytomas.","['GENIE-DFCI', 'GLASS Consortium', 'MSKCC', 'TCGA']",['Data download/export'],"['EGFR', 'CDKN2A', 'CDKN2B', 'IDH1', 'IDH2', 'TERT', 'MGMT']","['Download data', 'Query interface']",External (downloaded data),high,4.0,40828325,EGFR alteration is an adverse prognostic factor in IDH-mutant astrocytoma.,2025,pdf,2025-12-19T04:01:00.700302,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Colorectal cancer'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly describe how cBioPortal was used in the methodology. While the study analyzed large-scale transcriptomic, proteomic, and IHC cohorts including TCGA data, there is no specific mention of cBioPortal in the abstract or introduction provided. The citation of cBioPortal may be for reference purposes or data access, but specific usage details are not provided in the available text.",['TCGA'],['Citation only'],['GALNT7'],['Not specified'],Unclear,low,4.0,40824763,GALNT7 Stratifies dMMR/MSI Colorectal Cancer into Distinct Molecular Subsets Associated with Prognosis and PD-L1 Expression.,2025,abstract,2025-12-19T04:01:01.888076,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']",['Original research'],['TCGA'],"The paper mentions TCGA database as the source for transcriptomic profiling of TOPK mRNA expression levels in KIRC patients and other cancer types. While cBioPortal is not explicitly mentioned in the provided abstract and introduction, TCGA data analysis for gene expression and survival analysis in cancer studies typically involves cBioPortal as a data access and analysis platform. The study performed comprehensive expression analysis across multiple cancer types and paired-sample analysis.",['TCGA'],['Citation only'],"['TOPK', 'PD-L1', 'ERK2']",['Not specified'],Unclear,low,4.0,40826334,TOPK promotes immune suppression in kidney renal clear cell carcinoma and emerges as a prognostic and therapeutic target.,2025,pdf,2025-12-19T04:01:02.691612,,,,
"['Mutation analysis', 'Gene expression analysis']",['Other solid tumor'],"['Drug response/resistance', 'Biomarker discovery', 'Precision medicine']",['Original research'],['Not specified'],"The paper does not explicitly mention using cBioPortal in the abstract or introduction provided. While the study investigates TP53 mutations and their impact on radiotherapy response in endometrial cancer, and references clinical trial molecular sub-analyses, there is no clear indication that cBioPortal was directly used for data access, analysis, or visualization in this experimental study. The research primarily focuses on in vitro and in vivo experiments using cell lines and mouse models.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40826166,Synergistic effect of MDM2 inhibitors and radiotherapy in endometrial cancer.,2025,pdf,2025-12-19T04:01:02.942124,,,,
"['Gene expression analysis', 'Survival analysis', 'Copy number analysis', 'Mutation analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Breast cancer']","['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the methods or results sections. The study primarily used TCGA data accessed through the UCSC XENA database and GDC portal, along with other databases like GTEx, TISCH, TIMER2.0, and HPA for their pan-cancer analysis of RIN3. While cBioPortal is cited in the references, there is no clear description of how it was used for data access, analysis, or visualization in this study.",['TCGA'],['Citation only'],"['RIN3', 'RAB5B', 'RAB31', 'KRAS', 'BRCA1', 'BRCA2']",['Not specified'],Unclear,low,4.0,40830225,Ras and Rab interactor 3 as a prognostic biomarker and its impact on immune cell infiltration in cancer.,2025,pdf,2025-12-19T04:01:03.133802,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis']",['Leukemia/Lymphoma'],"['Tumor evolution', 'Pathway analysis']",['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. This appears to be an experimental study using conditional mouse models with Ezh2 Y641F mutations to investigate hematopoietic development and transformation. The study primarily involves in vivo mouse experiments and transcriptomic analysis of B-cell progenitors. cBioPortal may be cited in the references but no specific usage is described in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40823663,Developmental stage and cellular context determine oncogenic and molecular outcomes of <i>Ezh2</i> <sup>Y641F</sup> mutation in hematopoiesis.,2025,abstract,2025-12-19T04:01:03.244522,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis']",['Breast cancer'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],['Multiple sources'],"The paper mentions cBioPortal in the context of analyzing clinical datasets to examine JNK pathway inactivation and its association with metastatic burden in ER+ breast cancer. The authors analyzed the relationship between JNK pathway activity (pJNK levels) and patient response to endocrine therapy and CDK4/6 inhibitor treatment in both early-stage and metastatic breast cancer cohorts. However, specific details about how cBioPortal was used (which features, which datasets, or whether data was downloaded vs. analyzed on the platform) are not provided in the abstract and introduction sections.",[],['Citation only'],"['MAP2K7', 'MAPK8', 'MAPK9']",['Not specified'],Unclear,low,4.0,40826108,JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer.,2025,pdf,2025-12-19T04:01:03.316289,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],['Multiple sources'],cBioPortal was used to examine the mutational status of SDHA in breast cancer. The study utilized cBioPortal as one of multiple publicly available databases to assess SDHA alterations in breast cancer patients. The specific details of how cBioPortal was used beyond examining mutations are not clearly described in the abstract and introduction.,[],['Web-based analysis'],['SDHA'],['Query interface'],Unclear,medium,4.0,40821099,Exploring the critical role of SDHA in breast cancer proliferation: implications for novel therapeutic strategies.,2025,pdf,2025-12-19T04:01:05.328669,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the abstract or introduction provided. The study uses TCGA and GEO datasets to analyze G6PC1 expression and its prognostic implications in hepatocellular carcinoma, but no specific reference to cBioPortal platform, tools, or data access methods is mentioned in the provided text. It is possible cBioPortal was cited in references or used for data access, but this cannot be confirmed from the provided sections.",['TCGA'],['Citation only'],"['G6PC1', 'HNF4A']",['Not specified'],Unclear,low,4.0,40821770,G6PC1 expression as a prognostic biomarker associated with metabolic reprogramming and tumor microenvironment in hepatocellular carcinoma.,2025,pdf,2025-12-19T04:01:05.906597,,,,
"['Gene expression analysis', 'Other']",['Not specified'],['Methods/Tools development'],['Methods/Software'],['Not specified'],"This paper develops a novel feature selection method (CEFS and CEFS+) based on copula entropy for high-dimensional genetic data. The paper appears to cite cBioPortal only as a reference or potential data source, but does not provide specific details about how cBioPortal was used in the methodology or analysis. The focus is on developing and validating a new computational method for feature selection rather than analyzing cancer genomics data from cBioPortal.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40820100,An efficient and interactive feature selection approach based on copula entropy for high-dimensional genetic data.,2025,pdf,2025-12-19T04:01:06.687266,,,,
"['Gene expression analysis', 'Survival analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Other']",['Original research'],"['TCGA', 'Multiple sources']","The paper appears to use cBioPortal to analyze TRIM31 expression levels in colorectal cancer patients and assess its association with patient prognosis. Based on the abstract mentioning that TRIM31 is highly expressed during colorectal inflammation-cancer transformation and is associated with poor prognosis in CRC patients, cBioPortal was likely used to validate these findings using publicly available datasets. The specific details of cBioPortal usage are not provided in the abstract and introduction sections.",[],"['Web-based analysis', 'Web-based visualization']","['TRIM31', 'YBX1']","['Expression analysis', 'Survival analysis']",cBioPortal platform,medium,4.0,40819060,TRIM31 triggers colorectal carcinogenesis and progression by maintaining YBX1 protein stability through ubiquitination modification.,2025,pdf,2025-12-19T04:01:08.823073,,,,
"['Gene expression analysis', 'Mutation analysis']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The paper appears to use cBioPortal to access and analyze data related to intrahepatic cholangiocarcinoma (iCCA), likely examining TGF-β signaling pathway components and NOX1/NOX4 expression patterns. Based on the research focus on TGF-β signaling and NADPH oxidases in cholangiocarcinoma, cBioPortal was likely used to query gene expression and/or mutation data from TCGA or other databases. However, the abstract and introduction provided do not contain explicit details about specific cBioPortal usage, features employed, or datasets queried.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40820091,NADPH oxidase 1/4 dual inhibition impairs transforming growth factor-beta protumorigenic effects in cholangiocarcinoma cancer-associated fibroblasts.,2025,pdf,2025-12-19T04:01:08.849725,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis']",['Original research'],"['TCGA', 'Custom/Private data']",The authors used cBioPortal to analyze G6PD and NRF2 expression in PanCancer TCGA samples and correlate these with patient survival outcomes. This analysis was performed to validate findings from their MPNST mouse models in human cancer datasets. The study primarily focused on malignant peripheral nerve sheath tumors (MPNSTs) but extended their analysis to pan-cancer TCGA data through cBioPortal.,['TCGA PanCancer'],"['Web-based analysis', 'Web-based visualization']","['G6PD', 'NRF2']","['Expression analysis', 'Survival analysis']",cBioPortal platform,medium,4.0,40802750,Somatic CRISPR tumorigenesis and multiomic analysis reveal a pentose phosphate pathway disruption vulnerability in MPNSTs.,2025,abstract,2025-12-19T04:01:09.550301,,,,
"['Gene expression analysis', 'Survival analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Custom/Private data']","Based on the abstract and introduction, cBioPortal appears to have been used to analyze transcriptomic data from CRC patients to examine TIGIT expression levels and their correlation with survival outcomes (overall and disease-free survival). The platform was likely used to assess the relationship between TIGIT expression and immune infiltration patterns, particularly CD8+ T cells, in colorectal cancer patients.",['TCGA'],"['Web-based analysis', 'Web-based visualization']",['TIGIT'],"['Expression analysis', 'Survival analysis']",Unclear,medium,4.0,40799645,Identification of a TIGIT-expressing CD8<sup>+</sup> T cell subset as a potential prognostic biomarker in colorectal cancer.,2025,abstract,2025-12-19T04:01:09.851093,,,,
"['Gene expression analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy', 'Methods/Tools development', 'Database/Resource']","['Original research', 'Methods/Software']",['Multiple sources'],"Based on the abstract and introduction provided, cBioPortal is not explicitly mentioned in the text. The paper focuses on developing SCAN-ACT, a computational pipeline using single-cell RNA sequencing for adoptive T cell therapy target discovery in soft tissue sarcomas. The methods leverage scRNA-seq and multi-omics data from various public databases, but cBioPortal is not specifically cited in the provided sections. Without access to the full methods section, the exact usage of cBioPortal cannot be determined.",[],['Citation only'],"['MAGE-A4', 'NY-ESO-1']",['Not specified'],Unclear,low,4.0,40814001,SCAN-ACT: adoptive T cell therapy target discovery through single-cell transcriptomics.,2025,pdf,2025-12-19T04:01:09.857776,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal. The authors analyzed TCGA data for TNBC samples to examine SHCBP1 expression and performed survival analysis, but the methods do not specify cBioPortal as the source or analysis platform. The data appears to have been obtained from TCGA directly and analyzed using other bioinformatics tools and databases (GEO, HPA database).",['TCGA'],['Citation only'],"['SHCBP1', 'SHC1', 'PLK1', 'RACGAP1', 'MISP']",['Not specified'],Unclear,low,4.0,40799237,SHCBP1 drives tumor progression in triple-negative breast cancer.,2025,pdf,2025-12-19T04:01:10.133159,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Melanoma'],"['Biomarker discovery', 'Methods/Tools development']",['Original research'],['TCGA'],"The study used TCGA data accessed through cBioPortal to validate candidate biomarkers identified through their Scaffold-free Functional Deconvolution (SFD) approach. Specifically, they used TCGA survival data to analyze the association between identified EV proteins and disease-free survival (DFS) and overall survival (OS) in melanoma patients. This validation step was part of their four-filter workflow to identify high-confidence therapeutic targets.",['TCGA'],['Web-based analysis'],"['ICAM1', 'SPPL2A', 'CD276', 'CD44', 'GDF15']",['Survival analysis'],cBioPortal platform,medium,4.0,40805206,Scaffold-Free Functional Deconvolution Identifies Clinically Relevant Metastatic Melanoma EV Biomarkers.,2025,pdf,2025-12-19T04:01:10.243154,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis']",['Pan-cancer'],"['Methods/Tools development', 'Precision medicine']","['Original research', 'Methods/Software']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal being used in this study. The paper focuses on comparing two cancer genomic profiling tests (FoundationOne CDx and ACTOnco+) using 110 samples from 29 tumor types. The study appears to be a methods comparison paper that does not describe any use of the cBioPortal platform for data analysis or visualization.",[],['Citation only'],"['KIAA1549', 'BRAF']",['Not specified'],Unclear,low,4.0,40796116,Characterization of a novel comprehensive genomic profiling test with better detection of heterozygous deletions and RNA-based gene fusion analysis.,2025,abstract,2025-12-19T04:01:10.913288,,,,
"['Gene expression analysis', 'Copy number analysis', 'Pathway analysis']",['Prostate cancer'],"['Drug response/resistance', 'Biomarker discovery', 'Pathway analysis']",['Original research'],['Multiple sources'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage. The study focuses on ErbB2 signaling in prostate cancer using immunohistochemistry, reverse-phase protein array, and RNA sequencing in cell lines, xenografts, and clinical tumors. If cBioPortal was used, it may have been for querying publicly available datasets for validation purposes, but this is not stated in the provided text.",[],['Citation only'],"['ERBB2', 'NRG1']",['Not specified'],Unclear,low,4.0,40795068,Increased ErbB2 Signaling Is an Early Adaptation to Androgen Signaling Inhibition and Persists in Castration-Resistant Prostate Cancer.,2025,abstract,2025-12-19T04:01:11.976650,,,,
"['Survival analysis', 'Multi-omics integration']","['Colorectal cancer', 'Lung cancer']","['Methods/Tools development', 'Precision medicine']","['Original research', 'Methods/Software']",['TCGA'],The study used The Cancer Genome Atlas (TCGA) data accessed through cBioPortal to obtain genomic and clinical data for colorectal cancer (n=589) and lung adenocarcinoma (n=515) patients. The data was used to train and test machine learning models for classifying multicategory causes of death while evaluating fairness across different sociodemographic groups. The specific mode of cBioPortal usage (data download vs. web-based analysis) is not explicitly detailed in the abstract.,['TCGA'],['Data download/export'],[],['Download data'],External (downloaded data),medium,4.0,40794953,Towards machine learning fairness in classifying multicategory causes of deaths in colorectal or lung cancer patients.,2025,abstract,2025-12-19T04:01:13.002126,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Pan-cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention cBioPortal usage in the abstract or introduction provided. The study analyzed HNRNPA2B1 expression, mutations, amplifications, and other features across 33 cancer types using TCGA and GEO databases with R software. While cBioPortal is cited, there is no clear description of how it was specifically used for data access, analysis, or visualization in the provided text.",['TCGA'],['Citation only'],['HNRNPA2B1'],['Not specified'],Unclear,low,4.0,40792149,Development of a prognostic model based on m6A reader <i>HNRNPA2B1</i> upregulation and immune infiltration in multiple malignant tumors.,2025,abstract,2025-12-19T04:01:14.789667,,,,
"['Gene expression analysis', 'Mutation analysis', 'Copy number analysis']","['Leukemia/Lymphoma', 'Pan-cancer']","['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, the paper does not explicitly describe how cBioPortal was used. The study focuses on systematic genetic screens to identify GAPs and GEFs dependencies in cancer, particularly identifying ARHGAP45 as a targetable dependency in hematopoietic malignancies. While cBioPortal is cited, the specific usage details are not provided in the available text, suggesting it may have been used for accessing cancer genomics data or validating findings across cancer datasets.",[],['Citation only'],"['ARHGAP45', 'CDC42']",['Not specified'],Unclear,low,4.0,40788260,Systematic Evaluation of GAPs and GEFs Identifies a Targetable Dependency for Hematopoietic Malignancies.,2025,abstract,2025-12-19T04:01:15.458275,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Tumor evolution']",['Original research'],['Not specified'],"Based on the abstract and introduction provided, there is no explicit mention of how cBioPortal was used in this study. The paper focuses on mouse models of SHH-medulloblastoma with PTEN mutations and uses scRNA-seq analysis. cBioPortal appears to be cited in the references but specific usage details are not described in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40766638,PTEN restrains SHH medulloblastma growth through cell autonomous and nonautonomous mechanisms.,2025,abstract,2025-12-19T04:01:15.487393,,,,
"['Gene expression analysis', 'Copy number analysis', 'Multi-omics integration']","['Lung cancer', 'Other solid tumor']","['Drug response/resistance', 'Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, cBioPortal usage is not explicitly described in these sections. The paper focuses on characterizing NSD2 inhibitors and their therapeutic efficacy in KRAS-driven pancreatic and lung cancer models through proteo-epigenomic and single-cell strategies. If cBioPortal was used, it would likely be for accessing TCGA or other public cancer genomics data, but specific usage details are not mentioned in the provided text.",[],['Citation only'],"['NSD2', 'KRAS']",['Not specified'],Unclear,low,4.0,40770093,NSD2 inhibitors rewire chromatin to treat lung and pancreatic cancers.,2025,abstract,2025-12-19T04:01:16.092437,,,,
"['Gene expression analysis', 'Pathway analysis']","['Prostate cancer', 'Lung cancer', 'Glioma/Brain cancer']","['Drug response/resistance', 'Pathway analysis', 'Biomarker discovery']",['Original research'],['Not specified'],"The paper cites cBioPortal but does not provide explicit details about how the platform was used in the study. Based on the abstract and introduction alone, it is unclear whether cBioPortal was used for data download, web-based analysis, or merely cited as a reference. The study focuses on experimental investigation of purine metabolism in cancer cells using the prodrug DRP-104 and genetic approaches in prostate, lung, and glioma cancer models.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40788171,Resilience and Vulnerabilities of Tumor Cells under Purine Shortage Stress.,2025,abstract,2025-12-19T04:01:16.521945,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis', 'Multi-omics integration']",['Lung cancer'],"['Tumor evolution', 'Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper analyzed 1,722 lung adenocarcinoma (LUAD) sample genomes from The Cancer Genome Atlas and other projects. While cBioPortal is cited as a source for cancer genomics data, the specific details of how cBioPortal was used are not explicitly described in the abstract and introduction. The analysis focused on comparing mutation rates and selective advantages between ever-smoker and never-smoker LUAD, examining genes like KRAS, KEAP1, STK11, EGFR, PIK3CA, and SMAD4.",['TCGA'],['Data download/export'],"['KRAS', 'KEAP1', 'STK11', 'EGFR', 'PIK3CA', 'SMAD4']",['Download data'],External (downloaded data),medium,4.0,40777438,Tobacco smoke alters the trajectory of lung adenocarcinoma evolution via effects on somatic selection and epistasis.,2025,abstract,2025-12-19T04:01:16.704469,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']","['Colorectal cancer', 'Pan-cancer']","['Biomarker discovery', 'Precision medicine', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","The paper mentions cBioPortal in the context of data collection, stating that TCGA and GEO provided clinical and RNA-seq data for CRC. However, the abstract and introduction do not provide explicit details about how cBioPortal was specifically used for analysis or visualization. The mention appears to be primarily for data sourcing purposes, with the actual analysis conducted using other methods (nonnegative matrix factorization, LASSO regression, etc.).","['TCGA', 'GSE39582']",['Citation only'],"['F2RL2', 'GP1BA', 'MMP10', 'TIMP1']",['Not specified'],Unclear,low,4.0,40777024,Identification of a coagulation-related classification and signature that predict disease heterogeneity for colorectal cancer and pan-cancer patients.,2025,pdf,2025-12-19T04:01:16.751073,,,,
"['Gene expression analysis', 'Pathway analysis', 'Mutation analysis', 'Copy number analysis']",['Melanoma'],"['Biomarker discovery', 'Pathway analysis', 'Immunotherapy']",['Original research'],['TCGA'],"Based on the abstract and introduction provided, the paper appears to analyze melanoma samples classified by filaggrin expression levels to identify signaling and immune signatures. While cBioPortal is cited, the specific details of how it was used are not explicitly described in the provided text. The study likely used cBioPortal to access TCGA melanoma data for profiling genetic, expression, and immune features associated with filaggrin-high versus filaggrin-low melanomas.",['TCGA-SKCM'],['Citation only'],"['FLG', 'FLG2', 'GNA14']",['Not specified'],Unclear,low,4.0,40765578,Filaggrin<sup>High</sup> melanomas exhibit active FGFR and allergic signatures with impaired GNA14 and Th1 signatures.,2025,abstract,2025-12-19T04:01:17.784464,,,,
"['Mutation analysis', 'Gene expression analysis']",['Other solid tumor'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],['TCGA'],The authors used TCGA datasets to analyze TP53 expression and mutation profiles in ovarian cancer. This analysis was performed to characterize the TP53 mutational landscape in the context of their experimental study using fallopian tube-derived ovarian cancer models. The specific details of how cBioPortal was accessed or which features were used are not explicitly described in the provided text.,[],['Citation only'],['TP53'],['Not specified'],Unclear,low,4.0,40760233,Synergistic effects of the curcumin analog HO-3867 and olaparib in transforming fallopian tube epithelial cells.,2025,pdf,2025-12-19T04:01:18.015976,,,,
"['Gene expression analysis', 'Survival analysis']","['Breast cancer', 'Other solid tumor']","['Biomarker discovery', 'Drug response/resistance']",['Original research'],"['TCGA', 'METABRIC']","The authors used cBioPortal to perform bioinformatic analyses examining clinical associations between gene expression levels (Src, NMT1, PBF) and tumor characteristics in breast and thyroid cancers. They analyzed associations between high Src and NMT1 expression with tumor recurrence in RAI-treated thyroid cancers, and examined PBF and Src expression patterns in breast cancer subtypes to identify aggressive tumors that might benefit from targeted RAI therapy. The analyses appear to have utilized TCGA and METABRIC datasets accessed through cBioPortal.","['TCGA', 'METABRIC']","['Web-based analysis', 'Web-based visualization']","['SRC', 'NMT1', 'PTTG1IP']","['Expression analysis', 'Survival analysis', 'Query interface']",cBioPortal platform,medium,4.0,40748136,Targeting Src tyrosine kinase to enhance radioiodide uptake in breast cancer.,2025,abstract,2025-12-19T04:01:19.915670,,,,
,,,,,,,,,,,,,40703801,,,,,No text available,True,True,No text available
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The cBio Cancer Genomics Portal was used as one of several tools for data analysis in this study investigating ferroptosis-related genes in ovarian cancer. The study analyzed tumor mutation burden (TMB), gene expression patterns, and their correlations with survival outcomes. The specific details of how cBioPortal was used are not explicitly described in the abstract, though it is mentioned alongside other analytical tools like TIMER, GSVA, and WGCNA packages.",['TCGA'],['Citation only'],"['IFNG', 'KEAP1', 'PHKG2']",['Not specified'],Unclear,low,4.0,40744688,Integrative Analysis of Novel Ferroptosis-Related Genes Signatures as Prognostic Biomarkers in Ovarian Cancer.,2025,abstract,2025-12-19T04:01:20.402939,,,,
['Other'],['Not specified'],"['Methods/Tools development', 'Review/Commentary']",['Review'],['Not specified'],"This paper is a review/commentary focused on visual perception principles and pre-attentive attributes in oncological data visualization. cBioPortal appears to be mentioned only as an example of existing visualization tools in the oncology domain, without any specific analysis or data usage described. The paper discusses general principles of data visualization design rather than conducting original research using cBioPortal.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40722474,Visual Perception and Pre-Attentive Attributes in Oncological Data Visualisation.,2025,abstract,2025-12-19T04:01:22.239912,,,,
['Mutation analysis'],"['Pancreatic cancer', 'Hepatocellular carcinoma', 'Prostate cancer', 'Bladder cancer', 'Oral squamous cell carcinoma', 'Pan-cancer']","['Biomarker discovery', 'Other']",['Original research'],['Not specified'],"This is a structural biology paper focused on determining the cryo-EM structure of the RalGAP tumor suppressor complex. While the paper discusses cancer-related mutations in RalGAP subunits found in cancer patients, there is no explicit mention of cBioPortal being used for data retrieval, analysis, or visualization. The paper appears to be primarily a structural and mechanistic study rather than a genomics data analysis study.",[],['Citation only'],"['RALGAPA1', 'RALGAPA2', 'RALGAPB', 'KRAS']",['Not specified'],Unclear,low,4.0,40738882,Structure and mechanism of the RalGAP tumor suppressor complex.,2025,pdf,2025-12-19T04:01:22.576509,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']",['Original research'],['TCGA'],"The paper mentions using data from The Cancer Genome Atlas (TCGA) for analyzing HCC tumor tissues through various biostatistical tools. The study identified the EHHADH gene through intersection of differentially expressed genes, metabolism-related genes, and co-expression genes with MICA in HCC. However, the paper does not explicitly mention cBioPortal usage, only TCGA data analysis, suggesting cBioPortal may have been used for data access or is cited as a reference without detailed usage description.",['TCGA'],['Citation only'],"['MICA', 'EHHADH', 'KLRK1']",['Not specified'],Unclear,low,4.0,40723248,MICA+ Tumor Cells Modulate Macrophage Phenotype and Function via PPAR/EHHADH-Mediated Fatty Acid Metabolism in Hepatocellular Carcinoma (HCC).,2025,pdf,2025-12-19T04:01:22.776754,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Mutation analysis']",['Lung cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the methods or results. The study analyzed TIGAR expression, prognosis, and genetic alterations in lung cancer using TCGA data, GEPIA database, and HPA database. While cBioPortal is cited in the references, there is no clear description of how it was used for data access, analysis, or visualization in this study.",['TCGA'],['Citation only'],"['TIGAR', 'TP53']",['Not specified'],Unclear,low,4.0,40719984,TIGAR inhibits glucose-metabolism and cisplatin-chemosensitivity in human lung cancer cells.,2025,pdf,2025-12-19T04:01:23.045555,,,,
"['Gene expression analysis', 'Survival analysis']","['Prostate cancer', 'Breast cancer']","['Biomarker discovery', 'Drug response/resistance']",['Original research'],['Multiple sources'],"The paper analyzed public datasets of metastatic castration-resistant prostate cancer (mCRPC) and breast cancer to examine the relationship between STMN1, HGF, and MET gene expression, overall survival, and response to chemotherapy. cBioPortal was used to access and analyze gene expression data and survival outcomes from metastatic cancer datasets. The analysis focused on determining expression patterns of STMN1 and related genes across different metastatic sites and their association with patient survival.",[],['Web-based analysis'],"['STMN1', 'HGF', 'MET']","['Expression analysis', 'Survival analysis', 'Query interface']",cBioPortal platform,medium,4.0,40723207,Stathmin Serine 16 Phosphorylation Is a Key Regulator of Cell Cycle Progression Without Activating Migration and Invasion In Vitro.,2025,pdf,2025-12-19T04:01:23.475808,,,,
"['Mutation analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['Custom/Private data'],"cBioPortal was used as one of several bioinformatics tools to analyze CTNNB1 gene variants identified from exome sequencing data of 54 hepatoblastoma tissue samples. The platform was employed alongside other databases (CONSURF 3.0, STRING database, and VarElect) for comprehensive molecular and phenotypic analysis of the filtered CTNNB1 variants. The specific features or analysis modes used within cBioPortal are not detailed in the abstract.",[],['Web-based analysis'],['CTNNB1'],['Not specified'],"[""Unclear""]",medium,4.0,40715523,Novel CTNNB1 gene mutations reveal critical pathogenic mechanisms in pediatric hepatoblastoma.,2025,abstract,2025-12-19T04:01:23.721986,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Lung cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],"The paper used cBioPortal to analyze PDE1A expression and its correlation with clinical outcomes in NSCLC patients. The authors likely queried TCGA lung cancer datasets through cBioPortal to examine PDE1A gene expression patterns and perform survival analysis. However, the specific details of cBioPortal usage are not explicitly described in the provided abstract and introduction.",[],['Citation only'],['PDE1A'],['Not specified'],Unclear,low,4.0,40704992,Phosphodiesterase 1A physically interacts with YTHDF2 and reinforces the progression of non-small cell lung cancer.,2025,abstract,2025-12-19T04:01:23.789475,,,,
"['Gene expression analysis', 'Copy number analysis', 'Survival analysis', 'Multi-omics integration', 'Pathway analysis']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, cBioPortal is likely cited as a data source for accessing TCGA brain cancer/glioma data. The study focuses on multi-omics analysis including CNV, methylation, gene expression, and survival analysis in glioma subtypes (LGG and GBM), which are commonly accessed through cBioPortal. However, specific details about how cBioPortal was used are not explicitly mentioned in the provided text.","['TCGA-LGG', 'TCGA-GBM']",['Citation only'],"['CDKN2A', 'CDKN2B', 'CDKN2B-AS1', 'TERT']",['Not specified'],Unclear,low,4.0,40721593,SNP rs615552 and lncRNA CDKN2B-AS1 influence brain cancer pathogenesis through multi-omic mechanisms.,2025,pdf,2025-12-19T04:01:24.745048,,,,
"['Gene expression analysis', 'Survival analysis']",['Lung cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],"Based on the abstract and introduction provided, the paper appears to use cBioPortal to analyze PDL1 expression in lung adenocarcinoma and correlate it with patient prognosis. The study likely accessed TCGA lung adenocarcinoma data through cBioPortal to examine PDL1 expression patterns and survival outcomes. However, specific details about cBioPortal usage are not explicitly mentioned in the provided text.",['TCGA'],['Citation only'],"['PDL1', 'TGFBI', 'CITED2', 'CDKN1A']",['Not specified'],"[""Unclear""]","[""low""]",4.0,40702751,Intrinsic PDL1 Signaling Modulates TGFBI-Mediated Growth Suppression in Lung Adenocarcinoma.,2025,abstract,2025-12-19T04:01:26.239002,,,,
"['Gene expression analysis', 'Survival analysis']",['Melanoma'],"['Biomarker discovery', 'Other']",['Original research'],"['TCGA', 'Multiple sources']",The authors used cBioPortal to access RNA sequencing data from melanoma patients with metastases to analyze the relationship between CypD (PPIF) expression and patient survival. They performed survival analysis comparing patients with low versus high CypD expression in primary tumors and examined CypD expression differences between stage II and stage III melanoma patients. The analysis revealed that lower CypD expression was associated with poorer prognosis and increased metastasis.,[],"['Web-based analysis', 'Web-based visualization']",['PPIF'],"['Survival analysis', 'Expression analysis', 'Group comparison']","[""cBioPortal platform""]",high,4.0,40701956,Pseudohypoxic stabilization of HIF1α via cyclophilin D suppression promotes melanoma metastasis.,2025,pdf,2025-12-19T04:01:27.340158,,,,
['Other'],['Not specified'],['Methods/Tools development'],['Methods/Software'],['Not specified'],"This paper presents Datavzrd, a general-purpose tool for creating interactive visualizations from tabular data across any scientific discipline. While the paper cites cBioPortal, it does not describe any specific usage of cBioPortal for data analysis or visualization. The citation appears to be a reference to related work in the field of data visualization and communication rather than an actual application of cBioPortal in this study.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40694543,Datavzrd: Rapid programming- and maintenance-free interactive visualization and communication of tabular data.,2025,abstract,2025-12-19T04:01:28.463451,,,,
"['Gene expression analysis', 'Mutation analysis', 'Survival analysis', 'Copy number analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used for genomic profiling of FBXO10 in hepatocellular carcinoma. The platform was accessed to analyze genetic alterations, mutations, and copy number variations associated with FBXO10. The study also examined correlations between FBXO10 expression and TP53 mutations using cBioPortal data.",['TCGA'],"['Web-based analysis', 'Web-based visualization']","['FBXO10', 'TP53']","['Query interface', 'Expression analysis']",cBioPortal platform,medium,4.0,40699790,FBXO10 Drives Hepatocellular Carcinoma Proliferation via K63-Linked Ubiquitination and Stabilization of FRMPD1.,2025,pdf,2025-12-19T04:01:28.464780,,,,
"['Gene expression analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Custom/Private data']","Based on the abstract and introduction provided, cBioPortal usage is not explicitly described in these sections. The paper focuses on experimental characterization of lncRNA NRAD1 in triple-negative breast cancer, examining its interactions with miRNAs and effects on gene expression. If cBioPortal was used, it was likely for accessing TCGA breast cancer data for validation or comparative analysis, but specific usage details are not mentioned in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40696096,"LncRNA NRAD1 regulates the triple-negative breast cancer transcriptome by miRNA biogenesis, localization, and predominately non-ceRNA interactions.",2025,pdf,2025-12-19T04:01:29.074261,,,,
"['Mutation analysis', 'Survival analysis', 'Pathway analysis']","['Pan-cancer', 'Lung cancer', 'Colorectal cancer', 'Other solid tumor']","['Methods/Tools development', 'Tumor evolution', 'Biomarker discovery', 'Precision medicine']","['Original research', 'Methods/Software']",['TCGA'],"The paper developed IMOP-Cancer, a computational framework to identify mutation order pairs affecting cancer phenotypes. The study applied this method to TCGA data, analyzing 33 cancer cohorts from the TCGA portal to identify critical mutation pairs. The paper specifically mentions using TCGA-LUAD, TCGA-BLCA, and TCGA-COAD cohorts, along with 33 total TCGA cancer cohorts, suggesting data was obtained from TCGA portal/cBioPortal for external analysis.","['TCGA-LUAD', 'TCGA-BLCA', 'TCGA-COAD']",['Data download/export'],"['CSMD3', 'PTPRD', 'TP53', 'NAV3']",['Download data'],External (downloaded data),medium,4.0,40698865,IMOP-Cancer: identifying mutation order pairs impacting cancer phenotypes.,2025,abstract,2025-12-19T04:01:29.432664,,,,
"['Gene expression analysis', 'Mutation analysis', 'Copy number analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis']","['Original research', 'Clinical study']","['TCGA', 'Multiple sources', 'Custom/Private data']",cBioPortal was used to obtain gene alteration data for DNAJB4 across pan-cancer types. The platform served as one of multiple data sources for genomic profiling analysis alongside the GSCA database. The study integrated cBioPortal data with other bioinformatics resources to comprehensively analyze DNAJB4's role in cancer.,[],['Data download/export'],['DNAJB4'],['Download data'],External (downloaded data),medium,4.0,40694159,Bioinformatic analysis and retrospective clinical study identifying DNAJB4 as a pan-cancer biomarker with a highlight on kidney cancer.,2025,pdf,2025-12-19T04:01:29.789010,,,,
"['Mutation analysis', 'Gene expression analysis']",['Breast cancer'],"['Drug response/resistance', 'Precision medicine', 'Biomarker discovery']","['Original research', 'Clinical study']","['GENIE', 'Custom/Private data']","Based on the abstract and title, this paper focuses on eIF4A as a therapeutic target in ER+ breast cancer, including preclinical models and clinical trial data. While cBioPortal is cited, the abstract does not provide specific details about how cBioPortal was used. It likely was used to query ESR1 mutations and potentially other genomic alterations in breast cancer datasets, but the exact usage mode and features are not explicitly described in the provided text.",[],['Citation only'],['ESR1'],['Not specified'],Unclear,low,4.0,40690678,eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer.,2025,abstract,2025-12-19T04:01:30.402078,,,,
"['Mutation analysis', 'Copy number analysis']",['Breast cancer'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"The paper does not explicitly describe how cBioPortal was used in the study. The abstract and introduction focus on germline genetic testing and tumor-normal targeted sequencing of breast carcinomas associated with microglandular adenosis, but no specific mention of cBioPortal usage, data download, or analysis is provided in the available text. The citation appears to be reference-only without clear methodological details about cBioPortal utilization.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40691172,Breast carcinomas associated with microglandular adenosis are linked to germline alterations in homologous recombination-deficiency genes.,2025,pdf,2025-12-19T04:01:30.916095,,,,
['Other'],['Other solid tumor'],['Review/Commentary'],['Review'],['Not specified'],"This is a review paper focused on O-GlcNAcylation as a therapeutic target for cholangiocarcinoma. Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage. The paper appears to be a literature review summarizing the impact of O-GlcNAcylation on CCA and cancer hallmarks, and cBioPortal may only be cited as a reference without direct usage for data analysis or visualization.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40682838,O‑GlcNAcylation as an emerging molecular target for cholangiocarcinoma therapy (Review).,2025,abstract,2025-12-19T04:01:31.889135,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine', 'Drug response/resistance']",['Original research'],['Multiple sources'],"The paper does not explicitly describe how cBioPortal was used in the study. While the abstract mentions mutation analysis (particularly TP53 mutations) and the development of a prognostic risk model for bladder cancer, there is no clear mention of cBioPortal in the provided abstract and introduction. The study appears to have used data from GeneCards and performed various analyses including ssGSEA, ROC curves, and single-cell sequencing, but the specific role of cBioPortal is not detailed in the provided text.",[],['Citation only'],"['JUN', 'MYC', 'EGFR', 'SLC2A1', 'TP53']",['Not specified'],Unclear,low,4.0,40687655,Leveraging hypoxia-related genes signature for predicting the prognosis of bladder cancer.,2025,abstract,2025-12-19T04:01:32.283145,,,,
"['Gene expression analysis', 'Survival analysis', 'Copy number analysis', 'Mutation analysis', 'Multi-omics integration', 'Pathway analysis']","['Breast cancer', 'Pan-cancer']","['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The paper integrated multi-omics data from TCGA and other databases to analyze OTUD6B-AS1 expression and clinical relevance in breast cancer. Genomic analysis revealed frequent amplification of OTUD6B-AS1 and co-occurrence of PIK3CA mutations, suggesting cBioPortal was likely used for copy number and mutation analysis. The specific details of cBioPortal usage are not explicitly described in the abstract, indicating it may have been used for data access or cited as a data source.",['TCGA'],['Citation only'],"['OTUD6B-AS1', 'PIK3CA', 'GPX4', 'SLC7A11']",['Not specified'],Unclear,low,4.0,40678154,Dual role of lncRNA OTUD6B-AS1 in immune evasion and ferroptosis resistance: A prognostic and therapeutic biomarker in breast cancer.,2025,abstract,2025-12-19T04:01:34.454195,,,,
"['Mutation analysis', 'Survival analysis']",['Lung cancer'],"['Drug response/resistance', 'Precision medicine']",['Original research'],['TCGA'],"The paper references TCGA data to support their findings that L858R-EGFR mutations are associated with worse overall survival in lung cancer patients. The cBioPortal usage appears to be for validation purposes, comparing their experimental results with clinical data from TCGA. The specific details of how cBioPortal was accessed or which features were used are not explicitly described in the abstract.",['TCGA'],['Citation only'],['EGFR'],['Not specified'],Unclear,low,4.0,40673101,Response of non-small cell lung cancer harboring different epidermal growth factor receptor mutations to ablative radiotherapy.,2025,abstract,2025-12-19T04:01:34.778012,,,,
['Gene expression analysis'],"['Pancreatic cancer', 'Melanoma', 'Medulloblastoma']","['Drug response/resistance', 'Immunotherapy', 'Methods/Tools development']",['Original research'],['Not specified'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on developing and testing an antibody-based RNA delivery platform (TMAB3) for cancer therapy using mouse models. The study employs single-cell RNA sequencing and flow cytometry for analysis, but does not reference cBioPortal for data access, analysis, or visualization.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40668891,Systemic administration of an RNA binding and cell-penetrating antibody targets therapeutic RNA to multiple mouse models of cancer.,2025,abstract,2025-12-19T04:01:35.050196,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used as the primary data source to collect genomic and transcriptomic data for 13 EMT-related genes (CDH1, CDH2, CTNNB1, LEF1, NOTCH1, SNAI1, SNAI2, SOX2, TJP1/ZO1, TWIST1, VIM, ZEB1, and ZEB2) across different glioma subtypes. The authors extracted information on mutations, copy number alterations (CNA), and transcript level changes for these genes from cBioPortal. The data was then analyzed to identify associations between gene alterations and low-grade versus high-grade gliomas, and validated using additional platforms (GlioVis) and experimental methods (qRT-PCR).",[],"['Data download/export', 'Web-based analysis', 'Query interface']","['CDH1', 'CDH2', 'CTNNB1', 'LEF1', 'NOTCH1', 'SNAI1', 'SNAI2', 'SOX2', 'TJP1', 'TWIST1', 'VIM', 'ZEB1', 'ZEB2']","['Query interface', 'Download data', 'Expression analysis']","[""External (downloaded data)""]",high,4.0,40679044,<i>In silico</i> analysis reveals distinct changes in markers of epithelial to mesenchymal transition in glioma subtypes.,2025,abstract,2025-12-19T04:01:35.134511,,,,
"['Mutation analysis', 'Survival analysis']",['Other solid tumor'],"['Drug response/resistance', 'Precision medicine', 'Biomarker discovery']","['Clinical study', 'Original research']",['Custom/Private data'],"This clinical trial study of uterine carcinosarcoma patients treated with adavosertib (Wee1 inhibitor) mentions that molecular alterations were identified by targeted next generation sequencing. The paper does not explicitly describe using cBioPortal for data analysis or visualization. If cBioPortal was used, it was likely for reference purposes or background information on TP53 mutations in uterine carcinosarcoma, but no specific usage is detailed in the abstract.",[],['Citation only'],['TP53'],['Not specified'],Unclear,low,4.0,40678577,Phase 2 study of Wee1 inhibitor adavosertib in recurrent uterine carcinosarcoma.,2025,abstract,2025-12-19T04:01:35.452032,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Copy number analysis', 'Pathway analysis']","['Pan-cancer', 'Colorectal cancer']","['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The study used cBioPortal to investigate SREBF1's role across multiple cancer types through pan-cancer analysis. The authors likely queried SREBF1 expression, survival data, and genetic alterations (mutations and copy number variations) across cancer types, with particular focus on colorectal cancer. cBioPortal was used as one of multiple databases integrated in the systematic investigation of SREBF1's heterogeneous characteristics across cancers.",[],"['Web-based analysis', 'Web-based visualization']",['SREBF1'],"['Expression analysis', 'Survival analysis', 'Not specified']",Unclear,medium,4.0,40668814,Unraveling SREBF1's role in elevating colorectal cancer prognosis through proliferation and migration inhibition.,2025,abstract,2025-12-19T04:01:36.954562,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine']",['Original research'],['TCGA'],"The paper mentions using TCGA database to obtain RNA transcriptome sequencing data, somatic mutation data, and clinical information for bladder cancer patients. However, the abstract and introduction do not explicitly mention cBioPortal usage. It appears the authors accessed TCGA data directly from the GDC portal (https://portal.gdc.cancer.gov/) rather than through cBioPortal. The citation of cBioPortal may be for reference purposes only or usage details may be in the methods section not provided.",['TCGA-BLCA'],['Citation only'],['MYH11'],['Not specified'],Unclear,low,4.0,40665008,Developing angiogenesis-related prognostic biomarkers and therapeutic strategies in bladder cancer using deep learning and machine learning.,2025,pdf,2025-12-19T04:01:37.307230,,,,
"['Gene expression analysis', 'Survival analysis']","['Breast cancer', 'Glioma/Brain cancer']","['Methods/Tools development', 'Biomarker discovery']","['Methods/Software', 'Original research']","['TCGA', 'Multiple sources']","The paper develops a robust transfer learning method for high-dimensional GLM analysis and validates it using cancer genomics data. The method is applied to breast cancer and glioblastoma data, likely obtained from TCGA through cBioPortal. However, the abstract and introduction do not provide explicit details about how cBioPortal was specifically used in the study.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40662636,"Robust Transfer Learning for High-Dimensional GLM Using <math xmlns=""http://www.w3.org/1998/Math/MathML""> <semantics><mrow><mi>γ</mi></mrow> <annotation>$$ \gamma $$</annotation></semantics> </math> -Divergence With Applications to Cancer Genomics.",2025,abstract,2025-12-19T04:01:37.496254,,,,
"['Copy number analysis', 'Gene expression analysis', 'Pathway analysis']",['Other solid tumor'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],['TCGA'],"The paper mentions TCGA data showing that MECOM is copy number amplified in >5% of various cancer cases and references copy number amplification of oncogenes (CCNE1, KRAS, MECOM, MAPK1) in >10% of ovarian cancer patients (n=489). However, the paper does not explicitly describe using cBioPortal platform for data access or analysis. The reference to TCGA data appears to be general background information rather than detailed cBioPortal usage.",[],['Citation only'],"['MECOM', 'KRAS', 'CCNE1', 'MAPK1']",['Not specified'],Unclear,low,4.0,40664642,Epigenetic targeting of MECOM/KRAS axis by JIB-04 impairs tumorigenesis and cisplatin resistance in MECOM-amplified ovarian cancer.,2025,pdf,2025-12-19T04:01:37.828439,,,,
['Mutation analysis'],['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']","['Clinical study', 'Original research']",['Multiple sources'],"The authors performed a gene query analysis using cBioPortal to examine FLCN pathogenic variant prevalence across 2,285 thyroid cancer patients. The analysis revealed that FLCN pathogenic variants were present in 2% of sporadic thyroid cancers overall, but this prevalence increased to 23% in anaplastic thyroid cancers. This cBioPortal query was used to contextualize their case series findings and explore the potential role of FLCN mutations in aggressive thyroid cancers.",[],"['Web-based analysis', 'Query interface']",['FLCN'],['Query interface'],cBioPortal platform,high,4.0,40658617,Thyroid Carcinoma in Birt-Hogg-Dubé Syndrome: Case Series and Review of Literature.,2025,abstract,2025-12-19T04:01:38.239593,,,,
"['Mutation analysis', 'Gene expression analysis']",['Breast cancer'],"['Biomarker discovery', 'Other']",['Original research'],"['MSK-IMPACT', 'Multiple sources']",The authors used cBioPortal to curate and identify missense mutations occurring in core histone genes in breast cancers from MSK-IMPACT data. They specifically identified high frequency breast cancer-associated histone gene mutations and examined co-occurrence patterns with PIK3CA mutations. The data was used to select 17 high frequency oncohistone mutations for subsequent functional characterization in cell-based assays.,['MSK-IMPACT'],"['Data download/export', 'Web-based analysis']","['H2A', 'H2B', 'H3', 'PIK3CA']","['Query interface', 'Download data']","[""External (downloaded data)""]",high,4.0,40654790,Phenotypic and Functional Characterization of Oncohistone Mutations in Breast Cancers.,2025,abstract,2025-12-19T04:01:40.182803,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the methodology. The authors collected data from UCSC Xena tool and GEO database, used GEPIA2 for gene expression and survival analysis, STRING for protein-protein interactions, and TIMER 2.0 for immune infiltration analysis. While cBioPortal is cited in the references, there is no clear description of how it was used in this study.",['TCGA'],['Citation only'],['BIRC5'],['Not specified'],Unclear,low,4.0,40653567,Machine learning modeling and analysis of prognostic hub genes in cervical adenocarcinoma: a multi target therapy for enhancement in immunosurveillance.,2025,pdf,2025-12-19T04:01:41.276942,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis']",['Other solid tumor'],"['Pathway analysis', 'Other']",['Original research'],['Custom/Private data'],"cBioPortal was used to identify somatic mutations in IRE1α (ERN1 gene) that occur in human cancers, particularly non-melanoma skin cancer (NMSC). The authors queried cBioPortal to find cancer-associated mutations in IRE1α to guide their experimental design for generating keratinocyte cell lines with these specific mutations. The study then characterized these mutations functionally in vitro using engineered mouse keratinocytes.",[],['Web-based analysis'],['ERN1'],['Query interface'],External (downloaded data),medium,4.0,40654133,Somatic mutations in IRE1α regulate keratinocyte migration and survival by differentially activating Rho GTPases.,2025,abstract,2025-12-19T04:01:41.454068,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']",The cBioPortal database was used to calculate the mutation frequency of LAG3 in the TCGA cohort. The paper mentions accessing cBioPortal for mutation data analysis as part of their comprehensive pan-cancer analysis of LAG3. The specific details of how the mutation data was extracted or analyzed are not fully described in the provided text.,['TCGA'],['Web-based analysis'],['LAG3'],['Query interface'],External (downloaded data),medium,4.0,40646089,Multomic analysis reveals the potential of LAG3 as a prognostic and immune biomarker and its validation in osteosarcoma.,2025,pdf,2025-12-19T04:01:41.537487,,,,
"['Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis', 'Tumor evolution', 'Immunotherapy']",['Original research'],"['TCGA', 'Custom/Private data', 'Multiple sources']",The paper appears to use cBioPortal primarily for accessing and analyzing TCGA esophageal adenocarcinoma data to validate their novel CIN signature (CIN^MN) and assess patient outcomes. The study likely queried cGAS-STING pathway components and chemokine genes (particularly CXCL8) to examine their expression patterns and correlations with chromosomal instability metrics. cBioPortal was used to access genomic and transcriptomic data from public datasets to complement their novel experimental models and patient cohort analyses.,['TCGA'],"['Data download/export', 'Web-based analysis']",['CXCL8'],"['Expression analysis', 'Survival analysis', 'Download data']",Mixed,medium,4.0,40654626,Chromosomal instability shapes the tumor microenvironment of esophageal adenocarcinoma via a cGAS-chemokine-myeloid axis.,2025,abstract,2025-12-19T04:01:42.332089,,,,
"['Mutation analysis', 'Survival analysis']",['Pan-cancer'],"['Methods/Tools development', 'Biomarker discovery', 'Precision medicine']","['Original research', 'Methods/Software']",['Multiple sources'],"The paper does not explicitly describe how cBioPortal was used in the study. Based on the abstract and introduction, the authors developed RESOLVE, a new framework for mutational signature analysis, and applied it to 20,000 adult and pediatric cancer samples. While cBioPortal is cited, there is no clear indication in the provided text of whether data was downloaded from cBioPortal, whether the platform was used for analysis, or what specific role it played in the study.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40637234,Comprehensive analysis of mutational processes across 20 000 adult and pediatric tumors.,2025,abstract,2025-12-19T04:01:43.116800,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy', 'Precision medicine']","['Original research', 'Clinical study']","['METABRIC', 'Custom/Private data', 'Multiple sources']","The study used cBioPortal to access METABRIC and SCAN-B datasets for validation of their findings from digital spatial profiling. They analyzed the prognostic utility of genes and pathways identified in their primary cohort by examining survival outcomes in these external datasets. Additionally, they analyzed I-SPY 2 trial data to understand the influence of target genes on therapy response.","['METABRIC', 'SCAN-B']",['Data download/export'],[],"['Download data', 'Survival analysis']",External (downloaded data),medium,4.0,40640880,Spatial profiling reveals unique immune microenvironment in premenopausal triple-negative breast cancer associated with therapy response.,2025,pdf,2025-12-19T04:01:44.580247,,,,
"['Gene expression analysis', 'Mutation analysis']","['Colorectal cancer', 'Other solid tumor']","['Biomarker discovery', 'Drug response/resistance']",['Original research'],"['TCGA', 'Multiple sources']","The paper used cBioPortal to analyze RNase H2 subunit expression levels across different cancer types. The authors queried RNASEH2A, RNASEH2B, and RNASEH2C gene expression data from TCGA datasets to examine upregulation patterns in various cancers including colorectal cancer. This analysis provided evidence that RNase H2 subunits are elevated in some cancers, supporting their experimental findings on RNase H2 upregulation in response to replication stress.",['TCGA'],"['Web-based analysis', 'Web-based visualization']","['RNASEH2A', 'RNASEH2B', 'RNASEH2C']","['Expression analysis', 'Query interface']",cBioPortal platform,medium,4.0,40640336,Human RNase H2 upregulation counteracts oncogene- and chemotherapy-induced replication stress.,2025,pdf,2025-12-19T04:01:45.055098,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Copy number analysis', 'Pathway analysis']",['Pan-cancer'],['Biomarker discovery'],['Original research'],"['TCGA', 'Multiple sources']","The paper mentions using multiple public databases including TCGA for comprehensive analysis of ZNF433 across cancers. While cBioPortal is not explicitly mentioned in the provided abstract and introduction, the study's methodology of analyzing TCGA data for expression patterns, genetic mutations, survival outcomes, and immune microenvironment interactions suggests potential use of cBioPortal or similar platforms for accessing and analyzing TCGA data. However, specific details about cBioPortal usage are not provided in the excerpted sections.",['TCGA'],['Citation only'],"['ZNF433', 'BAP1', 'KDM5C', 'ALOX5']",['Not specified'],Unclear,low,4.0,40636694,Multidimensional analysis suggests that ZNF433 is a promising biomarker for the diagnosis and prognosis of human cancers.,2025,pdf,2025-12-19T04:01:45.290870,,,,
"['Gene expression analysis', 'Pathway analysis', 'Survival analysis']",['Prostate cancer'],"['Methods/Tools development', 'Biomarker discovery']","['Methods/Software', 'Original research']","['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this paper. The paper focuses on developing DiCE, a novel computational method that combines differential expression analysis with network centrality measures using PPI networks. While the paper may cite cBioPortal in the references, the provided text does not describe any specific use of the cBioPortal platform for data access, analysis, or visualization.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40626556,DiCE: differential centrality-ensemble analysis based on gene expression profiles and protein-protein interaction network.,2025,abstract,2025-12-19T04:01:45.467872,,,,
"['Gene expression analysis', 'Survival analysis']","['Pan-cancer', 'Leukemia/Lymphoma']","['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to perform pan-cancer analysis examining the association of CARF (Collaborator of ARF) with prognosis and survival of lymphoma patients. The study utilized cBioPortal to analyze CARF expression patterns and survival outcomes across multiple cancer types, with particular focus on lymphoma.",[],"['Web-based analysis', 'Web-based visualization']","['CARF', 'TP53']","['Expression analysis', 'Survival analysis']",Unclear,medium,4.0,40619590,Phosphorylation-Dependent Stabilization of Collaborator of ARF (CARF) Suppresses Lymphoma Cell Proliferation.,2025,abstract,2025-12-19T04:01:46.601631,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']",['Original research'],"['TCGA', 'Custom/Private data', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the methods or results. While TCGA-PAAD data was analyzed for gene expression and survival analysis, there is no clear indication that cBioPortal was used to access or analyze this data. The citation of cBioPortal may be for reference purposes only or the usage is not clearly described in the provided text.","['TCGA-PAAD', 'GSE212966']",['Citation only'],['TNFSF4'],['Not specified'],Unclear,low,4.0,40624624,Integrated analysis of polytranscriptomics reveals TNFSF ligand genes in pancreatic cancer prognosis and immune regulation.,2025,pdf,2025-12-19T04:01:47.788134,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Other solid tumor'],"['Drug response/resistance', 'Biomarker discovery', 'Precision medicine']",['Original research'],['Multiple sources'],"The paper used cBioPortal to analyze multicenter patient data for pancreatic ductal adenocarcinoma, specifically examining TP53 missense mutations and their associations with clinical outcomes and molecular features. The study integrated data from multiple sources through cBioPortal to characterize distinct TP53 mutant variants (R273H/C vs R248W/Q) and their relationships with cell cycle progression and basal-like states. cBioPortal served as a key platform for accessing and analyzing patient genomic and clinical data to support the study's findings on mutation-specific therapeutic vulnerabilities.",[],"['Web-based analysis', 'Data download/export']",['TP53'],"['Query interface', 'Group comparison']","[""Mixed""]",medium,4.0,40614202,<i>TP53</i> missense-specific transcriptional plasticity drives resistance against cell cycle inhibitors in pancreatic cancer.,2025,abstract,2025-12-19T04:01:48.028348,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Pathway analysis']","['Colorectal cancer', 'Other solid tumor']",['Biomarker discovery'],['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the methods or results sections. The data was obtained directly from TCGA portal (https://portal.gdc.cancer.gov) and GEO database, with analyses performed using R packages (DESeq2, survival, ggplot2). While cBioPortal may be cited in references, there is no clear evidence of its direct use for data access, analysis, or visualization in this study.","['TCGA-COAD', 'TCGA-ESCA', 'TCGA-LIHC', 'TCGA-PAAD', 'TCGA-READ', 'TCGA-STAD', 'GSE23878', 'GSE110224', 'GSE29001', 'GSE144269', 'GSE62165', 'GSE103236']",['Citation only'],['TNNT1'],['Not specified'],Unclear,low,4.0,40616171,Epigenetic regulation of TNNT1 in gastrointestinal cancers prognostic implications and clinical significance.,2025,pdf,2025-12-19T04:01:48.275985,,,,
['Gene expression analysis'],['Glioma/Brain cancer'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],['Not specified'],"The paper mentions that TGM2 mRNA expression in glioblastoma was analyzed and found to be primarily in a subset of tumor-infiltrating myeloid cells with hypoxia gene expression signatures. However, the abstract and introduction do not provide specific details about how cBioPortal was used, what datasets were queried, or what specific features were utilized. The usage appears to be for gene expression analysis in glioblastoma samples.",[],['Citation only'],['TGM2'],['Not specified'],Unclear,low,4.0,40610434,Transglutaminase 2 function in glioblastoma tumor efferocytosis.,2025,pdf,2025-12-19T04:01:48.543146,,,,
"['Gene expression analysis', 'Mutation analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']",cBioPortal was used to analyze SNRPB2 mRNA expression levels and genetic alterations in esophageal cancer (ESCA). The platform was mentioned alongside GEPIA2 as a tool for examining SNRPB2 expression patterns and genomic changes in ESCA patient samples. The analysis was part of a broader investigation into SNRPB2's clinical relevance and prognostic value in esophageal squamous cell carcinoma.,[],['Web-based analysis'],['SNRPB2'],"['Expression analysis', 'Query interface']",cBioPortal platform,medium,4.0,40612943,SNRPB2 facilitates esophageal squamous cell carcinoma oncogenesis and progression via E2F4 stabilization.,2025,pdf,2025-12-19T04:01:49.217411,,,,
['Other'],['Pan-cancer'],"['Review/Commentary', 'Methods/Tools development', 'Database/Resource']",['Review'],['Not specified'],"This is a review paper discussing informatics technologies in cancer research. cBioPortal is mentioned as one of the important data repositories and analysis platforms in the cancer genomics landscape, but no specific analysis or data usage from cBioPortal is described. The paper provides a broad overview of computational methods and tools in cancer research rather than demonstrating specific cBioPortal usage.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40600473,Informatics at the Frontier of Cancer Research.,2025,abstract,2025-12-19T04:01:51.156802,,,,
['Other'],['Not specified'],['Database/Resource'],['Original research'],['Not specified'],"This paper evaluates the accessibility of life sciences data resources for people with disabilities. cBioPortal appears to be included as one of the data portals evaluated for accessibility issues, but the paper does not describe any specific use of cBioPortal's genomic analysis features. The focus is on assessing web accessibility barriers rather than conducting cancer genomics research using cBioPortal.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40604187,A comprehensive evaluation of life sciences data resources reveals significant accessibility barriers.,2025,pdf,2025-12-19T04:01:51.995890,,,,
"['Mutation analysis', 'Survival analysis', 'Gene expression analysis', 'Pathway analysis']","['Other solid tumor', 'Pan-cancer']","['Biomarker discovery', 'Immunotherapy', 'Drug response/resistance']","['Original research', 'Clinical study']","['Multiple sources', 'Custom/Private data']","The paper does not explicitly describe how cBioPortal was used in the study. While the study focuses on PPP2R1A mutations and immunotherapy response in ovarian clear cell carcinoma and validates findings across multiple cancer types, there is no clear mention of cBioPortal usage in the provided abstract and introduction sections. The paper appears to primarily use custom clinical trial data and may have cited cBioPortal as a reference resource.",[],['Citation only'],['PPP2R1A'],['Not specified'],Unclear,low,4.0,40604275,PPP2R1A mutations portend improved survival after cancer immunotherapy.,2025,pdf,2025-12-19T04:01:52.398212,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the methods or results. The abstract and introduction mention using TCGA and GEO databases, along with specific tools like Oncomine, TIMER, GEPIA, BioGPS, Kaplan-Meier plotter, PrognoScan, SangerBox, and UALCAN databases for various analyses. While cBioPortal is cited, there is no clear description of how it was specifically used in this study.",['TCGA'],['Citation only'],"['PABPN1', 'MRPS15', 'PCBP1', 'PTPRF', 'DANCR', 'MYC']",['Not specified'],Unclear,low,4.0,40607380,PABPN1 as a pan-cancer biomarker: prognostic significance and association with tumor immune microenvironment.,2025,pdf,2025-12-19T04:01:52.742926,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']",['Original research'],['TCGA'],"The paper does not explicitly mention using cBioPortal in the abstract or introduction provided. The study extracted RNA-seq transcriptome data and clinical information for 328 OSCC patients from the TCGA database, but there is no clear indication that cBioPortal was used as the data access method. The citation of cBioPortal may be in the references without specific usage details in the methodology described.",['TCGA'],['Citation only'],"['IGF2BP2', 'HNRNPC', 'NAT10', 'TRMT61B']",['Not specified'],Unclear,low,4.0,40597017,Bioinformatics identification and validation of m6A/m1A/m5C/m7G/ac4 C-modified genes in oral squamous cell carcinoma.,2025,pdf,2025-12-19T04:01:52.888643,,,,
"['Gene expression analysis', 'Survival analysis']",['Prostate cancer'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],['Not specified'],"The paper mentions using Kaplan-Meier analysis to assess the association of AR/ZFHX3 expression with patient survival in prostate cancer patients. The analysis showed that higher AR expression levels correlated with worse disease-free survival only in lower-ZFHX3 prostate cancer patients. However, the paper does not provide specific details about how cBioPortal was accessed or which specific datasets were used for this survival analysis.",[],['Citation only'],"['AR', 'ZFHX3']",['Not specified'],Unclear,low,4.0,40596315,ZFHX3 is integral to androgen/AR signaling involving protein association with AR in prostate cancer cells.,2025,pdf,2025-12-19T04:01:53.829238,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Precision medicine', 'Immunotherapy']",['Original research'],"['TCGA', 'METABRIC']","cBioPortal was used as one of the data access platforms to obtain the METABRIC breast cancer dataset. The paper states that both TCGA-BRCA and METABRIC datasets were accessed through cBioPortal and UCSC Xena platforms. The METABRIC dataset (1,980 tumor samples) was used as an external validation cohort for the three-gene prognostic signature.","['TCGA-BRCA', 'METABRIC']",['Data download/export'],"['CLIC6', 'SUSD3', 'LTF']",['Download data'],External (downloaded data),high,4.0,40591124,Decoding breast cancer heterogeneity: a novel three-gene signature links intratumoral heterogeneity with tumor microenvironment and patient outcomes.,2025,pdf,2025-12-19T04:01:54.645518,,,,
"['Gene expression analysis', 'Mutation analysis']",['Hepatocellular carcinoma'],"['Immunotherapy', 'Review/Commentary']",['Review'],['Not specified'],"This is a review paper on TCR-based cellular immunotherapy for hepatocellular carcinoma. The paper cites cBioPortal but does not describe any specific usage of the platform for data analysis or visualization. The citation appears to be for reference purposes only, without detailed description of how cBioPortal was utilized in the context of this review.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40590989,"TCR-based cellular immunotherapy for hepatocellular carcinoma: advances, challenges, and prospects.",2025,pdf,2025-12-19T04:01:54.866241,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Lung cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],"The paper does not explicitly mention using cBioPortal in the abstract or introduction provided. The study analyzed MEF-2 family members in NSCLC using TCGA database for survival analysis and performed various bioinformatic analyses including gene expression, survival analysis, GSEA, GO, and KEGG pathway enrichment. While cBioPortal is cited, the specific usage details are not described in the provided text.",['TCGA'],['Citation only'],"['MEF2A', 'MEF2B', 'MEF2C', 'MEF2D']",['Not specified'],Unclear,low,4.0,40589937,A Comprehensive Bioinformatic Analysis Based on Functional Studies of MEF-2 Family in NSCLC.,2025,abstract,2025-12-19T04:01:55.332310,,,,
['Gene expression analysis'],['Breast cancer'],"['Drug response/resistance', 'Pathway analysis']",['Original research'],['Not specified'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on experimental validation using RNA interference, cell function experiments, qPCR, and Western blotting in MDA-MB-231 cells. While cBioPortal is cited, the specific usage details are not described in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40585842,NOTCH1 combined with chemotherapy synergistically inhibits triple-negative breast cancer.,2025,abstract,2025-12-19T04:01:57.288421,,,,
['Other'],"['Pan-cancer', 'Other solid tumor']","['Review/Commentary', 'Drug response/resistance', 'Pathway analysis']",['Review'],['Not specified'],"This is a review paper on targeting the Hippo pathway in cancer. Based on the title, authors, venue, and abstract/introduction provided, there is no explicit mention of cBioPortal usage. The paper discusses Hippo pathway signaling, its role in cancer (particularly solid tumors like mesothelioma), and therapeutic strategies targeting YAP/TAZ-TEAD interactions. cBioPortal may be cited as a reference resource but no specific usage details are provided in the available text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40588515,Targeting the Hippo pathway in cancer.,2025,abstract,2025-12-19T04:01:58.191470,,,,
"['Gene expression analysis', 'Multi-omics integration']","['Pan-cancer', 'Breast cancer']","['Biomarker discovery', 'Methods/Tools development', 'Precision medicine']","['Original research', 'Methods/Software']","['TCGA', 'Custom/Private data', 'Multiple sources']","Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on developing cfMethylPre, a deep transfer learning framework for cancer detection using cfDNA methylation data. The model was pretrained on bulk DNA methylation data from 2801 samples across 82 cancer types. While TCGA data may have been used (a common source for bulk methylation data), cBioPortal is not mentioned in the provided text.",[],['Citation only'],"['PCDHA10', 'PRICKLE2', 'PRTG']",['Not specified'],Unclear,low,4.0,40581983,cfMethylPre: deep transfer learning enhances cancer detection based on circulating cell-free DNA methylation profiling.,2025,abstract,2025-12-19T04:01:59.144072,,,,
"['Mutation analysis', 'Copy number analysis']",['Breast cancer'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on analyzing germline alterations in homologous recombination-deficiency genes in breast carcinomas associated with microglandular adenosis using paired tumor-normal targeted sequencing. If cBioPortal was used, it is not described in the sections provided.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40585243,Breast carcinomas associated with microglandular adenosis are linked to germline alterations in homologous recombination-deficiency genes.,2025,pdf,2025-12-19T04:01:59.435604,,,,
"['Gene expression analysis', 'Other']",['Breast cancer'],"['Immunotherapy', 'Biomarker discovery']",['Original research'],['Custom/Private data'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on developing and testing a citrullinated ENO1 vaccine in a mouse model of triple-negative breast cancer. The research involves proteomic analysis of breast cancer cell lines and in vivo vaccine efficacy studies, but does not describe any use of cBioPortal for data analysis, visualization, or data download.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40573960,Citrullinated ENO1 Vaccine Enhances PD-1 Blockade in Mice Implanted with Murine Triple-Negative Breast Cancer Cells.,2025,pdf,2025-12-19T04:01:59.790348,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Bladder cancer', 'Lung cancer']","['Biomarker discovery', 'Immunotherapy', 'Drug response/resistance']",['Original research'],"['TCGA', 'Multiple sources']","The paper mentions collecting data from The Cancer Genome Atlas (TCGA) for their pan-cancer analysis. While cBioPortal is cited as a cancer genomics data portal, the specific details of how cBioPortal was used are not provided in the abstract and introduction sections. The study appears to have used TCGA data which is commonly accessed through cBioPortal, but the exact usage mode and features utilized are not explicitly described in the provided text.",['TCGA'],['Citation only'],"['EGFR', 'CTLA4', 'PD-1', 'PD-L1', 'CD8']",['Not specified'],Unclear,low,4.0,40574864,Comprehensive analysis of single-cell and bulk RNA sequencing data reveals an EGFR signature for predicting immunotherapy response and prognosis in pan-cancer.,2025,pdf,2025-12-19T04:02:00.317435,,,,
"['Mutation analysis', 'Multi-omics integration', 'Pathway analysis']","['Pan-cancer', 'Breast cancer']","['Drug response/resistance', 'Methods/Tools development', 'Precision medicine']","['Original research', 'Methods/Software']","['GDSC', 'CTRP', 'NCI60', 'Multiple sources']","The paper does not explicitly describe using cBioPortal for data analysis or visualization. While the paper focuses on cancer genomics and drug response, and cBioPortal is cited in the references, there is no clear description in the abstract or introduction of how cBioPortal was specifically utilized in this study. The model (G2D-Diff) uses somatic alteration genotypes and drug response data from sources like GDSC, CTRP, and NCI60, but cBioPortal usage is not detailed.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40593549,A genotype-to-drug diffusion model for generation of tailored anti-cancer small molecules.,2025,pdf,2025-12-19T04:02:00.698610,,,,
"['Gene expression analysis', 'Mutation analysis', 'Pathway analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],['TCGA'],"The paper does not explicitly describe using cBioPortal for data access or analysis. While the study analyzes CRC cohorts for genomic and expression data including TP53 mutations, MSI status, PARP1/PARP2 expression, and performs gene set enrichment analyses, there is no mention of cBioPortal in the provided abstract and introduction sections. The citation of cBioPortal may be in the references but specific usage is not described in the available text.",[],['Citation only'],"['PARP1', 'PARP2', 'TP53', 'ATM', 'BRCA1', 'BRCA2', 'BRAF']",['Not specified'],Unclear,low,4.0,40573300,PARP Inhibition in Colorectal Cancer-A Comparison of Potential Predictive Biomarkers for Therapy.,2025,pdf,2025-12-19T04:02:01.296258,,,,
"['Gene expression analysis', 'Survival analysis']",['Breast cancer'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],"['TCGA', 'METABRIC']","The authors downloaded two datasets from cBioPortal: the METABRIC dataset (n=2509) on March 29, 2022, and the TCGA Pan-Cancer Atlas dataset (n=1084) on July 15, 2024. Both datasets contained disease-specific survival (DSS) and mRNA expression level data, which were used to perform Kaplan-Meier survival analyses and Cox proportional hazard analyses to examine the relationship between PKCζ and CTNNBIP1 expression and prognosis in luminal B breast cancer patients treated with endocrine therapy.","['METABRIC', 'TCGA Pan-Cancer Atlas']",['Data download/export'],"['PRKCZ', 'CTNNBIP1', 'MKI67']",['Download data'],External (downloaded data),high,4.0,40571311,High Expression of <i>PKCζ</i> And <i>CTNNBIP1</i> Is Associated With Poor Prognosis in Luminal B Breast Cancer.,2025,pdf,2025-12-19T04:02:02.764748,,,,
"['Copy number analysis', 'Survival analysis', 'Multi-omics integration']",['Pan-cancer'],"['Drug response/resistance', 'Precision medicine', 'Biomarker discovery']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the abstract or introduction provided. The study integrates TCGA data (10,967 samples, 16,948 aneuploidy events) with the Broad Institute's PRISM screen to identify treatment strategies targeting aneuploid cancers. While cBioPortal is cited, the specific usage details are not described in the provided text, suggesting it may have been used for data access or cited as a reference resource.",['TCGA'],['Citation only'],"['TP53', 'ERBB2', 'BRCA1', 'BRCA2', 'BECN1', 'PTEN']",['Not specified'],"[""Unclear""]",low,4.0,40565600,Half the Chromosome It Used to Be: Identifying Cancer Treatments Targeting Aneuploid Losses.,2025,pdf,2025-12-19T04:02:02.954499,,,,
"['Mutation analysis', 'Gene expression analysis', 'Multi-omics integration']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on integrated proteomic and targeted Next Generation Sequencing analysis of meningioma samples, analyzing driver mutations (NF2, AKT1, KLF4, and TRAF7) and identifying ANXA3 as a therapeutic target. The study appears to use custom/private data from their own patient samples rather than accessing public databases through cBioPortal.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40562609,Integrated proteomic and targeted Next Generation Sequencing reveal relevant heterogeneity in lower-grade meningioma and ANXA3 as a new target in NF2 mutated meningiomas.,2025,abstract,2025-12-19T04:02:04.502226,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine']",['Original research'],['TCGA'],"The paper analyzed RIPK1 mRNA expression in diffuse glioma databases from The Cancer Genome Atlas (TCGA) containing clinical, genomic, and transcriptomic information from 670 patients. The transcriptomic studies were carried out using USC Xena and R, suggesting that data was downloaded from TCGA (potentially via cBioPortal) for external analysis. The study examined RIPK1 expression in relation to survival, IDH mutation status, and other molecular features in glioma patients.",['TCGA'],['Data download/export'],"['RIPK1', 'IDH1', 'IDH2']",['Download data'],External (downloaded data),medium,4.0,40565018,RIPK1 in Diffuse Glioma Pathology: From Prognosis Marker to Potential Therapeutic Target.,2025,pdf,2025-12-19T04:02:05.211539,,,,
"['Gene expression analysis', 'Survival analysis']",['Melanoma'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],['TCGA'],The authors analyzed TCGA melanoma dataset to examine ALDH2 gene expression levels and their correlation with patient survival in metastatic melanoma. The analysis revealed that low ALDH2 expression correlates with poorer survival outcomes in metastatic melanoma patients. The specific platform or method used to access TCGA data (whether through cBioPortal or another source) is not explicitly stated in the provided text.,['TCGA'],['Citation only'],"['ALDH2', 'BRAF']",['Not specified'],Unclear,low,4.0,40558540,Downregulated <i>ALDH2</i> Contributes to Tumor Progression and Targeted Therapy Resistance in Human Metastatic Melanoma Cells.,2025,pdf,2025-12-19T04:02:05.393119,,,,
"['Mutation analysis', 'Methods/Tools development']","['Pan-cancer', 'Breast cancer', 'Lung cancer', 'Colorectal cancer', 'Prostate cancer']","['Methods/Tools development', 'Precision medicine']","['Original research', 'Methods/Software']",['TCGA'],The paper used cBioPortal to download mutation data from TCGA for 13 cancer types. The downloaded data was used to perform simulation-based analysis comparing mutational signatures between whole-exome sequencing and targeted sequencing approaches through downsampling experiments. The analysis was performed externally after data download.,['TCGA'],['Data download/export'],[],['Download data'],External (downloaded data),medium,4.0,40561160,Evaluation of potential of targeted sequencing through mutational signature simulation.,2025,abstract,2025-12-19T04:02:05.512221,,,,
['Other'],"['Breast cancer', 'Melanoma', 'Lung cancer', 'Colorectal cancer']",['Other'],['Original research'],['Not specified'],"This paper does not actually use cBioPortal for any analysis. The paper is a developmental biology study investigating MAP3K1 overexpression in mouse ocular surface epithelium development. While the introduction mentions that somatic MAP3K1 mutations are associated with various human cancers (breast, melanoma, lung, colorectal), cBioPortal is not cited or used in this study. This appears to be a developmental/embryological research paper focused on eyelid closure mechanisms in mice.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40558521,Mitogen-Activated Protein Kinase Kinase Kinase 1 Overexpression Disrupts Development of the Ocular Surface Epithelium.,2025,pdf,2025-12-19T04:02:05.979078,,,,
['Copy number analysis'],['Other solid tumor'],"['Drug response/resistance', 'Biomarker discovery', 'Precision medicine']",['Original research'],['Custom/Private data'],"The paper mentions identifying homozygous loss of the MTAP gene in approximately 54% (7/13) of MPNST patient-derived xenograft (PDX) lines. However, the abstract and introduction do not explicitly describe how cBioPortal was used in this study. The usage appears to be limited to citation or potentially for background information on MTAP deletion frequencies in cancer, but specific details about cBioPortal usage are not provided in the available text.",[],['Citation only'],"['MTAP', 'CDKN2A']",['Not specified'],Unclear,low,4.0,40553452,MTA-Cooperative PRMT5 Inhibitors Are Efficacious in MTAP-Deleted Malignant Peripheral Nerve Sheath Tumor Models.,2025,abstract,2025-12-19T04:02:06.073413,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Custom/Private data']","The paper used TCGA stomach adenocarcinoma (STAD) data to identify differentially expressed genes and perform survival analysis. The Cancer Genome Atlas data was used to identify 4633 differentially expressed genes which were intersected with genes from the GSE191275 dataset. Cox regression and LASSO analysis were performed to identify prognostic genes (SPARC and SERPINE1) and construct a survival prediction model, though the specific role of cBioPortal in accessing or analyzing this TCGA data is not explicitly detailed.",['TCGA-STAD'],['Citation only'],"['SPARC', 'SERPINE1']",['Not specified'],Unclear,low,4.0,40547168,Identification and validation of extracellular matrix-related genes in the progression of gastric cancer with intestinal metaplasia.,2025,abstract,2025-12-19T04:02:07.808273,,,,
"['Mutation analysis', 'Gene expression analysis', 'Multi-omics integration']",['Colorectal cancer'],"['Biomarker discovery', 'Tumor evolution']",['Original research'],"['TCGA', 'Multiple sources']","The paper used cBioPortal to access and analyze multiple public colorectal cancer datasets to identify IDH1 and IDH2 mutations at specific hotspots. The authors queried mutation data and likely examined associations with other molecular features like BRAF and KRAS mutations, as well as methylation phenotypes (CIMP). The analysis involved examining multiple public CRC datasets available through cBioPortal alongside in-house datasets.",[],"['Data download/export', 'Web-based analysis']","['IDH1', 'IDH2', 'BRAF', 'KRAS']","['Query interface', 'Download data']","[""Mixed""]",medium,4.0,40545636,Analysis of IDH1 and IDH2 mutations as causes of the hypermethylator phenotype in colorectal cancer.,2025,abstract,2025-12-19T04:02:08.741356,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Tumor evolution', 'Other']",['Original research'],"['TCGA', 'Custom/Private data']","The paper conducted a comprehensive analysis of mutations, copy number variations, and transcriptional changes of retinoic acid (RA) metabolism related genes in bladder cancer using data from cBioPortal. The authors analyzed mutation rates and gene amplification patterns, particularly identifying significant amplification in RDH10 and CYP26B1. The analysis was combined with single-cell transcriptome data and in vitro experimental validation to investigate the role of CYP26B1 in bladder cancer.",['TCGA-BLCA'],"['Data download/export', 'Web-based analysis']","['CYP26B1', 'RDH10']","['Query interface', 'Download data']",Mixed,medium,4.0,40535799,Retinoic acid metabolism related gene CYP26B1 promotes tumor stemness and tumor microenvironment remodeling in bladder cancer.,2025,pdf,2025-12-19T04:02:09.454580,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Copy number analysis', 'Pathway analysis']",['Pan-cancer'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to study the genetic alteration status of FCHSD1 across human pan-cancer. The authors accessed the cBioPortal website to analyze mutations, copy number alterations, and other genomic changes in FCHSD1 across multiple cancer types. This was part of a comprehensive multi-database approach to characterize FCHSD1 as a potential biomarker.",[],['Web-based analysis'],['FCHSD1'],['Query interface'],cBioPortal platform,medium,4.0,40535123,"Comprehensive pan-cancer analysis and experimental validation reveal FCHSD1 as a potential biomarker for diagnosis, immune infiltration, and prognosis.",2025,pdf,2025-12-19T04:02:10.338220,,,,
"['Gene expression analysis', 'Multi-omics integration']","['Pan-cancer', 'Leukemia/Lymphoma']","['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']",The study performed integrative analysis of pan-cancer microRNA and DUSP2 mRNA expression data across 32 cancer types to identify inverse correlations between oncogenic microRNA clusters and DUSP2 expression. cBioPortal was used as a data source for accessing cancer genomics data including expression profiles across multiple cancer types. The analysis combined in silico target prediction with expression data analysis to identify microRNAs potentially regulating DUSP2 in cancer contexts.,[],['Data download/export'],['DUSP2'],"['Expression analysis', 'Download data']",External (downloaded data),medium,4.0,40537745,"The MAP kinase negative regulator DUSP2 (dual specificity phosphatase 2) is controlled by oncogenic microRNA cluster miR-17-92, miR-106a-363 and miR-106b-25.",2025,pdf,2025-12-19T04:02:10.768593,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Lung cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The study used cBioPortal to analyze public genome databases, specifically examining UBR4 expression levels in lung adenocarcinoma (LUAD) patients. The analysis revealed high UBR4 expression associated with dysregulated cell cycle and impaired mitochondrial homeostasis. Additionally, UBR4 levels were correlated with tumor stage, mitophagy markers, and poor survival outcomes in LUAD patients.",[],"['Web-based analysis', 'Web-based visualization']",['UBR4'],"['Expression analysis', 'Survival analysis']",Unclear,medium,4.0,40531870,Tumor-promoting UBR4 coordinates impaired mitophagy-associated senescence and lung adenocarcinoma pathogenesis.,2025,abstract,2025-12-19T04:02:10.872489,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Melanoma'],"['Immunotherapy', 'Biomarker discovery']",['Original research'],['TCGA'],The authors used cBioPortal to access melanoma patient data to validate their pDC killing gene signature. They performed survival analysis to assess the prognostic value of their identified gene signature in melanoma patients. The gene signature derived from their experimental multi-omics profiling of imiquimod-activated pDCs was tested for clinical relevance using cBioPortal melanoma datasets.,[],"['Web-based analysis', 'Web-based visualization']",[],"['Survival analysis', 'Expression analysis']",cBioPortal platform,medium,4.0,40530418,Multi-omics and functional characterization of the tumor-killing capacity of Imiquimod-activated plasmacytoid dendritic cells.,2025,abstract,2025-12-19T04:02:11.591903,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration', 'Mutation analysis']",['Breast cancer'],"['Biomarker discovery', 'Precision medicine', 'Immunotherapy']",['Original research'],"['TCGA', 'METABRIC', 'Multiple sources']","The study used cBioPortal to obtain METABRIC cohort data as one of the independent validation cohorts for their ADME-related prognostic signature. The METABRIC dataset was used alongside TCGA-BRCA and GSE58812 to validate the predictive accuracy of their 5-gene risk signature for 1-, 3-, and 5-year survival in breast cancer patients. cBioPortal served as a data source for external validation of their prognostic model.","['TCGA-BRCA', 'METABRIC']",['Data download/export'],"['SLC7A5', 'HSD11B1', 'ADHFE1', 'GSTM2', 'TAP1']",['Download data'],External (downloaded data),high,4.0,40535120,Role of ADME genes in breast cancer prognosis: an analysis of risk scoring models based on multi-omics data.,2025,pdf,2025-12-19T04:02:11.824482,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']","['Pan-cancer', 'Bladder cancer']","['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The paper performed a pan-cancer analysis of DHCR24 expression across multiple cancer types using data from TCGA and other databases. While cBioPortal is not explicitly mentioned in the provided abstract and introduction, the study analyzed DHCR24 expression patterns, survival outcomes, and tumor stage correlations across different cancer types, which are typical analyses performed using cBioPortal for TCGA data. The study focused particularly on bladder cancer (BLCA) where DHCR24 was identified as an independent prognostic factor.",['TCGA'],['Citation only'],"['DHCR24', 'HRAS']",['Not specified'],Unclear,low,4.0,40535103,Pan-cancer analysis reveals the potential role of DHCR24 in bladder cancer via interactions with HRAS to facilitate cholesterol synthesis.,2025,pdf,2025-12-19T04:02:12.024014,,,,
['Gene expression analysis'],['Pan-cancer'],['Biomarker discovery'],['Original research'],['TCGA'],The authors used cBioPortal to query and analyze Aurora B (AURKB) and INCENP expression levels across different cancer types using TCGA data. This analysis was performed to contextualize their experimental findings on Aurora B and INCENP overexpression in non-transformed human cells by examining the expression patterns of these genes in human cancers. The cBioPortal analysis provided supporting evidence for the clinical relevance of their mechanistic findings.,['TCGA'],"['Web-based analysis', 'Web-based visualization']","['AURKB', 'INCENP']","['Expression analysis', 'Query interface']",cBioPortal platform,medium,4.0,40530423,Aurora B and INCENP co-overexpression severely disrupts mitosis and distinctly modifies the global transcriptional landscape.,2025,abstract,2025-12-19T04:02:12.660890,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used as one of multiple bioinformatics tools to analyze the MEX3 family genes in hepatocellular carcinoma. The study mentions cBioPortal in the list of tools used for comprehensive bioinformatics analysis, likely for mutation analysis and genomic alterations of MEX3 genes. The paper specifically notes that mutations in the MEX3A gene were frequently observed and associated with poor prognosis, suggesting cBioPortal was used to query mutation data.",['TCGA'],"['Web-based analysis', 'Web-based visualization']","['MEX3A', 'MEX3B', 'MEX3C', 'MEX3D', 'MMP14', 'TET3', 'SENP1', 'GTSE1', 'KIF18A']","['Query interface', 'Not specified']",Unclear,medium,4.0,40530133,Identification of the MEX3 family as potential biomarkers of hepatocellular carcinoma based on bioinformatics and experiments.,2025,abstract,2025-12-19T04:02:14.207918,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy', 'Tumor evolution']",['Original research'],['TCGA'],"The paper does not explicitly mention using cBioPortal in the abstract or introduction provided. The study analyzed TCGA somatic variant data using Maftools R package and performed immune cell composition analysis using CIBERSORT. While TCGA data was used, there is no clear indication that cBioPortal was the source or platform for data access or analysis based on the provided text.",['TCGA'],['Citation only'],[],['Not specified'],"[""Unclear""]",low,4.0,40529021,High intratumoral heterogeneity in clear cell renal cell carcinoma is associated with reduced immune response and survival.,2025,abstract,2025-12-19T04:02:14.576645,,,,
"['Mutation analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The study appears to be an independent retrospective analysis of 1509 formalin-fixed, paraffin-embedded tissue specimens using SNaPshot PCR and Qiagen Therascreen kit for FGFR3 mutation and fusion testing. If cBioPortal was used, it may have been for literature context or comparison purposes only, but this is not stated in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40521274,Clinical and Genomic Landscape of <i>FGFR3</i> Alterations Across Different Stages of Urothelial Cancer.,2025,abstract,2025-12-19T04:02:15.343908,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],['Not specified'],"Based on the abstract and introduction provided, cBioPortal usage is not explicitly described in these sections. The study focuses on establishing ECF-resistant gastric cancer cell lines and investigating NINJURIN2 as a biomarker for chemoresistance. While the paper may reference cBioPortal for validation or clinical data analysis, specific details about how cBioPortal was used are not mentioned in the provided text.",[],['Citation only'],"['NINJ2', 'CD44', 'VAV2']",['Not specified'],Unclear,low,4.0,40518514,Targeted inhibition of Ninjurin2 promotes chemosensitivity in chemoresistant gastric cancer by suppressing cancer-initiating cells.,2025,pdf,2025-12-19T04:02:16.037446,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration', 'Mutation analysis']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the methods or results sections provided. The study primarily uses TCGA-KIRC data accessed directly from TCGA portal and UCSC XENA for multi-omics analysis of CWH43 in clear cell renal cell carcinoma. While cBioPortal is cited in the references, there is no clear description of how it was used for data access, analysis, or visualization in this study.",['TCGA-KIRC'],['Citation only'],['CWH43'],['Not specified'],Unclear,low,4.0,40517334,Identification of CWH43 as a novel prognostic biomarker and therapeutic target in clear cell renal cell carcinoma by a multi-omics approach and correlation with autophagy progression.,2025,pdf,2025-12-19T04:02:18.155504,,,,
"['Gene expression analysis', 'Pathway analysis', 'Multi-omics integration', 'Survival analysis']",['Breast cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, cBioPortal is not explicitly mentioned in the visible text. The study uses data from GEO, UCSC Xena, and the Molecular Taxonomy of Breast Cancer International Consortium to analyze shared gene signatures between breast cancer and endometriosis. Without the full methods section visible, the specific role of cBioPortal cannot be determined from the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40512411,Unraveling the interrelationship between breast cancer and endometriosis based on multi-omics analysis.,2025,pdf,2025-12-19T04:02:18.511065,,,,
"['Gene expression analysis', 'Mutation analysis', 'Copy number analysis']",['Melanoma'],"['Biomarker discovery', 'Other']",['Original research'],['TCGA'],The authors analyzed CST (CTC1-STN1-TEN1) gene expression and alterations in cutaneous melanoma using the cBioPortal database. They examined the frequency of alterations in CST genes and compared expression levels between melanoma samples and normal tissues. This database analysis provided the rationale for their subsequent in vivo investigation using a conditional knockout mouse model.,[],"['Web-based analysis', 'Web-based visualization']","['CTC1', 'STN1', 'TEN1']","['Expression analysis', 'Query interface']",cBioPortal platform,medium,4.0,40501869,In vivo investigation of STN1 downregulation in melanoma formation in adult mice following UV irradiation.,2025,abstract,2025-12-19T04:02:18.771719,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Pathway analysis', 'Multi-omics integration']",['Lung cancer'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the methods or results sections. While TCGA data was used for analyzing EPHX4 expression, mutations, methylation, and survival in lung adenocarcinoma, there is no clear indication that cBioPortal was the platform used to access or analyze this data. The citation of cBioPortal may be for reference purposes only.",['TCGA-LUAD'],['Citation only'],['EPHX4'],['Not specified'],Unclear,low,4.0,40507905,Integrative Analysis of <i>EPHX4</i> as a Novel Prognostic and Diagnostic Biomarker in Lung Adenocarcinoma.,2025,pdf,2025-12-19T04:02:19.061685,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Prostate cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used as one of multiple public datasets to validate gene and protein expression of SLIT/ROBO pathway components (SLIT1, SLIT2, ROBO1, and ROBO4) in prostate cancer patients. The platform was used alongside other databases (The Human Protein Atlas, SurvExpress, and CamcAPP) to correlate expression alterations with patient prognosis and clinical outcomes. The study primarily focused on validating findings from transgenic mouse models using human clinical data from cBioPortal.",[],"['Web-based analysis', 'Citation only']","['SLIT1', 'SLIT2', 'ROBO1', 'ROBO4']","['Expression analysis', 'Not specified']",Unclear,medium,4.0,40508075,SLIT/ROBO Pathway and Prostate Cancer: Gene and Protein Expression and Their Prognostic Values.,2025,pdf,2025-12-19T04:02:19.450754,,,,
"['Copy number analysis', 'Gene expression analysis', 'Survival analysis']",['Breast cancer'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],"['TCGA', 'METABRIC']",The authors used cBioPortal to analyze eIF3e copy number alterations and expression data in breast cancer patients from TCGA and METABRIC datasets. They examined the association between eIF3e copy number and expression with patient survival outcomes. The analysis demonstrated that eIF3e copy number and an eIF3e-expression signature are associated with worsened outcomes for breast cancer patients.,"['TCGA', 'METABRIC']","['Web-based analysis', 'Data download/export']",['EIF3E'],"['Expression analysis', 'Survival analysis', 'Query interface']",Mixed,medium,4.0,40501575,eIF3d and eIF3e mediate selective translational control of hypoxia that can be inhibited by novel small molecules.,2025,abstract,2025-12-19T04:02:20.119753,,,,
"['Mutation analysis', 'Gene expression analysis']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Other']",['Original research'],['TCGA'],The paper used cBioPortal to query TCGA datasets for IDH1/2 mutation status and gene expression data in glioma samples. The data was used to examine the relationship between IDH mutations and telomere-related gene expression patterns. The analysis appears to have been performed using cBioPortal's web-based query and visualization tools to access TCGA glioma datasets.,['TCGA'],"['Web-based analysis', 'Web-based visualization']","['IDH1', 'IDH2', 'KDM4A']","['Query interface', 'Expression analysis']","[""cBioPortal platform""]",medium,4.0,40498073,R-2-hydroxyglutarate-mediated inhibition of KDM4A compromises telomere integrity.,2025,abstract,2025-12-19T04:02:22.014482,,,,
"['Gene expression analysis', 'Pathway analysis']",['Other solid tumor'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage. The study focuses on patient-derived ovarian cancer models (OCMs) screened with SUMO inhibitor ML-792, examining drug sensitivity, resistance mechanisms, and MYC's role. Without access to the full methods section, it appears cBioPortal may have been cited for reference purposes only or used minimally for background data queries.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40487451,"Targeting SUMOylation in ovarian cancer: Sensitivity, resistance, and the role of MYC.",2025,abstract,2025-12-19T04:02:24.096304,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly describe using cBioPortal for their primary analyses. The study performed comprehensive genomic characterization of sinonasal squamous cell carcinoma using high-throughput DNA sequencing on their own cohort. While TCGA data is mentioned as a data source and cBioPortal may have been used to access TCGA datasets for comparison with HPV-associated cervical and head and neck cancers, no specific cBioPortal features, tools, or analysis methods are described in the provided text.",['TCGA'],['Citation only'],[],['Not specified'],Unclear,low,4.0,40500270,Molecular patterns and mechanisms of tumorigenesis in HPV-associated and HPV-independent sinonasal squamous cell carcinoma.,2025,pdf,2025-12-19T04:02:24.279930,,,,
['Mutation analysis'],['Not specified'],['Methods/Tools development'],"['Methods/Software', 'Original research']",['Not specified'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage. The paper focuses on developing MDmis, a computational method that uses molecular dynamics simulations to predict pathogenicity of missense variants in intrinsically disordered protein regions. cBioPortal appears to be cited in the references but its specific role in the study is not described in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40462930,Molecular dynamics simulations of intrinsically disordered protein regions enable biophysical interpretation of variant effect predictors.,2025,abstract,2025-12-19T04:02:25.012496,,,,
"['Gene expression analysis', 'Pathway analysis']",['Other solid tumor'],"['Drug response/resistance', 'Pathway analysis']",['Original research'],['Not specified'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on investigating the therapeutic potential of Methyl mycophenolate (MMP) in gastric cancer through in vitro and in vivo experiments, including cell viability assays, RNA sequencing, Western blotting, and mouse xenograft models. cBioPortal may have been cited in the references or used for background research, but no specific usage is described in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40484944,Marine natural product Methyl mycophenolate inhibits gastric cancer growth through regulating p53 and the downstream pathways.,2025,pdf,2025-12-19T04:02:25.223905,,,,
"['Gene expression analysis', 'Survival analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],The authors used TCGA data to analyze Regnase-1 expression levels in colorectal cancer tissue and correlate it with patient prognosis. The analysis revealed that low Regnase-1 expression in colorectal cancer tissue was associated with poor prognosis. The specific platform used for accessing TCGA data (whether cBioPortal or another resource) is not explicitly stated in the abstract.,['TCGA'],['Citation only'],[],['Not specified'],Unclear,low,4.0,40460118,Epithelial Regnase-1 inhibits colorectal tumor growth by regulating IL-17 signaling via degradation of <i>NFKBIZ</i> mRNA.,2025,abstract,2025-12-19T04:02:25.721419,,,,
"['Gene expression analysis', 'Mutation analysis', 'Copy number analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to obtain clinical information from the Memorial Sloan Kettering Cancer Center and to validate/check results obtained from TCGA pan-cancer cohort analysis. The paper states ""Clinical information of the Memorial Sloan Kettering Cancer Center were obtained from cBioPortal"" and mentions that ""the results were checked using cBioPortal and GEO database.""","['TCGA pan-cancer', 'Memorial Sloan Kettering Cancer Center']",['Data download/export'],['SYTL4'],['Download data'],External (downloaded data),medium,4.0,40478518,Integrated analysis unraveling the immunologic and clinical prognostic values of synaptotagmin like 4 in pan-cancer.,2025,pdf,2025-12-19T04:02:26.282084,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']","['Colorectal cancer', 'Pan-cancer']","['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']",['Original research'],['TCGA'],"The paper mentions using the Cancer Genome Atlas (TCGA) database to investigate mRNA expression levels of SERPINE family genes in human cancer samples and normal tissues, and Kaplan-Meier analysis for prognosis. However, the abstract and introduction do not explicitly mention cBioPortal usage. The reference to TCGA database suggests potential cBioPortal usage for data access or analysis, but specific details about cBioPortal features or methodology are not provided in the available text.",['TCGA'],['Citation only'],"['SERPINE1', 'SERPINE2', 'SERPINE3']",['Not specified'],"[""Unclear""]",low,4.0,40463876,SerpinE2 promotes M2 polarization in macrophage to accelerate colorectal cancer progression.,2025,pdf,2025-12-19T04:02:27.009130,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Breast cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine', 'Immunotherapy']","['Original research', 'Clinical study']","['TCGA', 'METABRIC', 'Custom/Private data', 'Multiple sources']","The paper mentions TCGA Breast Cancer samples and METABRIC cohorts as reference datasets for their analysis. While cBioPortal is not explicitly mentioned in the provided abstract and introduction, these are standard datasets commonly accessed through cBioPortal. The study used TCGA data to create a reference cohort of 152 Basal-classified breast cancer samples for network analysis and validated findings in METABRIC cohort for pathological complete response and survival associations.","['TCGA Breast Cancer', 'METABRIC']",['Citation only'],[],['Not specified'],Unclear,low,4.0,40514415,Utilizing cohort-level and individual networks to predict best response in patients with metastatic triple negative breast cancer.,2025,pdf,2025-12-19T04:02:28.713883,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis']",['Lung cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Tumor evolution', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not provide explicit details about how cBioPortal was used in the study. While the paper focuses on ONECUT2 as a driver of plasticity in small cell lung cancer and investigates its role in neuroendocrine fate reprogramming, there is no clear mention of cBioPortal usage in the provided abstract and introduction sections. The citation appears to be reference-only without specific methodological details about data access or analysis through the platform.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40500731,ONECUT2 reprograms neuroendocrine fate and is an actionable therapeutic target in small cell lung cancer.,2025,pdf,2025-12-19T04:02:29.125977,,,,
"['Mutation analysis', 'Drug response/resistance']",['Pan-cancer'],"['Drug response/resistance', 'Precision medicine', 'Biomarker discovery']","['Original research', 'Clinical study']",['Custom/Private data'],"The paper does not explicitly describe using cBioPortal for data analysis or visualization. This is a preclinical companion study to the NCI-MPACT clinical trial that used patient-derived xenograft (PDX) models from the NCI PDMR repository. While the study involves mutation profiling and targeted therapy selection, there is no mention of cBioPortal being used for data access, analysis, or visualization in the provided abstract and introduction.",[],['Citation only'],"['TP53', 'MGMT']",['Not specified'],Unclear,low,4.0,40458731,Preclinical NCI-MPACT: prospective modeling of the mutation-based NCI-MPACT clinical trial therapeutic strategy in patient-derived xenograft models.,2025,pdf,2025-12-19T04:02:29.730941,,,,
"['Gene expression analysis', 'Survival analysis', 'Copy number analysis', 'Mutation analysis', 'Pathway analysis']",['Prostate cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Tumor evolution', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper analyzed transcriptomic data from 87,183 samples across 26 datasets to assess stemness and AR activity in prostate cancer progression. The study examined genomic alterations including MYC amplification and RB1 loss in relation to stemness scores across different stages of prostate cancer. cBioPortal was likely used to access and analyze TCGA and other public datasets for gene expression, copy number alterations, and clinical outcome correlations.",[],['Citation only'],"['MYC', 'RB1']",['Not specified'],Unclear,low,4.0,40458374,"Increasing Stemness Drives Prostate Cancer Progression, Plasticity, Therapy Resistance and Poor Patient Survival.",2025,abstract,2025-12-19T04:02:30.128488,,,,
"['Mutation analysis', 'Pathway analysis']",['Leukemia/Lymphoma'],"['Biomarker discovery', 'Tumor evolution']",['Original research'],['Multiple sources'],"The paper analyzed TP53 mutations in myeloid neoplasms including MDS, AML, AML-MRC, and therapy-related AML. The study compared mutation types, spectrum, and hot spots between disease categories and with solid tumors. While cBioPortal is cited, the specific details of how it was used are not provided in the abstract and introduction, suggesting it may have been used for data access or comparison purposes.",[],['Citation only'],['TP53'],['Not specified'],Unclear,low,4.0,40453522,Comparison of <i>TP53</i> mutations in myelodysplasia and acute leukemia suggests divergent roles in initiation and progression.,2024,abstract,2025-12-19T04:02:30.999538,,,,
"['Copy number analysis', 'Gene expression analysis', 'Survival analysis']",['Breast cancer'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],"['TCGA', 'METABRIC', 'Custom/Private data']","cBioPortal was used to analyze KDM4C amplification and expression patterns in breast cancer cohorts, particularly focusing on basal breast cancer subtypes. The authors likely queried TCGA and METABRIC datasets through cBioPortal to examine copy number alterations and gene expression of KDM4C and related genes. Survival analysis and correlation with clinical outcomes in breast cancer patients were also performed using cBioPortal data.","['TCGA', 'METABRIC']","['Data download/export', 'Web-based analysis']","['KDM4C', 'CTSL', 'GRHL2']","['Expression analysis', 'Download data', 'Query interface']","[""Mixed""]",medium,4.0,40457074,KDM4C inhibition blocks tumor growth in basal breast cancer by promoting cathepsin L-mediated histone H3 cleavage.,2025,abstract,2025-12-19T04:02:31.488666,,,,
"['Gene expression analysis', 'Pathway analysis']",['Prostate cancer'],"['Drug response/resistance', 'Pathway analysis', 'Biomarker discovery']",['Original research'],"['Custom/Private data', 'Multiple sources']","Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage. The study focuses on preclinical experiments and RNA sequencing data from clinical trials to investigate BCL2's role in castration resistance. Without access to the full methods section, it is unclear if cBioPortal was used for data access, validation, or comparative analysis.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40448998,BCL2 drives castration resistance in castration-sensitive prostate cancer by orchestrating reciprocal crosstalk between oncogenic pathways.,2025,abstract,2025-12-19T04:02:31.515998,,,,
"['Mutation analysis', 'Copy number analysis']",['Lung cancer'],"['Biomarker discovery', 'Precision medicine', 'Drug response/resistance']",['Original research'],['Custom/Private data'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The study used comprehensive genomic profiling (CGP) data from the FoundationOne database (Foundation Medicine) to analyze 503 RET fusion-positive NSCLC cases out of 72,596 total NSCLC cases. The analysis was performed using Foundation Medicine's proprietary sequencing platform (FoundationOneCDx) and does not describe any use of cBioPortal for data analysis, visualization, or data access.",['FoundationOne'],['Citation only'],"['RET', 'EGFR', 'BRCA1', 'BRAF', 'FGF12', 'FGFR1', 'KEAP1', 'KMT2D', 'KRAS', 'MDM2', 'MET', 'NF1', 'NSD3', 'PIK3CA', 'RB1', 'TP53', 'SETD2']",['Not specified'],Unclear,low,4.0,40452844,<i>RET</i> fusion driven (<i>RETfus+</i>) non-small cell lung cancer: a comprehensive genomic profiling study with histologic correlation.,2025,pdf,2025-12-19T04:02:32.350312,,,,
"['Gene expression analysis', 'Mutation analysis', 'Copy number analysis']",['Other solid tumor'],"['Biomarker discovery', 'Other']",['Original research'],"['TCGA', 'Custom/Private data']","The paper used cBioPortal to analyze genetic alterations (mutations and copy number alterations) and expression patterns of plectin (PLEC gene) in esophageal squamous cell carcinoma. The authors likely queried TCGA-ESCC datasets through cBioPortal to examine the oncogenic characteristics and genetic alterations of plectin in ESCC patients. The analysis was used to complement their experimental findings from cellular, molecular, and tissue-based studies.",['TCGA-ESCC'],"['Web-based analysis', 'Web-based visualization']","['PLEC', 'TP63', 'NOTCH1']","['Query interface', 'Expression analysis']",cBioPortal platform,medium,4.0,40449847,"Unraveling the Oncogenic Characteristics of the Cytolinker, Plectin, in Esophageal Squamous Cell Carcinoma.",2025,abstract,2025-12-19T04:02:32.953702,,,,
"['Gene expression analysis', 'Pathway analysis']","['Lung cancer', 'Breast cancer', 'Colorectal cancer', 'Prostate cancer']","['Drug response/resistance', 'Pathway analysis', 'Biomarker discovery']",['Original research'],['Not specified'],"The paper mentions using bioinformatics analysis to identify transcriptomic signatures and cancer-related pathways (TP53, PI3K, NRF2, and MYC) in the context of evaluating the anticancer effects of Psoralea bituminosa extracts. However, the abstract and introduction do not provide explicit details about how cBioPortal was specifically used, whether data was downloaded, or which features were utilized. The mention appears to be related to pathway analysis of gene expression profiles in cancer cell lines tested.",[],['Citation only'],"['TP53', 'PI3K', 'NRF2', 'MYC']",['Not specified'],Unclear,low,4.0,40447838,Phytochemical characterization and bioinformatics guided evaluation of antioxidant and cytotoxic effects of Psoralea bituminosa.,2025,pdf,2025-12-19T04:02:34.402010,,,,
['Other'],['Breast cancer'],['Methods/Tools development'],['Original research'],['Not specified'],"This paper does not appear to use cBioPortal for any analysis. The study focuses on structural biology and biochemical characterization of the BRCA2-RAD51 protein complex using crystallography, biochemical assays, and molecular biology techniques. While the paper studies BRCA2, a tumor suppressor relevant to cancer, there is no mention of cBioPortal usage in the abstract or introduction provided.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40441151,BRCA2 C-terminal clamp restructures RAD51 dimers to bind B-DNA for replication fork stability.,2025,abstract,2025-12-19T04:02:34.430127,,,,
"['Mutation analysis', 'Other']","['Lung cancer', 'Other solid tumor', 'Pan-cancer']","['Drug response/resistance', 'Precision medicine', 'Biomarker discovery']","['Original research', 'Clinical study']","['Custom/Private data', 'Multiple sources']","The paper does not explicitly describe using cBioPortal for data analysis or visualization. While the study focuses on MET mutations and their response to different TKI classes, there is no clear mention of cBioPortal usage in the abstract or introduction provided. The citation may be for reference purposes only or usage details may be in methods sections not provided.",[],['Citation only'],['MET'],['Not specified'],Unclear,low,4.0,40437874,Responsiveness of different MET tumour alterations to type I and type II MET inhibitors.,2025,abstract,2025-12-19T04:02:35.727586,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Copy number analysis', 'Multi-omics integration', 'Pathway analysis']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper conducted a pan-cancer systematic investigation of ELAVL1 using multi-omics datasets including expression patterns, prognostic significance, genomic alterations, and modifications. While cBioPortal is likely used as a data source for accessing TCGA and other cancer genomics data for the pan-cancer analysis, the specific details of how cBioPortal was utilized are not explicitly described in the provided abstract and introduction sections. The study focuses on ELAVL1 across multiple cancer types with particular emphasis on nasopharyngeal carcinoma (NPC).",[],['Citation only'],['ELAVL1'],['Not specified'],Unclear,low,4.0,40443402,Deciphering the role of <i>ELAVL1</i>: Insights from pan-cancer multiomics analyses with emphasis on nasopharyngeal carcinoma.,2025,pdf,2025-12-19T04:02:36.144551,,,,
"['Gene expression analysis', 'Mutation analysis', 'Survival analysis', 'Pathway analysis']","['Breast cancer', 'Other solid tumor']","['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy']",['Original research'],['TCGA'],"The paper analyzed EXO1 expression and genetic alterations in female-related cancers using TCGA data. While cBioPortal is not explicitly mentioned in the provided abstract and introduction, the study examined mutation frequencies, DNA methylation, and correlations with clinical characteristics across multiple cancer types including BRCA, UCEC, CESC, OV, THCA, and UCS. The analysis included prognostic associations, tumor immune microenvironment correlations, and drug sensitivity predictions.",['TCGA'],['Citation only'],['EXO1'],['Not specified'],Unclear,low,4.0,40433389,Deciphering the multifaceted role of <i>EXO1</i> in female-related cancers: implications for prognosis and therapeutic responsiveness.,2025,pdf,2025-12-19T04:02:36.326478,,,,
"['Gene expression analysis', 'Other']",['Pan-cancer'],"['Review/Commentary', 'Biomarker discovery', 'Drug response/resistance']",['Review'],['Not specified'],"This is a review paper on epigenetic regulation and alternative splicing dysregulation in cancer. The paper does not explicitly describe any direct use of cBioPortal for data analysis or visualization. cBioPortal may only be cited as a reference or resource in the context of discussing cancer genomics databases, but no specific usage details are provided in the abstract and introduction sections provided.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40430531,Epigenetic Regulation and Therapeutic Targeting of Alternative Splicing Dysregulation in Cancer.,2025,pdf,2025-12-19T04:02:38.708421,,,,
['Gene expression analysis'],['Breast cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']",The paper used cBioPortal to access and analyze gene expression data from TCGA breast cancer datasets as part of their bioinformatics workflow to identify novel CTC markers. The authors integrated primary tumor transcriptomic data from cBioPortal with breast cancer cell line expression data to identify genes overexpressed in breast cancer. This analysis was combined with single-cell CTC transcriptomic data to narrow down candidate markers for CTC detection.,['TCGA'],"['Data download/export', 'Web-based analysis']","['MARCKSL1', 'SLC9A3R1', 'RHOD']","['Expression analysis', 'Download data']",External (downloaded data),medium,4.0,40429857,Optimizing Detection of Circulating Tumor Cells in Breast Cancer: Unveiling New Markers for Clinical Applications.,2025,pdf,2025-12-19T04:02:38.710838,,,,
"['Gene expression analysis', 'Copy number analysis']",['Prostate cancer'],"['Biomarker discovery', 'Other']",['Original research'],['Not specified'],"The paper mentions that gene amplification of wild-type GNA13 is seen in 4.4% (19/429) of cases in androgen-independent metastatic prostate cancer, citing reference [21]. This appears to be a citation of previously published data rather than direct use of cBioPortal by the authors. No specific methodology for accessing or analyzing cBioPortal data is described in the provided text.",[],['Citation only'],['GNA13'],['Not specified'],Unclear,low,4.0,40430023,Gα13 Promotes Clonogenic Growth by Increasing Tolerance to Oxidative Metabolic Stress in Prostate Cancer Cells.,2025,pdf,2025-12-19T04:02:38.710240,,,,
"['Gene expression analysis', 'Copy number analysis', 'Pathway analysis', 'Survival analysis']",['Prostate cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The study analyzed clinicopathological, gene expression, and copy number data from three clinical prostate cancer cohorts obtained from cancer genomics databases to investigate the TWIK complex expression signature. The authors used statistical correlations and gene enrichment techniques to determine the clinical, biological, and therapeutic significance of TWIK expression in prostate cancer patients, examining associations with tumor stage, Gleason scores, prognostic grade groups, and therapy response.",[],['Data download/export'],"['KCNK1', 'KCNK6', 'KCNK7']",['Download data'],External (downloaded data),medium,4.0,40427758,TWIK Complex Expression in Prostate Cancer: Insights into the Biological and Therapeutic Significances of Potassium Ion Channels in Clinical Cancer.,2025,pdf,2025-12-19T04:02:39.215250,,,,
['Mutation analysis'],['Other solid tumor'],"['Review/Commentary', 'Drug response/resistance', 'Biomarker discovery']",['Review'],['Not specified'],"cBioPortal was used to determine the p53 mutation rate in head and neck squamous cell carcinoma (HNSCC) and compare it to other cancer types. The authors accessed the cBioPortal database (cbioportal.org) on February 1, 2025, and found that HNSCC has a p53 mutation rate of 68.26%, ranking fourth among all cancer types. This information was used to establish the rationale for developing anticancer treatment strategies targeting p53-mutated HNSCC.",[],"['Web-based analysis', 'Citation only']",['TP53'],['Query interface'],cBioPortal platform,medium,4.0,40426992,Strategies for Anticancer Treatment in p53-Mutated Head and Neck Squamous Cell Carcinoma.,2025,pdf,2025-12-19T04:02:40.060062,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Glioma/Brain cancer'],"['Review/Commentary', 'Biomarker discovery', 'Pathway analysis']",['Review'],['Not specified'],"This is a comprehensive review paper on TRIM proteins in glioma pathogenesis. Based on the abstract and introduction provided, there is no explicit description of how cBioPortal was used in this study. The paper appears to synthesize existing knowledge about TRIM protein functions in gliomas, and cBioPortal is likely cited as a reference or data source used in the literature being reviewed rather than being directly utilized by the authors for original analysis.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40424933,Unveiling the multifaceted functions of TRIM proteins in glioma pathogenesis.,2025,abstract,2025-12-19T04:02:40.608591,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Lung cancer', 'Pan-cancer']","['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, the paper appears to use cBioPortal for accessing LUAD datasets to perform meta-analysis screening for prognostic genes with bimodal expression patterns. The study examined KYNU expression in relation to LUAD mutations (KEAP1/STK11), metabolic alterations, and immune microenvironment states using bulk and single-cell transcriptomics data. Pan-cancer prognostic associations were also assessed, suggesting cBioPortal was used to access multiple cancer datasets for comparative analysis.",['TCGA-LUAD'],"['Data download/export', 'Web-based analysis']","['KYNU', 'KEAP1', 'STK11', 'EGFR', 'KRAS']","['Expression analysis', 'Survival analysis', 'Download data', 'Query interface']",Mixed,medium,4.0,40427178,"High <i>KYNU</i> Expression Is Associated with Poor Prognosis, <i>KEAP1</i>/<i>STK11</i> Mutations, and Immunosuppressive Metabolism in Patient-Derived but Not Murine Lung Adenocarcinomas.",2025,pdf,2025-12-19T04:02:40.800937,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']",['Original research'],['TCGA'],"The study analyzed TCGA mRNA-seq data to assess expression levels of fibronectin (FN1) and integrin subunits in papillary thyroid cancer (PTC), evaluating their relationship with clinical features including lymph node metastasis, cancer stage, and disease recurrence. The analysis examined differential expression between BRAFV600E-positive and RAS-mutated PTC tumors compared to normal thyroid tissue. The findings from the TCGA dataset analysis were subsequently validated using cell line models.",['TCGA'],['Data download/export'],"['FN1', 'ITGAV', 'BRAF']",['Not specified'],"[""External (downloaded data)""]",medium,4.0,40423510,Integrin-fibronectin interaction is a pivotal biological and clinical determinant in papillary thyroid carcinoma.,2025,abstract,2025-12-19T04:02:41.748236,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis']",['Other solid tumor'],"['Review/Commentary', 'Biomarker discovery', 'Precision medicine']",['Review'],['Not specified'],"This is a review paper on liposarcoma clinical treatment and prognosis. The paper mentions cBioPortal only as a reference to the SEER cancer statistics website (https://seer.cancer.gov/statfacts/html/soft.html) in the introduction when discussing soft tissue sarcoma epidemiology. There is no evidence of actual cBioPortal usage for data analysis, visualization, or data download in this review article.",[],['Citation only'],"['MDM2', 'CDK4', 'HMGA2', 'TSPAN31', 'FRS2', 'GLI1', 'DDR2', 'SDHC', 'FGFR', 'PIK3R3', 'DDIT3', 'FUS', 'EWSR1']",['Not specified'],Unclear,low,4.0,40421219,Challenges and hope: latest research trends in the clinical treatment and prognosis of liposarcoma.,2025,pdf,2025-12-19T04:02:43.089944,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","The study used cBioPortal to access TCGA bladder cancer data for analyzing DSC3 gene expression and its correlation with immune genes, molecular subtypes, and clinical outcomes. The authors evaluated DSC3 expression patterns in MIBC and NMIBC, its relationship with p53 mutation status, papillary vs non-papillary subtypes, and basal/squamous vs luminal molecular subtypes. They also analyzed the correlation between DSC3 expression and treatment response/survival outcomes using TCGA datasets accessed through cBioPortal.",['TCGA'],"['Data download/export', 'Web-based analysis']","['DSC3', 'TP53', 'CTLA4', 'TIGIT', 'FOXP3', 'PD1']","['Expression analysis', 'Survival analysis', 'Query interface']",Mixed,medium,4.0,40422563,Desmocollin-3 and Bladder Cancer.,2025,pdf,2025-12-19T04:02:43.759969,,,,
"['Gene expression analysis', 'Multi-omics integration']",['Colorectal cancer'],['Biomarker discovery'],['Original research'],['TCGA'],"The paper examined RNA, methylation, and protein levels of MYO5B and UNC45A in colon adenocarcinoma (COAD) samples compared to normal colon tissue. cBioPortal was likely used to access TCGA COAD data for gene expression and methylation analysis. The study integrated multiple data types including mRNA expression, DNA methylation, and microRNA data to understand the regulation of MYO5B and UNC45A in colorectal cancer.",['TCGA-COAD'],['Data download/export'],"['MYO5B', 'UNC45A']",['Download data'],"[""External (downloaded data)""]",medium,4.0,40409685,The Molecular Motor Myosin 5B and Its Folding Chaperone UNC45A Are Decreased in Colorectal Cancer.,2025,abstract,2025-12-19T04:02:43.899152,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, there is no explicit mention of cBioPortal being used in this study. The paper describes using TCGA-STAD, GTEx, and GEO datasets to analyze cuproptosis-related genes, but does not reference cBioPortal as a data source or analysis platform. The methods section mentions obtaining data directly from TCGA portal (https://portal.gdc.cancer.gov/) rather than through cBioPortal.","['TCGA-STAD', 'GSE84437', 'GSE29272']",['Citation only'],"['DLD', 'FDX1', 'LIPT1', 'DLAT', 'LIAS', 'PDHB', 'MTF1', 'GLS', 'CDKN2A', 'PDHA1']",['Not specified'],Unclear,low,4.0,40410601,Integration of cuproptosis-related gene signatures in stomach adenocarcinoma: implications for prognostic prediction and therapeutic strategies in cancer drug resistance.,2025,pdf,2025-12-19T04:02:45.431960,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']",The authors used cBioPortal to analyze the correlation between ARID1A mutations and prognosis in gastric cancer patients treated with immune checkpoint inhibitors (ICI). The analysis was performed via the cBioPortal website to evaluate the prognostic value of ARID1A mutations in the ICI-treated population. This analysis was part of their broader investigation into ARID1A-associated immune genes and their role in predicting immunotherapy efficacy.,['TCGA-STAD'],['Web-based analysis'],"['ARID1A', 'TP53']","['Query interface', 'Survival analysis']",cBioPortal platform,medium,4.0,40406134,Development and validation of an ARID1A-related immune genes risk model in evaluating prognosis and immune therapeutic efficacy for gastric cancer patients: a translational study.,2025,pdf,2025-12-19T04:02:46.184197,,,,
['Mutation analysis'],['Glioma/Brain cancer'],"['Methods/Tools development', 'Drug response/resistance']","['Original research', 'Methods/Software']",['Multiple sources'],"The paper appears to use cBioPortal to identify MGMT variants that are detectable in the general population and tumors. The authors mention finding MGMT variants in tumors, suggesting they queried cBioPortal databases to identify naturally occurring MGMT variants for their functional screening study. However, the specific details of cBioPortal usage are not extensively described in the abstract and introduction provided.",[],['Web-based analysis'],['MGMT'],['Query interface'],"[""Unclear""]","[""low""]",4.0,40398419,Identifying active and inhibitor-resistant MGMT variants for gene therapy.,2025,abstract,2025-12-19T04:02:46.572327,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Bladder cancer']","['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, cBioPortal is not explicitly mentioned in the text. The study uses TCGA data obtained from UCSC and analyzed through the Sangerbox platform. While the paper may cite cBioPortal in references, there is no clear description of direct cBioPortal usage in the provided sections. The analysis appears to have been conducted using other platforms and tools.","['TCGA-BLCA', 'TCGA']",['Citation only'],['RAP1GAP'],['Not specified'],Unclear,low,4.0,40405009,RAP1GAP is a prognostic biomarker and correlates with immune infiltrates in bladder cancer.,2025,pdf,2025-12-19T04:02:46.647282,,,,
"['Mutation analysis', 'Survival analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Precision medicine', 'Pathway analysis']","['Original research', 'Clinical study']","['METABRIC', 'MSK-IMPACT', 'Multiple sources']","The study integrated clinical and genomic data from 4,265 breast cancer patients from two major cohorts: the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC, n=2,509) and Memorial Sloan Kettering Cancer Center (MSK, n=1,756). The data was used to perform genetic profiling to identify TP53 mutations and PI3K/AKT pathway alterations, followed by survival outcome analysis using Kaplan-Meier and Cox proportional hazards models. While the specific mechanism of data access is not explicitly stated, the use of these well-known cBioPortal-hosted datasets suggests data was likely obtained through the cBioPortal platform.","['METABRIC', 'MSK-IMPACT']",['Data download/export'],"['TP53', 'AKT1', 'AKT2', 'AKT3', 'PIK3CA', 'PTEN', 'RICTOR']",['Download data'],External (downloaded data),medium,4.0,40403210,<i>TP53</i> Mutations and Phosphatidylinositol 3-Kinase/AKT Pathway Alterations Are Key Determinants of Breast Cancer Outcome Independent of Subtype and Stage.,2025,abstract,2025-12-19T04:02:47.731560,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Prostate cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the methods or results sections provided. The study primarily uses NHANES data for observational analysis, GWAS data for Mendelian randomization, and mentions GEPIA2, TCGA, GTEx, HPA, and TIMER2.0 for bioinformatics analyses. While TCGA data is used, there is no clear indication that cBioPortal was the platform used to access or analyze this data.",['TCGA'],['Citation only'],"['ADM5', 'INPP5B', 'NEURL4', 'TYK2']",['Not specified'],Unclear,low,4.0,40397285,"Multidimensional investigation of thyroid hormones and prostate cancer: insights from NHANES, Mendelian randomization, genetic markers, and bioinformatics analyses.",2025,pdf,2025-12-19T04:02:48.764858,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Lung cancer'],"['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']",['Original research'],"['TCGA', 'Custom/Private data', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the methods or results sections. The study utilized TCGA-LUAD data along with single-cell RNA-seq and spatial transcriptomics data from public sources, but there is no clear indication that cBioPortal was used for data access, analysis, or visualization. The citation of cBioPortal may be for reference purposes only or the usage is not described in the provided text.",['TCGA-LUAD'],['Citation only'],"['MDK', 'NCL', 'PD-1', 'CTLA-4']",['Not specified'],Unclear,low,4.0,40396179,Integrative single-cell and spatial transcriptomics analysis reveals MDK-NCL pathway's role in shaping the immunosuppressive environment of lung adenocarcinoma.,2025,pdf,2025-12-19T04:02:49.387287,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis']",['Lung cancer'],"['Biomarker discovery', 'Tumor evolution']",['Original research'],['Custom/Private data'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on comparing gene expression in SCLC patient samples to identify metastatic drivers, with subsequent experimental validation in models. cBioPortal may be cited in the references or methods section not provided here, but no specific usage details are evident from the text provided.",[],['Citation only'],"['FOXA2', 'ASCL1', 'NFIB', 'FOXA1', 'SOX2', 'SOX9']",['Not specified'],Unclear,low,4.0,40419484,FOXA2 promotes metastatic competence in small cell lung cancer.,2025,pdf,2025-12-19T04:02:49.423530,,,,
"['Gene expression analysis', 'Survival analysis', 'Copy number analysis']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The study used cBioPortal to analyze SF3B4 expression patterns and survival correlations across multiple cancer types in a pan-cancer analysis. The authors likely queried SF3B4 expression data and performed survival analysis using TCGA datasets available through cBioPortal. The platform was used to establish SF3B4's oncogenic properties across various cancer types, with hepatocellular carcinoma (HCC) serving as the primary experimental model.",[],"['Web-based analysis', 'Web-based visualization']","['SF3B4', 'BUB1']","['Expression analysis', 'Survival analysis']",Unclear,medium,4.0,40394232,Pan-cancer oncogenic properties and therapeutic potential of SF3B4.,2025,abstract,2025-12-19T04:02:50.002172,,,,
"['Copy number analysis', 'Gene expression analysis', 'Mutation analysis']",['Colorectal cancer'],['Biomarker discovery'],['Original research'],"['TCGA', 'Multiple sources']","The paper used TCGA data to analyze RBFOX1 copy number variations and mRNA expression levels in colorectal cancer. The study examined the correlation between RBFOX1 alterations and clinical pathological features including microsatellite instability status, tumor location, and BRAF mutations. While TCGA is mentioned as a data source, the specific role of cBioPortal in data access or analysis is not explicitly detailed in the abstract.",['TCGA'],['Data download/export'],"['RBFOX1', 'BRAF']",['Not specified'],External (downloaded data),medium,4.0,40395202,The Expression Characteristics of the RBFOX1 Gene in Colorectal Cancer.,2025,abstract,2025-12-19T04:02:50.226505,,,,
"['Gene expression analysis', 'Survival analysis', 'Copy number analysis', 'Pathway analysis']","['Breast cancer', 'Pan-cancer']","['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the methods or results. The study used TCGA data accessed through other platforms including UbiNet 2.0, GEPIA2, UALCAN, and CPTAC for analyzing DTL expression, genetic alterations, and clinical correlations in breast cancer. While cBioPortal is cited in the references, there is no clear description of direct usage of the cBioPortal platform or its specific features.","['TCGA-BRCA', 'TCGA pan-cancer']",['Citation only'],"['DTL', 'HK2', 'ENO1', 'PKM2', 'LDHA']",['Not specified'],Unclear,low,4.0,40391156,Rewired glycolysis by DTL accelerates oncometabolite L-lactate generation to promote breast cancer progression.,2025,pdf,2025-12-19T04:02:52.112331,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],['Biomarker discovery'],['Original research'],['Multiple sources'],"The paper does not explicitly describe how cBioPortal was used in the study. The authors primarily used TCGA and GEO databases for their analysis, downloading HNSCC/OSCC datasets directly from TCGA portal and GEO. While cBioPortal may be cited in the references, there is no clear mention of using cBioPortal's tools, features, or interface in the methods or results sections provided.","['TCGA-HNSC', 'TCGA-OSCC', 'GSE30784', 'GSE23558', 'GSE25099']",['Citation only'],"['CMA1', 'CTSG', 'OLR1', 'SPP1', 'AQP1', 'PTX3']",['Not specified'],Unclear,low,4.0,40386053,Exploring Renin-angiotensin System Genes as Novel Prognostic Biomarkers for Oral Squamous Cell Carcinoma.,2025,pdf,2025-12-19T04:02:53.079882,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Prostate cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']",The paper used cBioPortal to analyze FUT8 expression and clinical correlations in prostate cancer cohorts. The authors queried TCGA prostate cancer datasets through cBioPortal to examine FUT8 expression levels in relation to tumor grade and patient outcomes. This analysis was part of a broader study using multiple independent clinical cohorts to validate FUT8 as a therapeutic target in prostate cancer.,['TCGA'],"['Web-based analysis', 'Web-based visualization']",['FUT8'],"['Expression analysis', 'Query interface']","[""cBioPortal platform""]",medium,4.0,40387385,FUT8 Is a Critical Driver of Prostate Tumour Growth and Can Be Targeted Using Fucosylation Inhibitors.,2025,abstract,2025-12-19T04:02:53.445363,,,,
"['Mutation analysis', 'Multi-omics integration']",['Pan-cancer'],"['Precision medicine', 'Methods/Tools development']",['Methods/Software'],['Multiple sources'],Onkopus integrates cBioPortal as one of multiple databases and tools to provide comprehensive variant interpretation for precision oncology. cBioPortal appears to be used as a data source integrated into the Onkopus framework to provide information about genetic alterations and their clinical relevance. The paper describes Onkopus as a variant interpretation framework that aggregates information from multiple sources including cBioPortal to support variant prioritization and therapeutic decision-making.,[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40377094,Onkopus: precise interpretation and prioritization of sequence variants for biomedical research and precision medicine.,2025,abstract,2025-12-19T04:02:53.752122,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal is not explicitly mentioned in the provided abstract and methods sections of this paper. The study primarily uses TCGA data accessed directly, along with other databases like CCLE, GTEx, GEPIA2, UALCAN, StarBase, and CTD. While the paper cites cBioPortal (as indicated by the task description), the specific usage details are not described in the provided text. The analysis appears to have been conducted using external tools and R software rather than on the cBioPortal platform.",['TCGA'],['Citation only'],['LRFN4'],['Not specified'],Unclear,low,4.0,40386777,A comprehensive pan-cancer analysis of LRFN4: its potential as a prognostic biomarker and therapeutic target for immunotherapy.,2025,pdf,2025-12-19T04:02:53.752478,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Prostate cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],['TCGA'],"The study utilized the TCGA-PRAD (The Cancer Genome Atlas-Prostate Adenocarcinoma) dataset from cBioPortal, which included 421 prostate cancer patients. The data was used to identify tryptophan metabolism-related genes through differential expression analysis, univariate Cox regression, and LASSO regression analyses. The specific mode of cBioPortal usage (data download vs. web-based analysis) is not explicitly stated in the abstract.",['TCGA-PRAD'],['Data download/export'],[],['Not specified'],External (downloaded data),medium,4.0,40376539,Development and validation of tryptophan metabolism-related risk model and molecular subtypes for predicting postoperative biochemical recurrence in prostate cancer.,2025,abstract,2025-12-19T04:02:54.235948,,,,
['Mutation analysis'],['Pan-cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],['Multiple sources'],"The authors analyzed over 100,000 pancancer patient cases in cBioPortal to identify BRCA1/2 mutations occurring in patients with MSI-H status. They specifically searched for recurrent frameshift passenger mutation hotspots in BRCA1 and BRCA2 that occur at microsatellite sites. The analysis identified six recurrent hotspots that represented 17% of all truncating BRCA1/2 mutations in the cBioPortal dataset.",[],"['Web-based analysis', 'Query interface']","['BRCA1', 'BRCA2']",['Query interface'],"[""cBioPortal platform""]",high,4.0,40373258,Hotspot <i>BRCA1/2</i> Mutations in Tumors With Microsatellite Instability Suggest Passenger Mutation Status and Evaluation of Therapeutic Options.,2025,abstract,2025-12-19T04:02:55.527679,,,,
"['Gene expression analysis', 'Mutation analysis', 'Copy number analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal is mentioned in the introduction as one of the open-access databases and advanced computational tools that enable comprehensive analysis in cancer genomics research. However, the paper does not provide specific details about how cBioPortal was actually used in their analysis. The mutation analysis section mentions that MEX3A exhibited the highest alteration frequency (11%) primarily through gene amplifications, but the specific tool or platform used for this analysis is not explicitly stated.","['TCGA', 'GTEx', 'GEO']",['Citation only'],"['MEX3A', 'MEX3B', 'MEX3C', 'MEX3D', 'PDCD1', 'CD274', 'CTLA4']",['Not specified'],Unclear,low,4.0,40374855,Comprehensive bioinformatics analysis of MEX3 family genes in hepatocellular carcinoma.,2025,pdf,2025-12-19T04:02:56.322592,,,,
"['Mutation analysis', 'Copy number analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper describes a genomic profiling study of malignant peripheral nerve sheath tumors (MPNST) in Chinese patients using next-generation sequencing with a custom 706-gene panel. The analysis was performed using various bioinformatics tools (MuTect, PINDEL, Control-FREEC, STAR-fusion, IGV), but cBioPortal is not mentioned in the text provided. If cBioPortal is cited, it appears to be a citation only without direct usage described in these sections.",[],['Citation only'],"['NF1', 'CDKN2A', 'EED', 'SUZ12']",['Not specified'],Unclear,low,4.0,40369172,Genomic profiling and pathological assessment of malignant peripheral nerve sheath tumors.,2025,pdf,2025-12-19T04:02:57.265074,,,,
"['Gene expression analysis', 'Survival analysis']",['Breast cancer'],"['Biomarker discovery', 'Other']",['Original research'],"['TCGA', 'Not specified']",The authors used cBioPortal to analyze P2Y2 receptor (P2RY2) expression levels in breast cancer patients and correlate this with overall survival outcomes. They found that reduced P2Y2 expression correlates with poorer overall survival in breast cancer patients. The analysis appears to have been performed using cBioPortal's web-based tools to query TCGA breast cancer data.,['TCGA'],"['Web-based analysis', 'Web-based visualization']",['P2RY2'],"['Expression analysis', 'Survival analysis']",cBioPortal platform,medium,4.0,40362524,Disruption of P2Y2 Signaling Promotes Breast Tumor Cell Dissemination by Reducing ATP-Dependent Calcium Elevation and Actin Localization to Cell Junctions.,2025,pdf,2025-12-19T04:02:59.393554,,,,
"['Mutation analysis', 'Pathway analysis']","['Glioma/Brain cancer', 'Colorectal cancer', 'Leukemia/Lymphoma', 'Other solid tumor']","['Tumor evolution', 'Biomarker discovery', 'Precision medicine']",['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on genomic characterization of CMMRD-associated tumors using mutational signature analysis and references the COSMIC database for mutational signatures. cBioPortal may be cited in the references but does not appear to be actively used for data analysis or visualization in this study based on the provided text.",[],['Citation only'],"['MLH1', 'MSH2', 'MSH6', 'PMS2', 'POLE', 'POLD1']",['Not specified'],Unclear,low,4.0,40368937,Unraveling mutagenic processes influencing the tumor mutational patterns of individuals with constitutional mismatch repair deficiency.,2025,pdf,2025-12-19T04:02:59.551335,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Methods/Tools development', 'Database/Resource']","['Original research', 'Methods/Software']","['TCGA', 'ICGC', 'Multiple sources']","The authors developed tumor break load (TBL) as a new measure of structural variant-associated genomic instability and made this metric available in cBioPortal for the datasets analyzed in their study. They used pan-cancer data from TCGA, PCAWG, and CCLE to validate TBL's biological and clinical relevance. The TBL data has been integrated into cBioPortal as a resource for the research community.","['TCGA', 'PCAWG', 'CCLE']",['Database/Resource'],[],['Not specified'],"[""External (downloaded data)""]",high,4.0,40369102,Tumor break load quantitates structural variant-associated genomic instability with biological and clinical relevance across cancers.,2025,pdf,2025-12-19T04:02:59.612425,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","The cBioPortal database was used to evaluate genetic mutation profiles of SENP genes in hepatocellular carcinoma. The study mentions using cBioPortal as one of several databases for analyzing the SENP gene family, though specific details about which features or tools were used are not provided in the abstract and introduction sections.",[],['Web-based analysis'],"['SENP1', 'SENP2', 'SENP3', 'SENP5', 'SENP6', 'SENP7']",['Not specified'],Unclear,medium,4.0,40358846,Integrative analysis of the expression profile and prognostic values of SENP gene family in hepatocellular carcinoma.,2025,pdf,2025-12-19T04:02:59.876868,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Custom/Private data']","The paper does not explicitly mention using cBioPortal in the abstract or introduction provided. The study primarily analyzed TCGA data (163 GBM and 518 LGG cases) to assess LSM2 expression and prognostic value, and performed RNA sequencing on LSM2 knockdown cells. Without additional methods sections or explicit mentions, it appears cBioPortal may have been cited as a reference or potentially used for TCGA data access, but specific usage details are not provided in the excerpts given.","['TCGA-GBM', 'TCGA-LGG']",['Citation only'],"['LSM2', 'TLN1', 'FN1', 'IRF7', 'IDH1']",['Not specified'],Unclear,low,4.0,40365337,LSM2 drives glioma progression through alternative splicing dysregulation: a multi-omics approach to identify a potential therapeutic target.,2025,abstract,2025-12-19T04:02:59.944377,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],['Multiple sources'],"The paper mentions using public databases to assess claudin-1 expression in pancreatic cancer samples. Based on the abstract and introduction, cBioPortal appears to be one of the public databases consulted for expression and survival data in pancreatic ductal adenocarcinoma, though specific details about how it was used are not provided in the excerpts shown. The study primarily focuses on experimental validation using resected samples and cell lines with CRISPR/Cas9 knockout experiments.",[],['Citation only'],['CLDN1'],['Not specified'],Unclear,low,4.0,40361399,The Role of Claudin-1 in Enhancing Pancreatic Cancer Aggressiveness and Drug Resistance via Metabolic Pathway Modulation.,2025,pdf,2025-12-19T04:03:00.621028,,,,
"['Mutation analysis', 'Pathway analysis']","['Glioma/Brain cancer', 'Pan-cancer']","['Review/Commentary', 'Biomarker discovery', 'Pathway analysis']",['Review'],['Not specified'],"This is a review paper examining RAS mutations in CNS tumors, particularly glioblastoma. The paper does not explicitly describe using cBioPortal for any specific analysis or data retrieval. cBioPortal may be cited as a reference or general resource, but no specific usage details, datasets, or analyses performed using the platform are mentioned in the provided abstract and introduction.",[],['Citation only'],"['HRAS', 'KRAS', 'NRAS', 'KRAS4A', 'KRAS4B', 'NF1', 'EGFR', 'FGFR', 'BRAF', 'ARAF', 'CRAF', 'MEK1', 'MEK2', 'ERK1', 'ERK2']",['Not specified'],Unclear,low,4.0,40362343,The Role of RAS in CNS Tumors: A Key Player or an Overlooked Oncogene?,2025,pdf,2025-12-19T04:03:00.694313,,,,
['Mutation analysis'],['Pan-cancer'],"['Biomarker discovery', 'Immunotherapy', 'Review/Commentary']",['Review'],['Not specified'],"This is a perspective/review paper that discusses tumor mutational burden (TMB) as a biomarker for immunotherapy response across cancers. The paper does not describe specific usage of cBioPortal for data analysis or visualization. cBioPortal may be cited as a reference or resource in the context of discussing cancer genomics data, but no explicit methodology involving cBioPortal is described in the abstract or introduction.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40353818,"Of Context, Quality, and Complexity: Fine-Combing Tumor Mutational Burden in Immunotherapy-Treated Cancers.",2025,abstract,2025-12-19T04:03:01.538044,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],"['TCGA', 'Custom/Private data']",cBioPortal was used to analyze Wilms tumor patient data to examine the association between proteasome component expression levels and clinical outcomes. The authors found that increased levels of proteasome components were associated with anaplastic histology and worse prognosis in Wilms tumor patients. This analysis supported their experimental findings that proteasome activity is critical for anaplastic Wilms tumor cell survival.,[],"['Web-based analysis', 'Web-based visualization']",[],"['Expression analysis', 'Survival analysis']",cBioPortal platform,medium,4.0,40347939,Suppressing proteasome activity enhances sensitivity to actinomycin D in diffuse anaplastic Wilms tumor.,2025,abstract,2025-12-19T04:03:02.670171,,,,
"['Gene expression analysis', 'Mutation analysis']",['Pan-cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']",The authors used cBioPortal to identify a group of solid human tumors that lack functional p53 and ARF and show an expression signature of upregulated type I interferon response genes. They queried cancer genomics data to correlate p53/ARF mutation status with interferon-stimulated gene expression patterns across multiple tumor types. This analysis helped identify tumors that might be sensitive to selective JAK1 inhibitors based on their p53/ARF status and IFN signature.,[],"['Web-based analysis', 'Web-based visualization']","['TP53', 'CDKN2A']","['Query interface', 'Expression analysis']",Unclear,medium,4.0,40351125,Elevated Type I Interferon Signaling Defines the Proliferative Advantage of ARF and p53 Mutant Tumor Cells.,2025,abstract,2025-12-19T04:03:02.706316,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Melanoma'],"['Drug response/resistance', 'Immunotherapy', 'Biomarker discovery']",['Original research'],['Not specified'],"The paper used cBioPortal to analyze transcriptome data from melanoma patient samples to examine the association between MLKL expression levels and clinical outcomes. Specifically, they investigated the correlation between high MLKL expression and overall survival as well as durable clinical response to anti-PD-1 and/or anti-CTLA-4 checkpoint inhibitor immunotherapy. The analysis focused on validating their preclinical findings in human melanoma samples.",[],['Web-based analysis'],['MLKL'],"['Expression analysis', 'Survival analysis']",Unclear,medium,4.0,40345706,Defects in the necroptosis machinery are a cancer resistance mechanism to checkpoint inhibitor immunotherapy.,2025,abstract,2025-12-19T04:03:04.796004,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Leukemia/Lymphoma'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],['TCGA'],"The cBioPortal platform was used to analyze genetic alterations (mutations and copy number variations) in TNFAIP8 family genes (TNFAIP8, TNFAIP8L1, TNFAIP8L2, and TNFAIP8L3) within the TCGA AML dataset. The analysis revealed low frequency of genetic alterations, with TNFAIP8L1 being the only gene with mutations in 0.53% of cases. The platform was specifically mentioned in the Methods section as the tool for mutation analysis.",['TCGA'],['Web-based analysis'],"['TNFAIP8', 'TNFAIP8L1', 'TNFAIP8L2', 'TNFAIP8L3']",['Query interface'],cBioPortal platform,high,4.0,40335819,"Expression patterns, prognostic significance, and immune correlations of the TNFAIP8 family in acute myeloid leukemia: a comprehensive bioinformatics analysis.",2025,pdf,2025-12-19T04:03:05.490271,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Breast cancer'],"['Immunotherapy', 'Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'METABRIC']","The study used cBioPortal to analyze gene expression data from TCGA and METABRIC breast cancer datasets. The authors likely queried EYA3, CCL2, and NF-κB pathway genes to examine their expression patterns and correlations in triple-negative breast cancer patients. Survival analysis was likely performed to correlate gene expression with patient outcomes.","['TCGA', 'METABRIC']","['Web-based analysis', 'Data download/export']","['EYA3', 'CCL2']","['Expression analysis', 'Survival analysis', 'Query interface']",Mixed,medium,4.0,40333987,EYA3 regulation of NF-κB and CCL2 suppresses cytotoxic NK cells in the premetastatic niche to promote TNBC metastasis.,2025,abstract,2025-12-19T04:03:05.494547,,,,
['Gene expression analysis'],['Other solid tumor'],"['Biomarker discovery', 'Other']",['Original research'],['TCGA'],"The paper used cBioPortal to perform bioinformatics analyses to identify the most prominent stomach adenocarcinoma (STAD)-associated NADPH oxidase (NOX) gene. This analysis was conducted using TCGA stomach adenocarcinoma data to determine which NOX family member was most relevant to gastric cancer, which led to the identification and subsequent validation of NOX4 in their experimental studies.",['TCGA-STAD'],['Web-based analysis'],['NOX4'],"['Expression analysis', 'Query interface']",cBioPortal platform,medium,4.0,40325849,Hypoxia and Hypoxia-Reoxygenation Potentiate Helicobacter pylori Infection and Gastric Epithelial Cell Proliferation.,2025,abstract,2025-12-19T04:03:06.179570,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']",['Original research'],['TCGA'],"The study obtained genomic data of HNSCC patients from TCGA to investigate TP53 mutations and their impact on protein structure, function, and miRNA expression. The data was used to analyze mutation patterns, TP53 expression levels, miRNA expression (particularly hsa-mir-133b), and their associations with patient survival and prognosis. The analysis appears to have been conducted using downloaded data with various bioinformatics tools for computational analysis including structural modeling, docking studies, and molecular dynamics simulations.",['TCGA-HNSCC'],['Data download/export'],['TP53'],['Download data'],External (downloaded data),medium,4.0,40333905,The impact of mutations on TP53 protein and MicroRNA expression in HNSCC: Novel insights for diagnostic and therapeutic strategies.,2025,abstract,2025-12-19T04:03:06.362267,,,,
"['Mutation analysis', 'Pathway analysis']",['Other solid tumor'],"['Methods/Tools development', 'Biomarker discovery']","['Original research', 'Methods/Software']",['Custom/Private data'],"This paper does not appear to use cBioPortal directly. The study focuses on developing a whole-exome sequencing kit for porcine (pig) biomedical research models, analyzing mutations in pig breeds and Oncopig hepatocellular carcinoma samples. While the paper may cite cBioPortal in the context of cancer genomics research or comparative analysis, there is no evidence in the provided abstract and introduction that cBioPortal data or tools were used in this study.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40340757,Development of a whole-exome sequencing kit to facilitate porcine biomedical research.,2025,pdf,2025-12-19T04:03:06.458272,,,,
"['Gene expression analysis', 'Pathway analysis']",['Breast cancer'],"['Drug response/resistance', 'Immunotherapy', 'Biomarker discovery']",['Original research'],"['Custom/Private data', 'Multiple sources']","Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on analyzing publicly available transcriptomic data (GSE162187) and plasma samples from breast cancer patients treated with chemotherapy. The analysis appears to have been conducted using other bioinformatics tools and metabolomics/Luminex assays, without reference to cBioPortal platform or data.",['GSE162187'],['Citation only'],[],['Not specified'],Unclear,low,4.0,40322197,"Immune and Metabolic Reprogramming Induced by Paclitaxel, Capecitabine and Eribulin in Breast Cancer: Insights into Therapeutic Targets.",2025,pdf,2025-12-19T04:03:08.555983,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis']",['Prostate cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The study used cBioPortal to access publicly available genomic and proteome data from prostate cancer datasets to evaluate the expression of transient receptor potential (TRP) channels. The authors analyzed mRNA and protein expression levels of TRP family members, particularly MCOLN2 (TRPML2) and TRPM4, and examined their associations with ERG fusions and survival outcomes in prostate cancer patients. The analysis included expression profiling, mutation analysis, and survival correlations using data accessed through cBioPortal.",[],"['Web-based analysis', 'Web-based visualization']","['ERG', 'TMPRSS2', 'MCOLN2', 'TRPM4', 'TRPML1', 'TRPML2', 'TRPC1', 'TRPP3', 'TRPC1', 'TRPC2', 'TRPC3', 'TRPC4', 'TRPC5', 'TRPC6', 'TRPA1', 'TRPM1', 'TRPM2', 'TRPM3', 'TRPM5', 'TRPM6', 'TRPM7', 'TRPM8', 'TRPV1', 'TRPV2', 'TRPV3', 'TRPV4', 'TRPV5', 'TRPV6', 'MCOLN1', 'MCOLN3', 'PKD2', 'PKD2L1', 'PKD2L2']","['Expression analysis', 'Survival analysis', 'Query interface']",cBioPortal platform,medium,4.0,40332161,Transient Receptor Potential Channels in Prostate Cancer: Associations with ERG Fusions and Survival.,2025,pdf,2025-12-19T04:03:08.736778,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis']",['Prostate cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The paper used cBioPortal to analyze prostate cancer genomic and expression data, likely from TCGA datasets. The authors used cBioPortal for bioinformatics analysis to predict NSUN2 as a potential therapeutic target and to examine the relationship between FOXA1, NSUN2, and TRIM28 in prostate cancer. The specific details of cBioPortal usage are not extensively described in the provided abstract and introduction.",['TCGA'],"['Web-based analysis', 'Data download/export']","['NSUN2', 'FOXA1', 'TRIM28']","['Expression analysis', 'Not specified']","[""Unclear""]",medium,4.0,40319192,FOXA1-dependent NSUN2 facilitates the advancement of prostate cancer by preserving TRIM28 mRNA stability in a m5C-dependent manner.,2025,abstract,2025-12-19T04:03:08.958728,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine', 'Tumor evolution']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and title provided, there is no explicit mention of cBioPortal usage in this study. The paper describes an original research study investigating KRAS wild-type pancreatic ductal adenocarcinomas using targeted DNA sequencing, whole-exome sequencing, and targeted RNA sequencing on their own patient cohort. The molecular analyses appear to have been performed independently without reference to cBioPortal data or tools.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40317966,Clinicopathological and molecular characterization of KRAS wild-type pancreatic ductal adenocarcinomas reveals precursor lesions with oncogenic mutations and fusions in RAS pathway genes.,2025,abstract,2025-12-19T04:03:09.415583,,,,
"['Gene expression analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis', 'Drug response/resistance']",['Original research'],"['TCGA', 'Multiple sources']",cBioPortal was used for clinical validation through multi-omic analysis of head and neck squamous cell carcinoma (HNSCC) patient data. The authors performed genomic and proteomic analysis using cBioPortal to validate their experimental findings regarding the CD109/IL6Rα/STAT3/NRF2 pathway in SCC tumors. The paper mentions clinical validation was achieved through analysis of oral SCC tumors and head and neck SCC patient data from cBioPortal.,['TCGA-HNSC'],"['Web-based analysis', 'Web-based visualization']","['CD109', 'IL6R', 'STAT3', 'NFE2L2', 'SOD1', 'HMOX1']","['Expression analysis', 'Query interface']",cBioPortal platform,medium,4.0,40317079,IL-6-mediated tumorigenicity and antioxidant state in squamous cell carcinoma cells are driven by CD109 via stabilization of IL-6 receptor-alpha and activation of STAT3/NRF2 pathway.,2025,pdf,2025-12-19T04:03:11.021081,,,,
"['Gene expression analysis', 'Pathway analysis']",['Glioma/Brain cancer'],"['Immunotherapy', 'Biomarker discovery']",['Original research'],['Custom/Private data'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on single-cell RNA sequencing and spatial transcriptomics analysis of pediatric high-grade gliomas. If cBioPortal was used, it was likely only cited as a reference or for minor data validation purposes, but this is not evident from the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40315846,Dissecting the immune landscape in pediatric high-grade glioma reveals cell state changes under therapeutic pressure.,2025,abstract,2025-12-19T04:03:11.758232,,,,
"['Gene expression analysis', 'Copy number analysis']",['Breast cancer'],"['Immunotherapy', 'Pathway analysis']",['Original research'],"['TCGA', 'METABRIC']","The paper used cBioPortal to analyze the relationship between MYC amplification/expression and STING pathway components in breast cancer datasets. The authors likely queried TCGA and METABRIC breast cancer cohorts to examine MYC copy number alterations and gene expression patterns, and their correlation with STING (TMEM173) and related immune signaling genes. This analysis provided clinical context for their experimental findings showing MYC-mediated suppression of STING in triple-negative breast cancer cell lines.","['TCGA', 'METABRIC']","['Web-based analysis', 'Web-based visualization']","['MYC', 'TMEM173', 'STAT1', 'STAT3']","['Expression analysis', 'Query interface']",Unclear,medium,4.0,40311680,MYC controls STING levels to downregulate inflammatory signaling in breast cancer cells upon DNA damage.,2025,abstract,2025-12-19T04:03:11.931467,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Other']",['Original research'],['TCGA'],"Based on the abstract and introduction provided, the paper appears to focus on the mechanism of m6A-dependent mRNA decay and its interaction with tRNA modifications. The authors mention that dysregulation of m6A and mcm5s2U biogenesis pathways in cancer is associated with tumor aggressiveness and poor prognosis, suggesting they likely used cancer genomics databases like cBioPortal to analyze expression patterns and clinical correlations. However, specific details about cBioPortal usage are not explicitly mentioned in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40311619,tRNA modifications tune m<sup>6</sup>A-dependent mRNA decay.,2025,abstract,2025-12-19T04:03:11.999040,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Breast cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'METABRIC', 'Multiple sources']","The paper used cBioPortal to access and download genomic data from TCGA and METABRIC datasets for luminal breast cancer patients. The data included mutation profiles, copy number alterations, and clinical information for 1780 patients. The downloaded data was then analyzed externally to investigate associations between genetic alterations and recurrence risk in luminal breast cancer.","['TCGA', 'METABRIC']",['Data download/export'],"['PIK3CA', 'MAP3K1', 'CDH1', 'KMT2C', 'CBFB', 'TP53', 'RB1', 'PTPN22', 'BRCA2']",['Download data'],External (downloaded data),medium,4.0,40305907,Refining prognostic tools for luminal breast cancer: genetic insights and comprehensive analysis.,2025,abstract,2025-12-19T04:03:12.381171,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Mutation analysis', 'Copy number analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']",cBioPortal was used as one of multiple publicly available databases for integrative bioinformatics analysis in this study. The authors utilized cBioPortal to analyze genomic alterations and expression patterns of SLC35A family members in colorectal cancer. The specific details of how cBioPortal was used are not explicitly described in the provided abstract and introduction sections.,[],['Web-based analysis'],"['SLC35A1', 'SLC35A2', 'SLC35A3', 'SLC35A4', 'SLC35A5', 'MYC']",['Not specified'],Unclear,medium,4.0,40303483,Solute Carrier Family 35 A2 (SLC35A2) Promotes Tumor Progression through MYC-Mediated Pathways in Colorectal Cancer.,2025,pdf,2025-12-19T04:03:12.391785,,,,
,,,,,,,,,,,,,40287591,,,,,No text available,True,True,No text available
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']",cBioPortal was used to explore variants (mutations and copy number alterations) of the PBK/TOPK gene in breast cancer and to assess their prognostic implications. The study examined genetic alterations in PBK/TOPK across different breast cancer subtypes and evaluated whether these variants influenced patient prognosis.,['TCGA-Breast Cancer'],"['Web-based analysis', 'Web-based visualization']","['PBK', 'TOPK']","['Query interface', 'Mutation analysis']",cBioPortal platform,medium,4.0,40301429,"Correlation study of PBK/TOPK expression, prognosis, and immune infiltration in breast cancer.",2025,pdf,2025-12-19T04:03:14.913763,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Pathway analysis', 'Multi-omics integration']",['Lung cancer'],"['Precision medicine', 'Drug response/resistance', 'Methods/Tools development']","['Original research', 'Methods/Software']","['TCGA', 'Custom/Private data']","The paper describes CanSeer, a methodology for developing personalized cancer therapeutics using computational modeling. While the abstract and introduction mention using patient-specific genetic alterations and RNA-seq data for lung squamous cell carcinoma (LUSC) patients, the specific role of cBioPortal is not explicitly detailed in the provided text. The paper appears to focus on developing a novel computational framework that integrates multi-omics data for personalized therapy prediction.",['TCGA'],['Citation only'],[],['Not specified'],Unclear,low,4.0,40301468,CanSeer: a translational methodology for developing personalized cancer models and therapeutics.,2025,pdf,2025-12-19T04:03:15.034224,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract, this study conducted a comprehensive analysis of SAE1 in pancreatic adenocarcinoma (PAAD) integrating multiple data types including mRNA expression, immunohistochemistry, CRISPR cell line analysis, and single-cell RNA sequencing. While cBioPortal is cited, the specific usage is not detailed in the provided abstract and introduction, though it was likely used to access TCGA PAAD data for expression and clinical analysis. The study found SAE1 overexpression in PAAD and linked it to cell cycle and DNA replication pathways.",['TCGA-PAAD'],"['Data download/export', 'Web-based analysis']","['SAE1', 'FOXA1']","['Expression analysis', 'Not specified']",Unclear,low,4.0,40302186,SAE1 May Play a Pro-Carcinogenic Role in Pancreatic Adenocarcinoma: A Comprehensive Study Integrating Multiple Pieces of Evidence.,2025,abstract,2025-12-19T04:03:15.469062,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Pathway analysis']",['Pan-cancer'],['Biomarker discovery'],['Original research'],"['TCGA', 'Multiple sources']",The cBioPortal database was used to analyze genomic alterations of the SLC16A3 gene across pan-cancer samples. The study examined mutation patterns and copy number alterations in SLC16A3 to understand its genomic landscape in different cancer types. This analysis complemented their comprehensive pan-cancer investigation of SLC16A3 as a prognostic and diagnostic biomarker.,[],['Web-based analysis'],['SLC16A3'],['Not specified'],cBioPortal platform,medium,4.0,40301866,Comprehensive pan-cancer analysis identified SLC16A3 as a potential prognostic and diagnostic biomarker.,2025,pdf,2025-12-19T04:03:16.091413,,,,
"['Mutation analysis', 'Gene expression analysis', 'Multi-omics integration']",['Lung cancer'],"['Immunotherapy', 'Biomarker discovery', 'Precision medicine']",['Original research'],['TCGA'],"cBioPortal was used to download LUAD mutation data and clinical information from TCGA. Mutation data were downloaded on February 2, 2021, and clinical information including overall survival data was downloaded on May 23, 2021. The downloaded data were then analyzed externally using Python for immune clustering analysis and to examine the distribution of EGFR and KRAS mutations across identified patient clusters.",['TCGA-LUAD'],['Data download/export'],"['EGFR', 'KRAS']",['Download data'],External (downloaded data),high,4.0,40299444,Immune Clustering Reveals Molecularly Distinct Subtypes of Lung Adenocarcinoma.,2025,pdf,2025-12-19T04:03:16.842989,,,,
"['Mutation analysis', 'Pathway analysis']",['Other solid tumor'],"['Precision medicine', 'Drug response/resistance', 'Biomarker discovery']",['Original research'],['Multiple sources'],"The paper does not explicitly describe how cBioPortal was used in the methodology. Based on the abstract and introduction, the study performed comprehensive data mining and in silico analyses of thyroid cancer driver genes across global populations, but no specific mention of cBioPortal usage is provided in the text. It is likely that cBioPortal was cited as a reference or potentially used for data access, but the exact usage mode cannot be determined from the provided text.",[],['Citation only'],"['RET', 'BRAF', 'NRAS', 'KRAS', 'EPHA7']",['Not specified'],Unclear,low,4.0,40297138,Global analysis of actionable genomic alterations in thyroid cancer and precision-based pharmacogenomic strategies.,2025,abstract,2025-12-19T04:03:17.318705,,,,
"['Mutation analysis', 'Pathway analysis', 'Gene expression analysis']","['Colorectal cancer', 'Pan-cancer']","['Drug response/resistance', 'Pathway analysis', 'Precision medicine']",['Original research'],"['GENIE', 'Multiple sources']","The paper appears to use cBioPortal to analyze RAS mutation patterns and frequencies across different cancer types, particularly focusing on G12 and Q61 mutations. The study likely queried mutation data to understand the distribution of RAS mutations and their association with resistance mechanisms in colorectal cancer. Based on the abstract and title, cBioPortal was likely used to access genomic data from databases like GENIE to characterize RAS mutation patterns.",['GENIE'],"['Data download/export', 'Web-based analysis']","['KRAS', 'NRAS', 'HRAS', 'EGFR']","['Query interface', 'Download data']","[""External (downloaded data)""]",medium,4.0,40294008,Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations.,2025,abstract,2025-12-19T04:03:18.149333,,,,
"['Gene expression analysis', 'Other']",['Melanoma'],"['Tumor evolution', 'Methods/Tools development']",['Original research'],"['TCGA', 'Custom/Private data']",The paper used cBioPortal to access TCGA melanoma (SKCM) gene expression data to validate their findings about ITGB4 expression in melanoma. The authors likely queried ITGB4 expression levels in TCGA melanoma samples to provide context for their experimental findings in A375 melanoma cells. This appears to be a supplementary validation using publicly available data rather than a central component of their 3D genome architecture study.,['TCGA-SKCM'],"['Web-based analysis', 'Citation only']",['ITGB4'],['Expression analysis'],Unclear,medium,4.0,40292313,Deciphering pre-existing and induced 3D genome architecture changes involved in constricted melanoma migration.,2025,abstract,2025-12-19T04:03:18.407440,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Copy number analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']",cBioPortal was used to examine genetic alterations (mutations and copy number alterations) and survival outcomes in the TCGA-PAAD (pancreatic adenocarcinoma) dataset. The platform was accessed to analyze the genomic landscape of SLC transporter genes in PDAC patients and correlate these alterations with clinical outcomes.,['TCGA-PAAD'],"['Web-based analysis', 'Web-based visualization']","['SLC39A10', 'SLC22B5', 'SLC55A2', 'SLC30A6']","['Query interface', 'Not specified']",Mixed,medium,4.0,40282424,The Solute Carrier Superfamily as Therapeutic Targets in Pancreatic Ductal Adenocarcinoma.,2025,pdf,2025-12-19T04:03:18.460825,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration', 'Mutation analysis', 'Copy number analysis']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The study integrated TCGA/GTEx data from 33 cancer types for pan-cancer analysis of EOGT expression patterns and clinical significance. The authors performed multi-omics analysis including expression patterns, genomic variations, genomic instability, and tumor microenvironment interactions across multiple cancer types with particular focus on hepatocellular carcinoma (HCC). The analysis included 10 HCC cohorts and utilized various databases including GDSC/CTRP/PRISM for drug sensitivity analysis.","['TCGA', 'GTEx']",['Citation only'],"['EOGT', 'YAP', 'YY1', 'SLC22A15', 'AANAT', 'PD-L1', 'NOTCH1', 'SHCBP1']",['Not specified'],Unclear,low,4.0,40299340,Migrasome Marker Epidermal Growth Factor Domain-Specific <i>O</i>-GlcNAc Transferase: Pan-Cancer Angiogenesis Biomarker and the Potential Role of circ_0058189/miR-130a-3p/EOGT Axis in Hepatocellular Carcinoma Progression and Sorafenib Resistance.,2025,pdf,2025-12-19T04:03:18.934519,,,,
"['Mutation analysis', 'Copy number analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']","['Multiple sources', 'Custom/Private data']","The cBioPortal bioanalytical platform was employed to analyze thyroid carcinoma sequencing data from both the ORIEN-AVATAR database and several publicly available datasets. The authors used cBioPortal to identify cases with FLCN gene alterations, specifically focusing on mutational and copy number alteration (CNA) status in thyroid carcinomas. This analysis was used to determine the broader prevalence and significance of FLCN alterations across large thyroid cancer cohorts.",['ORIEN-AVATAR'],"['Web-based analysis', 'Query interface']","['FLCN', 'TP53', 'RB1']",['Query interface'],cBioPortal platform,high,4.0,40277780,"<i>Folliculin</i> (<i>FLCN</i>) in Thyroid Tumors: Incidence, Significance, and Role as a Driver Gene and Secondary Alteration.",2025,pdf,2025-12-19T04:03:21.576343,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],['Biomarker discovery'],['Original research'],"['TCGA', 'Multiple sources']","The cBioPortal database was used to explore the alteration features of MEF2 family genes (MEF2A, MEF2B, MEF2C, and MEF2D) in pancreatic cancer (PAAD). The study identified mutation types for these genes, including that MEF2A had truncating mutations with a specific G27Wfs*8 mutation point in the SRF-TF domain, while MEF2C and MEF2D showed missense mutations. The analysis was part of a comprehensive multi-database approach to characterize MEF2 genes as potential biomarkers in PAAD.",['TCGA Pancreas'],['Web-based analysis'],"['MEF2A', 'MEF2B', 'MEF2C', 'MEF2D']",['Query interface'],cBioPortal platform,high,4.0,40281485,"MEF2A, MEF2C, and MEF2D as potential biomarkers of pancreatic cancer?",2025,pdf,2025-12-19T04:03:21.835792,,,,
"['Gene expression analysis', 'Multi-omics integration', 'Pathway analysis', 'Survival analysis']",['Breast cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'Custom/Private data', 'Multiple sources']","The paper used cBioPortal to validate the expression patterns of GNPDA1 and SLC25A16 genes in breast cancer tissues through UALCAN analysis. The study integrated DNA methylation and microRNA data from Taiwan Biobank samples with public databases including GEO and performed validation using cBioPortal-associated tools. The analysis examined gene expression levels, methylation patterns, and their association with survival outcomes in breast cancer patients.",['TCGA'],"['Web-based analysis', 'Web-based visualization']","['GNPDA1', 'SLC25A16', 'BRCA1', 'BRCA2', 'ESR1']","['Expression analysis', 'Survival analysis']",Mixed,medium,4.0,40278313,Integrative Analysis of DNA Methylation and microRNA Reveals GNPDA1 and SLC25A16 Related to Biopsychosocial Factors Among Taiwanese Women with a Family History of Breast Cancer.,2025,pdf,2025-12-19T04:03:21.888813,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Pathway analysis', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used as one of multiple bioinformatics tools in this pan-cancer analysis of GTF2E2. The study employed cBioPortal to investigate GTF2E2's mutational landscape and potentially other genomic features across 33 cancer types using TCGA data. The specific details of cBioPortal usage are not extensively described in the abstract, suggesting it was one component of a comprehensive multi-tool analytical approach.",['TCGA'],['Web-based analysis'],"['GTF2E2', 'GPX4', 'ACSL4']",['Not specified'],"[""Unclear""]",medium,4.0,40267151,"Pan-cancer analysis and validation show GTF2E2's diagnostic, prognostic, and immunological roles in regulating ferroptosis in endometrial cancer.",2025,abstract,2025-12-19T04:03:22.151020,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The study used cBioPortal to access and analyze TCGA and Foundation Medicine, Inc. (FMI) datasets for clear cell RCC and papillary RCC. The authors queried mutation frequencies, gene amplifications, and expression data for MET, AXL, and SRC genes across these datasets. TCGA expression data from cBioPortal was used to validate immunohistochemistry findings on tumor stage and survival, and to examine correlations between AXL and c-MET expression.","['TCGA', 'Foundation Medicine']","['Data download/export', 'Web-based analysis']","['MET', 'AXL', 'SRC']","['Expression analysis', 'Query interface', 'Download data']","[""External (downloaded data)""]",high,4.0,40260977,"AXL and SRC in clear cell renal cell carcinoma: absence of mutations, rare alternative splicing events, but association of protein expression with poor prognosis.",2025,abstract,2025-12-19T04:03:23.458479,,,,
['Other'],['Pan-cancer'],['Review/Commentary'],['Review'],['Not specified'],"This is a review paper discussing epigenetic reprogramming and cancer hallmarks, with a focus on in vivo reprogramming studies. The paper cites cBioPortal but does not describe any specific usage of the platform for data analysis or visualization. The citation appears to be for reference purposes only in the context of discussing cancer genomics and genetic aberrations.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40259515,In Vivo Reprogramming Highlights Epigenetic Regulation That Shapes Cancer Hallmarks.,2025,abstract,2025-12-19T04:03:23.784602,,,,
"['Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],['TCGA'],"The paper mentions using TCGA EC (esophageal carcinoma) samples to investigate CDKN2B deletion status and RNA expression. While cBioPortal is not explicitly mentioned in the abstract or introduction, the study analyzes CDKN2B deletion status and gene expression data from TCGA, which is commonly accessed through cBioPortal. The researchers identified differentially expressed immune-associated genes between wild-type and deleted CDKN2B samples and constructed an immune prognostic model.",['TCGA-ESCA'],['Citation only'],"['CDKN2B', 'CDKN2A', 'CDK4', 'CDK6', 'GHRH', 'HIST1H2BE', 'MUC6']",['Not specified'],Unclear,low,4.0,40265174,A CDKN2B-Associated Immune Prognostic Model for Predicting Immune Cell Infiltration and Prognosis in Esophageal Carcinoma.,2025,pdf,2025-12-19T04:03:24.108489,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Colorectal cancer'],"['Database/Resource', 'Methods/Tools development', 'Precision medicine', 'Biomarker discovery']",['Methods/Software'],['Multiple sources'],"Based on the abstract and introduction provided, cBioPortal is likely cited as a reference or related resource in the context of cancer genomics databases. The paper describes the development of MIPD, a new database integrating molecules, imaging features, and clinical phenotypes for colorectal cancer. No specific details about how cBioPortal was used in the development or analysis of MIPD are provided in the available text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40257906,"MIPD: Molecules, Imagings, and Clinical Phenotype Integrated Database.",2025,abstract,2025-12-19T04:03:24.169730,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],['Biomarker discovery'],"['Original research', 'Meta-analysis']","['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper describes using the BEST online database for mRNA expression analysis, TCGA and GEO databases for gene expression data, and the CPADS database for clinical drug relevance assessment. The study also conducted a meta-analysis using STATA software. cBioPortal may be cited in the references but is not described as being used for data analysis or visualization in the sections provided.",['TCGA-STAD'],['Citation only'],"['PIEZO1', 'PIEZO2']",['Not specified'],Unclear,low,4.0,40257604,Comprehensive analysis of mRNA expression of Piezo1 and Piezo2 in tumor samples and their prognostic implications in gastric cancer.,2025,pdf,2025-12-19T04:03:24.755921,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],['TCGA'],"Based on the abstract and introduction provided, cBioPortal is likely cited as a reference or potential data source, but no specific details about how cBioPortal was used are mentioned. The study primarily describes using TCGA data to develop a lactate metabolism-based prognostic model for HNSC. Without explicit mention of cBioPortal usage in the provided text, it appears to be a citation-only reference.",['TCGA'],['Citation only'],[],['Not specified'],Unclear,low,4.0,40255484,The gene signature linked to lactate metabolism predicts the prognosis and correlates with the immune status of head and neck squamous cell carcinoma.,2025,abstract,2025-12-19T04:03:24.845924,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Leukemia/Lymphoma'],"['Biomarker discovery', 'Precision medicine', 'Immunotherapy']",['Original research'],['TCGA'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal being used in this study. The authors obtained RNA-seq and clinical data directly from The Cancer Genome Atlas (TCGA) database to identify disulfidptosis-related lncRNAs and construct a prognostic model for AML. The paper does not describe any specific use of cBioPortal's tools, features, or data access methods.",['TCGA'],['Citation only'],['SLC7A11'],['Not specified'],Unclear,low,4.0,40254646,Disulfidptosis-related LncRNAs forecast the prognosis of acute myeloid leukemia.,2025,pdf,2025-12-19T04:03:27.143311,,,,
"['Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['Multiple sources'],"The paper mentions cBioPortal in the context of genomic analysis, specifically for identifying copy number variations (CNVs) as drivers of PRC1 overexpression in Wilms tumor. However, the abstract and introduction do not provide explicit details about how cBioPortal was used, what specific features were accessed, or whether data was downloaded or analyzed on the platform. The primary data sources mentioned are TARGET database for bulk RNA-seq and GSE200256 for single-cell RNA-seq analysis.",[],['Citation only'],['PRC1'],['Not specified'],Unclear,low,4.0,40247060,PRC1 as an independent adverse prognostic factor in Wilms tumor via integrated bioinformatics and experimental validation.,2025,abstract,2025-12-19T04:03:28.474514,,,,
"['Mutation analysis', 'Gene expression analysis', 'Multi-omics integration']",['Melanoma'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The paper used cBioPortal to analyze melanoma patient data, specifically examining ARID2 mutations and their correlation with gene expression signatures. The authors validated their findings from experimental models by querying melanoma patient cohorts through cBioPortal to determine if the synaptic/neuronal gene signature associated with ARID2 loss in their cell line experiments was conserved in actual melanoma patients with ARID2 mutations.",['TCGA-SKCM'],"['Web-based analysis', 'Citation only']",['ARID2'],"['Query interface', 'Expression analysis', 'Not specified']",Unclear,medium,4.0,40252649,The SWI/SNF PBAF complex facilitates REST occupancy at repressive chromatin.,2025,abstract,2025-12-19T04:03:28.721818,,,,
"['Gene expression analysis', 'Other']",['Colorectal cancer'],"['Biomarker discovery', 'Other']",['Original research'],['Not specified'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The research focuses on experimental work using human cell lines (HCT116 colon cancer cells and CCD-18Co fibroblasts) and xenograft models to investigate the role of p53 deficiency and Meflin expression in tumor-fibroblast interactions. If cBioPortal was used, it may have been for preliminary data mining or validation, but this is not described in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40241262,p53 Deficiency in Colon Cancer Cells Promotes Tumor Progression Through the Modulation of Meflin in Fibroblasts.,2025,abstract,2025-12-19T04:03:29.307402,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Pan-cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis', 'Precision medicine']",['Original research'],['TCGA'],"The paper conducted a comprehensive pan-cancer analysis of NLRP1 using data from The Cancer Genome Atlas (TCGA). The study examined NLRP1 expression across various cancer types, investigated correlations with survival metrics, genetic alterations, immune infiltration, promoter methylation, and drug sensitivity. While cBioPortal is likely used as one of the databases for accessing TCGA data and performing genetic alteration analysis, the specific details of cBioPortal usage are not explicitly described in the abstract.",['TCGA'],['Citation only'],['NLRP1'],['Not specified'],Unclear,low,4.0,40237399,The NLRP1 Emerges as a Promising Therapeutic Target and Prognostic Biomarker Across Multiple Cancer Types: A Comprehensive Pan-Cancer Analysis.,2025,abstract,2025-12-19T04:03:29.619932,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],['Biomarker discovery'],['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and methods provided, there is no explicit mention of cBioPortal usage in this study. The authors used GEO datasets (GSE113255, GSE122401, GSE93415), TCGA STAD data from UCSC Xena database, Kaplan Meier plotter database, and The Human Protein Atlas. All analyses appear to have been conducted using R packages and other bioinformatics tools without reference to cBioPortal. This appears to be a citation-only paper or cBioPortal was not used at all.",['TCGA-STAD'],['Citation only'],"['ADAMTSL2', 'DSCC1', 'COL5A3', 'F2RL2', 'GRIN2D', 'IGSF6', 'IER5L', 'PLA2G7', 'PODNL1', 'RCN3', 'RTN4RL2', 'NOTCH1', 'NOTCH3', 'NOTCH4', 'HEY1']",['Not specified'],Unclear,low,4.0,40252157,ADAMTSL2 is an independent predictor for the prognosis of gastric cancer.,2025,pdf,2025-12-19T04:03:29.744100,,,,
"['Mutation analysis', 'Survival analysis']",['Other solid tumor'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],['Not specified'],The study used cBioPortal to analyze MYC mutations in ovarian cancer patients. They examined the prevalence of MYC alterations and performed survival analysis comparing patients with and without MYC mutations. The analysis revealed prevalent MYC mutations but found no significant survival differences between mutated and non-mutated patient groups.,[],"['Web-based analysis', 'Web-based visualization']",['MYC'],"['Mutation Mapper', 'Survival analysis']",cBioPortal platform,medium,4.0,40236999,Bioinformatics study and cytotoxicity of several curcumin analogues in ovarian cancer.,2025,abstract,2025-12-19T04:03:29.816750,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Copy number analysis']",['Pan-cancer'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, cBioPortal is not explicitly mentioned in the visible text. The study uses TCGA data and multiple bioinformatics platforms (TIMER2, GEPIA2, UALCAN, HPA) for analyzing DEFB1 expression, genetic alterations, survival, and immune infiltration across cancers. If cBioPortal was used, it was likely for querying genetic alterations or accessing TCGA data, but this is not clearly stated in the provided sections.","['TCGA-DLBC', 'TCGA-LAML']",['Citation only'],"['DEFB1', 'KLK1', 'BSND', 'CLCNKB']",['Not specified'],Unclear,low,4.0,40244529,Integrative genomic pan-cancer analysis reveals the prognostic significance of DEFB1 in tumors.,2025,pdf,2025-12-19T04:03:30.661594,,,,
"['Gene expression analysis', 'Multi-omics integration', 'Pathway analysis']","['Pan-cancer', 'Glioma/Brain cancer']","['Methods/Tools development', 'Biomarker discovery', 'Pathway analysis']","['Original research', 'Methods/Software']",['TCGA'],The authors used TCGA PanCancer Atlas data to apply their newly developed tool SQUID (stress quantification using integrated datasets) to profile mitochondrial stress signatures across cancer types. They specifically identified a signature of pyruvate import deficiency in IDH1-mutant glioma using their integrated transcriptomic and metabolomic analysis approach. The TCGA data was likely accessed through cBioPortal for download and external analysis with their custom tool.,['TCGA PanCancer Atlas'],['Data download/export'],['IDH1'],['Download data'],External (downloaded data),medium,4.0,40233762,Integrated analysis of transcriptional and metabolic responses to mitochondrial stress.,2025,abstract,2025-12-19T04:03:30.886853,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Other']",['Original research'],['Not specified'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on experimental work with xenografts, cell culture assays, and microarray-based gene expression analysis to study IGFBP5 in rhabdomyosarcoma. Patient data correlations are mentioned but the source and analysis platform are not specified in the provided text.",[],['Citation only'],"['IGFBP5', 'GAS2', 'PAX3', 'PAX7', 'FOXO1', 'IGF2', 'IGF1R', 'CTGF', 'DDR1']",['Not specified'],Unclear,low,4.0,40234830,Myogenic IGFBP5 levels in rhabdomyosarcoma are nourished by mesenchymal stromal cells and regulate growth arrest and apoptosis.,2025,pdf,2025-12-19T04:03:32.673720,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Pathway analysis']",['Pan-cancer'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the methods or abstract provided. The study primarily uses TCGA, TARGET, and GTEx data from the UCSC database for pan-cancer analysis of PPP1R3G. While cBioPortal is cited as a reference, there is no clear description of how it was used for data access, analysis, or visualization in the portions of the paper provided.","['TCGA', 'TARGET', 'GTEx']",['Citation only'],['PPP1R3G'],['Not specified'],Unclear,low,4.0,40232629,"Comprehensive pan-cancer analysis of PPP1R3G reveals its diagnostic, prognostic, and immunotherapeutic implications.",2025,pdf,2025-12-19T04:03:34.123170,,,,
['Mutation analysis'],['Not specified'],['Other'],"['Original research', 'Clinical study']",['Custom/Private data'],"This paper does not actually use cBioPortal. The study focuses on Pompe disease, a rare lysosomal storage disorder caused by GAA gene mutations, not cancer. The paper analyzes biochemical and genetic testing data from over 30,000 symptomatic patients using dried blood spots to diagnose Pompe disease. This is not a cancer genomics study and cBioPortal was likely cited only as a reference or mistakenly included in the citation list.",[],['Citation only'],[],['Not specified'],"[""Unclear""]",high,4.0,40225932,Biochemical and Genetic Testing of GAA in Over 30.000 Symptomatic Patients Suspected to Be Affected With Pompe Disease.,2024,abstract,2025-12-19T04:03:34.542677,,,,
"['Gene expression analysis', 'Pathway analysis']","['Pan-cancer', 'Leukemia/Lymphoma', 'Breast cancer']",['Methods/Tools development'],['Methods/Software'],"['TCGA', 'Multiple sources']","The paper describes TRANSECT, a new bioinformatics tool for transcriptome analysis. cBioPortal is mentioned as one of the existing tools that researchers use to interrogate publicly accessible expression data from large consortium projects like TCGA and GTEx. However, the paper does not describe specific usage of cBioPortal for their analyses; rather, it positions TRANSECT as a complementary tool that provides different analytical capabilities for mining these rich genomic resources.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40225790,TRanscriptome ANalysis of StratifiEd CohorTs (TRANSECT) enables automated assessment of global gene regulation linked to disparate expression in user defined genes and gene sets.,2025,abstract,2025-12-19T04:03:35.467667,,,,
"['Mutation analysis', 'Copy number analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on investigating clinical and genetic characteristics of 244 probands with multiple osteochondromas through mutation and copy number variant analysis in EXT1, EXT2, and PTPN11 genes. If cBioPortal is cited, it appears to be a reference citation only without clear description of how the platform was utilized for data analysis or visualization.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40225915,The Missing Piece of the Puzzle: Unveiling the Role of <i>PTPN11</i> Gene in Multiple Osteochondromas in a Large Cohort Study.,2024,abstract,2025-12-19T04:03:35.497292,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']",cBioPortal was used to access and analyze TCGA clear cell renal cell carcinoma (ccRCC) data for gene expression and survival analysis. The authors queried ANXA4 expression levels and performed survival analysis to correlate ANXA4 expression with patient outcomes. The platform was used to validate findings from their proteomics and single-cell RNA sequencing experiments using publicly available TCGA datasets.,['TCGA'],"['Web-based analysis', 'Web-based visualization']","['ANXA4', 'ELF3']","['Expression analysis', 'Survival analysis', 'Query interface']",cBioPortal platform,medium,4.0,40212597,"Versatile roles of annexin A4 in clear cell renal cell carcinoma: Impact on membrane repair, transcriptional signatures, and composition of the tumor microenvironment.",2025,abstract,2025-12-19T04:03:35.768357,,,,
"['Mutation analysis', 'Pathway analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine']",['Original research'],['Not specified'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal being used in this study. The paper focuses on a two-sample Mendelian randomization analysis using GWAS data to investigate causal relationships between plasma proteins and MAPK-activated colorectal cancers. cBioPortal may only be cited in the references without direct usage in the methodology.",[],['Citation only'],"['KRAS', 'NRAS', 'HRAS', 'BRAF', 'EGFR', 'MEK', 'ERK']",['Not specified'],Unclear,low,4.0,40210889,Genetically druggable targets for MAPK-activated colorectal cancer by a two-sample mendelian randomization analysis.,2025,pdf,2025-12-19T04:03:36.334431,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],The study used cBioPortal to analyze gene expression patterns and clinical outcomes in renal clear cell carcinoma (ccRCC) patients. The authors examined YAP1 and its target genes in ccRCC datasets to assess their upregulation and association with patient prognosis. cBioPortal was likely used to access TCGA kidney cancer data for expression and survival analysis.,['TCGA'],"['Web-based analysis', 'Web-based visualization']",['YAP1'],"['Expression analysis', 'Survival analysis']",Unclear,medium,4.0,40210757,Hyperactivated YAP1 is essential for sustainable progression of renal clear cell carcinoma.,2025,abstract,2025-12-19T04:03:37.648680,,,,
"['Mutation analysis', 'Gene expression analysis']",['Melanoma'],"['Drug response/resistance', 'Immunotherapy', 'Biomarker discovery']",['Original research'],['Not specified'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage. The paper focuses on experimental validation of USP7 inhibition in NRAS-mutant melanoma using cell lines and mouse models. While the paper cites cBioPortal, the specific usage details are not described in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40204067,Selective USP7 Inhibition Synergizes with MEK1/2 Inhibitor to Enhance Immune Responses and Potentiate Anti-PD-1 Therapy in NRAS-Mutant Melanoma.,2025,abstract,2025-12-19T04:03:37.727869,,,,
"['Gene expression analysis', 'Pathway analysis']",['Glioma/Brain cancer'],"['Methods/Tools development', 'Database/Resource']","['Methods/Software', 'Original research']",['Not specified'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this paper. The paper focuses on developing miRTalk, a computational method for inferring extracellular vesicle-derived miRNA-mediated cell-cell communication from single-cell RNA-seq data. The paper may cite cBioPortal in references but does not describe using it for data analysis or visualization in the sections provided.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40229908,Extracellular vesicle-derived miRNA-mediated cell-cell communication inference for single-cell transcriptomic data with miRTalk.,2025,pdf,2025-12-19T04:03:38.517695,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Pan-cancer'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, cBioPortal is not explicitly mentioned in the text. The study uses TCGA pan-cancer data and other databases (TISIDB, GTEx) for analyzing PVRIG expression, prognosis, and immune infiltration. Without explicit mention of cBioPortal in the provided sections, it appears the paper may only cite cBioPortal as a reference or the usage is described in methods sections not provided.","['TCGA pan-cancer', 'GTEx']",['Citation only'],"['PVRIG', 'CD226', 'CD112', 'PVR', 'CD96', 'TIGIT', 'CTLA4', 'PDCD1', 'CD274']",['Not specified'],Unclear,low,4.0,40204776,Integrating bioinformatics with experimental validation unveils immunological and prognostic significance of PVRIG in pan-cancer.,2025,pdf,2025-12-19T04:03:38.687996,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Multi-omics integration', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],['Multiple sources'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on integrating single-cell RNA sequencing, bulk RNA sequencing, radiomics from MRI, genomic data, and immunohistochemistry to investigate gamma-delta T cells in triple-negative breast cancer. The data sources mentioned include GEO datasets (GSE176078, GSE180286, GSE128223) but no reference to cBioPortal is found in the provided text.","['GSE176078', 'GSE180286', 'GSE128223']",['Citation only'],"['MUC16', 'DOCK11', 'LAMA2', 'RYR1']",['Not specified'],Unclear,low,4.0,40197136,Integrating multi-omics data reveals the antitumor role and clinical benefits of gamma-delta T cells in triple-negative breast cancer.,2025,pdf,2025-12-19T04:03:40.173775,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Other']",['Original research'],['TCGA'],"The study used the TCGA database (likely accessed through cBioPortal) to analyze MK2 (MAPKAPK2) expression in head and neck squamous cell carcinoma (HNSCC) samples. The analysis showed that MK2 expression was associated with more advanced cancers and faster cancer recurrence rates. This bioinformatic analysis complemented the experimental work using cell lines and mouse models to investigate MK2's role in HNSCC migration, invasion, and metastasis.",['TCGA-HNSC'],['Citation only'],['MAPKAPK2'],['Not specified'],Unclear,low,4.0,40185303,"MK2 promotes p16 negative head and neck cancer migration, invasion, and metastasis.",2025,abstract,2025-12-19T04:03:42.393090,,,,
['Mutation analysis'],['Pan-cancer'],"['Review/Commentary', 'Biomarker discovery']",['Review'],['Not specified'],"This is a review paper focused on post-translational modifications of the TIP60 protein and their role in cellular functions and cancer. The paper appears to use cBioPortal to examine cancer-associated mutations in TIP60, particularly analyzing the relationship between PTM sites and cancer mutations. However, the abstract and introduction provided do not contain explicit details about specific cBioPortal usage, datasets queried, or analysis methods employed.",[],['Citation only'],['KAT5'],['Not specified'],Unclear,low,4.0,40186325,Post-translational modifications of epigenetic modifier TIP60: their role in cellular functions and cancer.,2025,pdf,2025-12-19T04:03:43.522690,,,,
['Other'],['Not specified'],"['Review/Commentary', 'Methods/Tools development']",['Review'],['Not specified'],"This is a review paper focused on methods and technologies for studying the cell surface proteome (surfaceome). cBioPortal is likely cited as a reference resource in the context of cancer genomics databases, but no specific usage, analysis, or data extraction from cBioPortal is described in the abstract or introduction. The paper's focus is on proteomics methods rather than genomic data analysis.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40178992,Engineered Proteins and Chemical Tools to Probe the Cell Surface Proteome.,2025,abstract,2025-12-19T04:03:44.880951,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis']","['Breast cancer', 'Pan-cancer']","['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'METABRIC', 'Multiple sources']","The study used cBioPortal to analyze PPP2R1B (Aβ) expression and alterations across multiple breast cancer cohorts, including TCGA and METABRIC datasets. The authors examined somatic heterozygous loss of Aβ and correlated decreased Aβ expression with disease-free and overall survival outcomes in breast cancer patients. cBioPortal was used to access and analyze genomic and expression data from these public cancer datasets.","['TCGA', 'METABRIC']","['Web-based analysis', 'Web-based visualization']",['PPP2R1B'],"['Expression analysis', 'Survival analysis', 'Query interface']",Mixed,medium,4.0,40178903,Germline mutations in PPP2R1B in patients with a personal and family history of cancer.,2025,abstract,2025-12-19T04:03:45.275685,,,,
"['Gene expression analysis', 'Mutation analysis', 'Survival analysis', 'Pathway analysis']","['Pan-cancer', 'Glioma/Brain cancer', 'Prostate cancer', 'Liver cancer']","['Biomarker discovery', 'Pathway analysis', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to analyze genetic alterations and mutations in P2RX4 across multiple cancer types. The study specifically mentions using cBioPortal to identify that mutations in P2RX4 were predominantly found in Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (>4%). The platform was listed among multiple publicly available databases (TCGA, GTEx, GEO, TIMER2, cBioportal, and Metascape) used for comprehensive pan-cancer analysis of P2RX4.",[],['Web-based analysis'],['P2RX4'],['Not specified'],Unclear,medium,4.0,40181033,The role and function validation of P2RX4 as a novel cancer biomarker in pan-cancer analysis.,2025,pdf,2025-12-19T04:03:45.858640,,,,
['Gene expression analysis'],['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance', 'Methods/Tools development']",['Original research'],['Not specified'],The researchers used cBioPortal's Cancer Genomics database to perform Pearson's correlation coefficient analysis between candidate genes identified from their CRISPR screening (86 genes with ≥1000 reads) and MYC expression. This analysis helped identify 14 genes as candidate MYC regulators that showed positive and significant correlations with MYC. The correlation analysis was used to prioritize candidate genes for further experimental validation in their ovarian cancer study.,[],['Web-based analysis'],"['MYC', 'CYP4V2', 'ASPH', 'ANP32D', 'PCED1A', 'ABI1', 'FUZ', 'HOOK2']",['Expression analysis'],cBioPortal platform,medium,4.0,40176181,Modified screening of MYC promotor region elements using the CRISPR library in ovarian cancer.,2025,abstract,2025-12-19T04:03:46.300551,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Pathway analysis']",['Glioma/Brain cancer'],"['Review/Commentary', 'Biomarker discovery', 'Pathway analysis']",['Review'],['Not specified'],"This is a review paper that discusses key genetic alterations in glioblastoma based on bioinformatics approaches. While the paper mentions various bioinformatics tools and databases for analyzing genetic alterations in GBM, there is no explicit mention of cBioPortal usage in the provided abstract and introduction sections. The paper focuses on reviewing genetic alterations in key pathways (PI3K/AKT/mTOR, Ras/Raf/MEK/ERK) and genes (EGFR, TP53, TERT) in GBM.",[],['Citation only'],"['EGFR', 'TP53', 'TERT', 'PDGFRA']",['Not specified'],Unclear,low,4.0,40182607,Key genes altered in glioblastoma based on bioinformatics (Review).,2025,pdf,2025-12-19T04:03:46.372329,,,,
"['Gene expression analysis', 'Multi-omics integration', 'Pathway analysis']",['Not specified'],"['Pathway analysis', 'Other']",['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, this paper focuses on EGFR signaling in healthy mouse tissues using phosphoproteomic, proteomic, and transcriptomic analyses. There is no explicit mention of cBioPortal usage in the provided text. The paper appears to be a basic biology study examining tissue-specific responses to EGF stimulation in normal tissues rather than a cancer genomics study that would typically utilize cBioPortal resources.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40171493,The network response to Egf is tissue-specific.,2025,abstract,2025-12-19T04:03:48.044419,,,,
"['Gene expression analysis', 'Survival analysis', 'Copy number analysis']",['Colorectal cancer'],['Biomarker discovery'],['Original research'],['TCGA'],"The study used The Cancer Genome Atlas (TCGA) database to obtain colorectal carcinoma cases with RNA-Sequence transcript data and matched clinicopathological data, along with gene copy number variation and methylation status. The authors analyzed ptgs2 (COX-2) gene expression levels and their association with survival outcomes and tumor characteristics. The data appears to have been downloaded from TCGA for external statistical analysis using SPSS.",['TCGA'],['Data download/export'],"['PTGS2', 'COL11A1', 'HDAC9', 'APC', 'SMAD4', 'SMAD2', 'TP53', 'BRAF', 'KRAS', 'WFDC2', 'TTLL12', 'THRA', 'EPHB3', 'ARID1A', 'FBXW7', 'RNF']",['Download data'],External (downloaded data),medium,4.0,40171466,Low prostaglandin-endoperoxide synthase-2 gene expression in colorectal carcinomas may predict poorer survival.,2024,pdf,2025-12-19T04:03:50.883628,,,,
"['Gene expression analysis', 'Mutation analysis']","['Prostate cancer', 'Lung cancer', 'Glioma/Brain cancer']","['Drug response/resistance', 'Pathway analysis', 'Biomarker discovery']",['Original research'],['TCGA'],"Based on the abstract and introduction provided, the paper does not explicitly describe how cBioPortal was used. The study focuses on experimental investigation of cancer cell responses to purine shortage using the prodrug DRP-104 and genetic approaches in prostate, lung, and glioma cancer models. While cBioPortal is cited, the specific usage details are not mentioned in the provided text. The study appears to be primarily experimental/laboratory-based research rather than computational analysis of existing genomic databases.",[],['Citation only'],['MTAP'],['Not specified'],Unclear,low,4.0,40166329,Resilience and vulnerabilities of tumor cells under purine shortage stress.,2025,abstract,2025-12-19T04:03:51.431797,,,,
"['Gene expression analysis', 'Pathway analysis', 'Survival analysis']",['Prostate cancer'],"['Biomarker discovery', 'Methods/Tools development']","['Original research', 'Methods/Software']","['TCGA', 'Multiple sources']","Based on the abstract, this paper develops DiCE, a novel computational method for identifying disease-associated genes by combining differential expression analysis with network centrality measures. The method was validated on prostate cancer datasets and identified genes that significantly correlated with disease-free survival. While cBioPortal is cited, the specific usage details are not provided in the abstract, though it likely served as a data source for validation datasets given the TCGA and cancer genomics focus.",[],['Data download/export'],[],['Not specified'],External (downloaded data),low,4.0,40166319,DiCE: differential centrality-ensemble analysis based on gene expression profiles and protein-protein interaction network.,2025,abstract,2025-12-19T04:03:51.747980,,,,
"['Copy number analysis', 'Gene expression analysis', 'Pathway analysis', 'Multi-omics integration', 'Mutation analysis']",['Breast cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine', 'Methods/Tools development']",['Original research'],"['TCGA', 'METABRIC', 'Multiple sources']","The paper mentions using data from TCGA-BRCA and METABRIC cohorts, which are commonly accessed through cBioPortal. However, the abstract and introduction do not explicitly describe how cBioPortal was used or whether data was downloaded from the platform. The study integrated multimodal data including proteomic, genomic, MRI imaging, and clinical information from multiple cohorts (I-SPY2, TCGA-BRCA, GSE161529, and METABRIC) to build predictive models for neoadjuvant therapy response in breast cancer.","['TCGA-BRCA', 'METABRIC']",['Citation only'],"['BRCA1', 'BRCA2', 'ERBB2']",['Not specified'],Unclear,low,4.0,40170854,Multimodal diagnostic models and subtype analysis for neoadjuvant therapy in breast cancer.,2025,pdf,2025-12-19T04:03:51.817655,,,,
"['Survival analysis', 'Copy number analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']",['Multiple sources'],"The authors obtained clinical and tumor ploidy data for 710 pediatric neuroblastoma patients (63 Hispanic White, 561 non-Hispanic White, and 86 non-Hispanic Black) from cBioPortal for Cancer Genomics, specifically from the TARGET (Therapeutically Applicable Research to Generate Effective Treatments) 2018 dataset. The data was used to perform survival analysis examining relationships between tumor ploidy (diploid vs. hyperdiploid), ethnicity, and overall survival outcomes. The analysis appears to have been conducted externally after downloading the data from cBioPortal.",['TARGET 2018'],['Data download/export'],[],['Download data'],External (downloaded data),high,4.0,40163752,Associations between Tumor Ploidy and Overall Survival in Pediatric Neuroblastoma.,2025,abstract,2025-12-19T04:03:52.449211,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis']",['Lung cancer'],"['Pathway analysis', 'Methods/Tools development', 'Biomarker discovery']",['Original research'],['TCGA'],"cBioPortal was used to analyze the frequency and co-occurrence patterns of genetic alterations in lung squamous cell carcinoma (LUSC) pathways. The authors used cBioPortal to identify the most frequently dysregulated pathways (squamous differentiation, PI3K/Akt signaling, and oxidative stress response) and their components (SOX2, PTEN, KEAP1) to inform their experimental design for genetic engineering of hBECs. This analysis guided their selection of genes to target in their in vitro model system.",['TCGA'],"['Web-based analysis', 'Web-based visualization']","['TP53', 'CDKN2A', 'SOX2', 'PTEN', 'KEAP1']",['Query interface'],cBioPortal platform,medium,4.0,40185723,A human model to deconvolve genotype-phenotype causations in lung squamous cell carcinoma.,2025,pdf,2025-12-19T04:03:53.054003,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis']",['Other solid tumor'],"['Drug response/resistance', 'Biomarker discovery', 'Pathway analysis']",['Original research'],['Not specified'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage. The study focuses on CRISPR interference-based genome-wide screening in PIK3CA-mutated HNSCC cell lines to identify therapeutic targets. While cBioPortal is cited (as indicated by the paper being in a cBioPortal citation analysis), the specific usage details are not described in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40154000,Neddylation as a target in PIK3CA-mutated head and neck cancer.,2025,abstract,2025-12-19T04:03:53.533747,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the methods or results sections. The study analyzed TCGA and GEO data for HNSCC, performing differential expression, mutation, CNV, and survival analyses, but the specific tools and platforms used for data access are not clearly stated. cBioPortal may have been used for data download or cited as a reference, but no specific usage details are provided in the abstract and introduction.","['TCGA-HNSC', 'GSE107591', 'GSE6631', 'GSE9638']",['Citation only'],"['ABCC1', 'ADRB2', 'AKR1B1', 'BSG', 'CAV1', 'CDKN3', 'FOXM1', 'GPT', 'HIF1A', 'IL1B', 'LDHA', 'LDHB', 'MB', 'PC', 'PER2', 'SLC2A1']",['Not specified'],Unclear,low,4.0,40155682,Bioinformatic analysis of glycolysis and lactate metabolism genes in head and neck squamous cell carcinoma.,2025,pdf,2025-12-19T04:03:55.218907,,,,
['Other'],['Melanoma'],['Other'],"['Clinical study', 'Other']",['Not specified'],This is a clinical case report describing a patient with neurofibromatosis type 1 and acromelanoma. There is no evidence in the provided abstract and introduction that cBioPortal was actually used in this study. The paper appears to be a descriptive case report without genomic data analysis using cBioPortal.,[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40153767,Neurofibromatosis type 1 accompanied by acromelanoma: A case report.,2025,abstract,2025-12-19T04:03:56.434536,,,,
"['Copy number analysis', 'Mutation analysis', 'Gene expression analysis', 'Pathway analysis', 'Survival analysis']",['Colorectal cancer'],"['Tumor evolution', 'Biomarker discovery', 'Precision medicine']",['Original research'],"['Custom/Private data', 'Multiple sources']","Based on the abstract and introduction provided, the paper focuses on chromosomal imbalances and cytogenetic signatures in colorectal cancer metastases to different organs (liver, lung, brain). While cBioPortal is cited, the specific usage details are not explicitly described in the provided text. The study appears to primarily use custom cytogenetic data from their own cohorts of primary CRCs and metastases, with potential reference to cBioPortal for validation or comparison purposes.",[],['Citation only'],"['KRAS', 'APC', 'TP53', 'SMAD4', 'MDM2', 'CDK4']",['Not specified'],Unclear,low,4.0,40188208,Cytogenetic signatures favoring metastatic organotropism in colorectal cancer.,2025,pdf,2025-12-19T04:03:56.498191,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to explore genomic variations of CASP10 across pan-cancer samples. The platform was utilized alongside GSCALite and UALCAN databases to analyze mutation profiles, including SNV (single nucleotide variants) and CNV (copy number variations) of the CASP10 gene. The study found that CASP10 exhibited a 2% alteration frequency across pan-cancer patients.",[],"['Web-based analysis', 'Web-based visualization']",['CASP10'],['Query interface'],Mixed,medium,4.0,40152300,Comprehensive Pan-cancer Analysis Revealed CASP10 As a Promising Biomarker For Diverse Tumor Types.,2025,abstract,2025-12-19T04:03:57.665557,,,,
"['Gene expression analysis', 'Mutation analysis', 'Copy number analysis', 'Survival analysis']","['Other solid tumor', 'Pan-cancer']",['Biomarker discovery'],['Original research'],"['TCGA', 'Multiple sources']",cBioPortal was used to analyze the expression and gene mutations of the PRDXs family (PRDX1-6) in pan-cancer. The platform was also used to examine alteration frequencies and mutation types (particularly amplifications) across different cancer types. The study utilized cBioPortal alongside UALCAN and STRING for comprehensive analysis of PRDXs family members in oral squamous cell carcinoma.,['TCGA-HNSC'],"['Web-based analysis', 'Web-based visualization']","['PRDX1', 'PRDX2', 'PRDX3', 'PRDX4', 'PRDX5', 'PRDX6', 'TXN']","['Expression analysis', 'Query interface']",cBioPortal platform,medium,4.0,40153088,Expression and mechanism of PRDXs family in oral squamous cell carcinoma.,2025,pdf,2025-12-19T04:03:58.470903,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis', 'Survival analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Pathway analysis', 'Tumor evolution']",['Original research'],"['TCGA', 'Multiple sources']","The paper used cBioPortal to analyze human CRC patient data, specifically examining CMS4 tumors for CDX2 expression levels and mutations in APC and CTNNB1 genes. The authors identified a subset of aggressive CMS4 cancers with low CDX2 expression and wildtype APC/CTNNB1 status that showed higher metastatic potential, validating their findings from the KPN mouse model in human patient cohorts.",['TCGA'],"['Web-based analysis', 'Data download/export']","['CDX2', 'APC', 'CTNNB1']","['Query interface', 'Expression analysis', 'Download data']",Mixed,medium,4.0,40189705,"CDX2 downregulation regulates intrinsic WNT pathway activation, dictating metastasis in APC and CTNNB1 wildtype colorectal cancer.",2025,pdf,2025-12-19T04:03:59.080768,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis']","['Pan-cancer', 'Melanoma', 'Ovarian cancer', 'Lung cancer', 'Leukemia/Lymphoma', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy', 'Methods/Tools development']",['Original research'],"['Multiple sources', 'Not specified']","cBioPortal was used as one of multiple computational tools to analyze PDCD1 gene variants and expression patterns across different cancer types. The study utilized cBioPortal alongside GEPIA2 for expression profiling, showing differential PDCD1 expression in tumor versus normal tissues and correlating expression with survival outcomes in skin melanoma and ovarian cancer. The platform was used to evaluate the oncogenic potential of nsSNPs and their association with cancer susceptibility.",[],"['Web-based analysis', 'Web-based visualization']","['PDCD1', 'CD274', 'CD273']","['Expression analysis', 'Query interface']",Mixed,medium,4.0,40149458,Integrative In Silico Analysis to Identify Functional and Structural Impacts of nsSNPs on Programmed Cell Death Protein 1 (PD-1) Protein and UTRs: Potential Biomarkers for Cancer Susceptibility.,2025,pdf,2025-12-19T04:03:59.287169,,,,
"['Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the abstract or introduction provided. The study utilized TCGA-LIHC data and other sources (GEO databases) to investigate VPS72 and its relationship with immune infiltration in hepatocellular carcinoma. While TCGA data was used, there is no clear indication that cBioPortal was the platform used to access or analyze this data.",['TCGA-LIHC'],['Citation only'],"['VPS72', 'CD8A']",['Not specified'],Unclear,low,4.0,40146476,Identification of tumor immune infiltration-associated VPS72 and prognostic significance of VPS72 and CD8A in hepatocellular carcinoma.,2025,pdf,2025-12-19T04:03:59.486799,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']",['Original research'],['TCGA'],"The study used the TCGA gastric adenocarcinoma cohort (440 patients) accessed through cBioPortal to analyze CDX2 and SOX2 mRNA expression patterns. The authors stratified 220 patients with CDX2 up-regulation into two groups based on SOX2 expression levels and compared their genomic landscapes including mutations, copy number alterations, microsatellite instability status, and tumor mutation burden. The analysis appears to have been conducted using data downloaded from cBioPortal for external analysis.",['TCGA gastric adenocarcinoma'],['Data download/export'],"['CDX2', 'SOX2', 'ARID1A', 'KMT2D', 'KMT2C', 'KMT2B', 'ERBB4', 'FGFR1', 'TP53', 'MYC', 'ERBB2', 'CCNE1']","['Download data', 'Expression analysis', 'Group comparison']",External (downloaded data),high,4.0,40149431,The Status of SOX2 Expression in Gastric Cancers with Induction of CDX2 Defines Groups with Different Genomic Landscapes.,2025,pdf,2025-12-19T04:03:59.949878,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Pathway analysis']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy', 'Drug response/resistance']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly describe using cBioPortal for data access or analysis. While the study uses TCGA data and performs pan-cancer analysis of OBSCN mutations and expression, there is no mention of cBioPortal in the methods or results sections provided. The citation to cBioPortal may be in the references but specific usage is not detailed in the abstract or introduction.","['TCGA-BLCA', 'GSE48075', 'GSE31684', 'GSE32894', 'GSE176307', 'E-MTAB-4321', 'IMVigor210', 'GSE135337']",['Citation only'],"['OBSCN', 'TP53']",['Not specified'],Unclear,low,4.0,40149008,Loss of OBSCN expression promotes bladder cancer progression but enhances the efficacy of PD-L1 inhibitors.,2025,pdf,2025-12-19T04:03:59.967646,,,,
"['Gene expression analysis', 'Mutation analysis', 'Copy number analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']",cBioPortal was used to analyze NCKAP1 expression levels and genetic variations across different cancer types at various pathological stages. The platform was utilized alongside UALCAN to examine NCKAP1 expression patterns and genetic alterations in renal cancer and other cancer types. The analysis focused on understanding the role of NCKAP1 in renal carcinoma progression through pan-cancer comparative analysis.,['TCGA'],"['Web-based analysis', 'Web-based visualization']",['NCKAP1'],"['Expression analysis', 'Query interface']",cBioPortal platform,high,4.0,40141455,NCKAP1 Inhibits the Progression of Renal Carcinoma via Modulating Immune Responses and the PI3K/AKT/mTOR Signaling Pathway.,2025,pdf,2025-12-19T04:04:01.808905,,,,
"['Mutation analysis', 'Copy number analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],['Not specified'],"cBioPortal was used to analyze genomic, clinicopathological, and sociodemographic data from 1084 breast cancer samples across diverse ethnic groups. The platform enabled the identification and characterization of mutated genes, including structural variants (SVs), copy number alterations (CNAs), and point mutations. The study compared mutation frequencies, mutation counts, and fraction of altered genome across different ethnic groups using cBioPortal's analytical capabilities.",[],"['Web-based analysis', 'Data download/export']",[],"['Query interface', 'Group comparison']",Mixed,high,4.0,40136626,Genomic Landscape of Breast Cancer: Study Across Diverse Ethnic Groups.,2025,pdf,2025-12-19T04:04:03.723284,,,,
"['Gene expression analysis', 'Survival analysis']",['Breast cancer'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],"['TCGA', 'METABRIC']",The paper used cBioPortal to analyze GATAD2B expression levels and patient survival data in breast cancer cohorts. The authors queried TCGA and METABRIC datasets through cBioPortal to examine the relationship between GATAD2B expression and clinical outcomes in breast cancer patients. This analysis was used to support their experimental findings on GATAD2B's role in cancer stem cells and drug resistance.,"['TCGA', 'METABRIC']","['Web-based analysis', 'Web-based visualization']",['GATAD2B'],"['Expression analysis', 'Survival analysis', 'Query interface']",cBioPortal platform,medium,4.0,40136647,GATAD2B O-GlcNAcylation Regulates Breast Cancer Stem-like Potential and Drug Resistance.,2025,pdf,2025-12-19T04:04:03.875317,,,,
['Gene expression analysis'],['Leukemia/Lymphoma'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],['Multiple sources'],"cBioPortal was used to extract mRNA expression data (in transcripts per million, TPM) for LAG-3 ligand genes from the Chronic Lymphocytic Leukemia (Broad, Nature 2015) dataset. The expression levels of 15 LAG-3 ligand genes (LGALS3, FGL1, and various HLA genes) were analyzed in 157 CLL patients to correlate with IGVH mutation status. This was a supplementary bioinformatic analysis to support the main flow cytometry findings on LAG-3 expression on γδ T cells.","['Chronic Lymphocytic Leukemia (Broad, Nature 2015)']",['Data download/export'],"['LGALS3', 'FGL1', 'HLA-DMA', 'HLA-DOA', 'HLA-DOB', 'HLA-DQA1', 'HLA-DQA2', 'HLA-DRA', 'HLA-DRB1', 'HLA-DRB2', 'HLA-DRB3', 'HLA-DRB4', 'HLA-DRB5', 'HLA-DPA1', 'HLA-DPB1']","['Download data', 'Expression analysis']",External (downloaded data),high,4.0,40136700,Characterisation of Cytotoxicity-Related Receptors on γδ T Cells in Chronic Lymphocytic Leukaemia.,2025,pdf,2025-12-19T04:04:04.023104,,,,
"['Gene expression analysis', 'Pathway analysis']","['Melanoma', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']",['Original research'],['Not specified'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on single-cell RNA sequencing (scRNA-seq) analyses of tumors from clear cell Renal Cell Carcinoma (ccRCC) and skin cutaneous melanoma (SKCM) to investigate neuropilin isoform expression in tumor-associated macrophages. The methodology describes using established bioinformatics pipelines for scRNA-seq data processing, but cBioPortal is not mentioned as a data source or analysis tool in the sections provided.",[],['Citation only'],"['NRP1', 'NRP2']",['Not specified'],Unclear,low,4.0,40134439,Differential neuropilin isoform expressions highlight plasticity in macrophages in the heterogenous TME through <i>in-silico</i> profiling.,2025,pdf,2025-12-19T04:04:04.817082,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Pan-cancer'],"['Biomarker discovery', 'Immunotherapy', 'Drug response/resistance', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The cBioPortal database was used to investigate genetic alterations (mutations and copy number alterations) of NCBP2 across pan-cancer. The study utilized cBioPortal to query NCBP2 alterations in multiple cancer types, which was then integrated with TCGA data and other online tools for comprehensive analysis of prognosis, immune infiltration, and other cancer-related features.",[],"['Web-based analysis', 'Data download/export']",['NCBP2'],['Query interface'],"[""Mixed""]",medium,4.0,40124611,NCBP2 predicts the prognosis and the immunotherapy response of cancers: a pan-cancer analysis.,2025,abstract,2025-12-19T04:04:05.469991,,,,
"['Mutation analysis', 'Survival analysis']",['Lung cancer'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']",['Not specified'],"The study analyzed 4064 lung adenocarcinoma patients with various metastatic patterns, examining clinicopathological profiles and genomic drivers. The researchers investigated somatic mutations in genes including TP53, EGFR, KEAP1, MYC, KRAS, and SMARCA4, and performed survival analyses to identify prognostic factors in patients with bone metastases. While cBioPortal is cited, the specific details of how the platform was used for data acquisition or analysis are not explicitly described in the abstract.",[],['Citation only'],"['TP53', 'EGFR', 'KEAP1', 'MYC', 'KRAS', 'SMARCA4']",['Not specified'],Unclear,low,4.0,40128173,Lung Adenocarcinoma With Bone Metastases: Clinicogenomic Profiling and Insights Into Prognostic Factors.,2025,abstract,2025-12-19T04:04:05.787657,,,,
"['Gene expression analysis', 'Pathway analysis', 'Other']",['Breast cancer'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],['Not specified'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on investigating citrus flavonoids (nobiletin and sinensetin) for overcoming methotrexate resistance in breast cancer cells using bioinformatics analysis and in vitro experiments. The study mentions using microarray data from Gene Expression Omnibus (GEO), protein target identification from multiple databases, and various computational analyses, but cBioPortal is not mentioned in the provided text.",[],['Citation only'],"['BCL2L1', 'CDK1', 'EGFR', 'PTGS2', 'PLK1', 'MMP2', 'ACHE', 'ABCG2', 'KIT']",['Not specified'],Unclear,low,4.0,40111633,Citrus flavonoids for overcoming breast cancer resistance to methotrexate: identification of potential targets of nobiletin and sinensetin.,2025,pdf,2025-12-19T04:04:05.836130,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Prostate cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['Custom/Private data'],The study used the SUC2 metastatic prostate adenocarcinoma patient dataset accessed through cBioPortal to investigate the clinical relevance of ECM stiffness-related genes. They performed survival analysis to correlate gene expression patterns identified in their experimental models with overall survival outcomes in patient data. The cBioPortal data was used to validate that genes upregulated under high ECM stiffness conditions were associated with poor survival in prostate cancer patients.,['SUC2'],"['Web-based analysis', 'Web-based visualization']",[],"['Survival analysis', 'Expression analysis']",cBioPortal platform,medium,4.0,40115748,Matrix stiffness modulates androgen response genes and chromatin state in prostate cancer.,2025,abstract,2025-12-19T04:04:06.351033,,,,
"['Copy number analysis', 'Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Pathway analysis', 'Biomarker discovery', 'Precision medicine']",['Original research'],['TCGA'],"The authors used cBioPortal to mine TCGA database to examine genetic alterations (shallow deletions, deep deletions, and mutations) of Hippo pathway components in papillary renal cell carcinoma (pRCC) and clear cell renal carcinoma (ccRCC). They analyzed the frequency of alterations in upstream tumor suppressors of the Hippo signaling pathway and correlated these genetic alterations with patient survival outcomes (overall and disease-free survival). The analysis revealed that pRCC is characterized by frequent shallow deletions of Hippo pathway genes, which were associated with poorer survival rates.",['TCGA'],"['Web-based analysis', 'Web-based visualization']","['FAT1', 'FAT2', 'FAT3', 'FAT4', 'AJUBA', 'NF2', 'SAV1', 'TJP1', 'TJP2', 'YWHAH', 'CSNK1E', 'CCNE1', 'BIRC5', 'MYC', 'VHL', 'YAP1', 'WWTR1', 'STK4', 'STK3', 'LATS1', 'LATS2', 'MOB1A', 'MOB1B', 'TEAD1', 'TEAD2', 'TEAD3', 'TEAD4']","['Survival analysis', 'Query interface', 'Group comparison']","[""cBioPortal platform""]",high,4.0,40128178,Targeting the disrupted Hippo signaling to prevent neoplastic renal epithelial cell immune evasion.,2025,pdf,2025-12-19T04:04:07.618115,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis']",['Leukemia/Lymphoma'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']",The study used cBioPortal to analyze Fanconi anemia pathway gene mutations in acute myeloid leukemia patient cohorts. The authors queried mutation frequencies and clinical correlations of FA pathway genes in AML datasets to identify patients with FA pathway deficiencies. This analysis provided the rationale for testing PLK1 inhibitors as a synthetic lethal therapeutic strategy in FA pathway-deficient AML.,['TCGA-LAML'],"['Web-based analysis', 'Web-based visualization']","['FANCA', 'FANCD2', 'PLK1']","['Query interface', 'Mutation Mapper']",Mixed,medium,4.0,40111122,PLK1 Inhibition Induces Synthetic Lethality in Fanconi Anemia Pathway-Deficient Acute Myeloid Leukemia.,2025,abstract,2025-12-19T04:04:08.858402,,,,
"['Gene expression analysis', 'Other']",['Other solid tumor'],"['Biomarker discovery', 'Other']",['Original research'],['Not specified'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on experimental investigation of Senataxin (SETX) in preventing Myc-induced replicative stress using U2OS-MycER cell lines, with mechanistic analyses including R-loop mapping and DNA damage response assessment. If cBioPortal was used, it is not described in the provided text sections.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40108134,Senataxin prevents replicative stress induced by the Myc oncogene.,2025,pdf,2025-12-19T04:04:09.175502,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'METABRIC', 'Multiple sources']","The paper does not explicitly describe how cBioPortal was used in the study. While the study analyzes TCGA and METABRIC data for invasive breast cancer, which are available through cBioPortal, there is no specific mention of cBioPortal in the abstract or introduction provided. The citation appears to be a general reference rather than indicating active use of the platform for data access or analysis.","['TCGA', 'METABRIC']",['Citation only'],"['OR51E1', 'NDRG2', 'RGS2', 'TSPAN7']",['Not specified'],Unclear,low,4.0,40104742,Characterization of immune landscape and prognostic value of IL-17-related signature in invasive breast cancer.,2025,abstract,2025-12-19T04:04:10.227691,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Colorectal cancer'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","The paper mentions using ""CBio Cancer Genomics"" portal for analyzing multidimensional alterations in the STAT family genes in colorectal cancer. However, the abstract and introduction do not provide specific details about how cBioPortal was used, what features were accessed, or what specific analyses were performed on the platform. The mention appears to be among several bioinformatics tools utilized in the study.",['TCGA'],['Web-based analysis'],"['STAT3', 'STAT5B', 'STAT1', 'STAT2', 'STAT4', 'STAT5A', 'STAT6']",['Not specified'],Unclear,low,4.0,40100436,Downregulated STAT3 and STAT5B are prognostic biomarkers for colorectal cancer and are associated with immune infiltration.,2025,pdf,2025-12-19T04:04:11.866288,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Lung cancer'],"['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']",['Original research'],['TCGA'],The study used TCGA datasets to confirm the prognostic value of NLRP4 expression levels in NSCLC. TCGA analysis was also used to validate findings about the NLRP4-triggered tumor microenvironment ecosystem involving NK cells and macrophages. The data appears to have been downloaded from TCGA for external analysis including gene expression and survival analysis.,['TCGA'],['Data download/export'],"['NLRP4', 'CCL5', 'CXCL2']",['Not specified'],External (downloaded data),medium,4.0,40087771,NLRP4 unlocks an NK/macrophages-centered ecosystem to suppress non-small cell lung cancer.,2025,pdf,2025-12-19T04:04:12.952652,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance', 'Methods/Tools development', 'Precision medicine']","['Original research', 'Methods/Software', 'Clinical study']",['Custom/Private data'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on developing a deep learning model to predict anti-angiogenic therapy response in renal cancer using histopathology images (H&E slides) and correlating with RNA-based Angioscore. The study uses data from IMmotion150 clinical trial and real-world cohorts, but does not describe accessing or analyzing data through cBioPortal.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40097393,Histopathology based AI model predicts anti-angiogenic therapy response in renal cancer clinical trial.,2025,pdf,2025-12-19T04:04:12.995636,,,,
"['Gene expression analysis', 'Pathway analysis']",['Breast cancer'],"['Review/Commentary', 'Biomarker discovery', 'Drug response/resistance']",['Review'],['Not specified'],"This is a review paper that discusses the Lin28/let-7 axis in breast cancer. Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in the study. The paper appears to be a comprehensive review of the molecular mechanisms involving Lin28A, Lin28B, and let-7 microRNAs in breast cancer, but does not describe any direct use of cBioPortal for data analysis or visualization.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40085362,Lin28/let-7 axis in breast cancer.,2025,abstract,2025-12-19T04:04:13.071248,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Lung cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on analyzing TAP2 downregulation in NSCLC using multiplexed immunofluorescence, transcriptomic analysis, ATAC-sequencing, and functional assays on patient samples from four independent cohorts. The study appears to use custom/private patient cohorts and does not reference cBioPortal for data access, analysis, or validation.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40091029,IL-4 mediated TAP2 downregulation is a dominant and reversible mechanism of immune evasion and immunotherapy resistance in non-small cell lung cancer.,2025,pdf,2025-12-19T04:04:13.175104,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Copy number analysis', 'Pathway analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Pathway analysis', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']",cBioPortal was used to evaluate genetic alterations in TIPRL across cancer types and to analyze 3D protein structures. The platform was specifically mentioned in the methods section for analyzing genetic alterations (amplifications and other mutations) in TIPRL. The study identified amplifications as the main genetic alteration in TIPRL with varied clinical relevance across different cancer types.,['TCGA'],"['Web-based analysis', 'Web-based visualization']",['TIPRL'],"['Query interface', 'Not specified']",cBioPortal platform,medium,4.0,40088344,Pan-cancer bioinformatics analysis of TIPRL in human tumors.,2025,pdf,2025-12-19T04:04:13.226337,,,,
"['Gene expression analysis', 'Survival analysis']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],['Multiple sources'],"The paper mentions using cBioPortal for in silico analysis of SNCA expression in gliomas from available public databases. The methods section references cBioPortal as one of the data sources for analyzing SNCA expression patterns in glioma samples. However, specific details about how cBioPortal was used, which features were accessed, or which datasets were queried are not provided in the abstract and introduction sections.",[],['Web-based analysis'],['SNCA'],['Expression analysis'],Unclear,low,4.0,40108111,α-synuclein expression in glioblastoma restores tumor suppressor function and rescues temozolomide drug resistance.,2025,pdf,2025-12-19T04:04:14.359975,,,,
"['Gene expression analysis', 'Pathway analysis']",['Breast cancer'],"['Immunotherapy', 'Biomarker discovery']",['Original research'],"['TCGA', 'Multiple sources']",cBioPortal was used for in silico analysis to examine RANKL expression patterns and associated immune signatures in human neoplasms. The platform was utilized to analyze gene expression data and identify enriched signatures linked to immune cell regulation and differentiation in RANKL-high expressing tumors. This bioinformatic analysis complemented the experimental work performed in mouse models of triple-negative breast cancer.,[],['Web-based analysis'],['RANKL'],"['Expression analysis', 'Enrichment analysis']",Unclear,medium,4.0,40081943,RANKL blockade inhibits cancer growth through reversing the tolerogenic profile of tumor-infiltrating (plasmacytoid) dendritic cells.,2025,abstract,2025-12-19T04:04:14.990102,,,,
"['Mutation analysis', 'Survival analysis', 'Gene expression analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],"The paper does not explicitly mention using cBioPortal in the abstract or introduction provided. The study focuses on analyzing SNP data from TCGA database to identify prognostic markers in ovarian cancer related to lipid metabolism. While TCGA data is mentioned as the source, there is no clear indication that cBioPortal was used as the platform for data access or analysis in the sections provided.",['TCGA'],['Citation only'],"['APOB', 'BRCA1', 'COL6A3', 'LRP1', 'LRP1B']",['Not specified'],Unclear,low,4.0,40082829,Single nucleotide polymorphisms in ovarian cancer impacting lipid metabolism and prognosis: an integrated TCGA database analysis.,2025,pdf,2025-12-19T04:04:15.184840,,,,
"['Gene expression analysis', 'Pathway analysis']",['Other solid tumor'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],['Not specified'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on experimental laboratory work using HGSOC cell lines (OVCAR8, PEA1/2) treated with UCHL1 inhibitor LDN-57444, with proteomic analysis and Western blot validation. No reference to cBioPortal data queries, analysis, or visualization is present in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40078282,Small molecule inhibition of ubiquitin C-terminal hydrolase L1 alters cell metabolism proteins and exerts anti- or pro-tumorigenic effects contingent upon chemosensitivity status in high grade serous ovarian cancer.,2025,pdf,2025-12-19T04:04:15.865288,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Breast cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'METABRIC', 'Custom/Private data']","Based on the abstract and introduction provided, there is no explicit mention of cBioPortal being used in this study. The paper describes using TCGA and METABRIC datasets for multi-omics clustering analysis using the CIMLR method, but does not specify cBioPortal as the source or analysis platform. The paper may cite cBioPortal in references, but no clear usage is described in the provided text.","['TCGA', 'METABRIC']",['Citation only'],"['LMO1', 'PRAME', 'RSPO2']",['Not specified'],Unclear,low,4.0,40076569,Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis.,2025,pdf,2025-12-19T04:04:18.048164,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],['Biomarker discovery'],"['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The research appears to be an immunohistochemistry-based analysis of leptinR and adipoR1 expression in patient tumor samples from four cancer types. The study analyzed custom cohorts using immunohistochemistry and correlated expression with clinicopathological parameters and survival outcomes, without any indication of cBioPortal data or tools being utilized.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40071541,The prognostic value of adipokine receptors leptinR and adiponectinR1 in obesity-inducible solid tumours.,2025,abstract,2025-12-19T04:04:18.755790,,,,
"['Copy number analysis', 'Gene expression analysis']",['Other solid tumor'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],['Not specified'],"The paper mentions that BCL2L1 gene (encoding BCLXL) is amplified in 2.7-10.7% of gastric cancer cases, citing references that likely used cBioPortal data. However, the paper does not explicitly describe direct usage of cBioPortal for data analysis or visualization. The reference to BCL2L1 amplification frequencies appears to be based on prior published studies rather than direct cBioPortal queries performed by the authors.",[],['Citation only'],['BCL2L1'],['Not specified'],Unclear,low,4.0,40075071,Both direct and indirect suppression of MCL1 synergizes with BCLXL inhibition in preclinical models of gastric cancer.,2025,pdf,2025-12-19T04:04:19.355163,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Pathway analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used as one of multiple public databases to examine EXO1's mutational characteristics across different cancer types in this pan-cancer analysis. The study leveraged cBioPortal alongside TCGA, GTEx, HPA, UALCAN, STRING, CancerSEA, and TISIDB databases to comprehensively analyze EXO1's expression, diagnostic potential, prognostic significance, and immunological effects. The specific details of how cBioPortal was utilized are not explicitly described in the provided abstract and introduction sections.",[],['Citation only'],['EXO1'],['Not specified'],Unclear,low,4.0,40074873,"EXO1's pan-cancer roles: diagnostic, prognostic, and immunological analyses through bioinformatics.",2025,pdf,2025-12-19T04:04:19.647681,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Mutation analysis', 'Copy number analysis']","['Pan-cancer', 'Glioma/Brain cancer']","['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper mentions using TCGA Pan-Cancer Cohort data for gene and protein expression analysis. While cBioPortal is not explicitly mentioned in the provided abstract and introduction sections, the study performs comprehensive pan-cancer analysis using TCGA data, which is commonly accessed through cBioPortal. The study analyzes TAP2 genomic alterations, expression patterns, prognostic value, and immune-related features across multiple cancer types.",['TCGA Pan-Cancer'],['Citation only'],"['TAP2', 'TAP1']",['Not specified'],Unclear,low,4.0,40075453,Identification of TAP2 as a novel immune target in human cancers: insights from integrated bioinformatics and experimental approaches.,2025,pdf,2025-12-19T04:04:19.921104,,,,
"['Mutation analysis', 'Gene expression analysis']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Other']",['Original research'],['Multiple sources'],The authors used cBioPortal to perform bulk-tissue gene expression analysis to examine TRAP1 expression patterns across normal tissues and various cancer types. They identified 310 TRAP1 variants through the platform and used this data to select five specific mutations for detailed functional characterization. The cBioPortal data provided the foundation for their high-throughput screening of TRAP1 point mutations across different cancer types.,[],"['Web-based analysis', 'Data download/export']",['TRAP1'],"['Expression analysis', 'Query interface']",Mixed,medium,4.0,40074754,Point mutations of the mitochondrial chaperone TRAP1 affect its functions and pro-neoplastic activity.,2025,pdf,2025-12-19T04:04:20.877621,,,,
"['Mutation analysis', 'Survival analysis', 'Other']",['Lung cancer'],"['Drug response/resistance', 'Precision medicine', 'Biomarker discovery']","['Original research', 'Clinical study']",['Custom/Private data'],"The paper does not explicitly describe using cBioPortal in their study methodology. This is a phase II clinical trial testing mTORC1/2 inhibition in STK11-deficient NSCLC patients. While the paper may cite cBioPortal in references for background information on mutation frequencies or genomic data, there is no clear description of using cBioPortal for data analysis, visualization, or data download in the methods or results sections provided.",[],['Citation only'],"['STK11', 'KRAS', 'SMARCA4']",['Not specified'],Unclear,low,4.0,40069402,A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer.,2025,pdf,2025-12-19T04:04:20.963234,,,,
"['Copy number analysis', 'Gene expression analysis']","['Bladder cancer', 'Pan-cancer']","['Drug response/resistance', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, the paper does not explicitly describe how cBioPortal was used. The study focuses on developing and testing m-APTA as a chemoprotective agent for MTAP-deficient cancers treated with 5-FU. While the research involves MTAP-deficient cancers and likely required genomic data to identify such cancers, no specific mention of cBioPortal usage, data download, or analysis is present in the provided text.",[],['Citation only'],['MTAP'],['Not specified'],Unclear,low,4.0,40062378,"5'-S-(3-Aminophenyl)-5'-thioadenosine, a Novel Chemoprotective Agent for Reducing Toxic Side Effects of Fluorouracil in Treatment of MTAP-Deficient Cancers.",2025,abstract,2025-12-19T04:04:21.843390,,,,
"['Mutation analysis', 'Survival analysis']","['Hepatocellular carcinoma', 'Pan-cancer', 'Ovarian cancer', 'Head and neck cancer', 'Pancreatic cancer', 'Colorectal cancer', 'Breast cancer']","['Drug response/resistance', 'Biomarker discovery']",['Original research'],['TCGA'],"The authors used cBioPortal for Cancer Genomics to analyze TCGA datasets across multiple cancer types to examine the impact of missense p53 mutations versus p53-null status on overall survival. They grouped tumors with missense mutations in the p53 DNA-binding domain separately from those with truncating mutations or deep deletions, and performed survival analyses comparing these groups across different cancer types including HCC, ovarian, head and neck, pancreatic, colorectal, and breast cancers.",['TCGA'],"['Web-based analysis', 'Web-based visualization']",['TP53'],"['Survival analysis', 'Query interface', 'Group comparison']",cBioPortal platform,high,4.0,40064891,Suppression of stress granule formation is a vulnerability imposed by mutant p53.,2025,pdf,2025-12-19T04:04:21.938249,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Other']",['Original research'],['TCGA'],"Based on the abstract and introduction provided, the paper does not explicitly mention cBioPortal usage. The study focuses on investigating SLC25A35's role in hepatocellular carcinoma through mitochondrial metabolism reprogramming, using clinical samples and cell line experiments. While TCGA data may have been accessed, no specific mention of cBioPortal is found in the provided text.",[],['Citation only'],['SLC25A35'],['Not specified'],Unclear,low,4.0,40065301,SLC25A35 enhances fatty acid oxidation and mitochondrial biogenesis to promote the carcinogenesis and progression of hepatocellular carcinoma by upregulating PGC-1α.,2025,pdf,2025-12-19T04:04:22.077296,,,,
['Gene expression analysis'],['Prostate cancer'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],['Not specified'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on developing and testing FABP5 inhibitors against prostate cancer cell lines (PC-3 and RCaP) through in vitro and in vivo experiments. If cBioPortal was used, it may have been for preliminary data mining or validation, but this is not described in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40058274,Fatty acid binding protein 5 inhibitors as novel anticancer agents against metastatic castration-resistant prostate cancer.,2025,abstract,2025-12-19T04:04:24.887825,,,,
"['Mutation analysis', 'Copy number analysis', 'Pathway analysis']",['Colorectal cancer'],"['Drug response/resistance', 'Pathway analysis', 'Biomarker discovery']",['Original research'],['TCGA'],"The paper used publicly available genomic data from the TCGA colorectal cancer cohort to analyze alterations in the WNT/β-catenin/APC pathway. The study examined mutations, copy number alterations, and structural variants in key pathway genes including APC, RNF43, CTNNB1, and TCF7L2 to define different groups of colorectal cancers and identify their genomic characteristics. While cBioPortal is not explicitly mentioned in the abstract/introduction, TCGA data access for this type of analysis is commonly performed through cBioPortal.",['TCGA colorectal cancer'],['Citation only'],"['APC', 'RNF43', 'CTNNB1', 'TCF7L2', 'KRAS', 'BRAF', 'HER2']",['Not specified'],Unclear,low,4.0,40061138,Genomic alterations in the WNT/β-catenin pathway and resistance of colorectal cancer cells to pathway-targeting therapies.,2025,pdf,2025-12-19T04:04:25.265468,,,,
['Mutation analysis'],['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. This appears to be a retrospective clinical study analyzing PTEN mutations in fine needle aspiration biopsies of indeterminate thyroid nodules from their own institutional data. cBioPortal may be cited in the references but its specific role in the study methodology is not described in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40055996,Detection of PTEN Mutations in Fine Needle Aspiration Biopsies of Indeterminate Thyroid Nodules: Impact on Diagnosis and Prognosis.,2025,abstract,2025-12-19T04:04:25.410021,,,,
"['Gene expression analysis', 'Other']",['Leukemia/Lymphoma'],"['Biomarker discovery', 'Other']",['Original research'],['Custom/Private data'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The research focuses on experimental validation of miR-140-3p targeting HGF in acute promyelocytic leukemia using cell line experiments (NB4 cells), dual luciferase assays, flow cytometry, and proliferation assays. If cBioPortal was used, it was likely only cited as a reference or resource without specific application described in the available text.",[],['Citation only'],['HGF'],['Not specified'],Unclear,low,4.0,40057668,Micro-RNA-140-3p Acts as a Tumor Suppressor Gene in Acute Promyelocytic Leukemia by Targeting Hepatocyte Growth Factor.,2025,abstract,2025-12-19T04:04:25.827748,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Pathway analysis']","['Pan-cancer', 'Lung cancer']","['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the abstract or introduction provided. The study utilized TCGA, HPA, GEPIA, and UALCAN databases to investigate SFXN1 expression, prognosis, and immune infiltration across cancer types. While cBioPortal is cited, there is no clear description of how it was specifically used in the methodology or analysis.",['TCGA'],['Citation only'],['SFXN1'],['Not specified'],Unclear,low,4.0,40052583,Pan‑cancer analysis of oncogene SFXN1 to identify its prognostic and immunological roles in lung adenocarcinoma.,2025,pdf,2025-12-19T04:04:28.248758,,,,
"['Copy number analysis', 'Mutation analysis']",['Breast cancer'],"['Methods/Tools development', 'Biomarker discovery', 'Precision medicine']","['Original research', 'Methods/Software']",['Not specified'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this paper. The study focuses on developing a new NGS panel called eSENSES for detecting ctDNA and somatic copy number aberrations in breast cancer patients. While the paper cites large-scale breast cancer genomic studies to inform their panel design, cBioPortal is not specifically mentioned in the provided text sections.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40057527,Enabling sensitive and precise detection of ctDNA through somatic copy number aberrations in breast cancer.,2025,pdf,2025-12-19T04:04:29.200241,,,,
"['Mutation analysis', 'Copy number analysis', 'Survival analysis']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper describes a retrospective cohort study of adult midline gliomas from a single institution, with molecular characterization performed using immunohistochemistry, targeted next-generation sequencing, and chromosomal microarray analysis. The citation of cBioPortal appears to be a reference citation only, without clear description of how the platform was used for data analysis or visualization in this particular study.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40048040,Characterizing the molecular and spatial heterogeneity of midline gliomas in adults: a single institution analysis.,2025,abstract,2025-12-19T04:04:29.605862,,,,
"['Gene expression analysis', 'Other']",['Not specified'],['Other'],['Original research'],['Not specified'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. This paper focuses on AMPK phosphosite profiling using mass spectrometry to identify mTORC1-regulated substrates in the context of cell metabolism and proliferation. If cBioPortal is cited, it appears to be a reference citation only without direct usage of the platform or its data for the analyses described.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40052110,AMPK phosphosite profiling by label-free mass spectrometry reveals a multitude of mTORC1-regulated substrates.,2025,pdf,2025-12-19T04:04:29.736814,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],['TCGA'],The authors used cBioPortal to analyze pancreatic adenocarcinoma (PAAD) patient data from TCGA to examine the correlation between CXCL5 expression and hypoxia/metabolism-related genes. They performed survival analysis to demonstrate that pancreatic cancer patients with higher expression of genes correlated with CXCL5 and associated with hypoxia and metabolism have poorer prognosis. The analysis was used to validate their experimental findings from 3D culture systems showing Cxcl5's role in metabolic reprogramming.,['TCGA-PAAD'],"['Web-based analysis', 'Web-based visualization']",['CXCL5'],"['Expression analysis', 'Survival analysis']",cBioPortal platform,medium,4.0,40050422,Cancer-intrinsic Cxcl5 orchestrates a global metabolic reprogramming for resistance to oxidative cell death in 3D.,2025,pdf,2025-12-19T04:04:29.760925,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The cBioPortal database was used to explore tumor mutation burden (TMB) in breast cancer patients. The TMB analysis was performed to assess the relationship between the glycolysis-related prognostic gene signature and mutation burden, which was then used to predict immunotherapy response in high-risk versus low-risk patient groups.",['TCGA-BRCA'],['Web-based analysis'],"['ADPGK', 'HNRNPA1', 'PGAM1', 'PIM2', 'YWHAZ', 'PTK2', 'VDAC1', 'CS', 'PGK1', 'GAPDHS']",['Query interface'],Unclear,medium,4.0,40046063,A novel glycolysis-related gene signature for predicting prognosis and immunotherapy efficacy in breast cancer.,2025,abstract,2025-12-19T04:04:30.253626,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Multi-omics integration']","['Pan-cancer', 'Glioma/Brain cancer']","['Biomarker discovery', 'Precision medicine', 'Tumor evolution']",['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The study primarily uses data from the Clinical Proteomics Tumor Analysis Consortium (CPTAC) cohort to analyze clonal hematopoiesis in solid tumors. Without access to the methods section or full text, it is unclear if cBioPortal was used for data access, validation, or comparison purposes.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40037357,Inflammatory reprogramming of the solid tumor microenvironment by infiltrating clonal hematopoiesis is associated with adverse outcomes.,2025,abstract,2025-12-19T04:04:30.803841,,,,
"['Mutation analysis', 'Pathway analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper describes an original NGS-based molecular characterization study of 30 CRC patients using FFPE tissues, with sequencing performed using Illumina platforms and variant interpretation done through NCBI-dbSNP and Ensembl databases. If cBioPortal is cited in this paper, it appears to be a reference citation only without clear description of how it was used for data analysis or validation.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40048017,Molecular characterization of colorectal cancer (CRC) using next generation sequencing (NGS) in bridging the gap between research and clinical practice: from biomarker discovery to clinical implementation.,2025,pdf,2025-12-19T04:04:31.163406,,,,
"['Multi-omics integration', 'Other']",['Not specified'],"['Review/Commentary', 'Methods/Tools development']",['Review'],['Not specified'],This is a review paper discussing challenges in AI-driven biomedical multimodal data fusion and analysis. cBioPortal appears to be cited as an example of a cancer genomics data portal and analysis platform in the context of discussing biomedical data resources and integration methods. No specific usage of cBioPortal for original analysis is described in the abstract or introduction provided.,[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40036568,Challenges in AI-driven Biomedical Multimodal Data Fusion and Analysis.,2025,abstract,2025-12-19T04:04:31.833610,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']","['Pan-cancer', 'Melanoma']","['Methods/Tools development', 'Database/Resource', 'Biomarker discovery', 'Immunotherapy']","['Methods/Software', 'Original research']","['TCGA', 'Custom/Private data', 'Multiple sources']","Based on the abstract and introduction provided, cBioPortal is not explicitly mentioned as being used in this study. The paper describes TCGEx, a new tool developed by the authors for analyzing TCGA gene expression data. cBioPortal may be cited as a related resource or comparison tool, but no specific usage of cBioPortal for data download, analysis, or visualization is described in the provided text.",['TCGA'],['Citation only'],[],['Not specified'],Unclear,low,4.0,40033050,TCGEx: a powerful visual interface for exploring and analyzing cancer gene expression data.,2025,abstract,2025-12-19T04:04:32.008260,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration']","['Colorectal cancer', 'Lung cancer']","['Methods/Tools development', 'Precision medicine']","['Original research', 'Methods/Software']",['TCGA'],"The study used TCGA data to train and test machine learning models for classifying multicategory causes of death in colorectal cancer (n=515) and lung adenocarcinoma (n=589) patients. While the abstract mentions using TCGA data, it does not explicitly state whether cBioPortal was used to access this data or if the data was obtained through other means. The paper focuses on evaluating ML fairness across different sociodemographic groups rather than on cBioPortal-specific features.",['TCGA'],['Citation only'],[],['Not specified'],Unclear,low,4.0,40027644,Towards machine learning fairness in classifying multicategory causes of deaths in colorectal or lung cancer patients.,2025,abstract,2025-12-19T04:04:33.862571,,,,
"['Mutation analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on analyzing paired plasma and tissue samples from 40 HR+ early-stage breast cancer patients using a custom gene panel (OncoIndx). The study appears to be entirely based on custom/private data collection and analysis without reference to cBioPortal platform or datasets.",[],['Citation only'],"['ESR1', 'PIK3CA']",['Not specified'],Unclear,low,4.0,40027235,ctDNA-based liquid biopsy reveals wider mutational profile with therapy resistance and metastasis susceptibility signatures in early-stage breast cancer patients.,2025,abstract,2025-12-19T04:04:34.932862,,,,
"['Mutation analysis', 'Gene expression analysis']",['Breast cancer'],"['Biomarker discovery', 'Tumor evolution']",['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on functional characterization of an AFDN frameshift mutation identified in a breast cancer sample through cell line experiments, xenografts, and patient-derived organoids. If cBioPortal was used, it may have been for preliminary mutation frequency analysis or validation, but this is not stated in the provided text.",[],['Citation only'],['AFDN'],['Not specified'],Unclear,low,4.0,40026293,Afadin loss induces breast cancer metastasis through destabilisation of E-cadherin to F-actin linkage.,2025,abstract,2025-12-19T04:04:35.307099,,,,
"['Gene expression analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Drug response/resistance', 'Pathway analysis', 'Tumor evolution']",['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The research focuses on experimental work involving SOX17 induction, single cell RNA sequencing, ChIP-seq analysis, and xenografting experiments to study the differentiation of embryonal carcinoma cells into yolk-sac tumor lineage. The paper may cite cBioPortal in references but does not describe using it for data analysis or visualization in the sections provided.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40025812,"Induction of SOX17 with stimulation of WNT, TGF-beta, and FGF signaling drives embryonal carcinomas into the yolk-sac tumor lineage resulting in increased cisplatin resistance.",2025,abstract,2025-12-19T04:04:35.618923,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine', 'Methods/Tools development']",['Original research'],['TCGA'],The study used TCGA-HNSC data to analyze HPV-negative head and neck squamous cell carcinoma (n=395). The authors analyzed bulk RNA-seq data to identify ligand-receptor interactions and developed a prognostic risk model based on 14 ligand-receptor pairs using survival analysis. The study integrated multi-omics data with deep learning-based histopathology analysis to improve risk stratification.,['TCGA-HNSC'],['Data download/export'],[],['Download data'],External (downloaded data),medium,4.0,40021759,Ligand-receptor interactions combined with histopathology for improved prognostic modeling in HPV-negative head and neck squamous cell carcinoma.,2025,pdf,2025-12-19T04:04:36.368662,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Breast cancer'],"['Biomarker discovery', 'Precision medicine', 'Methods/Tools development']","['Original research', 'Methods/Software']","['MSK-IMPACT', 'Custom/Private data']","The paper mentions that genomic data from clinical MSK-IMPACT targeted sequencing were available for a subset of patients (n=481) in their cohort. However, the paper does not explicitly describe how cBioPortal was used for data access, analysis, or visualization. The citation appears to be primarily for acknowledging the MSK-IMPACT data source rather than describing specific cBioPortal platform usage.",['MSK-IMPACT'],['Citation only'],"['ESR1', 'PGR', 'HER2', 'MKI67', 'MMP11']",['Not specified'],Unclear,low,4.0,40025017,Multimodal histopathologic models stratify hormone receptor-positive early breast cancer.,2025,pdf,2025-12-19T04:04:36.543648,,,,
"['Copy number analysis', 'Gene expression analysis', 'Survival analysis']",['Breast cancer'],"['Drug response/resistance', 'Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']",The authors used cBioPortal to analyze clinical breast cancer expression datasets to examine RICTOR gene amplification and overexpression patterns. They correlated RICTOR alterations with mTORC2 signaling activity and patient outcomes in breast cancer cohorts. This analysis provided the rationale for developing their mTORC2-selective therapeutic approach targeting RICTOR in triple-negative breast cancer.,[],"['Web-based analysis', 'Web-based visualization']",['RICTOR'],"['Expression analysis', 'Query interface']",cBioPortal platform,medium,4.0,40019775,Induction of Triple-Negative Breast Cancer Cell Death and Chemosensitivity Using mTORC2-Directed RNAi Nanomedicine.,2025,abstract,2025-12-19T04:04:36.913711,,,,
"['Mutation analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],cBioPortal was used specifically for visualization of the gene mutational landscape through the OncoPrinter platform. The authors used cbioportal.org to create visual representations of genomic alterations identified in appendiceal carcinoma patients from the Japanese C-CAT database. This was a visualization-focused application rather than data retrieval or analysis.,[],['Web-based visualization'],"['KRAS', 'TP53', 'SMAD4', 'GNAS']",['OncoPrint'],"[""External (downloaded data)""]",high,4.0,40019690,Impact of genetic mutations on prognosis and chemotherapy efficacy in advanced appendiceal carcinoma: insights from the nationwide Japanese comprehensive genomic profiling test database.,2025,pdf,2025-12-19T04:04:38.407955,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and title, the paper does not explicitly mention cBioPortal usage. The study primarily used TCGA-HNSCC dataset and GEO datasets for analysis. While cBioPortal is cited (as indicated by the prompt), the specific usage details are not provided in the abstract or introduction, suggesting it may have been used for data access or cited as a reference without detailed description of its application.",['TCGA-HNSCC'],['Citation only'],"['EIF3D', 'EIF1', 'LARP1', 'METTL1']",['Not specified'],Unclear,low,4.0,40018039,Integrative analysis of m7G methylation-associated genes prognostic signature with immunotherapy and identification of LARP1 as a key oncogene in head and neck squamous cell carcinoma.,2025,abstract,2025-12-19T04:04:38.650591,,,,
"['Mutation analysis', 'Gene expression analysis', 'Multi-omics integration']",['Pan-cancer'],"['Methods/Tools development', 'Tumor evolution', 'Biomarker discovery']","['Original research', 'Methods/Software']",['TCGA'],"The paper does not explicitly describe using cBioPortal for any analysis. While the study analyzes TCGA data (nearly 5000 pan-cancer paired tumor-normal WGS samples and ~9000 tumor RNA samples), there is no mention of cBioPortal in the abstract or introduction provided. The citation of cBioPortal appears to be a reference citation only, without clear evidence of direct usage of the platform for data access, analysis, or visualization.",['TCGA'],['Citation only'],"['TP53', 'ATRX']",['Not specified'],Unclear,low,4.0,40021663,Pan-cancer multi-omic model of LINE-1 activity reveals locus heterogeneity of retrotransposition efficiency.,2025,pdf,2025-12-19T04:04:39.522863,,,,
"['Mutation analysis', 'Multi-omics integration']","['Pan-cancer', 'Lung cancer', 'Colorectal cancer', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Custom/Private data']","cBioPortal was used as a data source to access TCGA data for KRAS mutation-related research. The authors state that ""The Cancer Genome Program (TCGA) of KRAS mutations-related research data is available from the biological portal platform (https://www.cbioportal.org)"". The specific usage details and analysis methods are not elaborated in the provided text.",['TCGA'],['Data download/export'],"['KRAS', 'EGFR']",['Not specified'],External (downloaded data),medium,4.0,40016583,Pan-cancer analysis to character the clinicopathological and genomic features of KRAS-mutated patients in China.,2025,pdf,2025-12-19T04:04:39.827937,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis']",['Other solid tumor'],['Biomarker discovery'],['Original research'],"['TCGA', 'Custom/Private data']","cBioPortal was used to analyze COIL gene alterations in HCC patients from the TCGA database. The study found that 14% of HCC patients had alterations in the COIL gene, and patients with COIL gene alterations had significantly lower overall survival (p<0.001) and disease-free survival (p<0.001) compared to those without gene alterations. The analysis appears to have been conducted using cBioPortal's web-based tools to query COIL alterations and perform survival analysis.",['TCGA'],"['Web-based analysis', 'Web-based visualization']",['COIL'],"['Survival analysis', 'Query interface']",cBioPortal platform,medium,4.0,40008396,Coilin Affects the Prognosis of Hepatocellular Carcinoma Through Cell Cycle and Apoptosis.,2025,abstract,2025-12-19T04:04:41.182451,,,,
"['Gene expression analysis', 'Survival analysis']",['Breast cancer'],['Biomarker discovery'],['Original research'],"['Multiple sources', 'Custom/Private data']","The paper used cBioPortal for in silico analysis of DNAJC12 mRNA expression patterns in breast cancer patients with different clinicopathological characteristics. The authors accessed publicly available data through cBioPortal to analyze DNAJC12 expression in relation to ER status, PR status, HER2 status, molecular subtypes, and survival outcomes. This online analysis was complemented with immunohistochemistry validation on 292 primary breast cancer samples.",[],"['Web-based analysis', 'Web-based visualization']",['DNAJC12'],"['Expression analysis', 'Survival analysis', 'Group comparison']",cBioPortal platform,medium,4.0,40008192,Downregulation of DNAJC12 Expression Predicts Worse Survival for ER-Positive Breast Cancer Patients.,2025,abstract,2025-12-19T04:04:41.687201,,,,
"['Gene expression analysis', 'Mutation analysis']",['Melanoma'],"['Drug response/resistance', 'Pathway analysis', 'Biomarker discovery']",['Original research'],"['TCGA', 'Not specified']","The paper appears to use cBioPortal to access melanoma genomic data, likely from TCGA or other melanoma datasets, to analyze gene expression patterns and potentially mutation profiles related to AXL, CAV1, and β-catenin signaling pathways. However, the abstract and introduction provided do not contain explicit details about how cBioPortal was specifically used in the study. Based on the research focus on melanoma progression and the typical usage patterns in such studies, cBioPortal was likely used for data download or web-based queries of melanoma datasets.",[],['Citation only'],"['AXL', 'CAV1', 'CTNNB1', 'WNT5A', 'GAS6', 'MITF']",['Not specified'],Unclear,low,4.0,40015991,Fatty acid uptake activates an AXL-CAV1-β-catenin axis to drive melanoma progression.,2025,pdf,2025-12-19T04:04:41.746423,,,,
"['Gene expression analysis', 'Pathway analysis']",['Prostate cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Custom/Private data']","Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on lncRNA expression analysis in prostate cancer patients of African versus European descent using a systems biology approach. If cBioPortal was used, it may have been for accessing TCGA prostate cancer data, but this is not clearly stated in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40004558,Unveiling Racial Disparities in Localized Prostate Cancer: A Systems-Level Exploration of the lncRNA Landscape.,2025,abstract,2025-12-19T04:04:42.010188,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Drug response/resistance', 'Immunotherapy', 'Biomarker discovery']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal being used in this study. The study focuses on immune monitoring of trabectedin therapy in soft tissue sarcoma patients using deep immunophenotyping, gene expression profiling, and soluble proteome analysis from their own clinical cohort. cBioPortal may only be cited in the references without direct usage in the analysis.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40007535,Immune monitoring of trabectedin therapy in refractory soft tissue sarcoma patients - the IMMUNYON study.,2025,abstract,2025-12-19T04:04:42.820544,,,,
"['Gene expression analysis', 'Pathway analysis']",['Melanoma'],"['Biomarker discovery', 'Tumor evolution']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, the study analyzed the coagulome (coagulation-related genes) in skin cutaneous melanoma (SKCM) using bulk-tumor and single-cell analyses. The paper appears to have used cBioPortal to access TCGA SKCM data for analyzing gene expression patterns of coagulation-related genes across primary tumors, metastatic samples, and circulating tumor cells. The specific usage details of cBioPortal are not explicitly described in the provided text.",['TCGA-SKCM'],['Data download/export'],['F3'],['Not specified'],External (downloaded data),medium,4.0,40003901,The Dynamic Landscape of the Coagulome of Metastatic Malignant Melanoma.,2025,abstract,2025-12-19T04:04:43.100841,,,,
"['Gene expression analysis', 'Survival analysis', 'Copy number analysis', 'Mutation analysis']",['Other solid tumor'],['Biomarker discovery'],['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used as one of multiple databases to analyze SPOCK1 in gynecological cancers (ovarian serous cystadenocarcinoma, cervical squamous cell carcinoma and endocervical adenocarcinoma, and uterine corpus endometrial carcinomas). The study integrated data from cBioPortal along with other databases including GEPIA2, TCGA, Kaplan-Meier Plotter, GeneMANIA, UALCAN, and TIMER to examine gene expression, survival outcomes, and immune cell correlations. The specific features or analysis modes used within cBioPortal are not explicitly detailed in the abstract.","['OV', 'CESC', 'UCEC']",['Web-based analysis'],['SPOCK1'],['Not specified'],"[""Unclear""]",medium,4.0,40001977,The Clinopathological and Prognostic Significance of <i>SPOCK1</i> in Gynecological Cancers: A Bioinformatics Based Analysis.,2025,abstract,2025-12-19T04:04:44.523277,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Copy number analysis', 'Multi-omics integration']","['Pan-cancer', 'Breast cancer', 'Gastric cancer', 'Esophageal cancer', 'Liver cancer', 'Prostate cancer', 'Pancreatic cancer']","['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The cBioPortal database was used to investigate genetic alterations of MIDN across cancers, including analyzing the genetic alteration rate and types, mutation site information, and mutation co-occurrence. The study found that MIDN was mutated in 1.7% of cancers with deep deletion being the dominant mutation type. This genomic analysis was one component of a comprehensive multi-database approach to characterize MIDN as a cancer biomarker.",['TCGA'],"['Web-based analysis', 'Web-based visualization']",['MIDN'],"['Query interface', 'Mutation Mapper']",cBioPortal platform,high,4.0,40002690,"Comprehensive Analysis Reveals Midnolin as a Potential Prognostic, Therapeutic, and Immunological Cancer Biomarker.",2025,pdf,2025-12-19T04:04:44.941529,,,,
"['Gene expression analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],['Multiple sources'],"Based on the abstract and introduction provided, cBioPortal is not explicitly mentioned in the text. The study uses multiple publicly available transcriptomics and proteomics datasets including The Human Protein Atlas database to identify TM4SF4 as a therapeutic target in HCC. Without the full methods section or results, it is unclear if cBioPortal was used for data access or analysis.",[],['Citation only'],"['TM4SF4', 'GPC3']",['Not specified'],Unclear,low,4.0,39999090,Multiomics in silico analysis identifies TM4SF4 as a cell surface target in hepatocellular carcinoma.,2025,pdf,2025-12-19T04:04:45.530296,,,,
"['Gene expression analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Other']",['Original research'],['TCGA'],"The authors interrogated The Cancer Genome Atlas (TCGA) database to correlate DCLK1 expression with tumor stage, grade, and invasion-associated proteins in head and neck squamous cell carcinoma. The study used TCGA data to validate their experimental findings regarding DCLK1's role in HNSCC invasion. The specific method of accessing TCGA data (whether through cBioPortal or other means) is not explicitly detailed in the provided text.",['TCGA'],['Citation only'],['DCLK1'],['Not specified'],Unclear,low,4.0,39994636,DCLK1-mediated regulation of invadopodia dynamics and matrix metalloproteinase trafficking drives invasive progression in head and neck squamous cell carcinoma.,2025,pdf,2025-12-19T04:04:46.200078,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly describe using cBioPortal in the methods or results sections provided. While the study analyzes TCGA-BRCA data and performs survival analysis, gene expression analysis, and immune-related gene identification, there is no clear mention of cBioPortal being used for data access, analysis, or visualization. cBioPortal may only be cited in the references without direct usage in the study.",['TCGA-BRCA'],['Citation only'],"['EPHB6', 'CD2', 'CXCL13']",['Not specified'],Unclear,low,4.0,39994456,Establishing a prognostic model with immune-related genes and investigating EPHB6 expression pattern in breast cancer.,2025,pdf,2025-12-19T04:04:47.425282,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis', 'Tumor evolution']",['Original research'],"['TCGA', 'Custom/Private data']","Based on the abstract and title, this paper studies RBM10 loss-of-function mutations in thyroid cancers with distant metastases. The paper likely used cBioPortal to access TCGA thyroid cancer data to analyze RBM10 mutation frequencies and their association with metastatic disease. The study focuses on understanding how RBM10 loss affects splicing of cytoskeletal and ECM transcripts leading to metastatic competency.",[],['Citation only'],['RBM10'],['Not specified'],Unclear,low,4.0,39992626,RBM10 loss promotes metastases by aberrant splicing of cytoskeletal and extracellular matrix mRNAs.,2025,abstract,2025-12-19T04:04:47.658953,,,,
['Other'],['Pan-cancer'],['Review/Commentary'],['Review'],['Not specified'],"This is a review paper discussing p53's metabolic functions and implications for cancer therapy. Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage. The paper appears to cite cBioPortal as a reference but does not describe specific analyses or data queries performed using the platform.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39986611,Metabolic regulation by p53: Implications for cancer therapy.,2025,abstract,2025-12-19T04:04:47.674106,,,,
"['Mutation analysis', 'Pathway analysis', 'Gene expression analysis']",['Melanoma'],"['Tumor evolution', 'Drug response/resistance', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to analyze the frequency of co-occurring mutations in melanoma patients with BRAFV600E. The authors queried melanoma datasets to determine that RAC1 mutations or PTEN inactivation occur together with BRAFV600E in 26% of melanomas, supporting their hypothesis that secondary mutations are required to overcome BRAFV600E-induced feedback inhibition of RAC1 and enable full malignant transformation.",['TCGA'],"['Web-based analysis', 'Query interface']","['BRAF', 'RAC1', 'PTEN']","['Query interface', 'Mutation Mapper']",Mixed,medium,4.0,39992718,Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration.,2025,abstract,2025-12-19T04:04:47.715941,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis']","['Breast cancer', 'Colorectal cancer']","['Biomarker discovery', 'Immunotherapy', 'Tumor evolution']",['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage. The study appears to be an experimental mouse model study using a syngeneic 4T1 breast cancer cell line with Msh2 knockout to model MSI-H cancer. The paper may cite cBioPortal in references for context or comparison purposes, but no specific usage of the platform for data analysis, visualization, or data download is described in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39985912,Effect of MisMatch repair deficiency on metastasis occurrence in a syngeneic mouse model.,2025,abstract,2025-12-19T04:04:49.259922,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy']",['Original research'],['Multiple sources'],"The paper does not provide explicit details about how cBioPortal was used in the study. Based on the abstract and introduction, the study obtained a standardized pan-cancer dataset from public databases and performed comprehensive bioinformatics analysis using R software. cBioPortal may have been cited as a potential data source or referenced in the methods, but specific usage details are not provided in the available text.",[],['Citation only'],['RGS5'],['Not specified'],Unclear,low,4.0,39985100,A pan-cancer analysis of the oncogenic and immunological roles of RGS5 in clear cell renal cell carcinomas based on in vitro experiment validation.,2025,abstract,2025-12-19T04:04:50.179928,,,,
"['Gene expression analysis', 'Survival analysis']","['Breast cancer', 'Lung cancer', 'Ovarian cancer', 'Pan-cancer']","['Drug response/resistance', 'Biomarker discovery']",['Original research'],"['TCGA', 'Multiple sources']",The authors used The Cancer Genomics Atlas (TCGA) data to investigate patient survival and cancer cell characteristics in relation to SETD1A and EME1 expression in HR-deficient tumors. They also used DepMap alongside TCGA to assess correlations between gene expression and PARPi sensitivity. The specific platform used to access TCGA data (whether cBioPortal or other) is not explicitly stated in the provided text.,['TCGA'],['Citation only'],"['SETD1A', 'EME1', 'BRCA1', 'BRCA2', 'ATM']",['Not specified'],Unclear,low,4.0,39994444,SETD1A-dependent EME1 transcription drives PARPi sensitivity in HR deficient tumour cells.,2025,pdf,2025-12-19T04:04:50.771068,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Pathway analysis']","['Original research', 'Clinical study']","['TCGA', 'Custom/Private data']","The study used TCGA PanCancer Atlas colorectal adenocarcinoma cohort data to evaluate transcriptional changes between early-age-onset (EAO, n=82) and later-age-onset (LAO, n=510) CRC patients. Gene-set enrichment analysis was performed on TCGA data, which revealed downregulation of immune-related pathways in EAO CRCs. The paper does not explicitly describe the specific method of accessing or analyzing the TCGA data through cBioPortal.",['TCGA PanCancer Atlas colorectal adenocarcinoma'],['Citation only'],"['KRAS', 'BRAF']",['Not specified'],Unclear,low,4.0,39980836,Micro-environmental changes indicate potential for subclinical intestinal tissue damage in early-age-onset colorectal cancer patients.,2025,abstract,2025-12-19T04:04:50.781212,,,,
['Other'],['Other solid tumor'],['Review/Commentary'],['Review'],['Not specified'],"This is an Expert Recommendation article that defines a research framework for appendiceal tumours. The paper does not describe any specific use of cBioPortal for data analysis, visualization, or data download. cBioPortal appears to be cited only as a reference or resource in the context of discussing research priorities and challenges for this rare cancer type.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39979656,Defining a 'cells to society' research framework for appendiceal tumours.,2025,abstract,2025-12-19T04:04:51.609430,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis']",['Other solid tumor'],"['Drug response/resistance', 'Pathway analysis', 'Immunotherapy']",['Original research'],['TCGA'],cBioPortal was used to query TCGA head and neck squamous cell carcinoma (HNSCC) data to assess the frequency of PTEN alterations and PIK3CA mutations/amplifications in this cancer type. The platform was likely used to obtain genomic alteration frequencies and potentially visualize the co-occurrence of these PI3K pathway alterations. This analysis provided the rationale for studying PTEN-deficient and PIK3CA-altered HNSCC tumors in their experimental models.,['TCGA-HNSC'],"['Web-based analysis', 'Web-based visualization']","['PTEN', 'PIK3CA']",['Query interface'],cBioPortal platform,medium,4.0,39976130,Blockade of the PGE2 Pathway Inhibits the Growth of PTEN-Deficient HNSCC Tumors.,2025,abstract,2025-12-19T04:04:52.485009,,,,
['Other'],['Breast cancer'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],['Not specified'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal being used in this study. The paper focuses on Mendelian randomization analysis using freely available genetic data to explore causal relationships between immune cell phenotypes and breast cancer risk. cBioPortal may only be cited in the references without direct usage in the methodology.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39969618,Mendelian randomization study identifying immune cell phenotypes associated with breast cancer risk.,2025,abstract,2025-12-19T04:04:52.853058,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Prostate cancer'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Meta-analysis']","['TCGA', 'Multiple sources']","The paper appears to cite cBioPortal as a reference or potential data source for prostate cancer genomics data, but does not provide explicit details about how cBioPortal was used in the analysis. The study primarily focuses on integrating single-cell and bulk RNA-sequencing data from multiple PCa datasets to develop a prognostic gene expression signature. Without specific mention of cBioPortal usage in the abstract or introduction, it is likely that cBioPortal was cited as a reference resource rather than actively used for data download or analysis.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39973042,Integration of single-cell and bulk RNA-sequencing data reveals the prognostic potential of epithelial gene markers for prostate cancer.,2025,abstract,2025-12-19T04:04:53.493100,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Melanoma'],"['Drug response/resistance', 'Immunotherapy', 'Pathway analysis']",['Original research'],"['TCGA', 'Custom/Private data']","The study used cBioPortal to analyze gene expression data from melanoma patients, specifically examining the correlation between a GLI2 transcriptional signature and resistance to anti-PD-1 immunotherapy in stage IV melanoma patients. The analysis appears to have utilized TCGA melanoma datasets to validate the clinical relevance of their GLI2 signature in the context of immunotherapy resistance.",['TCGA-SKCM'],"['Web-based analysis', 'Data download/export']",['GLI2'],"['Expression analysis', 'Query interface']","[""Mixed""]",medium,4.0,39970333,GLI2 Facilitates Tumor Immune Evasion and Immunotherapeutic Resistance by Coordinating WNT and Prostaglandin Signaling.,2025,abstract,2025-12-19T04:04:53.636728,,,,
['Gene expression analysis'],['Colorectal cancer'],"['Biomarker discovery', 'Other']",['Original research'],['TCGA'],"Based on the abstract and introduction provided, this paper appears to focus on the role of OXER1 in intestinal barrier integrity and oxidative stress response, primarily using zebrafish models and cultured human cells. While the paper studies mechanisms relevant to inflammation and cancer (mutagenesis, cancerogenesis), the provided text does not explicitly describe cBioPortal usage. If cBioPortal was used, it was likely for querying OXER1 expression in colorectal cancer datasets from TCGA, but this cannot be confirmed from the provided excerpts.",[],['Citation only'],['OXER1'],['Not specified'],"[""Unclear""]","[""low""]",4.0,39974905,The G-protein coupled receptor OXER1 is a tissue redox sensor essential for intestinal epithelial barrier integrity.,2025,abstract,2025-12-19T04:04:53.797689,,,,
"['Gene expression analysis', 'Mutation analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Other']",['Original research'],['Not specified'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage. The study focuses on experimental work with isogenic cell lines (HCT116, DLD-1, and hTERT-RPE1) to study p53 phenotypes and identify downstream targets. If cBioPortal is cited in this paper, it appears to be a reference citation only without detailed description of how it was used in the methodology.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39969205,Robust p53 phenotypes and prospective downstream targets in telomerase-immortalized human cells.,2025,abstract,2025-12-19T04:04:54.896893,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Pathway analysis']",['Leukemia/Lymphoma'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction, the paper uses RNA transcriptome and clinical data from multiple AML cohorts including TCGA-AML to develop and validate a prognostic model. The paper mentions using data from TCGA-AML along with other cohorts (GSE106291, GSE146173, Beat AML) for model development and validation. While cBioPortal is cited, the specific details of how cBioPortal was used are not explicitly described in the provided abstract and introduction sections.",['TCGA-AML'],['Citation only'],['SMAD3'],['Not specified'],Unclear,low,4.0,39955536,Machine learning-based bulk RNA analysis reveals a prognostic signature of 13 cell death patterns and potential therapeutic target of SMAD3 in acute myeloid leukemia.,2025,abstract,2025-12-19T04:04:56.438598,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']",cBioPortal was used to assess genetic alterations in ASCL1 in breast cancer. The database was also used to investigate the relationship between ASCL1 expression and key gene mutations in BC through the TIMER2.0 database integration. The study utilized cBioPortal alongside COSMIC to evaluate mutation patterns and genetic alterations of ASCL1.,[],"['Web-based analysis', 'Citation only']",['ASCL1'],['Not specified'],Unclear,medium,4.0,39963143,An integrative analysis of ASCL1 in breast cancer and inhibition of ASCL1 increases paclitaxel sensitivity by activating ferroptosis via the CREB1/GPX4 axis.,2025,abstract,2025-12-19T04:04:56.439726,,,,
"['Copy number analysis', 'Gene expression analysis', 'Mutation analysis', 'Pathway analysis']","['Pan-cancer', 'Leukemia/Lymphoma']","['Review/Commentary', 'Biomarker discovery', 'Pathway analysis']",['Review'],"['TCGA', 'Multiple sources']","This review paper utilized cBioPortal to analyze the extent and patterns of 17p deletion across multiple cancer types. The authors employed a data-driven approach using cBioPortal to demarcate deletion boundaries and identify common loss-of-function gene signatures associated with del17p in various cancers. cBioPortal served as a key resource for accessing and analyzing copy number alteration data, particularly focusing on the 17p region containing TP53 and other genes.",['TCGA'],"['Web-based analysis', 'Web-based visualization', 'Data download/export']",['TP53'],"['Query interface', 'Download data']",Mixed,medium,4.0,39966556,Deletion of 17p in cancers: Guilt by (p53) association.,2025,abstract,2025-12-19T04:04:57.587020,,,,
"['Gene expression analysis', 'Multi-omics integration']",['Glioma/Brain cancer'],"['Database/Resource', 'Biomarker discovery']",['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, cBioPortal is not explicitly mentioned as being used in this study. This paper describes the creation of new transcriptomics and epigenomics datasets from FFPE brain tumor samples to provide an independent cohort for validation purposes. The paper appears to be presenting a new resource/database rather than analyzing existing cBioPortal data.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39955294,Transcriptomics and epigenomics datasets of primary brain cancers in formalin-fixed paraffin embedded format.,2025,abstract,2025-12-19T04:04:58.782715,,,,
['Other'],['Not specified'],['Other'],['Original research'],['Not specified'],"This paper does not appear to use cBioPortal for any analysis. The study is focused on experimental work in budding yeast (Saccharomyces cerevisiae) investigating how oncohistone H3 E97K mutations affect CENP-A mislocalization and chromosomal instability. While the paper discusses relevance to human cancers, there is no evidence of cBioPortal data access, analysis, or visualization in the abstract or introduction provided.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39945320,Oncohistone H3 E97K mutation facilitates CENP-A mislocalization and chromosomal instability in budding yeast.,2025,abstract,2025-12-19T04:04:58.879694,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Custom/Private data']","The authors used TCGA datasets to validate their findings from their own EC cohort. Specifically, they analyzed TCGA data to examine whether the expression of differentially expressed cytokine and chemokine genes (CCL20, CXCL10, and CSF2) identified in their in vitro experiments with Fusobacterium nucleatum-exposed EC cells was associated with poor prognosis in esophageal cancer patients. The analysis appears to have been performed using TCGA data accessed through cBioPortal or similar resources for validation purposes.",['TCGA'],['Citation only'],"['CCL20', 'CXCL10', 'CSF2']",['Not specified'],Unclear,low,4.0,39951185,Activation of the tumor cell-intrinsic STING pathway induced by Fusobacterium nucleatum is associated with poor prognosis in esophageal cancer patients.,2025,abstract,2025-12-19T04:04:58.954423,,,,
"['Mutation analysis', 'Gene expression analysis', 'Copy number analysis']",['Other solid tumor'],"['Biomarker discovery', 'Tumor evolution']",['Original research'],"['TCGA', 'Multiple sources']",cBioPortal was used to analyze mutation patterns and co-occurrence of KDM5C mutations with Y chromosome loss in clear cell renal cell carcinoma patient cohorts. The authors queried TCGA and other ccRCC datasets through cBioPortal to identify the frequency of KDM5C mutations in male versus female patients and to examine the relationship between KDM5C mutation status and loss of chromosome Y (which harbors KDM5D). This analysis provided the clinical context and rationale for their experimental studies on KDM5C and KDM5D function.,['TCGA'],"['Web-based analysis', 'Web-based visualization']","['KDM5C', 'KDM5D']","['Query interface', 'Mutation Mapper']",cBioPortal platform,medium,4.0,39955388,KDM5C and KDM5D mutations have different consequences in clear cell renal cell carcinoma cells.,2025,abstract,2025-12-19T04:04:58.990492,,,,
"['Copy number analysis', 'Gene expression analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Methods/Tools development']",['Original research'],['TCGA'],The authors used TCGA data from the HGSOC dataset (n=316) to identify cancer-driver genes affected by somatic copy number alterations. They developed a scoring system that integrates information from different genetic alterations and applied it to the TCGA-HGSOC dataset accessed through cBioPortal. The data was used to identify amplification and deletion frequencies of RNF144B and PPP2R2A genes in ovarian cancer patients.,['TCGA-HGSOC'],['Data download/export'],"['RNF144B', 'PPP2R2A']",['Download data'],External (downloaded data),medium,4.0,39948107,Characterization of RNF144B and PPP2R2A identified by a novel approach using TCGA data in ovarian cancer.,2025,abstract,2025-12-19T04:04:59.085693,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis']",['Other solid tumor'],"['Biomarker discovery', 'Tumor evolution']",['Original research'],"['TCGA', 'Multiple sources']",The paper used cBioPortal to analyze PROX1 expression and mutation data in liver cancer patients. The authors queried TCGA liver cancer datasets through cBioPortal to validate their findings about PROX1's role in hepatocyte identity and liver tumorigenesis. The analysis included examination of PROX1 expression levels and their correlation with patient outcomes in hepatocellular carcinoma and cholangiocarcinoma.,['TCGA'],"['Web-based analysis', 'Web-based visualization']",['PROX1'],"['Expression analysis', 'Query interface']",cBioPortal platform,medium,4.0,39948437,Active repression of cell fate plasticity by PROX1 safeguards hepatocyte identity and prevents liver tumorigenesis.,2025,abstract,2025-12-19T04:05:00.315109,,,,
,,,,,,,,,,,,,39897128,,,,,No text available,True,True,No text available
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration', 'Copy number analysis', 'Mutation analysis']",['Pan-cancer'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","This study performed a pan-cancer analysis of SOX2 across over 30 cancer types, examining genetic alterations, transcriptomic changes, and epigenetic modifications. The authors likely used cBioPortal to access TCGA data for analyzing SOX2 expression patterns, survival outcomes, and correlations with immune checkpoint genes across multiple cancer types. The study integrated mutation, copy number, expression, and clinical data to evaluate SOX2 as a prognostic biomarker and potential therapeutic target in cancer immunotherapy.",['TCGA'],"['Data download/export', 'Web-based analysis']",['SOX2'],"['Expression analysis', 'Survival analysis', 'Download data']","[""Mixed""]",medium,4.0,39944324,Pan-cancer analysis of SOX2: Prognostic implications and potential as a therapeutic target in immune checkpoint modulation.,2025,abstract,2025-12-19T04:05:00.956287,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis']","['Pan-cancer', 'Lung cancer']","['Pathway analysis', 'Biomarker discovery', 'Review/Commentary']",['Review'],"['TCGA', 'Not specified']","Based on the title and context, this appears to be a review paper focusing on KEAP1-NRF2 interactions in cancer. The paper likely uses cBioPortal to query mutation and expression data for KEAP1 and NRF2 genes across cancer types. Given the review nature and focus on these specific genes, cBioPortal was likely used for data visualization and querying existing genomic datasets, particularly TCGA data.",[],['Citation only'],"['KEAP1', 'NRF2']",['Not specified'],Unclear,low,4.0,39941813,KEAP1-NRF2 Interaction in Cancer: Competitive Interactors and Their Role in Carcinogenesis.,2025,abstract,2025-12-19T04:05:02.633274,,,,
"['Gene expression analysis', 'Pathway analysis']",['Pan-cancer'],"['Methods/Tools development', 'Precision medicine', 'Drug response/resistance']",['Methods/Software'],['Not specified'],"This paper describes VIBE, a new R package for visualization of bulk RNA expression data. cBioPortal is not explicitly mentioned as being used in this study; it appears to be cited only as a reference to existing tools in the field. The paper focuses on developing a new tool rather than using cBioPortal for analysis.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39943991,VIBE: an R-package for VIsualization of Bulk RNA Expression data for therapeutic targeting and disease stratification.,2024,abstract,2025-12-19T04:05:02.954144,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']","['Pan-cancer', 'Colorectal cancer']","['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The study utilized cBioPortal for pan-cancer analysis of TNMD (Tendomodulin), examining gene expression patterns, mutation profiles, and survival associations across multiple cancer types. The platform was used to analyze TNMD expression and genetic alterations in colorectal cancer and other malignancies, with particular focus on its diagnostic and prognostic value. The analysis integrated data from multiple bioinformatics databases including cBioPortal to comprehensively characterize TNMD's role in cancer.",[],"['Web-based analysis', 'Web-based visualization']",['TNMD'],"['Expression analysis', 'Survival analysis', 'Query interface']",Mixed,medium,4.0,39934677,Tendomodulin in pan-cancer analysis: exploring its impact on immune modulation and uncovering functional insights in colorectal cancer.,2025,abstract,2025-12-19T04:05:04.420352,,,,
['Copy number analysis'],['Pan-cancer'],"['Drug response/resistance', 'Precision medicine']",['Original research'],['Not specified'],"Based on the abstract and introduction provided, this paper focuses on structure-based drug design to develop PRMT5 inhibitors that selectively target MTAP-deleted cancer cells. While the paper discusses MTAP gene deletion as a therapeutic vulnerability, there is no explicit mention of cBioPortal usage in the provided text. The paper appears to be primarily a medicinal chemistry study focused on inhibitor design and mechanism of action rather than a genomics data analysis study.",[],['Citation only'],"['MTAP', 'PRMT5']",['Not specified'],"[""Unclear""]","[""low""]",4.0,39919252,MTA-Cooperative PRMT5 Inhibitors: Mechanism Switching Through Structure-Based Design.,2025,abstract,2025-12-19T04:05:05.001866,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis']",['Breast cancer'],"['Drug response/resistance', 'Precision medicine', 'Biomarker discovery']","['Clinical study', 'Original research']",['Custom/Private data'],"This case report describes a patient with HR+/HER2+ metastatic breast cancer who was managed through molecular tumor board discussions. The paper mentions genomic alterations including GATA3 and NOTCH2 mutations, MCL1 and CKS1B amplifications, and ERBB3/KRAS overexpression as potential resistance mechanisms to trastuzumab deruxtecan. While cBioPortal may have been cited as a reference resource, the paper does not explicitly describe how cBioPortal was used for data analysis or visualization in this specific case.",[],['Citation only'],"['GATA3', 'NOTCH2', 'MCL1', 'CKS1B', 'ERBB3', 'KRAS', 'HER2']",['Not specified'],Unclear,low,4.0,39931207,Case report: Near-complete response to neratinib-based treatment in HR-positive <i>HER2</i>-amplified metastatic breast cancer refractory to trastuzumab deruxtecan.,2024,abstract,2025-12-19T04:05:05.636680,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Prostate cancer']","['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","The paper appears to cite cBioPortal as one of multiple bioinformatics tools used in their pan-cancer analysis of DPH2. The study conducted comprehensive analysis including expression, prognosis, immune infiltration, cell death, and methylation across 33 cancer types. However, the abstract and introduction do not provide specific details about how cBioPortal was used or what specific features were accessed.",[],['Citation only'],['DPH2'],['Not specified'],Unclear,low,4.0,39928200,"DPH2 is a biomarker associated with cell death, immunity and prognosis based on pan-cancer analysis.",2025,abstract,2025-12-19T04:05:05.730662,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine', 'Drug response/resistance']",['Original research'],"['TCGA', 'Multiple sources']","The paper cites cBioPortal but does not provide explicit details about how it was used in the study. The study primarily used TCGA-STAD database for identifying expression patterns and prognostic relevance of anoikis-related genes, along with external validation cohorts (GSE66229, GSE15459, GSE84437). Based on the abstract and introduction, cBioPortal may have been used for data access or cited as a reference, but specific usage details are not described.",['TCGA-STAD'],['Citation only'],['CRABP2'],['Not specified'],Unclear,low,4.0,39910129,Integrative analysis of anoikis-related prognostic signature to evaluate the immune landscape and predict therapeutic response in stomach adenocarcinoma.,2025,abstract,2025-12-19T04:05:05.790592,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","The paper mentions using data from various databases to assess ZC3H12D expression in HNSCC and other tumors. While cBioPortal is cited, the abstract and introduction do not provide explicit details about how cBioPortal was specifically used. The study primarily utilized UALCAN, TIMER2, and other databases for expression analysis, survival analysis, and immune infiltration assessment. cBioPortal appears to be one of multiple data sources consulted but specific usage details are not clearly described in the provided text.",[],['Citation only'],['ZC3H12D'],['Not specified'],Unclear,low,4.0,39907408,ZC3H12D upregulation in head and neck squamous cell carcinoma: a potential prognostic biomarker associated with immune infiltration.,2025,abstract,2025-12-19T04:05:05.812325,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Custom/Private data']","The study used cBioPortal for bioinformatics analysis to examine the correlation between expression levels of TTC7B, PI4KA, and FTO across human tissues and in various cancers. The authors likely queried gene expression data and performed correlation analysis to identify that these genes are consistently downregulated in many cancers. The analysis appears to have been performed using cBioPortal's web-based tools to analyze TCGA data, which informed their subsequent experimental validation in colon cancer patient samples.",['TCGA'],"['Web-based analysis', 'Web-based visualization']","['TTC7B', 'PI4KA', 'FTO']","['Expression analysis', 'Query interface']",cBioPortal platform,medium,4.0,39897037,TTC7B triggers the PI4KA-AKT1-RXRA-FTO axis and inhibits colon cancer cell proliferation by increasing RNA methylation.,2025,abstract,2025-12-19T04:05:06.561089,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis']",['Other solid tumor'],"['Tumor evolution', 'Drug response/resistance', 'Biomarker discovery']",['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The research focuses on genetically-defined organoid models derived from murine and human oral/esophageal tissues to study squamous cell carcinoma evolution. The study appears to be primarily experimental using custom organoid models rather than utilizing cBioPortal for data analysis or visualization. cBioPortal may only be cited in the references without direct usage in the methodology.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39896470,Genetically Defined Organoid Models Reveal Mechanisms Driving Squamous Cell Neoplastic Evolution and Identify Potential Therapeutic Vulnerabilities.,2025,abstract,2025-12-19T04:05:08.082077,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Tumor evolution', 'Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Custom/Private data']","Based on the abstract and introduction provided, the paper does not explicitly mention how cBioPortal was used in the study. The study appears to focus on whole-genome sequencing analysis of 51 HPV-positive head and neck squamous cell carcinomas to investigate HPV integration patterns and intratumor heterogeneity. If cBioPortal was used, it was likely for accessing TCGA data or validating findings, but specific usage details are not provided in the excerpts given.",[],['Citation only'],['ATM'],['Not specified'],Unclear,low,4.0,39865078,Intratumor heterogeneity of HPV integration in HPV-associated head and neck cancer.,2025,abstract,2025-12-19T04:05:08.931405,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],['Multiple sources'],"The paper mentions using ""multiple online tools for bioinformatics analyses"" to study CC chemokine ligands (CCLs) in colorectal cancer. While cBioPortal is cited in the references, the abstract and introduction do not provide specific details about how cBioPortal was used, what features were accessed, or what data was obtained from it. The study appears to have used various databases including ONCOMINE for expression analysis, but the specific role of cBioPortal is not clearly described in the provided text.",[],['Citation only'],"['CCL1', 'CCL2', 'CCL3', 'CCL4', 'CCL5', 'CCL6', 'CCL11', 'CCL21', 'CCL26', 'CCL27', 'CCL28', 'RELA', 'NFKB1', 'HCK', 'LYN', 'LCK', 'ATR', 'ATM', 'CSNK1G2', 'NEK2', 'CDK2']",['Not specified'],Unclear,low,4.0,39859340,Identification of Immune Infiltration-Associated CC Motif Chemokine Ligands as Biomarkers and Targets for Colorectal Cancer Prevention and Immunotherapy.,2025,pdf,2025-12-19T04:05:10.048943,,,,
"['Gene expression analysis', 'Mutation analysis']",['Other solid tumor'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],['TCGA'],"The paper mentions that TCGA dataset analyses were used to identify MAPK pathway mutations in approximately 18% of HNSCC patient tumors. However, the abstract and introduction do not provide explicit details about direct cBioPortal usage, though TCGA data analysis is referenced. The study is primarily a laboratory-based investigation of MYC overexpression and MEK inhibition in HNSCC cell lines and xenograft models.",['TCGA'],['Citation only'],"['MYC', 'EGFR', 'HRAS', 'KRAS', 'NRAS', 'ARAF', 'BRAF', 'CRAF', 'MEK1', 'MEK2', 'MAPK1', 'MAPK3']",['Not specified'],Unclear,low,4.0,39859304,MYC Overexpression Enhances Sensitivity to MEK Inhibition in Head and Neck Squamous Cell Carcinoma.,2025,pdf,2025-12-19T04:05:11.093087,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis']",['Pan-cancer'],['Biomarker discovery'],['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to analyze FOXM1 genomic alterations across the TCGA Pan-Cancer Atlas dataset. Specifically, the authors used cBioPortal's OncoPrint algorithm to calculate and visualize genomic alterations (mutations, copy number changes) for FOXM1 across multiple cancer types. This analysis was part of a broader investigation into FOXM1's role as a pan-cancer upregulated transcription factor.",['TCGA Pan-Cancer Atlas'],"['Web-based analysis', 'Web-based visualization']",['FOXM1'],['OncoPrint'],cBioPortal platform,high,4.0,39858603,Pan-Cancer Upregulation of the <i>FOXM1</i> Transcription Factor.,2025,pdf,2025-12-19T04:05:11.138468,,,,
['Gene expression analysis'],['Pan-cancer'],"['Methods/Tools development', 'Other']",['Original research'],['TCGA'],"Based on the paper title and abstract, this is a structural biology study focused on determining the cryo-EM structure and regulation of human NAD kinase (NADK). While the paper cites cBioPortal, the abstract and introduction do not provide specific details about how cBioPortal was used. It appears cBioPortal may have been used to examine NADK expression patterns across cancer types, but the exact usage is not described in the provided text.",[],['Citation only'],['NADK'],['Not specified'],Unclear,low,4.0,39854463,Cryo-EM structure and regulation of human NAD kinase.,2025,abstract,2025-12-19T04:05:11.312838,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Methods/Tools development', 'Precision medicine']",['Original research'],"['TCGA', 'Custom/Private data']","cBioPortal was used to download clinical data for patients with high-grade serous ovarian cancer from the TCGA-OV Pan-Cancer dataset. The clinical data obtained from cBioPortal was matched with data from the GDC portal using TCGA patient IDs and then merged for model training and validation. The data was accessed on October 1, 2023.",['TCGA-OV Pan-Cancer'],['Data download/export'],[],['Download data'],External (downloaded data),high,4.0,39856778,Spatial transcriptome reveals histology-correlated immune signature learnt by deep learning attention mechanism on H&E-stained images for ovarian cancer prognosis.,2025,pdf,2025-12-19T04:05:11.650192,,,,
"['Gene expression analysis', 'Survival analysis']",['Breast cancer'],['Biomarker discovery'],"['Original research', 'Clinical study']","['TCGA', 'Multiple sources']","The study used cBioPortal along with GEPIA to perform computational analysis of SERPINA1 gene expression in breast cancer. The analysis examined SERPINA1 expression levels across different breast cancer molecular subtypes and evaluated associations with prognosis, disease-free survival, and overall survival. This computational analysis complemented their experimental work measuring serum α1-AT protein levels in breast cancer patients.",[],"['Web-based analysis', 'Web-based visualization']",['SERPINA1'],"['Expression analysis', 'Survival analysis']",cBioPortal platform,medium,4.0,39851465,Serum α1-AT Levels and <i>SERPINA1</i> Molecular Analysis in Breast Cancer: An Experimental and Computational Study.,2024,pdf,2025-12-19T04:05:12.591929,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Mutation analysis']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, there is no explicit mention of cBioPortal being used in this study. The paper describes using data from TCGA and Gene Expression Omnibus (GEO) databases, along with the Sangerbox database for various analyses. The study focuses on lnc-MAPKAPK5-AS1 expression, methylation, prognosis, and immune infiltration in hepatocellular carcinoma, but does not specifically reference cBioPortal as a tool or data source in the provided text.",['TCGA-LIHC'],['Citation only'],['MAPKAPK5'],['Not specified'],Unclear,low,4.0,39850723,The role of lnc‑MAPKAPK5‑AS1 in immune cell infiltration in hepatocellular carcinoma: Bioinformatics analysis and validation.,2025,pdf,2025-12-19T04:05:13.371566,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Pathway analysis', 'Precision medicine']",['Original research'],['Custom/Private data'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on analyzing two independent medulloblastoma RNA-sequencing cohorts (MB-PBTA and MTAB-10767) using WGCNA, survival analysis, and other bioinformatics approaches to investigate ferroptosis-related gene expression. While cBioPortal is cited as a cancer genomics portal, the specific usage details are not described in the provided text.","['MB-PBTA', 'MTAB-10767']",['Citation only'],"['CCT3', 'SNX5', 'SQOR', 'G3BP1', 'CARS1', 'SLC39A14', 'FAM98A', 'FXR1', 'TFAP2C', 'ATF4', 'IL6', 'CBS', 'FANCD2', 'GPX4', 'MYC']",['Not specified'],Unclear,low,4.0,39857430,Ferroptosis Transcriptional Regulation and Prognostic Impact in Medulloblastoma Subtypes Revealed by RNA-Seq.,2025,pdf,2025-12-19T04:05:13.417563,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Mutation analysis', 'Copy number analysis']",['Breast cancer'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","The study analyzed TCGA breast cancer data (n=1,069) alongside the SCAN-B cohort (GSE96058, n=3,273) to investigate ARC gene expression. TCGA data was likely accessed through cBioPortal for gene expression analysis, mutation analysis (SNV, indel), copy number alterations (fraction altered), and survival outcomes. The analysis examined relationships between ARC expression and various genomic features including homologous recombination deficiency, intratumor heterogeneity, mutation rates, and immune cell infiltration patterns.",['TCGA'],['Data download/export'],['ARC'],['Download data'],External (downloaded data),medium,4.0,39850523,"Activity-Regulated Cytoskeleton-Associated Protein Gene Expression Is Associated With High Infiltration of Stromal Cells and Immune Cells, but With Less Cancer Cell Proliferation and Better Overall Survival in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancers.",2025,abstract,2025-12-19T04:05:14.586488,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy']",['Original research'],"['TCGA', 'METABRIC', 'Multiple sources']","The paper analyzed VEGFA gene expression across multiple breast cancer cohorts including TCGA and METABRIC. While these datasets are available through cBioPortal, the abstract does not explicitly describe how cBioPortal was used or whether data was accessed through the platform. The study appears to have analyzed publicly available datasets that are hosted on cBioPortal, but the specific method of data access and analysis is not clearly stated in the provided text.","['TCGA', 'METABRIC', 'GSE173839', 'GSE96058', 'GSE25066', 'GSE163882', 'GSE34138', 'GSE20194']",['Citation only'],['VEGFA'],['Not specified'],Unclear,low,4.0,39850522,"<i>VEGFA</i> Gene Expression in Breast Cancer Is Associated With Worse Prognosis, but Better Response to Chemotherapy and Immunotherapy.",2025,abstract,2025-12-19T04:05:15.314644,,,,
"['Gene expression analysis', 'Mutation analysis', 'Pathway analysis']",['Leukemia/Lymphoma'],"['Drug response/resistance', 'Biomarker discovery', 'Pathway analysis']",['Original research'],['Not specified'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this paper. The study focuses on experimental work using Lmo2 transgenic mouse models, patient-derived xenografts, and single-cell RNA-sequencing data from primary ETP-ALL samples. While the paper may cite cBioPortal in the references or methods section not provided here, no specific usage of the platform for data analysis, visualization, or data download is described in the available text.",[],['Citation only'],"['LMO2', 'LYL1', 'FLT3', 'STAT5', 'IL7R', 'NOTCH1']",['Not specified'],Unclear,low,4.0,39849166,Targeting LMO2-induced autocrine FLT3 signaling to overcome chemoresistance in early T-cell precursor acute lymphoblastic leukemia.,2025,pdf,2025-12-19T04:05:16.433565,,,,
"['Gene expression analysis', 'Mutation analysis']","['Breast cancer', 'Lung cancer']","['Drug response/resistance', 'Biomarker discovery']",['Original research'],['Not specified'],"Based on the abstract and introduction provided, cBioPortal is cited in this paper but specific details about how it was used are not explicitly described in these sections. The study focuses on YES1-driven EGFR expression in triple-negative breast cancer and non-small cell lung cancer, including analysis of EGFR mutations like T790M. Without access to the methods section, the exact usage of cBioPortal cannot be determined from the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39847459,Exploiting YES1-Driven EGFR Expression Improves the Efficacy of EGFR Inhibitors.,2025,abstract,2025-12-19T04:05:16.582903,,,,
"['Gene expression analysis', 'Survival analysis']",['Pan-cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy', 'Precision medicine', 'Methods/Tools development']","['Original research', 'Methods/Software']","['TCGA', 'Custom/Private data']","The paper used TCGA data from The Cancer Genome Atlas to classify tumor types into four subgroups based on the MVD gene score and T cell-inflamed gene expression profile. The study applied their newly developed MVD gene signature to large public datasets where IHC data are unavailable, including TCGA pan-cancer data, to explore correlations with clinical treatment indications. The specific mechanism of accessing TCGA data (whether through cBioPortal or other sources) is not explicitly detailed in the abstract.",['TCGA'],['Citation only'],[],['Not specified'],Unclear,low,4.0,39835481,Development of a Microvessel Density Gene Signature and Its Application in Precision Medicine.,2025,abstract,2025-12-19T04:05:17.723231,,,,
"['Copy number analysis', 'Gene expression analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']",['Original research'],['Multiple sources'],"The authors analyzed publicly available data from cBioPortal to validate their findings in an independent cohort of 265 liposarcoma samples (both well-differentiated and dedifferentiated). They examined NTRK gene amplification status across this dataset and found that 23 cases (8.6%) showed mutually exclusive amplification of NTRK genomic loci, confirming their primary findings in a non-preselected patient population.",[],['Web-based analysis'],"['NTRK1', 'NTRK2', 'NTRK3']",['Query interface'],cBioPortal platform,medium,4.0,39839837,NTRK amplification occurs frequently in pan-TRK immunopositive dedifferentiated liposarcomas.,2024,abstract,2025-12-19T04:05:17.761353,,,,
"['Mutation analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Breast cancer'],"['Biomarker discovery', 'Methods/Tools development']","['Original research', 'Methods/Software']","['TCGA', 'Multiple sources']",The paper used cBioPortal to obtain breast cancer mutation data from TCGA. The mutation data was downloaded and used in conjunction with survival data and protein-protein interaction networks to identify protein communities under mutation and survival burdens. The analysis was performed externally using their novel graph neural network approach rather than on the cBioPortal platform itself.,['TCGA'],['Data download/export'],"['BRCA2', 'SUPT6H', 'RAD21']",['Download data'],External (downloaded data),medium,4.0,39838298,A graph neural network approach for hierarchical mapping of breast cancer protein communities.,2025,pdf,2025-12-19T04:05:17.949785,,,,
"['Mutation analysis', 'Methods/Tools development']","['Head and neck cancer', 'Breast cancer', 'Lung cancer', 'Colorectal cancer']","['Methods/Tools development', 'Biomarker discovery']","['Original research', 'Methods/Software']",['TCGA'],"The paper does not explicitly describe using cBioPortal in their methodology. The study focuses on developing an ensemble machine learning approach to evaluate pathogenicity prediction algorithms for distinguishing driver from passenger mutations in cancer. While TCGA data was used for HNSC and other cancer types, there is no clear mention of cBioPortal being used for data access, analysis, or visualization in the provided abstract and introduction sections.",['TCGA-HNSC'],['Citation only'],[],['Not specified'],Unclear,low,4.0,39833905,An ensemble machine learning-based performance evaluation identifies top In-Silico pathogenicity prediction methods that best classify driver mutations in cancer.,2025,pdf,2025-12-19T04:05:20.322196,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']","['Pan-cancer', 'Leukemia/Lymphoma', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],['TCGA'],"The authors used cBioPortal to analyze FLT3 alterations (mutations, fusions, amplifications, deletions) and mRNA expression levels across multiple cancer types from the TCGA Pan-Cancer Atlas. They assessed the frequency of FLT3 alterations and evaluated the prognostic value of FLT3 mutations in different cancer types using cBioPortal's integrated analysis tools. The platform was specifically used to access and analyze data from 105 cancer studies in the TCGA pipeline.",['TCGA Pan-Cancer Atlas'],"['Web-based analysis', 'Web-based visualization']",['FLT3'],"['Query interface', 'Expression analysis', 'Survival analysis']",Mixed,high,4.0,39833282,"FLT3 is associated with dendritic cell infiltration, tertiary lymphoid structure construction, and predict response to checkpoint inhibitors immunotherapy in solid cancers.",2025,pdf,2025-12-19T04:05:20.351740,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Mutation analysis']",['Pan-cancer'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used as one of multiple web platforms and software tools for comprehensive data analysis in this pan-cancer study of CENPN. The authors listed cBioPortal (CBio Cancer Genomics Portal) among their methods for analyzing TCGA data, though specific details about which cBioPortal features were used are not explicitly described in the provided abstract and introduction sections. The study appears to have used cBioPortal for querying and analyzing CENPN expression and potentially mutation data across 33 cancer types.",['TCGA'],['Web-based analysis'],['CENPN'],['Not specified'],Unclear,medium,4.0,39832113,Pan-cancer analysis and single-cell analysis identifies the CENPN as a biomarker for survival prognosis and immunotherapy.,2025,pdf,2025-12-19T04:05:20.602546,,,,
"['Mutation analysis', 'Survival analysis', 'Other']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']","['TCGA', 'Custom/Private data']",The authors used The Cancer Genome Atlas (TCGA) cervical cancer database to validate their finding that cervical cancers caused by HPV types outside of phylogenetic clade α9 had higher recurrence frequency than those caused by α9 types. The TCGA data was used for comparative analysis to support their primary findings from their own patient cohort. The specific method of accessing TCGA data (whether through cBioPortal or other means) is not explicitly stated in the abstract.,['TCGA cervical cancer'],['Citation only'],[],['Not specified'],Unclear,low,4.0,39830266,"Serum, Cell-Free, HPV-Human DNA Junction Detection and HPV Typing for Predicting and Monitoring Cervical Cancer Recurrence.",2025,abstract,2025-12-19T04:05:20.832941,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Mutation analysis', 'Copy number analysis']",['Pan-cancer'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],['TCGA'],"Based on the abstract and introduction provided, this paper does not explicitly mention using cBioPortal. The study uses TCGA data accessed through TIMER2.0 for gene expression analysis and other public databases. While cBioPortal is cited in the paper, there is no clear description of how it was used for data access, analysis, or visualization in the methods section provided.",['TCGA'],['Citation only'],['DIO2'],['Not specified'],Unclear,low,4.0,39821172,"The thyroid hormone activating enzyme, DIO2, is a potential pan-cancer biomarker and immunotherapy target.",2025,pdf,2025-12-19T04:05:21.566726,,,,
['Other'],['Breast cancer'],"['Drug response/resistance', 'Review/Commentary']",['Review'],['Not specified'],"This is a review article on HER2-positive breast cancer treatment and resistance mechanisms. Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage, data analysis, or specific features utilized. The paper appears to cite cBioPortal in the references but does not describe any direct usage of the platform for data analysis or visualization.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39821040,HER2-Positive Breast Cancer Treatment and Resistance.,2025,abstract,2025-12-19T04:05:22.483658,,,,
['Other'],['Breast cancer'],"['Review/Commentary', 'Drug response/resistance', 'Precision medicine']",['Review'],['Not specified'],This is a review article focusing on CDK4/6 inhibitors in HR+/HER2- early breast cancer. The paper does not describe any actual use of cBioPortal for data analysis or visualization. cBioPortal appears to be cited only as a reference or general resource without specific usage details provided in the abstract and introduction sections.,[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39820840,Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2- Early Breast Cancer.,2025,pdf,2025-12-19T04:05:22.513867,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],"['TCGA', 'Multiple sources']","The authors used cBioPortal to analyze SIRT7 mRNA expression levels in HNSCC patient samples compared to non-tumor samples. They also used cBioPortal to perform survival analysis, comparing overall survival rates between HNSCC patients with higher versus lower SIRT7 expression. Additionally, they examined the correlation between SIRT7 mRNA expression and tumor stage using data from cBioPortal.",['TCGA-HNSC'],"['Web-based analysis', 'Web-based visualization']",['SIRT7'],"['Expression analysis', 'Survival analysis', 'Group comparison']",cBioPortal platform,high,4.0,39820554,Loss of Sirtuin 7 impairs cell motility and proliferation and enhances S-phase cell arrest after 5-fluorouracil treatment in head and neck cancer.,2025,pdf,2025-12-19T04:05:23.712381,,,,
"['Gene expression analysis', 'Survival analysis']",['Breast cancer'],['Biomarker discovery'],['Original research'],"['TCGA', 'METABRIC', 'Custom/Private data']","The paper used TCGA data (n=854) to evaluate BRI3BP gene expression at the mRNA level in invasive breast cancer. The study examined associations between BRI3BP expression and clinicopathological characteristics including tumor grade, size, and lymph vascular invasion. However, the abstract does not explicitly mention cBioPortal as the source or method for accessing TCGA data, so cBioPortal usage is unclear and may only be cited in references.","['TCGA', 'METABRIC']",['Citation only'],['BRI3BP'],['Not specified'],Unclear,low,4.0,39816562,The clinicopathological significance of BRI3BP in women with invasive breast cancer.,2024,abstract,2025-12-19T04:05:23.902772,,,,
"['Gene expression analysis', 'Pathway analysis', 'Multi-omics integration']",['Breast cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis']",['Original research'],['Multiple sources'],"The paper mentions cBioPortal only in the context of noting that proteasomal subunits experience RNA and protein expression changes more frequently than mutations in cancers, with a reference to https://www.phosphosite.org. This appears to be a general citation acknowledging the resource rather than describing specific data analysis or queries performed using cBioPortal. No specific datasets, genes, or analysis features from cBioPortal are described in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39814910,Loss of correlated proteasomal subunit expression selectively promotes the 20S<sup>High</sup> state which underlies luminal breast tumorigenicity.,2025,pdf,2025-12-19T04:05:24.051289,,,,
"['Mutation analysis', 'Pathway analysis']",['Pan-cancer'],"['Review/Commentary', 'Pathway analysis', 'Precision medicine']",['Review'],['Not specified'],"This is a review paper that discusses the functional impact of cancer genomic mutations through protein-protein interactions. Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage, specific analyses performed using the platform, or data downloaded from it. The paper appears to cite cBioPortal as a relevant resource in the cancer genomics field but does not describe specific usage of the platform for original analyses.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39810024,Decoding the functional impact of the cancer genome through protein-protein interactions.,2025,abstract,2025-12-19T04:05:26.135589,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Pan-cancer'],"['Immunotherapy', 'Biomarker discovery']",['Original research'],"['TCGA', 'Multiple sources']",cBioPortal was used to analyze the clinical correlation between ETV7 expression and patient outcomes across various human cancers. The authors examined ETV7 expression levels in relation to disease progression and responsiveness to immune checkpoint blockade therapy using data from multiple cancer types available through cBioPortal. This analysis supported their finding that ETV7 expression is negatively correlated with clinical outcomes and immunotherapy response.,[],"['Web-based analysis', 'Citation only']",['ETV7'],"['Expression analysis', 'Not specified']",Unclear,medium,4.0,39805956,ETV7 limits the antiviral and antitumor efficacy of CD8<sup>+</sup> T cells by diverting their fate toward exhaustion.,2025,abstract,2025-12-19T04:05:26.433146,,,,
"['Gene expression analysis', 'Pathway analysis', 'Survival analysis']",['Breast cancer'],"['Drug response/resistance', 'Immunotherapy', 'Biomarker discovery']",['Original research'],"['Custom/Private data', 'Multiple sources']","Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this paper. The study focuses on experimental mouse models of metastatic breast cancer and bulk RNA-Seq analysis of laser-capture microdissected lung metastases. While the paper may cite cBioPortal in the full text or methods section not provided here, no specific usage details are evident from the available content.",[],['Citation only'],['ACVRL1'],['Not specified'],Unclear,low,4.0,39808498,An activin receptor-like kinase 1-governed monocytic lineage shapes an immunosuppressive landscape in breast cancer metastases.,2025,pdf,2025-12-19T04:05:26.987541,,,,
"['Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Melanoma']","['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The paper analyzed whole exome and bulk RNA sequencing data from a pan-cancer cohort of 25,775 patients and melanoma cohorts using cBioPortal. RECQL4 copy number variations and expression levels were assessed for patient outcomes across multiple cancer types. The study utilized cBioPortal to access and analyze large-scale genomic and transcriptomic data to investigate RECQL4's role in immune checkpoint inhibitor response.",[],['Data download/export'],['RECQL4'],['Download data'],External (downloaded data),medium,4.0,39812592,RECQL4 affects MHC class II-mediated signalling and favours an immune-evasive signature that limits response to immune checkpoint inhibitor therapy in patients with malignant melanoma.,2025,abstract,2025-12-19T04:05:27.024608,,,,
"['Gene expression analysis', 'Other']",['Breast cancer'],"['Biomarker discovery', 'Other']",['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The research focuses on experimental laboratory work using breast cancer cell lines (MDA-MB-231 and MDA-MB-231-br) and brain endothelial cells (hCMEC/D3) to investigate extracellular vesicles and VCP protein effects. The study appears to be entirely experimental/in vitro work without bioinformatics analysis using cBioPortal.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39802400,"Valosin-containing protein (VCP), a component of tumor-derived extracellular vesicles, impairs the barrier integrity of brain microvascular endothelial cells.",2025,abstract,2025-12-19T04:05:28.059212,,,,
"['Mutation analysis', 'Copy number analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine', 'Pathway analysis']",['Original research'],"['GENIE', 'Multiple sources']","The study utilized genomic data from the AACR GENIE registry (v15.1) and other genomic datasets to characterize genomic alterations in biliary tract cancers. The researchers analyzed mutational patterns, co-occurrence of alterations, and their impact on overall survival across different BTC subtypes (intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder cancer). The analysis examined anatomic and geographic heterogeneity in genomic profiles and identified clinically significant co-alterations in genes like IDH1, FGFR2, TP53, KRAS, and ERBB2/HER2.",['AACR GENIE v15.1'],['Data download/export'],"['IDH1', 'FGFR2', 'TP53', 'ERBB2', 'HER2', 'SMAD4', 'KRAS', 'BAP1', 'PBRM1']",['Download data'],External (downloaded data),high,4.0,39803868,"Genomic Profiling of Biliary Tract Cancers: Comprehensive Assessment of Anatomic and Geographic Heterogeneity, Co-Alterations and Outcomes.",2025,abstract,2025-12-19T04:05:29.711829,,,,
"['Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']","['Pan-cancer', 'Breast cancer']","['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis']",['Original research'],"['TCGA', 'ICGC', 'Multiple sources']","cBioPortal was used as one of several bioinformatics databases to conduct comprehensive analyses of MRPL24 in human cancers. The platform was specifically mentioned for pan-cancer analysis of TCGA/ICGC data, which revealed significant amplification of MRPL24 across multiple cancer types, with the highest amplification rate of 60% observed in metastatic breast cancer. The study integrated cBioPortal data with other databases (UALCAN, TIMER, Prognoscan, TISIDB, KM Plotter, The Human Protein Atlas) to evaluate MRPL24's clinicopathological significance.","['TCGA', 'ICGC']","['Web-based analysis', 'Web-based visualization']","['MRPL24', 'MYC', 'BRD4', 'WNT3', 'STAT3', 'ERBB2', 'ERBB3', 'GRB2', 'PIK3CA', 'AKT1', 'MAPK3', 'MAPK1']","['Expression analysis', 'Not specified']",Unclear,medium,4.0,39802327,"MRPL24 drives breast cancer metastasis and stemness by targeting c-MYC, BRD4, and STAT3.",2025,abstract,2025-12-19T04:05:30.244510,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Copy number analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine', 'Immunotherapy', 'Drug response/resistance']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, cBioPortal is not explicitly mentioned in the text. The study uses TCGA data for kidney renal clear cell carcinoma (KIRC) analysis, including single-cell RNA-seq, spatial transcriptome, and bulk RNA-seq analysis to develop an ADME-related prognostic signature. While TCGA data is commonly accessed through cBioPortal, the specific usage of cBioPortal is not described in the provided sections.",['TCGA-KIRC'],['Citation only'],[],['Not specified'],Unclear,low,4.0,39779746,Identifying ADME-related gene signature for immune landscape and prognosis in KIRC by single-cell and spatial transcriptome analysis.,2025,pdf,2025-12-19T04:05:31.185255,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Other']",['Original research'],"['TCGA', 'Multiple sources']","The paper used cBioPortal for bioinformatics analysis to investigate the diagnostic and prognostic value of PER3 in gliomas. The analysis included examining PER3 expression levels, correlation with immune cell infiltration and immune checkpoint genes, and ROC curve analysis to differentiate between GBM tissues and normal tissues. The cBioPortal data was used to validate PER3 as a biomarker before conducting experimental validation in zebrafish models.",[],"['Web-based analysis', 'Citation only']",['PER3'],"['Expression analysis', 'Survival analysis', 'Not specified']",Unclear,medium,4.0,39771050,DEHP-Induced Glioblastoma in Zebrafish Is Associated with Circadian Dysregulation of PER3.,2024,abstract,2025-12-19T04:05:31.654864,,,,
"['Gene expression analysis', 'Survival analysis']",['Breast cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'METABRIC', 'Custom/Private data']",The TCGA cohort data were extracted using the Genomic Data Commons Data Portal and cBioPortal websites to obtain RNASeqV2-derived mRNA expression data. cBioPortal was used as one of the data sources for accessing TCGA breast cancer gene expression data for DSCC1. The analysis focused on correlating DSCC1 mRNA expression with clinicopathological features and patient outcomes.,"['TCGA', 'METABRIC']",['Data download/export'],['DSCC1'],['Download data'],External (downloaded data),high,4.0,39768811,"Prognostic Significance of DSCC1, a Biomarker Associated with Aggressive Features of Breast Cancer.",2024,pdf,2025-12-19T04:05:33.212169,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Pan-cancer'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, this pan-cancer study analyzed CD276 expression levels, survival outcomes, immune cell infiltration, and associated signaling pathways across multiple cancer types. While cBioPortal is cited, the specific details of how it was used are not explicitly described in the provided text. The study likely used cBioPortal to access TCGA pan-cancer data for CD276 expression and survival analysis.",[],['Citation only'],['CD276'],['Not specified'],Unclear,low,4.0,39766794,A Pan-Cancer Analysis of the Oncogenic Role of CD276 in Human Tumors.,2024,abstract,2025-12-19T04:05:33.771173,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']",['Original research'],['TCGA'],"The study used TCGA gastric cancer cohort data to compare gastric adenocarcinomas with CDX2 mRNA induction versus those without CDX2 induction. The analysis examined mutations (TP53, KMT2B), copy number alterations (MYC amplifications), gene expression patterns (CDX2, HNF4A, SOX2, PD-L1, CLDN18), and survival outcomes. While the paper mentions TCGA data is publicly available and references cBioPortal in the context of accessing cancer genomics data, the specific details of how cBioPortal was used are not explicitly described in the provided abstract and introduction.",['TCGA gastric cancer'],['Citation only'],"['CDX2', 'TP53', 'KMT2B', 'MYC', 'HNF4A', 'SOX2', 'CD274', 'CLDN18']",['Not specified'],Unclear,low,4.0,39768557,Gastric Adenocarcinomas with CDX2 Induction Show Higher Frequency of <i>TP53</i> and <i>KMT2B</i> Mutations and <i>MYC</i> Amplifications but Similar Survival Compared with Cancers with No CDX2 Induction.,2024,pdf,2025-12-19T04:05:34.357538,,,,
"['Gene expression analysis', 'Mutation analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Tumor evolution']",['Original research'],['TCGA'],"The authors used cBioPortal to access TCGA Head and Neck Squamous Cell Carcinoma (HNSC) data to validate their findings from mouse models. They analyzed genomic alterations, particularly focusing on FAT1, TP53, CDKN2A, and YAP pathway components in human HNSC samples. The data was used to examine the frequency of alterations and correlate tumor initiating cell transcriptional programs with patient survival outcomes.",['TCGA-HNSC'],['Data download/export'],"['FAT1', 'TP53', 'CDKN2A', 'YAP1', 'WWTR1']","['Download data', 'Query interface']",External (downloaded data),medium,4.0,39779672,YAP-driven malignant reprogramming of oral epithelial stem cells at single cell resolution.,2025,pdf,2025-12-19T04:05:35.020895,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration']","['Pan-cancer', 'Breast cancer', 'Colorectal cancer', 'Glioma/Brain cancer', 'Lung cancer', 'Other solid tumor']","['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the abstract or introduction provided. While the study analyzes pan-cancer genomic data including TCGA data for gene expression, survival, immune characteristics, and drug sensitivity analyses of HTGPCR genes, there is no clear statement about cBioPortal being used as a data source or analysis platform. The citation of cBioPortal may be for reference purposes only.",[],['Citation only'],"['HTR1D', 'HTR2C', 'HTR2A', 'HTR2B', 'HTR7', 'HTR4']",['Not specified'],Unclear,low,4.0,39766808,"5-Hydroxytryptamine G-Protein-Coupled Receptor Family Genes: Key Players in Cancer Prognosis, Immune Regulation, and Therapeutic Response.",2024,abstract,2025-12-19T04:05:34.971347,,,,
"['Mutation analysis', 'Survival analysis']",['Other solid tumor'],"['Review/Commentary', 'Biomarker discovery', 'Precision medicine']",['Review'],['Not specified'],"This is a review paper on molecular subtypes of vulvar squamous cell carcinoma (VSCC) focusing on HPV status and TP53 mutations. Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage. The paper discusses molecular subclassification of VSCC into HPV-associated, HPV-independent with TP53 mutations, and HPV-independent with wild-type TP53, but does not describe any specific use of cBioPortal for data analysis or visualization.",[],['Citation only'],['TP53'],['Not specified'],"[""Unclear""]","[""low""]",4.0,39766115,Molecular Subtypes of Vulvar Squamous Cell Carcinoma: The Significance of HPV-Independent/p53 Wild Type.,2024,abstract,2025-12-19T04:05:35.662871,,,,
"['Mutation analysis', 'Survival analysis']",['Colorectal cancer'],"['Drug response/resistance', 'Immunotherapy', 'Precision medicine', 'Biomarker discovery']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The study utilized clinical and genomic data from the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) repository in Japan, not cBioPortal. The paper may cite cBioPortal in references, but the actual data source and analysis platform used was the C-CAT repository.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39765187,"Efficacy of pembrolizumab in microsatellite-stable, tumor mutational burden-high metastatic colorectal cancer: genomic signatures and clinical outcomes.",2025,abstract,2025-12-19T04:05:35.708609,,,,
['Other'],['Not specified'],['Methods/Tools development'],['Methods/Software'],['Not specified'],"This paper introduces Marsilea, a Python library for creating composable visualizations. cBioPortal's OncoPrint is mentioned as an example of existing composable visualization approaches for displaying mutation events in patient cohorts. The paper does not use cBioPortal for data analysis or visualization; it only cites OncoPrint as a reference example of complex visualization in the biological domain.",[],['Citation only'],[],['Not specified'],Unclear,high,4.0,39762969,Marsilea: an intuitive generalized paradigm for composable visualizations.,2025,pdf,2025-12-19T04:05:37.240390,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Mutation analysis']",['Melanoma'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Custom/Private data']","The study utilized TCGA data to analyze FER1L4 expression levels and correlate them with clinicopathological features in melanoma patients. The authors examined the relationship between FER1L4 expression, BRAF mutations, metastatic status, and patient survival outcomes. While TCGA data was explicitly mentioned, the specific role of cBioPortal as the data access platform is not clearly stated in the abstract.",['TCGA'],['Citation only'],"['FER1L4', 'BRAF']",['Not specified'],Unclear,low,4.0,39764216,Fer-1 like family member 4 pseudogene: novel potential diagnostic and prognostic biomarker for cutaneous melanoma.,2024,abstract,2025-12-19T04:05:38.323079,,,,
"['Gene expression analysis', 'Mutation analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],"Based on the abstract and introduction provided, cBioPortal usage is not explicitly described in these sections. The paper focuses on experimental validation of SMYD3 function in HPV-negative HNSCC using cell lines, xenografts, and CUT&RUN assays. While TCGA data may have been accessed through cBioPortal for validation or correlation analyses (common in such studies), specific usage details are not mentioned in the provided text.",[],['Citation only'],"['SMYD3', 'UHRF1', 'SNAI1', 'TWIST1', 'ZEB1', 'FN1', 'VIM', 'CCND1', 'CCNE1']",['Not specified'],Unclear,low,4.0,39762343,SMYD3 drives cell cycle and epithelial-mesenchymal transition pathways through dual gene transcriptional repression and activation in HPV-negative head and neck cancer.,2025,pdf,2025-12-19T04:05:40.397620,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],"Based on the abstract and introduction provided, the paper appears to use cBioPortal to access TCGA data for analyzing IGFBP2 expression in endometrial cancer and its correlation with prognosis. The study likely queried IGFBP2 expression data and performed survival analysis to demonstrate that high IGFBP2 expression correlates with poor prognosis in EC patients. However, specific details about cBioPortal usage are not explicitly mentioned in the provided text.",['TCGA'],['Web-based analysis'],"['IGFBP2', 'PKM2', 'HIF1A']","['Expression analysis', 'Survival analysis']","[""Unclear""]",medium,4.0,39761954,IGFBP2 Promotes Proliferation and Glycolysis of Endometrial Cancer by Regulating PKM2/HIF-1α Axis.,2025,abstract,2025-12-19T04:05:40.455943,,,,
"['Gene expression analysis', 'Survival analysis']",['Prostate cancer'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']","['TCGA', 'Custom/Private data']","Based on the abstract and introduction provided, the paper does not explicitly describe how cBioPortal was used. The study focuses on measuring plasma levels of splicing factors (SRRM1, SNRNP200, SRSF3) in clinical samples and performing in vivo functional studies. While TCGA data may have been accessed through cBioPortal for validation or comparison purposes, no specific details about cBioPortal usage are mentioned in the provided text.",[],['Citation only'],"['SRRM1', 'SNRNP200', 'SRSF3', 'AR']",['Not specified'],Unclear,low,4.0,39758250,Clinical value of circulating splicing factors in prostate cancer: SRRM1 as a novel predictive biomarker and therapeutic target.,2024,abstract,2025-12-19T04:05:41.065361,,,,
"['Copy number analysis', 'Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Methods/Tools development']",['Original research'],['TCGA'],"The authors used data from The Cancer Genome Atlas (TCGA) to identify frequently copy number-amplified and up-regulated genes in hepatocellular carcinoma, specifically finding that these genes reside on human chromosomes 1q and 8q. They also analyzed human HCC data to examine correlations between MRPL9, VPS72, or GBA1 expression levels and patient survival. The TCGA data was used to guide the design of their in vivo CRISPRa screening experiments targeting these amplified genes.",['TCGA'],"['Data download/export', 'Web-based analysis']","['ZBTB7B', 'VPS72', 'GBA1', 'MRPL9', 'MYC']","['Expression analysis', 'Survival analysis', 'Download data']","[""Mixed""]",medium,4.0,39761726,"In Vivo CRISPR Activation Screening Reveals Chromosome 1q Genes VPS72, GBA1, and MRPL9 Drive Hepatocellular Carcinoma.",2025,abstract,2025-12-19T04:05:41.978531,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'METABRIC']",The study used cBioPortal to obtain the METABRIC dataset for external validation of their stemness-risk model. The METABRIC cohort data from cBioPortal was used to validate the 5-gene stemness model that was initially developed using TCGA-BRCA data. The paper explicitly states that both TCGA-BRCA and METABRIC datasets were obtained from cBioPortal and UCSC Xena.,"['TCGA-BRCA', 'METABRIC']",['Data download/export'],['PIK3CA'],['Download data'],External (downloaded data),high,4.0,39755992,Characterization of stem cell landscape and identification of stemness-relevant prognostic gene signature to aid immunotherapy in breast cancer.,2025,pdf,2025-12-19T04:05:42.509410,,,,
"['Copy number analysis', 'Other']","['Pan-cancer', 'Glioma/Brain cancer', 'Other solid tumor']","['Drug response/resistance', 'Precision medicine', 'Biomarker discovery']",['Original research'],['Not specified'],"The paper focuses on the development and preclinical characterization of TNG908, a PRMT5 inhibitor targeting MTAP-deleted cancers. While the paper discusses MTAP deletion as a biomarker occurring in 10-15% of human cancers, there is no explicit mention of cBioPortal usage in the abstract or introduction provided. The citation appears to be for background information on cancer genomics rather than active use of the platform.",[],['Citation only'],"['MTAP', 'PRMT5']",['Not specified'],Unclear,low,4.0,39756156,"TNG908 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor developed for the treatment of MTAP-deleted cancers.",2025,abstract,2025-12-19T04:05:42.602321,,,,
['Other'],['Not specified'],['Methods/Tools development'],['Original research'],['Not specified'],"This paper does not actually use cBioPortal for any analysis. It is a biophysical study investigating how mutations to the transcription factor MAX affect DNA binding selectivity and kinetics using microfluidic techniques (STAMMP and k-STAMMP). The paper focuses on protein-DNA interactions and folding pathways, not cancer genomics data analysis. cBioPortal may be cited in references but is not utilized in the research.",[],['Citation only'],[],['Not specified'],"[""Unclear""]","[""low""]",4.0,39805837,Mutations to transcription factor MAX allosterically increase DNA selectivity by altering folding and binding pathways.,2025,pdf,2025-12-19T04:05:43.124099,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Multi-omics integration']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy', 'Drug response/resistance']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used as one of multiple data sources in this pan-cancer study of SMAD3. The authors utilized cBioPortal to analyze gene mutations and potentially other genomic features of SMAD3 across various cancer types. The specific details of how cBioPortal was used are limited in the abstract, but it appears to have been used alongside TCGA, GTEx, HPA, UALCAN and other databases for comprehensive multiomic characterization.",[],"['Data download/export', 'Citation only']",['SMAD3'],['Not specified'],External (downloaded data),medium,4.0,39753728,"Multiomic characterization, immunological and prognostic potential of SMAD3 in pan-cancer and validation in LIHC.",2025,abstract,2025-12-19T04:05:44.475888,,,,
"['Gene expression analysis', 'Mutation analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Custom/Private data']","The authors used the cBioPortal platform to interrogate TCGA RNA-Seq data comparing HNSCC tumor samples (n=515) to normal tissue (n=82) for differential expression of nuclear receptor genes. They examined 48 nuclear receptor genes and 19 nuclear receptor cofactors, identifying that 99% of tumor samples had some form of alteration (predominantly expression changes) compared to normal tissue. The platform was used to identify significant differences in nuclear receptor expression, particularly finding downregulation of PPARG, RORC, and NCOA1 in tumors.",['TCGA-HNSC'],"['Web-based analysis', 'Web-based visualization']","['PPARG', 'RORC', 'NCOA1']","['Expression analysis', 'Group comparison', 'Query interface']","[""cBioPortal platform""]",high,4.0,39754894,Analysis of nuclear receptor expression in head and neck cancer.,2025,abstract,2025-12-19T04:05:44.809927,,,,
"['Gene expression analysis', 'Copy number analysis', 'Survival analysis']",['Breast cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],['METABRIC'],"The METABRIC dataset for breast cancer was obtained from the cBioPortal public domain. The authors retrieved gene expression data for MET, ESR1, and ESR2, as well as putative copy number alterations (CNAs) for MET from cBioPortal. The data was then analyzed externally to investigate correlations between gene expression, copy number alterations, clinicopathologic characteristics, and survival outcomes.",['METABRIC'],['Data download/export'],"['MET', 'ESR1', 'ESR2']","['Download data', 'Query interface']",External (downloaded data),high,4.0,39742369,The Impact of the Coexpression of <i>MET</i> and <i>ESR</i> Genes on Prognosticators and Clinical Outcomes of Breast Cancer: An Analysis for the METABRIC Dataset.,2024,abstract,2025-12-19T04:05:45.623467,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],['TCGA'],"cBioPortal was used to analyze TBK1 genetic alterations in endometrial cancer (UCEC), including identification of mRNA downregulation and missense mutations. The platform was used to examine mutation patterns and expression data from TCGA uterine corpus endometrial carcinoma datasets. Additionally, Kaplan-Meier plotter analysis was performed to correlate TBK1 expression levels with patient prognosis in UCEC.",['TCGA-UCEC'],"['Web-based analysis', 'Web-based visualization']",['TBK1'],"['Mutation Mapper', 'Expression analysis', 'Query interface']",cBioPortal platform,medium,4.0,39744441,TBK1 inhibitor amlexanox exerts anti-cancer effects against endometrial cancer by regulating AKT/NF-κB signaling.,2025,abstract,2025-12-19T04:05:46.759629,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and methods, this paper does not explicitly mention using cBioPortal. The study utilized TCGA, GTEx, CELL, and GEO databases accessed through various platforms including UCSC, R packages, and other web-based tools. The analysis was performed using R software and multiple online platforms, but cBioPortal is not mentioned in the provided text as a data source or analysis platform.",['TCGA TARGET GTEx (PANCAN)'],['Citation only'],['CYFIP2'],['Not specified'],Unclear,low,4.0,39739214,CYFIP2: potential pancreatic cancer biomarker and immunotherapeutic target.,2024,pdf,2025-12-19T04:05:48.046433,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Copy number analysis', 'Pathway analysis']","['Pan-cancer', 'Melanoma']","['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","The paper mentions examining genomic alterations and mutational landscape of DCLRE1B in the Materials and Methods section, suggesting cBioPortal may have been used for mutation and copy number analysis. However, the abstract and introduction provided do not contain explicit details about how cBioPortal was specifically utilized. The primary data sources mentioned are TCGA, GTEx, and TARGET databases accessed through UCSC Xena.","['TCGA', 'GTEx', 'TARGET']",['Citation only'],['DCLRE1B'],['Not specified'],Unclear,low,4.0,39738287,DCLRE1B as a novel prognostic biomarker associated with immune infiltration: a pancancer analysis.,2024,pdf,2025-12-19T04:05:48.983428,,,,
"['Mutation analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']",['Multiple sources'],"The study performed a retrospective analysis of 937 CCA patients using data from cBioPortal to examine KRAS mutation profiles and their association with survival outcomes. The cBioPortal data was used to determine the prevalence of KRAS mutations (15.6%) and identify common variants including G12D (37.0%), G12V (24.0%), and Q61H (8.2%). The analysis demonstrated that patients harboring KRAS mutations exhibited decreased overall and recurrence-free survival.",[],"['Data download/export', 'Web-based analysis']","['KRAS', 'PTEN']","['Survival analysis', 'Query interface']",Mixed,high,4.0,39730186,"<i>KRAS</i> Mutations in Cholangiocarcinoma: Prevalence, Prognostic Value, and <i>KRAS</i> G12/G13 Detection in Cell-Free DNA.",2025,pdf,2025-12-19T04:05:49.096889,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']",['Original research'],['TCGA'],"The paper mentions analyzing DNA copy number and mutation status of ASXL family genes (ASXL1, ASXL2, ASXL3) using TCGA data. While cBioPortal is cited in the references, the abstract and introduction do not provide specific details about how cBioPortal was used - whether for data download, web-based analysis, or visualization. The study focuses on HNSCC (head and neck squamous cell carcinoma) and uses TCGA data to analyze ASXL gene expression, mutations, and copy number alterations in relation to prognosis and immune infiltration.",['TCGA'],['Citation only'],"['ASXL1', 'ASXL2', 'ASXL3']",['Not specified'],Unclear,low,4.0,39732849,Integrative analysis of ASXL family genes reveals ASXL2 as an immunoregulatory molecule in head and neck squamous cell carcinoma.,2024,pdf,2025-12-19T04:05:49.897171,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to analyze gene expression profiles and survival outcomes in Head and Neck Squamous Cell Carcinoma (HNSCC) datasets. The study specifically examined the expression and prognostic significance of FST, VRK3, and SGK1 genes that were identified from P. gingivalis-treated keratinocytes. The analysis revealed that upregulation of FST correlated with poor prognosis in HNSCC patients.",[],"['Web-based analysis', 'Web-based visualization']","['FST', 'VRK3', 'SGK1']","['Expression analysis', 'Survival analysis']",cBioPortal platform,medium,4.0,39717877,Differential gene expression profile in <i>Porphyromonas gingivalis</i> treated human gingival keratinocytes and their role in the development of HNSCC.,2025,abstract,2025-12-19T04:05:50.813104,,,,
"['Gene expression analysis', 'Mutation analysis', 'Pathway analysis']",['Breast cancer'],"['Drug response/resistance', 'Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']",['Not specified'],"The paper does not explicitly mention using cBioPortal in the abstract or introduction provided. While the study involves genomic analysis of metaplastic breast cancer and mentions multi-omic analyses and molecular aberrations in PI3K and iNOS pathways, there is no clear reference to cBioPortal usage in the text provided. The paper may cite cBioPortal in references but specific usage details are not evident in the sections provided.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39737957,NOS inhibition sensitizes metaplastic breast cancer to PI3K inhibition and taxane therapy via c-JUN repression.,2024,pdf,2025-12-19T04:05:50.990274,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine', 'Methods/Tools development']","['Original research', 'Methods/Software']",['TCGA'],"The paper does not explicitly mention using cBioPortal. The study collected data from TCGA-KIRC (The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma dataset) including clinical information, WSI pathology data, mRNA expression, miRNA expression, and DNA methylation data. While TCGA data is available through cBioPortal, the paper does not specify cBioPortal as the data source or analysis platform used.",['TCGA-KIRC'],['Citation only'],[],['Not specified'],Unclear,low,4.0,39713797,A multimodal ensemble approach for clear cell renal cell carcinoma treatment outcome prediction.,2024,abstract,2025-12-19T04:05:51.244478,,,,
"['Multi-omics integration', 'Survival analysis', 'Gene expression analysis', 'Copy number analysis']","['Pan-cancer', 'Breast cancer']","['Methods/Tools development', 'Biomarker discovery', 'Precision medicine']","['Original research', 'Methods/Software']",['TCGA'],The authors used TCGA cancer datasets to validate their novel DMOIT (Denoised Multi-Omics Integration approach based on Transformer) method. They conducted two tasks: survival time classification across different cancer types and estrogen receptor status classification for breast cancer. The data appears to have been downloaded from TCGA (likely via cBioPortal or similar repositories) for external analysis using their newly developed deep learning framework.,['TCGA'],['Data download/export'],[],['Download data'],External (downloaded data),medium,4.0,39720180,DMOIT: denoised multi-omics integration approach based on transformer multi-head self-attention mechanism.,2024,pdf,2025-12-19T04:05:51.429005,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Drug response/resistance', 'Pathway analysis', 'Biomarker discovery']",['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of how cBioPortal was used in this study. The paper focuses on experimental work using CRISPR/Cas9-generated isogenic cell lines with PIK3CA mutations and multi-omics analysis. cBioPortal may have been cited for reference purposes or used for preliminary data exploration, but specific usage details are not provided in the available text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39709507,PIK3CA mutation fortifies molecular determinants for immune signaling in vascular cancers.,2025,abstract,2025-12-19T04:05:54.141417,,,,
"['Copy number analysis', 'Mutation analysis', 'Gene expression analysis']","['Pan-cancer', 'Other solid tumor']","['Drug response/resistance', 'Biomarker discovery', 'Precision medicine']",['Original research'],"['GENIE', 'Multiple sources']","Based on the abstract and introduction provided, the paper does not explicitly mention cBioPortal usage. However, given that this is a study analyzing KRAS wild-type amplification across cancer cell lines and patient data, and that cBioPortal is cited, it is likely that cBioPortal was used to query KRAS copy number alterations and mutation status in patient cohorts. The specific usage details are not provided in the excerpts given, suggesting either citation only or usage details may be in the methods section not provided.",[],['Citation only'],['KRAS'],['Not specified'],Unclear,low,4.0,39711431,Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification.,2025,abstract,2025-12-19T04:05:54.243602,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly describe how cBioPortal was used in the study. While the research involves analysis of PDAC subtypes, gene expression, and clinical outcomes using transcriptomic and proteomic data, there is no clear mention of cBioPortal usage in the provided abstract and introduction. The citation appears to be a reference only without detailed description of specific cBioPortal features or data access methods.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39762215,Spatial tumor immune heterogeneity facilitates subtype co-existence and therapy response in pancreatic cancer.,2025,pdf,2025-12-19T04:05:55.025580,,,,
"['Gene expression analysis', 'Mutation analysis']",['Breast cancer'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],['Multiple sources'],"The paper mentions using the Broad Institute DepMap dataset to identify TNBC vulnerabilities and dependencies, including ITGAV vulnerability. While cBioPortal is not explicitly mentioned in the provided abstract and introduction, the authors reference using genetic screens and dependency scores from DepMap for 26 breast cancer cell lines. The specific usage of cBioPortal itself is not clearly described in the provided text.",[],['Citation only'],"['ITGAV', 'ITGB3', 'ITGB5', 'ITGB4', 'ITGA3', 'ITGA6']",['Not specified'],Unclear,low,4.0,39707454,Cilengitide sensitivity is predicted by overall integrin expression in breast cancer.,2024,pdf,2025-12-19T04:05:55.620764,,,,
"['Mutation analysis', 'Copy number analysis', 'Survival analysis', 'Multi-omics integration']","['Pan-cancer', 'Lung cancer']","['Biomarker discovery', 'Drug response/resistance', 'Precision medicine', 'Tumor evolution']",['Original research'],"['MSK-IMPACT', 'GENIE', 'TCGA', 'Multiple sources']","This study utilized cBioPortal as a major data source for large-scale pan-cancer genomic analysis, analyzing sequencing data from 48,179 cancer patients to investigate biallelic inactivation patterns in tumor suppressor genes. The authors performed allele-specific analysis of mutations and copy number alterations across multiple cancer types, with particular focus on KEAP1 zygosity as a predictive biomarker in lung cancer. cBioPortal likely served as the primary platform for accessing MSK-IMPACT, GENIE, and TCGA datasets for this comprehensive genomic analysis.","['MSK-IMPACT', 'GENIE', 'TCGA']","['Data download/export', 'API access']","['KEAP1', 'TP53', 'PTEN', 'RB1', 'NF1', 'CDKN2A', 'STK11', 'SMAD4', 'APC', 'VHL', 'TSC1', 'TSC2', 'BRCA1', 'BRCA2']","['Download data', 'Query interface']",External (downloaded data),high,4.0,39701102,Pan-cancer analysis of biallelic inactivation in tumor suppressor genes identifies KEAP1 zygosity as a predictive biomarker in lung cancer.,2025,abstract,2025-12-19T04:05:56.206289,,,,
"['Gene expression analysis', 'Mutation analysis', 'Survival analysis', 'Pathway analysis']",['Leukemia/Lymphoma'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The paper used RNA-seq data from The Cancer Genome Atlas (TCGA) AML study for functional genomics analysis. The study investigated FMNL1 expression patterns, associations with mutational status (including WT1 mutations), and correlations with clinical outcomes and drug sensitivity in AML patients. While TCGA data was utilized, the specific mechanism of data access (whether through cBioPortal or direct TCGA access) is not explicitly stated in the abstract.",['TCGA-AML'],['Citation only'],"['FMNL1', 'WT1']",['Not specified'],Unclear,low,4.0,39697714,Emerging functions of FMNL1 in myeloid neoplasms: insights from bioinformatics to biological and pharmacological landscapes.,2024,abstract,2025-12-19T04:05:57.634710,,,,
"['Mutation analysis', 'Copy number analysis']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper describes molecular profiling of six adult primary leptomeningeal gliomatosis cases using various techniques including DNA methylation profiling, mutation analysis, and copy number analysis, but does not reference cBioPortal as a tool or data source. If cBioPortal is cited, it appears to be a citation only without clear description of how it was used in the methodology.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39692003,"Molecular profile of adult primary leptomeningeal gliomatosis aligns with glioblastoma, IDH-wildtype.",2025,abstract,2025-12-19T04:05:58.039172,,,,
['Gene expression analysis'],['Not specified'],['Other'],['Original research'],['Not specified'],"This paper does not appear to use cBioPortal at all. The study focuses on cerebellar granule cell differentiation and trans-differentiation to Purkinje cells in the context of Jdp2 gene depletion. This is a neuroscience/developmental biology study examining neural cell differentiation, not a cancer genomics study. There is no mention of cBioPortal in the provided abstract and introduction text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39695141,Trans-differentiation of Jdp2-depleted Gaba-receptor-positive cerebellar granule cells to Purkinje cells.,2024,pdf,2025-12-19T04:05:58.045655,,,,
['Mutation analysis'],"['Breast cancer', 'Ovarian cancer', 'Pancreatic cancer', 'Prostate cancer']","['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. This paper focuses on analyzing germline PALB2 pathogenic/likely pathogenic variants in a Slovenian cohort of hereditary breast and ovarian cancer families using next-generation sequencing at the Institute of Oncology Ljubljana. The study appears to be entirely based on institutional data collection and analysis without reference to cBioPortal.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39696405,Two recurrent pathogenic/likely pathogenic variants in PALB2 account for half of PALB2 positive families in Slovenia.,2024,pdf,2025-12-19T04:05:58.046287,,,,
"['Mutation analysis', 'Survival analysis', 'Copy number analysis']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Tumor evolution', 'Precision medicine']","['Original research', 'Clinical study']","['TCGA', 'Multiple sources', 'Custom/Private data']","The study analyzed 46 butterfly glioblastoma (bGB) patients from publicly available datasets including TCGA-GBM, CPTAC-GBM, IvyGAP, and UPENN-GBM. These public datasets were likely accessed through cBioPortal to obtain molecular and clinical data for comparison with their institutional cohort (K-cohort). The data was used to validate their findings about distinct subtypes of butterfly glioblastomas and their molecular characteristics.","['TCGA-GBM', 'CPTAC-GBM']",['Data download/export'],"['TERT', 'MGMT', 'H3F3A', 'HIST1H3B', 'BRAF']",['Download data'],External (downloaded data),medium,4.0,39687791,"Radiological, clinical, and molecular analyses reveal distinct subtypes of butterfly glioblastomas affecting the prognosis.",2024,abstract,2025-12-19T04:05:58.096611,,,,
"['Gene expression analysis', 'Mutation analysis', 'Pathway analysis']",['Other solid tumor'],"['Drug response/resistance', 'Biomarker discovery', 'Pathway analysis']",['Original research'],['Not specified'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on experimental analysis of ANXA7 in thyroid cancer cells, including RNA sequencing and protein profiling, but does not describe accessing or using cBioPortal for data analysis or visualization. If cBioPortal is cited, it appears to be a reference citation only without detailed usage description in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39684934,Role of Annexin 7 (ANXA7) as a Tumor Suppressor and a Regulator of Drug Resistance in Thyroid Cancer.,2024,abstract,2025-12-19T04:05:59.811827,,,,
"['Gene expression analysis', 'Survival analysis']",['Leukemia/Lymphoma'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine']",['Original research'],['Multiple sources'],"Based on the abstract and introduction provided, cBioPortal is not explicitly mentioned in the text. The study analyzed approximately 2500 DLBCL samples from public databases to identify prognostic gene signatures, but the specific role of cBioPortal (if any) is not described in the provided sections. It appears cBioPortal may only be cited as a reference or potential data source without detailed usage information.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39684518,Development and Validation of a Novel Four Gene-Pairs Signature for Predicting Prognosis in DLBCL Patients.,2024,abstract,2025-12-19T04:06:00.788846,,,,
['Mutation analysis'],['Pan-cancer'],"['Methods/Tools development', 'Precision medicine']","['Methods/Software', 'Original research']",['Multiple sources'],"Based on the abstract and introduction provided, cBioPortal is not explicitly mentioned as being used in this study. The paper describes the development of PredictONCO, a new web tool for predicting the functional impact of missense mutations in cancer-associated proteins. While cBioPortal may be cited in the references as a related resource or for context, there is no clear description of how cBioPortal data or features were utilized in the development or validation of PredictONCO.",[],['Citation only'],"['TP53', 'FGFR1']",['Not specified'],Unclear,low,4.0,39687752,"Analysis of mutations in precision oncology using the automated, accurate, and user-friendly web tool PredictONCO.",2024,abstract,2025-12-19T04:06:01.256816,,,,
['Gene expression analysis'],"['Pan-cancer', 'Breast cancer', 'Colorectal cancer', 'Lung cancer', 'Other solid tumor']","['Biomarker discovery', 'Other']",['Original research'],['Not specified'],"The paper mentions that MGP has been shown to be dysregulated in several tumors including cervical, ovarian, urogenital, breast, colorectal, and lung cancers. The study analyzes correlations between MGP expression and transcription factor expression levels in several cancer types. However, the abstract and introduction do not explicitly describe how cBioPortal was used or whether it was the source of the cancer expression data analyzed.",[],['Citation only'],"['MGP', 'YY1', 'GATA1', 'RUNX2']",['Not specified'],Unclear,low,4.0,39684309,Transcriptional Regulation of the Human MGP Promoter: Identification of Downstream Repressors.,2024,pdf,2025-12-19T04:06:01.912978,,,,
['Other'],"['Lung cancer', 'Pan-cancer']","['Review/Commentary', 'Pathway analysis', 'Drug response/resistance']",['Review'],['Not specified'],"This is a review paper focusing on RAS oncogene-mediated mechanisms in cancer, particularly lung cancer, from the perspective of DNA replication stress and senescence. Based on the abstract and introduction provided, there is no explicit description of how cBioPortal was used in this study. The paper appears to be a comprehensive review of RAS biology and potential therapeutic strategies rather than an original research article utilizing cBioPortal for data analysis.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39682179,Oncogenic RAS in Cancers from the DNA Replication Stress and Senescence Perspective.,2024,abstract,2025-12-19T04:06:03.273582,,,,
['Other'],['Other solid tumor'],"['Drug response/resistance', 'Review/Commentary', 'Precision medicine']",['Review'],['Not specified'],"This is a narrative review paper discussing PARP inhibitors in testicular germ cell tumors. Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in the study. The paper appears to be a literature review discussing treatment strategies and mechanisms of cisplatin resistance in TGCTs, without describing any specific data analysis using cBioPortal.",[],['Citation only'],"['BRCA1', 'BRCA2', 'ATM', 'CHEK2']",['Not specified'],"[""Unclear""]","[""low""]",4.0,39678373,PARP inhibitors in testicular germ cell tumors: what we know and what we are looking for.,2024,abstract,2025-12-19T04:06:03.939033,,,,
"['Gene expression analysis', 'Pathway analysis']",['Other solid tumor'],"['Drug response/resistance', 'Pathway analysis']",['Original research'],['TCGA'],"The paper mentions conducting ""publicly available database searches"" as part of their methodology to define the endocannabinoid system milieu in ovarian cancer. Based on the abstract and introduction, cBioPortal appears to have been used to query publicly available data, likely TCGA ovarian cancer datasets, though specific details about the exact usage are not provided in the abstract. The primary focus of the study was experimental work with cell lines and patient-derived tumor slices rather than computational analysis.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39677720,Cannabidiol promotes apoptosis and downregulation of oncogenic factors.,2024,abstract,2025-12-19T04:06:04.255882,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis']",['Lung cancer'],"['Biomarker discovery', 'Tumor evolution']",['Original research'],['TCGA'],The study used cBioPortal to analyze clinical LUAD specimens from TCGA datasets. The authors examined the correlation between FBXO45 loss and genomic instability in human lung adenocarcinoma samples to validate their findings from the mouse model. This analysis confirmed a positive correlation between loss of FBXO45 and genomic instability in clinical specimens.,['TCGA-LUAD'],['Web-based analysis'],['FBXO45'],['Not specified'],"[""Unclear""]",medium,4.0,39672818,Loss of Fbxo45 in AT2 cells leads to insufficient histone supply and initiates lung adenocarcinoma.,2025,abstract,2025-12-19T04:06:04.343548,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],['Biomarker discovery'],['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used alongside UALCAN and TCGA databases to analyze the relationships between MBD2 expression, clinicopathological features, and survival outcomes in HNSCC patients. The platform was used to assess MBD2 expression patterns and their association with overall survival (OS) and disease-free survival (DFS) in head and neck squamous cell carcinoma. The specific usage details and features employed are not explicitly described in the abstract.",['TCGA'],"['Web-based analysis', 'Web-based visualization']",['MBD2'],"['Expression analysis', 'Survival analysis']",Unclear,medium,4.0,39676597,Knockdown of Methylation-Related Gene MBD2 Blocks Cell Growth by Upregulating p21 Expression in Head and Neck Squamous Cell Carcinoma.,2024,abstract,2025-12-19T04:06:05.325551,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Colorectal cancer'],"['Biomarker discovery', 'Precision medicine', 'Immunotherapy']","['Original research', 'Clinical study']","['TCGA', 'Custom/Private data', 'Multiple sources']","The paper used TCGA colorectal cancer data for validation of their 3-gene signature (GTF3A, PKM, and VEGFA) and performed survival analysis. The TCGA cohort (435 patients) was used to validate the prognostic value of the gene signature initially discovered in their Augusta University cohort. While the abstract mentions TCGA data was used for validation, specific details about whether cBioPortal was the direct source or how it was accessed are not explicitly stated in the provided text.",['TCGA'],['Citation only'],"['GTF3A', 'PKM', 'VEGFA']",['Not specified'],Unclear,low,4.0,39673574,Identification of a distinctive immunogenomic gene signature in stage-matched colorectal cancer.,2024,abstract,2025-12-19T04:06:06.142289,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Prostate cancer'],"['Biomarker discovery', 'Pathway analysis', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, the paper appears to focus on androgen receptor transcriptional programs in prostate cancer using genome-wide approaches. The study examines gene signatures correlating with prognosis and luminal phenotypes in PCa patients, which likely involved analysis of public datasets such as TCGA. However, specific details about cBioPortal usage are not explicitly mentioned in the provided text, suggesting it may have been used for accessing prostate cancer datasets or validating gene expression signatures.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39672812,Canonical androgen response element motifs are tumor suppressive regulatory elements in the prostate.,2024,abstract,2025-12-19T04:06:06.161467,,,,
"['Mutation analysis', 'Other']",['Melanoma'],"['Immunotherapy', 'Methods/Tools development']","['Methods/Software', 'Original research']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal being used in this study. The paper focuses on developing a novel tool (LRMAHpan) for HLA presentation prediction using mass spectrometry data and deep learning approaches. The study appears to use custom mass spectrometry data and applies the tool to melanoma patient cohorts, but cBioPortal usage is not described in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39669561,LRMAHpan: a novel tool for multi-allelic HLA presentation prediction using Resnet-based and LSTM-based neural networks.,2024,abstract,2025-12-19T04:06:06.921979,,,,
['Mutation analysis'],['Not specified'],"['Precision medicine', 'Other']","['Original research', 'Clinical study']",['Custom/Private data'],"This paper does not appear to use cBioPortal for its analysis. The study focuses on disorders of somatic mosaicism (DoSM) caused by postzygotic variants in PI3K/AKT/mTOR and RAS/MAPK pathway genes, using a custom deep sequencing NGS assay on 936 individuals. The paper may cite cBioPortal in references but does not describe using the platform for data access, analysis, or visualization.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39669237,Co-existence of 2 clinically significant variants causing disorders of somatic mosaicism.,2023,abstract,2025-12-19T04:06:07.106863,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Tumor evolution', 'Immunotherapy']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The research appears to be an original investigation analyzing RNA from 262 cervical biopsies collected from women in a low-and-middle-income country, focusing on HPV types and gene expression patterns during cancer progression. The study uses custom/private data from their own patient cohort rather than data from cBioPortal. If cBioPortal is cited in the full paper, it may be for reference purposes only or for comparative analysis not described in the abstract.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39672307,Analysis of the progression of cervical cancer in a low-and-middle-income country: From pre-malignancy to invasive disease.,2025,abstract,2025-12-19T04:06:07.118626,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Pan-cancer'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the methods or results sections. The analysis was performed using TCGA, GEO, and HPA databases with R language and online tools including STRING, TISIDB, and TISCH2, but cBioPortal is not specifically mentioned as one of the tools used. If cBioPortal was used, it was likely only for citation purposes or data access without explicit acknowledgment.",['TCGA'],['Citation only'],['DHX34'],['Not specified'],Unclear,low,4.0,39668816,"DHX34 as a promising biomarker for prognosis, immunotherapy and chemotherapy in Pan-Cancer: A Comprehensive Analysis and Experimental Validation.",2024,abstract,2025-12-19T04:06:09.292070,,,,
"['Gene expression analysis', 'Pathway analysis']",['Melanoma'],"['Drug response/resistance', 'Biomarker discovery', 'Precision medicine']",['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on experimental work with melanoma cell lines investigating PLK1 inhibitors and mitochondrial signatures. If cBioPortal was used, it may have been for validation or comparison purposes, but this is not evident from the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39658088,Mitochondrial signatures shape phenotype switching and apoptosis in response to PLK1 inhibitors.,2025,abstract,2025-12-19T04:06:10.743084,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['Multiple sources'],"cBioPortal was used to analyze selenoprotein expression, mutations, and copy number variations in gynecological malignancies, particularly ovarian cancer. The study analyzed 25 selenoproteins and found that ovarian cancer had the highest mutation frequency (52.91%) among gynecological malignancies. The platform was used alongside other tools (GEPIA, Kaplan-Meier plotter, TIMER) for comprehensive multi-omics analysis.",[],"['Web-based analysis', 'Web-based visualization']","['DIO3', 'GPX4', 'SECISBP2', 'SELM', 'SELP', 'SELO', 'SELT']","['Expression analysis', 'Query interface']",Mixed,medium,4.0,39663776,Comprehensive analysis of selenoprotein gene expression and prognostic value in ovarian cancer.,2024,pdf,2025-12-19T04:06:10.860287,,,,
['Other'],['Other solid tumor'],['Review/Commentary'],['Review'],['Not specified'],"This is a review paper focusing on the role of NSD histone methyltransferases in head and neck and cervical cancers, particularly virus-induced cancers. The abstract and introduction provided do not contain any explicit mention of cBioPortal usage, data queries, or specific analyses performed using the platform. The paper appears to be a literature review discussing the therapeutic potential of targeting NSD proteins in cancer.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39645166,The oncogenic role of the NSD histone methyltransferases in head and neck and cervical cancers.,2025,abstract,2025-12-19T04:06:11.367268,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The cBioPortal for Cancer Genomics was used to perform mutation analysis of nerve-cancer crosstalk-related genes in pancreatic ductal adenocarcinoma. The authors accessed cBioPortal's web resource to explore, visualize, and analyze multidimensional cancer genomics data related to the 42 NCCGs identified in their study. The specific details of which genes were queried or what exact analyses were performed are not fully described in the provided text.",['TCGA-PAAD'],"['Web-based analysis', 'Web-based visualization']","['NGFR', 'CHRNB2', 'CHRNA10', 'KRAS', 'NRG1', 'NTRK']",['Not specified'],"[""cBioPortal platform""]",medium,4.0,39660330,Establishment and analysis of a prognostic model of pancreatic ductal adenocarcinomas based on nerve-cancer crosstalk-related genes.,2024,pdf,2025-12-19T04:06:11.697057,,,,
"['Survival analysis', 'Mutation analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine', 'Immunotherapy']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on a retrospective analysis of surgically resected pancreatic ductal adenocarcinoma patients from a single institution (1990-2023), examining MSI-H/MMRd/Lynch syndrome-associated cases versus matched controls. The study appears to use institutional data with survival analysis performed using generalized estimating equation Cox models, without clear indication of cBioPortal involvement.",[],['Citation only'],"['MLH1', 'MSH2', 'MSH6', 'PMS2']",['Not specified'],Unclear,low,4.0,39656390,"Survival of Patients with Resected Microsatellite Instability-High, Mismatch Repair Deficient, and Lynch Syndrome-Associated Pancreatic Ductal Adenocarcinomas.",2025,abstract,2025-12-19T04:06:11.700528,,,,
"['Gene expression analysis', 'Pathway analysis', 'Other']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal being used in this study. The study primarily uses microarray data from GEO (GSE53800) and performs bioinformatics analysis using R software. cBioPortal may only be cited in the references without direct usage in the methodology.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39649886,Unraveling the role of PBK in glioblastoma: from molecular mechanisms to therapeutic targets.,2024,abstract,2025-12-19T04:06:11.824972,,,,
['Other'],['Pan-cancer'],"['Review/Commentary', 'Database/Resource']",['Review'],['Not specified'],This is a review paper describing NIH resources and programs for oncology drug discovery and development. cBioPortal is mentioned as one of the regularly curated databases available through NIH resources that encompasses genomics and clinical datasets. No specific analysis or usage of cBioPortal is described in the paper.,[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39637905,Navigating the oncology drug discovery and development process with programmes supported by the National Institutes of Health.,2024,abstract,2025-12-19T04:06:12.017272,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']",['Original research'],"['TCGA', 'Custom/Private data']","The paper does not explicitly mention using cBioPortal in the abstract or introduction. The study obtained GBM transcriptome and clinical data from TCGA via the UCSC Xena platform, not cBioPortal. While the paper may cite cBioPortal in references, there is no clear description of cBioPortal usage for data access, analysis, or visualization in the provided text.",['TCGA'],['Citation only'],"['SUV39H1', 'TP53', 'PTEN']",['Not specified'],"[""Unclear""]","[""low""]",4.0,39640533,Comprehensive gene set enrichment and variation analyses identify <i>SUV39H1</i> as a potential prognostic biomarker for glioblastoma immunorelevance.,2024,abstract,2025-12-19T04:06:12.728088,,,,
"['Gene expression analysis', 'Pathway analysis', 'Mutation analysis']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']",The study used cBioPortal to analyze NTRK fusion-positive patients and explore correlations between NTRK fusions and tumor invasion/migration through bioinformatics analysis of public databases. The authors analyzed gene expression patterns and coexpression of ECM1 and NOVA1 with NTRKs in thyroid cancer (THCA) and pancancer datasets. The analysis focused on identifying genes associated with epithelial-mesenchymal transition (EMT) pathway activity across various cancer types.,['TCGA-THCA'],"['Web-based analysis', 'Web-based visualization']","['NTRK1', 'NTRK2', 'NTRK3', 'ECM1', 'NOVA1']","['Expression analysis', 'Query interface']",Mixed,medium,4.0,39639242,NTRK fusion promotes tumor migration and invasion through epithelial-mesenchymal transition and closely interacts with ECM1 and NOVA1.,2024,abstract,2025-12-19T04:06:13.185166,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']","['Pan-cancer', 'Pancreatic cancer', 'Prostate cancer', 'Colorectal cancer', 'Breast cancer', 'Glioma/Brain cancer', 'Melanoma']","['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis', 'Immunotherapy', 'Review/Commentary']",['Review'],['Not specified'],"This is a comprehensive review paper on TRPM channels in human cancers. Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage. The paper reviews the roles of TRPM family members in various cancers and their mechanisms in tumorigenesis. If cBioPortal is cited, it appears to be as a reference or potential data source rather than for specific analyses performed by the authors.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39633507,TRPM channels in human cancers: regulatory mechanism and therapeutic prospects.,2024,abstract,2025-12-19T04:06:16.619013,,,,
"['Gene expression analysis', 'Mutation analysis', 'Survival analysis']",['Pan-cancer'],"['Biomarker discovery', 'Other']",['Original research'],['TCGA'],The study used cBioPortal to access and analyze The Cancer Genome Atlas (TCGA) data to support their findings about TTC28's role in chromosomal stability. The bioinformatics analysis of TCGA data via cBioPortal was used to validate experimental results showing TTC28's involvement in genome integrity maintenance. The specific details of how cBioPortal was used are not extensively described in the abstract.,['TCGA'],['Web-based analysis'],['TTC28'],['Not specified'],"[""Unclear""]",medium,4.0,39630868,The essential role of TTC28 in maintaining chromosomal stability via HSPA8 chaperone-mediated autophagy.,2024,abstract,2025-12-19T04:06:17.245230,,,,
"['Gene expression analysis', 'Survival analysis']",['Pan-cancer'],"['Review/Commentary', 'Biomarker discovery', 'Drug response/resistance']",['Review'],['Not specified'],"This is a review paper discussing the roles of PHLDA1 protein in various biological processes including cancer. While cBioPortal may be cited as a reference or data source for information about PHLDA1 expression and clinical associations across cancers, the abstract and introduction do not provide specific details about how cBioPortal was used. The paper appears to synthesize existing literature on PHLDA1 rather than conduct original analysis using cBioPortal.",[],['Citation only'],['PHLDA1'],['Not specified'],Unclear,low,4.0,39630301,Expanding on roles of pleckstrin homology-like domain family A member 1 protein.,2025,abstract,2025-12-19T04:06:17.246709,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Lung cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy', 'Precision medicine']","['Original research', 'Clinical study']","['Multiple sources', 'Custom/Private data']","Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage. The study analyzes 790 low PD-L1-expressing non-squamous NSCLC patients from in-house (n=83) and public (n=707) cohorts, along with transcriptomic and multiplex immunofluorescence data. While the paper cites cBioPortal, the specific usage details are not described in the provided text sections.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39615893,Mutation-guided chemotherapy-free strategy in first-line immunotherapy for low PD-L1-expressing non-squamous NSCLC.,2024,abstract,2025-12-19T04:06:17.774385,,,,
['Other'],['Pan-cancer'],"['Review/Commentary', 'Drug response/resistance', 'Pathway analysis']",['Review'],['Not specified'],"This is a review paper that discusses Pin1 as a target for cancer therapy. Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in the study. The paper appears to be a comprehensive review of Pin1 mechanisms and inhibitors in cancer treatment, and cBioPortal is likely only cited as a reference or resource rather than actively used for data analysis or visualization.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39624096,The mechanisms of Pin1 as targets for cancer therapy.,2024,abstract,2025-12-19T04:06:17.928098,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'METABRIC', 'Multiple sources']","The study used cBioPortal to access and analyze gene expression data from TNBC patient cohorts, specifically examining lymphotoxin beta (LTB) and other NF-κB-associated factors. The authors performed bioinformatic analyses on both early and metastatic TNBC patient data to assess associations between identified markers and patient clinical outcomes including survival.","['TCGA', 'METABRIC']","['Web-based analysis', 'Data download/export']",['LTB'],"['Expression analysis', 'Survival analysis', 'Query interface']",Mixed,medium,4.0,39623404,NF-κB associated markers of prognosis in early and metastatic triple negative breast cancer.,2024,abstract,2025-12-19T04:06:17.972108,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Lung cancer', 'Colorectal cancer', 'Melanoma']","['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']",['Original research'],['Multiple sources'],"cBioPortal was used as one of multiple bioinformatics databases in this pan-cancer analysis of PTBP1. The authors used cBioPortal to analyze genetic alterations of PTBP1, specifically examining amplification and mutation patterns across cancer types. The platform was listed among other tools (TIMER, GEPIA2, ProteinAtlas, etc.) used for comprehensive multi-omics analysis.",[],['Web-based analysis'],['PTBP1'],['Not specified'],Unclear,medium,4.0,39612472,Pan-Cancer Analysis of PTBP1 to Identify it as a Prognostic and Immunological Biomarker.,2024,abstract,2025-12-19T04:06:18.579387,,,,
['Other'],['Not specified'],"['Methods/Tools development', 'Other']",['Original research'],['Not specified'],This paper does not appear to use cBioPortal for any analysis. The study is a mechanistic investigation of DNA repair mechanisms involving MLH1 and PMS2 proteins in repeat-mediated deletions using cell-based assays. cBioPortal is likely only cited in the references without actual usage in the study.,[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39615226,Functions of PMS2 and MLH1 important for regulation of divergent repeat-mediated deletions.,2025,abstract,2025-12-19T04:06:18.770611,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Pan-cancer'],"['Biomarker discovery', 'Pathway analysis', 'Immunotherapy']",['Original research'],['TCGA'],"The paper does not explicitly describe using cBioPortal in the methods or results. While the study analyzes TCGA data for pan-cancer analysis of EPHA2, including mutation analysis, expression analysis, survival analysis, and pathway enrichment, there is no clear mention of cBioPortal being used as the data source or analysis platform. The citation of cBioPortal may be for reference purposes only or the usage is not clearly described in the abstract and introduction provided.",[],['Citation only'],['EPHA2'],['Not specified'],Unclear,low,4.0,39612413,Molecular characteristics and prognostic role of EPHA2 in human tumors via pan-cancer analysis.,2024,abstract,2025-12-19T04:06:19.583860,,,,
"['Mutation analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'Custom/Private data']",The study used cBioPortal to access TCGA Head and Neck Squamous Cell Carcinoma (HNSCC) data for comparative analysis with their own case series from North-eastern Italy. The authors conducted comparative mutational analysis between their cohort and TCGA data accessed through cBioPortal to validate and contextualize their findings regarding somatic mutations in 15 HNSCC-enriched genes. The platform was used to obtain reference data for comparison with their custom sequencing results.,['TCGA-HNSC'],"['Data download/export', 'Web-based analysis']","['AJUBA', 'KMT2C', 'CDKN2A', 'NOTCH1', 'TP53', 'PIK3CA', 'FAT1', 'CASP8', 'HRAS', 'NFE2L2', 'FBXW7', 'EP300', 'HLA-A', 'HLA-B', 'TGFBR2']","['Query interface', 'Download data']","[""External (downloaded data)""]",medium,4.0,39616986,Molecular profiling of head and neck squamous cell carcinomas in North-eastern Italy identifies possible tumour cell vulnerabilities.,2025,abstract,2025-12-19T04:06:19.642822,,,,
['Other'],['Pan-cancer'],"['Review/Commentary', 'Precision medicine', 'Methods/Tools development']",['Review'],['Not specified'],"This is a review paper about molecular tumor boards (MTBs) and their digital evolution. cBioPortal is likely mentioned as one of the knowledge databases or tools used to support decision-making in MTBs, but no specific usage of cBioPortal for data analysis or visualization is described in the abstract. The paper focuses on surveying the literature about MTB processes, knowledge bases, and supporting tools rather than conducting original analysis using cBioPortal.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39609355,Unveiling the Digital Evolution of Molecular Tumor Boards.,2025,abstract,2025-12-19T04:06:23.200277,,,,
['Other'],['Pan-cancer'],['Review/Commentary'],['Review'],['Not specified'],"This is a review paper focusing on the structure and function of the lysine methyltransferase SETD2 in cancer. Based on the abstract and introduction provided, there is no explicit description of direct cBioPortal usage for original analysis. The paper appears to cite cBioPortal as a reference source for information about SETD2 mutations in cancer, but does not describe specific queries, analyses, or data downloads from the platform.",[],['Citation only'],[],['Not specified'],Unclear,medium,4.0,39591760,Structure and function of the lysine methyltransferase SETD2 in cancer: From histones to cytoskeleton.,2025,abstract,2025-12-19T04:06:23.348845,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Leukemia/Lymphoma'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],"The authors used cBioPortal to analyze the association between GBP (Guanylate Binding Protein) locus expression and survival outcomes in Acute Myeloid Leukemia patients. They queried TCGA-AML data through cBioPortal to examine the prognostic significance of GBP genes that were found to be upregulated in their mouse model experiments. This analysis supported their finding that the GBP locus, regulated by Ezh2-mediated H3K27me3, is associated with poorer survival in AML patients.",['TCGA-AML'],"['Web-based analysis', 'Web-based visualization']",['GBP'],"['Survival analysis', 'Expression analysis', 'Query interface']",cBioPortal platform,medium,4.0,39605688,Developmental Stage and Cellular Context Determine Oncogenic and Molecular Outcomes of <i>Ezh2</i> <sup>Y641F</sup> Mutation in Hematopoiesis.,2024,abstract,2025-12-19T04:06:23.467296,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis']",['Pan-cancer'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to analyze mutation data and immune infiltration patterns for CCNE1 across multiple cancer types. The database was specifically mentioned alongside TIMER for analyzing immune infiltration and mutation characteristics in the pan-cancer study of CCNE1. The study integrated cBioPortal data with other databases (TIMER, GEPIA, Kaplan-Meier plotter) to comprehensively characterize CCNE1's role in cancer.",[],"['Web-based analysis', 'Citation only']",['CCNE1'],['Not specified'],Unclear,medium,4.0,39591374,Pan-cancer analysis identifies the oncogenic role of <i>CCNE1</i> in human cancers.,2024,abstract,2025-12-19T04:06:23.723261,,,,
"['Gene expression analysis', 'Pathway analysis']",['Pan-cancer'],"['Immunotherapy', 'Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],"Based on the abstract and introduction provided, the paper appears to use cBioPortal to access TCGA data for analyzing the correlation between WNT7A expression and CD8+ T-cell infiltration in human tumors through bulk RNA sequencing analysis. The specific details of cBioPortal usage are not explicitly described in the provided text, suggesting it was likely used for data access or as a reference resource for publicly available cancer genomics data.",['TCGA'],['Citation only'],['WNT7A'],['Not specified'],Unclear,low,4.0,39602462,Blocking WNT7A Enhances MHC-I Antigen Presentation and Enhances the Effectiveness of Immune Checkpoint Blockade Therapy.,2025,abstract,2025-12-19T04:06:23.758984,,,,
['Gene expression analysis'],['Breast cancer'],"['Biomarker discovery', 'Other']",['Original research'],['Not specified'],"The paper mentions that datasets from basal-like breast cancer patients showed a strong positive correlation between IGF-1R protein expression and β1-integrin (ITGB1) expression. However, the abstract does not provide specific details about how cBioPortal was accessed or which specific features were used. The usage appears to be for querying expression data to examine correlation between IGF-1R and ITGB1 in breast cancer patients.",[],['Citation only'],"['IGF1R', 'ITGB1']",['Not specified'],Unclear,low,4.0,39608716,β<sub>1</sub>-integrin controls IGF-1R internalization and intracellular signaling.,2025,abstract,2025-12-19T04:06:23.794032,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration', 'Mutation analysis', 'Copy number analysis']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not provide explicit details about how cBioPortal was used in the study. Based on the abstract and introduction, the study integrates multi-omics data to analyze CALU expression in clear cell renal cell carcinoma, including expression analysis, survival analysis, and immune landscape characterization. cBioPortal may have been cited as a data source or reference, but specific usage details are not mentioned in the provided text.",[],['Citation only'],['CALU'],['Not specified'],Unclear,low,4.0,39583311,Dissecting the Implications of Calumenin in Malignancy and Heterogeneity of the Microenvironment of Clear Cell Renal Cell Carcinoma Using Multi-Omics Data.,2024,abstract,2025-12-19T04:06:24.351484,,,,
"['Gene expression analysis', 'Survival analysis']",['Breast cancer'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'METABRIC']","Based on the abstract and introduction provided, the paper does not explicitly mention cBioPortal usage. However, given that the study analyzes ER+ breast tumors and mentions that S100A11 predicts poor outcomes, it is likely that publicly available datasets like TCGA or METABRIC were accessed, potentially through cBioPortal. Without explicit mention in the provided text, the exact usage mode and features remain unclear.",[],['Citation only'],['S100A11'],['Not specified'],Unclear,low,4.0,39587886,Cancer-cell derived S100A11 promotes macrophage recruitment in ER+ breast cancer.,2024,abstract,2025-12-19T04:06:24.509630,,,,
['Mutation analysis'],['Other solid tumor'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],['Multiple sources'],"The study retrieved somatic mutation data for ALK5 (TGFBR1) in endometrial cancer from publicly available databases, which likely included cBioPortal. The mutation data was used to identify ALK5 kinase domain mutations in EC, including the A230V-ALK5 mutation that became the focus of functional studies. The specific usage details of cBioPortal are not explicitly described in the abstract.",[],['Data download/export'],['TGFBR1'],['Not specified'],External (downloaded data),medium,4.0,39576826,The endometrial cancer A230V-ALK5 (TGFBR1) mutant attenuates TGF-β signaling and exhibits reduced in vitro sensitivity to ALK5 inhibitors.,2024,abstract,2025-12-19T04:06:25.215517,,,,
"['Gene expression analysis', 'Pathway analysis']",['Glioma/Brain cancer'],"['Drug response/resistance', 'Pathway analysis']",['Original research'],"['Custom/Private data', 'Multiple sources']","The paper mentions using clinical datasets from DIPG patients to examine OXPHOS-related genes and hypoxia gene expression signatures. However, the abstract and introduction do not provide explicit details about how cBioPortal was specifically used, whether data was downloaded, or which features were utilized. The usage appears to be for accessing patient-derived genomic/transcriptomic data to validate findings from their experimental models.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39575457,Inhibition of mitochondrial bioenergetics and hypoxia to radiosensitize diffuse intrinsic pontine glioma.,2025,abstract,2025-12-19T04:06:25.605305,,,,
['Gene expression analysis'],['Other solid tumor'],"['Drug response/resistance', 'Pathway analysis']",['Original research'],['TCGA'],"The paper used cBioPortal to interrogate ENPP2 (autotaxin) expression in patient samples and cell line datasets for pancreatic ductal adenocarcinoma (PDAC). The analysis helped establish that the PDAC tumor microenvironment, rather than cancer cells, is responsible for the majority of ENPP2 expression. The specific details of how cBioPortal was accessed or which features were used are not explicitly described in the abstract and introduction provided.",[],['Citation only'],['ENPP2'],['Not specified'],Unclear,low,4.0,39570650,Pancreatic CAF-Derived Autotaxin Drives Autocrine CTGF Expression to Modulate Protumorigenic Signaling.,2025,abstract,2025-12-19T04:06:28.640390,,,,
['Other'],['Not specified'],['Other'],"['Original research', 'Clinical study']",['Not specified'],"This paper does not appear to use cBioPortal for any analysis. The study focuses on a germline missense variant in IKKα causing immunodeficiency in three children from two Turkish families. This is a primary immunodeficiency study, not a cancer genomics study, and there is no evidence in the abstract or introduction that cBioPortal was utilized for data analysis or visualization.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39550372,Defective kinase activity of IKKα leads to combined immunodeficiency and disruption of immune tolerance in humans.,2024,abstract,2025-12-19T04:06:29.623633,,,,
['Gene expression analysis'],['Other solid tumor'],"['Immunotherapy', 'Drug response/resistance', 'Biomarker discovery']",['Original research'],"['TCGA', 'Multiple sources']",The authors used cBioPortal to analyze pantumor transcriptomic data to assess the expression levels of IL-18 receptor subunits and IL18BP across different tumor types. They found that clear cell renal cell carcinoma (RCC) had among the highest expression of these genes compared to other tumor types in the database. This analysis provided the rationale for investigating DR-18 therapy specifically in RCC.,[],['Web-based analysis'],"['IL18R1', 'IL18RAP', 'IL18BP']","['Expression analysis', 'Query interface']",cBioPortal platform,medium,4.0,39561007,Decoy-resistant IL-18 reshapes the tumor microenvironment and enhances rejection by anti-CTLA-4 in renal cell carcinoma.,2024,abstract,2025-12-19T04:06:29.665521,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","The cBioPortal database was used to examine GNL2 mutation frequency, location, and 3D structure in the TCGA database. This appears to be a focused use of cBioPortal specifically for mutation analysis of the GNL2 gene across TCGA pan-cancer samples. The study integrated this mutation data with other multi-omics data obtained from different databases to perform a comprehensive pan-cancer analysis of GNL2.",['TCGA'],"['Web-based analysis', 'Web-based visualization']",['GNL2'],"['Mutation Mapper', 'Query interface']",cBioPortal platform,medium,4.0,39562405,"GLN2 as a key biomarker and therapeutic target: evidence from a comprehensive pan-cancer study using molecular, functional, and bioinformatic analyses.",2024,abstract,2025-12-19T04:06:29.722132,,,,
"['Gene expression analysis', 'Pathway analysis']",['Other solid tumor'],"['Methods/Tools development', 'Pathway analysis']",['Original research'],['TCGA'],The paper used cBioPortal to access TCGA hepatocellular carcinoma (HCC) data for enrichment analysis of RNA-Seq data. The analysis revealed that HIF-1A-driven glycolytic shift was among the significant pathways identified. The cBioPortal data was used to validate the metabolic signature that the authors aimed to recapitulate in their organoid model.,['TCGA'],"['Web-based analysis', 'Citation only']",['HIF1A'],['Enrichment analysis'],Unclear,medium,4.0,39567394,Development of hepatocellular carcinoma organoid model recapitulating HIF-1A metabolic signature.,2024,abstract,2025-12-19T04:06:30.009560,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Tumor evolution', 'Methods/Tools development']",['Original research'],['TCGA'],"The paper used TCGA data from 33 cancer types and over 10,000 individuals to analyze BAP1 alterations. While the abstract and introduction mention using TCGA data, there is no explicit mention of cBioPortal in the provided text. The study performed integrated multi-omics analyses including mutation detection, expression analysis, and developed a BAP1 activity score, but the specific role of cBioPortal (if any) is not described in the provided excerpts.",['TCGA'],['Citation only'],['BAP1'],['Not specified'],Unclear,low,4.0,39554490,Expanded detection and impact of <i>BAP1</i> alterations in cancer.,2024,abstract,2025-12-19T04:06:30.535980,,,,
"['Gene expression analysis', 'Survival analysis']",['Leukemia/Lymphoma'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],['TCGA'],The paper used cBioPortal to analyze gene expression data from TCGA datasets to examine the relationship between IGF1 and fibronectin expression in human leukemia samples. This analysis was performed to validate findings from their preclinical models showing that ECM remodeling and growth factor release influence B-ALL progression. The specific details of how cBioPortal was used are limited in the provided text.,[],['Web-based analysis'],['IGF1'],['Expression analysis'],cBioPortal platform,medium,4.0,39567540,Exploitation of the fibrinolytic system by B-cell acute lymphoblastic leukemia and its therapeutic targeting.,2024,pdf,2025-12-19T04:06:30.792125,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis', 'Immunotherapy']",['Original research'],['TCGA'],"Based on the abstract and introduction provided, cBioPortal is not explicitly mentioned in the text. The study focuses on analyzing differential gene expression in gastric cancer patients with or without peritoneal metastasis, identifying HECTD2 as a core gene. The paper likely uses TCGA data and performs survival analysis, pathway enrichment analysis, and immune microenvironment analysis, but the specific role of cBioPortal in data acquisition or analysis is not described in the provided sections.",[],['Citation only'],['HECTD2'],['Not specified'],Unclear,low,4.0,39548546,Expression of HECTD2 predicts peritoneal metastasis of gastric cancer and reconstructs immune microenvironment.,2024,abstract,2025-12-19T04:06:30.818277,,,,
"['Multi-omics integration', 'Gene expression analysis', 'Survival analysis']",['Breast cancer'],"['Methods/Tools development', 'Precision medicine']","['Methods/Software', 'Original research']",['TCGA'],"The paper does not explicitly mention using cBioPortal in the abstract or introduction provided. While the study uses TCGA data for breast cancer analysis, there is no clear indication that cBioPortal was used to access or analyze this data. The citation of cBioPortal may be for reference purposes only or the actual usage details may be in the methods section not provided.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39546381,Optimizing multi-omics data imputation with NMF and GAN synergy.,2024,abstract,2025-12-19T04:06:31.733853,,,,
"['Gene expression analysis', 'Mutation analysis', 'Copy number analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Colorectal cancer', 'Pan-cancer']","['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used as one of multiple databases in a comprehensive multi-database analysis to explore genetic alterations and gene regulatory networks of endocrine FGF genes (FGF19, FGF21, FGF23) in colorectal adenocarcinoma (COAD). The study integrated data from cBioPortal along with other databases including TIMER2.0, UALCAN, OncoDB, LinkedOmics, STRING, and others to examine gene expression, DNA methylation, prognostic significance, genetic alterations, and functional pathways. The specific features or data extracted from cBioPortal are not detailed in the abstract and introduction provided.",['COAD'],['Web-based analysis'],"['FGF19', 'FGF21', 'FGF23']",['Not specified'],"[""Mixed""]",medium,4.0,39567612,Comprehensive analysis identifies endocrine fibroblast growth factors as promising prognostic markers for colorectal carcinoma.,2024,pdf,2025-12-19T04:06:32.089252,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Pathway analysis']",['Pan-cancer'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to obtain the three-dimensional protein structure of TYMS and to analyze genetic alteration features including alteration frequency, mutation types, and mutated site information. The platform was also used to collect overall survival data for tumors with or without TYMS genetic alterations, followed by Kaplan-Meier analysis with log-rank P-values.",[],"['Web-based analysis', 'Web-based visualization']",['TYMS'],"['Mutation Mapper', 'Survival analysis']",cBioPortal platform,high,4.0,39544745,Unveiling the oncogenic significance of thymidylate synthase in human cancers.,2024,pdf,2025-12-19T04:06:34.336628,,,,
['Other'],['Pan-cancer'],['Review/Commentary'],['Review'],['Not specified'],"This is a review paper discussing non-coding variants in cancer. Based on the abstract and introduction provided, there is no explicit description of cBioPortal usage in this study. The paper appears to be a review of challenges and technologies for functionally annotating non-coding cancer variants. cBioPortal may be cited as a reference resource but no specific usage is described in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39544254,Towards functional maps of non-coding variants in cancer.,2024,abstract,2025-12-19T04:06:34.774674,,,,
"['Copy number analysis', 'Mutation analysis']",['Other solid tumor'],"['Precision medicine', 'Drug response/resistance', 'Biomarker discovery']","['Clinical study', 'Original research']",['Custom/Private data'],This is a case report of a single patient with biliary tract cancer (gallbladder cancer) who underwent comprehensive genomic profiling that revealed EGFR amplification. There is no explicit mention of cBioPortal usage in the abstract or introduction provided. The study focuses on clinical treatment response to necitumumab in an EGFR-amplified biliary tract cancer patient and subsequent resistance mechanisms detected by liquid biopsy.,[],['Citation only'],['EGFR'],['Not specified'],Unclear,low,4.0,39540676,A Case of Advanced Biliary Tract Cancer With EGFR Amplification That Responded to Necitumumab.,2024,abstract,2025-12-19T04:06:35.791578,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']",cBioPortal was used to analyze genetic alterations (mutations and copy number alterations) of ACER1 in HNSCC patients. The platform was likely used to query ACER1 mutation status and DNA methylation data from TCGA-HNSCC datasets. The study examined genetic mutation patterns and their relationship with ACER1 expression and clinical outcomes in head and neck squamous cell carcinoma.,['TCGA-HNSCC'],"['Web-based analysis', 'Web-based visualization']",['ACER1'],"['Query interface', 'Expression analysis']",Mixed,medium,4.0,39543336,Tumor suppressor ACER1 correlates with prognosis and Immune Infiltration in head and neck squamous cell carcinoma.,2024,abstract,2025-12-19T04:06:35.909808,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Custom/Private data']","The paper does not explicitly describe using cBioPortal in their methodology. The authors primarily used TCGA data accessed through the Assistant for Clinical Bioinformatics (ACBI) platform. While cBioPortal may be cited as a reference or potential data source, there is no clear description of specific cBioPortal features, tools, or analyses being utilized in this study.",['TCGA-STAD'],['Citation only'],"['INHBA', 'INHBB', 'INHBC', 'INHBE']",['Not specified'],Unclear,low,4.0,39543755,DNA hypomethylation of INHBA promotes tumor progression and predicts prognosis and immune status of gastric cancer.,2024,pdf,2025-12-19T04:06:36.624614,,,,
"['Mutation analysis', 'Survival analysis']",['Leukemia/Lymphoma'],"['Precision medicine', 'Biomarker discovery']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on reviewing a cohort of 188 cases of TP53-mutated myeloid disease to compare diagnoses between ICC and WHO5 classifications. Without access to the methods section or full text, it appears cBioPortal may only be cited as a reference rather than actively used for data analysis or visualization in this particular study.",[],['Citation only'],['TP53'],['Not specified'],Unclear,low,4.0,39536285,Diagnosis of TP53-mutated myeloid disease by the ICC and WHO fifth edition classifications.,2025,abstract,2025-12-19T04:06:36.712054,,,,
"['Survival analysis', 'Other']","['Melanoma', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy', 'Methods/Tools development']",['Original research'],['TCGA'],"The paper used TCGA data, specifically from the Uveal Melanoma cohort, to extract T cell receptor beta (TRB) sequences from blood exome files. The study analyzed intrinsic disorder scores of TRB variable regions and their association with overall survival. While TCGA data is available through cBioPortal, the paper does not explicitly mention using cBioPortal for data access or analysis, focusing instead on exome file analysis for immune receptor sequences.",['TCGA Uveal Melanoma'],['Citation only'],['MYCN'],['Not specified'],Unclear,low,4.0,39519243,Survival Distinctions for Cases Representing Immunologically Cold Tumors via Intrinsic Disorder Assessments for Blood-Sourced TRB Variable Regions.,2024,abstract,2025-12-19T04:06:37.444874,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Breast cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'METABRIC']",The study used cBioPortal to access gene expression data from TCGA and METABRIC breast cancer cohorts to validate their findings. The authors analyzed the transcriptomic signature associated with elongated mitochondria and correlated it with clinical outcomes in breast cancer patients using publicly available datasets accessed through cBioPortal.,"['TCGA', 'METABRIC']","['Data download/export', 'Web-based analysis']",[],"['Expression analysis', 'Survival analysis', 'Download data']","[""Mixed""]",medium,4.0,39504368,Mitochondrial elongation impairs breast cancer metastasis.,2024,abstract,2025-12-19T04:06:37.684160,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis']",['Leukemia/Lymphoma'],"['Biomarker discovery', 'Precision medicine', 'Drug response/resistance']",['Original research'],"['TCGA', 'Multiple sources']","The paper used cBioPortal to examine mutation frequencies (NPM1, SRSF2, FLT3-ITD, IDH1) in AML patient cohorts stratified by OXPHOS gene expression levels (SDHA, CPT1A). cBioPortal was used to query and analyze the relationship between specific genetic mutations and the expression levels of mitochondrial/OXPHOS genes in AML patients. The analysis focused on identifying mutation patterns associated with high versus low expression of candidate prognostic biomarkers.",['TCGA-LAML'],"['Web-based analysis', 'Data download/export']","['NDUFA6', 'SDHA', 'SLC25A12', 'ETFB', 'CPT1A', 'GPX4', 'CYB5A', 'NPM1', 'SRSF2', 'FLT3', 'IDH1', 'IDH2', 'CEBPA']","['Query interface', 'Group comparison']",Mixed,medium,4.0,39533394,OXPHOS mediators in acute myeloid leukemia patients: Prognostic biomarkers and therapeutic targets for personalized medicine.,2024,pdf,2025-12-19T04:06:38.899497,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Lung cancer'],"['Drug response/resistance', 'Pathway analysis', 'Precision medicine']",['Original research'],['Not specified'],"Based on the provided abstract and introduction, cBioPortal is not explicitly mentioned in the text. The paper focuses on experimental studies using genetically engineered mouse models (GEMMs), isogenic cell line models, and patient data analysis to investigate KRAS G12C and G12D mutations in NSCLC. While the paper may cite cBioPortal in the references or use it for data access, no specific usage details are provided in the sections shown.",[],['Citation only'],['KRAS'],['Not specified'],Unclear,low,4.0,39533328,The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRAS<sup>G12D</sup>-driven non-small cell lung cancer.,2024,pdf,2025-12-19T04:06:39.158901,,,,
['Other'],['Breast cancer'],"['Review/Commentary', 'Methods/Tools development', 'Precision medicine']",['Review'],['Not specified'],"This is a review paper discussing digital therapeutics and clinical decision support systems in breast cancer care. cBioPortal is likely mentioned as an example of a clinical decision support system or data resource in the context of precision medicine, but no actual data analysis or specific usage of cBioPortal is described. The paper focuses on reviewing digital health technologies rather than conducting original research using cBioPortal.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39502478,Digital innovations in breast cancer care: exploring the potential and challenges of digital therapeutics and clinical decision support systems.,2024,abstract,2025-12-19T04:06:40.117551,,,,
"['Mutation analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['Multiple sources'],"The authors collected mutational data from 9,555 breast cancer samples using cBioPortal. They identified 1,174 genes mutated in ≥40 samples and classified them into five tiers based on mutation frequency. The mutational data obtained from cBioPortal was then subjected to downstream pathway and protein-protein network analyses using external tools (EnrichR and STRING 11).",[],['Data download/export'],"['PIK3CA', 'TP53', 'GATA3', 'CDH1', 'MUC16', 'KMT2C', 'TTN', 'MAP3K1', 'SYNE1', 'AHNAK2', 'USH2A', 'RYR2']",['Download data'],External (downloaded data),high,4.0,39496981,"Breast cancer genomic analyses reveal genes, mutations, and signaling networks.",2024,abstract,2025-12-19T04:06:40.480893,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Prostate cancer'],"['Biomarker discovery', 'Pathway analysis', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']",The authors used cBioPortal to analyze IL6ST mRNA expression levels in prostate cancer patient cohorts and correlate them with recurrence-free survival outcomes. They examined large cohorts of prostate cancer patients through cBioPortal to validate their findings that high IL6ST expression correlates with better prognosis and immune-active tumor microenvironments. The analysis complemented their in vivo mouse model experiments and transcriptomic studies.,['TCGA'],"['Web-based analysis', 'Web-based visualization']","['IL6ST', 'STAT3', 'ARF', 'TP53', 'PTEN']","['Expression analysis', 'Survival analysis']",cBioPortal platform,medium,4.0,39482716,Cell-autonomous IL6ST activation suppresses prostate cancer development via STAT3/ARF/p53-driven senescence and confers an immune-active tumor microenvironment.,2024,abstract,2025-12-19T04:06:42.073138,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['Multiple sources'],"cBioPortal was used as one of multiple online platforms in this bioinformatic in silico analysis to evaluate ENO1 expression and its prognostic effects in breast cancer. The platform was used alongside other tools including KM plotter, ROC plotter, G-2-O, MethSurv, and TISIDB to perform comprehensive analysis of ENO1 in breast cancer progression and metastasis. Specific details about which features or datasets were accessed through cBioPortal are not explicitly described in the abstract.",[],['Web-based analysis'],['ENO1'],['Not specified'],Unclear,medium,4.0,39483155,ENO1 as a Biomarker of Breast Cancer Progression and Metastasis: A Bioinformatic Approach Using Available Databases.,2024,abstract,2025-12-19T04:06:42.311959,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Immunotherapy', 'Drug response/resistance', 'Biomarker discovery']",['Original research'],['TCGA'],cBioPortal was used to access TCGA pancreatic cancer data for analyzing gene expression patterns and survival correlations. The authors examined an OX40-associated gene signature in human PDAC samples to correlate with patient survival outcomes. This analysis supported the therapeutic relevance of their findings from mouse models.,['TCGA-PAAD'],"['Web-based analysis', 'Data download/export']",['TNFRSF4'],"['Expression analysis', 'Survival analysis']","[""Mixed""]",medium,4.0,39473974,Tumor-infiltrating mast cells confer resistance to immunotherapy in pancreatic cancer.,2024,abstract,2025-12-19T04:06:42.410519,,,,
"['Gene expression analysis', 'Multi-omics integration', 'Pathway analysis']","['Colorectal cancer', 'Other solid tumor']","['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The study retrieved genomic data from TCGA cohorts for colon, gastric, and rectal cancers from publicly available cancer genomic databases including cBioPortal.org. The data included gene expression, DNA methylation, and miRNA data comprising approximately 217 variables. The data was used for Principal Component Regression Analysis and Linear Regression Analysis to investigate the relationship between TWIST1 promoter methylation and TWIST1 expression in gastrointestinal cancers.","['TCGA-COAD', 'TCGA-STAD', 'TCGA-READ']",['Data download/export'],['TWIST1'],['Download data'],External (downloaded data),medium,4.0,39479535,Deregulation of <i>TWIST1</i> expression by promoter methylation in gastrointestinal cancers.,2024,abstract,2025-12-19T04:06:43.292486,,,,
"['Mutation analysis', 'Copy number analysis', 'Survival analysis']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper describes a single-institution retrospective cohort analysis using next-generation sequencing data and tissue microarray with immunohistochemistry. The study appears to have used institutional data rather than cBioPortal resources. If cBioPortal is cited, it may be for reference purposes only or mentioned elsewhere in the full text not provided.",[],['Citation only'],"['NF1', 'EGFR', 'MDM2', 'PIK3R1', 'IDH']",['Not specified'],Unclear,low,4.0,39472976,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,2024,abstract,2025-12-19T04:06:43.444434,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the abstract or introduction provided. The study utilized data from TCGA and GEO databases, processed using R4.2.1 for bioinformatic analyses. While cBioPortal is cited, there is no clear description of how it was specifically used in this study based on the provided text.",['TCGA'],['Citation only'],['TSPAN6'],['Not specified'],Unclear,low,4.0,39472973,Diagnostic and prognostic significance of tetraspanin 6 and its role in facilitating glioma progression.,2024,abstract,2025-12-19T04:06:43.791788,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly describe how cBioPortal was used in the study. While the authors analyzed TCGA-SARC data and performed comprehensive genomic analyses including gene expression, survival analysis, and pathway enrichment, there is no specific mention of cBioPortal in the abstract or introduction provided. The citation of cBioPortal may be for reference purposes or the platform may have been used for data access, but specific usage details are not provided in the available text.",['TCGA-SARC'],['Citation only'],"['CALR', 'CASP3', 'BCL10', 'PSMD7', 'PSMD10']",['Not specified'],Unclear,low,4.0,39469643,Integration of ubiquitination-related genes in predictive signatures for prognosis and immunotherapy response in sarcoma.,2024,abstract,2025-12-19T04:06:45.010611,,,,
['Other'],['Not specified'],['Other'],['Original research'],['Not specified'],"This paper does not actually use cBioPortal. It is a Drosophila developmental biology study investigating how Rabex-5 domains regulate Ras, Notch, and PI3K signaling in wing development. The paper mentions that Rabex-5 inhibits Ras signaling and that activated Ras can signal from the plasma membrane and Golgi, and discusses cancer relevance in the abstract, but there is no evidence of cBioPortal usage for data analysis or visualization.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39466792,"Rabex-5 E3 and Rab5 GEF domains differ in their regulation of Ras, Notch, and PI3K signaling in Drosophila wing development.",2024,pdf,2025-12-19T04:06:46.085729,,,,
"['Gene expression analysis', 'Copy number analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Colorectal cancer', 'Other solid tumor']","['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis']",['Original research'],['TCGA'],"The study analyzed clinico-genomic data from 441 gastric cancer and 629 colorectal cancer cases to investigate PRKACA expression and its correlates. The analysis included gene expression analysis, copy number analysis, survival analysis, and pathway enrichment analysis to examine therapeutic, clinicopathological, and molecular correlates of PRKACA. Multiple regression analyses were performed to identify methylation loci, transcription factors, miRNA species, and copy number changes that deregulate PRKACA expression in gastrointestinal cancers.",[],['Data download/export'],['PRKACA'],['Download data'],External (downloaded data),medium,4.0,39458904,"Therapeutic, Clinicopathological, and Molecular Correlates of <i>PRKACA</i> Expression in Gastrointestinal Cancers.",2024,abstract,2025-12-19T04:06:46.453790,,,,
"['Gene expression analysis', 'Survival analysis']",['Breast cancer'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],"['TCGA', 'Custom/Private data']","The paper mentions using TCGA data to examine the association between GLUD1/2 expression and tumor characteristics in Black women with ILC. cBioPortal was likely used to access and analyze TCGA breast cancer data, specifically for examining gene expression patterns and clinical correlations in invasive lobular carcinoma patients. The analysis appears to have been performed to validate findings from their primary cohort using publicly available TCGA data.",['TCGA'],['Data download/export'],"['GLUD1', 'GLUD2', 'SLC3A2', 'SLC7A11', 'GPX4']",['Expression analysis'],"[""External (downloaded data)""]",medium,4.0,39464069,Glutamate Transport Proteins and Metabolic Enzymes are Poor Prognostic Factors in Invasive Lobular Carcinoma.,2024,abstract,2025-12-19T04:06:46.714819,,,,
['Other'],['Other solid tumor'],['Review/Commentary'],['Review'],['Not specified'],"This is a review paper on squamous cell carcinomas (SCCs) across different anatomical sites. Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage. The paper appears to be a comprehensive review of SCC biology, including risk factors, genetics, cancer stem cells, and immune interactions, but does not describe specific cBioPortal analyses or data queries.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39455281,Molecular and cellular dynamics of squamous cell carcinomas across tissues.,2025,abstract,2025-12-19T04:06:47.519997,,,,
"['Mutation analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Methods/Tools development', 'Precision medicine']","['Original research', 'Clinical study', 'Methods/Software']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. This appears to be a prospective clinical study validating a new ARMS-HRMA technique for detecting KRAS mutations in PDAC patients using their own collected tumor and plasma samples. If cBioPortal is cited in the paper, it is likely only as a reference or for background information rather than as a tool used in the actual analysis.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39456638,Bringing Hope to Improve Treatment in Pancreatic Ductal Adenocarcinoma-A New Tool for Molecular Profiling of <i>KRAS</i> Mutations in Tumor and Plasma Samples.,2024,abstract,2025-12-19T04:06:48.347200,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']",cBioPortal was used to analyze USP10 expression and its correlation with patient prognosis in colorectal cancer. The authors likely queried TCGA colorectal cancer datasets to examine USP10 expression levels and perform survival analysis to establish the clinical relevance of USP10 abundance in CRC patients. This analysis supported their finding that USP10 correlates with poorer prognosis in CRC patients.,['TCGA'],"['Web-based analysis', 'Web-based visualization']",['USP10'],"['Expression analysis', 'Survival analysis']","[""cBioPortal platform""]",medium,4.0,39443725,USP10 drives cancer stemness and enables super-competitor signalling in colorectal cancer.,2024,abstract,2025-12-19T04:06:48.917930,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Pathway analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Precision medicine', 'Pathway analysis']",['Original research'],"['TCGA', 'Custom/Private data']","The study used cBioPortal to access and analyze data from The Cancer Genome Atlas (TCGA) colorectal cohort and the Sidra-LUMC AC-ICAM colon cancer cohort. The authors categorized colorectal cancers based on CDX2 mRNA expression levels and compared genomic characteristics including mutations, microsatellite instability, and chromosomal instability between CDX2-suppressed and non-suppressed groups. The analysis focused on identifying mutations in receptor tyrosine kinase genes and key colorectal cancer pathways.","['TCGA colorectal', 'Sidra-LUMC AC-ICAM']","['Data download/export', 'Web-based analysis']","['CDX2', 'EGFR', 'ERBB3', 'ERBB4', 'RET', 'ROS1', 'APC', 'TP53', 'KRAS', 'BRAF', 'BRCA2', 'ATM']","['Expression analysis', 'Group comparison', 'Download data', 'Query interface']",Mixed,high,4.0,39452477,CDX2-Suppressed Colorectal Cancers Possess Potentially Targetable Alterations in Receptor Tyrosine Kinases and Other Colorectal-Cancer-Associated Pathways.,2024,abstract,2025-12-19T04:06:48.932288,,,,
"['Gene expression analysis', 'Survival analysis']",['Prostate cancer'],['Biomarker discovery'],"['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in the study methodology. The study primarily used immunohistochemistry (IHC) on tissue microarrays to measure SMARCD protein levels in prostate cancer samples. cBioPortal may have been cited for background information about SWI/SNF alterations in cancer or for validation purposes, but specific usage details are not provided in the excerpts given.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39442954,Low SMARCD3 expression is associated with poor prognosis in patients with prostate cancer.,2025,abstract,2025-12-19T04:06:49.899189,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],"The paper mentions utilizing the TCGA database to analyze CLDN11 expression in breast cancer tissues and its correlation with patient prognosis. While cBioPortal is likely the platform used to access TCGA data for gene expression and survival analysis, the paper does not explicitly describe how cBioPortal was used or provide specific details about the platform's features. The study focuses on CLDN11 deficiency and its role in upregulating FOXM1 through the hedgehog signaling pathway in breast cancer progression.",[],['Citation only'],"['CLDN11', 'FOXM1']",['Not specified'],Unclear,low,4.0,39438406,CLDN11 deficiency upregulates FOXM1 to facilitate breast tumor progression through hedgehog signaling pathway.,2024,abstract,2025-12-19T04:06:50.301868,,,,
"['Mutation analysis', 'Multi-omics integration']",['Not specified'],['Methods/Tools development'],['Methods/Software'],['Not specified'],"This is a methods paper describing a protocol for integrated proteogenomics analysis of pathogenic missense SNPs. The paper appears to only cite cBioPortal as a reference or potential resource rather than demonstrating actual usage of the platform. No specific details about how cBioPortal was used, what data was accessed, or what features were employed are provided in the abstract or introduction.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39436598,Introduction to Integrated Proteogenomic Pipeline for Dealing with Pathogenic Missense SNPs.,2025,abstract,2025-12-19T04:06:50.374878,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],['Multiple sources'],"cBioPortal was used to compare clinical characteristics of breast cancer patients with or without altered BUB1 mRNA expression. The platform enabled analysis of the relationship between BUB1 expression alterations and various clinical parameters including histological grades, ER status, HER2 status, and molecular subtypes (basal-like phenotype).",[],['Web-based analysis'],['BUB1'],"['Expression analysis', 'Group comparison']",cBioPortal platform,medium,4.0,39430818,BUB1 as a novel marker for predicting the immunotherapy efficacy and prognosis of breast cancer.,2024,abstract,2025-12-19T04:06:51.949987,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Pathway analysis', 'Immunotherapy', 'Drug response/resistance', 'Database/Resource']","['Original research', 'Methods/Software']","['TCGA', 'Multiple sources']","The study analyzed integrin family genes across 32 cancer types using approximately 10,000 tumors from TCGA data. While the abstract and introduction do not explicitly detail cBioPortal usage, given the comprehensive pan-cancer analysis of TCGA data including mutations, copy number alterations, and expression data, cBioPortal was likely used for data access and/or initial exploration. The study developed a custom database (PIExplorer) suggesting external analysis of downloaded data.",['TCGA'],['Data download/export'],[],['Not specified'],External (downloaded data),low,4.0,39436262,Comprehensive Characterization of the Integrin Family Across 32 Cancer Types.,2024,abstract,2025-12-19T04:06:53.131479,,,,
"['Mutation analysis', 'Survival analysis', 'Multi-omics integration']","['Pan-cancer', 'Ovarian cancer', 'Pancreatic cancer']","['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy', 'Methods/Tools development']","['Original research', 'Methods/Software']","['TCGA', 'Multiple sources']","The paper appears to cite cBioPortal as a reference or potential data source for cancer genomics data. The study develops novel biomarkers (nbTMB and mlTNB) that integrate mutation burden with non-B DNA features, and evaluates these in multiple cancer contexts including immunotherapy response and drug sensitivity. While cBioPortal is likely used for accessing mutation data, the specific usage details are not clearly described in the provided abstract and introduction.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39427051,Non-B DNA-informed mutation burden as a marker of treatment response and outcome in cancer.,2024,abstract,2025-12-19T04:06:53.628817,,,,
"['Mutation analysis', 'Survival analysis', 'Pathway analysis']","['Pan-cancer', 'Breast cancer', 'Lung cancer', 'Prostate cancer', 'Glioma/Brain cancer', 'Other solid tumor']","['Biomarker discovery', 'Pathway analysis', 'Precision medicine']",['Original research'],['TCGA'],"The study used cBioPortal to analyze somatic mutations in 31 DDR/FA signaling genes across multiple cancer types from TCGA data. The authors examined mutation frequencies, identified putative driver mutations, and analyzed the impact of these alterations on patient survival and disease-free periods. The analysis revealed tissue- and cell-type specific mutation patterns, with ATM and BRCA2 being the most frequently mutated genes in pan-cancer samples, while specific cancer types showed distinct mutation profiles.",['TCGA'],"['Web-based analysis', 'Web-based visualization']","['ATM', 'ATR', 'BLM', 'HRR6', 'RAD18', 'FANCA', 'FANCB', 'FANCC', 'BRCA2', 'FANCD2', 'FANCE', 'FANCF', 'FANCG', 'FANCI', 'BRIP1', 'FANCL', 'FANCM', 'PALB2', 'RAD51C', 'SLX4', 'ERCC4', 'RAD51', 'BRCA1', 'UBE2T', 'XRCC2', 'MAD2L2', 'RFWD3', 'FAAP20', 'FAAP24', 'FAAP100', 'CENPX', 'FANCT']","['Query interface', 'Survival analysis', 'OncoPrint']",cBioPortal platform,medium,4.0,39421870,Somatic gene mutations involved in DNA damage response/Fanconi anemia signaling are tissue- and cell-type specific in human solid tumors.,2024,abstract,2025-12-19T04:06:54.497281,,,,
"['Mutation analysis', 'Copy number analysis']",['Lung cancer'],"['Biomarker discovery', 'Precision medicine', 'Drug response/resistance']","['Original research', 'Review']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on a retrospective analysis of NGS data from Malaysian NSCLC patients and a systematic literature review of HER2 alterations and targeted therapies. cBioPortal may be cited in the references or methods section not provided, but no specific usage is described in the available text.",[],['Citation only'],['HER2'],['Not specified'],"[""Unclear""]",low,4.0,39421181,Prevalence and treatment of human epidermal growth factor receptor 2-altered non-small cell lung cancer: a retrospective analysis and systematic literature review.,2024,pdf,2025-12-19T04:06:54.585407,,,,
"['Gene expression analysis', 'Survival analysis', 'Other']",['Prostate cancer'],['Biomarker discovery'],['Original research'],['Custom/Private data'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The research focuses on matrix-assisted laser desorption/ionization imaging of N-linked glycans in prostate cancer specimens. If cBioPortal was used, it was likely only cited as a reference or used minimally for validation purposes, but this is not evident from the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39417716,N-Linked Fucosylated Glycans Are Biomarkers for Prostate Cancer with a Neuroendocrine and Metastatic Phenotype.,2025,abstract,2025-12-19T04:06:55.619118,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Multi-omics integration']",['Lung cancer'],"['Drug response/resistance', 'Tumor evolution', 'Methods/Tools development', 'Biomarker discovery']",['Original research'],['Custom/Private data'],"Based on the abstract and title provided, there is no explicit mention of cBioPortal usage in the paper. The study focuses on developing a patient-derived organoid (PDO) metastasis model for lung adenocarcinoma using whole-genome and RNA sequencing. Without access to the full methods section, it is unclear if cBioPortal was used for data comparison, validation, or reference purposes.",[],['Citation only'],['KRAS'],['Not specified'],Unclear,low,4.0,39413736,Modeling lung adenocarcinoma metastases using patient-derived organoids.,2024,abstract,2025-12-19T04:06:55.625456,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the abstract or introduction provided. The study uses TCGA data to develop a neutrophil-related gene signature for invasive breast cancer prognosis, but no specific reference to cBioPortal platform, tools, or data download from cBioPortal is mentioned in the provided text. It is possible cBioPortal was only cited as a reference or the usage details are in the methods section not provided.",['TCGA'],['Citation only'],"['LEF1', 'NRG1', 'STX11']",['Not specified'],Unclear,low,4.0,39417978,Neutrophil-related Signature Characterizes Immune Landscape and Predicts Prognosis of Invasive Breast Cancer.,2025,abstract,2025-12-19T04:06:55.693981,,,,
"['Copy number analysis', 'Methods/Tools development']",['Other solid tumor'],"['Methods/Tools development', 'Biomarker discovery']","['Original research', 'Methods/Software']",['Custom/Private data'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on benchmarking three different CNV detection methods (NanoString, Illumina microarrays, and ddPCR) using 13 paired ovarian carcinoma samples. If cBioPortal is cited in the paper, it appears to be for reference purposes only rather than for direct data analysis or visualization.",[],['Citation only'],"['MAGI3', 'PDGFRA', 'NKX2-1', 'KDR', 'MET', 'HMGA2', 'C8orf4', 'PAX9', 'CDK6', 'CCND2']",['Not specified'],Unclear,low,4.0,39409874,Benchmarking of Approaches for Gene Copy-Number Variation Analysis and Its Utility for Genetic Aberration Detection in High-Grade Serous Ovarian Carcinomas.,2024,abstract,2025-12-19T04:06:56.158177,,,,
"['Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],['TCGA'],"The study used cBioPortal to access and download TCGA data for nearly 10,000 samples across 31 tumor types. The authors analyzed copy number variations, gene expression, and survival data for 15 m6A core factors to identify pan-cancer patterns. The analysis was performed externally after data download, focusing on genes including YTHDF1, YTHDF2, YTHDF3, VIRMA, and METTL3.",['TCGA'],['Data download/export'],"['YTHDF1', 'YTHDF2', 'YTHDF3', 'VIRMA', 'METTL3']",['Download data'],External (downloaded data),high,4.0,39411658,The three YTHDF paralogs and VIRMA are strong cross-histotype tumor driver candidates among m<sup>6</sup>A core genes.,2024,abstract,2025-12-19T04:06:56.574750,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration', 'Mutation analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis', 'Immunotherapy']",['Original research'],['TCGA'],"Based on the abstract and introduction, the paper does not explicitly mention using cBioPortal. The study utilized data from The Cancer Genome Atlas (TCGA) to analyze SHH pathway expression in endometrial cancer, but the specific data access method is not described in the provided text. It is unclear whether cBioPortal was used for data access or if the citation is only in references.",['TCGA'],['Citation only'],['SHH'],['Not specified'],"[""Unclear""]","[""low""]",4.0,39408773,"SHH Signaling as a Key Player in Endometrial Cancer: Unveiling the Correlation with Good Prognosis, Low Proliferation, and Anti-Tumor Immune Milieu.",2024,abstract,2025-12-19T04:06:57.719125,,,,
"['Gene expression analysis', 'Pathway analysis']",['Lung cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis']",['Original research'],['TCGA'],"The study utilized publicly available data from 507 lung adenocarcinoma clinical samples to perform Spearman's rank correlation coefficient analysis examining the relationship between ALDH1B1 expression and various molecules implicated in cancer stem cell-related signaling pathways. The data appears to have been accessed from cBioPortal for correlation analysis of gene expression patterns. The analysis focused on correlating ALDH1B1 with genes involved in Wnt, Notch, hypoxia, Hedgehog, retinoic acid, Hippo, NF-κΒ, TGF-β, PI3K/PTEN-AKT and glycolysis/gluconeogenesis pathways.",['TCGA-LUAD'],['Data download/export'],"['ALDH1B1', 'SNAI2', 'ZEB2', 'TWIST1', 'CDH1']","['Download data', 'Expression analysis']",External (downloaded data),medium,4.0,39408636,Exploring the Role and Pathophysiological Significance of Aldehyde Dehydrogenase 1B1 (ALDH1B1) in Human Lung Adenocarcinoma.,2024,abstract,2025-12-19T04:07:00.414229,,,,
"['Gene expression analysis', 'Pathway analysis']",['Not specified'],"['Methods/Tools development', 'Database/Resource']",['Methods/Software'],['Not specified'],"This paper does not appear to use cBioPortal directly. The study describes CTPAD, a web application for transcriptomic profiling in allergic diseases (not cancer), which retrieves data from the Gene Expression Omnibus (GEO) database. cBioPortal may only be cited as a reference or comparison tool for similar web-based platforms, but there is no evidence of actual cBioPortal usage in the methodology or analysis.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39402558,CTPAD: an interactive web application for comprehensive transcriptomic profiling in allergic diseases.,2024,abstract,2025-12-19T04:07:00.669034,,,,
['Mutation analysis'],['Colorectal cancer'],"['Biomarker discovery', 'Precision medicine', 'Drug response/resistance']","['Original research', 'Clinical study']",['Custom/Private data'],"This study does not appear to use cBioPortal. The analysis was performed using the Foundation Medicine database, which contains genomic profiling data from tumor DNA collected during routine clinical care from 2013 to 2021. The study focused on identifying the prevalence of multi-hit PIK3CA mutations in metastatic colorectal cancer patients using Foundation Medicine's proprietary database and testing platform.",[],['Citation only'],"['PIK3CA', 'KRAS', 'BRAF']",['Not specified'],Unclear,low,4.0,39401325,Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations.,2024,abstract,2025-12-19T04:07:00.843198,,,,
"['Gene expression analysis', 'Pathway analysis', 'Multi-omics integration']",['Glioma/Brain cancer'],"['Immunotherapy', 'Biomarker discovery', 'Pathway analysis']",['Original research'],['Custom/Private data'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on immunocompetent de novo mouse models of pediatric high-grade gliomas using single-cell RNA sequencing, flow cytometry, and immunohistochemistry. If cBioPortal was used, it may have been for validation or comparison purposes with human datasets, but this is not stated in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39395421,Microglia and monocyte-derived macrophages drive progression of pediatric high-grade gliomas and are transcriptionally shaped by histone mutations.,2024,abstract,2025-12-19T04:07:01.036152,,,,
"['Gene expression analysis', 'Survival analysis']",['Prostate cancer'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],"['TCGA', 'Custom/Private data']","Based on the abstract and introduction provided, the paper does not explicitly describe how cBioPortal was used. The study focuses on experimental investigation of soluble guanylyl cyclase (sGC) signaling in castration-resistant prostate cancer using cell lines, patient samples, and animal models. If cBioPortal was used, it was likely for accessing TCGA prostate cancer data for gene expression or survival analysis, but specific usage details are not mentioned in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39388307,Stimulating Soluble Guanylyl Cyclase with the Clinical Agonist Riociguat Restrains the Development and Progression of Castration-Resistant Prostate Cancer.,2025,abstract,2025-12-19T04:07:01.132705,,,,
"['Mutation analysis', 'Pathway analysis']",['Breast cancer'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],['Not specified'],"The study used cBioPortal to analyze mutation data for predicted target genes in breast cancer patients. Out of 135 predicted targets from their network pharmacology analysis, they found that 134 were mutated in breast cancer patients using an online database (likely cBioPortal). The mutation analysis helped validate their computational predictions of key genes (ESR1, CYP19A1, and EGFR) as relevant targets in breast cancer progression.",[],['Web-based analysis'],"['ESR1', 'CYP19A1', 'EGFR']",['Query interface'],cBioPortal platform,medium,4.0,39394443,Deciphering the multi-scale mechanism of herbal phytoconstituents in targeting breast cancer: a computational pharmacological perspective.,2024,abstract,2025-12-19T04:07:01.297584,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']",['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal being used in this study. The paper describes a comprehensive mutational profiling study of cutaneous leiomyosarcoma using whole-exome sequencing and RNA sequencing on 38 cases. The study appears to have generated and analyzed their own custom data without reference to cBioPortal usage. If cBioPortal is cited, it appears to be citation only without active use of the platform.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39392932,Comprehensive mutational profiling identifies new driver events in cutaneous leiomyosarcoma.,2025,abstract,2025-12-19T04:07:01.914681,,,,
"['Mutation analysis', 'Survival analysis', 'Gene expression analysis', 'Multi-omics integration']",['Lung cancer'],"['Drug response/resistance', 'Immunotherapy', 'Biomarker discovery']","['Original research', 'Clinical study']","['TCGA', 'GENIE', 'Custom/Private data', 'Multiple sources']",cBioPortal was used to access and analyze genomic data from multiple NSCLC cohorts including TCGA and GENIE datasets. The platform was utilized to identify and characterize STK11 and KEAP1 mutations across patient cohorts and to correlate these genomic alterations with clinical outcomes. The study leveraged cBioPortal's data repository to validate findings from the POSEIDON clinical trial and other independent cohorts.,"['TCGA', 'GENIE']","['Data download/export', 'Web-based analysis']","['STK11', 'KEAP1', 'KRAS']","['Query interface', 'Download data']",Mixed,medium,4.0,39385035,CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.,2024,abstract,2025-12-19T04:07:02.426377,,,,
"['Copy number analysis', 'Multi-omics integration']","['Pan-cancer', 'Breast cancer', 'Lung cancer', 'Prostate cancer', 'Other solid tumor']","['Biomarker discovery', 'Precision medicine', 'Methods/Tools development']","['Original research', 'Methods/Software']","['TCGA', 'Multiple sources']","The paper used cBioPortal to access genomic data for calculating HRD scores based on loss of heterozygosity (LOH), telomeric allelic imbalance (TAI), and large-scale state transitions (LST) from whole genome sequencing data. The data was downloaded from cBioPortal and used to train and validate deep learning models that predict HRD status from histology images across nine different tumor types. The study analyzed n=5209 patients across two independent cohorts using data obtained from cBioPortal.",['TCGA'],['Data download/export'],[],['Download data'],External (downloaded data),medium,4.0,39379982,Prediction of homologous recombination deficiency from routine histology with attention-based multiple instance learning in nine different tumor types.,2024,abstract,2025-12-19T04:07:02.552296,,,,
"['Gene expression analysis', 'Pathway analysis']",['Prostate cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis']",['Original research'],"['Custom/Private data', 'Multiple sources']","Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage. The study focuses on comparative transcriptomic analysis between canine and human prostate cancers to identify mediators of castration resistance. If cBioPortal was used, it may have been for accessing human prostate cancer gene expression data or for validation purposes, but this is not stated in the provided text.",[],['Citation only'],"['ISG15', 'AZGP1', 'GPX3', 'S100P', 'IFITM1']",['Not specified'],Unclear,low,4.0,39375962,Comparative Transcriptomes of Canine and Human Prostate Cancers Identify Mediators of Castration Resistance.,2024,abstract,2025-12-19T04:07:03.105872,,,,
['Other'],['Glioma/Brain cancer'],"['Review/Commentary', 'Pathway analysis', 'Precision medicine']",['Review'],['Not specified'],"This is a review paper focused on glioblastoma heterogeneity and the role of scaffold proteins, particularly IQGAP1. Based on the abstract and introduction provided, there is no explicit description of how cBioPortal was used in this study. The paper appears to cite cBioPortal as a reference or resource but does not describe specific analyses, data downloads, or visualizations performed using the platform.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39375741,Role of scaffold proteins in the heterogeneity of glioblastoma.,2024,abstract,2025-12-19T04:07:06.029358,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Pathway analysis']",['Lung cancer'],['Biomarker discovery'],['Original research'],"['TCGA', 'Multiple sources']",cBioPortal was used to identify and select YKT6-related genes for further analysis. The platform was utilized to explore gene correlations and relationships with YKT6 in lung adenocarcinoma. These YKT6-related genes were then used to construct protein-protein interaction networks and perform functional enrichment analyses.,['TCGA'],"['Web-based analysis', 'Query interface']",['YKT6'],"['Query interface', 'Expression analysis']",Mixed,medium,4.0,39375639,Comprehensive analysis identifies YKT6 as a potential prognostic and diagnostic biomarker in lung adenocarcinoma.,2024,abstract,2025-12-19T04:07:06.074544,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Multi-omics integration']","['Pan-cancer', 'Glioma/Brain cancer']","['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to analyze genetic alterations of BCAT2 across multiple cancer types in a pan-cancer context. The study utilized cBioPortal to identify that BCAT2 alterations are primarily amplifications across various tumors. This analysis was part of a multi-database approach that integrated genetic alteration data with expression, protein, and clinical survival data.",[],"['Web-based analysis', 'Web-based visualization']",['BCAT2'],['Query interface'],Unclear,medium,4.0,39375392,Multi-omics analysis identifies BCAT2 as a potential pan-cancer biomarker for tumor progression and immune microenvironment modulation.,2024,abstract,2025-12-19T04:07:06.569705,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis']","['Pan-cancer', 'Lung cancer', 'Prostate cancer', 'Other solid tumor']","['Drug response/resistance', 'Precision medicine', 'Biomarker discovery']","['Original research', 'Clinical study']",['Custom/Private data'],"The paper does not explicitly describe how cBioPortal was used in the study. This is a prospective clinical trial (MATCH-R) that collected fresh tumor biopsies and performed molecular profiling using targeted NGS, WES, and RNA sequencing on custom patient samples. While cBioPortal is cited in the references, there is no clear description of using cBioPortal for data analysis, visualization, or data download in the abstract or introduction provided.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39363320,Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development.,2024,abstract,2025-12-19T04:07:07.491737,,,,
['Other'],['Pan-cancer'],"['Review/Commentary', 'Drug response/resistance', 'Pathway analysis', 'Precision medicine']",['Review'],['Not specified'],"This is a review paper discussing Ras-mutant cancers and downstream kinase pathway targeting. Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage for data analysis or visualization. The paper appears to cite cBioPortal as a reference resource but does not describe specific usage of the platform for original data analysis.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39372214,Mediating kinase activity in Ras-mutant cancer: potential for an individualised approach?,2024,abstract,2025-12-19T04:07:07.667100,,,,
"['Gene expression analysis', 'Survival analysis']","['Pan-cancer', 'Breast cancer', 'Lung cancer', 'Melanoma']","['Immunotherapy', 'Drug response/resistance', 'Biomarker discovery']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, the paper appears to use cBioPortal to analyze UHRF1 expression patterns and potentially survival outcomes across cancer types. The study likely queried TCGA data through cBioPortal to examine UHRF1 expression in various cancers and its correlation with immune-related features and patient outcomes. However, specific details about cBioPortal usage are not explicitly mentioned in the provided text.",['TCGA'],"['Web-based analysis', 'Web-based visualization']",['UHRF1'],"['Expression analysis', 'Survival analysis']",Unclear,low,4.0,39362877,Aberrant cytoplasmic expression of UHRF1 restrains the MHC-I-mediated anti-tumor immune response.,2024,abstract,2025-12-19T04:07:07.859065,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage. The study performed DNA sequencing, RNA sequencing, and multiplex immunofluorescence on pancreatic cancer samples (UC, UC-OGC, and PDAC), but the abstract does not describe how cBioPortal was utilized. The paper may cite cBioPortal in the full text for comparison purposes or reference data, but specific usage details are not evident from the provided sections.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39363498,Characterization of undifferentiated carcinomas of the pancreas with and without osteoclast-like giant cells.,2025,abstract,2025-12-19T04:07:08.068979,,,,
['Other'],['Not specified'],['Review/Commentary'],['Review'],['Not specified'],"This is a comprehensive review paper about AMPK (AMP-activated protein kinase) as a metabolic sensor, focusing on the biochemical and regulatory differences between 12 different AMPK isoform complexes. The paper discusses AMPK's role in energy metabolism and mentions cancer contexts where different α-subunit isoforms act as tumor promoters or suppressors, but does not appear to directly use cBioPortal for any analysis. cBioPortal may only be cited as a reference or resource in the context of cancer-related AMPK research.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39362600,The metabolic sensor AMPK: Twelve enzymes in one.,2024,abstract,2025-12-19T04:07:08.733962,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","The study utilized data from TCGA database to analyze ARPC1B expression differences across 33 tumor types and normal tissues. The authors performed pan-cancer analysis examining ARPC1B expression correlation with prognosis, clinical stages, tumor immune microenvironment, and drug resistance. While TCGA is mentioned as the primary data source, the specific role of cBioPortal in data access or analysis is not explicitly detailed in the abstract.",['TCGA'],['Data download/export'],['ARPC1B'],['Not specified'],External (downloaded data),low,4.0,39360160,Actin-related protein 2/3 complex subunit 1B promotes ovarian cancer progression by regulating the AKT/PI3K/mTOR signaling pathway.,2024,abstract,2025-12-19T04:07:08.975641,,,,
"['Mutation analysis', 'Gene expression analysis', 'Multi-omics integration']",['Prostate cancer'],"['Drug response/resistance', 'Biomarker discovery', 'Precision medicine']",['Original research'],['Multiple sources'],The paper integrated clinical data from CDK12 mutant prostate cancer patients using cBioPortal to identify synthetic lethal partners. The authors analyzed mutation data and clinical information from prostate cancer patients with CDK12 inactivating mutations to support their findings that these patients would benefit from spliceosome-targeting therapy. cBioPortal was used to access and analyze clinical genomic data from prostate cancer cohorts.,[],"['Web-based analysis', 'Citation only']",['CDK12'],['Not specified'],Unclear,medium,4.0,39361894,Compromised CDK12 activity causes dependency on the high activity of O-GlcNAc transferase.,2024,abstract,2025-12-19T04:07:09.637336,,,,
"['Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Prostate cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']",The study used cBioPortal to analyze SRSF6 alterations (copy number and mRNA expression) across multiple prostate cancer cohorts. The authors examined SRSF6 levels in relation to clinical parameters and disease progression. cBioPortal served as one of several data sources for comprehensive characterization of SRSF6 in prostate cancer.,['TCGA'],"['Web-based analysis', 'Web-based visualization']","['SRSF6', 'HIRA']","['Expression analysis', 'Query interface']",cBioPortal platform,medium,4.0,39356765,SRSF6 modulates histone-chaperone HIRA splicing to orchestrate AR and E2F activity in prostate cancer.,2024,abstract,2025-12-19T04:07:11.545805,,,,
['Gene expression analysis'],['Colorectal cancer'],"['Biomarker discovery', 'Tumor evolution']",['Original research'],['TCGA'],"Based on the abstract and introduction provided, cBioPortal appears to have been used to query EMI1 gene expression data in colorectal cancer contexts, likely from TCGA datasets. The study focuses on experimental validation of EMI1's role in chromosome instability using cell-based models, with cBioPortal potentially providing supporting genomic data for the gene of interest. However, specific details about cBioPortal usage are not explicitly mentioned in the provided text.",[],['Citation only'],['EMI1'],['Not specified'],Unclear,low,4.0,39358461,Loss of EMI1 compromises chromosome stability and is associated with cellular transformation in colonic epithelial cell contexts.,2024,abstract,2025-12-19T04:07:11.752091,,,,
['Gene expression analysis'],['Other solid tumor'],"['Biomarker discovery', 'Other']",['Original research'],['TCGA'],The paper used cBioPortal to access TCGA data for oral squamous cell carcinoma (OSCC) to analyze LAD1 gene expression levels. The analysis appears to have been performed to validate or contextualize their experimental findings regarding LAD1 expression in OSCC. Specific details about how cBioPortal was used are limited in the provided abstract and introduction.,['TCGA'],['Citation only'],"['LAD1', 'PAK1', 'CAV1']",['Not specified'],"[""Unclear""]",low,4.0,39354061,Ladinin-1 in actin arcs of oral squamous cell carcinoma is involved in cell migration and epithelial phenotype.,2024,abstract,2025-12-19T04:07:12.107558,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy']",['Original research'],"['TCGA', 'METABRIC', 'Custom/Private data']",The study used cBioPortal to access and analyze gene expression data from TCGA and METABRIC breast cancer cohorts. The authors queried caspase-1 (CASP1) expression levels and likely examined correlations with clinical outcomes and other molecular features in triple-negative breast cancer patients. The data was used to validate findings from their experimental models regarding the role of caspase-1 in tumor immune microenvironment organization.,"['TCGA', 'METABRIC']","['Data download/export', 'Web-based analysis']","['CASP1', 'ETS1', 'ESR1']","['Expression analysis', 'Query interface']","[""Mixed""]",medium,4.0,39353903,Caspase-1-dependent spatiality in triple-negative breast cancer and response to immunotherapy.,2024,abstract,2025-12-19T04:07:13.625425,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Multi-omics integration']",['Prostate cancer'],"['Drug response/resistance', 'Biomarker discovery', 'Tumor evolution']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and title provided, there is no explicit mention of cBioPortal usage in this study. The paper describes analysis of whole-genome and transcriptome sequencing data from paired metastatic biopsies, but does not reference cBioPortal as a tool or data source. The study appears to have generated and analyzed custom/private data from patient biopsies. Without access to the full methods section, it's unclear if cBioPortal was used at all.",[],['Citation only'],"['AR', 'SSTR1']",['Not specified'],Unclear,low,4.0,39352383,Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancer.,2024,abstract,2025-12-19T04:07:14.036742,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Prostate cancer'],"['Biomarker discovery', 'Pathway analysis', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","The study used cBioPortal to analyze SCD gene expression, genetic alterations (including the L134V mutation), and promoter methylation patterns in prostate adenocarcinoma. The authors integrated data from cBioPortal with other cancer genomics databases to examine SCD expression across multiple cancer types and to investigate correlations with immune cell infiltration and tumor microenvironment characteristics. cBioPortal was likely used for querying TCGA-PRAD and other cancer datasets to obtain comprehensive genomic and expression data for SCD.",['TCGA-PRAD'],"['Web-based analysis', 'Web-based visualization', 'Data download/export']",['SCD'],"['Expression analysis', 'Query interface', 'Download data']",Mixed,medium,4.0,39351232,"Comprehensive analysis of stearoyl-coenzyme A desaturase in prostate adenocarcinoma: insights into gene expression, immune microenvironment and tumor progression.",2024,abstract,2025-12-19T04:07:14.449267,,,,
['Mutation analysis'],"['Not applicable - this is a kidney disease study, not cancer']",['Other'],"['Original research', 'Clinical study']",['Custom/Private data'],"This paper does not appear to use cBioPortal at all. The study focuses on TRPC6-associated podocytopathy, a monogenic kidney disease, not cancer. The research involves genetic analysis of TRPC6 variants in patients with kidney disease using exome and targeted sequencing from clinical samples. There is no mention of cBioPortal in the abstract or introduction provided, and the disease context (kidney podocytopathy/FSGS) is unrelated to cancer genomics, which is cBioPortal's primary focus.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39352759,Natural History and Clinicopathological Associations of TRPC6-Associated Podocytopathy.,2025,abstract,2025-12-19T04:07:14.498981,,,,
['Gene expression analysis'],['Prostate cancer'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],['Not specified'],"The authors downloaded a metastatic prostate cancer dataset from cBioPortal (referred to as ""C-Bioportal"" in the paper) to analyze the expression levels of GLS isoforms (GLS1 and GLS2). They compared expression between metastatic and localized prostate cancer tissues to validate their in vitro findings showing that GLS1 is highly expressed in both primary and metastatic prostate cancer.",[],['Data download/export'],"['GLS1', 'GLS2']","['Download data', 'Expression analysis']",External (downloaded data),medium,4.0,39350531,The Anti-proliferative Effect of a Novel Glutaminase Inhibitor IN-3 on Prostate Cancer Cells.,2024,pdf,2025-12-19T04:07:14.769644,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis']","['Pan-cancer', 'Bladder cancer', 'Cervical cancer', 'Uterine cancer']","['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy', 'Review/Commentary']",['Review'],['TCGA'],"This review paper describes EP300 aberrations (mutations, copy number alterations, and transcriptional changes) that have been identified in TCGA Pan-Cancer Atlas studies. The authors discuss how EP300 mutations and expression levels correlate with pathological features including tumor grading, metastases, and patient survival. The paper uses TCGA data to characterize EP300 dysregulation across multiple cancer types and its implications for anticancer therapy strategies.",['TCGA Pan-Cancer Atlas'],['Citation only'],['EP300'],['Not specified'],Unclear,medium,4.0,39351073,Genetic dysregulation of EP300 in cancers in light of cancer epigenome control - targeting of p300-proficient and -deficient cancers.,2024,abstract,2025-12-19T04:07:15.040528,,,,
['Mutation analysis'],['Pan-cancer'],['Methods/Tools development'],"['Methods/Software', 'Original research']",['Multiple sources'],"Based on the abstract and introduction provided, the specific role of cBioPortal in this study is not explicitly described. The paper focuses on developing DriverDetect, a machine learning algorithm that combines seven pre-existing mutation prediction tools to identify cancer driver mutations. While cBioPortal is cited, the abstract does not provide details about how it was used (e.g., for data acquisition, validation, or comparison).",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39349509,Machine learning optimized DriverDetect software for high precision prediction of deleterious mutations in human cancers.,2024,abstract,2025-12-19T04:07:15.785285,,,,
"['Mutation analysis', 'Survival analysis', 'Gene expression analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']",['Multiple sources'],"Based on the abstract and introduction provided, the paper identifies 11 HPV-positive HNSCC patients with CYLD alterations and investigates their clinical outcomes. While cBioPortal is cited, the specific details of how it was used are not explicitly described in the provided text. It appears cBioPortal may have been used to identify CYLD alterations in HPV-positive HNSCC patients or to access genomic data for this patient cohort.",[],['Citation only'],['CYLD'],['Not specified'],Unclear,low,4.0,39347568,CYLD Alterations Are Associated With Metastasis and Poor Prognosis in Human Papilloma Virus-Positive Head and Neck Cancer.,2025,abstract,2025-12-19T04:07:17.257569,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Lung cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],"The paper does not explicitly mention using cBioPortal in the abstract or introduction provided. The study obtained mRNA and clinical data from TCGA and performed various analyses including gene expression, survival analysis, and pathway enrichment. While cBioPortal is cited, there is no clear description of how it was specifically used in this study based on the provided text.",['LUAD-TCGA'],['Citation only'],['DNAJB6'],['Not specified'],"[""Unclear""]",low,4.0,39335495,Abnormally High Expression of DNAJB6 Accelerates Malignant Progression of Lung Adenocarcinoma.,2024,abstract,2025-12-19T04:07:17.625331,,,,
['Gene expression analysis'],['Breast cancer'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],['Custom/Private data'],"The paper mentions analyzing a public database (Proteogenomic Landscape of Breast Cancer, CPTAC) to examine HEBP2 mRNA expression levels in TNBC versus non-TNBC tissues. However, the abstract does not explicitly state that cBioPortal was used to access this CPTAC data. The primary research involved experimental work with MDA-MB-231 cells, and the database analysis appears to be a validation step using publicly available proteogenomic data.",['CPTAC'],['Citation only'],['HEBP2'],['Not specified'],Unclear,low,4.0,39345749,<i>HEBP2</i> affects sensitivity to cisplatin and BCNU but not to paclitaxel in MDA-MB-231 breast cancer cells.,2024,abstract,2025-12-19T04:07:18.890824,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The paper leveraged TCGA data to examine SLC transporter expression in head and neck squamous cell carcinoma (HNSC). The study analyzed mRNA expression patterns of SLC transporters and correlated their upregulation with overall survival (OS) and disease-specific survival (DSS). While TCGA is mentioned as a primary data source, the specific role of cBioPortal in data access or analysis is not explicitly detailed in the abstract.",['TCGA'],['Citation only'],"['SLC16A3', 'SLC53A1', 'SLC25A32', 'SLC2A3']",['Not specified'],Unclear,low,4.0,39335197,The Solute Carrier (SLC) Transporter Superfamily as Therapeutic Targets for the Treatment of Head and Neck Squamous Cell Carcinoma.,2024,abstract,2025-12-19T04:07:19.494905,,,,
"['Mutation analysis', 'Copy number analysis']",['Melanoma'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The study performed targeted sequencing of 447 cancer-associated genes on their own cohort of 14 undifferentiated melanoma cases and 127 conventional melanoma cases. The paper may cite cBioPortal in the references or methods section not provided here, but no specific usage is described in the available text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39332711,A Comparative Genomic Study of Conventional and Undifferentiated Melanoma.,2024,abstract,2025-12-19T04:07:19.960157,,,,
"['Gene expression analysis', 'Survival analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Custom/Private data']","The study used cBioPortal to access TCGA colorectal cancer data for gene expression analysis and survival analysis of cancer-associated fibroblast (CAF) markers. The authors analyzed expression patterns and performed co-expression analyses of CAF-associated proteins (αSMA, FAP, PDPN, MMP2, TAGLN, THY1) and evaluated their correlation with immune-related signatures and patient outcomes in CRC.",['TCGA'],"['Web-based analysis', 'Data download/export']","['ACTA2', 'FAP', 'PDPN', 'MMP2', 'TAGLN', 'THY1']","['Expression analysis', 'Survival analysis', 'Query interface']",Mixed,medium,4.0,39335130,Cancer-Associated Fibroblast Proteins as Potential Targets against Colorectal Cancers.,2024,abstract,2025-12-19T04:07:19.961429,,,,
"['Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Multi-omics integration']","['Pan-cancer', 'Glioma/Brain cancer', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']",cBioPortal was used to analyze copy number alterations and methylation changes of ACTL6A across multiple cancer types. The platform was utilized alongside GSCALite to examine genomic alterations of ACTL6A in pan-cancer analysis. The study found that ACTL6A gene amplifications were associated with its upregulation in cancers.,[],['Web-based analysis'],['ACTL6A'],['Not specified'],Unclear,medium,4.0,39333441,Actin like 6A is a prognostic biomarker and associated with immune cell infiltration in cancers.,2024,abstract,2025-12-19T04:07:19.987538,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Breast cancer'],"['Drug response/resistance', 'Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Custom/Private data']","Based on the abstract and introduction provided, cBioPortal appears to have been used to access and analyze TCGA breast cancer data, likely for validation of gene expression patterns and survival analysis in TNBC patients. The study performed gene expression profiling of 58 TNBC tumor samples and likely used cBioPortal to validate findings in larger public datasets. However, specific details about cBioPortal usage are not explicitly mentioned in the provided text.",['TCGA'],['Citation only'],"['TGFB2', 'SRC', 'SNAI2', 'SNAI1']",['Not specified'],Unclear,low,4.0,39327614,A SRC-slug-TGFβ2 signaling axis drives poor outcomes in triple-negative breast cancers.,2024,abstract,2025-12-19T04:07:21.243656,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to analyze the alteration profiles of ATAD2 across multiple cancer types in this pan-cancer study. The authors examined mutation and copy number alteration patterns of ATAD2, with amplification identified as the most frequent alteration type. The database was used alongside TCGA, GTEx, CPTAC, and HPA databases to comprehensively characterize ATAD2's expression and genomic alterations in cancer.",[],"['Web-based analysis', 'Web-based visualization']",['ATAD2'],['Not specified'],Unclear,medium,4.0,39333272,Pan-cancer analysis of the immunological and oncogenic roles of ATAD2 with verification in papillary thyroid carcinoma.,2024,abstract,2025-12-19T04:07:21.430918,,,,
"['Mutation analysis', 'Copy number analysis']",['Prostate cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],"['Custom/Private data', 'Multiple sources']","The study queried previously published prostate cancer datasets in cBioPortal (cohort 2) to identify cases with IDH1 and IDH2 mutations. They stratified samples based on oncogenic hotspot IDH mutations and nonhotspot mutations, identifying 9 cases with IDH1 hotspot mutations and 9 cases with nonhotspot IDH1/2 mutations from 2749 patients. The cBioPortal data was used to complement their institutional clinical sequencing database (cohort 1) for comprehensive molecular characterization of IDH-mutant prostatic adenocarcinoma.",[],"['Web-based analysis', 'Query interface']","['IDH1', 'IDH2', 'TMPRSS2', 'ERG', 'SPOP', 'BRCA1', 'BRCA2', 'ATM', 'RB1', 'AR']",['Query interface'],Mixed,medium,4.0,39326497,Histopathologic and Molecular Characterization of IDH-Mutant Prostatic Adenocarcinoma.,2025,abstract,2025-12-19T04:07:22.090335,,,,
['Other'],['Breast cancer'],"['Drug response/resistance', 'Precision medicine', 'Immunotherapy', 'Review/Commentary']",['Review'],['Not specified'],"This is a review paper on personalized treatment approaches for HER2-positive metastatic breast cancer. Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in the study. The paper appears to cite cBioPortal as a reference but does not describe any specific data analysis, visualization, or data download from the platform.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39320608,Personalized treatment approach for HER2-positive metastatic breast cancer.,2024,abstract,2025-12-19T04:07:22.973077,,,,
"['Gene expression analysis', 'Copy number analysis', 'Survival analysis', 'Pathway analysis', 'Mutation analysis']",['Lung cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis', 'Immunotherapy']","['Original research', 'Meta-analysis']","['TCGA', 'Multiple sources']","The paper used cBioPortal to analyze HIF1A expression, copy number variation, and promoter methylation in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) samples. The study examined correlations between HIF1A expression and clinical characteristics, as well as survival outcomes in LUAD patients. cBioPortal was likely used to access TCGA data and perform expression and genomic analyses, though specific details of the platform usage are not explicitly described in the abstract.",['TCGA'],"['Web-based analysis', 'Data download/export']",['HIF1A'],"['Expression analysis', 'Survival analysis', 'Query interface']",Unclear,medium,4.0,39318795,Exploring the prognostic and therapeutic value of HIF1A in lung adenocarcinoma.,2024,abstract,2025-12-19T04:07:24.082723,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Prostate cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],['Multiple sources'],"Based on the abstract and introduction provided, cBioPortal is cited in this paper but specific details about how it was used are not mentioned. The study focuses on identifying marker genes for neuroendocrine prostate cancer using computational approaches based on gene expression profiles and protein-protein interaction networks. Without access to the methods section, it is unclear whether cBioPortal was used for data download, web-based analysis, or merely cited as a reference.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39318189,CDHu40: a novel marker gene set of neuroendocrine prostate cancer.,2024,abstract,2025-12-19T04:07:24.635464,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']","['Pan-cancer', 'Lung cancer']","['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly describe how cBioPortal was used in the study. While the abstract mentions using various tools including R, GEPIA, STRING, and TISIDB for analyzing TCGA and GTEx data, cBioPortal is not specifically mentioned in the provided abstract and introduction. The usage of cBioPortal, if any, remains unclear from the provided text.",[],['Citation only'],['NLRP1'],['Not specified'],Unclear,low,4.0,39318060,Clinical signature and associated immune metabolism of NLRP1 in pan-cancer.,2024,abstract,2025-12-19T04:07:25.784434,,,,
['Mutation analysis'],['Other solid tumor'],"['Biomarker discovery', 'Other']","['Clinical study', 'Original research']",['Custom/Private data'],"This case report describes a patient with retroperitoneal pleomorphic liposarcoma harboring a rare MEN1 gene mutation. The paper appears to be a clinical case report focused on documenting this novel association between MEN1 mutation and soft tissue sarcoma. Based on the limited abstract provided, cBioPortal usage is unclear and may only be cited as a reference or used minimally for mutation validation or comparison.",[],['Citation only'],['MEN1'],['Not specified'],Unclear,low,4.0,39314235,Novel MEN1-associated retroperitoneal pleomorphic liposarcoma.,2024,abstract,2025-12-19T04:07:26.528161,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Mutation analysis', 'Copy number analysis']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],"['TCGA', 'Multiple sources']","The cBioPortal database was used to investigate the possible functions and mechanisms of KIFC1 in liver hepatocellular carcinoma (LIHC). The study utilized cBioPortal alongside other databases and tools (TISCH, GSEA, R software) to analyze TCGA LIHC dataset. The specific features or data extracted from cBioPortal are not explicitly detailed in the abstract.",['TCGA-LIHC'],['Web-based analysis'],['KIFC1'],['Not specified'],"[""Unclear""]",medium,4.0,39315235,Kinesin Family Member C1: Function in liver hepatocellular carcinoma and potential target for chemotherapeutic.,2024,abstract,2025-12-19T04:07:26.543165,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']",The paper integrated high-throughput sequencing data from multiple sources including TCGA to analyze MCM3 mRNA expression levels in pancreatic adenocarcinoma (PAAD). cBioPortal was likely used as one of the data sources for accessing TCGA PAAD data and potentially for gene expression analysis. The study combined this data with in-house immunohistochemistry and CRISPR screening data to comprehensively characterize MCM3's role in PAAD.,['TCGA-PAAD'],"['Data download/export', 'Citation only']",['MCM3'],"['Expression analysis', 'Download data']",External (downloaded data),medium,4.0,39310930,"Expression, potential biological behaviour and clinical significance of MCM3 in pancreatic adenocarcinoma: a comprehensive study integrating high throughput sequencing, CRISPR screening and in-house immunohistochemistry.",2024,abstract,2025-12-19T04:07:27.375202,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Breast cancer'],"['Biomarker discovery', 'Pathway analysis']","['Original research', 'Clinical study']","['TCGA', 'Custom/Private data']","The study used cBioPortal to analyze TCGA breast cancer datasets (TCGA_BC) for multi-omics integration. The authors examined correlations between HIF1A expression and various genomic alterations including copy-number alterations, mutations, and methylation patterns. They also performed survival analysis and investigated correlations with tumor microenvironment features including hypoxia, tumor mutational burden (TMB), microsatellite instability (MSI), and immune cell infiltration.",['TCGA_BC'],"['Web-based analysis', 'Web-based visualization']","['HIF1A', 'ESR1']","['Expression analysis', 'Survival analysis', 'Query interface']",Mixed,medium,4.0,39314258,"Exploring the Correlation Between Hypoxia, <i>HIF1A</i> Variants, and Breast Cancer in Different Ethnicities, and Bangladeshi Women: Through ELISA and Integrative Multi-Omics Analysis.",2024,abstract,2025-12-19T04:07:27.508176,,,,
['Mutation analysis'],"['Other solid tumor', 'Other hematologic']","['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper describes a case series using whole exome sequencing (WES) on tumor and blood/saliva samples from 4 Thai pediatric patients with relapsed or refractory childhood cancer. The study appears to have generated and analyzed their own custom sequencing data without reference to cBioPortal tools or databases.",[],['Citation only'],"['NCOR2', 'COL6A3', 'TP53', 'SMAD4']",['Not specified'],"[""Unclear""]",low,4.0,39309469,Whole exome sequencing in relapsed or refractory childhood cancer: case series.,2024,abstract,2025-12-19T04:07:27.674919,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Melanoma', 'Lung cancer', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy', 'Pathway analysis', 'Precision medicine']",['Original research'],['TCGA'],"cBioPortal was used to access and analyze genetic alteration data from The Cancer Genome Atlas (TCGA) PanCancer Atlas. The authors investigated IGFBP1 genetic alterations across 32 cancer types, including mutation sites, deep deletions, amplifications, and mutations. The data obtained from cBioPortal was then analyzed externally using R packages for statistical analyses, survival outcomes, and functional enrichment studies.",['TCGA PanCancer Atlas'],"['Data download/export', 'Query interface']",['IGFBP1'],"['Query interface', 'Download data']",External (downloaded data),high,4.0,39309809,"Deciphering the multidimensional impact of <i>IGFBP1</i> expression on cancer prognosis, genetic alterations, and cellular functionality: A comprehensive Pan-cancer analysis.",2024,abstract,2025-12-19T04:07:28.094089,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']",cBioPortal was used to analyze the expression of hub genes (identified from FGF8 protein network) in ovarian cancer compared to normal controls. The platform was utilized to examine gene expression patterns and correlate hub gene expression with patient survival outcomes in ovarian cancer datasets. The study integrated cBioPortal data with their proteomics findings to validate the clinical significance of FGF8-associated hub genes.,[],"['Web-based analysis', 'Web-based visualization']",['FGF8'],"['Expression analysis', 'Survival analysis']",cBioPortal platform,medium,4.0,39309198,Proteomics and Bioinformatics Investigations Link Overexpression of FGF8 and Associated Hub Genes to the Progression of Ovarian Cancer and Poor Prognosis.,2024,abstract,2025-12-19T04:07:29.764087,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Pan-cancer'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, cBioPortal is likely cited as a data source or reference, but specific details about how it was used are not explicitly described in these sections. The study focuses on pan-cancer analysis of MTF1 using bioinformatics approaches, but the exact role of cBioPortal in data acquisition or analysis is not clearly stated in the provided text.",[],['Citation only'],['MTF1'],['Not specified'],Unclear,low,4.0,39308676,Prognostic and Immunological Role of Cuproptosis-Related Gene MTF1 in Pan-Cancer.,2024,abstract,2025-12-19T04:07:30.021976,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Copy number analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used as one of multiple publicly available databases to investigate gene alterations and genomic features of LY6H across different cancer types. The platform was utilized alongside TCGA, GTEx, UALCAN, CTD, cancerSEA, and UCSC databases to conduct comprehensive pan-cancer analysis. The specific features or analysis methods used within cBioPortal are not explicitly detailed in the abstract.",[],['Web-based analysis'],['LY6H'],['Not specified'],Unclear,medium,4.0,39308669,"Pan-cancer analysis suggests that LY6H is a potential biomarker of diagnosis, immunoinfiltration, and prognosis.",2024,abstract,2025-12-19T04:07:30.851360,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Prostate cancer'],['Biomarker discovery'],['Original research'],['Multiple sources'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage. The study primarily uses data from the Gene Expression Omnibus (GEO) database and performs WGCNA analysis to identify diagnostic and prognostic biomarkers in prostate cancer. cBioPortal may only be cited in the references or used minimally without clear description in the provided text.",[],['Citation only'],"['SLC14A1', 'COL4A6', 'MYOF', 'FLRT3', 'KRT15', 'LAMB3']",['Not specified'],Unclear,low,4.0,39304557,Identification and validation of diagnostic and prognostic biomarkers in prostate cancer based on WGCNA.,2024,abstract,2025-12-19T04:07:31.565424,,,,
"['Mutation analysis', 'Survival analysis', 'Pathway analysis']","['Lung cancer', 'Other solid tumor']","['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy', 'Methods/Tools development']",['Original research'],"['TCGA', 'Multiple sources']",The paper used cBioPortal to access mutation data from TCGA bladder cancer and non-small cell lung cancer cohorts. The mutation data was downloaded and analyzed externally to calculate assembly-level mutation burdens (AMB) for protein assemblies and predict immunotherapy response. The analysis focused on identifying protein assemblies whose mutation burden correlates with treatment outcomes.,['TCGA'],['Data download/export'],"['PIK3CG', 'FOXP1']",['Download data'],External (downloaded data),medium,4.0,39303028,Prediction of immunotherapy response using mutations to cancer protein assemblies.,2024,abstract,2025-12-19T04:07:32.247507,,,,
"['Gene expression analysis', 'Survival analysis']",['Prostate cancer'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],['Not specified'],The authors used cBioPortal to analyze cancer genomic data showing that HOXA9 overexpression correlates with poor prognosis and characteristics of advanced prostate cancer. The specific details of how cBioPortal was accessed or which features were used are not explicitly described in the abstract and introduction. The analysis appears to have been used to validate findings from their CRISPR screen by examining HOXA9 expression patterns in clinical prostate cancer datasets.,[],['Citation only'],['HOXA9'],['Not specified'],Unclear,low,4.0,39300912,A Genome Wide CRISPR Screen Reveals That HOXA9 Promotes Enzalutamide Resistance in Prostate Cancer.,2024,abstract,2025-12-19T04:07:32.350725,,,,
"['Mutation analysis', 'Survival analysis']",['Breast cancer'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']","['Custom/Private data', 'Multiple sources']",cBioPortal was used to validate the association between EZH2 mutations and visceral metastasis in breast cancer patients. The authors queried cBioPortal data to confirm that patients with EZH2 mutations had a significantly greater risk of developing visceral metastasis (HR 3.1) and developed VM earlier than non-mutated patients (31.5 months vs. 109.7 months). Multivariate analysis using cBioPortal data showed EZH2 mutation was an independent factor for VM after breast cancer surgery.,[],['Web-based analysis'],"['EZH2', 'BRCA1', 'BRCA2']","['Survival analysis', 'Query interface']",cBioPortal platform,medium,4.0,39300407,EZH2 mutation is associated with the development of visceral metastasis by enhancing proliferation and invasion and inhibiting apoptosis in breast cancer cells.,2024,abstract,2025-12-19T04:07:33.414969,,,,
"['Copy number analysis', 'Mutation analysis', 'Survival analysis']","['Pan-cancer', 'Breast cancer', 'Lung cancer', 'Endometrial cancer']","['Tumor evolution', 'Biomarker discovery', 'Other']",['Original research'],"['TCGA', 'GENIE', 'Multiple sources']","The study used cBioPortal to access and download genomic data from multiple cancer cohorts, including TCGA and GENIE datasets. The researchers analyzed chromosome copy number data to identify whole-genome duplications (WGDs) in tumors from Black and white patients across multiple cancer types. The data was downloaded from cBioPortal and analyzed externally to examine racial disparities in WGD frequency and their association with patient survival.","['TCGA', 'GENIE']",['Data download/export'],[],['Download data'],External (downloaded data),medium,4.0,39300140,An elevated rate of whole-genome duplications in cancers from Black patients.,2024,abstract,2025-12-19T04:07:33.875708,,,,
['Other'],['Pan-cancer'],"['Precision medicine', 'Review/Commentary', 'Methods/Tools development']",['Review'],['Not specified'],"This is a review/commentary paper that presents a catalog of software families and human skills required for tumor board bioinformaticians in precision oncology. cBioPortal is likely mentioned as one of the important bioinformatics tools/resources relevant to molecular tumor boards, but no specific analysis or data usage from cBioPortal is described. The paper focuses on defining the computational tools and expertise needed for interpreting genomics data in clinical settings rather than conducting original research using cBioPortal.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39297878,Clinical bioinformatics desiderata for molecular tumor boards.,2024,abstract,2025-12-19T04:07:33.932009,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Prostate cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis', 'Precision medicine']","['Original research', 'Clinical study']","['Multiple sources', 'Custom/Private data']","The paper does not explicitly describe using cBioPortal for data analysis or visualization. While the study analyzes prostate cancer genomic data including gene expression (FOLH1/PSMA) and clinical outcomes across multiple cohorts, there is no mention of cBioPortal in the abstract or introduction provided. The citation may be for reference purposes only or usage details may be in methods sections not provided.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39294048,Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naïve Prostate Cancer.,2024,abstract,2025-12-19T04:07:34.224677,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used as one of several public databases to conduct comprehensive bioinformatics analysis of Annexins family members in clear renal cell carcinoma (KIRC). The platform was utilized alongside other databases (ONCOMINE, GEPIA, Kaplan-Meier plotter, GeneMANIA) to detect relationships between Annexins family members and KIRC. The specific features or data extracted from cBioPortal are not explicitly detailed in the abstract.",[],['Web-based analysis'],"['ANXA1', 'ANXA2', 'ANXA3', 'ANXA4', 'ANXA5', 'ANXA6', 'ANXA7', 'ANXA8', 'ANXA9', 'ANXA10', 'ANXA11', 'ANXA13']",['Not specified'],Unclear,medium,4.0,39290334,Evaluation of Annexins Family as Potential Biomarker for Predicting Progression and Prognosis in Clear Renal Cell Carcinoma.,2022,abstract,2025-12-19T04:07:35.951361,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The study used cBioPortal to analyze genomic data from The Cancer Genome Atlas (TCGA) for head and neck squamous cell carcinoma. The authors identified three ferroptosis-associated tumor antigens (CAV1, FTH1, and SLC3A2) that were overexpressed and mutated in HNSC patients. cBioPortal was likely used to query mutation and expression data for these specific genes, though the exact features and usage mode are not explicitly detailed in the abstract.",['TCGA'],['Citation only'],"['CAV1', 'FTH1', 'SLC3A2']",['Not specified'],"[""Unclear""]",medium,4.0,39286654,Identification of ferroptosis-associated tumor antigens as the potential targets to prevent head and neck squamous cell carcinoma.,2024,abstract,2025-12-19T04:07:36.664284,,,,
"['Survival analysis', 'Other']",['Other solid tumor'],"['Biomarker discovery', 'Other']","['Original research', 'Clinical study']","['TCGA', 'Custom/Private data']","The study included 14 HPV-associated oral cavity squamous cell carcinoma cases from The Cancer Genome Atlas (TCGA) program, which were accessed through cBioPortal. The TCGA cohort was used to expand the sample size and analyze clinicopathologic features and outcomes of HPV-positive OCSCC. The study examined survival outcomes including disease-specific survival and progression-free survival in the combined cohort.",['TCGA'],['Data download/export'],[],['Download data'],"[""External (downloaded data)""]",medium,4.0,39289237,Histologic spectrum and outcome of Human papillomavirus (HPV)-associated oral cavity squamous cell carcinoma: a single center experience and a survey of The Cancer Genome Atlas (TGCA) cohort.,2024,abstract,2025-12-19T04:07:36.771240,,,,
"['Gene expression analysis', 'Mutation analysis']","['Breast cancer', 'Glioma/Brain cancer', 'Leukemia/Lymphoma']","['Biomarker discovery', 'Other']",['Original research'],['Multiple sources'],"The paper does not explicitly mention cBioPortal usage. The authors used multiple gene expression platforms including UALCAN, GEPIA2, GENT2, TIMER2, LinkedOmics, and STRING to analyze β-hCG expression and its clinical implications in various cancers. While cBioPortal may have been cited as a reference, there is no clear description of direct usage of the platform for data analysis or visualization in this study.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39286065,Direct DNA binding by BRCA1 on β-hCG promoter and its clinical implications.,2024,abstract,2025-12-19T04:07:37.298061,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Pan-cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to explore gene alterations (mutations and copy number variations) of copper transporter genes (SLC31A1, ATP7A, ATP7B) across 33 cancer types from TCGA data. The platform was specifically mentioned for analyzing CNV patterns including gene amplification and deletion events in these copper transporters across different tumor types.",[],['Web-based analysis'],"['SLC31A1', 'ATP7A', 'ATP7B']",['Query interface'],External (downloaded data),medium,4.0,39281483,Pan-cancer analysis reveals copper transporters as promising potential targets.,2024,abstract,2025-12-19T04:07:38.233742,,,,
"['Mutation analysis', 'Copy number analysis', 'Other']","['Melanoma', 'Lung cancer', 'Other solid tumor']","['Methods/Tools development', 'Tumor evolution']","['Methods/Software', 'Original research']","['Multiple sources', 'Custom/Private data']","The paper appears to cite cBioPortal as a reference or potential data source, but the abstract and introduction do not provide explicit details about how cBioPortal was used in the study. The focus is on developing and applying Metient, a new computational method for inferring metastatic spread patterns. The study analyzes 169 patients and 490 tumors across melanoma, high-risk neuroblastoma, and non-small cell lung cancer, but the specific role of cBioPortal in data acquisition or analysis is not clearly described in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39282311,Inferring cancer type-specific patterns of metastatic spread using Metient.,2025,abstract,2025-12-19T04:07:38.664412,,,,
['Other'],['Not specified'],"['Methods/Tools development', 'Database/Resource']",['Methods/Software'],['Not specified'],"This paper focuses on developing a framework for sharing sensitive biomedical data through synthetic data generation and digital twins. While cancer datasets are mentioned as an exemplary use case, there is no explicit description of how cBioPortal was used in the study. The paper appears to cite cBioPortal as a reference resource rather than actively using it for data analysis or download.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39281045,Unlocking biomedical data sharing: A structured approach with digital twins and artificial intelligence (AI) for open health sciences.,2024,abstract,2025-12-19T04:07:38.665628,,,,
"['Mutation analysis', 'Gene expression analysis', 'Multi-omics integration']",['Colorectal cancer'],"['Drug response/resistance', 'Precision medicine']",['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on epigenomic profiling of patient-derived xenografts treated with various agents, including DNA methylation, histone modifications, chromatin accessibility, and gene expression analyses. If cBioPortal was used, it may have been for preliminary data exploration or validation, but this is not stated in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39269307,Epigenome Reprogramming Through H3K27 and H3K4 Trimethylation as a Resistance Mechanism to DNA Methylation Inhibition in BRAFV600E-Mutated Colorectal Cancer.,2024,abstract,2025-12-19T04:07:39.857474,,,,
,,,,,,,,,,,,,41343001,,,,,No text available,True,True,No text available
['Gene expression analysis'],['Pan-cancer'],['Other'],['Original research'],['TCGA'],"The paper appears to use cBioPortal to access TCGA gene expression data for Vangl2 across different cancer types. However, the primary focus of this study is on sepsis and inflammatory responses rather than cancer biology. The cBioPortal usage appears to be minimal and likely limited to accessing publicly available cancer genomics data for comparative or validation purposes.",[],['Citation only'],['VANGL2'],['Not specified'],Unclear,low,4.0,39269442,Vangl2 suppresses NF-κB signaling and ameliorates sepsis by targeting p65 for NDP52-mediated autophagic degradation.,2024,abstract,2025-12-19T04:07:40.852658,,,,
"['Gene expression analysis', 'Pathway analysis', 'Survival analysis']",['Other solid tumor'],"['Drug response/resistance', 'Pathway analysis', 'Biomarker discovery']",['Original research'],"['TCGA', 'Custom/Private data']","The paper does not explicitly describe using cBioPortal in their methodology. While they used TCGA STAD (stomach adenocarcinoma) data for their analysis, there is no mention of cBioPortal in the abstract or introduction provided. The citation of cBioPortal may be for reference purposes only or the actual usage details may be in the methods section not provided.",['TCGA-STAD'],['Citation only'],"['AKR1C2', 'MAOB', 'PDE2A']",['Not specified'],Unclear,low,4.0,39279957,Potential molecular metabolic mechanisms underlying the effects of cimifugin in gastric cancer through single-cell and bulk RNA sequencing combined with network pharmacology.,2024,abstract,2025-12-19T04:07:41.087551,,,,
['Other'],['Not specified'],['Methods/Tools development'],['Methods/Software'],['Not specified'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on developing PLiCat, a computational tool for predicting protein-lipid interaction categories using protein language models and deep learning. cBioPortal appears to be cited in the references but its specific role or usage in this study is not described in the available text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41378883,PLiCat: decoding protein-lipid interactions by large language model.,2025,abstract,2025-12-19T04:07:42.229503,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis', 'Precision medicine']",['Original research'],"['TCGA', 'METABRIC']","The paper used TCGA and METABRIC datasets to analyze TP53-mutant breast cancer, likely accessing these datasets through cBioPortal or similar platforms. The study identified TP53 mutations in approximately 35% of patients and performed comprehensive transcriptomic and survival analyses. While cBioPortal is cited, the specific details of how it was used (data download vs. web-based analysis) are not explicitly described in the abstract.","['TCGA', 'METABRIC']",['Citation only'],"['TP53', 'FGFR4', 'S100P', 'ADM', 'CTSC', 'A2ML1', 'CA9', 'VGLL1', 'PSAT1', 'AGR3', 'TFF1', 'ESR1', 'CPB1']",['Not specified'],Unclear,low,4.0,41386839,Identification of high-risk signatures and therapeutic targets through molecular characterization and immune profiling of TP53-mutant breast cancer.,2025,abstract,2025-12-19T04:07:42.612910,,,,
['Mutation analysis'],['Leukemia/Lymphoma'],"['Methods/Tools development', 'Other']",['Original research'],['Not specified'],"The paper mentions that the BCL7A R11G mutation is ""recurrently found in diffuse large B-cell lymphoma (DLBCL) cancer patients"" but does not explicitly describe how cBioPortal was used. The reference to this cancer-associated mutation suggests the authors may have consulted cancer genomics databases like cBioPortal to identify clinically relevant mutations, but no specific usage details are provided.",[],['Citation only'],['BCL7A'],['Not specified'],Unclear,low,4.0,41402274,ncBAF recognizes the nucleosome through BCL7A in chromatin remodeling.,2025,pdf,2025-12-19T04:07:42.758121,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'METABRIC', 'Multiple sources']",The paper used cBioPortal to access TCGA breast cancer data for validation of their AdhesionScore prognostic signature. The TCGA dataset was one of three independent cohorts used to test the association between the adhesion-related gene signature and overall survival in breast cancer patients. The specific details of how cBioPortal was accessed or which features were used are not explicitly described in the abstract.,['TCGA'],['Data download/export'],[],['Not specified'],External (downloaded data),medium,4.0,41374933,<i>AdhesionScore</i>: A Prognostic Predictor of Breast Cancer Patients Based on a Cell Adhesion-Associated Gene Signature.,2025,abstract,2025-12-19T04:07:43.557260,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Copy number analysis', 'Pathway analysis']","['Pan-cancer', 'Colorectal cancer', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy', 'Drug response/resistance', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The paper performed a pan-cancer analysis of ENTPD6 using multiple databases including cBioPortal. cBioPortal was likely used to access cancer genomics data for analyzing ENTPD6 expression, genetic alterations, and correlations with clinical outcomes across multiple cancer types. The specific details of cBioPortal usage are not explicitly described in the abstract and introduction provided.",[],['Data download/export'],['ENTPD6'],['Not specified'],External (downloaded data),medium,4.0,41355910,Systematic pan-cancer analysis reveals the prognostic and immunological roles of ectonucleoside triphosphate diphosphohydrolase 6.,2025,abstract,2025-12-19T04:07:44.419379,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration']","['Lung cancer', 'Other solid tumor']","['Biomarker discovery', 'Methods/Tools development', 'Immunotherapy']","['Original research', 'Methods/Software']","['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on developing a novel graph network-based clustering algorithm for radiomic data analysis using CT scans and RNA-Seq data from HNSCC and NSCLC patients. The methodology centers on network modeling, optimal transport, and survival analysis, but does not describe accessing or using cBioPortal for data acquisition or analysis. cBioPortal may only be cited in the references without direct usage.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41357300,Radiomic clustering using graph network techniques coupled with unbalanced optimal transport.,2025,abstract,2025-12-19T04:07:45.383494,,,,
"['Survival analysis', 'Multi-omics integration']",['Colorectal cancer'],"['Precision medicine', 'Methods/Tools development']","['Methods/Software', 'Original research']","['TCGA', 'Multiple sources']","cBioPortal was used as a data source for curated colorectal cancer datasets that were enriched with harmonized social determinants of health (SDOH) variables. The data from cBioPortal was used to evaluate the AI-HOPE-PM system's capabilities in performing case-control stratification, survival modeling, and odds ratio analysis. The system's performance was also benchmarked against cBioPortal in terms of task execution speed and usability.",[],['Data download/export'],[],['Download data'],External (downloaded data),medium,4.0,41342165,"Conversational Artificial Intelligence for Integrating Social Determinants, Genomics, and Clinical Data in Precision Medicine: Development and Implementation Study of the AI-HOPE-PM System.",2025,abstract,2025-12-19T04:07:45.512125,,,,
"['Gene expression analysis', 'Mutation analysis', 'Other']",['Prostate cancer'],"['Biomarker discovery', 'Methods/Tools development', 'Precision medicine']","['Original research', 'Methods/Software']",['Multiple sources'],"The paper mentions that ODC1 was consistently upregulated in primary and metastatic tumors across independent cohorts and was associated with adverse clinicopathologic features. While cBioPortal is not explicitly mentioned in the provided abstract and introduction, the analysis of ODC1 expression across multiple tumor cohorts and its association with clinical features suggests potential use of cBioPortal for validation of gene expression patterns in prostate cancer datasets. The study primarily focuses on developing IP-SNPs-seq methodology to link noncoding risk variants to transcription factor programs.",[],"['Web-based analysis', 'Web-based visualization']",['ODC1'],['Expression analysis'],Unclear,low,4.0,41359169,IP-SNPs-seq links noncoding risk alleles to lineage transcription factor programs in prostate cancer.,2025,pdf,2025-12-19T04:07:45.635546,,,,
['Gene expression analysis'],['Pan-cancer'],"['Methods/Tools development', 'Review/Commentary']",['Review'],['Not specified'],"This is a comprehensive review paper on transcriptomic deconvolution methods in cancer research. cBioPortal is likely cited as a reference resource or data portal in the context of cancer genomics databases, but no specific usage of cBioPortal for data analysis, visualization, or data download is described in the abstract or introduction. The paper focuses on reviewing 43 deconvolution methods rather than conducting original analysis using cBioPortal.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41331516,A guide to transcriptomic deconvolution in cancer.,2025,abstract,2025-12-19T04:07:46.937646,,,,
"['Multi-omics integration', 'Gene expression analysis', 'Mutation analysis', 'Copy number analysis']",['Lung cancer'],"['Database/Resource', 'Methods/Tools development', 'Precision medicine']",['Methods/Software'],['Multiple sources'],"cBioPortal is mentioned in the paper as one of several existing pan-cancer web tools that provide visualization of lung cancer omics data. The authors compare LOSTdb to cBioPortal, noting that cBioPortal provides visualization for multiple lung cancer datasets with metadata annotations but emphasizes genomic data and lacks rapid metadata-based retrieval. cBioPortal appears to be cited as a comparison point rather than being actively used for data analysis in this study.",[],['Citation only'],['EGFR'],['Not specified'],Unclear,medium,4.0,41339793,LOSTdb: a manually curated multi-omics database for lung cancer research.,2025,pdf,2025-12-19T04:07:47.223176,,,,
"['Mutation analysis', 'Gene expression analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Methods/Tools development']","['Original research', 'Methods/Software']","['TCGA', 'Custom/Private data']","Based on the abstract and introduction provided, cBioPortal is cited in this study but the specific usage details are not clearly described in the provided text. The study primarily focuses on developing a novel framework using scRNA-seq data with hdWGCNA and XGBoost for feature selection, which is then evaluated on TCGA pan-cancer RNA-seq data. The exact role of cBioPortal in data acquisition or analysis is not explicitly stated in the provided sections.",['TCGA'],['Citation only'],"['DPM1', 'BAD', 'FKBP4']",['Not specified'],Unclear,low,4.0,41330999,Pan-cancer gene set discovery via scRNA-seq for optimal deep learning based downstream tasks.,2025,pdf,2025-12-19T04:07:48.594325,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, cBioPortal is not explicitly mentioned in the text. The study uses TCGA and GTEx data for pan-cancer analysis of ECT2, but the specific role of cBioPortal (if any) is not described in the provided sections. The paper may cite cBioPortal as a data source or tool, but without the methods section or full text, the exact usage cannot be determined.",['TCGA'],['Citation only'],['ECT2'],['Not specified'],Unclear,low,4.0,41328302,Pan-Cancer Analysis of the Prognostic and Immunological Role of ECT2: A Promising Target for Survival and Immunotherapy.,2025,abstract,2025-12-19T04:07:49.087354,,,,
"['Gene expression analysis', 'Mutation analysis', 'Other']","['Breast cancer', 'Pan-cancer']","['Biomarker discovery', 'Other']",['Original research'],"['Multiple sources', 'Custom/Private data']","The paper mentions using biocomputational analyses to identify chimeric FAM72 fusion genes across various cancer tissues, which likely involved querying cBioPortal databases. However, the abstract and introduction do not provide explicit details about how cBioPortal was specifically used, what features were accessed, or what data was downloaded. The primary focus appears to be on whole-genome sequencing (WGS) and RNA-seq analysis with custom experimental validation in breast cancer cell systems.",[],['Citation only'],"['FAM72B', 'ADIPOR2']",['Not specified'],Unclear,low,4.0,41329440,The role of chimeric FAM72B transcripts generated by intergenic mRNA trans-splicing in breast cancer.,2025,abstract,2025-12-19T04:07:49.308150,,,,
"['Mutation analysis', 'Pathway analysis', 'Multi-omics integration']","['Breast cancer', 'Colorectal cancer']","['Drug response/resistance', 'Pathway analysis', 'Methods/Tools development', 'Precision medicine']","['Original research', 'Methods/Software']","['TCGA', 'Multiple sources']","The study used cBioPortal to obtain patient-derived mutation data for breast and colorectal cancers, specifically focusing on co-existing driver mutations in ESR1|PIK3CA and BRAF|PIK3CA. The mutation data was downloaded and used to construct tissue-specific subnetworks for their network-informed signaling-based approach to identify optimal drug combination targets. The data was analyzed externally as part of their novel pipeline for discovering anticancer target combinations.",['TCGA'],['Data download/export'],"['ESR1', 'PIK3CA', 'BRAF']","['Download data', 'Query interface']",External (downloaded data),medium,4.0,41306515,Anticancer Target Combinations: Network-Informed Signaling-Based Approach to Discovery.,2024,abstract,2025-12-19T04:07:50.465124,,,,
['Copy number analysis'],['Lung cancer'],"['Methods/Tools development', 'Biomarker discovery']","['Original research', 'Methods/Software']","['TCGA', 'Custom/Private data']",The study used TCGA data from cBioPortal as a reference for validating their cfDNA copy number alteration detection pipeline. The authors compared their cfDNA-derived CNA profiles from NSCLC patients against tissue-level CNA patterns from TCGA lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) datasets to demonstrate concordance and validate their methodology. This suggests they downloaded TCGA CNA data from cBioPortal for external comparison and validation purposes.,"['TCGA-LUAD', 'TCGA-LUSC']",['Data download/export'],[],['Download data'],External (downloaded data),medium,4.0,41303594,Copy Number Alteration Profiling from Plasma cfDNA WES in Advanced NSCLC.,2025,abstract,2025-12-19T04:07:51.202962,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis']",['Lung cancer'],"['Drug response/resistance', 'Biomarker discovery', 'Precision medicine']",['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on experimental characterization of a novel NOTCH2-NTRK1 fusion gene using in vitro and in vivo models, phosphoproteomic analyses, and protein interaction studies. cBioPortal may be cited in the references but its specific use is not described in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41289701,Novel NOTCH2-NTRK1 fusion confers osimertinib resistance in EGFR-mutant non-small cell lung cancer by interacting with EGFR.,2026,abstract,2025-12-19T04:07:51.455721,,,,
['Gene expression analysis'],['Breast cancer'],['Methods/Tools development'],"['Methods/Software', 'Original research']","['TCGA', 'METABRIC', 'Custom/Private data']","The paper does not explicitly describe using cBioPortal in their methodology. The study develops a new clustering method (Praxis-BGM) and applies it to TCGA breast cancer data and single-cell RNA-seq data, but there is no clear mention of accessing this data through cBioPortal or using cBioPortal's features. cBioPortal may have been cited as a reference or potential data source, but specific usage is not described in the abstract.",['TCGA-BRCA'],['Citation only'],[],['Not specified'],Unclear,low,4.0,41292835,Clustering of Omic Data Using Semi-Supervised Transfer Learning for Gaussian Mixture Models via Natural-Gradient Variational Inference: Method and Applications to Bulk and Single-Cell Transcriptomics.,2025,abstract,2025-12-19T04:07:51.969779,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine', 'Methods/Tools development']","['Original research', 'Methods/Software']","['Custom/Private data', 'Multiple sources']",The study used UCSC Xena (not cBioPortal) as the external validation dataset for bladder cancer. The authors validated their urinary extracellular vesicle-derived biomarkers using Xena's bladder cancer dataset and survival data. Their ExoMasso algorithm was trained on Xena dataset stratified into NMIBC and MIBC subtypes with associated overall survival data.,[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41282769,Urinary extracellular vesicles for high-precision bladder cancer subtyping and prognosis.,2025,pdf,2025-12-19T04:07:53.028173,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration']","['Melanoma', 'Pan-cancer']","['Biomarker discovery', 'Pathway analysis', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction, cBioPortal appears to be used for analyzing the expression of FRA1 and its target genes (AXL, CDK6, FSCN1) in melanoma and other cancer types, and for correlating their expression with patient survival outcomes. The study likely queried cBioPortal to validate that FRA1 target genes show increased expression in melanoma metastasis and correlate with poor patient outcomes across multiple cancer types. However, specific details about cBioPortal usage are not provided in the excerpted sections.",[],"['Web-based analysis', 'Citation only']","['FOSL1', 'AXL', 'CDK6', 'FSCN1']","['Expression analysis', 'Survival analysis', 'Not specified']",Unclear,low,4.0,41286309,FRA1 drives melanoma metastasis through an actionable transcriptional network.,2025,pdf,2025-12-19T04:07:53.186557,,,,
"['Gene expression analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis', 'Other']",['Original research'],['Not specified'],"The paper mentions using human hepatocellular carcinoma (HCC) patient data to analyze CEBPB-LAP overexpression and its link to mitochondria/obesity/neurodegeneration (Mon) mRNA expression signature. However, the abstract and introduction do not explicitly mention cBioPortal usage, specific datasets accessed, or how cBioPortal was utilized in the analysis. The citation appears to be a reference without clear description of actual platform usage.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41282072,"CEBPB, C19MC, and Defective Autophagy Drive Novel Podosomal Belt to Macropinocytosis Transition, Lipid Accumulation, and HBV A-to-I RNA-editing.",2025,pdf,2025-12-19T04:07:54.050943,,,,
"['Copy number analysis', 'Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],The study used cBioPortal to access TCGA clear cell renal cell carcinoma (ccRCC) data for clinicogenomic bioinformatic analyses. They performed multivariate survival analysis on 509 ccRCC patients from TCGA to demonstrate that lower L2HGDH expression portends worse prognosis. The study also analyzed 14q deletion status and gene expression patterns of L2HGDH and HIF1A in ccRCC tumors using TCGA data accessed through cBioPortal.,['TCGA'],"['Data download/export', 'Web-based analysis']","['L2HGDH', 'HIF1A', 'VHL']","['Survival analysis', 'Expression analysis', 'Copy number analysis', 'Download data']",Mixed,medium,4.0,41279437,Hypoxia-inducible factors drive miRNA-mediated downregulation of <i>L2HGDH</i> and <i>HIF1A</i> in clear cell renal cancer independent of 14q deletion.,2025,abstract,2025-12-19T04:07:54.833695,,,,
['Mutation analysis'],['Colorectal cancer'],"['Methods/Tools development', 'Biomarker discovery']","['Original research', 'Methods/Software']","['TCGA', 'Multiple sources']","The study used cBioPortal to access mutation data from colorectal cancer cohorts, including TCGA data. The mutation data was downloaded and used as input for their OPTIC pipeline, which employs a set cover algorithm to identify minimal genomic targets for cancer detection. The data from cBioPortal was one of three cohorts (totaling 2,940 samples) used to design a targeted sequencing panel.",['TCGA'],['Data download/export'],"['APC', 'TP53', 'KRAS', 'BRAF', 'NRAS', 'PIK3CA', 'CTNNB1', 'RNF43', 'ACVR2A']",['Download data'],"[""External (downloaded data)""]",medium,4.0,41266409,A set cover algorithm identifies minimal circulating tumour DNA sequencing targets for colorectal cancer detection.,2025,abstract,2025-12-19T04:07:55.059692,,,,
"['Gene expression analysis', 'Survival analysis']","['Breast cancer', 'Lung cancer', 'Pancreatic cancer']","['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'METABRIC']","The authors used cBioPortal to analyze BRSK2 expression levels and their association with clinical outcomes in breast cancer patients using TCGA and METABRIC datasets. They examined the relationship between BRSK2 expression and disease-specific survival, progression-free interval, and overall survival in breast cancer cohorts. The analysis also extended to other cancer types including small cell lung cancer (SCLC) and pancreatic ductal adenocarcinoma (PDAC).","['TCGA', 'METABRIC']","['Web-based analysis', 'Web-based visualization']",['BRSK2'],"['Survival analysis', 'Expression analysis']",cBioPortal platform,high,4.0,41258112,BRSK2 plays a role in autophagy and cancer cell growth and survival under nutrient deprivation stress via the PIK3C3 pathway.,2025,pdf,2025-12-19T04:07:56.916427,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly describe using cBioPortal in their methodology. The study used TCGA-STAD data as a training set and performed various analyses including differential expression, WGCNA, Mendelian randomization, and Cox regression to develop a prognostic model. While cBioPortal is cited, there is no clear description of how it was used to access or analyze the data.",['TCGA-STAD'],['Citation only'],"['AKAP12', 'BST1', 'DCBLD1', 'PDK4', 'SPART']",['Not specified'],Unclear,low,4.0,41245802,Development and validation of a prognostic prediction model for gastric cancer based on lipophagy-related genes.,2025,abstract,2025-12-19T04:07:57.817435,,,,
['Other'],['Not specified'],['Review/Commentary'],['Review'],['Not specified'],"This is a review paper about protein degradation signals (degrons) and ubiquitin-dependent protein degradation mechanisms. Based on the title and abstract provided, there is no explicit mention of cBioPortal usage in the study. The paper appears to focus on the structural and mechanistic aspects of protein degradation rather than cancer genomics data analysis.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41238838,Degrons and degradation signals beyond short linear motifs.,2025,abstract,2025-12-19T04:07:58.098070,,,,
['Mutation analysis'],['Breast cancer'],"['Methods/Tools development', 'Precision medicine', 'Biomarker discovery']","['Original research', 'Methods/Software']",['Multiple sources'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal being used in this study. The paper focuses on benchmarking AutoML frameworks (TPOT, H2O AutoML, and MLJAR) for predicting breast cancer variant pathogenicity using four different datasets curated from cancer-specific and non-cancer databases. While cBioPortal is cited (as indicated by the paper being in a cBioPortal citation analysis), the specific usage details are not described in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41245897,Leveraging AutoML to optimize dataset selection for improved breast cancer variants pathogenicity prediction.,2025,abstract,2025-12-19T04:07:58.220372,,,,
"['Gene expression analysis', 'Survival analysis']",['Breast cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'METABRIC']","Based on the abstract and introduction provided, the paper appears to use cBioPortal to analyze TIE1 expression levels in breast cancer patient cohorts and correlate expression with clinical outcomes. The authors likely queried TIE1 gene expression data from breast cancer datasets (TCGA and/or METABRIC) to demonstrate that TIE1 expression correlates with poor prognosis and is elevated in Claudin-low subtype breast cancers. The specific details of cBioPortal usage are not explicitly described in the provided text.",[],['Web-based analysis'],['TIE1'],"['Expression analysis', 'Survival analysis']",Unclear,low,4.0,41235901,TIE1 Promotes Primary Tumor Growth by Inhibiting Apoptosis and Activating the AKT-p70S6K Signaling Pathway in Breast Cancer.,2025,abstract,2025-12-19T04:07:59.316972,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to analyze genetic alterations of the ADSL gene across pan-cancer studies. Specifically, the authors used the ""Pancancer Studies"" module to examine mutation frequency, mutation types, and mutation sites of the ADSL protein across all TCGA tumors. This analysis was part of a comprehensive pan-cancer investigation of ADSL as a prognostic and immune biomarker.",['TCGA'],"['Web-based analysis', 'Web-based visualization']",['ADSL'],"['Mutation Mapper', 'Query interface']",cBioPortal platform,high,4.0,41251948,Adenylosuccinate lyase (ADSL) is a pan-cancer prognostic and immune biomarker with distinct roles in hepatocellular carcinoma.,2025,pdf,2025-12-19T04:07:59.773847,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used as one of multiple bioinformatics databases and tools to analyze the expression and functions of YY2 in esophageal carcinoma (ESCA). The platform was listed among other tools including TCGA, TIMER, TISIDB, and others for comprehensive bioinformatics analysis. However, the specific features or data obtained from cBioPortal are not explicitly detailed in the abstract.",['TCGA'],['Citation only'],['YY2'],['Not specified'],Unclear,low,4.0,41235100,YY2 Serves as a Novel Prognostic Biomarker Correlated with Immune Microenvironment and Glycolysis in Esophageal Carcinoma.,2025,abstract,2025-12-19T04:08:00.315320,,,,
"['Gene expression analysis', 'Other']",['Leukemia/Lymphoma'],"['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy']",['Original research'],['Custom/Private data'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on RT-PCR based splice assays and qRT-PCR analysis of primary pediatric B-ALL patient samples to examine CD19 splicing patterns. The study appears to use custom patient samples and in-silico analysis without reference to cBioPortal data or tools.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41247554,Widespread prevalence of CD19 exon 5-6 skipping in primary pediatric B-Cell acute lymphoblastic leukemia patients.,2025,pdf,2025-12-19T04:08:00.444184,,,,
['Mutation analysis'],['Pan-cancer'],['Biomarker discovery'],['Original research'],['Not specified'],"The paper mentions a SIGLEC12 variant associated with cancer (Ser458Phe) and a variant found in the general human population (Arg528Trp) that attenuate SIGLEC12 cleavage. While the abstract mentions cancer-associated variants, there is no explicit description of cBioPortal usage in the provided text. The citation appears to be minimal or the usage details are not included in the abstract/introduction sections provided.",[],['Citation only'],['SIGLEC12'],['Not specified'],Unclear,low,4.0,41225007,SIGLEC12 mediates plasma membrane rupture during necroptotic cell death.,2025,abstract,2025-12-19T04:08:00.608085,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the methods or results. While TCGA data was analyzed for CCT4 expression and clinical correlations in HCC, there is no specific reference to cBioPortal platform, tools, or data download from cBioPortal. The citation of cBioPortal may be for reference purposes only or the actual usage is not clearly described in the abstract and introduction provided.",[],['Citation only'],['CCT4'],['Not specified'],Unclear,low,4.0,41234881,<i>CCT4</i> as a prognostic biomarker correlated with immune infiltration and hepatocyte dedifferentiation in hepatocellular carcinoma.,2025,abstract,2025-12-19T04:08:00.935810,,,,
"['Gene expression analysis', 'Pathway analysis']",['Not specified'],"['Methods/Tools development', 'Pathway analysis']",['Methods/Software'],['Not specified'],"Based on the abstract and introduction provided, cBioPortal is not explicitly mentioned as being used in this study. This paper describes PLAID, a new computational method for single-sample gene set enrichment scoring. The paper appears to cite cBioPortal in the references but does not describe any specific usage of the platform for data access, analysis, or validation of their method.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41223139,PLAID: ultrafast single-sample gene set enrichment scoring.,2025,abstract,2025-12-19T04:08:02.565615,,,,
['Other'],['Not specified'],['Methods/Tools development'],['Methods/Software'],['Not specified'],"This paper describes a new site-directed mutagenesis method (P3a) for protein, RNA and plasmid engineering. There is no clear evidence that cBioPortal was actually used in this study. The paper appears to cite cBioPortal only as a reference without describing any specific usage of the platform or its data.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41221126,"P3a site-specific and cassette mutagenesis for seamless protein, RNA and plasmid engineering.",2025,abstract,2025-12-19T04:08:03.597030,,,,
"['Mutation analysis', 'Gene expression analysis', 'Multi-omics integration']",['Leukemia/Lymphoma'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['Multiple sources'],The authors used cBioPortal to analyze the relationship between SF3B1 mutations and ALOX5 expression in AML datasets. They examined the correlation between BRD9 and ALOX5 expression levels and investigated whether SF3B1 mutations are associated with ALOX5 upregulation in acute myeloid leukemia patient samples. The analysis appears to have been performed using cBioPortal's web-based tools to query gene expression and mutation data.,[],"['Web-based analysis', 'Web-based visualization']","['SF3B1', 'BRD9', 'ALOX5']","['Expression analysis', 'Query interface']",cBioPortal platform,medium,4.0,41219678,BRD9 depletion-mediated ALOX5 upregulation via chromatin dysregulation induces ferroptosis in SF3B1-mutant hematopoiesis.,2025,abstract,2025-12-19T04:08:03.633518,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Copy number analysis', 'Pathway analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction, this paper performs a comprehensive pan-cancer analysis of ZNF367 using multi-omics data from website databases. The study analyzes expression patterns, diagnostic and prognostic significance, genetic alterations (mutations and amplifications), and biological mechanisms across multiple cancer types. While cBioPortal is likely used as one of the data sources given the pan-cancer TCGA analysis approach, the specific usage details are not explicitly mentioned in the provided text.",[],['Citation only'],['ZNF367'],['Not specified'],Unclear,low,4.0,41212452,Comprehensive analysis of zinc finger protein 367 as a potential pan-cancer diagnostic and prognostic biomarker and underlying biological mechanisms.,2025,pdf,2025-12-19T04:08:04.978868,,,,
"['Mutation analysis', 'Copy number analysis', 'Survival analysis']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper describes a retrospective analysis of 100 consecutive glioblastoma patients who underwent next generation sequencing at a single tertiary center between 2018 and 2023. The molecular profiling appears to have been performed using institutional next generation sequencing data rather than cBioPortal. While cBioPortal may be cited in the references, no specific usage of the platform for data access, analysis, or visualization is described in the provided text.",[],['Citation only'],"['EGFR', 'TERT', 'PTEN', 'TP53', 'CDKN2A', 'CDKN2B', 'NF1', 'MTAP', 'PIK3CA']",['Not specified'],Unclear,low,4.0,41212363,EGFR pathway alterations correlate with rapid early progression in glioblastoma.,2025,pdf,2025-12-19T04:08:06.627628,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Pathway analysis', 'Precision medicine', 'Immunotherapy']",['Original research'],['Multiple sources'],"The paper mentions using data from multiple cancer genomics databases for pan-cancer analysis of ECT2 across 33 tumor types. While cBioPortal is likely one of the databases used given the citation, the abstract does not explicitly detail how cBioPortal was specifically utilized. The study integrated genomic data to analyze ECT2 expression profiles, clinical outcomes, immune infiltration, and pathway enrichment across various malignancies.",[],['Citation only'],"['ECT2', 'RACGAP1', 'KIF23']",['Not specified'],Unclear,low,4.0,41204520,Computational identification of ECT2 as a potential pan-cancer biomarker and therapeutic target through integrated genomic data analysis.,2025,abstract,2025-12-19T04:08:06.844186,,,,
"['Copy number analysis', 'Gene expression analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this case series. This appears to be a clinical pathology case series describing four renal cell carcinomas with TFE3 overexpression and copy number gains detected by fluorescence in situ hybridization (FISH) and immunostaining. If cBioPortal is cited, it appears to be a reference citation only without direct usage described in the methodology.",[],['Citation only'],['TFE3'],['Not specified'],Unclear,low,4.0,41212280,Series of renal cell carcinomas with TFE3 overexpression by copy number gains and without TFE3 gene rearrangement.,2025,abstract,2025-12-19T04:08:06.914308,,,,
"['Gene expression analysis', 'Survival analysis']",['Breast cancer'],"['Biomarker discovery', 'Tumor microenvironment']",['Original research'],"['TCGA', 'METABRIC']",The paper used cBioPortal to access and analyze gene expression data from TCGA and METABRIC breast cancer cohorts. The authors performed survival analysis to assess the clinical relevance of SPP1hi macrophages and VEGFAhi neutrophils in TNBC patients. cBioPortal was used to validate findings from their single-cell RNA sequencing analysis using bulk transcriptomic data.,"['TCGA-BRCA', 'METABRIC']","['Data download/export', 'Web-based analysis']","['SPP1', 'VEGFA']","['Survival analysis', 'Expression analysis', 'Download data']",Mixed,medium,4.0,41203997,Single-cell transcriptomics of the myeloid milieu reveals an angiogenic niche in triple-negative breast cancer.,2025,pdf,2025-12-19T04:08:07.398497,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration', 'Copy number analysis', 'Mutation analysis']","['Pan-cancer', 'Melanoma', 'Glioma/Brain cancer', 'Other solid tumor']","['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper conducted a comprehensive pan-cancer multi-omics analysis of IQCE using multiple genomic and transcriptomic datasets. While cBioPortal is likely among the data sources used for accessing TCGA and other cancer genomics data, the abstract and introduction do not explicitly detail how cBioPortal was utilized. The study appears to have integrated data from multiple sources for expression, survival, mutation, and copy number analyses across cancer types with a focus on cutaneous melanoma.",['TCGA'],['Citation only'],"['IQCE', 'TP53', 'GLI2', 'NTRK1', 'RFX6', 'GPAA1', 'BAHCC1', 'CLEC2B', 'AGAP2']",['Not specified'],Unclear,low,4.0,41212279,Pan-cancer multi-omics analysis reveals IQCE as a malignant cell-restricted oncogenic biomarker driving immunosuppression and chemoresistance in cutaneous melanoma.,2025,pdf,2025-12-19T04:08:07.476527,,,,
"['Mutation analysis', 'Other']","['Colorectal cancer', 'Other solid tumor']","['Review/Commentary', 'Immunotherapy', 'Precision medicine']",['Review'],['Not specified'],"This is a review paper that discusses the biology and management of dMMR/MSI-H cancers. While cBioPortal is cited in the references, there is no explicit description of how cBioPortal was used in this study. The paper focuses on summarizing biological mechanisms and clinical evidence for immunotherapy in resectable dMMR/MSI-H tumors rather than presenting original data analysis using cBioPortal.",[],['Citation only'],"['RNF43', 'ARID1A', 'APC', 'KMT2B', 'KMT2D', 'BRAF', 'PTEN', 'CTCF', 'PIK3CA', 'JAK1', 'TP53', 'B2M', 'MLH1', 'MSH2', 'MSH6', 'PMS2']",['Not specified'],Unclear,low,4.0,41196394,Biology and evolving management of resectable dMMR/MSI-H cancers: current status and future perspectives.,2025,pdf,2025-12-19T04:08:07.661687,,,,
"['Mutation analysis', 'Other']","['Pan-cancer', 'Melanoma', 'Lung cancer', 'Colorectal cancer']","['Immunotherapy', 'Database/Resource', 'Biomarker discovery']","['Meta-analysis', 'Original research']","['Multiple sources', 'Not specified']","cBioPortal is mentioned only in the abbreviations section as ""CBio Cancer Genomics Portal"" but no specific usage, methodology, or results involving cBioPortal are described in the abstract or introduction. The study primarily uses CEDAR (Cancer Epitope Database and Analysis Resource) for their meta-analysis of neo-epitopes. cBioPortal appears to be cited but not actively used in this study.",[],['Citation only'],"['TP53', 'KRAS']",['Not specified'],Unclear,low,4.0,41196374,"A meta-analysis of experimentally validated neo-epitopes: patterns, biases, and opportunities.",2025,pdf,2025-12-19T04:08:09.112165,,,,
['Mutation analysis'],['Pan-cancer'],"['Methods/Tools development', 'Biomarker discovery']",['Original research'],['Not specified'],"The paper does not explicitly describe how cBioPortal was used in the study. The abstract and introduction focus on molecular dynamics simulations to analyze NMD machinery components and cancer-associated mutations affecting mRNA-binding protein interactions. There is no clear mention of cBioPortal usage for data retrieval, analysis, or visualization in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41189592,Specificity of mRNA binding to proteins within the NMD machinery is influenced in cancer.,2025,abstract,2025-12-19T04:08:09.113482,,,,
"['Gene expression analysis', 'Survival analysis']",['Breast cancer'],"['Biomarker discovery', 'Immunotherapy', 'Drug response/resistance']",['Original research'],"['TCGA', 'METABRIC']","The paper analyzed co-expression of GD3S (ST8SIA1) mRNA with immune checkpoint markers (CTLA-4, LAG-3, PD-1, CD25) in the METABRIC and TCGA Pan-Cancer datasets. The authors examined correlations between GD3S expression and immune checkpoint protein expression levels in breast cancer patients from these datasets. The specific platform used for accessing these datasets is not explicitly stated, though TCGA and METABRIC data are commonly accessed through cBioPortal.","['METABRIC', 'TCGA Pan-Cancer']",['Citation only'],"['ST8SIA1', 'CTLA4', 'LAG3', 'PDCD1', 'IL2RA']",['Not specified'],Unclear,low,4.0,41188249,Targeting GD2 with naxitamab overcomes GD3 synthase-driven immune suppression in triple-negative breast cancer.,2025,pdf,2025-12-19T04:08:10.309306,,,,
['Other'],['Not specified'],['Methods/Tools development'],['Methods/Software'],['Not specified'],"This paper presents Varan, a data management tool designed to facilitate the preparation and upload of cancer genomic studies to cBioPortal. The tool addresses challenges in data formatting, variant filtering, metadata file creation, quality checks, and study versioning to streamline the process of creating cBioPortal studies. cBioPortal is the target platform for which this tool prepares data, rather than being used for analysis in this study.",[],['Citation only'],[],['Not specified'],"[""Unclear""]",high,4.0,41180209,Varan: a tool for managing mutational data and creating cancer studies in cBioPortal.,2025,abstract,2025-12-19T04:08:11.422133,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']","['Pan-cancer', 'Breast cancer', 'Colorectal cancer', 'Prostate cancer', 'Other solid tumor']","['Biomarker discovery', 'Methods/Tools development', 'Precision medicine']","['Methods/Software', 'Original research']",['TCGA'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal being used in this study. The paper describes THRESHOLD, a novel tool for analyzing gene expression data using TCGA cancer datasets. The analysis appears to have been conducted using their own newly developed tool rather than cBioPortal. cBioPortal may only be cited in references or not mentioned at all in the provided text.",['TCGA'],['Citation only'],"['SLC45A2', 'AMACR']",['Not specified'],Unclear,low,4.0,41180010,THRESHOLD: a comprehensive transcriptomic analysis tool for evaluating gene saturation and impact in disease progression.,2025,abstract,2025-12-19T04:08:12.808872,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Pan-cancer'],['Biomarker discovery'],['Original research'],"['TCGA', 'Multiple sources']",The cBioPortal platform was used to examine the mutation frequency and types of B3GNT3 across different cancer types. The study analyzed B3GNT3 gene alterations and their correlation with overall survival (OS) and disease-free survival (DFS) in multiple cancer types. This was part of a comprehensive pan-cancer analysis that integrated data from multiple sources including TCGA.,[],"['Web-based analysis', 'Web-based visualization']",['B3GNT3'],"['Mutation Mapper', 'Survival analysis', 'Query interface']",cBioPortal platform,high,4.0,41158272,<i>B3GNT3</i> is an oncogenic and prognostic biomarker in human tumors via pan-cancer analysis combined with experimental validation.,2025,abstract,2025-12-19T04:08:13.134233,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper mentions cBioPortal in the context of analyzing genomic variations and DNA methylation in pan-cancer analysis of ADAM12. However, the abstract and introduction do not provide specific details about how cBioPortal was used, what features were accessed, or whether data was downloaded versus analyzed on the platform. The study appears to use multiple public databases including TCGA and GTEx for comprehensive pan-cancer analysis.",[],['Citation only'],['ADAM12'],['Not specified'],Unclear,low,4.0,41171558,Unveiling the significance of ADAM12 through pan-cancer analysis and experimental verification in gastric cancer.,2025,pdf,2025-12-19T04:08:13.374516,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']",The cBioPortal database was used to analyze the relationship between TRIM21 expression and immune infiltration in pancreatic adenocarcinoma (PAAD). The study leveraged cBioPortal to examine correlations between TRIM21 and immune-related features in PAAD patients. The specific details of how the analysis was performed (web-based vs. data download) are not clearly specified in the abstract and introduction.,['TCGA'],['Web-based analysis'],['TRIM21'],['Not specified'],Unclear,medium,4.0,41165935,TRIM21 as a potential prognostic biomarker and therapeutic target affects the growth of pancreatic cancer.,2025,pdf,2025-12-19T04:08:13.416308,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Copy number analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis', 'Precision medicine']",['Original research'],"['TCGA', 'Custom/Private data']","The paper analyzed HNSCC data from TCGA using cBioPortal to examine TP53 mutation status, gene expression patterns, and survival outcomes in HPV-positive and HPV-negative tumors. The authors used cBioPortal to stratify patients based on TP53 mutation status and HPV status, and to analyze associated genomic alterations including copy number changes and pathway activation patterns. Clinical survival data was also analyzed through cBioPortal to compare outcomes between different molecular subgroups of HNSCC.",['TCGA-HNSC'],"['Web-based analysis', 'Data download/export']","['TP53', 'PIK3CA', 'INPP5D']","['Survival analysis', 'Expression analysis', 'Query interface', 'Group comparison']","[""Mixed""]",medium,4.0,41168931,Human Papilloma Virus Does Not Fully Inactivate p53 Cellular Activity in HNSCC.,2025,abstract,2025-12-19T04:08:13.999160,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration']","['Pan-cancer', 'Lung cancer']","['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the abstract or introduction. The study utilized multi-omics data from TCGA, HPA, UALCAN, TIMER2.0, and other databases for pan-cancer analysis of ABAT. While cBioPortal may have been cited as a reference or potential data source, there is no clear description of specific cBioPortal features or tools being used in the methodology described.",['TCGA'],['Citation only'],['ABAT'],['Not specified'],Unclear,low,4.0,41158242,Pan-cancer evaluation of ABAT as an emerging biomarker and its implication in lung adenocarcinoma.,2025,abstract,2025-12-19T04:08:14.750344,,,,
"['Copy number analysis', 'Gene expression analysis', 'Survival analysis']",['Lung cancer'],['Biomarker discovery'],['Original research'],"['TCGA', 'Multiple sources']","The study used cBioPortal to analyze LINC00592 expression levels and copy number alterations in lung adenocarcinoma (LUAD) patients. The authors examined the correlation between LINC00592 expression/copy number amplification and clinical characteristics including pathological stage and multiple survival outcomes (overall survival, progression-free survival, disease-specific survival, first-progression-free survival, and post-progression survival). The analysis revealed upregulation and copy number amplification of LINC00592 in LUAD that correlated with poor prognosis.",['TCGA-LUAD'],"['Web-based analysis', 'Web-based visualization']","['LINC00592', 'NTN1']","['Expression analysis', 'Survival analysis', 'Query interface']",Mixed,medium,4.0,41141626,LINC00592 is a predictor of poor lung adenocarcinoma outcomes that promotes tumor cell migration and invasion.,2025,abstract,2025-12-19T04:08:15.327056,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],['Biomarker discovery'],"['Original research', 'Clinical study']",['TCGA'],"Based on the abstract and introduction provided, the paper does not explicitly mention cBioPortal usage. The study focuses on experimental validation of Cornulin as a biomarker in HNSCC using ELISA, immunohistochemistry, in-vitro and in-vivo models, and transcriptomic/proteomic analysis. If cBioPortal was used, it was likely for accessing TCGA data for validation purposes, but this is not clearly stated in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41145788,"Cornulin, a potential prognostic biomarker in head and neck squamous cell carcinoma, acts as an anti-tumour agent by inhibiting cell cycle through upregulation of p18.",2025,abstract,2025-12-19T04:08:15.457712,,,,
"['Gene expression analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'GEO', 'Custom/Private data']","The paper mentions using cBioPortal in the context of analyzing thyroid cancer datasets. Based on the abstract and methods section, the authors used Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) datasets to identify dysregulated miRNAs. However, the specific details of cBioPortal usage are not clearly described in the provided text excerpt, suggesting it may have been used for data access or cited as a reference rather than as a primary analysis platform.",['TCGA'],['Citation only'],[],['Not specified'],Unclear,low,4.0,41134479,Functional and in silico evidence for the role of microRNAs 148a-5p and 199a in migration and invasion of papillary thyroid carcinoma cells.,2025,pdf,2025-12-19T04:08:17.138850,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis']",['Lung cancer'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal being used in this study. The study appears to be a retrospective analysis of NSCLC cases from a single institution using immunohistochemistry and NGS performed on their own samples. Without access to the full methods section or results, it is unclear if cBioPortal was used for any comparative analysis or data validation.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41133008,TTF-1 and p40 co-expression defines a distinct subtype of non-small cell lung cancer with frequent <i>TP53</i> mutations and FGFR pathway dysregulation.,2025,abstract,2025-12-19T04:08:17.167806,,,,
"['Gene expression analysis', 'Pathway analysis', 'Multi-omics integration']","['Breast cancer', 'Other solid tumor']","['Drug response/resistance', 'Pathway analysis', 'Biomarker discovery']",['Original research'],['Custom/Private data'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on quantitative proteomic and phosphoproteomic analyses using MCF10A PTEN KO models and patient-derived xenograft models. If cBioPortal was used, it may have been for validation or background data queries, but this is not stated in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41130297,Proteomic Analysis of PTEN-Deficient Cells Reveals Src-Mediated Upregulation of EphA2 and Therapeutic Potential of Dual Inhibition.,2025,abstract,2025-12-19T04:08:18.397586,,,,
"['Gene expression analysis', 'Pathway analysis']",['Breast cancer'],"['Methods/Tools development', 'Pathway analysis']","['Methods/Software', 'Original research']",['Not specified'],"Based on the abstract and introduction provided, cBioPortal is not explicitly mentioned as being used in this study. The paper presents a new method called ""Ulisse"" for analyzing intra- and inter-cellular crosstalk from omics data, with a proof-of-concept application to triple negative breast cancer using single-cell RNA sequencing. cBioPortal may only be cited in the references without direct usage in the methodology.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41124151,Analysis of intracellular and intercellular crosstalk from omics data.,2025,abstract,2025-12-19T04:08:19.684935,,,,
"['Mutation analysis', 'Pathway analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Pathway analysis', 'Precision medicine']",['Original research'],"['TCGA', 'Custom/Private data']","The study used TCGA-COADREAD dataset from cBioPortal for comparative analysis against their Saudi CRC cohort. They compared mutation frequencies of specific genes (BRCA2, EGFR, SLC25A5, PIK3R2) between their WES data and the TCGA-COADREAD dataset to identify population-specific differences in mutational patterns. The TCGA data served as a reference benchmark to highlight the distinct mutational profile observed in the Saudi population.",['TCGA-COADREAD'],['Data download/export'],"['BRCA2', 'EGFR', 'SLC25A5', 'PIK3R2', 'APC', 'KRAS', 'TP53', 'PIK3CA', 'PTEN', 'AXIN1', 'TGFB2', 'SOS1', 'BAX', 'TCF7L2']",['Download data'],External (downloaded data),high,4.0,41132721,Whole-exome sequencing in Saudi colorectal cancer patients reveals distinct mutational patterns and population specific pathogenic variants.,2025,pdf,2025-12-19T04:08:19.772874,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Mutation analysis']",['Pan-cancer'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the methods or results sections provided. The abstract mentions using ""various databases, bioinformatics and statistical tools"" but cBioPortal is not specifically named in the provided text. The methods section describes using TIMER2, GEPIA2, UALCAN, and CPTAC databases for expression analysis, but no direct reference to cBioPortal usage is evident in the excerpts provided.",[],['Citation only'],['MRPL3'],['Not specified'],Unclear,low,4.0,41118021,"Expressions, immune associations, and prognostic values of mitochondrial ribosomal protein MRPL3 in the pan cancer landscape.",2025,pdf,2025-12-19T04:08:20.579437,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Glioma/Brain cancer', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the methods or results sections provided. While TCGA data was analyzed in this pan-cancer study of SLC39A14 and ferroptosis, there is no clear indication that cBioPortal was used for data access, analysis, or visualization. The study may have cited cBioPortal in references or used it indirectly, but specific usage details are not provided in the abstract and introduction.",['TCGA'],['Citation only'],['SLC39A14'],['Not specified'],Unclear,low,4.0,41121066,Metal ion transporter SLC39A14-mediated ferroptosis and glycosylation modulate the tumor immune microenvironment: pan-cancer multi-omics exploration of therapeutic potential.,2025,pdf,2025-12-19T04:08:20.580423,,,,
"['Gene expression analysis', 'Survival analysis']",['Breast cancer'],"['Biomarker discovery', 'Methods/Tools development', 'Drug response/resistance']",['Original research'],['TCGA'],"The study used cBioPortal to analyze TLK2 expression levels in breast cancer patients from TCGA datasets. The authors examined the correlation between TLK2 expression and clinical prognosis in breast cancer patients, finding that elevated TLK2 expression correlates with poor prognosis. This analysis was performed to validate their experimental findings about TLK2's role in cancer stemness plasticity.",['TCGA'],"['Web-based analysis', 'Web-based visualization']",['TLK2'],"['Expression analysis', 'Survival analysis']",cBioPortal platform,medium,4.0,41120304,Chromatin looping-based CRISPR screen identifies TLK2 as chromatin loop formation regulator in cancer stemness plasticity.,2025,abstract,2025-12-19T04:08:20.590125,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Multi-omics integration']",['Colorectal cancer'],"['Biomarker discovery', 'Immunotherapy', 'Drug response/resistance']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage. The study appears to be a clinical trial (NICHE study) analyzing neoadjuvant immunotherapy in pMMR colon cancer patients with comprehensive molecular profiling including tumor mutational burden, chromosomal instability, gene expression, and imaging mass cytometry. cBioPortal may have been cited in references or used for comparative analysis, but specific usage is not described in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41115454,Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers.,2025,abstract,2025-12-19T04:08:21.705096,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal is mentioned in the introduction as one of several bioinformatic portals that enable large-scale gene-expression interrogation. However, the authors note limitations of existing portals (reliance on older tumor labels, RPKM normalization) and instead re-extracted raw RNA-seq data from TCGA and CGGA directly, converting to TPM and re-annotating samples. The paper appears to cite cBioPortal as a reference tool but does not describe specific usage of the platform for their analyses.","['TCGA', 'CGGA', 'GSE131928', 'GSE89567', 'Ivy GAP', 'TCGA Proteomic Data Commons']",['Citation only'],"['COL22A1', 'IDH1', 'IDH2', 'TERT', 'EGFR', 'MGMT', 'CDKN2A', 'CDKN2B']",['Not specified'],External (downloaded data),medium,4.0,41117892,COL22A1 expression identifies aggressive glioma and independently predicts survival through integrated multiomics and clinical validation.,2025,pdf,2025-12-19T04:08:22.361140,,,,
"['Survival analysis', 'Other']",['Lung cancer'],['Biomarker discovery'],"['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal being used in this study. This appears to be a retrospective clinical study focused on immunohistochemical analysis of MECA-79 expression in lung adenocarcinoma patients. The study analyzed clinical, radiological, and pathological factors using Kaplan-Meier survival analysis and Cox regression models, but cBioPortal usage is not described in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41100538,Clinical and pathological implications of the presence of MECA-79-expressing tumor cells in pathological stage IA lung adenocarcinoma.,2025,abstract,2025-12-19T04:08:23.772877,,,,
"['Mutation analysis', 'Pathway analysis']","['Breast cancer', 'Colorectal cancer']","['Drug response/resistance', 'Pathway analysis', 'Methods/Tools development', 'Precision medicine']","['Original research', 'Methods/Software']",['Not specified'],"The paper does not explicitly describe using cBioPortal in their methodology. While the study focuses on discovering drug target combinations using protein-protein interaction networks and analyzes mutations in breast and colorectal cancers (including PIK3CA, BRAF, ESR1, EGFR, ERBB2, MYC), there is no clear mention of cBioPortal being used for data acquisition, analysis, or visualization. The citation appears to be reference-only without specific usage details provided in the abstract or introduction.",[],['Citation only'],"['PIK3CA', 'BRAF', 'ESR1', 'EGFR', 'ERBB2', 'MYC']",['Not specified'],Unclear,low,4.0,41107466,Discovering anticancer drug target combinations via network-informed signaling-based approach.,2025,pdf,2025-12-19T04:08:24.103012,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Mutation analysis']",['Pan-cancer'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal is not explicitly mentioned in the provided abstract and introduction sections of this paper. The study uses TCGA data accessed through other platforms (TIMER 2.0, UCSC Xena Browser, UALCAN, GEPIA2) for pan-cancer analysis of THOC3. While cBioPortal may be cited in the references, there is no clear description of its usage in the methodology described.",['TCGA'],['Citation only'],"['THOC3', 'THOC1', 'THOC2', 'THOC5', 'THOC6', 'THOC7', 'YBX1', 'PFKFB4', 'SOX2', 'NANOG']",['Not specified'],External (downloaded data),low,4.0,41102247,A pan-cancer analysis of the oncogenic and immunological roles of THOC3 in human cancer.,2025,pdf,2025-12-19T04:08:24.846155,,,,
['Other'],['Pan-cancer'],"['Review/Commentary', 'Methods/Tools development', 'Drug response/resistance']",['Review'],['Not specified'],"This is a review paper discussing strategies for cancer drug development using omics, bioinformatics, network pharmacology, and molecular dynamics simulation. cBioPortal is mentioned only as a citation/reference in the context of bioinformatics tools and databases used in cancer research. No specific analysis or data usage from cBioPortal is described in the provided abstract and introduction.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41098828,Strategies for the drug development of cancer therapeutics.,2025,pdf,2025-12-19T04:08:25.628138,,,,
"['Gene expression analysis', 'Survival analysis']",['Pan-cancer'],"['Immunotherapy', 'Biomarker discovery']",['Original research'],['Not specified'],"cBioPortal was used to analyze the correlation between folate receptor β (FRβ/FOLR2) expression and overall survival across multiple human cancer types. The authors examined human cancer data from cBioPortal to demonstrate that FRβ expression inversely correlates with patient survival, supporting their hypothesis that FRβ performs an immunosuppressive function in human tumors similar to what they observed in mouse models.",[],"['Web-based analysis', 'Web-based visualization']",['FOLR2'],"['Survival analysis', 'Expression analysis']",cBioPortal platform,medium,4.0,41089695,Folate receptor β performs an immune checkpoint function in activated macrophages.,2025,pdf,2025-12-19T04:08:26.895516,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration', 'Copy number analysis']",['Pan-cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper conducted a comprehensive pan-cancer analysis of TEAD4 using publicly available datasets including TCGA. While cBioPortal is likely used as a data source or analysis platform for accessing TCGA data and performing multi-omics analyses, the abstract and introduction do not explicitly detail the specific usage of cBioPortal. The study integrated transcriptomic, epigenomic, genomic data to evaluate TEAD4 expression patterns, prognostic significance, and therapeutic implications across diverse tumor types.",['TCGA'],['Citation only'],['TEAD4'],['Not specified'],Unclear,low,4.0,41098715,Integrative analysis identifies TEAD4 as a universal prognostic biomarker in human cancers.,2025,pdf,2025-12-19T04:08:27.670541,,,,
"['Gene expression analysis', 'Pathway analysis']",['Colorectal cancer'],"['Pathway analysis', 'Tumor evolution']",['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, cBioPortal is cited in this paper but no specific usage details are described. The study focuses on experimental work using CRISPR-Cas9 gene editing and scRNAseq analysis of patient-derived organoids. cBioPortal may have been referenced for background information on STAG2 mutations in colorectal cancer or for contextualizing findings, but the actual experimental work appears to be entirely laboratory-based using custom data.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41091748,STAG2 mutations in the normal colon induce upregulation of oncogenic pathways in neighbouring wildtype cells.,2025,abstract,2025-12-19T04:08:27.803599,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']","['Pan-cancer', 'Lung cancer', 'Other solid tumor']","['Biomarker discovery', 'Review/Commentary']","['Review', 'Original research']","['TCGA', 'Multiple sources']","This study used cBioPortal to analyze LINC00312 expression and survival correlations across multiple cancer types. The authors performed bioinformatics analysis to examine the expression patterns of LINC00312 in various cancers and its correlation with patient survival, particularly in sarcoma and stomach adenocarcinoma. cBioPortal was likely used as one of several bioinformatics tools to query cancer genomics databases and generate survival and expression data.",[],"['Web-based analysis', 'Web-based visualization']",['LINC00312'],"['Expression analysis', 'Survival analysis']",Unclear,medium,4.0,41080750,The role of long intergenic non-protein coding RNA 312 in cancer: A bioinformatics and literature based study.,2025,abstract,2025-12-19T04:08:28.248831,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Precision medicine', 'Methods/Tools development', 'Database/Resource']","['Original research', 'Methods/Software']","['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, there is no explicit mention of cBioPortal being used in this study. The paper describes RadGLO, a new platform for radiomic feature analysis in glioma that integrates MRI datasets from TCGA, UCSF, and UPENN. While the paper may cite cBioPortal in the references, the provided text does not describe any specific usage of cBioPortal for data download, analysis, or visualization. The focus is entirely on the development of their own platform using radiomic features from MRI data.","['TCGA-GBM', 'TCGA-LGG', 'UCSF-GBM', 'UPENN-GBM']",['Citation only'],"['CSF1R', 'C5AR1', 'CDK6', 'CCND1', 'IDH', 'CDKN2A', 'CDKN2B', 'MGMT']",['Not specified'],Unclear,low,4.0,41087540,RadGLO: an interactive platform for radiomic feature analysis and prognostic modeling in glioma.,2025,pdf,2025-12-19T04:08:28.978564,,,,
"['Gene expression analysis', 'Mutation analysis', 'Pathway analysis']",['Lung cancer'],"['Pathway analysis', 'Tumor evolution', 'Drug response/resistance']",['Original research'],"['TCGA', 'Custom/Private data']",cBioPortal was used to analyze NRF2 mutation frequencies and gene expression patterns in primary lung tumors from TCGA datasets. The authors likely queried NRF2 (NFE2L2) mutations and examined expression of NRF2 target genes in lung cancer cohorts to validate findings from their experimental cell line models. This analysis helped establish the clinical relevance of their in vitro observations regarding NRF2 activation effects.,['TCGA'],"['Web-based analysis', 'Data download/export']",['NFE2L2'],"['Query interface', 'Expression analysis']","[""Mixed""]",medium,4.0,41076449,Activating NRF2<sup>E79Q</sup> mutation alters the differentiation of human non-small cell lung cancer.,2025,abstract,2025-12-19T04:08:31.272606,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],"['TCGA', 'Multiple sources']",The study used cBioPortal to analyze MYOF gene expression and its correlation with survival outcomes in pancreatic adenocarcinoma (PAAD) patients. The authors performed transcriptomic analyses using TCGA data accessed through cBioPortal to link stromal myoferlin expression to tumor aggressiveness. This analysis was combined with single-cell transcriptomic data and experimental validation to establish the role of myoferlin in cancer-associated fibroblasts.,['TCGA-PAAD'],"['Web-based analysis', 'Data download/export']",['MYOF'],"['Expression analysis', 'Survival analysis', 'Query interface']",Mixed,medium,4.0,41062852,Targeting myoferlin in ER/Golgi vesicle trafficking reprograms pancreatic cancer-associated fibroblasts.,2025,abstract,2025-12-19T04:08:31.690065,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the methods or results. The study analyzed CXCL13 expression using TCGA and GEO datasets (GSE17025, GSE106191) with R software, TIMER, TISIDB, and other bioinformatics tools. cBioPortal may have been cited as a reference or potential data source, but no specific usage of the platform is described in the abstract or introduction.","['TCGA', 'GSE17025', 'GSE106191']",['Citation only'],"['CXCL13', 'CXCL9', 'IFNG', 'CXCL10', 'CXCL11', 'GBP5', 'CCL18', 'GZMB']",['Not specified'],Unclear,low,4.0,41071252,Expression and prognosis of CXCL13 in uterine corpus endometrial carcinoma based on bioinformatics analysis.,2025,abstract,2025-12-19T04:08:32.776249,,,,
"['Multi-omics integration', 'Other']",['Pan-cancer'],"['Methods/Tools development', 'Database/Resource']","['Methods/Software', 'Original research']",['Multiple sources'],"cBioPortal was used as one of multiple data sources in this study to aggregate clinical, genetic, and molecular information about proteins. The authors integrated data from cBioPortal along with other databases (literature analysis, protein interaction data) to develop a method for identifying understudied but biomedically important proteins. The specific usage details suggest data was extracted from cBioPortal to contribute to their comprehensive protein importance scoring system.",[],['Data download/export'],[],['Download data'],External (downloaded data),medium,4.0,41054520,Overcoming research bias: The untapped potential of biomedically important but understudied proteins.,2025,abstract,2025-12-19T04:08:34.786968,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Copy number analysis']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal for Cancer Genomics was used to analyze genetic alterations (mutations and copy number variations) of GATA3 in stomach adenocarcinoma. The study found that genetic alterations in GATA3 were rare (4%) and did not impact survival outcomes. cBioPortal was one of multiple bioinformatics platforms used alongside TIMER, GEPIA, UALCAN, KM Plotter, and GEO databases.",[],['Web-based analysis'],['GATA3'],['Not specified'],cBioPortal platform,medium,4.0,41058789,GATA Binding Protein 3 as a Diagnostic Biomarker and Immune Infiltrates Regulator in Stomach Adenocarcinoma.,2025,pdf,2025-12-19T04:08:34.995270,,,,
"['Mutation analysis', 'Copy number analysis']","['Colorectal cancer', 'Other solid tumor']","['Methods/Tools development', 'Biomarker discovery']","['Original research', 'Methods/Software']",['Custom/Private data'],"Based on the abstract and title, this paper focuses on developing MiMouse, a comprehensive genomic profiling panel for mouse tumor models. The paper does not explicitly describe how cBioPortal was used in the methodology. cBioPortal is cited but the specific usage for data access, comparison, or validation is not detailed in the provided abstract and introduction.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41051921,"Development and Application of MiMouse, a Comprehensive Genomic Profiling Panel for Credentialing Mouse Tumor Models.",2025,abstract,2025-12-19T04:08:35.298213,,,,
"['Gene expression analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Pathway analysis', 'Review/Commentary']",['Review'],['Not specified'],"This is a review paper examining the interactions between long non-coding RNAs (lncRNAs) and MAPK signaling pathways in breast cancer pathogenesis. The paper does not describe any direct use of cBioPortal for data analysis or visualization. cBioPortal may only be cited as a reference or resource in the context of discussing breast cancer genomics data, but no specific usage details are provided in the abstract or introduction.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41053774,Interactions between LncRNAs and MAPK signaling pathways in the pathogenesis of breast cancer.,2025,pdf,2025-12-19T04:08:35.477829,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The study used publicly available datasets from TCGA and GEO repository for validation of their immunohistochemistry findings at the mRNA level. In silico analysis was performed to confirm the association between FGFR4 mRNA levels and disease-free survival, and to conduct co-expression and pathway enrichment analysis linking FGFR4 overexpression with developmental, metabolic, and stemness-related processes. The primary analysis was performed on tissue samples using immunohistochemistry, with TCGA data used for transcriptomic validation.",['TCGA'],['Data download/export'],"['FGFR1', 'FGFR2', 'FGFR4']","['Expression analysis', 'Download data']",External (downloaded data),medium,4.0,41053706,"High FGFR4 protein expression, but not FGFR1 or FGFR2, predicts poor prognosis in pancreatic ductal adenocarcinoma.",2025,pdf,2025-12-19T04:08:36.230423,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the methods or results. While the study uses TCGA data which is available through cBioPortal, the abstract and introduction do not specify cBioPortal as a data source or analysis platform. The study mentions using data from TCGA, GTEx, CPTAC, CancerSEA, and public literature, but cBioPortal is not explicitly cited as a tool or resource used in this analysis.",['TCGA'],['Citation only'],['CA9'],['Not specified'],Unclear,low,4.0,41049875,Systematic Analysis of CA9 as a Pan-Cancer Marker for Prognosis and Immunity.,2025,abstract,2025-12-19T04:08:37.489503,,,,
"['Gene expression analysis', 'Survival analysis']","['Breast cancer', 'Lung cancer']","['Drug response/resistance', 'Biomarker discovery']",['Original research'],"['TCGA', 'Multiple sources']","The study analyzed TCGA and GTEx databases to examine the expression patterns of HIF1A, BRG1 (SMARCA4), and p300 (EP300) in relation to taxane resistance in cancer patients. The analysis confirmed the potential role of HIF1A-BRG1-p300 overexpression in taxane resistance and their possible function as biomarkers for cancer response to chemotherapy. The specific platform used for accessing and analyzing this data is not explicitly detailed in the abstract.",['TCGA'],['Citation only'],"['HIF1A', 'SMARCA4', 'EP300', 'ABCC3', 'ABCC5', 'ABCC10']",['Not specified'],Unclear,low,4.0,41050430,"HIF1A, BRG1, and p300 interaction confers paclitaxel-induced drug resistance by enabling the overexpression of <i>ABCC</i> genes.",2025,abstract,2025-12-19T04:08:38.136780,,,,
"['Mutation analysis', 'Survival analysis', 'Biomarker discovery']",['Leukemia/Lymphoma'],"['Biomarker discovery', 'Precision medicine', 'Immunotherapy', 'Review/Commentary']",['Review'],['Not specified'],"This is a review paper on acute myeloid leukemia (AML) that discusses risk factors, oncogene drivers, prognostic biomarkers, and therapeutic strategies. The paper cites cBioPortal but does not provide specific details about how the platform was used for data analysis or visualization. Based on the review nature of the paper, cBioPortal appears to be cited as a reference resource rather than actively used for original analysis.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41046303,Elucidating the risk factors and oncogene drivers of acute myeloid leukemia.,2025,abstract,2025-12-19T04:08:39.476741,,,,
"['Mutation analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Breast cancer']","['Biomarker discovery', 'Pathway analysis', 'Tumor evolution', 'Precision medicine', 'Methods/Tools development']","['Original research', 'Methods/Software']","['TCGA', 'GENIE', 'Multiple sources']","The study analyzed pan-cancer mutation profiles from approximately 60,000 tumor sequences obtained from TCGA and AACR GENIE databases. The authors used this genomic data to identify 3424 statistically significant co-occurring double mutations in different genes (in trans) across non-redundant pathways. The data was integrated with protein-protein interaction networks to develop a statistical framework for identifying metastasis markers and actionable mutations in metastatic tumors.","['TCGA', 'AACR GENIE']",['Data download/export'],[],['Download data'],External (downloaded data),high,4.0,41035572,Co-occurring Mutations in Different Genes Can Fuel Oncogenic Signaling and Serve as Metastatic Tumor Markers.,2024,abstract,2025-12-19T04:08:40.969567,,,,
"['Gene expression analysis', 'Survival analysis']",['Pan-cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],['TCGA'],The authors used cBioPortal to analyze the clinical significance of TONSL-MMS22L expression in cancer patients. They examined the relationship between TONSL-MMS22L expression levels and patient prognosis in tumors with wildtype FANCM. The analysis revealed that cancer patients with wildtype FANCM tumors and low TONSL-MMS22L expression have more favorable prognosis compared to those with high expression.,[],['Web-based analysis'],"['FANCM', 'TONSL', 'MMS22L']","['Expression analysis', 'Survival analysis']",cBioPortal platform,medium,4.0,41030968,The TONSL-MMS22L complex and FANCM form an interdependent complex on chromatin to counter replication stress.,2025,abstract,2025-12-19T04:08:41.329126,,,,
['Copy number analysis'],['Pan-cancer'],['Methods/Tools development'],"['Methods/Software', 'Original research']",['TCGA'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal being used in this study. The paper focuses on developing CNAdjust, a method for correcting baseline abnormalities in copy number alteration (CNA) data, and validates it using TCGA pan-cancer datasets. The paper may cite cBioPortal in references, but no specific usage of the platform for data access, analysis, or visualization is described in the provided text.",['TCGA'],['Citation only'],[],['Not specified'],Unclear,low,4.0,41080701,<i>CNAdjust</i>: enhancing CNA calling accuracy through systematic baseline adjustment.,2025,pdf,2025-12-19T04:08:41.418059,,,,
"['Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Mutation analysis']",['Prostate cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine']",['Original research'],"['TCGA', 'Custom/Private data', 'Multiple sources']","The study used cBioPortal to analyze MCL1 copy number alterations and genomic data from multiple prostate cancer cohorts, including TCGA primary prostate cancer and the SU2C/PCF metastatic CRPC cohort. The authors examined MCL1 copy number gains and amplifications across different disease stages, assessed their association with clinical outcomes including progression-free interval, and analyzed the genomic landscape of chromosome 1q21 where MCL1 is located.","['TCGA', 'SU2C/PCF']","['Web-based analysis', 'Web-based visualization']","['MCL1', 'AR']","['Survival analysis', 'Expression analysis', 'Query interface']",Mixed,medium,4.0,41062500,"Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer.",2025,pdf,2025-12-19T04:08:41.793724,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Pan-cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the abstract or introduction. The study used TCGA, GTEx, TIMER 2.0, and GEPIA2 databases for pan-cancer analysis of CD90, examining expression differences, patient prognosis, mutation frequency, and immune cell infiltration. While cBioPortal is cited, there is no clear description of how it was specifically used in the methodology based on the provided text.","['TCGA-KIRP', 'TCGA-UVM']",['Citation only'],['CD90'],['Not specified'],Unclear,low,4.0,41042271,"Prognostic, mutational, and immunologic analysis of CD90 in pan-cancer and validation of DHDK as a drug candidate.",2025,abstract,2025-12-19T04:08:41.863983,,,,
"['Survival analysis', 'Multi-omics integration']",['Pan-cancer'],"['Methods/Tools development', 'Database/Resource']","['Methods/Software', 'Original research']","['TCGA', 'Multiple sources']","SurvBoard is a benchmarking framework for multi-omics cancer survival models that uses data from multiple sources including TCGA. While the abstract and introduction do not explicitly detail cBioPortal usage, given that this is a multi-omics benchmarking study using TCGA data and cBioPortal is cited, it is likely that cBioPortal was used as one of the data sources for downloading standardized cancer genomics data. The paper focuses on developing a standardized framework for evaluating survival prediction models across different cancer types and omics modalities.",['TCGA'],['Data download/export'],[],['Download data'],External (downloaded data),medium,4.0,41031875,SurvBoard: standardized benchmarking for multi-omics cancer survival models.,2025,abstract,2025-12-19T04:08:42.530733,,,,
"['Gene expression analysis', 'Survival analysis', 'Copy number analysis']",['Other solid tumor'],['Biomarker discovery'],"['Original research', 'Clinical study']","['TCGA', 'Custom/Private data']",The study retrieved RNA-sequencing data from the TCGA-HNSC cohort to validate the correlated expression of CDC20 and UBCH10 genes observed in their prospective Eastern-Indian patient cohort. The TCGA data was used to perform gene expression correlation analysis and validate cellular ploidy status in silico. The study appears to have downloaded TCGA data for external analysis rather than using cBioPortal's web-based analysis tools directly.,['TCGA-HNSC'],['Data download/export'],"['CDC20', 'UBCH10']",['Not specified'],External (downloaded data),medium,4.0,41029491,A signature of correlated CDC20 and UBCH10 expression indicates poor prognosis in primary head and neck squamous cell carcinoma.,2025,abstract,2025-12-19T04:08:43.483220,,,,
"['Multi-omics integration', 'Gene expression analysis', 'Copy number analysis']","['Glioma/Brain cancer', 'Pan-cancer']",['Methods/Tools development'],"['Methods/Software', 'Original research']","['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, cBioPortal is mentioned in the context of TCGA data sources. The paper describes MOADE, a new multimodal autoencoder method for deconvoluting bulk multi-omics data. While TCGA data is referenced as a major cancer genomics initiative, the specific usage of cBioPortal in this study is not explicitly detailed in the provided text. The paper appears to focus on methodological development using multi-omics data from various sources including TCGA.",['TCGA'],['Citation only'],[],['Not specified'],Unclear,low,4.0,41029754,MOADE: a multimodal autoencoder for dissociating bulk multi-omics data.,2025,pdf,2025-12-19T04:08:44.546232,,,,
"['Gene expression analysis', 'Other']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']","['TCGA', 'Custom/Private data']","The study used TCGA data to compare GLRX2 gene expression patterns in bladder cancer. The authors validated their experimental findings of GLRX2 expression in tumor tissues and invasive tumors by confirming these patterns with TCGA data available through cBioPortal. Additionally, DepMap analysis was performed to identify GLRX2 as a potential therapeutic target for personalized treatment of UBC patients.",['TCGA'],"['Web-based analysis', 'Data download/export']",['GLRX2'],['Expression analysis'],"[""Mixed""]",medium,4.0,41028098,GLRX2 polymorphism and oxidative stress levels impact urothelial bladder cancer outcomes.,2025,pdf,2025-12-19T04:08:44.597988,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['Multiple sources'],"The cBioPortal database was used to analyze mutational and copy number variation (CNV) data from 237 osteosarcoma samples. The analysis revealed minimal mutations in CXCR1 and CXCR2, with no alterations in CXCR3, CXCR4, CXCR5, and CXCR7. CNV analysis showed some level of amplification in CXCR1 and CXCR2, but no significant alterations in the copy numbers of the other CXCR family genes.",[],['Data download/export'],"['CXCR1', 'CXCR2', 'CXCR3', 'CXCR4', 'CXCR5', 'CXCR7']",['Download data'],External (downloaded data),high,4.0,41024311,"C-X-C chemokine receptor family genes in osteosarcoma: expression profiles, regulatory networks, and functional impact on tumor progression.",2025,pdf,2025-12-19T04:08:45.929175,,,,
['Other'],['Not specified'],['Other'],['Original research'],['Not specified'],"This paper focuses on the structural and evolutionary analysis of Argonaute proteins across diverse lineages. The study integrates structural, sequence, phylogenetic, and disease-related mutational data to understand Argonaute evolution. There is no clear indication in the abstract or introduction that cBioPortal was actually used for any analysis; the paper appears to be primarily focused on protein structure and evolution rather than cancer genomics.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41020504,Structural and evolutionary determinants of Argonaute function.,2025,abstract,2025-12-19T04:08:47.735229,,,,
['Other'],['Pan-cancer'],"['Precision medicine', 'Methods/Tools development']",['Original research'],['Not specified'],"Based on the abstract, this paper evaluates AI chatbots' ability to interpret molecular data for precision oncology treatment decisions using 50 patient scenarios with clinical and molecular data. The paper does not explicitly describe how cBioPortal was used in the study. It appears cBioPortal may have been cited as a reference resource or potentially used to obtain molecular data for the patient scenarios, but the specific usage is not clear from the provided abstract.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,41014149,Chatbot assistance in precision oncology treatment decision-making.,2025,abstract,2025-12-19T04:08:48.071784,,,,
"['Mutation analysis', 'Gene expression analysis', 'Multi-omics integration']",['Other solid tumor'],['Biomarker discovery'],['Original research'],['Custom/Private data'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on analyzing FABP3 methylation as a biomarker for thyroid nodules using Methylation 850K array, RNA-Sequencing, and mass spectrometry on their own collected tissue samples. The study appears to be entirely based on custom/private data from their patient cohorts without reference to cBioPortal data or tools.",[],['Citation only'],"['FABP3', 'BRAF']",['Not specified'],Unclear,low,4.0,41019337,<i>FABP3</i> methylation as a novel biomarker for the differentiation and classification of benign and malignant thyroid nodules.,2025,pdf,2025-12-19T04:08:48.218863,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Immunotherapy', 'Tumor evolution', 'Methods/Tools development']",['Original research'],"['TCGA', 'Multiple sources']","The paper analyzed exomes and matched transcriptomes from human tumors and healthy tissues to quantify nonsense-mediated mRNA decay (NMD) efficiency. The study examined how somatic copy number alterations and germline variants affect NMD efficiency, and investigated associations with cancer patient survival and immunotherapy responses. While cBioPortal is cited in the references, the specific usage details are not explicitly described in the provided abstract and introduction sections.",['TCGA'],['Citation only'],"['SMG5', 'SMG7', 'PMF1', 'GON4L', 'KDM6B', 'UPF1']",['Not specified'],Unclear,low,4.0,41023738,"Variable efficiency of nonsense-mediated mRNA decay across human tissues, tumors and individuals.",2025,pdf,2025-12-19T04:08:49.618291,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Copy number analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to retrieve single nucleotide variant (SNV) data for multiple cancer types and methylation data from HM27 and HM450 arrays. The data was obtained from the Cancer Genomics Portal (cBioPortal) as part of a comprehensive pan-cancer analysis of STX7 expression, mutation patterns, and clinical associations across 33 cancer types.",[],['Data download/export'],['STX7'],['Download data'],External (downloaded data),high,4.0,40999361,Syntaxin-7 promotes EMT and tumor progression via NF-κB signaling and is associated with macrophage infiltration: pan-cancer analysis and experimental validation in hepatocellular carcinoma.,2025,pdf,2025-12-19T04:08:51.458612,,,,
"['Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the methods or results. The study used TCGA data for integrative analysis of transcriptomic profiles, protein expression data, and somatic copy number alterations, but the specific platform or method for accessing this data is not stated. Other tools mentioned include TNMplot, The Human Protein Atlas, SRplot for GO enrichment, and GEO datasets for survival analysis, but cBioPortal is not explicitly referenced.",['TCGA'],['Citation only'],['SSTR2'],['Not specified'],Unclear,low,4.0,41002582,Somatostatin Receptor 2 Overexpression in Hepatocellular Carcinoma: Implications for Cancer Biology and Therapeutic Applications.,2025,abstract,2025-12-19T04:08:52.069026,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Colorectal cancer'],"['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used as one of multiple bioinformatics tools to analyze TIMP3 in colorectal cancer. The platform was likely used to investigate genetic alterations and potentially expression patterns of TIMP3 in CRC patients. However, the abstract does not provide specific details about which features of cBioPortal were utilized or what specific analyses were performed using this platform.",[],['Web-based analysis'],['TIMP3'],['Not specified'],Unclear,medium,4.0,41009435,An Integrative Bioinformatics Approach to Investigating TIMP3 and Immune Cell Infiltration: Prognostic and Clinicopathological Implications.,2025,abstract,2025-12-19T04:08:52.476073,,,,
"['Gene expression analysis', 'Survival analysis']",['Breast cancer'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']","['TCGA', 'Custom/Private data']","The Cancer Genome Atlas (TCGA) data were used for validation purposes in this study of young women with ER-positive, HER2-negative breast cancer. The study primarily analyzed a retrospective cohort from a single institution using PAM50/Prosigna genomic testing, with TCGA data serving as an external validation dataset. The specific manner in which cBioPortal was accessed or utilized is not explicitly detailed in the abstract.",['TCGA'],['Citation only'],[],['Not specified'],Unclear,low,4.0,40997745,"Genomic and clinical features in young women with estrogen receptor-positive, HER2-negative breast cancer.",2025,abstract,2025-12-19T04:08:53.734496,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],['TCGA'],"The paper does not explicitly describe using cBioPortal in the methodology. While the study analyzes TCGA ovarian cancer data and performs comprehensive bioinformatic analyses including gene expression profiling, survival analysis, and immune landscape characterization, there is no clear mention of cBioPortal being used for data acquisition, analysis, or visualization in the provided abstract and introduction sections. cBioPortal may only be cited as a reference or potential data source.",['TCGA'],['Citation only'],['CRHR1'],['Not specified'],Unclear,low,4.0,40998924,Lysosome-related molecular subtypes reveal prognostic signatures and immunotherapeutic implications in ovarian cancer.,2025,pdf,2025-12-19T04:08:54.321543,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Immunotherapy', 'Biomarker discovery']",['Original research'],['TCGA'],"cBioPortal was used to access demographic and pathologic data for 543 endometrial cancer patients from TCGA. The authors specifically mention that demographic and pathologic data are available from https://www.cbioportal.org/. The γδ T cell repertoire data was obtained from a separate source (https://gdt.moffitt.org/), but patient clinical information was retrieved from cBioPortal.",['TCGA'],['Data download/export'],[],['Download data'],External (downloaded data),high,4.0,41021035,The protective role of γδ T cells in endometrial cancer.,2025,pdf,2025-12-19T04:08:54.788919,,,,
['Gene expression analysis'],['Glioma/Brain cancer'],"['Drug response/resistance', 'Biomarker discovery']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal being used in this study. The paper describes a preclinical evaluation using patient-derived GBM cells and a phase 0/1 clinical trial, with gene expression changes observed (CDKN2A/N2B, CDK4), but does not reference cBioPortal as a data source or analysis tool. If cBioPortal is cited, it appears to be a citation only without clear usage details in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40994426,Preclinical Evaluation of the Efficacy of a Cyclin-dependent Kinase Inhibitor Ribociclib in Combination with Letrozole Against Patient-Derived Glioblastoma Cells.,2025,abstract,2025-12-19T04:08:55.352756,,,,
"['Mutation analysis', 'Copy number analysis', 'Survival analysis']",['Glioma/Brain cancer'],"['Precision medicine', 'Biomarker discovery']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper describes a retrospective analysis of pediatric brain tumors using pathology review, immunohistochemistry, and brain tumor-targeted next-generation sequencing for reclassification according to WHO CNS5 criteria. The study appears to use custom institutional data from patients diagnosed between 1997 and 2023, with no clear indication that cBioPortal was used for data access, analysis, or visualization.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40980447,Revisiting pediatric HGGs and PNETs according to the WHO CNS5 criteria: A clinical and genomic retrospective analysis.,2025,abstract,2025-12-19T04:08:58.142723,,,,
"['Mutation analysis', 'Other']",['Pan-cancer'],"['Review/Commentary', 'Biomarker discovery', 'Precision medicine']",['Review'],['Not specified'],"This is a review paper on circulating tumor DNA (ctDNA) analysis in cancer management. cBioPortal is likely cited as a reference resource or database in the context of cancer genomics and molecular profiling, but no specific usage of the platform for data analysis or visualization is described in the abstract or introduction provided.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40977813,Circulating tumor DNA in patients with cancer: insights from clinical laboratory.,2025,abstract,2025-12-19T04:08:58.302282,,,,
"['Mutation analysis', 'Pathway analysis']","['Pan-cancer', 'Lung cancer', 'Colorectal cancer', 'Melanoma', 'Other solid tumor']","['Drug response/resistance', 'Review/Commentary', 'Precision medicine']",['Review'],['Not specified'],"This is a comprehensive review article on the evolution of direct RAS inhibitors and their clinical development. While the paper discusses RAS mutations across multiple cancer types and mentions mutation frequencies, there is no explicit description of cBioPortal usage in the provided abstract and introduction. The paper appears to cite cBioPortal as a reference but does not describe specific analyses or data queries performed using the platform.",[],['Citation only'],"['KRAS', 'NRAS', 'HRAS']",['Not specified'],Unclear,low,4.0,40993828,Evolution of direct RAS inhibitors: from undruggable target to clinical breakthroughs.,2025,pdf,2025-12-19T04:08:58.852069,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']","['Pan-cancer', 'Bladder cancer', 'Kidney cancer', 'Colorectal cancer', 'Thyroid cancer', 'Gastric cancer', 'Liver cancer']","['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to examine mutation profiles of PRKD1 across multiple cancer types. The study mentions using cBioPortal for mutation analysis as part of a comprehensive bioinformatics approach that also included other databases like TIMER, GEPIA, and UALCAN for expression analysis and Kaplan-Meier plotter for survival analysis. The specific details of how cBioPortal was used are not elaborated in the provided text.",[],['Web-based analysis'],['PRKD1'],['Not specified'],Unclear,medium,4.0,40984898,"Protein Kinase D1 (PRKD1) as a Diagnostic, Prognostic, and Immunomodulatory Biomarker in Human Cancers.",2025,pdf,2025-12-19T04:08:59.934255,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration', 'Pathway analysis']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the methods or results. While TCGA data was used (GBMLGG cohort downloaded from UCSC Xena browser), there is no clear indication that cBioPortal was accessed for data retrieval, analysis, or visualization. The citation to cBioPortal may be a general reference rather than indicating actual usage in this study.","['TCGA GBMLGG', 'CGGA mRNAseq-325', 'GSE72951', 'GSE79671', 'GSE81465', 'GSE103224', 'GSE74529']",['Citation only'],"['COL4A2', 'JMJD6', 'ITGA1', 'ITGB1', 'VEGF']",['Not specified'],Unclear,low,4.0,40993804,JMJD6-driven epigenetic activation of COL4A2 reprograms glioblastoma vascularization via integrin α1β1-dependent PI3K/MAPK signaling.,2025,pdf,2025-12-19T04:09:00.347913,,,,
"['Mutation analysis', 'Pathway analysis']",['Pan-cancer'],"['Drug response/resistance', 'Precision medicine', 'Biomarker discovery']",['Original research'],['Multiple sources'],"The paper used the COSMIC database v100 as the primary source for identifying 298 rare K/N/HRAS variants for functional analysis. While cBioPortal is cited, the abstract and introduction do not explicitly describe how cBioPortal was used in this study. The main focus was on experimental functional validation using 3T3 cell assays and drug sensitivity testing rather than bioinformatic analysis through cBioPortal.",[],['Citation only'],"['KRAS', 'NRAS', 'HRAS']",['Not specified'],Unclear,low,4.0,40970755,Functional Analysis of Rare RAS Variants of Unknown Significance.,2025,abstract,2025-12-19T04:09:00.706992,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],['Biomarker discovery'],"['Original research', 'Clinical study']","['TCGA', 'Custom/Private data']","The study used TCGA data from cBioPortal to validate their immunohistochemistry findings on HSP27 and HSP70 expression in laryngeal squamous cell carcinoma. They analyzed transcriptomic and survival data from 112 LSCC cases in the TCGA cohort, performing Kaplan-Meier and Cox regression analyses to assess the association between HSP expression levels and overall survival outcomes.",['TCGA'],['Data download/export'],"['HSPB1', 'HSPA1A']",['Download data'],External (downloaded data),medium,4.0,40971071,Low expression of HSP27 and HSP70 predicts poor prognosis in laryngeal squamous cell carcinoma.,2025,pdf,2025-12-19T04:09:01.691283,,,,
"['Mutation analysis', 'Other']",['Pan-cancer'],"['Review/Commentary', 'Biomarker discovery', 'Precision medicine']",['Review'],['Not specified'],"This is a review paper in Spanish about circulating tumor DNA (ctDNA) in cancer patients from a clinical laboratory perspective. The paper does not appear to directly use cBioPortal for any analysis or data retrieval. If cBioPortal is mentioned, it would likely be only as a citation or reference to available cancer genomics resources, but no specific usage is described in the provided abstract and introduction.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40977810,[Not Available].,2025,pdf,2025-12-19T04:09:01.822600,,,,
"['Mutation analysis', 'Other']",['Pan-cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine']",['Original research'],['Multiple sources'],"The paper used cBioPortal to analyze mutation frequencies of genes identified in their CRISPR screen across different cancer types. The authors queried cBioPortal to determine the prevalence of mutations in synthetic lethal partners of EXO1, including FA pathway genes, BRCA1-A complex components, and ZRSR2, to identify cancer vulnerabilities that could be therapeutically targeted. This analysis helped establish the clinical relevance of their findings by showing which cancers harbor mutations in genes synthetic lethal with EXO1.",[],['Web-based analysis'],"['EXO1', 'ZRSR2', 'BRCA1', 'FANCG', 'FEN1', 'MRE11A', 'RAD50']",['Query interface'],cBioPortal platform,medium,4.0,41006228,"EXO1 as a therapeutic target for Fanconi Anaemia, ZRSR2 and BRCA1-A complex deficient cancers.",2025,pdf,2025-12-19T04:09:03.547671,,,,
"['Gene expression analysis', 'Survival analysis']",['Breast cancer'],['Biomarker discovery'],['Original research'],['TCGA'],"The study used TCGA data to analyze MARCKS expression in breast cancer. The analysis revealed that high MARCKS expression significantly correlates with ER negativity through multivariate analysis, suggesting its potential role as a prognostic indicator in aggressive breast cancer subtypes. The specific platform used for accessing TCGA data (whether cBioPortal or other sources) is not explicitly stated in the abstract.",['TCGA'],['Citation only'],"['HER2', 'MARCKS']",['Not specified'],Unclear,low,4.0,40940979,HER2 Interactome Profiling Reveals MARCKS as a Candidate Marker Associated with Aggressive Breast Cancer.,2025,abstract,2025-12-19T04:09:04.252656,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis']",['Breast cancer'],"['Drug response/resistance', 'Immunotherapy', 'Review/Commentary']",['Review'],['Not specified'],"This is a review paper on immunotherapy resistance in triple-negative breast cancer (TNBC). While cBioPortal is cited in the references, the paper does not explicitly describe any direct usage of cBioPortal for data analysis, visualization, or data download. The paper focuses on summarizing molecular mechanisms, tumor microenvironment, and therapeutic implications of immunotherapy resistance in TNBC.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40936705,"Immunotherapy resistance in triple-negative breast cancer: Molecular mechanisms, tumor microenvironment, and therapeutic implications.",2025,pdf,2025-12-19T04:09:05.391021,,,,
"['Mutation analysis', 'Survival analysis', 'Pathway analysis']",['Colorectal cancer'],"['Methods/Tools development', 'Precision medicine', 'Pathway analysis', 'Biomarker discovery']","['Original research', 'Methods/Software']","['TCGA', 'MSK-IMPACT', 'GENIE', 'Multiple sources']","AI-HOPE-TP53 integrates harmonized datasets from cBioPortal including TCGA, MSK-IMPACT, and AACR Project GENIE for analysis of TP53 pathway alterations in early-onset colorectal cancer. The platform uses these cBioPortal datasets to perform mutation profiling, Kaplan-Meier survival analysis, and odds ratio estimation across clinical and demographic subgroups. The data from cBioPortal was integrated into a conversational AI system that translates natural language queries into analytical workflows.","['TCGA', 'MSK-IMPACT', 'AACR Project GENIE']","['Data download/export', 'API access']",['TP53'],['Download data'],External (downloaded data),high,4.0,40940961,AI-HOPE-TP53: A Conversational Artificial Intelligence Agent for Pathway-Centric Analysis of TP53-Driven Molecular Alterations in Early-Onset Colorectal Cancer.,2025,abstract,2025-12-19T04:09:05.599099,,,,
"['Gene expression analysis', 'Survival analysis']",['Lung cancer'],['Biomarker discovery'],['Original research'],"['TCGA', 'Multiple sources']","The study used public datasets including The Cancer Genome Atlas (TCGA) to evaluate the clinical relevance of LRP11 expression in lung adenocarcinoma patients. The authors assessed LRP11 expression levels and their association with patient prognosis using TCGA data, though the specific method of data access (whether through cBioPortal or direct TCGA access) is not explicitly stated in the abstract.",['TCGA'],['Citation only'],['LRP11'],['Not specified'],"[""Unclear""]",low,4.0,40930994,Low-Density Lipoprotein Receptor-Related Protein 11 Promotes Proliferation in Lung Adenocarcinoma.,2025,abstract,2025-12-19T04:09:06.325640,,,,
['Gene expression analysis'],"['Colorectal cancer', 'Prostate cancer']","['Biomarker discovery', 'Other']",['Original research'],['Not specified'],The paper does not provide clear evidence of direct cBioPortal usage. The study focuses on experimental laboratory work examining CAVII expression in cancer cell lines under hypoxic conditions and homologous CAH genes in C. elegans. cBioPortal appears to be cited only as a reference without specific details about how it was used for data retrieval or analysis.,[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40917301,"Different hypoxic response of human <i>CAVII</i> and <i>Caenorhabditis elegans</i> homologous genes <i>CAH-3, CAH-4, CAH-5</i>.",2025,abstract,2025-12-19T04:09:07.013047,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the abstract or introduction provided. While the study uses TCGA data and other genomic datasets (GSE76019, GSE76021) for analyzing adrenocortical carcinoma, there is no clear indication that cBioPortal was used for data access, analysis, or visualization. The citation of cBioPortal may be for reference purposes only or the usage details may be in the methods section not provided.","['TCGA', 'GSE76019', 'GSE76021']",['Citation only'],"['DHCR7', 'PD-1', 'PD-L1', 'PD-L2', 'CTLA4']",['Not specified'],Unclear,low,4.0,40968257,Multi-modal characterization of metabolic and immune gene clusters in adrenocortical carcinoma treatment.,2025,pdf,2025-12-19T04:09:07.701088,,,,
"['Mutation analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']","['TCGA', 'Custom/Private data']","The study compared the mutational frequencies of gastric cancer driver genes in Puerto Rican Hispanics (PRH) to TCGA data, which appears to have been accessed through cBioPortal for comparative analysis. The authors used TCGA as a reference cohort (majority non-Hispanic) to benchmark the mutation frequencies observed in their PRH cohort. The specific mode of cBioPortal usage (web-based query, data download, or API) is not explicitly detailed in the abstract.",['TCGA'],['Citation only'],"['TP53', 'CDH1', 'ARID1A', 'KMT2D', 'CBLB', 'MYH11']",['Not specified'],Unclear,low,4.0,40926327,Actionable Genes and Carcinogenic Pathways for Gastric Cancer in Latinos.,2025,abstract,2025-12-19T04:09:07.852387,,,,
"['Gene expression analysis', 'Survival analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],The authors analyzed the Cancer Genome Atlas (TCGA) data to evaluate WNT2B expression in human colon cancer samples compared to healthy controls. They found that WNT2B expression was downregulated in human CRC samples and that this downregulation predicted significantly lower patient survival. The analysis appears to have used TCGA data accessed through cBioPortal or similar resources to perform expression and survival analyses.,['TCGA'],"['Web-based analysis', 'Web-based visualization']",['WNT2B'],"['Expression analysis', 'Survival analysis']","[""Unclear""]","[""medium""]",4.0,40909730,Loss of WNT2B Increases Progression from Dysplasia to Colorectal Cancer.,2025,abstract,2025-12-19T04:09:07.914810,,,,
['Gene expression analysis'],"['Lung cancer', 'Other solid tumor']","['Review/Commentary', 'Biomarker discovery', 'Drug response/resistance']",['Review'],['Not specified'],"This is a review article about SEZ6 as a therapeutic target in neuroendocrine carcinomas, particularly small cell lung cancer (SCLC). The paper does not explicitly describe using cBioPortal for any analysis. If cBioPortal is mentioned, it appears to be only as a citation or reference to existing data rather than active use by the authors for this review.",[],['Citation only'],"['SEZ6', 'ASCL1']",['Not specified'],"[""Unclear""]","[""low""]",4.0,40911432,Seizure-Related Homolog Protein 6 (SEZ6): Biology and Therapeutic Target in Neuroendocrine Carcinomas.,2025,abstract,2025-12-19T04:09:08.516796,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration', 'Copy number analysis', 'Mutation analysis']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper used cBioPortal to analyze genomic alterations and expression patterns of PPIH across multiple cancer types. The study integrated multi-omics data including mutation, copy number, and expression data to assess PPIH's prognostic relevance and associations with the tumor microenvironment. cBioPortal served as one of the data sources for comprehensive pan-cancer analysis of PPIH.",[],"['Data download/export', 'Web-based analysis']",['PPIH'],"['Expression analysis', 'Download data']",Mixed,medium,4.0,40895540,eQTL and multi-omics integration reveal PPIH as a prognostic and immunotherapeutic biomarker.,2025,abstract,2025-12-19T04:09:10.988468,,,,
['Gene expression analysis'],"['Lung cancer', 'Breast cancer']",['Other'],['Original research'],['Not specified'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on investigating how iron levels modulate lipid peroxidation and ferroptosis in FLASH radiotherapy, using cell lines (A549 and MDA-MB-231) and mouse models. The methods section shows molecular biology techniques (siRNA transfection, qRT-PCR) but does not reference cBioPortal for data analysis or visualization.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40897687,Tissue-specific iron levels modulate lipid peroxidation and the FLASH radiotherapy effect.,2025,pdf,2025-12-19T04:09:11.021876,,,,
"['Copy number analysis', 'Gene expression analysis']",['Melanoma'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['Not specified'],"The paper does not explicitly describe how cBioPortal was used in the study. While the research focuses on LZTR1 amplification in acral melanomas and its oncogenic functions, there is no clear mention of cBioPortal usage in the provided abstract and introduction sections. The authors may have used cBioPortal for preliminary data mining or validation, but specific usage details are not provided in the excerpted text.",[],['Citation only'],"['LZTR1', 'BRAF', 'NRAS']",['Not specified'],Unclear,low,4.0,40885854,LZTR1 is a melanoma oncogene that promotes invasion and suppresses apoptosis.,2025,pdf,2025-12-19T04:09:11.837840,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Lung cancer'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'MSK-IMPACT', 'Multiple sources']","The authors retrieved mutational and clinical information from the cBioPortal database for the MSKCC-NSCLC dataset (350 samples) and TCGA-NSCLC dataset (997 samples). They downloaded processed mutational, gene expression, and clinical data from cBioPortal to analyze the correlation between MED12 mutations and survival, clinical outcomes, genomic features, and immune infiltration in NSCLC patients receiving immunotherapy.","['MSKCC-NSCLC', 'TCGA-NSCLC']",['Data download/export'],"['MED12', 'STAT1', 'TAP2', 'TP53', 'KRAS', 'EPHA5', 'PTPRD', 'PTPRT']",['Download data'],External (downloaded data),high,4.0,40888963,MED12-STAT1-TAP2 axis regulates CD8 + T cell cytotoxicity and mediates immunotherapy outcome in non-small cell lung cancer.,2025,pdf,2025-12-19T04:09:12.094836,,,,
"['Mutation analysis', 'Gene expression analysis']",['Melanoma'],"['Methods/Tools development', 'Biomarker discovery']","['Original research', 'Methods/Software']",['Not specified'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage. The paper describes the development of a zebrafish-based genetic screening system using Cas9 knocked into the mitfa locus to study melanocyte development and melanoma. cBioPortal may have been cited in the references or used for background data, but specific usage details are not provided in the abstract/introduction.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40879132,Identifying in vivo genetic dependencies of melanocyte and melanoma development.,2025,abstract,2025-12-19T04:09:13.364339,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],['TCGA'],"Based on the abstract and introduction provided, the paper appears to focus on experimental investigation of PI5P4Kα in pancreatic cancer using cell lines and xenograft models. While cBioPortal is cited, the abstract does not provide specific details about how cBioPortal was used. It is likely that cBioPortal was used to query TCGA data for gene expression and/or survival analysis related to PI5P4Kα in pancreatic cancer patients, but the exact usage cannot be determined from the provided text.",['TCGA'],['Citation only'],['PIP4K2A'],['Not specified'],Unclear,low,4.0,40884794,PI5P4Kα promotes glucose and iron acquisition to support metabolic fitness in pancreatic cancer.,2025,abstract,2025-12-19T04:09:13.539347,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],['TCGA'],"The paper does not explicitly describe using cBioPortal in the methods or results sections provided. While cBioPortal may be cited as a reference or potential data source, the abstract and introduction do not contain specific details about how cBioPortal was utilized for data access, analysis, or visualization. The study focuses on analyzing cuproptosis-related genes, particularly CDKN2A, in hepatocellular carcinoma using bioinformatics approaches, but the specific role of cBioPortal is not clarified in the provided text.",[],['Citation only'],['CDKN2A'],['Not specified'],Unclear,low,4.0,40884619,Systematic analysis identifies CDKN2A as a prognostic biomarker for hepatocellular carcinoma.,2025,pdf,2025-12-19T04:09:13.888330,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The study analyzed RNA-Seq data from the Oncology Research Information Exchange Network (ORIEN) alliance for Stages II and III colorectal cancer patients. If cBioPortal was used, it may have been cited as a reference or used for validation purposes, but this is not evident from the provided text.",[],['Citation only'],"['HRAS', 'KRAS', 'NRAS']",['Not specified'],Unclear,low,4.0,40879062,Proto-Oncogene HRAS Transcript Level and Overall Survival in Stages II and III Colorectal Cancer.,2025,abstract,2025-12-19T04:09:13.906070,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper mentions using TCGA-ESCA data for survival associations evaluation using UALCAN, not cBioPortal. While TCGA data was used in the study, there is no explicit mention of cBioPortal being used for data access, analysis, or visualization. The citation of cBioPortal appears to be a general reference rather than indicating actual usage in this study.",['TCGA-ESCA'],['Citation only'],"['SCARB1', 'SERPINH1', 'DSC2', 'COL1A1', 'SPARC', 'MMP1']",['Not specified'],Unclear,low,4.0,40872572,Evaluating Potential Therapeutic Targets and Drug Repurposing Based on the Esophageal Cancer Subtypes.,2025,abstract,2025-12-19T04:09:14.830039,,,,
"['Gene expression analysis', 'Mutation analysis', 'Survival analysis', 'Pathway analysis']",['Lung cancer'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],['Multiple sources'],"Based on the abstract and introduction provided, cBioPortal is not explicitly mentioned in the text. The study focuses on PTTG family genes in lung adenocarcinoma using clinical samples, cell lines, and various bioinformatics analyses including expression, methylation, mutation, and molecular docking studies. Without explicit mention of cBioPortal in the provided sections, the usage remains unclear, though the paper may cite it as a reference or data source in sections not provided.",[],['Citation only'],"['PTTG1', 'PTTG2', 'PTTG3P']",['Not specified'],Unclear,low,4.0,40877987,"Decoding the PTTG family's contribution to LUAD pathogenesis: a comprehensive study on expression, epigenetics, and therapeutic interventions.",2025,pdf,2025-12-19T04:09:15.380879,,,,
"['Gene expression analysis', 'Survival analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],"Based on the abstract and introduction provided, the paper appears to use cBioPortal to analyze SALL2 expression levels and their correlation with patient survival in colorectal cancer. The study examined the association between reduced SALL2 expression and poorer overall patient survival, likely using TCGA colorectal cancer datasets available through cBioPortal. The platform was likely used for gene expression analysis and survival analysis to establish SALL2 as a potential prognostic biomarker.",['TCGA'],"['Web-based analysis', 'Web-based visualization']","['SALL2', 'AXIN2']","['Expression analysis', 'Survival analysis']",Unclear,medium,4.0,40869218,<i>SALL2</i>-Mediated Suppression of WNT Signaling Through Transcriptional Control of <i>AXIN2</i> in Colorectal Cancer Cells.,2025,abstract,2025-12-19T04:09:17.288065,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis', 'Review/Commentary']",['Review'],['Not specified'],"This is a review paper summarizing the role of Pyk2 kinase in glioblastoma progression and therapeutic targeting. Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage, data queries, or specific analyses performed using the platform. The paper appears to cite cBioPortal in references but does not describe specific usage details.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40867240,The Role of Pyk2 Kinase in Glioblastoma Progression and Therapeutic Targeting.,2025,abstract,2025-12-19T04:09:17.680336,,,,
"['Mutation analysis', 'Survival analysis', 'Multi-omics integration']",['Colorectal cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine', 'Methods/Tools development']","['Original research', 'Methods/Software']",['Multiple sources'],"AI-HOPE-RTK-RAS operates on harmonized multi-dimensional datasets obtained from cBioPortal, integrating clinical, genomic, and demographic data for colorectal cancer cohorts. The system uses cBioPortal data as its backend data source to enable real-time, dialogue-driven analysis of RTK-RAS pathway alterations, including mutation frequency profiling, survival modeling, and stratified analyses. The platform appears to download and integrate cBioPortal data into its custom analytics pipeline rather than using cBioPortal's web interface directly.",[],"['Data download/export', 'API access']","['KRAS', 'NRAS', 'BRAF', 'EGFR', 'CBL', 'MAPK3', 'NF1']",['Download data'],External (downloaded data),high,4.0,40868090,Precision Oncology Through Dialogue: AI-HOPE-RTK-RAS Integrates Clinical and Genomic Insights into RTK-RAS Alterations in Colorectal Cancer.,2025,abstract,2025-12-19T04:09:17.759969,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Colorectal cancer'],"['Drug response/resistance', 'Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],"The authors used cBioPortal to analyze mutation frequencies and prognostic significance of genes in colorectal cancer, specifically identifying TP53 and KRAS as the second and third most frequently mutated genes. They also performed transcriptomic analyses to examine gene expression patterns associated with wild-type TP53 and mutant KRAS in relation to ferroptosis susceptibility. The platform was used to access TCGA colorectal cancer data for mutation analysis and gene expression profiling.",['TCGA'],"['Web-based analysis', 'Web-based visualization']","['TP53', 'KRAS']","['Mutation Mapper', 'Expression analysis', 'Query interface']","[""Mixed""]",medium,4.0,40867923,Using Integrated Bioinformatics Analysis to Identify Saponin Formosanin C as a Ferroptosis Inducer in Colorectal Cancer with p53 and Oncogenic KRAS.,2025,abstract,2025-12-19T04:09:19.206721,,,,
"['Gene expression analysis', 'Pathway analysis', 'Other']",['Pan-cancer'],"['Biomarker discovery', 'Review/Commentary']",['Review'],['Not specified'],"This is a narrative review and in silico analysis focused on the lncRNA LINC01133 in various cancer types. The paper does not provide explicit details about cBioPortal usage in the abstract or introduction. Given the nature of the study as a review with in silico structural analysis of LINC01133, cBioPortal may have been cited as a reference or used for general data queries, but specific usage details are not described in the provided text.",[],['Citation only'],['LINC01133'],['Not specified'],Unclear,low,4.0,40863724,"The Good, the Bad, or Both? Unveiling the Molecular Functions of LINC01133 in Tumors.",2025,abstract,2025-12-19T04:09:20.033737,,,,
"['Mutation analysis', 'Survival analysis', 'Pathway analysis']",['Colorectal cancer'],"['Pathway analysis', 'Precision medicine', 'Methods/Tools development']","['Methods/Software', 'Original research']",['Multiple sources'],"AI-HOPE-WNT integrates harmonized data from cBioPortal as its backend data source to enable natural language-driven analysis of WNT pathway dysregulation in colorectal cancer. The platform interfaces with cBioPortal data to perform mutation frequency analysis, odds ratio testing, survival modeling, and subgroup stratification across genomic, clinical, and demographic variables. The tool was validated by recapitulating findings from previous studies and conducting exploratory analyses of WNT pathway genes including APC, RNF43, AXIN1, and AXIN2.",[],"['Data download/export', 'API access']","['APC', 'RNF43', 'AXIN1', 'AXIN2']",['Download data'],External (downloaded data),high,4.0,40860720,Conversational AI agent for precision oncology: AI-HOPE-WNT integrates clinical and genomic data to investigate WNT pathway dysregulation in colorectal cancer.,2025,abstract,2025-12-19T04:09:20.080993,,,,
"['Copy number analysis', 'Gene expression analysis', 'Multi-omics integration', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine']",['Original research'],"['TCGA', 'METABRIC', 'Custom/Private data', 'Multiple sources']","The paper used cBioPortal to access and analyze genomic and clinical data from TCGA and METABRIC breast cancer cohorts. The authors examined NF1 copy number status, gene expression patterns, and their associations with clinical outcomes in ER+/HER2- breast cancers. cBioPortal served as a data source for validating their findings about NF1 status and CDK4/6 pathway activity across large patient cohorts.","['TCGA', 'METABRIC']","['Data download/export', 'Web-based analysis']","['NF1', 'CCND1']","['Query interface', 'Download data', 'Expression analysis']","[""Mixed""]",medium,4.0,40864686,NF1-depleted ER<sup>+</sup> breast cancers are differentially sensitive to CDK4/6 inhibitors.,2025,abstract,2025-12-19T04:09:20.182309,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'METABRIC', 'Multiple sources']","The paper does not explicitly mention using cBioPortal. The authors analyzed TCGA breast cancer RNA-seq data and METABRIC cohort data using Gene Set Enrichment Analysis (GSEA) to examine hypoxia and ribosome biogenesis signatures. While these datasets are available through cBioPortal, there is no direct citation or mention of cBioPortal being used for data access or analysis in the provided text.","['TCGA-BRCA', 'METABRIC', 'GSE202203']",['Citation only'],['HIF1A'],['Not specified'],Unclear,low,4.0,40866413,Hypoxic stress incites HIF1α-driven ribosome biogenesis that can be exploited by targeting RNA Polymerase I.,2025,pdf,2025-12-19T04:09:20.568633,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction, the paper does not explicitly mention cBioPortal usage. The study utilized TCGA and GEO datasets to analyze ferroptosis- and cuproptosis-related genes in hepatocellular carcinoma. While cBioPortal is cited, there is no clear description of how it was used for data access, analysis, or visualization in the provided text.",['TCGA'],['Citation only'],"['SLC1A5', 'SLC7A11', 'CBS', 'GABARAPL1', 'FLT3', 'MT3', 'ADM', 'CDKN2A', 'GLS']",['Not specified'],Unclear,low,4.0,40860678,Analysis of novel therapeutic targets and construction of a prognostic model for hepatocellular carcinoma.,2025,abstract,2025-12-19T04:09:21.269503,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis']",['Lung cancer'],['Biomarker discovery'],['Original research'],['Multiple sources'],"cBioPortal was used to perform mutational and copy number variation analyses of cadherin genes (CDH1, CDH2, and CDH3) in NSCLC. The study identified frequent alterations in these genes through cBioPortal's analysis capabilities. The platform was used alongside other databases (Human Protein Atlas, Kaplan-Meier database) to comprehensively characterize cadherin gene dysregulation in NSCLC.",[],['Web-based analysis'],"['CDH1', 'CDH2', 'CDH3']",['Not specified'],Unclear,medium,4.0,40860670,Prognostic role and functional impact of cadherin genes in non-small cell lung cancer tumorigenesis: mechanistic insights from <i>in silico</i> and <i>in vitro</i> analyses.,2025,abstract,2025-12-19T04:09:22.419582,,,,
"['Mutation analysis', 'Gene expression analysis']",['Other solid tumor'],"['Biomarker discovery', 'Other']",['Original research'],['Multiple sources'],"The authors used cBioPortal to retrieve mutation data for SRCAP and other components of the SRCAP chromatin remodeling complex across multiple cancer types. They analyzed mutation frequencies in keratinocyte carcinomas (particularly cSCC with 176 patients) and pan-cancer data (>91,000 patients) to identify SRCAP as a frequently mutated gene and to discover a mutational hotspot at amino acid positions 1878/1879. The cBioPortal data was used to characterize the distribution and types of SRCAP mutations across different cancer types, particularly focusing on truncating mutations.",[],"['Data download/export', 'Web-based analysis']",['SRCAP'],"['Query interface', 'Download data']",Mixed,high,4.0,40858549,A dominant SRCAP truncating mutation promotes squamous cell carcinoma progression.,2025,pdf,2025-12-19T04:09:24.403541,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']","['Pan-cancer', 'Lung cancer', 'Breast cancer', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the methods or results. The abstract and introduction mention obtaining pan-cancer mRNA expression data from TCGA and GTEx, protein expression from HPA database, and using other tools like STRING, GSCA database, and TCGAplot for various analyses. While cBioPortal is cited, there is no clear description of how it was specifically used in this study.",[],['Citation only'],['TRPM4'],['Not specified'],Unclear,low,4.0,40860345,Comprehensive Insights Into the Role of TRPM4 in Pan-Cancer Progression and Immune Regulation.,2025,pdf,2025-12-19T04:09:24.689822,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Copy number analysis', 'Pathway analysis']",['Pan-cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the methodology or results sections provided. The study utilized other databases including TIMER2, UALCAN, GEPIA2, and Human Protein Atlas for pan-cancer analysis of PTPN6. While cBioPortal is cited, there is no clear description of how it was used for data analysis or visualization in this study.",['TCGA'],['Citation only'],['PTPN6'],['Not specified'],Unclear,low,4.0,40853435,Pan-cancer analysis of PTPN6: prognostic significance and functional implications in tumor progression.,2025,pdf,2025-12-19T04:09:24.965950,,,,
"['Gene expression analysis', 'Pathway analysis', 'Mutation analysis', 'Copy number analysis']",['Breast cancer'],"['Drug response/resistance', 'Biomarker discovery', 'Pathway analysis']",['Original research'],['Multiple sources'],"cBioPortal was used to analyze genetic alterations (mutations and copy number alterations) for selected hub genes (UTGs) identified from the protein-protein interaction network. The analysis was performed across 15 breast cancer studies to validate MDM2, STAT3, TGFB1, and MAPK1 as potential therapeutic targets. The genetic alteration analysis confirmed that MDM2 had the highest alteration frequency among the candidate genes.",[],"['Web-based analysis', 'Web-based visualization']","['MDM2', 'STAT3', 'TGFB1', 'MAPK1']",['Query interface'],cBioPortal platform,high,4.0,40849706,In Silico Analysis Reveals MDM2 as a Potential Target of Ursolic Acid for Overcoming Tamoxifen Resistance in Breast Cancer.,2025,pdf,2025-12-19T04:09:25.625161,,,,
"['Copy number analysis', 'Gene expression analysis', 'Survival analysis']",['Pan-cancer'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],"['TCGA', 'Multiple sources']",The authors used cBioPortal to mine publicly available data to determine the types and prevalence of genetic lesions (copy number alterations) at the B3GNT5 locus across various cancers. They also assessed the impact of increased B3GNT5 expression on patient outcomes using survival analysis. The analysis appears to have been conducted using cBioPortal's web-based tools to query pan-cancer datasets.,[],"['Web-based analysis', 'Web-based visualization']",['B3GNT5'],"['Expression analysis', 'Survival analysis', 'Query interface']",cBioPortal platform,medium,4.0,40847295,Regulation of EMT-MET and chemoresistance by the Lc3Cer-synthase B3GNT5.,2025,pdf,2025-12-19T04:09:26.265010,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],"['TCGA', 'Custom/Private data']","The paper does not provide explicit details about how cBioPortal was used in the study. Based on the abstract and introduction, the study primarily conducted RT-qPCR experiments on OC cell lines and functional assays. While the study likely accessed TCGA data for ovarian cancer analysis, the specific role of cBioPortal in data acquisition or analysis is not clearly described in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40832836,Mechanistic Insights Into the Tumor-Driving and Diagnostic Roles of KCTD Family Genes in Ovarian Cancer: An Integrated In Silico and In Vitro Analysis.,2025,abstract,2025-12-19T04:09:26.584503,,,,
"['Gene expression analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['Not specified'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on experimental validation of CHML function in HCC using CRISPR-Cas9 knockout, transcriptome sequencing, and untargeted metabolomics. cBioPortal may have been cited in the full paper for background information or validation purposes, but no specific usage is described in the provided sections.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40842592,CHML regulates migration and invasion in hepatocellular carcinoma via transcriptional and metabolic reprogramming.,2025,pdf,2025-12-19T04:09:27.187030,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Pan-cancer'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used as one of multiple databases in this comprehensive pan-cancer analysis of CISD1. The platform was utilized to analyze gene mutations and likely other genomic alterations of CISD1 across multiple cancer types. cBioPortal was listed among several bioinformatics tools (TCGA, GTEx, THPA, GEPIA2.0, etc.) used to evaluate CISD1's roles in cancer diagnosis, prognosis, and immunotherapy response.",[],"['Web-based analysis', 'Citation only']",['CISD1'],['Not specified'],Unclear,medium,4.0,40831536,"Exploring CISD1 as a multifaceted biomarker in cancer: Implications for diagnosis, prognosis, and immunotherapeutic response.",2025,abstract,2025-12-19T04:09:27.670156,,,,
"['Mutation analysis', 'Pathway analysis', 'Gene expression analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis', 'Methods/Tools development', 'Precision medicine']","['Original research', 'Methods/Software']",['TCGA'],"The study used cBioPortal to obtain genomic data from TCGA esophageal cancer samples to identify mutations and alterations in oncogenic signaling pathways (mTOR, PTEN, p53, PI3K/AKT). This genomic data was used as ground truth labels to train a deep learning model that predicts pathway deregulation and metastatic potential from H&E-stained histopathology images. The cBioPortal data served as the molecular annotation source for correlating with imaging features.",['TCGA'],['Data download/export'],"['MTOR', 'PTEN', 'TP53', 'PIK3CA', 'AKT1']","['Download data', 'Query interface']",External (downloaded data),medium,4.0,40842012,OncoMet: a deep learning framework for the prediction of oncogenic signaling pathways and metastasis in esophageal cancer patients using histopathology images from primary tumors.,2025,pdf,2025-12-19T04:09:27.861559,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Precision medicine', 'Methods/Tools development']","['Original research', 'Methods/Software']","['TCGA', 'Custom/Private data']","The paper does not explicitly mention using cBioPortal in the abstract or introduction provided. The study developed a deep learning model (LUNAR) to predict glioma recurrence using clinical, mutation, and mRNA-expression data from TCGA and GLASS datasets. While TCGA data is commonly accessed through cBioPortal, no specific mention of cBioPortal usage, data download, or analysis is present in the provided text.","['TCGA', 'GLASS']",['Citation only'],[],['Not specified'],Unclear,low,4.0,40830273,A deep learning model to predict glioma recurrence using integrated genomic and clinical data.,2025,pdf,2025-12-19T04:09:28.678431,,,,
['Gene expression analysis'],['Pan-cancer'],"['Biomarker discovery', 'Other']",['Original research'],['TCGA'],"The authors performed comparative analysis of TCGA datasets from tumor databases to examine expression patterns of CEBPZ, NOC2L and NOC3L across different tumor types. The analysis revealed contrasting expression patterns across tumor types, suggesting context-dependent roles in cancer. The study used cBioPortal to access TCGA data for gene expression analysis across multiple cancer types.",[],['Web-based analysis'],"['CEBPZ', 'NOC2L', 'NOC3L']","['Expression analysis', 'Query interface']",Unclear,medium,4.0,40827841,"Drosophila and human cell studies reveal a conserved role for CEBPZ, NOC2L and NOC3L in rRNA processing and tumorigenesis.",2025,abstract,2025-12-19T04:09:30.462079,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],['Multiple sources'],"cBioPortal was used to examine genetic alterations (mutations, copy number alterations) in EXOSC family genes in HNSC. The analysis revealed that EXOSC4 had the highest genetic alteration frequency (8%), primarily due to amplification. The platform was used to query and analyze genomic alterations across all EXOSC family members (EXOSC1-10).",['TCGA-HNSC'],['Web-based analysis'],"['EXOSC1', 'EXOSC2', 'EXOSC3', 'EXOSC4', 'EXOSC5', 'EXOSC6', 'EXOSC7', 'EXOSC8', 'EXOSC9', 'EXOSC10']",['Query interface'],External (downloaded data),medium,4.0,40830179,Comprehensive bioinformatics analysis of EXOSC family genes in head and neck squamous cell carcinoma.,2025,pdf,2025-12-19T04:09:31.486681,,,,
"['Mutation analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine']","['Original research', 'Clinical study']","['TCGA', 'MSK-IMPACT', 'Custom/Private data', 'Multiple sources']","The paper assembled a multinational cohort of 2,012 bladder cancer patients from multiple sources including TCGA and MSK-IMPACT. TCGA bladder cancer data (412 muscle-invasive, high-grade urothelial tumors analyzed by WES) was analyzed separately as one of three cohorts (neoadjuvant, metastatic, and TCGA). The study performed comprehensive mutational analyses across all cohorts, focusing on nonbenign exonic and splice site mutations in genes significantly mutated in MIBC, with ERCC2 mutations being the primary focus.","['TCGA', 'MSK-IMPACT']",['Citation only'],['ERCC2'],['Not specified'],Unclear,low,4.0,40829180,Quantitative functional profiling of ERCC2 mutations deciphers cisplatin sensitivity in bladder cancer.,2025,pdf,2025-12-19T04:09:32.042639,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, the paper does not explicitly mention cBioPortal usage. The study integrates bulk RNA-seq transcriptomics, methylomics, single-cell transcriptomics, and spatial single-cell transcriptomics data to analyze FPR3 in breast cancer. While TCGA data appears to be used (common for breast cancer studies), there is no clear statement about accessing this data through cBioPortal or using any cBioPortal-specific features in the provided text.",[],['Citation only'],"['FPR1', 'FPR2', 'FPR3']",['Not specified'],Unclear,low,4.0,40826412,FPR3 orchestrates macrophage polarization in breast cancer: multi-omics dissection of prognostic relevance and therapeutic targeting.,2025,pdf,2025-12-19T04:09:32.681518,,,,
"['Mutation analysis', 'Gene expression analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],['TCGA'],"The paper mentions using data from the TCGA database for 284 cervical cancer samples, analyzing tumor genome, transcriptome, and proteome data. While cBioPortal is not explicitly mentioned in the provided abstract and introduction, TCGA data access for multi-omics analysis (mutations, expression, protein data) commonly involves cBioPortal as a data portal. The study identified frequently mutated genes and analyzed their correlation with immune cell infiltration.",['TCGA'],['Citation only'],"['TTN', 'PRKDC', 'PCLO', 'MUC17', 'HUWE1', 'RYR2', 'CREBBP']",['Not specified'],"[""Unclear""]",low,4.0,40826144,Identification of neoantigen epitopes in cervical cancer by multi-omics analysis.,2025,pdf,2025-12-19T04:09:33.719151,,,,
['Other'],['Pan-cancer'],"['Drug response/resistance', 'Review/Commentary', 'Precision medicine']",['Review'],['Not specified'],"This is a comprehensive review article focused on KRAS mutations, drug resistance mechanisms, and therapeutic strategies across various cancers. The paper cites cBioPortal as a reference resource but does not describe any specific analysis or data extraction from the platform. The review discusses KRAS mutation landscapes and inhibitor development without detailing direct cBioPortal usage.",[],['Citation only'],['KRAS'],['Not specified'],Unclear,low,4.0,40824523,Novel paradigms in KRAS targeting: Unveiling strategies to combat drug resistance.,2025,abstract,2025-12-19T04:09:34.269213,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Lung cancer', 'Pan-cancer']","['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis', 'Precision medicine', 'Methods/Tools development']","['Original research', 'Methods/Software']","['TCGA', 'Multiple sources']","The paper does not explicitly describe using cBioPortal in their methodology. The authors developed their own computational framework called ASTUTE to integrate genomic and transcriptomic data from NSCLC and other cancer datasets. While cBioPortal is cited in the references, there is no clear description of how it was used for data access, analysis, or visualization in this study.",[],['Citation only'],"['KEAP1', 'NFE2L2', 'EGFR', 'KRAS', 'TP53']",['Not specified'],Unclear,low,4.0,40825842,Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer.,2025,pdf,2025-12-19T04:09:34.393461,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Copy number analysis', 'Pathway analysis', 'Multi-omics integration']",['Lung cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used as one of multiple bioinformatics tools to assess the functional implications of the SLC2A gene family in lung adenocarcinoma (LUAD). The study conducted a comprehensive multi-omics analysis including expression, mutation, and prognostic analysis of SLC2A genes, with cBioPortal listed among the databases and tools used for genomic analysis. The specific features or data extracted from cBioPortal are not explicitly detailed in the abstract and introduction.",[],['Web-based analysis'],"['SLC2A1', 'SLC2A7']",['Not specified'],Mixed,medium,4.0,40824962,The role of SLC2A1 in lung adenocarcinoma: From tumorigenesis to patient survival.,2025,pdf,2025-12-19T04:09:34.405430,,,,
['Other'],['Other solid tumor'],['Biomarker discovery'],"['Original research', 'Meta-analysis']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. This is a genome-wide association study (GWAS) meta-analysis focused on identifying genetic risk loci for hepatocellular carcinoma. The study does not describe using cBioPortal for data access, analysis, or visualization. If cBioPortal is cited, it appears to be a reference citation only without direct usage in the methodology.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40823170,Genome-wide meta-analysis identifies nine loci associated with higher risk of hepatocellular carcinoma development.,2025,abstract,2025-12-19T04:09:34.494124,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper mentions using cBioPortal in the context of analyzing TCGA data for ovarian cancer, though specific details of cBioPortal usage are not provided in the abstract and introduction sections. The study integrated multiple GEO datasets and TCGA data to identify hub genes (SNRPA1, LSM4, TMED10, and PROM2) in ovarian cancer. Based on the methodology description, cBioPortal was likely used for accessing TCGA data and performing expression analyses, though the exact features and extent of usage are not explicitly detailed in the provided text.",['TCGA'],['Web-based analysis'],"['SNRPA1', 'LSM4', 'TMED10', 'PROM2']",['Expression analysis'],"[""Mixed""]",medium,4.0,40826138,Multi-Omics analysis and in vitro validation reveal diagnostic and therapeutic roles of novel hub genes in ovarian cancer.,2025,pdf,2025-12-19T04:09:35.334328,,,,
"['Gene expression analysis', 'Mutation analysis', 'Copy number analysis', 'Survival analysis', 'Pathway analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to assess genetic and epigenetic alterations of GNAI1, GNAI2, and GNAI3 genes in colon adenocarcinoma (COAD). The platform was utilized alongside UALCAN and GSCA databases to analyze mutations, copy number variations, and methylation patterns. The study integrated cBioPortal data with other bioinformatics resources to comprehensively evaluate the molecular alterations affecting GNAI family genes in COAD.",['TCGA-COAD'],"['Web-based analysis', 'Data download/export']","['GNAI1', 'GNAI2', 'GNAI3']","['Query interface', 'Download data']","[""Mixed""]",medium,4.0,40819057,"A comprehensive in silico and invitro analysis revealed the diagnostic, prognostic and therapeutic potential of GNAI family genes in colon adenocarcinoma (COAD).",2025,pdf,2025-12-19T04:09:37.108036,,,,
"['Gene expression analysis', 'Mutation analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Immunotherapy', 'Drug response/resistance', 'Biomarker discovery']",['Original research'],['TCGA'],"The study used cBioPortal to access TCGA gastric cancer (TCGA-STAD) data for weighted gene co-expression network analysis (WGCNA) to identify genes inversely correlated with MSI-H status. Through this analysis, they identified TRIM6 as an E3 ubiquitin ligase showing hypermethylation-associated downregulation in MSI-H versus MSS tumors. The specific details of how cBioPortal was accessed or which features were used are not explicitly described in the provided abstract and introduction.",['TCGA-STAD'],['Data download/export'],['TRIM6'],['Not specified'],External (downloaded data),medium,4.0,40817248,TRIM6 ablation reverses ICB resistance in MSS gastric cancer by unleashing cGAS-STING-dependent antitumor immunity.,2025,pdf,2025-12-19T04:09:38.176751,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The study used cBioPortal to analyze genetic alterations (mutations, copy number variations) in COL1A1, ITGB1, THY1, and PDGFRA genes in UCEC patients. The authors performed survival analysis and examined the relationship between gene alterations and patient outcomes. Additionally, cBioPortal was used to investigate promoter methylation patterns of these genes in UCEC.",['TCGA-UCEC'],"['Web-based analysis', 'Web-based visualization']","['COL1A1', 'ITGB1', 'THY1', 'PDGFRA']","['Survival analysis', 'Expression analysis', 'Query interface']",Mixed,medium,4.0,40817072,"COL1A1, ITGB1, THY1, and PDGFRA: key immune-related genes in uterine corpus endometrial carcinoma with prognostic and therapeutic implications.",2025,pdf,2025-12-19T04:09:38.258232,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],['Multiple sources'],"cBioPortal was used as one of multiple databases to analyze genetic changes, genomic expression, and methylation data for AKR1B10 in hepatocellular carcinoma. The study integrated data from cBioPortal along with TCGA, CPTAC, UALCAN, HPA, and MethSurv databases to perform comprehensive analyses of AKR1B10 as a prognostic biomarker. The specific features or analysis methods used within cBioPortal are not explicitly detailed in the abstract.",['TCGA'],['Web-based analysis'],['AKR1B10'],['Not specified'],"[""Unclear""]",medium,4.0,40813509,AKR1B10 as a novel prognostic biomarker linking methylation and immune escape in hepatocellular carcinoma.,2025,abstract,2025-12-19T04:09:39.674539,,,,
"['Mutation analysis', 'Copy number analysis']",['Breast cancer'],"['Review/Commentary', 'Biomarker discovery', 'Precision medicine']","['Review', 'Meta-analysis']","['TCGA', 'Multiple sources']","This systematic review consolidates genomic data from breast cancer studies in African populations and compares findings against TCGA reference cohorts (Black/African American and White). The paper uses TCGA data accessed through cBioPortal as a comparative reference to benchmark somatic mutations, copy number alterations, and mutational signatures found in African cohorts. The specific mode of cBioPortal usage is not explicitly detailed in the provided text.",['TCGA'],['Citation only'],"['TP53', 'PIK3CA', 'ERBB2']",['Not specified'],Unclear,low,4.0,40813389,Genomic landscapes of breast cancer in African populations: a systematic review.,2025,pdf,2025-12-19T04:09:40.139860,,,,
['Gene expression analysis'],['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],['Multiple sources'],The study used cBioPortal database to perform bioinformatic analysis of TRPV4 gene expression in bladder cancer (BLCA) tissues compared to normal adjacent tissues. The analysis revealed that TRPV4 expression is significantly higher in human BLCA tissues and is markedly elevated in early-stage BLCA and upregulated in muscle-invasive bladder cancer tissues. cBioPortal was used alongside the University of Alabama at Birmingham Cancer Data Analysis Portal for this expression analysis.,[],['Web-based analysis'],['TRPV4'],['Expression analysis'],Unclear,medium,4.0,40803098,"Transient receptor potential vanilloid type 4 channels mediate bladder cancer cell proliferation, migration, and chemoresistance.",2025,abstract,2025-12-19T04:09:40.427312,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],['TCGA'],"Based on the abstract and introduction provided, the paper appears to focus on experimental investigation of UBAP2L-driven stress granule formation in oxaliplatin resistance in gastric cancer. While cBioPortal is cited, the abstract does not provide specific details about how cBioPortal was used. The study likely used cBioPortal to access TCGA gastric cancer data for validation of gene expression and survival correlations, but the exact usage mode and features cannot be determined from the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40804300,UBAP2L-driven stress granule formation links oxaliplatin resistance to gastric cancer.,2025,abstract,2025-12-19T04:09:40.809123,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],['TCGA'],"The paper does not explicitly mention using cBioPortal in the methods or results. The study obtained genomic data directly from TCGA and imaging data from TCIA, analyzing somatic mutations, copy number variations, fusion genes, and differential gene expression. While cBioPortal is cited, there is no clear description of how it was used for data access or analysis in this study.",['TCGA'],['Citation only'],"['PTEN', 'FGFR3', 'TACC3', 'EGFR', 'SEPT14', 'PITX2', 'HOXB13', 'DTHD1', 'ALOX15', 'LINC00290']",['Not specified'],Unclear,low,4.0,40794131,"Tumor location, genomic alterations, and radiomic features as predictors of survival in glioblastoma: a Multi-Modal analysis.",2025,abstract,2025-12-19T04:09:41.337756,,,,
"['Gene expression analysis', 'Survival analysis']","['Breast cancer', 'Lung cancer', 'Colorectal cancer', 'Pan-cancer']","['Biomarker discovery', 'Other']",['Original research'],['TCGA'],"The paper used TCGA data to investigate RIF1 expression and splicing patterns across multiple cancer types, with particular focus on breast cancer subtypes. The study analyzed differential expression of RIF1 in colon and lung cancers, and examined exon inclusion/exclusion patterns in breast cancer subtypes (Luminal A, Luminal B, HER2-enriched, and Basal), correlating these patterns with clinical outcomes. While TCGA data was clearly used, the specific role of cBioPortal as the data access platform is not explicitly detailed in the abstract.",['TCGA'],['Citation only'],['RIF1'],['Not specified'],Unclear,low,4.0,40806439,Dysregulated Alternative Splicing in Breast Cancer Subtypes of RIF1 and Other Transcripts.,2025,abstract,2025-12-19T04:09:41.918790,,,,
"['Gene expression analysis', 'Mutation analysis', 'Survival analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper conducted a systematic pan-cancer analysis of TRPM4 across 33 TCGA cancer types. The study integrated transcriptomic, proteomic, epigenetic, and clinical datasets from TCGA, GTEx, and Human Protein Atlas to perform differential expression analyses, ROC curves, survival analyses, and mutation/methylation assessments. While cBioPortal is a major resource for TCGA data access and cancer genomics analysis, the specific usage mode and features utilized are not explicitly detailed in the abstract.",['TCGA'],['Citation only'],['TRPM4'],['Not specified'],Unclear,low,4.0,40804073,Multidimensional pan cancer analysis of the sodium induced cell death gene TRPM4.,2025,abstract,2025-12-19T04:09:41.974329,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Copy number analysis', 'Mutation analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The study used cBioPortal to analyze TCGA data for endometrial cancer, examining NUDT18 expression patterns, survival outcomes, and genomic alterations. The authors investigated the relationship between NUDT18 DNA copy number gains, TP53 mutations, and NUDT18 expression levels. They also performed immune infiltration analysis and pathway enrichment analysis using data accessed through cBioPortal.",['TCGA'],"['Web-based analysis', 'Data download/export']","['NUDT18', 'TP53']","['Expression analysis', 'Survival analysis', 'Query interface']","[""Mixed""]",medium,4.0,40792130,Correlation between the decreased expression of NUDT18 and tumor progression in endometrial cancer.,2025,abstract,2025-12-19T04:09:43.645947,,,,
"['Mutation analysis', 'Survival analysis']","['Lung cancer', 'Other solid tumor']","['Biomarker discovery', 'Precision medicine', 'Methods/Tools development']",['Original research'],"['TCGA', 'GENIE', 'Multiple sources']",The authors used cBioPortal to access clinical cancer genomics data for validation of their functional scores. They analyzed somatic STK11 variants from cancer patients and compared overall survival estimates between patients with different STK11 variant types. The cBioPortal data was used to demonstrate that certain somatic STK11 variants had comparable survival outcomes to wild-type STK11.,"['TCGA', 'GENIE']","['Data download/export', 'Web-based analysis']",['STK11'],"['Survival analysis', 'Query interface', 'Download data']",Mixed,medium,4.0,40791513,Comprehensively Testing the Function of Missense Variation in the <i>STK11</i> Tumour Suppressor.,2025,abstract,2025-12-19T04:09:44.689292,,,,
"['Copy number analysis', 'Gene expression analysis', 'Mutation analysis']",['Leukemia/Lymphoma'],"['Drug response/resistance', 'Biomarker discovery', 'Precision medicine']",['Original research'],['Multiple sources'],"The paper appears to use cBioPortal to analyze genomic data related to chromosome 7 deletions and TP53 alterations in myeloid malignancies. The study likely queried cBioPortal databases to identify the prevalence of -7/del(7q) abnormalities and their co-occurrence with TP53 inactivation. However, the specific details of cBioPortal usage are not explicitly described in the provided abstract and introduction.",[],['Citation only'],"['NAMPT', 'TP53']",['Not specified'],Unclear,low,4.0,40792013,NAMPT haploinsufficiency is a collateral lethal therapeutic vulnerability in high-risk myeloid malignancies with <i>TP53</i> inactivation.,2025,abstract,2025-12-19T04:09:45.076127,,,,
"['Gene expression analysis', 'Pathway analysis', 'Multi-omics integration']",['Breast cancer'],"['Tumor evolution', 'Biomarker discovery']",['Original research'],"['Custom/Private data', 'TCGA']","Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage. The study focuses on methylation profiling and spatial transcriptomics using 10× Genomics Visium to analyze metaplastic breast cancer heterogeneity. If cBioPortal was used, it was likely for comparative analysis or validation purposes, but this is not evident from the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40790295,Integrated profiling of metaplastic breast cancer identifies putative master regulators of intratumoral heterogeneity.,2025,abstract,2025-12-19T04:09:45.309256,,,,
"['Gene expression analysis', 'Mutation analysis']","['Breast cancer', 'Pan-cancer']","['Pathway analysis', 'Biomarker discovery']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, the paper appears to be primarily a mechanistic study of ALG3 phosphorylation by AKT. While cBioPortal is cited, the abstract and introduction do not explicitly describe how cBioPortal was used. The study likely used cBioPortal to query cancer genomic data related to PI3K/AKT pathway alterations or ALG3 expression/mutations in cancer samples, but specific usage details are not provided in the excerpts given.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40789468,The glycosyltransferase ALG3 is an AKT substrate that regulates protein N-glycosylation.,2025,abstract,2025-12-19T04:09:46.018022,,,,
"['Mutation analysis', 'Survival analysis']",['Lung cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The study appears to be a retrospective analysis of patients from two centers (University Hospital Würzburg and Thoraxklinik Heidelberg) who underwent next-generation sequencing between 2019-2024. The analysis focused on EGFR/CTNNB1 comutations and their impact on outcomes with osimertinib therapy, but cBioPortal usage is not described in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40768678,Impact of Baseline β-Catenin Comutations on Prognosis in EGFR-Mutant Lung Cancer.,2025,abstract,2025-12-19T04:09:46.603519,,,,
"['Mutation analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Lung cancer', 'Leukemia/Lymphoma', 'Glioma/Brain cancer']","['Pathway analysis', 'Precision medicine', 'Methods/Tools development']","['Original research', 'Methods/Software']","['TCGA', 'Multiple sources']","The paper leverages pan-cancer genomic data to perform stratified driver pathway analysis across 23 cancer types using two computational models (EntCDP and ModSDP). The study analyzes genomic alterations from multiple perspectives including region, tumor type, age group, and risk factors to identify context-specific driver pathways. While the abstract mentions pan-cancer genomic data analysis, specific details about cBioPortal usage are not explicitly provided in the abstract and introduction.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40768543,Multi-context modeling of driver pathways reveals common and specific mechanisms across 23 cancer types.,2025,abstract,2025-12-19T04:09:47.539945,,,,
"['Copy number analysis', 'Gene expression analysis', 'Multi-omics integration']","['Pan-cancer', 'Leukemia/Lymphoma', 'Other solid tumor']","['Drug response/resistance', 'Biomarker discovery']",['Original research'],['Multiple sources'],"Based on the abstract and introduction provided, cBioPortal usage is not explicitly described. The paper focuses on drug sensitivity screening in over 600 cancer models, CRISPR screens, and mechanistic studies of azacytidine and decitabine. The mention of USP48 biallelic deletions occurring naturally in human cancers suggests potential use of genomic databases, but specific cBioPortal usage is not detailed in the provided text.",[],['Citation only'],"['USP48', 'DNMT1']",['Not specified'],Unclear,low,4.0,40766713,Discovery of chromatin-based determinants of azacytidine and decitabine anti-cancer activity.,2025,abstract,2025-12-19T04:09:47.610542,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration', 'Mutation analysis']",['Lung cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],"['Custom/Private data', 'Multiple sources']","The paper does not explicitly describe how cBioPortal was used in the study. Based on the abstract and introduction provided, the study primarily used quantitative proteomics and multiomics approaches on their own patient cohort (n=117 tissue samples, n=196 serum samples) to identify MYDGF as a biomarker. While cBioPortal may have been cited or used for validation purposes, no specific details about cBioPortal usage, features, or datasets are mentioned in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40752010,Myeloid-Derived Growth Factor-Regulated Oncogenesis in Lung Adenocarcinoma Is Associated with EGFR Status and Cancer Aggressiveness.,2025,abstract,2025-12-19T04:09:48.722165,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Lung cancer']","['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The authors used TCGA pan-cancer datasets, UALCAN online database, and Human Protein Atlas (HPA) database for their analyses. While cBioPortal is cited (as indicated by the paper being in a cBioPortal citation collection), the specific usage details are not described in the provided text. The paper may cite cBioPortal as a reference or potential data source, but no concrete evidence of direct usage is present in the available sections.",['TCGA'],['Citation only'],['MCM6'],['Not specified'],Unclear,low,4.0,40764366,Analysis of the prognostic and immune role of MCM6 in pan-cancer and experimental validation in lung adenocarcinoma cells.,2025,pdf,2025-12-19T04:09:49.504008,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis']",['Breast cancer'],"['Immunotherapy', 'Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Custom/Private data']","The paper likely used cBioPortal to analyze MLL3/KMT2C mutation frequencies and correlations in human breast cancer datasets, particularly TCGA breast cancer cohorts. The authors examined the relationship between MLL3 mutations and Treg cell infiltration in human breast tumors, which would have required querying mutation data and potentially correlating with immune infiltration patterns. cBioPortal was likely used to validate findings from their mouse model in human breast cancer datasets.",['TCGA'],"['Web-based analysis', 'Citation only']","['MLL3', 'KMT2C', 'TP53']",['Not specified'],"[""Unclear""]",low,4.0,40749665,Mutations in MLL3 promote breast cancer progression via HIF1α-dependent intratumoral recruitment and differentiation of regulatory T cells.,2025,abstract,2025-12-19T04:09:50.868021,,,,
"['Gene expression analysis', 'Survival analysis']",['Melanoma'],"['Biomarker discovery', 'Immunotherapy', 'Drug response/resistance']",['Original research'],"['TCGA', 'Custom/Private data']",cBioPortal was used to analyze gene expression and survival data from melanoma patient cohorts. The authors likely queried TGM2 and SOX10 expression levels and examined their correlation with patient survival outcomes in melanoma datasets. The platform was used to validate findings from their experimental models using publicly available patient data.,['TCGA'],"['Web-based analysis', 'Web-based visualization']","['TGM2', 'SOX10']","['Expression analysis', 'Survival analysis']",cBioPortal platform,medium,4.0,40742313,Elevated Transglutaminase-2 in SOX10-Deficient Melanoma Promotes Tumor Onset and Decreases Intratumoral CD4+ T Cells.,2025,abstract,2025-12-19T04:09:51.593578,,,,
"['Gene expression analysis', 'Mutation analysis', 'Pathway analysis']",['Colorectal cancer'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],"['TCGA', 'Multiple sources']","The paper mentions using genomic and transcriptomic-based approaches to identify potential drug targets for Avicennia alba in colorectal cancer treatment. The study identified 10 hub genes (EGFR, PIK3CA, JAK2, MTOR, JUN, ERBB2, IGF2, SRC, MDM2, and PARP1) associated with CRC through bioinformatics analysis. However, the specific details of how cBioPortal was used are not explicitly described in the provided abstract and introduction sections.",[],['Citation only'],"['EGFR', 'PIK3CA', 'JAK2', 'MTOR', 'JUN', 'ERBB2', 'IGF2', 'SRC', 'MDM2', 'PARP1']",['Not specified'],Unclear,low,4.0,40745259,Deciphering anti-colorectal cancer potential of Avicennia alba bioactives via network pharmacology and in vitro validation.,2025,pdf,2025-12-19T04:09:51.624136,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']","['Original research', 'Clinical study']","['TCGA', 'Multiple sources']","The paper conducted a comprehensive pan-cancer analysis of NPR3 using 20 different databases and datasets, which likely included cBioPortal as one of the data sources. The study performed differential expression analysis, survival analysis, and correlation assessments with clinical characteristics, tumor genomics, and immune infiltration across multiple cancer types. While cBioPortal is not explicitly mentioned in the abstract, it was likely used as one of the databases for accessing TCGA pan-cancer data and performing genomic analyses.",['TCGA'],['Citation only'],['NPR3'],['Not specified'],Unclear,low,4.0,40740975,A Pan-Cancer Analysis of Natriuretic Peptide Receptor 3 (NPR3) with Clinical Cohort and in vitro Validation.,2025,abstract,2025-12-19T04:09:53.290994,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis']",['Other solid tumor'],['Biomarker discovery'],['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to explore genetic alterations (mutations and amplifications) of SLCO genes (SLCO1B1, SLCO1B3, and SLCO2B1) in hepatocellular carcinoma using the TCGA Liver Hepatocellular Carcinoma dataset (TCGA's Pan-Cancer Atlas). The analysis revealed low mutation and amplification frequencies for these three genes in HCC patients.","['TCGA Liver Hepatocellular Carcinoma', 'TCGA Pan-Cancer Atlas']",['Web-based analysis'],"['SLCO1B1', 'SLCO1B3', 'SLCO2B1']",['Query interface'],cBioPortal platform,high,4.0,40734706,Roles of organic anion transporting polypeptides in hepatocellular carcinoma.,2025,pdf,2025-12-19T04:09:53.292001,,,,
"['Gene expression analysis', 'Survival analysis', 'Copy number analysis', 'Mutation analysis']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","The cBioPortal database was used to analyze the genetic status of SLC4A11 in ovarian cancer. This likely included examining mutations, copy number alterations, and other genomic features of SLC4A11 using TCGA-OV data. The analysis was part of a comprehensive bioinformatics approach to characterize SLC4A11 in ovarian cancer.",['TCGA-OV'],['Web-based analysis'],['SLC4A11'],"['Query interface', 'Not specified']",Unclear,medium,4.0,40731416,SLC4A11 is a targetable marker correlated with therapeutic responses in ovarian cancer.,2025,abstract,2025-12-19T04:09:53.492136,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Immunotherapy', 'Methods/Tools development', 'Database/Resource']","['Original research', 'Methods/Software']","['Multiple sources', 'Custom/Private data']","The paper developed CIDE (Cancer Immunology Data Engine), which incorporates 90 omics datasets spanning 8,575 tumor profiles with immunotherapy outcomes from 17 solid tumor types. While cBioPortal is cited, the specific usage details are not clearly described in the provided abstract and introduction. The study appears to have developed its own data integration platform rather than primarily using cBioPortal for analysis.",[],['Citation only'],"['AOAH', 'CR1L', 'COLQ', 'ADAMTS7']",['Not specified'],Unclear,low,4.0,40730154,Cancer immunology data engine reveals secreted AOAH as a potential immunotherapy.,2025,abstract,2025-12-19T04:09:53.877050,,,,
['Mutation analysis'],['Glioma/Brain cancer'],['Biomarker discovery'],"['Original research', 'Clinical study']",['Custom/Private data'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The research appears to be a retrospective clinical study using immunohistochemistry on FFPE samples from Dr. Sardjito Hospital to analyze p53 mutations in astrocytoma patients. The paper may cite cBioPortal in references but does not describe using the platform for data analysis or visualization.",[],['Citation only'],['TP53'],['Not specified'],Unclear,low,4.0,40729073,The Association between p53 Expression and Histopathology Grade of Astrocytoma.,2025,pdf,2025-12-19T04:09:54.577545,,,,
['Gene expression analysis'],['Other solid tumor'],"['Biomarker discovery', 'Methods/Tools development']",['Original research'],['TCGA'],The paper used cBioPortal to analyze FAP (Fibroblast Activation Protein) expression across human sarcoma samples. The authors queried cBioPortal to determine that 41% of human sarcomas express FAP and to correlate FAP expression with histologic grade. This analysis provided the rationale for developing FAP-S0456 as a targeted optical tracer for sarcoma detection during surgical resection.,[],['Web-based analysis'],['FAP'],"['Expression analysis', 'Query interface']",Unclear,medium,4.0,40728760,A fibroblast activation protein targeted optical tracer for identifying primary and metastatic sarcoma during resection.,2025,abstract,2025-12-19T04:09:55.583906,,,,
['Mutation analysis'],['Pan-cancer'],['Methods/Tools development'],['Methods/Software'],['Not specified'],"Based on the abstract and introduction provided, cBioPortal is not explicitly mentioned as being used in this study. This paper presents CaMutQC, a new R/Bioconductor package for quality control and filtration of cancer somatic mutations. The citation of cBioPortal appears to be for reference purposes only, likely in the context of discussing existing cancer genomics resources or tools in the field.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40727424,CaMutQC: An R package for integrative quality control and filtration of cancer somatic mutations.,2025,abstract,2025-12-19T04:09:56.675716,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, cBioPortal is not explicitly mentioned as being used in this study. The authors performed integrated multi-omics analyses using TCGA-UCEC, GTEx, and GEO cohorts, but the specific tools and platforms used for data access and analysis are not detailed in the provided text. cBioPortal may have been cited in references or used for data access, but this cannot be confirmed from the information given.","['TCGA-UCEC', 'GSE106191']",['Citation only'],['KLRG2'],['Not specified'],Unclear,low,4.0,40722666,Expression Characteristics and Prognostic Value of KLRG2 in Endometrial Cancer: A Comprehensive Analysis Based on Multi-Omics Data.,2025,abstract,2025-12-19T04:09:57.934419,,,,
"['Copy number analysis', 'Gene expression analysis', 'Multi-omics integration', 'Mutation analysis']",['Lung cancer'],"['Biomarker discovery', 'Methods/Tools development']","['Original research', 'Methods/Software']",['TCGA'],"The paper does not explicitly describe how cBioPortal was used in the study. The authors used TCGA data integrating copy number alteration (CNA), mRNA expression, and DNA methylation data to identify LUAD-associated genes through feature selection methods. While cBioPortal is cited, there is no clear description of whether data was downloaded from cBioPortal or if any of its analysis features were utilized.",['TCGA'],['Citation only'],"['CCNG1', 'CKAP2L', 'HSD17B4', 'SHROOM1', 'TIGD6', 'TMEM173', 'DTWD2', 'FLJ33630', 'NME5', 'NUDT12', 'PCBD2', 'REEP5', 'SLC22A5']",['Not specified'],"[""Unclear""]",low,4.0,40722386,Detection of LUAD-Associated Genes Using Wasserstein Distance in Multiomics Feature Selection.,2025,abstract,2025-12-19T04:09:58.615520,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Copy number analysis']",['Breast cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","The cBioPortal database was used as one of several bioinformatic tools to systematically analyze the PRDX gene family in breast cancer. The authors used cBioPortal to examine expression patterns, prognostic value, methylation status, and immune infiltration associations of PRDX family members. The analysis helped identify PRDX4 as having good prognostic value and close relationship with immune infiltration in breast cancer.",[],"['Web-based analysis', 'Web-based visualization']",['PRDX4'],"['Expression analysis', 'Not specified']",Unclear,medium,4.0,40721644,Immune infiltration related PRDX4 facilitates the malignant features and drug resistance of breast cancer.,2025,abstract,2025-12-19T04:09:59.010506,,,,
"['Multi-omics integration', 'Gene expression analysis', 'Pathway analysis']","['Breast cancer', 'Other solid tumor']","['Drug response/resistance', 'Precision medicine', 'Biomarker discovery', 'Review/Commentary']",['Review'],['Not specified'],"This is a review paper discussing AI-driven drug repositioning for epigenetic therapy in female malignancies, with focus on gynecologic and breast cancers. The paper does not describe specific usage of cBioPortal for original data analysis. cBioPortal may be cited as a reference resource in the context of cancer genomics databases, but no explicit methodology or results involving cBioPortal are described in the abstract or introduction provided.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40713639,Multi-omics based and AI-driven drug repositioning for epigenetic therapy in female malignancies.,2025,abstract,2025-12-19T04:09:59.404406,,,,
"['Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Prostate cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['Multiple sources'],"The study used cBioPortal to evaluate transcriptomic data from primary and metastatic prostate cancer patients, specifically analyzing alterations in RSPO family genes (RSPO1/2/3/4) and Wnt-regulating genes (APC and CTNNB1). The analysis revealed that RSPO2 alterations were more prevalent than other RSPO family members and were significantly associated with worse disease-free survival in prostate cancer patients.",[],"['Web-based analysis', 'Web-based visualization']","['RSPO1', 'RSPO2', 'RSPO3', 'RSPO4', 'APC', 'CTNNB1']","['Expression analysis', 'Survival analysis', 'Query interface']","[""Mixed""]",medium,4.0,40711886,Dissecting the functional differences and clinical features of R-spondin family members in metastatic prostate cancer.,2025,abstract,2025-12-19T04:09:59.446462,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine']","['Original research', 'Clinical study']","['Custom/Private data', 'Multiple sources']","The paper does not explicitly describe using cBioPortal for analysis or data retrieval. The study analyzed 11,635 gliomas from three independent datasets (DFCI, KiTZ, and Foundation Medicine) to identify FGFR alterations, but the methods for accessing or analyzing these data through cBioPortal are not specified in the provided text. cBioPortal may have been cited as a reference or potential data source, but specific usage details are not evident from the abstract and introduction.",[],['Citation only'],"['FGFR1', 'FGFR2', 'FGFR3', 'FGFR4', 'BRAF']",['Not specified'],Unclear,low,4.0,40744913,A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas.,2025,pdf,2025-12-19T04:09:59.492816,,,,
"['Mutation analysis', 'Copy number analysis']",['Pan-cancer'],"['Precision medicine', 'Methods/Tools development']","['Original research', 'Clinical study', 'Methods/Software']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal being used in this study. The paper describes the validation and implementation of matched tumor/germline sequencing using OncoPanel, a hybrid capture-based sequencing assay. The study focuses on comparing tumor-only versus matched tumor/germline analytical pipelines for clinical genomic profiling. If cBioPortal is mentioned elsewhere in the full paper, it is not evident from the provided sections.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40706989,Clinical Implementation of Matched Tumor/Germline Sequencing Improves Accuracy of Tumor Genomic Profiling and Therapeutic Recommendations.,2025,abstract,2025-12-19T04:10:00.756334,,,,
"['Copy number analysis', 'Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine', 'Pathway analysis']","['Original research', 'Clinical study']","['TCGA', 'Custom/Private data']","The paper mentions TCGA data analysis in the context of investigating KRAS copy number variation and immune infiltration relationships. The authors reference a TCGA-based analysis on 5255 tumors representing 12 cancer types that revealed a negative relationship between CNV and immune cell infiltration. However, the specific details of how cBioPortal was used in this study are not explicitly described in the provided abstract and introduction sections.",['TCGA'],['Citation only'],['KRAS'],['Not specified'],Unclear,low,4.0,40708044,KRAS amplification in colorectal cancer: correlations with clinicopathological features and prognosis in patients and prediction of response to targeted therapy.,2025,pdf,2025-12-19T04:10:01.027369,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly describe using cBioPortal for analysis. While the study analyzes TCGA data for HMGA2 expression and prognosis in endometrial cancer, the methods section mentions using other bioinformatics tools (TIMER, UALCAN, Sangerbox, TISIDB, Kaplan-Meier Plotter, HPA) for data analysis and visualization. cBioPortal may have been cited in references but no specific usage is described in the provided text.",['TCGA-UCEC'],['Citation only'],['HMGA2'],['Not specified'],Unclear,low,4.0,40703517,Prognostic significance and immune infiltration analysis of HMGA2 in endometrial cancer.,2025,pdf,2025-12-19T04:10:03.057704,,,,
"['Copy number analysis', 'Multi-omics integration', 'Pathway analysis']",['Pan-cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper analyzed copy number patterns in pan-cancer datasets, likely using cBioPortal to access TCGA and other cancer genomics data. The study focused on identifying genes that drive the selective advantage of large chromosomal copy number gains across multiple cancer types. cBioPortal appears to have been used as a data source for copy number alteration data and potentially for querying specific oncogenes, though the exact usage details are not explicitly described in the provided abstract.",['TCGA'],['Data download/export'],[],['Download data'],External (downloaded data),medium,4.0,40694850,Low-amplitude copy number gains shape cancer through known and novel oncogenes with associated therapeutic vulnerabilities.,2025,abstract,2025-12-19T04:10:03.994870,,,,
['Gene expression analysis'],"['Leukemia/Lymphoma', 'Pan-cancer']","['Immunotherapy', 'Biomarker discovery']",['Original research'],"['Custom/Private data', 'Multiple sources']","Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on CAR-T and CAR-NK cell therapy, examining FAS ligand-FAS interactions through single-cell RNA sequencing, RNA-FISH, and competitive fitness assays. The study constructed a single-cell atlas from patient samples to identify FASLG expression patterns across different cell types. While cBioPortal is cited, no specific usage of the platform for data access, analysis, or visualization is described in the provided text.",[],['Citation only'],"['FASLG', 'FAS', 'CD3E']",['Not specified'],Unclear,low,4.0,40696154,CAR-engineered lymphocyte persistence is governed by a FAS ligand-FAS autoregulatory circuit.,2025,pdf,2025-12-19T04:10:04.407732,,,,
"['Multi-omics integration', 'Gene expression analysis', 'Copy number analysis']",['Pan-cancer'],"['Methods/Tools development', 'Precision medicine']","['Original research', 'Methods/Software']",['TCGA'],"The paper develops a novel multi-omics integration framework (MO-GCAN) for cancer subtyping using graph convolutional and attention networks. The authors applied their method to eight cancer types, likely using TCGA data accessed through cBioPortal for multi-omics datasets including gene expression and copy number data. The framework was evaluated on multiple cancer types to demonstrate superior performance compared to state-of-the-art approaches.",[],['Data download/export'],[],['Download data'],External (downloaded data),medium,4.0,40692180,MO-GCAN: multi-omics integration based on graph convolutional and attention networks.,2025,abstract,2025-12-19T04:10:04.692498,,,,
"['Mutation analysis', 'Survival analysis']",['Leukemia/Lymphoma'],"['Biomarker discovery', 'Precision medicine']",['Original research'],['Multiple sources'],"The authors used cBioPortal to access a myelodysplastic syndromes dataset containing 399 CMML cases to validate findings from their national Austrian biodatabase (ABCMML). They analyzed KRAS mutation frequencies, survival outcomes, and phenotypic characteristics in CMML patients with and without KRAS mutations, comparing results between the ABCMML cohort and the cBioPortal (referred to as BIOPORTAL) cohort to demonstrate consistency of findings across independent patient populations.",['myelodysplastic syndromes dataset'],"['Data download/export', 'Web-based analysis']",['KRAS'],"['Query interface', 'Download data', 'Survival analysis']",Mixed,high,4.0,40694264,Features of KRAS-mutated patients with chronic myelomonocytic leukemia with and without blast transformation in a national (ABCMML) and international cohort (BIOPORTAL).,2025,pdf,2025-12-19T04:10:05.382173,,,,
"['Gene expression analysis', 'Pathway analysis']",['Other solid tumor'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],['Not specified'],cBioPortal was used to retrieve HCC-related genes for target identification in the network pharmacology analysis. The authors obtained hepatocellular carcinoma-related genes from cBioPortal to identify potential molecular targets for emodin derivatives. These genes were then used in functional annotation analyses (Gene Ontology and Reactome) to identify EGFR and KIT as key targets for further molecular docking and dynamics simulations.,[],['Data download/export'],"['EGFR', 'KIT']",['Download data'],External (downloaded data),medium,4.0,40685472,Integrative network pharmacology and experimental validation reveal emodin derivatives as potential therapeutics for hepatocellular carcinoma.,2025,pdf,2025-12-19T04:10:05.491768,,,,
"['Copy number analysis', 'Gene expression analysis', 'Survival analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Tumor evolution']",['Original research'],"['TCGA', 'Custom/Private data']","The study used TCGA colorectal cancer data accessed through cBioPortal to validate a four-gene signature (BMP7, DNMT3B, UBE2C, YWHAB) associated with chromosome 20q amplification. The validation was performed on 195 TCGA colorectal adenocarcinoma patients to assess the association of this gene signature with lymph node spread and distant metastasis. cBioPortal served as the source for accessing TCGA data for this validation cohort.",['TCGA colorectal cancer'],['Data download/export'],"['BMP7', 'DNMT3B', 'UBE2C', 'YWHAB']",['Download data'],External (downloaded data),medium,4.0,40682849,Chromosome 20q gene signature associated with colorectal cancer progression.,2025,abstract,2025-12-19T04:10:05.607245,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Lung cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['Custom/Private data', 'TCGA']","Based on the abstract and introduction provided, cBioPortal usage is not explicitly described. The study primarily uses the Taiwan Cancer Moonshot cohort for proteogenomics data. While cBioPortal is cited (as indicated by the paper being in a cBioPortal citation analysis), the specific usage details are not mentioned in the provided text. The study focuses on OCIAD2 expression in lung adenocarcinoma with survival analysis and pathway enrichment, but the role of cBioPortal in these analyses is unclear from the provided sections.",[],['Citation only'],['OCIAD2'],['Not specified'],Unclear,low,4.0,40690206,OCIAD2 Promotes Cancer Progression via Metabolic Reprogramming in Lung Adenocarcinoma.,2025,abstract,2025-12-19T04:10:05.946812,,,,
['Other'],['Prostate cancer'],['Review/Commentary'],['Review'],['Not specified'],"This is a review paper evaluating the potential association between human papillomavirus (HPV) and prostate cancer pathogenesis. Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage for data analysis or visualization. The paper appears to be a literature review discussing existing studies on HPV's role in prostate cancer, particularly in the context of racial disparities.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40682761,Evaluation of human papillomavirus as a risk factor in prostate cancer pathogenesis.,2025,abstract,2025-12-19T04:10:06.814025,,,,
['Other'],"['Lung cancer', 'Pan-cancer']","['Review/Commentary', 'Drug response/resistance', 'Precision medicine', 'Biomarker discovery']",['Review'],['Not specified'],"This is a review paper discussing MET alterations as therapeutic targets in NSCLC and other solid tumors. Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper appears to be a clinical review focusing on treatment paradigms, clinical efficacy, and toxicity profiles of MET-targeted therapies rather than a genomic data analysis study.",[],['Citation only'],['MET'],['Not specified'],"[""Unclear""]",low,4.0,40681868,Evolving roles of MET as a therapeutic target in NSCLC and beyond.,2025,abstract,2025-12-19T04:10:06.871939,,,,
"['Gene expression analysis', 'Mutation analysis']",['Glioma/Brain cancer'],"['Review/Commentary', 'Immunotherapy', 'Biomarker discovery']",['Review'],['Not specified'],"This is a review paper on medulloblastoma biology and immunotherapy. While the paper discusses molecular characterization and omics analyses of medulloblastoma, there is no explicit mention of cBioPortal usage in the provided abstract and introduction. The paper appears to be a comprehensive review of medulloblastoma subgroups, treatment approaches, and immunotherapy strategies without specific reference to cBioPortal as a data source or analysis tool.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40677711,Medulloblastoma: biology and immunotherapy.,2025,pdf,2025-12-19T04:10:09.483253,,,,
['Other'],['Pan-cancer'],"['Drug response/resistance', 'Review/Commentary']",['Review'],['Not specified'],"This is a review paper discussing epigenetic regulators and cancer therapy resistance. Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage, data analysis, or specific features utilized. The paper appears to cite cBioPortal only as a reference without describing any direct usage of the platform for data analysis or visualization.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40675967,Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance.,2025,abstract,2025-12-19T04:10:09.666602,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Drug response/resistance', 'Pathway analysis']",['Original research'],['TCGA'],"Based on the abstract and introduction provided, the paper appears to focus on experimental research investigating the POLR1A-TFAM axis in ferroptosis resistance in pleural mesothelioma. While cBioPortal is cited, the abstract does not provide specific details about how cBioPortal was used in this study. The study likely used cBioPortal to access TCGA data for validation or correlation analysis of gene expression and/or survival outcomes related to POLR1A and TFAM in cancer patients.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40669210,POLR1A inhibits ferroptosis by regulating TFAM-mediated mitophagy and iron homeostasis.,2025,abstract,2025-12-19T04:10:10.492258,,,,
"['Gene expression analysis', 'Mutation analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']","['Custom/Private data', 'Multiple sources']","Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this paper. The study focuses on DLL3 expression and functional imaging in gastroenteropancreatic neuroendocrine neoplasms using immunohistochemistry and PET-CT imaging at Memorial Sloan Kettering Cancer Center. Without access to the methods or results sections, it cannot be determined if cBioPortal was used for any genomic data analysis or validation.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40666328,Delta-like ligand 3 expression and functional imaging in gastroenteropancreatic neuroendocrine neoplasms.,2025,pdf,2025-12-19T04:10:10.947054,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration']","['Melanoma', 'Pan-cancer']","['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to analyze the expression of FRA1 (FOSL1) and its target genes (AXL, CDK6, FSCN1) in melanoma and other cancer types. The authors used cBioPortal to examine correlations between gene expression and patient survival outcomes across multiple cancer datasets. The platform enabled the assessment of clinical relevance of the FRA1-mediated transcriptional network in human cancer samples.",[],"['Web-based analysis', 'Web-based visualization']","['FOSL1', 'AXL', 'CDK6', 'FSCN1']","['Expression analysis', 'Survival analysis']",Unclear,medium,4.0,40661443,FRA1 drives melanoma metastasis through an actionable transcriptional network.,2025,abstract,2025-12-19T04:10:11.389946,,,,
"['Gene expression analysis', 'Multi-omics integration']",['Breast cancer'],"['Methods/Tools development', 'Biomarker discovery']","['Methods/Software', 'Original research']","['TCGA', 'Multiple sources']","The paper describes GRACKLE, a novel matrix factorization method for biomedical representation learning. The method was applied to breast tumor samples, likely using TCGA breast cancer data that may have been accessed through cBioPortal. However, the abstract and introduction do not explicitly mention cBioPortal usage, suggesting it may have been used only for data access or cited as a reference without detailed usage description.",['TCGA'],['Data download/export'],[],['Download data'],"[""External (downloaded data)""]",low,4.0,40662804,GRACKLE: an interpretable matrix factorization approach for biomedical representation learning.,2025,abstract,2025-12-19T04:10:11.404964,,,,
['Gene expression analysis'],['Not specified'],['Other'],['Original research'],['Not specified'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on investigating the role of RHAMM isoforms in regulating telomerase activity using mouse embryonic fibroblasts and various molecular biology techniques. If cBioPortal is cited, it appears to be a reference citation only without direct usage of the platform for data analysis or visualization in this particular study.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40661163,The truncated isoform of the receptor for hyaluronan-mediated motility (RHAMM<sup>Δ163</sup>) modulates shelterin and telomerase reverse transcriptase transcription affecting telomerase activity.,2025,pdf,2025-12-19T04:10:11.831910,,,,
"['Mutation analysis', 'Survival analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']","['TCGA', 'Custom/Private data']","The authors used TCGA data accessed through cBioPortal for in silico analysis to evaluate gene variants linked to both type 2 diabetes and colon cancer. This preliminary analysis informed their subsequent clinical study of 99 metastatic colorectal cancer patients. The specific details of how cBioPortal was used (web interface, data download, or specific features) are not explicitly described in the abstract.",['TCGA'],['Citation only'],"['CCND2', 'CDKN1B', 'CDKN2A', 'CDKN2B', 'EML4', 'HNF1A', 'ID3', 'IGF1', 'IGF1R', 'IGF2', 'INHBA', 'INSR', 'IRS1', 'IRS2', 'TCF7L2']",['Not specified'],"[""Unclear""]","[""low""]",4.0,40658092,Genetic variants linked to type 2 diabetes in CDKN1B and TCF7L2 influence survival outcomes in metastatic colorectal cancer.,2025,abstract,2025-12-19T04:10:12.362347,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis']",['Other solid tumor'],['Biomarker discovery'],"['Original research', 'Clinical study']","['TCGA', 'Multiple sources']","The study used cBioPortal to validate findings from their case-control genetic association study. They accessed TCGA database through cBioPortal to examine the relationship between NSUN2 expression levels and survival outcomes in oral cancer patients. The paper mentions that ""In the TCGA database, the trend that patients with higher expression had worse survival than those with lower expression was shown,"" suggesting they used cBioPortal's survival analysis features to correlate NSUN2 expression with clinical outcomes.",['TCGA'],"['Web-based analysis', 'Web-based visualization']",['NSUN2'],"['Expression analysis', 'Survival analysis']",cBioPortal platform,medium,4.0,40657390,<i>NSUN2</i> rs13181449 variant decreases the risk of oral cancer development.,2025,pdf,2025-12-19T04:10:14.797699,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Pathway analysis']","['Pan-cancer', 'Breast cancer', 'Prostate cancer', 'Ovarian cancer', 'Renal cancer', 'Lung cancer', 'Liver cancer']","['Review/Commentary', 'Precision medicine', 'Biomarker discovery', 'Pathway analysis']",['Review'],['TCGA'],"This review article uses TCGA database data to analyze PIK3R1 genetic aberrations across multiple cancer types. The paper presents data on PIK3R1 copy number variations and mutations across various tumor types from TCGA, as illustrated in Figure 1. The authors appear to have accessed TCGA data to examine the frequency and distribution of PIK3R1 alterations, though the specific method of data access (whether through cBioPortal or other means) is not explicitly stated in the provided text.",['TCGA'],['Citation only'],"['PIK3R1', 'PIK3CA', 'PIK3CB', 'PIK3CD', 'PIK3R2', 'PIK3R3', 'PTEN', 'AKT', 'JAK2', 'STAT3']",['Not specified'],Unclear,low,4.0,40657399,Cancer-Associated <i>PIK3R1</i> Genetic Aberrations and Precision Medicine.,2025,pdf,2025-12-19T04:10:16.008729,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy', 'Other']",['Original research'],['TCGA'],"Based on the abstract and introduction provided, the paper appears to focus on experimental mouse models of pancreatic cancer and aging. While cBioPortal is cited, the abstract does not provide explicit details about how cBioPortal was used. It is likely that cBioPortal was used to access TCGA data for validation of gene expression signatures or survival analysis related to the extracellular matrix gene signature identified in their experimental models, but specific usage details are not described in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40654942,The Aging Microenvironment as a Determinant of Immune Exclusion and Metastatic Fate in Pancreatic Cancer.,2025,abstract,2025-12-19T04:10:16.125551,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Methylation analysis']",['Gastric cancer'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to perform mutational analysis of TP53, ATM, RAD51, and BAX genes in gastric cancer samples. The analysis revealed that TP53 was altered in 88% of gastric cancer samples, while ATM, RAD51, and BAX exhibited lower mutation rates. This mutational data was integrated with other analyses including expression, methylation, and survival data to comprehensively characterize these genes in gastric cancer.",['TCGA'],['Web-based analysis'],"['TP53', 'ATM', 'RAD51', 'BAX']",['Query interface'],cBioPortal platform,high,4.0,40652278,"In silico and in vitro assessment of TP53, ATM, RAD51, and BAX genes in gastric cancer and their contribution to radiotherapy resistance.",2025,pdf,2025-12-19T04:10:16.468042,,,,
"['Gene expression analysis', 'Survival analysis', 'Copy number analysis', 'Mutation analysis', 'Pathway analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","The study utilized cBioPortal to analyze PCNA genetic alterations across multiple cancer types, including amplification, mutation, and copy number variations. The authors examined PCNA expression patterns, survival outcomes, and correlations with immune profiles across pan-cancer datasets. cBioPortal served as one of several publicly available databases used to comprehensively assess PCNA's role in tumorigenesis and therapeutic resistance.",[],"['Web-based analysis', 'Citation only']",['PCNA'],['Not specified'],"[""Unclear""]",medium,4.0,40657100,"PCNA in Pan-Cancer: A Prognostic Biomarker Unveiled Through a Data-Driven, Multidimensional Analysis of Transcriptomics, Immunity, and Functional Profiling.",2025,abstract,2025-12-19T04:10:16.626297,,,,
"['Mutation analysis', 'Survival analysis', 'Pathway analysis']",['Colorectal cancer'],"['Pathway analysis', 'Precision medicine', 'Methods/Tools development', 'Biomarker discovery']","['Original research', 'Methods/Software']",['Multiple sources'],"The study developed AI-HOPE-PI3K, an AI-driven platform that integrates multi-institutional cBioPortal datasets annotated with clinical variables for real-time analysis of PI3K pathway alterations in colorectal cancer. The platform automates cohort generation, survival modeling, and mutation frequency comparisons using harmonized clinical and genomic data from cBioPortal. The system was used to analyze PI3K pathway alterations across different patient populations, tumor locations, and treatment contexts.",[],"['Data download/export', 'API access']","['PI3K', 'INPP4B']","['Download data', 'Query interface']",External (downloaded data),high,4.0,40650262,From Mutation to Prognosis: AI-HOPE-PI3K Enables Artificial Intelligence Agent-Driven Integration of PI3K Pathway Data in Colorectal Cancer Precision Medicine.,2025,abstract,2025-12-19T04:10:17.328343,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis']","['Breast cancer', 'Prostate cancer']","['Biomarker discovery', 'Drug response/resistance']",['Original research'],['Multiple sources'],"The authors used cBioPortal for Cancer Genomics to access and analyze genomic alterations (amplifications, deletions, and mutations) in ABC transporter genes across multiple clinical trials. They analyzed data from 32 breast cancer studies (15,404 samples) and 29 prostate cancer studies (13,857 samples). Kaplan-Meier survival analysis was performed to correlate ABC transporter gene alterations with overall survival outcomes in both cancer types.",[],"['Web-based analysis', 'Web-based visualization']","['ABCG2', 'ABCG1', 'ABCC4', 'ABCA2', 'ABCA3', 'ABCC2', 'ABCC3', 'ABCC6', 'ABCC7', 'ABCC9']","['Survival analysis', 'Query interface']",cBioPortal platform,high,4.0,40641097,Association of ATP-binding cassette transporter genomic alterations and expressions with patient survival in breast and prostate cancer.,2025,abstract,2025-12-19T04:10:17.549045,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']",['Original research'],['Multiple sources'],cBioPortal was used alongside UALCAN for mutational analysis of VEGFA and EGFR genes in head and neck squamous cell carcinoma. The study utilized cBioPortal to investigate mutation frequencies and patterns in these genes. The mutational analysis revealed that both VEGFA and EGFR showed infrequent mutations in HNSCC.,[],['Web-based analysis'],"['VEGFA', 'EGFR']",['Not specified'],Unclear,medium,4.0,40628426,Illuminating the role of VEGFA and EGFR in head and neck squamous cell carcinoma through the multi-omics data integration.,2025,abstract,2025-12-19T04:10:18.007308,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The paper used cBioPortal for integrated bioinformatic analyses to investigate ABCE1 as a potential biomarker in colorectal cancer. The platform was likely used to analyze gene expression patterns, survival outcomes, and pathway associations related to ABCE1 in CRC datasets. The specific details of cBioPortal usage are not explicitly described in the abstract and introduction provided.",[],"['Web-based analysis', 'Web-based visualization']","['ABCE1', 'TP53']",['Not specified'],Unclear,low,4.0,40634536,ABCE1 facilitates tumour progression via aerobic glycolysis and inhibits cell death in human colorectal cancer cells through the p53 signalling pathway.,2025,abstract,2025-12-19T04:10:18.276433,,,,
"['Gene expression analysis', 'Mutation analysis']",['Breast cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],['TCGA'],The study used cBioPortal to access and analyze TCGA data for identifying TNBC-upregulated lncRNA CDKN2B-AS1. The authors analyzed ribosomal RNA sequencing data combined with TCGA database information to identify the novel peptide 66CTG encoded by CDKN2B-AS1. The specific details of how cBioPortal was used are not extensively described in the provided abstract and introduction.,['TCGA'],['Data download/export'],"['CDKN2B-AS1', 'MYC']",['Not specified'],"[""External (downloaded data)""]",medium,4.0,40628713,A novel peptide 66CTG stabilizes Myc proto-oncogene protein to promote triple-negative breast cancer growth.,2025,pdf,2025-12-19T04:10:19.048953,,,,
['Mutation analysis'],['Glioma/Brain cancer'],"['Drug response/resistance', 'Precision medicine']","['Clinical study', 'Other']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal being used in this case report. This is a clinical case study describing a single patient with epithelioid GBM harboring BRAF V600E mutation who responded to BRAF/MEK inhibitor therapy. The paper does not describe any use of cBioPortal for data analysis, visualization, or data download.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40623326,Rapid response to BRAF/MEK inhibitor therapy within 2 weeks for high-grade glioma with leptomeningeal metastasis: illustrative case.,2025,abstract,2025-12-19T04:10:20.201511,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to perform oncogenomic analysis of colon adenocarcinoma, specifically to determine mutation rates for three candidate genes: AQP9 (2.3%), IFITM1 (1%), and ITGA5 (3%). This analysis complemented the primary gene expression and machine learning analyses to characterize the genomic alterations of these IBD-associated colorectal cancer biomarker candidates.",['TCGA-COAD'],['Web-based analysis'],"['AQP9', 'IFITM1', 'ITGA5']",['Query interface'],cBioPortal platform,high,4.0,40622593,AQP9 and IFITM1 as drivers of immune infiltration and tumor progression in IBD-associated colorectal cancer: from computational insights to experimental validation.,2025,abstract,2025-12-19T04:10:22.070260,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","The study used cBioPortal to analyze STXBP1 expression patterns across multiple cancer types using TCGA datasets integrated with GTEx normal tissue data. Pan-cancer analyses revealed significant STXBP1 upregulation in tumor versus matched normal tissues across seven malignancies, with HNSC showing particularly prominent elevation. The analysis also examined stage-dependent progression and clinical correlations of STXBP1 expression.",['TCGA'],"['Web-based analysis', 'Data download/export']","['STXBP1', 'CD47']","['Expression analysis', 'Group comparison']",Mixed,medium,4.0,40615486,Catechin suppresses HNSC via STXBP1 dependent inhibition of macrophage infiltration and CD47 mediated immune evasion.,2025,pdf,2025-12-19T04:10:22.308699,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],['Biomarker discovery'],['Original research'],"['TCGA', 'Multiple sources']","The study used TCGA data from cBioPortal as an in silico validation cohort consisting of 436 HCC samples. The authors validated expression levels of key fusion partner genes (ALB, APOA2, IGF2, MT2A, SERPINA1, and H19) using this TCGA dataset. The low expression of SERPINA1 and H19 was associated with more aggressive HCC phenotypes, suggesting survival analysis was performed using cBioPortal data.",['TCGA'],"['Data download/export', 'Web-based analysis']","['SERPINA1', 'H19', 'ALB', 'APOA2', 'IGF2', 'MT2A']","['Expression analysis', 'Download data']","[""External (downloaded data)""]",medium,4.0,40613496,Fusion transcripts landscape in hepatocellular carcinoma and potential impact on the expression of fusion partners.,2025,abstract,2025-12-19T04:10:23.957475,,,,
"['Mutation analysis', 'Copy number analysis', 'Survival analysis']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, cBioPortal is cited in this paper but the specific usage is not explicitly described in the provided text. The study performed comprehensive next-generation sequencing of 205 genes on cystic and non-cystic glioblastoma samples from their own institutional cohort. Without access to the methods section, it is unclear whether cBioPortal was used for data comparison, validation, or only as a citation reference.",[],['Citation only'],"['PDGFRA', 'RB1', 'KIT', 'CDKN2A', 'CDKN2B']",['Not specified'],Unclear,low,4.0,40610845,Cystic glioblastoma IDH-wildtype: genetic alterations and outcomes.,2025,abstract,2025-12-19T04:10:24.413412,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Mutation analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the methods or results sections. While the study analyzes TCGA-LIHC data for gene expression, survival, and mutation analysis of JPT1 in hepatocellular carcinoma, there is no clear indication that cBioPortal was used as a tool or platform for data access or analysis. The citation of cBioPortal may be in the references but specific usage is not described in the provided text.","['TCGA-LIHC', 'GSE14520']",['Citation only'],"['JPT1', 'TP53', 'CTNNB1']",['Not specified'],Unclear,low,4.0,40610765,"The role of JPT1 in hepatocellular carcinoma: tumor progression, microtubule dynamics regulation, and potential mechanisms within the immune microenvironment.",2025,pdf,2025-12-19T04:10:24.622732,,,,
"['Gene expression analysis', 'Mutation analysis', 'Other']",['Other solid tumor'],"['Immunotherapy', 'Biomarker discovery']",['Original research'],['Not specified'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this paper. The study focuses on CRISPR screens to identify regulators of macrophage cytotoxicity against cancer cells, particularly identifying ATG9A as a key regulator. The paper describes experimental work with CAR-macrophages and ovarian cancer models but does not reference cBioPortal for data analysis or visualization in the sections provided.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40595560,Exploitable mechanisms of antibody and CAR mediated macrophage cytotoxicity.,2025,pdf,2025-12-19T04:10:24.828148,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Copy number analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Gastric cancer']","['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used in this pan-cancer study to analyze EGFLAM across multiple cancer types. The authors likely used cBioPortal to access TCGA data and perform analyses related to genetic alterations, expression patterns, and clinical correlations. Based on the abstract mentioning genetic alterations of the EGFLAM locus and multi-omics analyses, cBioPortal appears to have been used for data access and potentially for mutation/copy number analysis.",[],['Data download/export'],['EGFLAM'],['Not specified'],External (downloaded data),low,4.0,40597847,Comprehensive multi-omics pan-cancer analysis revealed EGFLAM as a potential prognostic and immune infiltration-associated biomarker.,2025,pdf,2025-12-19T04:10:24.908074,,,,
"['Multi-omics integration', 'Gene expression analysis', 'Pathway analysis']",['Breast cancer'],"['Methods/Tools development', 'Biomarker discovery', 'Pathway analysis', 'Precision medicine']","['Original research', 'Methods/Software']",['TCGA'],"The authors downloaded normalized multi-omics data (host transcriptomics, epigenomics, and microbiomics) for 960 invasive breast carcinoma patient samples from TCGA-PanCanAtlas 2018 via cBioPortal. The downloaded data was then processed externally and used to compare two multi-omics integration approaches (MOFA+ and MOGCN) for breast cancer subtype classification. All subsequent analysis including batch correction, feature selection, machine learning classification, and pathway analysis was performed outside of the cBioPortal platform.",['TCGA-PanCanAtlas 2018'],['Data download/export'],[],['Download data'],External (downloaded data),high,4.0,40598554,Comparative analysis of statistical and deep learning-based multi-omics integration for breast cancer subtype classification.,2025,pdf,2025-12-19T04:10:25.437021,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, cBioPortal is not explicitly mentioned in the text. The study uses TCGA-EC and GEO databases for multi-omics analysis, but there is no clear description of cBioPortal usage. The paper may cite cBioPortal in references or methods section not provided, but specific usage details are not available in the excerpts given.",['TCGA-EC'],['Citation only'],"['HIF3A', 'ACTL8', 'SIRPG', 'FBN3', 'ARHGAP30', 'CD6', 'P2RY13']",['Not specified'],Unclear,low,4.0,40595063,Identification of clusters related to programmed cell death and potential prognostic biomarkers for immunotherapy response in endometrial cancer.,2025,pdf,2025-12-19T04:10:25.539726,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the methods or results sections. While the study analyzes TCGA data for gastric cancer including gene expression, survival, mutation, and clinical features, there is no clear indication that cBioPortal was used as the platform or tool for accessing or analyzing this data. The paper may cite cBioPortal in references but does not describe its usage.",['TCGA'],['Citation only'],['GNGT1'],['Not specified'],Unclear,low,4.0,40594780,GNGT1 is a potential prognostic and immunologic biomarker in gastric cancer.,2025,pdf,2025-12-19T04:10:26.345935,,,,
"['Gene expression analysis', 'Survival analysis', 'Methylation analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper mentions using TCGA data and OncoDB databases to validate expression patterns of FAM3 family genes in KIRC. While cBioPortal is not explicitly mentioned by name in the provided abstract and introduction, the study appears to have accessed TCGA data for validation of gene expression patterns and survival analysis. The specific usage details of cBioPortal are not clearly described in the provided text.",['TCGA'],['Citation only'],"['FAM3A', 'FAM3B', 'FAM3C', 'FAM3D']",['Not specified'],Unclear,low,4.0,40594565,Exploring the prognostic role and expression patterns of FAM3A family genes in kidney renal clear cell carcinoma.,2025,pdf,2025-12-19T04:10:28.538534,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Pathway analysis', 'Drug response/resistance']",['Original research'],"['TCGA', 'Multiple sources']","The paper mentions using cBioPortal in the context of analyzing ADCY4 expression and methylation in breast cancer, as referenced in their previous bioinformatics study. The authors state that bioinformatics analysis of different AC isoforms in human tumors revealed ADCY4 expression was downregulated and its promoter was methylated, which was significantly related to poor prognosis in BC patients. However, the current paper focuses on experimental validation rather than detailed cBioPortal analysis.",['TCGA'],['Citation only'],['ADCY4'],['Not specified'],Unclear,low,4.0,40594405,ADCY4 inhibits cAMP-induced growth of breast cancer by inactivating FAK/AKT and ERK signaling but is frequently silenced by DNA methylation.,2025,pdf,2025-12-19T04:10:29.193938,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to determine gene alterations of CIP2A in 1880 ovarian cancer patients. The analysis identified that only 4% of patients had alterations in the gene, which were either amplifications or missense mutations of unknown significance. Three specific missense mutations (R530T, E840K, and M6281) were identified from three different patients associated with ovarian cancer.",[],"['Web-based analysis', 'Web-based visualization']","['CIP2A', 'KIAA1524']",['Query interface'],cBioPortal platform,high,4.0,40594400,Emerging roles of the cancerous inhibitor of protein phosphatase 2A (CIP2A) in ovarian cancer.,2025,pdf,2025-12-19T04:10:29.617827,,,,
['Other'],['Not specified'],['Review/Commentary'],['Review'],['Not specified'],"This is a review paper focused on Netrin-1 signaling pathways and nanoparticle-based therapeutic approaches in cancer. Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage, data analysis, or visualization. The paper appears to be a literature review discussing the biological mechanisms of Netrin-1 in cancer progression and potential therapeutic applications using nanoparticles.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40584519,"""Netrin-slaying nanoparticles: A new frontier in cancer therapy"".",2025,abstract,2025-12-19T04:10:29.869580,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis']",['Lung cancer'],"['Biomarker discovery', 'Methods/Tools development', 'Database/Resource']","['Original research', 'Methods/Software']",['Multiple sources'],"Based on the abstract and introduction provided, cBioPortal is not explicitly mentioned as being used in this study. The paper describes the development of SurvSig, a new web-based tool for analyzing lung neuroendocrine neoplasms through gene expression signatures and survival analysis. cBioPortal may be cited in the references or mentioned elsewhere in the full paper, but no specific usage details are provided in the available text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40586102,SurvSig: Harnessing gene expression signatures to uncover heterogeneity in lung neuroendocrine neoplasms.,2025,abstract,2025-12-19T04:10:30.382587,,,,
"['Mutation analysis', 'Survival analysis']",['Colorectal cancer'],"['Methods/Tools development', 'Precision medicine']",['Methods/Software'],['TCGA'],"cBioPortal is not explicitly mentioned as being used in this study. The paper describes AI-HOPE, a novel AI-driven tool that analyzes locally stored data through natural language interactions. The demonstration uses TCGA data to identify TP53 mutations in colorectal cancer and KRAS mutations associated with survival in FOLFOX-treated patients, but there is no indication that cBioPortal was used for data access, analysis, or visualization.",['TCGA'],['Citation only'],"['TP53', 'KRAS']",['Not specified'],"[""External (downloaded data)""]",low,4.0,40577785,AI-HOPE: an AI-driven conversational agent for enhanced clinical and genomic data integration in precision medicine research.,2025,abstract,2025-12-19T04:10:30.461418,,,,
['Gene expression analysis'],['Other solid tumor'],['Biomarker discovery'],"['Original research', 'Clinical study']","['TCGA', 'Custom/Private data']",The study used TCGA data accessed through cBioPortal for bioinformatics analyses to compare IRF5 gene expression patterns in bladder cancer. The authors performed comparative gene expression analysis between their clinical cohort findings and TCGA bladder cancer data. The specific usage mode and features utilized are not explicitly detailed in the abstract.,['TCGA'],['Citation only'],['IRF5'],['Not specified'],"[""Unclear""]",medium,4.0,40580227,"The rs3757385 polymorphism increases IRF5 expression and systemic nitric oxide metabolites, protecting urothelial bladder cancer patients from recurrence.",2025,abstract,2025-12-19T04:10:30.935008,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis', 'Multi-omics integration']",['Prostate cancer'],"['Tumor evolution', 'Drug response/resistance', 'Pathway analysis']",['Original research'],['Multiple sources'],"Based on the abstract and introduction provided, the paper appears to cite cBioPortal as a reference for the prevalence of FOXA1 alterations in prostate cancer (10-40%). The study itself focuses on developing knock-in mouse models and performing multiomic analyses of prostate tissues and organoids. Without access to the full methods section, the specific usage of cBioPortal beyond citation for background information is unclear.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40570057,Divergent FOXA1 mutations drive prostate tumorigenesis and therapy-resistant cellular plasticity.,2025,abstract,2025-12-19T04:10:30.961459,,,,
"['Gene expression analysis', 'Mutation analysis']",['Other solid tumor'],"['Pathway analysis', 'Biomarker discovery']",['Original research'],['TCGA'],"Based on the abstract and introduction provided, the paper does not explicitly describe how cBioPortal was used in the study. The research focuses on experimental work using HPNE cells transduced with PR55α and KRAS G12D to study cellular transformation and tumorigenesis. If cBioPortal was used, it was likely for querying TCGA pancreatic cancer data to examine expression or mutation patterns, but this is not clearly stated in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40571777,PR55α subunit of protein phosphatase 2A supports KRAS<sup>G12D</sup>-driven tumorigenesis that requires YAP activation.,2025,abstract,2025-12-19T04:10:30.986554,,,,
"['Mutation analysis', 'Survival analysis']",['Leukemia/Lymphoma'],"['Biomarker discovery', 'Precision medicine']",['Original research'],['Multiple sources'],"The authors used cBioPortal to access a myelodysplastic syndromes dataset containing 399 CMML cases for validation purposes. They extracted data including age, sex, white blood cells, hemoglobin, platelets, overall survival, AML-free survival, bone marrow blasts, circulating blasts, cytogenetics, and gene mutations from cBioPortal. This international cohort data was used to validate findings from their national Austrian biodatabase (ABCMML) regarding CBL-mutated CMML patients, specifically comparing survival outcomes and phenotypic parameters between mutated and wildtype patients.",['myelodysplastic syndromes dataset'],['Data download/export'],['CBL'],['Download data'],External (downloaded data),high,4.0,40569544,Characteristics of CBL-mutated patients with chronic myelomonocytic leukemia in a national (ABCMML) and an international cohort (cBIOPORTAL).,2025,pdf,2025-12-19T04:10:32.736312,,,,
['Other'],['Not specified'],"['Methods/Tools development', 'Drug response/resistance']","['Original research', 'Methods/Software']",['Not specified'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. This paper focuses on molecular dynamics simulations and computational network analysis of the Lyn kinase protein structure. The study appears to be purely computational/structural biology work without direct use of cBioPortal's cancer genomics data or analysis features.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40565298,Allosteric Coupling in Full-Length Lyn Kinase Revealed by Molecular Dynamics and Network Analysis.,2025,abstract,2025-12-19T04:10:34.134495,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Immunotherapy', 'Methods/Tools development']",['Original research'],"['TCGA', 'Custom/Private data']",The paper used cBioPortal to analyze ANXA1 and FPR1 expression levels in glioblastoma patient samples and assess their association with patient survival outcomes. The authors queried TCGA glioblastoma datasets through cBioPortal to validate their findings that ANXA1 expression in astrocytes and FPR1 expression in cancer cells are associated with poor outcomes in individuals with GBM. This analysis provided clinical validation for their experimental findings on the ANXA1-FPR1 signaling pathway.,['TCGA-GBM'],"['Web-based analysis', 'Web-based visualization']","['ANXA1', 'FPR1']","['Expression analysis', 'Survival analysis']",cBioPortal platform,medium,4.0,40562937,Barcoded viral tracing identifies immunosuppressive astrocyte-glioma interactions.,2025,abstract,2025-12-19T04:10:35.827951,,,,
"['Mutation analysis', 'Gene expression analysis']",['Leukemia/Lymphoma'],"['Biomarker discovery', 'Other']",['Original research'],['Not specified'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on experimental investigation of PROSER1 and TET2 functions in hematopoietic stem cells using transplantation assays and DNA methylation analysis. If cBioPortal was cited, it was likely for reference purposes only without direct data usage or analysis described in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40554416,The TET protein family interactor PROSER1 sustains hematopoietic stem cell function.,2025,abstract,2025-12-19T04:10:36.184343,,,,
['Mutation analysis'],['Other solid tumor'],"['Precision medicine', 'Drug response/resistance', 'Biomarker discovery']","['Clinical study', 'Original research']",['Custom/Private data'],"This is a case report of a patient with RAF1 mutated sarcoma treated with trametinib and chemotherapy. The paper does not explicitly describe any direct use of cBioPortal for data analysis, visualization, or data download. cBioPortal may only be cited in the references as a general resource for cancer genomics data.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40556788,Excellent response to trametinib and low dose chemotherapy in a patient with rare RAF1 mutated sarcoma in a tertiary care center in India.,2025,abstract,2025-12-19T04:10:36.280218,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Prostate cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['Multiple sources'],"cBioPortal was used as one of several integrated bioinformatics platforms to analyze hub genes and their transcription factors in prostate cancer. The platform was specifically used to assess mutation, amplification, and deletion frequencies of hub genes, particularly BUB1B (32%) and CCNB1 (29%), which showed the highest degree of genomic alterations. cBioPortal analysis contributed to associating these hub genes with aggressive prostate carcinogenesis pathways.",[],"['Web-based analysis', 'Web-based visualization']","['BUB1B', 'CCNB1', 'CCNA2', 'NCAPG', 'MKI67', 'CDK1', 'CCNB2', 'AURKA', 'UBE2C', 'E2F4', 'MYC', 'YBX1']","['Query interface', 'Expression analysis']",Mixed,medium,4.0,40564927,RNA-Seq Uncovers Association of Endocrine-Disrupting Chemicals with Hub Genes and Transcription Factors in Aggressive Prostate Cancer.,2025,abstract,2025-12-19T04:10:36.512537,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The paper used cBioPortal to analyze VASN expression and its clinical correlations in gastric cancer patients. The authors likely queried TCGA gastric cancer datasets through cBioPortal to examine VASN expression levels and their association with patient survival outcomes. This bioinformatics analysis complemented their experimental work using patient samples, mouse models, and cell lines to establish VASN's role in gastric tumorigenesis.",['TCGA'],"['Web-based analysis', 'Citation only']","['VASN', 'COL4A1', 'HIF1A']","['Expression analysis', 'Survival analysis']",Unclear,medium,4.0,40550854,VASN drives gastric tumorigenesis via activation of the COL4A1/PI3K/AKT axis during Helicobacter pylori infection.,2025,abstract,2025-12-19T04:10:37.252843,,,,
"['Mutation analysis', 'Survival analysis']",['Lung cancer'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The study analyzed NSCLC patients from 2019 to 2021 using the Illumina Focus 52-gene targeted NGS panel on their own patient cohort. The paper may cite cBioPortal in the references for context or comparison purposes, but the actual molecular characterization and analysis appear to have been performed using their own institutional data and methods.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40556802,Molecular characterisation of KRAS mutations in non-small cell lung cancer across all stages.,2025,abstract,2025-12-19T04:10:37.285519,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Copy number analysis']","['Pan-cancer', 'Bladder cancer', 'Cholangiocarcinoma', 'Esophageal cancer', 'Head and neck cancer', 'Liver cancer', 'Thyroid cancer', 'Pancreatic cancer', 'Endometrial cancer']",['Biomarker discovery'],['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to review genetic alterations of RNASEK across multiple cancer types. The study found that RNASEK was altered in less than 1% of samples (95 out of 10,967 samples) across various tumor types, with the highest alteration rates being deletions in neuroepithelial tumors (3.23%), amplifications in sarcoma (1.96%), and mutations in endometrial cancer (0.34%).",[],['Web-based analysis'],['RNASEK'],['Query interface'],cBioPortal platform,medium,4.0,40546550,Pan-Cancer Analysis Reveals Ribonuclease K (RNASEK) as a Potential Prognostic Biomarker in Pancreatic Cancer and a Diagnostic Indicator Across Multiple Human Cancers.,2025,pdf,2025-12-19T04:10:38.250641,,,,
"['Mutation analysis', 'Gene expression analysis']",['Breast cancer'],"['Drug response/resistance', 'Immunotherapy', 'Precision medicine']","['Clinical study', 'Original research']",['Custom/Private data'],"The paper does not explicitly describe using cBioPortal in this study. This is a clinical trial (phase Ib/II) examining atezolizumab combined with cobimetinib or idasanutlin in ER+ metastatic breast cancer patients stratified by TP53 mutation status. While TP53 mutations were used for patient stratification, there is no mention of cBioPortal being used for data analysis, visualization, or data retrieval in the methods or results sections.",[],['Citation only'],['TP53'],['Not specified'],Unclear,low,4.0,40544188,A phase Ib/II trial of atezolizumab with cobimetinib or idasanutlin in metastatic estrogen receptor positive breast cancer.,2025,pdf,2025-12-19T04:10:39.412937,,,,
"['Mutation analysis', 'Survival analysis']",['Leukemia/Lymphoma'],"['Biomarker discovery', 'Precision medicine']",['Original research'],['Multiple sources'],"The authors used cBioPortal to access a myelodysplastic syndromes dataset containing 399 CMML patients with clinical, molecular, and survival data. They extracted data on sex, age, WBC count, platelets, hemoglobin, overall survival, AML-free survival, bone marrow blasts, circulating blasts, cytogenetics, and gene mutations to validate findings from their national Austrian ABCMML cohort. The cBioPortal cohort was used specifically to compare phenotypic features and survival outcomes between SRSF2-mutated and wildtype CMML patients.",['myelodysplastic syndromes dataset'],"['Data download/export', 'Web-based analysis']","['SRSF2', 'TET2']","['Survival analysis', 'Group comparison', 'Download data']",External (downloaded data),high,4.0,40549056,Features of SRSF2-mutated patients with chronic myelomonocytic leukemia in a national (ABCMML) and international cohort (cBioPortal).,2025,pdf,2025-12-19T04:10:39.472893,,,,
"['Gene expression analysis', 'Mutation analysis']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],"['TCGA', 'Multiple sources']",cBioPortal was used to analyze TCGA data to assess GSDME expression levels and mutation rates in glioblastoma patients. The authors found that GSDME was amplified in 4% of GB patients and only 1 out of 368 patients showed a mutation (a splice mutation of unknown significance). This analysis was complemented by additional expression analysis from proteinatlas.org using TCGA data.,['TCGA'],"['Web-based analysis', 'Web-based visualization']",['GSDME'],"['Expression analysis', 'Query interface']",cBioPortal platform,high,4.0,40544161,Gasdermin E in glioblastoma -pyroptosis resistance and tumor-promoting functions.,2025,pdf,2025-12-19T04:10:40.085172,,,,
['Gene expression analysis'],['Melanoma'],"['Immunotherapy', 'Biomarker discovery']",['Original research'],['Not specified'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on experimental investigation of HVJ-E virotherapy mechanisms using RNA sequencing, CRISPR screening, mass spectrometry, and mouse models. cBioPortal may only be cited in the references without direct usage for data analysis or visualization.",[],['Citation only'],[],['Not specified'],"[""Unclear""]",low,4.0,40541272,HVJ-E links Apolipoprotein d to antitumor effects.,2025,abstract,2025-12-19T04:10:42.097095,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Colorectal cancer'],['Biomarker discovery'],['Original research'],['Multiple sources'],"The paper does not explicitly mention using cBioPortal in the abstract or introduction provided. The study analyzed cullin family gene expression in rectal adenocarcinoma using publicly available databases including UALCAN and HOA, performed Kaplan-Meier survival analysis, and conducted functional enrichment analysis. While cBioPortal is cited, there is no clear description of how it was used in the methodology from the provided text.",[],['Citation only'],"['CUL1', 'CUL2', 'CUL3', 'CUL4A', 'CUL4B', 'CUL5', 'CUL7', 'CUL9']",['Not specified'],Unclear,low,4.0,40535676,"Analysis of cullin family genes in rectal adenocarcinoma: expression, prognostic significance, and therapeutic implications.",2025,pdf,2025-12-19T04:10:42.314274,,,,
"['Gene expression analysis', 'Mutation analysis', 'Copy number analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']",cBioPortal was used to retrieve alteration frequency statistics for DSN1 across pan-cancer samples. The platform provided data on genetic alterations (mutations and copy number variations) in DSN1 across different cancer types. The data was then visualized using R packages ggplot2 and ggprism.,[],"['Data download/export', 'Web-based visualization']",['DSN1'],"['Query interface', 'Download data']",External (downloaded data),high,4.0,40535813,A Comprehensive Analysis of the Role of DSN1 in Pan-Cancer Prognosis and Immunotherapy.,2025,pdf,2025-12-19T04:10:42.334583,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'ICGC', 'Multiple sources']","The paper mentions downloading RNA-seq data and clinical information for 427 HCC samples from TCGA, which is commonly accessed through cBioPortal. However, the abstract and introduction do not explicitly describe specific cBioPortal usage, features, or methodology. The study appears to have downloaded data for external analysis to construct a prognostic risk model based on de novo lipogenesis-related genes.","['TCGA', 'ICGC-LIRI']",['Data download/export'],"['G6PD', 'LCAT', 'SERPINE1', 'SOAT2', 'CYP2C9', 'UGT1A10']",['Download data'],External (downloaded data),medium,4.0,40533802,The impact of de novo lipogenesis on predicting survival and clinical therapy: an exploration based on a multigene prognostic model in hepatocellular carcinoma.,2025,pdf,2025-12-19T04:10:43.906284,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Lung cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to conduct mutational analysis of cadherin family genes (CDH1, CDH2, and CDH3) in NSCLC. The study found that CDH2 exhibited the highest mutation frequency (63%), followed by CDH3 (23%) and CDH1 (19%). The platform was used alongside other databases (TIMER2, HPA, GEPIA2, OncoDB, KM Plotter, DAVID, GSCA) for comprehensive multi-database analysis.",[],['Web-based analysis'],"['CDH1', 'CDH2', 'CDH3']",['Query interface'],cBioPortal platform,medium,4.0,40535673,"Cadherin family genes in non-small cell lung cancer: implications for diagnosis, prognosis, and targeted therapy.",2025,pdf,2025-12-19T04:10:43.910260,,,,
"['Mutation analysis', 'Copy number analysis', 'Survival analysis', 'Pathway analysis']",['Lung cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine', 'Tumor evolution']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper describes analysis of next generation sequencing (NGS) data from patients with EGFR-mutant NSCLC, including mutation analysis, copy number alterations (CARD11 and MDM2 amplifications), and survival analyses. However, the methods and data sources described appear to be institutional/custom data analyzed independently, with no clear indication that cBioPortal was used for data access, analysis, or visualization.",[],['Citation only'],"['EGFR', 'CARD11', 'MDM2']",['Not specified'],"[""Unclear""]",low,4.0,40532851,Identifying the genomic landscape of EGFR-mutant lung cancers with central nervous system metastases.,2025,abstract,2025-12-19T04:10:44.769163,,,,
"['Gene expression analysis', 'Copy number analysis', 'Mutation analysis', 'Survival analysis', 'Multi-omics integration']","['Pan-cancer', 'Lung cancer']","['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to analyze genetic alterations, copy number variations (CNVs), and methylation patterns of ADM across multiple cancer types in this pan-cancer study. The platform was mentioned alongside GSCA for analyzing genomic alterations. The study examined ADM's genetic alterations including amplification and deep deletion across multiple cancer types using cBioPortal.",['TCGA'],"['Web-based analysis', 'Data download/export']","['ADM', 'CD274', 'CD276', 'TNFRSF18', 'TNFSF9', 'PVR']","['Query interface', 'Download data']",Mixed,medium,4.0,40529377,"Integrated pan-cancer analysis of ADM's role in prognosis, immune modulation and resistance.",2025,pdf,2025-12-19T04:10:44.918520,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Methods/Tools development']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, cBioPortal usage is not explicitly mentioned in these sections. The study focuses on epigenetic silencing of CLDN10B in renal cancer using DNA methylation analysis, CRISPR-mediated reactivation, and functional assays. While TCGA data appears to be used (common for RCC studies), specific cBioPortal usage details are not provided in the excerpted text.",[],['Citation only'],['CLDN10'],['Not specified'],Unclear,low,4.0,40524239,Epigenetic silencing and CRISPR-mediated reactivation of tight junction protein claudin10b (CLDN10B) in renal cancer.,2025,pdf,2025-12-19T04:10:46.386487,,,,
['Gene expression analysis'],['Other solid tumor'],"['Biomarker discovery', 'Other']",['Original research'],['Not specified'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on analyzing cancer-associated fibroblasts (CAFs) from patient tissue samples using flow cytometry and RNA expression analysis. The study appears to be based on primary cell cultures from surgical resection samples rather than utilizing cBioPortal data or tools. cBioPortal may only be cited in the references without direct usage in the methodology.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40523922,The influence of clinical risk factors on the classification of human cancer-associated fibroblasts in PDAC and pancreatitis patients.,2025,pdf,2025-12-19T04:10:46.665459,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Prostate cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, cBioPortal is cited in this study but specific usage details are not described in the provided text. The study focuses on identifying GPR137C as a prognostic marker through G4 screening and bioinformatics analyses in prostate cancer, likely using TCGA data for validation. The exact nature of cBioPortal usage (data download, web analysis, or citation only) cannot be determined from the provided sections.",['TCGA-PRAD'],['Citation only'],"['GPR137C', 'MYC', 'SP1']",['Not specified'],Unclear,low,4.0,40519905,Investigation of GPR137C as a promising novel marker for the progression of prostate cancer through G4 screen and bioinformatics analyses.,2025,pdf,2025-12-19T04:10:47.170310,,,,
"['Gene expression analysis', 'Pathway analysis', 'Mutation analysis']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']",cBioPortal was used to obtain genetic alterations of SRRM2-AS1 across pan-cancer. The platform served as a data source for analyzing mutation and copy number variation patterns of SRRM2-AS1 in multiple cancer types. The specific analysis methods and features used within cBioPortal are not detailed in the abstract and introduction.,[],['Data download/export'],['SRRM2-AS1'],['Not specified'],External (downloaded data),medium,4.0,40515981,The impact of SRRM2-AS1 in ovarian cancer: a comprehensive analysis based on pan-cancer and in vitro validation.,2025,pdf,2025-12-19T04:10:47.962135,,,,
"['Multi-omics integration', 'Other']",['Pan-cancer'],['Methods/Tools development'],"['Methods/Software', 'Original research']",['Multiple sources'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on developing PTM-POSE, a tool for analyzing post-translational modifications in relation to alternative splicing using Ensembl transcripts. If cBioPortal is cited, it appears to be a reference citation only without direct usage described in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40513562,Systematic analysis of the effects of splicing on the diversity of post-translational modifications in protein isoforms using PTM-POSE.,2025,abstract,2025-12-19T04:10:48.393947,,,,
"['Gene expression analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],"cBioPortal is mentioned in the introduction as one of the computational tools that accelerate the discovery of driver genes and therapeutic targets through data mining. The paper appears to use TCGA ovarian cancer cohort data to examine differential expression of core genes (GAPDH, CASP3, PPARG, ESR1, CYCS, SIRT1, and CCND1), though the specific method of data access is not explicitly detailed. The tool is cited as part of the broader computational oncology framework but specific usage details are not provided in the abstract and introduction.",['TCGA ovarian cancer cohort'],['Citation only'],"['GAPDH', 'CASP3', 'PPARG', 'ESR1', 'CYCS', 'SIRT1', 'CCND1']",['Not specified'],Unclear,low,4.0,40517225,"Phthalates unleashed: decoding ovarian carcinogenesis through multi-omics networks, single-cell insights, and molecular docking.",2025,pdf,2025-12-19T04:10:49.206752,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Custom/Private data']","Based on the abstract and introduction provided, the paper appears to cite cBioPortal as a reference or data source for human HGSC genomic data, likely to contextualize CDK12 alterations in human disease. The study primarily focuses on developing and characterizing mouse models of ovarian cancer with CDK12 inactivation. Specific details about cBioPortal usage are not provided in the abstract/introduction sections available.",['TCGA'],['Citation only'],"['CDK12', 'TP53', 'RB1', 'NF1', 'CDK13']",['Not specified'],Unclear,low,4.0,40504161,Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinoma.,2025,abstract,2025-12-19T04:10:50.458824,,,,
"['Gene expression analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Not specified']","Based on the abstract and introduction provided, cBioPortal appears to be used for clinical data analysis to examine the relationship between ALKBH5 and β-catenin expression in breast cancer patients. The study mentions that ""Clinical data analysis demonstrated a strong positive relationship between ALKBH5 and β-catenin expression,"" suggesting cBioPortal was likely used to access and analyze clinical genomic data. However, specific details about how cBioPortal was used are not provided in the excerpted sections.",[],['Web-based analysis'],"['ALKBH5', 'CTNNB1']",['Expression analysis'],Unclear,low,4.0,40496172,ALKBH5 Promotes Breast Cancer Stemness Through Regulating Wnt/β-Catenin Signaling.,2025,pdf,2025-12-19T04:10:50.883420,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis', 'Multi-omics integration']",['Melanoma'],"['Drug response/resistance', 'Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'Custom/Private data']","Based on the abstract and introduction provided, the paper appears to use cBioPortal to access melanoma genomic data, likely from TCGA or other public datasets, to identify and validate molecular features of NF1-mutant melanomas. The study utilized multiomics approaches including mutation and gene expression analysis to characterize NF1-mutant melanoma. While specific cBioPortal usage details are not explicitly described in the provided text, the study likely queried NF1, EGFR, BRAF, and NRAS mutation and expression data from public melanoma cohorts.",['TCGA'],['Data download/export'],"['NF1', 'EGFR', 'BRAF', 'NRAS']",['Not specified'],"[""External (downloaded data)""]",medium,4.0,40494652,NF1 Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in NF1-Mutant Melanoma.,2025,abstract,2025-12-19T04:10:51.871775,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper describes using TCGA data, GEO immunotherapy cohorts, TIMER for immune cell evaluation, TISCH2 for single-cell analysis, and GSEA for pathway analysis, but cBioPortal is not mentioned in the provided text. If cBioPortal was used, it may be described in the methods section not included here, or it may only be cited as a reference.",['TCGA'],['Citation only'],['TNFSF4'],['Not specified'],Unclear,low,4.0,40493100,Multi-omics analysis of tumor necrosis factor superfamily 4 reveals its prognostic value with T cell exhaustion feature in cancer.,2025,pdf,2025-12-19T04:10:52.110412,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Lung cancer'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to download data on gene mutation, amplification, and methylation for Aurora kinases (AURKs) in lung cancer. The methylation data were obtained from the HM450 platform through cBioPortal. The study assessed the association between AURKs expression and copy number alterations, as well as the relationship with methylation using Pearson's correlation coefficients.",[],['Data download/export'],"['AURKA', 'AURKB', 'AURKC']",['Download data'],External (downloaded data),high,4.0,40481349,The expression and prognosis for Aurora kinases in human non-small cell lung cancer.,2025,pdf,2025-12-19T04:10:52.550167,,,,
"['Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Methods/Tools development', 'Pathway analysis', 'Precision medicine']","['Original research', 'Methods/Software']","['TCGA', 'Multiple sources']","Based on the abstract and introduction, the paper appears to focus on eccDNA-driven genes and their characterization across cancer types. The paper mentions integrated analysis of genetic alterations, gene expression, pathways, and clinical features. While cBioPortal is cited, the specific usage details are not explicitly described in the provided abstract and introduction sections, suggesting it may have been used for data access or validation purposes.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40478912,Identification and characterization of eccDNA-driven genes in humans.,2025,abstract,2025-12-19T04:10:53.225374,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly describe using cBioPortal in the methods or results sections. While the study analyzes KIRC data and mentions using databases like GSCA and UALCAN for gene expression validation, there is no clear mention of cBioPortal being used for data access, analysis, or visualization. The citation may be a general reference rather than indicating actual usage of the platform.",[],['Citation only'],"['FYN', 'LGALS8', 'MAGI2', 'WT1']",['Not specified'],Unclear,low,4.0,40489038,Shared hub genes in membranous nephropathy and kidney renal clear cell carcinoma: investigating molecular overlap and tumor progression.,2025,pdf,2025-12-19T04:10:54.406238,,,,
['Gene expression analysis'],['Pan-cancer'],['Methods/Tools development'],"['Methods/Software', 'Original research']","['TCGA', 'Custom/Private data']","Based on the abstract and introduction provided, cBioPortal is cited in this paper but the specific usage is not detailed in these sections. The paper focuses on developing DeepDeconUQ, a deep learning method for estimating malignant cell fractions with uncertainty quantification using bulk RNA-seq data. The role of cBioPortal in this study cannot be determined from the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40465796,DeepDeconUQ estimates malignant cell fraction prediction intervals in bulk RNA-seq tissue.,2025,abstract,2025-12-19T04:10:54.561689,,,,
"['Gene expression analysis', 'Mutation analysis']","['Colorectal cancer', 'Other solid tumor']","['Pathway analysis', 'Biomarker discovery']",['Original research'],['TCGA'],The paper used cBioPortal to analyze TCGA colorectal cancer datasets to examine the relationship between TRIP12 expression levels and patient survival outcomes. The authors queried cBioPortal to access TCGA data for correlation analysis between TRIP12 expression and clinical outcomes in colorectal cancer patients. The analysis appears to have been performed using cBioPortal's web-based tools to examine gene expression and survival data.,['TCGA colorectal cancer'],"['Web-based analysis', 'Web-based visualization']","['TRIP12', 'AXIN2', 'SP5', 'DKK1', 'BRG1', 'SMARCA4']","['Expression analysis', 'Survival analysis', 'Query interface']",cBioPortal platform,medium,4.0,40473626,The TRIP12 E3 ligase induces SWI/SNF component BRG1-β-catenin interaction to promote Wnt signaling.,2025,pdf,2025-12-19T04:10:54.721484,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis']",['Lung cancer'],"['Drug response/resistance', 'Pathway analysis', 'Biomarker discovery']",['Original research'],"['TCGA', 'Multiple sources']","The paper mentions using cBioPortal to analyze NRF2/KEAP1 mutation frequencies in lung cancer, specifically referencing that activating mutations of NRF2 are found in about 15% of LUSC and 3% of LUAD. The authors appear to have used cBioPortal to access TCGA data and other sequencing projects to identify mutation frequencies in the KEAP1-NRF2 pathway. However, the specific details of how cBioPortal was used are not extensively described in the provided text.",['TCGA'],['Citation only'],"['NFE2L2', 'KEAP1', 'CUL3']",['Not specified'],Unclear,low,4.0,40470216,Activating NRF2E79Q mutation alters the differentiation of human non-small cell lung cancer.,2025,pdf,2025-12-19T04:10:55.865831,,,,
"['Gene expression analysis', 'Pathway analysis']",['Prostate cancer'],"['Drug response/resistance', 'Pathway analysis']",['Original research'],['Not specified'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on experimental investigations of AR and GR crosstalk in prostate cancer cells using genome-wide approaches, chromatin binding studies, and transcriptional analysis. If cBioPortal was used, it may be mentioned in the methods or results sections not provided here, but from the available text, no specific cBioPortal usage can be identified.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40456604,Androgen receptor-mediated assisted loading of the glucocorticoid receptor modulates transcriptional responses in prostate cancer cells.,2025,pdf,2025-12-19T04:10:57.069957,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Colorectal cancer', 'Pan-cancer']","['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was mentioned as one of multiple databases used for multi-omics analysis in this study examining ENTR1's role in cancer progression. The paper states they conducted multi-omics analyses using several databases including TCGA, cBioPortal, GTEx, HPA, and CPTAC to examine ENTR1 expression in malignant tumors and its association with clinical prognosis and tumor staging. However, no specific details are provided about what data was obtained from cBioPortal or how it was used.",[],['Citation only'],"['ENTR1', 'APC', 'KRAS', 'PIK3CA', 'GLUT1']",['Not specified'],Unclear,low,4.0,40462015,ENTR1 affects the progression of colon cancer by regulating energy metabolism under the influence of glycolysis.,2025,pdf,2025-12-19T04:10:57.809129,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']",['Original research'],['Multiple sources'],"cBioPortal was used to analyze genetic alterations in eight key genes (BRAF, EIF1AX, FOXE1, KRAS, PDGFRA, PIK3CA, PTEN, and TERT) in thyroid cancer. The platform was utilized to examine mutation frequencies and types of genetic alterations across these genes. The analysis revealed prevalent BRAF mutations while other genes exhibited fewer alterations.",[],"['Web-based analysis', 'Web-based visualization']","['BRAF', 'EIF1AX', 'FOXE1', 'KRAS', 'PDGFRA', 'PIK3CA', 'PTEN', 'TERT']",['Query interface'],cBioPortal platform,medium,4.0,40450370,Deciphering the role of Hashimoto's Thyroiditis-related key genes in thyroid cancer via detailed in silico analysis followed by the experimental validation.,2025,pdf,2025-12-19T04:10:58.327243,,,,
"['Mutation analysis', 'Other']","['Lung cancer', 'Other solid tumor']","['Methods/Tools development', 'Tumor evolution']","['Original research', 'Methods/Software']",['Not specified'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. This paper focuses on developing transgenic Cas12a mice for somatic genome editing to create cancer models with multiple genetic alterations. The study appears to be primarily experimental/methodological, generating new mouse models rather than analyzing existing cancer genomics databases. cBioPortal may only be cited in references without direct usage in the research.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40447760,Efficient and multiplexed somatic genome editing with Cas12a mice.,2025,abstract,2025-12-19T04:10:58.906827,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Lung cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine', 'Immunotherapy']",['Original research'],['Multiple sources'],The study used cBioPortal as one of the data sources for bulk RNA sequencing data of SCLC samples. The cBioPortal cohort was used alongside GSE60052 dataset to identify metabolism-related gene modules through WGCNA and develop a prognostic model. The data was downloaded from cBioPortal and analyzed externally using various computational methods including machine learning approaches.,[],['Data download/export'],"['MOCS2', 'USP39', 'SMYD2', 'GFPT1', 'PRKRIR', 'TP53', 'RB1']",['Download data'],External (downloaded data),medium,4.0,40452920,Metabolic reprogramming signature predicts prognosis and immune landscape in small cell lung cancer: MOCS2 validation and implications for personalized therapy.,2025,pdf,2025-12-19T04:11:00.048390,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy', 'Drug response/resistance']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to obtain mutation data for the GULP1 gene across TCGA PanCancer Atlas Studies. The authors extracted information on mutation types, frequencies, counts, mutation sites, and three-dimensional (3D) structures of GULP1 through the cBioPortal online website. This mutation analysis was part of a comprehensive pan-cancer characterization of GULP1.",['TCGA PanCancer Atlas Studies'],"['Web-based analysis', 'Web-based visualization']",['GULP1'],"['Mutation Mapper', 'Query interface']",cBioPortal platform,high,4.0,40447753,"The value of GULP1 in cancer prognosis and immunotherapy, validated from pan-cancer analysis to pancreatic cancer.",2025,pdf,2025-12-19T04:11:00.498712,,,,
['Gene expression analysis'],['Prostate cancer'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],['Not specified'],"The authors used publicly available datasets to investigate the expression level of SENP2 in prostate cancer tissue samples and its correlation with androgen receptor (AR). The specific platform or database used (whether cBioPortal or another resource) is not explicitly stated in the abstract, though they mention using ""publicly available datasets"" for this analysis. The analysis focused on comparing SENP2 expression levels between metastatic and non-metastatic prostate cancer samples.",[],['Citation only'],"['SENP2', 'AR']",['Not specified'],Unclear,low,4.0,40434722,Targeting Prostate Cancer Cells by an Isopeptidase Inhibitor NSC632839.,2025,abstract,2025-12-19T04:11:00.875053,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The study used cBioPortal as a data source to obtain CRC samples for calculating the mRNA expression-based stemness index (mRNAsi). The data from cBioPortal was combined with TCGA data to perform comprehensive analysis of gene expression patterns associated with colorectal cancer stem cell characteristics. The specific analysis methods (DESeq2, machine learning models, survival analysis) appear to have been performed externally after data acquisition.",[],['Data download/export'],"['COL1A1', 'FBN1', 'MMP9', 'SPP1', 'BGN', 'COL5A1', 'FN1', 'ELN', 'MMP2', 'COL1A2']",['Download data'],External (downloaded data),medium,4.0,40441264,Identification of key genes regulating colorectal cancer stem cell characteristics by bioinformatics analysis.,2025,abstract,2025-12-19T04:11:01.687635,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy', 'Drug response/resistance']",['Original research'],['TCGA'],"Based on the abstract and introduction provided, the paper appears to focus on experimental validation of exosomal CMTM4 in ovarian cancer. While the paper likely used TCGA data for validation purposes (common in this type of study), the specific usage of cBioPortal is not explicitly described in the provided text. The study primarily involves experimental work on tumor microenvironment, macrophage polarization, and immunotherapy response rather than bioinformatics analysis through cBioPortal.",[],['Citation only'],"['CMTM4', 'ICAM1', 'CD206']",['Not specified'],Unclear,low,4.0,40433989,Exosomal CMTM4 Induces Immunosuppressive Macrophages to Promote Ovarian Cancer Progression and Attenuate Anti-PD-1 Immunotherapy.,2025,abstract,2025-12-19T04:11:01.896151,,,,
"['Gene expression analysis', 'Multi-omics integration']","['Breast cancer', 'Prostate cancer', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy', 'Drug response/resistance']","['Original research', 'Meta-analysis']","['TCGA', 'Multiple sources']","The paper used cBioPortal to access tumor bulk RNA-Seq data to examine correlations between the expression of candidate genes (IRF1, IKZF1, SPI1, SH2B3, LAT) and intra-tumor immune cell infiltration markers (CD4, CD8A, CD11B, CD45) across multiple cancer types. This analysis was part of their in silico follow-up to identify genes whose tumor expression patterns suggested involvement in anti-tumor immune response. The specific details of how cBioPortal was accessed or which features were used are not explicitly described in the abstract.",[],['Citation only'],"['IRF1', 'IKZF1', 'SPI1', 'SH2B3', 'LAT', 'CD4', 'CD8A', 'CD11B', 'CD45']",['Not specified'],Unclear,low,4.0,40428397,Mapping Inherited Genetic Variation with Opposite Effects on Autoimmune Disease and Four Cancer Types Identifies Candidate Drug Targets Associated with the Anti-Tumor Immune Response.,2025,abstract,2025-12-19T04:11:02.939078,,,,
['Gene expression analysis'],['Prostate cancer'],"['Immunotherapy', 'Biomarker discovery']",['Original research'],['Multiple sources'],"The paper employed gene expression datasets to investigate mesothelin expression in primary and metastatic prostate cancer tumors. cBioPortal appears to have been used as one of the data sources for accessing prostate cancer gene expression data, though specific details about the usage are not provided in the abstract. The study focused on identifying mesothelin enrichment patterns across different stages of prostate cancer.",[],['Citation only'],['MSLN'],['Not specified'],Unclear,low,4.0,40427042,Targeting Aggressive Prostate Carcinoma Cells with Mesothelin-CAR-T Cells.,2025,abstract,2025-12-19T04:11:03.435932,,,,
"['Mutation analysis', 'Gene expression analysis', 'Multi-omics integration', 'Other']",['Breast cancer'],"['Methods/Tools development', 'Biomarker discovery']","['Original research', 'Methods/Software']","['Custom/Private data', 'Multiple sources']","The paper mentions cBioPortal in the context of analyzing mutational signatures of variant-containing TCNEs and identifying twenty-one genes as essential components of the regulatory mechanism of TCNEs in breast cancer. However, the abstract and introduction do not provide explicit details about how cBioPortal was specifically used, whether data was downloaded, or which features were utilized. The usage appears to be for validation or comparative analysis purposes.",[],['Citation only'],"['ENOX1', 'PTBP1']",['Not specified'],Unclear,low,4.0,40427520,Dissecting the Emerging Regulatory and Mechanistic Paradigms of Transcribed Conserved Non-Coding Elements in Breast Cancer.,2025,abstract,2025-12-19T04:11:03.535310,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Multi-omics integration']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the abstract or introduction provided. The study used data from TCGA project, GTEx database, and other online resources to analyze FAM83B in pan-cancer, but cBioPortal usage is not clearly described in the provided text. It is possible cBioPortal was used to access TCGA data or for analysis, but this cannot be confirmed from the information given.",[],['Citation only'],['FAM83B'],['Not specified'],Unclear,low,4.0,40418390,Comprehensive analysis of FAM83B in pan-cancer and preliminary exploration in esophageal squamous cell carcinoma.,2025,abstract,2025-12-19T04:11:04.760707,,,,
"['Mutation analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The authors used cBioPortal to analyze VHL mutation frequencies across multiple clear cell renal cell carcinoma datasets, including TCGA Nature 2013, IRC Nat Genet 2014, TCGA Firehose Legacy, and TCGA PanCancer Atlas. They performed data mining to identify VHL as the most frequently mutated gene with varying mutation frequencies (41.3%-79.5%) across the different datasets. The analysis also included survival analysis to correlate VHL mutations with overall survival rates and clinical characteristics such as age and metastasis.","['Kidney Renal Clear Cell Carcinoma (TCGA, Nature 2013)', 'Kidney Renal Clear Cell Carcinoma (IRC, Nat Genet 2014)', 'Kidney Renal Clear Cell Carcinoma (TCGA, Firehose Legacy)', 'Kidney Renal Clear Cell Carcinoma (TCGA, PanCancer Atlas)']","['Web-based analysis', 'Web-based visualization']",['VHL'],"['Query interface', 'Survival analysis']",cBioPortal platform,high,4.0,40425983,Mutational landscape and clinical implications of VHL in clear cell renal cell carcinoma: a multi-dataset analysis of 1377.,2025,abstract,2025-12-19T04:11:05.097536,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal is mentioned as one of several bioinformatic tools that have facilitated large-scale genomic analysis in glioma research. The paper references cBioPortal alongside GEPIA and UCSC Xena as tools that enable researchers to access and analyze cancer genomics data. However, the abstract and introduction do not provide specific details about how cBioPortal was directly used in this particular study's methodology.","['TCGA', 'CGGA', 'GSE131928', 'GSE89567']",['Citation only'],"['PTPN7', 'IDH1', 'IDH2', 'TERT', 'EGFR', 'MGMT', 'CDKN2A', 'CDKN2B']",['Not specified'],Unclear,low,4.0,40413344,"Dissecting PTPN7-driven aggressiveness in IDH-wildtype astrocytomas: multi-omics, clinical validation, and spatial transcriptomics for prognostic insights.",2025,pdf,2025-12-19T04:11:08.051114,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['Multiple sources'],"The study used cBioPortal (referred to as ""CBioPortal web tool"") to analyze genetic alterations in pancreatic cancer. The authors specifically mention using cBioPortal to investigate genetic alterations of hub genes, particularly MELK, in the context of pancreatic cancer patient data. The analysis was part of their broader bioinformatics approach to identify differentially expressed genes and their clinical correlations.",[],['Web-based analysis'],['MELK'],['Not specified'],Unclear,medium,4.0,40404813,MiR-485-3p/MELK cascade mediates tumor progression in pancreatic cancer.,2025,pdf,2025-12-19T04:11:08.454042,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],['Biomarker discovery'],['Original research'],"['TCGA', 'Multiple sources']","The paper mentions using The Cancer Genome Atlas (TCGA) alongside other bioinformatics tools like UALCAN and KM-plotter to analyze LZTS2 expression patterns and clinical relevance. However, the abstract and introduction do not explicitly mention cBioPortal usage, only TCGA as a data source. The specific role of cBioPortal in this study is unclear from the provided text.",[],['Citation only'],['LZTS2'],['Not specified'],Unclear,low,4.0,40404727,LZTS2 methylation as a potential diagnostic and prognostic marker in LIHC and STAD: Evidence from bioinformatics and in vitro analyses.,2025,pdf,2025-12-19T04:11:08.678739,,,,
"['Gene expression analysis', 'Multi-omics integration', 'Other']",['Pan-cancer'],"['Drug response/resistance', 'Precision medicine', 'Methods/Tools development']","['Original research', 'Methods/Software']","['TCGA', 'Multiple sources']","The paper mentions applying DeepCCDS to solid tumor samples from The Cancer Genome Atlas (TCGA) to demonstrate its applicability. However, the abstract and introduction do not provide specific details about how cBioPortal was used to access or analyze TCGA data. The primary focus is on developing a deep learning framework for predicting cancer cell drug sensitivity using cancer driver signals and prior knowledge networks.",['TCGA'],['Citation only'],[],['Not specified'],Unclear,low,4.0,40397390,DeepCCDS: Interpretable Deep Learning Framework for Predicting Cancer Cell Drug Sensitivity through Characterizing Cancer Driver Signals.,2025,abstract,2025-12-19T04:11:09.381105,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration', 'Mutation analysis']",['Breast cancer'],"['Drug response/resistance', 'Biomarker discovery', 'Pathway analysis']",['Original research'],['Multiple sources'],"The paper performed a comprehensive multi-omics analysis using publicly available transcriptomics and whole-exome sequencing data from tamoxifen-sensitive and tamoxifen-resistant luminal A breast cancer patient samples. While cBioPortal is cited as a cancer genomics portal, the specific details of how cBioPortal was used are not explicitly described in the abstract and introduction provided. The study identified EPAS1 as a key hypoxic mediator through analysis of patient data and validated findings in cell lines and xenograft models.",[],['Citation only'],['EPAS1'],['Not specified'],Unclear,low,4.0,40393248,Targeting EPAS-1/HIF-2α Pathway to Address Endocrine Resistance in Luminal A Type Breast Cancer.,2025,abstract,2025-12-19T04:11:10.030715,,,,
"['Gene expression analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],"The authors downloaded bulk RNA-seq data (RSEM batch-normalized from Illumina HiSeq_RNASeqV2) and clinical data files from the HNSC PanCancer Atlas 2018 dataset via cBioPortal. The HPV status of patients was obtained from the clinical data summary available on cBioPortal. All subsequent analyses including dimensionality reduction (PCA, UMAP), differential gene expression, and gene ontology analysis were performed externally using R packages (Seurat, ggplot2).","['HNSC PanCancer Atlas 2018', 'hnsc_tcga_pan_can_atlas_2018']",['Data download/export'],[],['Download data'],External (downloaded data),high,4.0,40400005,Analysis of divergent gene expression between HPV + and HPV- head and neck squamous cell carcinoma patients.,2025,pdf,2025-12-19T04:11:10.185126,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The cBioPortal web platform was used to analyze genomic alterations of CLEC3B across pan-cancer datasets. The study mentions accessing cBioPortal (https://www.cbioportal.) in the Genomic Alterations Analysis section, though the full URL and specific details are truncated in the provided text. Based on the methods section, cBioPortal appears to have been used to examine mutation patterns and genomic alterations of CLEC3B across multiple cancer types.",['TCGA'],"['Web-based analysis', 'Web-based visualization']","['CLEC3B', 'TP53']",['Not specified'],Unclear,low,4.0,40416711,<i>CLEC3B</i> as a Prognostic and Immunological Biomarker in Pan-Cancer: Multi-Omics Profiling and Validation in Pancreatic Cancer and Exosomes.,2025,pdf,2025-12-19T04:11:11.280782,,,,
"['Copy number analysis', 'Survival analysis', 'Mutation analysis']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']","['TCGA', 'Custom/Private data']",cBioPortal was used to access and review pathology reports for TCGA patients (TCGA-GBM and TCGA-LGG cohorts) to assess morphological grading criteria. The authors screened TCGA patients with IDH-mutated gliomas for CDKN2A/B deletion and morphological WHO grade 4 criteria by reviewing pathology reports available through the cBioPortal platform.,"['TCGA-GBM', 'TCGA-LGG']",['Web-based analysis'],"['IDH', 'CDKN2A', 'CDKN2B']",['Query interface'],cBioPortal platform,high,4.0,40392514,CDKN2A/B status versus morphology in diagnosing WHO grade 4 IDH-mutated astrocytomas: what is the clinical relevance?,2025,pdf,2025-12-19T04:11:11.331083,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Lung cancer'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to explore and analyze the mutational profile of SMARCA4 in non-small cell lung cancer (NSCLC) tumors from the TCGA repository. The platform was utilized to identify the frequency of disruptive mutations and deletions in SMARCA4 in lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC). The analysis revealed that disruptive mutations in SMARCA4 were present in 8% of LUAD and 4% of LUSC cases, with gene deletions observed in 1% of the population.","['TCGA-LUAD', 'TCGA-LUSC']","['Web-based analysis', 'Query interface']","['SMARCA4', 'EGFR', 'ALK', 'ROS', 'BRAF', 'RET', 'MET']","['Query interface', 'Mutation analysis']",cBioPortal platform,high,4.0,40404793,In silico evaluation of the immunogenic profile of lung cancers with SMARCA4 genetic alterations.,2025,pdf,2025-12-19T04:11:11.968458,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Custom/Private data']","The paper does not explicitly mention using cBioPortal in the methods or results sections provided. The study primarily uses TCGA data and GEO datasets (GSE108474, GSE103668) to analyze CCL19 expression and its prognostic value in breast cancer. While TCGA data is mentioned, there is no clear indication that cBioPortal was used to access or analyze this data.",['TCGA-BRCA'],['Citation only'],['CCL19'],['Not specified'],Unclear,low,4.0,40392467,The expression and prognostic value of CCL19 in breast cancer.,2025,pdf,2025-12-19T04:11:12.180001,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Pan-cancer'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used as one of several databases to study AUNIP gene variation and mutation analysis across pan-cancer. The paper mentions using cBioPortal alongside TCGA, GTEx, TIMER, GEPIA2, and GSCALite databases to comprehensively analyze AUNIP expression, prognosis, gene variation, and drug sensitivity. Mutation analysis showed that AUNIP had the highest frequency of genetic changes in cholangiocarcinoma (CHOL).",[],"['Web-based analysis', 'Citation only']",['AUNIP'],['Not specified'],Unclear,low,4.0,40386627,AUNIP was a candidate marker for prognosis and immunology in pan-cancer.,2025,pdf,2025-12-19T04:11:14.117633,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The paper appears to have used cBioPortal to analyze SNRPE expression patterns and perform survival analysis in breast cancer patients. The authors likely queried clinical samples from breast cancer patients through cBioPortal to determine the impact of SNRPE on tumor prognosis and assess immune infiltration levels. However, specific details about cBioPortal usage are not explicitly mentioned in the provided abstract and introduction sections.",[],['Citation only'],['SNRPE'],['Not specified'],Unclear,low,4.0,40386046,Targeting SNRPE to Induce Pyroptosis Enhances Antitumor Immunity in Breast Cancer.,2025,pdf,2025-12-19T04:11:14.712488,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis']",['Breast cancer'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],"['TCGA', 'Multiple sources']","The paper used cBioPortal to analyze the relationship between GD3 synthase (ST8SIA1) expression and TP53 mutations in breast cancer patient datasets. The authors examined the co-occurrence of GD3S upregulation with specific p53 mutations, particularly hotspot mutations, in breast cancer tumors. cBioPortal was likely used to query TCGA breast cancer data to establish the clinical correlation between p53 mutation status and GD3S expression levels.",['TCGA'],"['Web-based analysis', 'Citation only']","['TP53', 'ST8SIA1']",['Not specified'],Unclear,medium,4.0,40382494,GD3 synthase drives resistance to p53-induced apoptosis in breast cancer by modulating mitochondrial function.,2025,pdf,2025-12-19T04:11:15.038015,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The study used TCGA thyroid cancer dataset for validation of hub genes (CLTA, EDIL3, HAPLN1, and HIP1). The authors analyzed mutations and copy number variations (CNVs) in these hub genes, with CLTA and HIP1 showing significant amplifications. They also conducted survival analysis to assess the impact of these genes on survival outcomes in TC patients, finding that higher expression of HAPLN1 and HIP1 was associated with poor survival.",['TCGA'],"['Web-based analysis', 'Web-based visualization']","['CLTA', 'EDIL3', 'HAPLN1', 'HIP1']","['Expression analysis', 'Survival analysis', 'Query interface']",Mixed,medium,4.0,40372556,"Identification and functional characterization of hub genes CLTA, EDIL3, HAPLN1, and HIP1 as diagnostic biomarkers and therapeutic targets in thyroid cancer and Hashimoto's thyroiditis.",2025,pdf,2025-12-19T04:11:16.416746,,,,
"['Mutation analysis', 'Survival analysis']",['Leukemia/Lymphoma'],"['Biomarker discovery', 'Precision medicine']",['Original research'],['Multiple sources'],"The authors used cBioPortal to access a myelodysplastic syndromes dataset containing 399 CMML cases with clinical, laboratory, and molecular data. They analyzed this cohort to validate findings from their national Austrian ABCMML database, specifically examining the impact of NRAS mutations on overall survival, AML-free survival, and phenotypic parameters. The cBioPortal data served as an independent validation cohort for their national findings.",['myelodysplastic syndromes'],['Data download/export'],['NRAS'],"['Download data', 'Query interface']",External (downloaded data),high,4.0,40372530,Characteristics of NRAS-mutated patients with chronic myelomonocytic leukemia in a national (ABCMML) and an international cohort (cBioPortal).,2025,pdf,2025-12-19T04:11:16.559372,,,,
"['Gene expression analysis', 'Survival analysis']",['Lung cancer'],"['Immunotherapy', 'Biomarker discovery', 'Drug response/resistance']",['Original research'],['TCGA'],"The paper used cBioPortal to analyze USP2 and CD47 expression levels in lung cancer patients from TCGA datasets. The authors examined the correlation between USP2 expression and patient response to anti-PD-1 immunotherapy, as well as the relationship between USP2 and CD47 expression levels. Clinical data from cBioPortal was used to validate their experimental findings that low USP2 expression predicts better response to PD-1 blockade therapy.",['TCGA'],"['Data download/export', 'Web-based analysis']","['USP2', 'CD47']","['Expression analysis', 'Download data']","[""External (downloaded data)""]",medium,4.0,40379682,USP2 inhibition unleashes CD47-restrained phagocytosis and enhances anti-tumor immunity.,2025,pdf,2025-12-19T04:11:16.693845,,,,
"['Gene expression analysis', 'Pathway analysis']",['Lung cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The authors analyzed TCGA database gene expression profiles comparing normal lungs, lung adenocarcinoma, and lung squamous cell carcinoma across different age groups. They identified upregulated pathways including inflammatory response, TNFA signaling via NFκB, and interferon-gamma response. The analysis was performed alongside GTEx database analysis to understand aging-associated changes in lung tissue and their relationship to cancer risk.",['TCGA'],['Citation only'],[],['Not specified'],Unclear,low,4.0,40365571,Inflammation Promotes Aging-Associated Oncogenesis in the Lung.,2025,abstract,2025-12-19T04:11:17.055509,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Colorectal cancer'],"['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']",['Original research'],['TCGA'],"The study conducted a comprehensive analysis of colorectal cancer datasets from The Cancer Genome Atlas (TCGA) to identify potential regulators of immunotherapy response. The analysis revealed that RBM15 is highly expressed in colorectal cancer and correlates with poor patient prognosis. While cBioPortal is not explicitly mentioned in the abstract/introduction, TCGA data analysis was performed to examine RBM15 expression and its correlation with clinical outcomes.",['TCGA'],['Citation only'],"['RBM15', 'FH', 'METTL3', 'ITGBL1', 'PLOD3', 'KPNA2', 'YTHDF1']",['Not specified'],Unclear,low,4.0,40370450,RBM15-mediated metabolic reprogramming boosts immune response in colorectal cancer.,2025,pdf,2025-12-19T04:11:17.605631,,,,
"['Multi-omics integration', 'Mutation analysis', 'Gene expression analysis']",['Pan-cancer'],"['Precision medicine', 'Review/Commentary', 'Methods/Tools development', 'Biomarker discovery']",['Review'],['Not specified'],"This is a review paper discussing AI-powered genomic analysis and multiomics integration in precision oncology. cBioPortal is mentioned in the context of available cancer genomics databases and analysis resources, but no specific usage, analysis, or data download from cBioPortal is described in the provided abstract and introduction. The paper appears to cite cBioPortal as one of the available resources in the field rather than using it for original analysis.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40371349,Advancing precision oncology with AI-powered genomic analysis.,2025,pdf,2025-12-19T04:11:17.950509,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Pan-cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The paper utilized cBioPortal to access and analyze TCGA data for investigating RASD1 expression across multiple cancer types. The study examined RASD1 mRNA expression patterns, promoter methylation, survival correlations, and immune cell infiltration associations using data from The Cancer Genome Atlas. cBioPortal served as one of the data sources alongside Human Protein Atlas and GTEx databases for this pan-cancer analysis.",['TCGA'],['Data download/export'],"['RASD1', 'KRAS', 'PTEN']",['Not specified'],External (downloaded data),medium,4.0,40362656,Pan-Cancer Analysis Identifies a Ras-Related GTPase as a Potential Modulator of Cancer.,2025,abstract,2025-12-19T04:11:18.189103,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Lung cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy']",['Original research'],['Multiple sources'],"The paper used publicly available transcriptomic data to characterize ANXA1 expression in SCLC, though the specific role of cBioPortal is not explicitly detailed in the abstract. The study analyzed gene expression patterns, immune infiltrates, and associations with tumor microenvironment features using RNA-seq data. The exact usage of cBioPortal versus other public databases is not clearly specified in the provided text.",[],['Citation only'],['ANXA1'],['Not specified'],Unclear,low,4.0,40361334,Roles of Annexin A1 Expression in Small Cell Lung Cancer.,2025,abstract,2025-12-19T04:11:21.056250,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Pathway analysis', 'Tumor evolution']",['Original research'],"['TCGA', 'Multiple sources']","The paper analyzed TCGA-LGG dataset focusing on telomere maintenance mechanisms in lower-grade gliomas. The study examined telomere length variations, pathway activity, and survival data across IDH subtypes, with analysis of ATRX and IDH mutation status. While cBioPortal is cited as a source for TCGA data access, the specific mode of usage (web-based vs. data download) is not explicitly detailed in the provided abstract and introduction.",['TCGA-LGG'],['Data download/export'],"['TERT', 'ATRX', 'IDH', 'RAD51']",['Download data'],External (downloaded data),medium,4.0,40362411,Telomere Maintenance Pathways in Lower-Grade Gliomas: Insights from Genetic Subtypes and Telomere Length Dynamics.,2025,abstract,2025-12-19T04:11:21.972746,,,,
"['Mutation analysis', 'Copy number analysis']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Tumor evolution']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper describes genetic analysis through next-generation sequencing with a targeted gene panel on radiation-induced meningioma samples from their own patient database. The study appears to have used custom/private data from their institution without reference to cBioPortal for data access, analysis, or visualization.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40359980,"Radiation-Induced Meningiomas Have an Aggressive Clinical Course: Genetic Signature Is Limited to <i>NF2</i> Alterations, and Epigenetic Signature Is H3K27me3 Loss.",2025,abstract,2025-12-19T04:11:22.417507,,,,
"['Gene expression analysis', 'Mutation analysis', 'Survival analysis', 'Pathway analysis']","['Prostate cancer', 'Other solid tumor']","['Review/Commentary', 'Biomarker discovery', 'Pathway analysis', 'Drug response/resistance']",['Review'],['Not specified'],"This is a mini-review paper on RASGAPs in urological cancers (prostate, bladder, and renal cell carcinoma). Based on the title and abstract provided, cBioPortal is likely cited as a reference or data source for information about RAS pathway alterations and RASGAP expression/mutations in urological cancers, but specific usage details are not provided in the abstract. The paper appears to be a systematic review synthesizing existing knowledge rather than presenting original analysis using cBioPortal.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40361412,A Systematic Analysis of Expression and Function of RAS GTPase-Activating Proteins (RASGAPs) in Urological Cancers: A Mini-Review.,2025,abstract,2025-12-19T04:11:22.452795,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Prostate cancer'],"['Drug response/resistance', 'Pathway analysis', 'Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The study used cBioPortal to analyze clinical and genomic data from prostate cancer cohorts, particularly focusing on the co-occurrence and mutual exclusivity of SPOP mutations and CHD1 deletions. The authors likely queried TCGA prostate adenocarcinoma datasets to examine the genetic alterations and their clinical associations in prostate cancer patients. cBioPortal was used to validate the genetic interactions between SPOP and CHD1 alterations in human prostate cancer cohorts.",['TCGA-PRAD'],"['Web-based analysis', 'Web-based visualization']","['SPOP', 'CHD1', 'SREBP2', 'AR']","['Query interface', 'Web-based visualization']",Mixed,medium,4.0,40360905,CHD1 loss reprograms SREBP2-driven cholesterol synthesis to fuel androgen-responsive growth and castration resistance in SPOP-mutated prostate tumors.,2025,abstract,2025-12-19T04:11:22.938851,,,,
"['Gene expression analysis', 'Survival analysis', 'Copy number analysis', 'Mutation analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper mentions utilizing various databases to systematically examine SF3B6 expression, genetic variation, and clinical correlations across multiple cancer types. While cBioPortal is likely among the databases used for pan-cancer analysis (given the comprehensive multi-omics approach including mutation, copy number, methylation, and expression data), the abstract and introduction do not explicitly detail how cBioPortal was specifically used or which features were accessed. The study appears to have downloaded and integrated data from multiple sources for external analysis.",[],['Citation only'],"['SF3B6', 'NEIL3', 'NEK2', 'KIF4A', 'TROAP', 'FANCD2']",['Not specified'],Unclear,low,4.0,40356980,Bioinformatics analysis across pan-cancer and experimental validation in hepatocellular carcinoma revealed the oncogenic role of SF3B6.,2025,pdf,2025-12-19T04:11:23.405757,,,,
"['Gene expression analysis', 'Mutation analysis']","['Leukemia/Lymphoma', 'Other solid tumor']","['Biomarker discovery', 'Methods/Tools development']",['Original research'],['Custom/Private data'],cBioPortal is mentioned in the keywords section of the paper but no specific usage is described in the abstract or introduction. The paper focuses on experimental RNA-seq analysis following U2AF1 knockdown/overexpression in cell lines to study chimeric RNA formation and splicing regulation. There is no clear indication that cBioPortal data or tools were actually utilized in the study methodology.,[],['Citation only'],['U2AF1'],['Not specified'],Unclear,low,4.0,40346396,Revealing the role of U2AF1 in splicing regulation and chimeric RNA dynamics.,2025,pdf,2025-12-19T04:11:24.147540,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],['Biomarker discovery'],['Original research'],['Multiple sources'],"The paper mentions utilizing online databases to assess the relationship between SPHK1 expression and ovarian cancer metastasis, recurrence and patient outcome. While cBioPortal is likely one of these databases given the citation, the abstract and introduction do not provide specific details about how cBioPortal was used. The study appears to have used online databases for gene expression and survival analysis related to SPHK1 in ovarian cancer.",[],['Citation only'],['SPHK1'],['Not specified'],Unclear,low,4.0,40356021,Identification of Sphingosine Kinase 1 as a Novel Protein Regulated by High Molecular Weight Hyaluronan in Ovarian Cancer.,2025,abstract,2025-12-19T04:11:24.162762,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper mentions retrieving gene expression, mutation, copy number variation, and clinical information from TCGA dataset in the Materials and Methods section. However, the abstract and introduction do not provide explicit details about whether cBioPortal was used to access this TCGA data or if data was obtained through other means. The paper focuses on developing a six-gene immune activation signature for hepatocellular carcinoma prognosis using TCGA and GEO datasets, with validation across multiple cohorts.",['TCGA'],['Citation only'],"['RORC', 'CDC6', 'TP53', 'PTTG1', 'LYZ', 'TMED9']",['Not specified'],Unclear,low,4.0,40356904,An immune cell activation signature reflected hepatocellular carcinoma heterogeneity and predicted clinical outcomes.,2025,pdf,2025-12-19T04:11:24.231953,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']",['Original research'],['TCGA'],"The paper does not explicitly mention cBioPortal usage in the abstract or introduction provided. The study conducted comprehensive multi-omics analyses using TCGA data and specialized bioinformatics tools to analyze LMO2 across cancers, with focus on ccRCC. While cBioPortal is cited, the specific usage details are not described in the provided text.",[],['Citation only'],"['LMO2', 'ZC3H13', 'GATA2', 'BEX1']",['Not specified'],Unclear,low,4.0,40344914,LMO2 confers value as a potential immunotherapy marker in pan-cancer analysis and inhibits progression of Clear Cell Renal Cell Carcinoma.,2025,abstract,2025-12-19T04:11:24.619067,,,,
"['Mutation analysis', 'Survival analysis', 'Gene expression analysis']",['Leukemia/Lymphoma'],"['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'Custom/Private data', 'Multiple sources']",cBioPortal was used to obtain metadata for The Cancer Genome Atlas (TCGA) cohort. The authors accessed TCGA data through cBioPortal (https://www.cbioportal.org/) to support their analysis of germline CHEK2 variants in hematopoietic malignancies. The specific details of how the TCGA metadata was used in the analysis are not elaborated in the provided text.,['TCGA'],['Data download/export'],['CHEK2'],['Download data'],External (downloaded data),medium,4.0,40335619,Predisposition to hematopoietic malignancies by deleterious germline CHEK2 variants.,2025,pdf,2025-12-19T04:11:26.996656,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis']",['Colorectal cancer'],['Biomarker discovery'],['Original research'],['Not specified'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on analyzing Gper1 expression and its role in colorectal cancer progression in a sex-dependent manner using patient tissue samples and CRC cell lines (DLD1 and LoVo). The study examines gene expression, survival outcomes, and cellular metabolism but does not reference cBioPortal as a data source or analysis platform in the sections provided.",[],['Citation only'],"['GPER1', 'ESR1', 'ESR2', 'TP53']",['Not specified'],"[""Unclear""]","[""low""]",4.0,40321663,Differences in the role of Gper1 in colorectal cancer progression depending on sex.,2025,pdf,2025-12-19T04:11:28.343875,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Lung cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, the paper employs a multi-omics approach integrating transcriptomic and clinical patient data from public databases to evaluate MTX2 expression and prognostic relevance in lung adenocarcinoma. While cBioPortal is cited, the specific details of how it was used are not explicitly described in the provided text. The study appears to have used public databases including TCGA for data analysis, which suggests potential cBioPortal usage for data access or visualization, but the exact usage mode cannot be definitively determined from the provided excerpt.",['TCGA'],['Citation only'],['MTX2'],['Not specified'],Unclear,low,4.0,40302794,Integration of multi-omics and single-cell transcriptome reveals mitochondrial outer membrane protein-2 (MTX-2) as a prognostic biomarker and characterizes ubiquinone metabolism in lung adenocarcinoma.,2025,pdf,2025-12-19T04:11:29.532942,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Mutation analysis']","['Pan-cancer', 'Colorectal cancer', 'Pancreatic cancer', 'Melanoma', 'Lung cancer']","['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the methods or results. The study primarily used TIMER2.0, GEPIA, TISCH, TISIDB databases to analyze GJB5 expression and immune features across pan-cancer datasets from TCGA. While cBioPortal is cited in the references, there is no clear description of how it was used for data access, analysis, or visualization in this study.",['TCGA'],['Citation only'],['GJB5'],['Not specified'],Unclear,low,4.0,40295550,Pan-cancer analysis of GJB5 as a novel prognostic and immunological biomarker.,2025,pdf,2025-12-19T04:11:29.550273,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Mutation analysis']",['Lung cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the methods or results sections. The abstract and introduction describe using bioinformatic tools including TIMER2.0, UALCAN, and HPA database to analyze PRDX family expression and prognostic value in LUAD from TCGA data. While cBioPortal may have been cited as a reference or potential data source, there is no clear description of direct cBioPortal usage for data analysis or visualization in the provided text.",['TCGA'],['Citation only'],"['PRDX1', 'PRDX2', 'PRDX3', 'PRDX4', 'PRDX5', 'PRDX6', 'EGFR']",['Not specified'],Unclear,low,4.0,40303499,Malignant features related PRDX1 associated with osimertinib sensitivity of EGFR-mutant lung adenocarcinoma.,2025,pdf,2025-12-19T04:11:29.552792,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine', 'Review/Commentary']",['Review'],['Multiple sources'],"This is a review paper discussing NRP1 (Neuropilin-1) as a therapeutic target in cancer. The paper mentions the use of multi-omics approaches and integration of data from multiple databases to understand cancer's molecular and clinical features. However, the abstract and introduction do not provide specific details about direct cBioPortal usage, suggesting this may be a citation-only reference or the platform may be mentioned as one of several databases used in the field for cancer genomics analysis.",[],['Citation only'],['NRP1'],['Not specified'],Unclear,low,4.0,40277760,Neuropilin-1: A Multifaceted Target for Cancer Therapy.,2025,abstract,2025-12-19T04:11:29.924633,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']",['Original research'],['Multiple sources'],"The study used cBioPortal as one of multiple public databases to assess gene expression, mutation frequency, and immune infiltration patterns related to the LOX family in glioma. The platform was likely used to obtain genomic and clinical data for comprehensive analysis of LOX family genes. Specific details about how cBioPortal was used are not explicitly described in the abstract.",[],['Data download/export'],"['LOX', 'LOXL1', 'LOXL2', 'LOXL3', 'LOXL4']",['Not specified'],External (downloaded data),medium,4.0,40270974,Exploring the role of LOX family in glioma progression and immune modulation.,2025,abstract,2025-12-19T04:11:29.987933,,,,
['Mutation analysis'],"['Ovarian cancer', 'Lung cancer', 'Breast cancer', 'Renal cancer']","['Drug response/resistance', 'Biomarker discovery', 'Precision medicine']",['Original research'],['Multiple sources'],"The study performed in silico analysis using data from 101,562 tumor samples to identify variants in the SLC34A2 gene that lead to amino acid substitutions within the MX35 epitope of NaPi2b. The analysis identified 17 unique variants affecting the MX35 epitope region. The most prevalent mutation (c.989C>T, p.T330M) was then validated through genomic DNA sequencing of patient samples and functional studies using site-directed mutagenesis to assess its impact on monoclonal antibody recognition.",[],['Data download/export'],['SLC34A2'],['Download data'],External (downloaded data),medium,4.0,40265411,T330M Substitution in the Sodium-Dependent Phosphate Transporter NaPi2b Abolishes the Efficacy of Monoclonal Antibodies Against MX35 Epitope.,2025,abstract,2025-12-19T04:11:30.220444,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis']",['Breast cancer'],"['Biomarker discovery', 'Other']",['Original research'],"['TCGA', 'METABRIC', 'Multiple sources']",The paper used cBioPortal to analyze G6PC3 expression and mutation data across breast cancer datasets. The authors queried TCGA and METABRIC breast cancer cohorts through cBioPortal to examine G6PC3 alterations and their clinical associations. cBioPortal was used to access publicly available breast cancer genomic data for validation of their experimental findings regarding G6PC3's role in genome maintenance.,"['TCGA-BRCA', 'METABRIC']","['Web-based analysis', 'Web-based visualization']","['G6PC3', 'BRCA1', 'BRCA2']","['Query interface', 'Expression analysis']",cBioPortal platform,medium,4.0,40261702,G6PC3 promotes genome maintenance and is a candidate mammary tumor suppressor.,2025,pdf,2025-12-19T04:11:30.425893,,,,
"['Mutation analysis', 'Survival analysis', 'Copy number analysis']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal being used in this study. The paper describes analysis of circulating tumor DNA from patients enrolled in a clinical trial (CALGB 90601), but does not reference cBioPortal for data access, analysis, or visualization. The study appears to have used custom sequencing data from patient plasma samples rather than accessing public databases through cBioPortal.",[],['Citation only'],"['TERT', 'PIK3CA', 'ERBB2']",['Not specified'],Unclear,low,4.0,40256659,Circulating Tumor DNA and Response to Cisplatin-based Chemotherapy in Patients with Metastatic Urothelial Carcinoma Enrolled in CALGB 90601 (Alliance).,2025,abstract,2025-12-19T04:11:30.544275,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Pathway analysis']",['Pan-cancer'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, cBioPortal is not explicitly mentioned in the text. The study uses TCGA and GTEx databases for expression analysis, survival analysis, and mutation analysis of TRIP13 across multiple cancer types. While cBioPortal may have been used as a data source or analysis platform (as it commonly hosts TCGA data), no specific mention of cBioPortal usage, features, or methodology is present in the provided sections.",[],['Citation only'],"['TRIP13', 'CDC20', 'RAD1', 'MAD2L1']",['Not specified'],Unclear,low,4.0,40253660,Thyroid hormone receptor interacting protein 13 is associated with prognosis and immunotherapy efficacy in human cancers: a pan-cancer analysis.,2025,pdf,2025-12-19T04:11:33.615629,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],['Biomarker discovery'],['Original research'],['Multiple sources'],"The paper used cBioPortal along with other bioinformatics databases to analyze the expression and prognosis of P4HA1 in gastric cancer. The specific details of how cBioPortal was used are not explicitly described in the provided abstract and introduction sections, suggesting it was one of several bioinformatics tools used for initial expression and prognostic analysis. The main focus of the study was on experimental validation using Western blot, RT-qPCR, and functional assays in gastric cancer cell lines.",[],['Citation only'],['P4HA1'],['Not specified'],Unclear,low,4.0,40253309,P4HA1 is highly expressed in gastric cancer and promotes proliferation and metastasis of gastric cancer cells.,2025,pdf,2025-12-19T04:11:34.531410,,,,
['Other'],['Not specified'],['Review/Commentary'],['Review'],['Not specified'],"This is a review paper focused on inborn errors of immunity due to somatic mosaicism, which is not directly related to cancer genomics. cBioPortal appears to be cited only as a reference or mentioned in passing, as the paper's focus is on immune system disorders rather than cancer. No specific usage of cBioPortal for data analysis or visualization is described in the abstract or introduction.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40232243,Identifying genetic errors of immunity due to mosaicism.,2025,abstract,2025-12-19T04:11:35.063787,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],"['TCGA', 'Multiple sources']",The study utilized cBioPortal to access and analyze the ovarian TCGA cohort (n = 182) for bioinformatics analysis of TP73 transcripts. The analysis examined gene expression patterns and likely investigated correlations with clinical outcomes in ovarian cancer patients. cBioPortal served as a data source for publicly available TCGA ovarian cancer genomic data to complement the authors' experimental findings.,['TCGA ovarian cancer'],"['Data download/export', 'Web-based analysis']",['TP73'],"['Expression analysis', 'Query interface']","[""External (downloaded data)""]",medium,4.0,40244040,Transcription Factor p73 Is a Predictor of Platinum Resistance and Promotes Aggressive Epithelial Ovarian Cancers.,2025,abstract,2025-12-19T04:11:35.504960,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],['TCGA'],"The authors used cBioPortal to access and analyze TCGA bladder cancer (BLCA) data to examine YB-1 (Y-Box binding protein 1) mRNA expression levels across different bladder cancer subtypes (basal/squamous, urothelial, and luminal). They analyzed YB-1 expression patterns in the TCGA BLCA cohort and correlated these with patient outcomes to support their hypothesis that XVir-N-31 oncolytic virotherapy would be effective in squamous bladder cancer.",['TCGA-BLCA'],['Web-based analysis'],['YBX1'],"['Expression analysis', 'Group comparison']",cBioPortal platform,medium,4.0,40251219,Oncolytic virotherapy provides a potent therapy option for squamous bladder cancer.,2025,pdf,2025-12-19T04:11:35.727818,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper used cBioPortal to analyze CDCA genes in breast cancer, conducting mutational analysis, copy number variation (CNV) analysis, methylation analysis, and survival analysis using public databases. The study examined mutation rates, amplification events, and correlations between CDCA gene expression and patient survival outcomes. cBioPortal likely served as one of the public databases for accessing TCGA breast cancer data and performing these multi-omics analyses.",['TCGA-BRCA'],"['Web-based analysis', 'Web-based visualization']","['CDCA2', 'CDCA3', 'CDCA4', 'CDCA5', 'CDCA7', 'CDCA8']","['Mutation Mapper', 'Survival analysis', 'Expression analysis']","[""Unclear""]",medium,4.0,40245179,Decoding the Role of CDCA Genes in Breast Cancer Progression: Insights From in Silico and Functional Assay.,2025,abstract,2025-12-19T04:11:35.895899,,,,
"['Survival analysis', 'Other']",['Leukemia/Lymphoma'],"['Immunotherapy', 'Biomarker discovery', 'Clinical study']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on analyzing PET-CT scans to evaluate extranodal disease sites and their impact on CAR T-cell therapy response in large B-cell lymphoma patients. The study appears to be a retrospective clinical analysis of imaging data and clinical outcomes without reference to genomic data analysis through cBioPortal.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40229268,CAR T-cell therapy response varies by extranodal disease site in large B-cell lymphoma.,2025,pdf,2025-12-19T04:11:36.409853,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Mutation analysis']",['Breast cancer'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction, the paper appears to use cBioPortal as a data source for breast cancer genomic and clinical data, likely including TCGA-BRCA data. The study developed a CoQ10-related prognostic model and analyzed mutational profiles, immune infiltration, and treatment responses. However, specific details about how cBioPortal was used are not provided in the abstract/introduction.",['TCGA-BRCA'],['Data download/export'],[],['Not specified'],External (downloaded data),medium,4.0,40225007,Development of coenzyme Q10-related molecular subtypes and a prognostic signature for predicting breast cancer prognosis and response to immunotherapy.,2025,abstract,2025-12-19T04:11:36.744990,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],"['ICGC', 'Multiple sources']","Based on the provided abstract and introduction, there is no explicit mention of cBioPortal being used in this study. The paper focuses on analyzing PCAWG (Pan-Cancer Analysis of Whole Genomes) data from ICGC to identify prognosis markers across 13 cancer types using 17 molecular features. While the paper references TCGA data in the background section, there is no clear indication that cBioPortal was utilized for data access, analysis, or visualization in this particular study.",['PCAWG'],['Citation only'],"['KRAS', 'RB1']",['Not specified'],Unclear,low,4.0,40221813,Comprehensive analysis of prognosis markers with molecular features derived from pan-cancer whole-genome sequences.,2025,pdf,2025-12-19T04:11:37.200014,,,,
['Other'],['Colorectal cancer'],"['Review/Commentary', 'Biomarker discovery', 'Pathway analysis']",['Review'],['Not specified'],This is a review paper that compiles current knowledge on BMP antagonists and their role in colorectal cancer development. The paper cites cBioPortal but does not describe any specific usage of the platform for data analysis or visualization. The citation appears to be a reference to the resource rather than describing active use of cBioPortal tools or data in this review.,[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40212011,BMP signalling in colorectal cancer: losing the yin to WNTs yang.,2025,abstract,2025-12-19T04:11:37.199190,,,,
['Other'],['Not specified'],['Other'],['Original research'],['Not specified'],"This paper does not appear to use cBioPortal. The study focuses on nephronophthisis (NPHP), a non-cancerous kidney disease, investigating the role of FBW7-SOX9-WNT4 pathway in fibrosis and kidney function decline. The research involves mouse models with kidney-specific deletion of Fbxw7 and does not involve cancer genomics data or cBioPortal analysis.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40211043,SOX9-dependent fibrosis drives renal function in nephronophthisis.,2025,abstract,2025-12-19T04:11:38.653763,,,,
"['Copy number analysis', 'Gene expression analysis', 'Mutation analysis']","['Colorectal cancer', 'Pan-cancer']","['Drug response/resistance', 'Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']",cBioPortal was used to analyze the co-deletion pattern of APC and SRP19 genes in colorectal cancer patients. The authors likely queried cBioPortal to examine copy number alterations and the frequency of heterozygous APC/SRP19 loss across cancer datasets. This analysis provided evidence that SRP19 is almost always codeleted with APC in tumors with heterozygous APC loss.,['TCGA'],"['Web-based analysis', 'Web-based visualization']","['APC', 'SRP19']","['Query interface', 'Expression analysis']",Mixed,medium,4.0,40208946,<i>SRP19</i> and the protein secretion machinery is a targetable vulnerability in cancers with <i>APC</i> loss.,2025,abstract,2025-12-19T04:11:40.751954,,,,
['Other'],['Not specified'],"['Drug response/resistance', 'Methods/Tools development']",['Original research'],['Not specified'],"This paper focuses on the design and evaluation of bivalent K-Ras inhibitors targeting farnesyltransferase and geranylgeranyltransferase I. The study is primarily a drug development/medicinal chemistry paper that tests novel inhibitors in biochemical and cellular assays. There is no clear evidence that cBioPortal was used for data analysis, visualization, or data download in this study.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40200839,Design and Evaluation of Bivalent K-Ras Inhibitors That Target the CAAX Binding Site and the Acidic Surface of Farnesyltransferase and Geranylgeranyltransferase I.,2025,abstract,2025-12-19T04:11:41.510496,,,,
"['Copy number analysis', 'Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],['TCGA'],cBioPortal was used to analyze COPS5 genomic alterations in hepatocellular carcinoma clinical samples. The authors examined COPS5 amplification and overexpression patterns in HCC patient cohorts and assessed their association with patient prognosis. The platform was likely used to access TCGA-HCC data for copy number and expression analysis.,['TCGA-HCC'],"['Web-based analysis', 'Web-based visualization']",['COPS5'],"['Expression analysis', 'Query interface']",Unclear,medium,4.0,40198582,COPS5 Triggers Ferroptosis Defense by Stabilizing MK2 in Hepatocellular Carcinoma.,2025,abstract,2025-12-19T04:11:41.774293,,,,
"['Copy number analysis', 'Survival analysis', 'Pathway analysis']",['Lung cancer'],"['Biomarker discovery', 'Pathway analysis']","['Original research', 'Meta-analysis']",['Multiple sources'],"The authors performed a meta-analysis of public cBioPortal datasets spanning 25 lung cancer studies to identify cancer driver genes with copy number alterations associated with overall patient survival. They identified ten copy-number altered genes enriched in deceased lung cancer patients, with MRPS17 amplification showing significant association with lower patient survival rates. The cBioPortal data was used to identify candidate genes for subsequent functional validation experiments in cell lines.",[],"['Web-based analysis', 'Web-based visualization']",['MRPS17'],"['Survival analysis', 'Query interface']",Mixed,medium,4.0,40201023,Mitochondrial Ribosomal Protein S17 Silencing Inhibits Proliferation and Invasiveness of Lung Cancer Cells.,2025,abstract,2025-12-19T04:11:42.118757,,,,
"['Mutation analysis', 'Multi-omics integration']","['Lung cancer', 'Pan-cancer']","['Tumor evolution', 'Biomarker discovery']",['Original research'],"['TCGA', 'GENIE', 'Multiple sources']","The authors used cBioPortal to analyze co-occurrence patterns of splicing factor mutations (U2AF1) and oncogene mutations (KRAS) across cancer genomes. They performed comprehensive analysis of mutation co-enrichment patterns, specifically examining U2AF1 S34F with KRAS G12S mutations and U2AF1 I24T with KRAS Q61R mutations in lung adenocarcinoma and other cancer types. The analysis revealed significant enrichment of these mutation pairs in cancer genomic datasets.","['TCGA', 'GENIE']","['Web-based analysis', 'Data download/export']","['U2AF1', 'KRAS']","['Query interface', 'Group comparison']","[""Mixed""]",medium,4.0,40196662,U2AF1 mutations rescue deleterious exon skipping induced by KRAS mutations.,2025,abstract,2025-12-19T04:11:43.179346,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Copy number analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to analyze genetic alterations (mutations, copy number variations) in NDRG family genes in cervical cancer. The platform was utilized to examine the correlation between NDRG gene alterations and clinical outcomes. The study also analyzed DNA methylation patterns of NDRG genes using cBioPortal data.",[],"['Web-based analysis', 'Web-based visualization']","['NDRG1', 'NDRG2', 'NDRG3']","['Query interface', 'Expression analysis']",Mixed,medium,4.0,40190258,NDRG1/2 as a prognostic predictive biomarker of cervical cancer and its correlation with immune infiltration.,2025,abstract,2025-12-19T04:11:43.355252,,,,
"['Mutation analysis', 'Survival analysis', 'Copy number analysis']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper describes a Japanese cohort study using custom gene panel sequencing for driver gene analysis in glioblastoma patients. While cBioPortal is cited, the specific usage details are not described in the provided text, suggesting it may have been cited for reference purposes or used minimally for data comparison.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40189724,"Analysis of clinical, histological, and genomic information of molecular glioblastoma in a Japanese glioma cohort.",2025,abstract,2025-12-19T04:11:43.666222,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Copy number analysis', 'Mutation analysis']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']",['Original research'],['Multiple sources'],"cBioPortal was used to explore gene changes, protein interactions, and biological functions of EFNA1-5 genes in pancreatic adenocarcinoma. The database was utilized alongside other tools (GSEA and GSCALite) to investigate genetic alterations and molecular mechanisms. The specific features used and whether data was downloaded or analyzed on the platform are not explicitly detailed in the abstract.",[],['Web-based analysis'],"['EFNA1', 'EFNA2', 'EFNA3', 'EFNA4', 'EFNA5']",['Not specified'],Unclear,medium,4.0,40190415,Role of EFNAs in Shaping the Tumor Immune Microenvironment and Their Impact on Pancreatic Adenocarcinoma Prognosis.,2025,abstract,2025-12-19T04:11:43.855714,,,,
"['Mutation analysis', 'Multi-omics integration', 'Pathway analysis']","['Pan-cancer', 'Other solid tumor']","['Methods/Tools development', 'Database/Resource', 'Biomarker discovery']","['Original research', 'Methods/Software']",['Multiple sources'],"The paper mentions using cBioPortal in the context of decoding pediatric cancer genomes and identifying recurrently mutated assemblies and cancer proteins. The study integrated their multimodal cell map data with cancer genomic data to identify 21 recurrently mutated assemblies and implicate 102 validated new cancer proteins. However, specific details about how cBioPortal was accessed or which features were used are not provided in the abstract and introduction sections.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40205054,Multimodal cell maps as a foundation for structural and functional genomics.,2025,pdf,2025-12-19T04:11:44.041907,,,,
"['Gene expression analysis', 'Survival analysis', 'Other']",['Colorectal cancer'],"['Biomarker discovery', 'Immunotherapy', 'Methods/Tools development']",['Original research'],['Custom/Private data'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on spatial analysis of stage III colorectal cancers using Hyperion Imaging Mass Cytometry (IMC) with a 16-antibody panel to characterize the tumor microenvironment. The study appears to use custom tissue samples from Intermountain Healthcare and does not describe accessing or analyzing data from cBioPortal. If cBioPortal is mentioned, it may only be in the references as a citation.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40189697,The single-cell spatial landscape of stage III colorectal cancers.,2025,pdf,2025-12-19T04:11:45.119148,,,,
"['Gene expression analysis', 'Survival analysis', 'Copy number analysis', 'Multi-omics integration', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, the paper appears to use cBioPortal for accessing breast cancer genomic data, particularly for analyzing CCNB1, PLK1, and HPSE genes. The study integrates transcriptomics, proteomics, DNA methylation, and immune infiltration data, likely utilizing cBioPortal for data retrieval and initial analysis. The paper mentions analyzing DNA methylation, copy number variations (CNV), and alterations in BRCA (breast cancer) datasets, which are commonly accessed through cBioPortal.",['TCGA-BRCA'],"['Data download/export', 'Web-based analysis']","['CCNB1', 'PLK1', 'HPSE', 'MKI67', 'CDK1']","['Expression analysis', 'Survival analysis', 'Download data']",Mixed,medium,4.0,40186712,"Multi-omics insights into the roles of CCNB1, PLK1, and HPSE in breast cancer progression: implications for prognosis and immunotherapy.",2025,pdf,2025-12-19T04:11:47.928270,,,,
['Other'],['Pan-cancer'],['Review/Commentary'],['Review'],['Not specified'],"This is a review paper on phosphoinositide kinases (PI4Ks and PIPKs) in cancer. Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage for original data analysis. The paper likely cites cBioPortal as a reference or resource in the context of discussing cancer genomics data, but no specific analysis, data download, or visualization using cBioPortal is described in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40181165,Phosphoinositide kinases in cancer: from molecular mechanisms to therapeutic opportunities.,2025,abstract,2025-12-19T04:11:48.224295,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']","['Pan-cancer', 'Lung cancer']","['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the abstract or introduction provided. The study utilized multiple databases including TCGA, GTEx, HPA, and the UCSC Xena database for pan-cancer analysis of CLEC12A. While cBioPortal is cited, there is no clear description of how it was specifically used in the methodology sections provided.",['TCGA'],['Citation only'],['CLEC12A'],['Not specified'],Unclear,low,4.0,40181336,Pan-cancer analysis identifies CLEC12A as a potential biomarker and therapeutic target for lung adenocarcinoma.,2025,pdf,2025-12-19T04:11:48.674519,,,,
"['Mutation analysis', 'Survival analysis', 'Pathway analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],"The authors used cBioPortal to obtain mutational data for WNT ligands in colorectal cancer patients. They analyzed mutations in WNT genes, particularly WNT5A, to identify regional specificity and selectivity for conserved sequences. The clinical and mutational data from cBioPortal was then combined with computational structural biology approaches (folding energy calculations, elastic network modeling, and molecular dynamics simulations) to predict functional consequences of these mutations.",['TCGA'],['Data download/export'],['WNT5A'],['Download data'],External (downloaded data),medium,4.0,40165370,Predicted functional consequences of WNT ligand mutations in colorectal cancer.,2025,abstract,2025-12-19T04:11:49.327002,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'ICGC', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the abstract or introduction provided. The study utilized TCGA and ICGC databases for bulk RNA sequencing data and GEO database for single-cell sequencing data to analyze SH3D21 expression and clinical significance in hepatocellular carcinoma. While cBioPortal is cited, there is no clear description of how it was specifically used in the methodology based on the provided text.","['TCGA', 'ICGC']",['Citation only'],['SH3D21'],['Not specified'],Unclear,low,4.0,40179068,Integrating bulk and single-cell RNA sequencing reveals SH3D21 promotes hepatocellular carcinoma progression by activating the PI3K/AKT/mTOR pathway.,2025,abstract,2025-12-19T04:11:49.583650,,,,
['Other'],"['Pan-cancer', 'Colorectal cancer', 'Other solid tumor']","['Review/Commentary', 'Immunotherapy', 'Precision medicine', 'Biomarker discovery']",['Review'],['Not specified'],"This is a comprehensive review article on MSI-H/dMMR cancers that discusses epidemiology, pathogenesis, biology and treatment. cBioPortal is likely cited as a reference resource or database for cancer genomics data related to MSI-H/dMMR tumors, but no specific analysis or data extraction from cBioPortal is described in the abstract or introduction. The paper focuses on synthesizing existing knowledge rather than performing original data analysis.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40181086,"Epidemiology, pathogenesis, biology and evolving management of MSI-H/dMMR cancers.",2025,abstract,2025-12-19T04:11:49.587456,,,,
"['Gene expression analysis', 'Multi-omics integration']",['Pan-cancer'],"['Database/Resource', 'Biomarker discovery']",['Methods/Software'],['Multiple sources'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal being used in this study. The paper describes PCMR (PreCancerous Molecular Resource), a new database focused on precancerous lesions that integrates multi-omics data from GEO and other sources. The paper may cite cBioPortal as an example of existing cancer databases that focus primarily on invasive malignancies rather than precancerous lesions, but no actual usage of cBioPortal for data analysis or retrieval is described in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40169679,PCMR: a comprehensive precancerous molecular resource.,2025,pdf,2025-12-19T04:11:50.398878,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the methods or results sections. The study primarily used GEO datasets (GSE57545, GSE157153), TCGA, GTEx, and other databases like ONCOMINE, PrognoScan, GEPIA, TIMER, and Kaplan-Meier Plotter for their analyses. While cBioPortal is cited in the references, there is no clear description of how it was used in this specific study.",[],['Citation only'],"['CXCL12', 'ARID1A', 'PTEN', 'PIK3CA', 'KRAS', 'IL17', 'STAT3', 'FOXP3']",['Not specified'],Unclear,low,4.0,40166682,The expression of autophagy-related gene CXCL12 in endometriosis associated ovarian cancer and pan-cancer analysis.,2025,pdf,2025-12-19T04:11:50.581187,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Mutation analysis']",['Lung cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The paper conducted a comprehensive bioinformatics analysis of CKS1B in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) using publicly available transcriptomic datasets. The study performed differential gene expression analysis, survival analysis, immune infiltration correlation, and pathway enrichment analysis to evaluate the oncogenic role and prognostic value of CKS1B. While cBioPortal is likely used as one of the data sources for accessing TCGA data and performing analyses, the specific details of cBioPortal usage are not explicitly described in the provided abstract and introduction.","['TCGA-LUAD', 'TCGA-LUSC']","['Web-based analysis', 'Data download/export']",['CKS1B'],"['Expression analysis', 'Survival analysis', 'Not specified']",Unclear,medium,4.0,40165937,Exploring the oncogenic role and prognostic value of <i>CKS1B</i> in human lung adenocarcinoma and squamous cell carcinoma.,2025,pdf,2025-12-19T04:11:50.991003,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Prostate cancer'],"['Biomarker discovery', 'Pathway analysis', 'Precision medicine']",['Original research'],['Multiple sources'],"The authors obtained normalized gene expression data, mutation calls, and copy number calls for three of the four mCRPC cohorts (FHCC, WCM, and ECDT) directly from cBioPortal. These data were then aggregated with a fourth cohort (WCDT) and analyzed externally to investigate transcriptomic, mutational, and clinical differences by race in metastatic castration-resistant prostate cancer patients.","['FHCC', 'WCM', 'ECDT', 'WCDT']",['Data download/export'],"['TMPRSS2', 'ERG', 'TP53', 'AR', 'CDK12', 'MYC']",['Download data'],External (downloaded data),high,4.0,40164700,Racial variation in the advanced prostate cancer genome.,2025,pdf,2025-12-19T04:11:51.531038,,,,
"['Gene expression analysis', 'Other']",['Pan-cancer'],"['Review/Commentary', 'Biomarker discovery']",['Review'],['Not specified'],"This is a review paper on the miR-99 family in cancer. Based on the abstract and introduction provided, there is no explicit description of how cBioPortal was used in this study. The paper appears to be a literature review summarizing research on miR-99a, miR-99b, and miR-100 in various cancers, and cBioPortal is likely only cited as a reference or resource rather than actively used for analysis.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40161350,MicroRNA-99 family in cancer: molecular mechanisms for clinical applications.,2025,abstract,2025-12-19T04:11:53.643978,,,,
"['Mutation analysis', 'Multi-omics integration']",['Pan-cancer'],"['Drug response/resistance', 'Precision medicine', 'Methods/Tools development']","['Original research', 'Methods/Software']","['TCGA', 'GENIE', 'Multiple sources']",cBioPortal was used as a data source to obtain mutation data from cancer genomics datasets. The authors likely downloaded mutation data from TCGA and/or GENIE datasets through cBioPortal to train and validate their DruID drug response prediction model using clinical-grade NGS panel gene sets (~300 genes). The mutation data from cBioPortal was used as input features for their machine learning model to predict chemotherapy response.,[],['Data download/export'],[],['Download data'],External (downloaded data),medium,4.0,40160429,A multi-task domain-adapted model to predict chemotherapy response from mutations in recurrently altered cancer genes.,2025,abstract,2025-12-19T04:11:54.411512,,,,
"['Gene expression analysis', 'Survival analysis']",['Breast cancer'],"['Biomarker discovery', 'Immunotherapy', 'Tumor evolution']",['Original research'],"['TCGA', 'METABRIC']",The study used cBioPortal to analyze NCOR2 expression levels and their correlation with MHC class I molecule expression and patient survival outcomes in breast cancer cohorts. The authors queried TCGA and METABRIC datasets through cBioPortal to examine the relationship between NCOR2 expression and metastasis-free survival in triple negative breast cancer patients. This analysis provided clinical validation for their experimental findings that NCOR2 represses MHC class I expression and promotes metastatic progression.,"['TCGA', 'METABRIC']","['Web-based analysis', 'Web-based visualization']",['NCOR2'],"['Expression analysis', 'Survival analysis', 'Query interface']",cBioPortal platform,medium,4.0,40161756,NCOR2 represses MHC class I molecule expression to drive metastatic progression of breast cancer.,2025,abstract,2025-12-19T04:11:55.764006,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Copy number analysis', 'Multi-omics integration']","['Pan-cancer', 'Colorectal cancer']","['Biomarker discovery', 'Immunotherapy', 'Drug response/resistance']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the abstract or introduction. The study primarily used TCGA and GTEx data downloaded from the UCSC database, along with other databases like GEPIA, GSCA, and CancerSEA for various analyses. While cBioPortal may have been cited as a reference or potential data source, there is no clear description of its direct usage in the methodology described.",[],['Citation only'],['NMNAT1'],['Not specified'],Unclear,low,4.0,40160196,Prognostic and Immunological Significance of NMNAT1 in Colorectal and Pan-Cancer Contexts.,2025,abstract,2025-12-19T04:11:55.788353,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis']",['Leukemia/Lymphoma'],"['Drug response/resistance', 'Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Custom/Private data']","Based on the abstract and title provided, cBioPortal appears to have been used to access genomic data for myeloid malignancies (MDS/AML) to analyze mutational profiles and potentially gene expression patterns. The study demonstrates that ATRA response occurs independently of cytogenetics and mutational profile, suggesting that cBioPortal data was likely used to characterize the genomic landscape of patient samples. However, specific details about how cBioPortal was used are not provided in the abstract.",['TCGA'],['Citation only'],[],['Not specified'],Unclear,low,4.0,40154481,A niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignancies.,2025,abstract,2025-12-19T04:11:56.109295,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and title provided, there is no explicit mention of cBioPortal usage in this study. The study focuses on immunohistochemistry (IHC) analysis of transcriptional subtyping markers (KRT81/HNF1A and GATA6) in pancreatic cancer patient cohorts and validation using RNAseq data. If cBioPortal was used, it may have been for accessing RNAseq expression data for validation purposes, but this is not clearly stated in the provided text.",[],['Citation only'],"['KRT81', 'HNF1A', 'GATA6']",['Not specified'],Unclear,low,4.0,40149962,"The Prognostic, Predictive and Clinicopathological Implications of KRT81/HNF1A- and GATA6-Based Transcriptional Subtyping in Pancreatic Cancer.",2025,abstract,2025-12-19T04:11:56.217405,,,,
"['Gene expression analysis', 'Survival analysis']",['Prostate cancer'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"This study does not appear to use cBioPortal directly. The research is a clinical immunohistochemistry study examining p53 protein expression in prostate cancer specimens from 84 patients at the DC VA Medical Center. The study focuses on correlating p53 IHC staining patterns with clinical outcomes, but does not mention accessing or analyzing data from cBioPortal.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40149338,Investigating Intensity and Percentage of p53 Nuclear Expression in Prostate Cancer: Findings from a Cohort of U.S. Military Veterans.,2025,abstract,2025-12-19T04:11:56.313534,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],['Multiple sources'],"cBioPortal was used as one of multiple databases to investigate transcriptional and survival data of GDF family members (GDF1-3, GDF5-7, GDF9-11, and GDF15) in gastric cancer patients. The platform was utilized alongside other databases including GEPIA, TCGA, TIMER, TISIDB, UALCAN, HPA, GEO, and DAVID to comprehensively analyze expression patterns and prognostic values of GDFs in gastric cancer.",[],['Web-based analysis'],"['GDF1', 'GDF2', 'GDF3', 'GDF5', 'GDF6', 'GDF7', 'GDF9', 'GDF10', 'GDF11', 'GDF15']",['Not specified'],"[""Unclear""]",medium,4.0,40153751,Comprehensive analysis of GDFs as therapeutic targets and prognosis biomarkers in gastric cancer.,2025,abstract,2025-12-19T04:11:56.336475,,,,
"['Gene expression analysis', 'Survival analysis']",['Breast cancer'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],['Not specified'],The authors performed in silico analysis using cBioPortal to examine the association between p70S6K1 (RPS6KB1) mRNA expression levels and prognosis in triple-negative breast cancer patients with diabetes mellitus. They also validated galectin-3 (LGALS3) gene expression in diabetic TNBC patients and assessed its correlation with overall survival and disease-free survival using cBioPortal data.,[],"['Web-based analysis', 'Web-based visualization']","['RPS6KB1', 'LGALS3']","['Expression analysis', 'Survival analysis']",cBioPortal platform,medium,4.0,40149589,"Targeting p70S6K1 Inhibits Glycated Albumin-Induced Triple-Negative Breast Cancer Cell Invasion and Overexpression of Galectin-3, a Potential Prognostic Marker in Diabetic Patients with Invasive Breast Cancer.",2025,abstract,2025-12-19T04:11:57.407549,,,,
"['Mutation analysis', 'Survival analysis']",['Leukemia/Lymphoma'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']",['Multiple sources'],"The study used cBioPortal to access and analyze a CMML cohort to validate findings from the Austrian biodatabase (ABCMML). The authors compared RUNX1-mutated versus wildtype patients in the cBioPortal CMML cohort, analyzing survival outcomes (overall survival and AML-free survival) and clinical phenotypes (thrombocytopenia and platelet counts). This international cohort from cBioPortal served as an independent validation dataset for their national findings.",[],"['Web-based analysis', 'Web-based visualization']",['RUNX1'],"['Survival analysis', 'Group comparison', 'Query interface']",cBioPortal platform,high,4.0,40138085,Features of RUNX1-mutated patients with chronic myelomonocytic leukemia in a national (ABCMML) and international cohort (cBioPortal).,2025,abstract,2025-12-19T04:11:57.785154,,,,
"['Gene expression analysis', 'Survival analysis']",['Pan-cancer'],"['Biomarker discovery', 'Review/Commentary']",['Review'],['Not specified'],"This is a comprehensive review paper on Galectins in cancer. While the paper discusses biomarkers and cancer genomics broadly, there is no explicit mention of cBioPortal usage in the provided abstract and introduction sections. The paper appears to be a literature review synthesizing existing knowledge about Galectins' roles in cancer biology and therapy, without describing specific data analysis using cBioPortal.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40134029,Multifaceted roles of Galectins: from carbohydrate binding to targeted cancer therapy.,2025,pdf,2025-12-19T04:11:59.606674,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Leukemia/Lymphoma'],['Biomarker discovery'],['Original research'],['Multiple sources'],"The paper used cBioPortal to perform mutational analysis of the identified differentially expressed genes (SP3, CSNK1A1, STYX, SIRT5, and MGEA5) in DLBC patients. The analysis revealed that CSNK1A1 exhibited a 2.7% mutation frequency in DLBC patients, while the other genes showed no mutations. The specific details of how cBioPortal was accessed or which features were used are not explicitly described in the provided abstract and introduction.",[],['Web-based analysis'],"['SP3', 'CSNK1A1', 'STYX', 'SIRT5', 'MGEA5']",['Mutation Mapper'],Unclear,medium,4.0,40128844,Identification and functional characterization of key biomarkers in diffuse large B-cell lymphoma: emphasis on STYX as a prognostic marker and therapeutic target.,2025,pdf,2025-12-19T04:12:01.052754,,,,
['Gene expression analysis'],['Melanoma'],"['Immunotherapy', 'Biomarker discovery', 'Tumor evolution']",['Original research'],['Not specified'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage. The study focuses on age-associated changes in the melanoma tumor microenvironment, specifically examining TREM1/2-expressing macrophages and their role in melanoma progression and metastasis. Without access to the methods section or results, it is unclear if or how cBioPortal was utilized in this research.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40126543,Age-Associated Modulation of TREM1/2-Expressing Macrophages Promotes Melanoma Progression and Metastasis.,2025,abstract,2025-12-19T04:12:01.104362,,,,
"['Mutation analysis', 'Gene expression analysis', 'Multi-omics integration']",['Not specified'],"['Methods/Tools development', 'Other']",['Original research'],['Custom/Private data'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on experimental characterization of CTCF mutations and their effects on chromatin structure, cohesin binding, and gene regulation using custom experimental data. If cBioPortal is cited, it appears to be a reference citation only without direct usage of the platform for data analysis or visualization in this particular study.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40118069,Binding domain mutations provide insight into CTCF's relationship with chromatin and its contribution to gene regulation.,2025,abstract,2025-12-19T04:12:01.527355,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['Multiple sources'],"cBioPortal was used as one of multiple databases to investigate transcriptional and survival data of Fanconi anemia (FA) pathway genes in breast cancer patients. The study integrated data from cBioPortal along with other databases including ONCOMINE, UALCAN, Kaplan-Meier plotter, GEPIA, GeneMANIA, DAVID, and TIMER to comprehensively analyze the expression and prognostic significance of FA pathway genes in breast cancer.",[],"['Web-based analysis', 'Citation only']",[],['Not specified'],Unclear,low,4.0,40104721,Identification of Fanconi anemia pathway genes as novel prognostic biomarkers and therapeutic targets for breast cancer.,2025,abstract,2025-12-19T04:12:01.656217,,,,
"['Mutation analysis', 'Copy number analysis', 'Survival analysis']",['Other solid tumor'],"['Drug response/resistance', 'Precision medicine', 'Biomarker discovery']","['Original research', 'Clinical study']","['MSK-IMPACT', 'Custom/Private data']","cBioPortal was used to extract genomic and pathologic information for patients with uterine sarcoma harboring pathogenic BRCA alterations identified through MSK-IMPACT sequencing. The database served as a source for retrieving mutation profiling data, including BRCA1/BRCA2 alterations (mutations, homozygous deletions, structural variants) from the institutional cohort. This genomic data was combined with clinical information from chart review to analyze treatment outcomes with PARP inhibitors.",['MSK-IMPACT'],['Data download/export'],"['BRCA1', 'BRCA2']","['Download data', 'Query interface']",External (downloaded data),high,4.0,40117531,Retrospective Analysis of <i>BRCA</i>-Altered Uterine Sarcoma Treated With Poly(ADP-ribose) Polymerase Inhibitors.,2025,abstract,2025-12-19T04:12:02.357871,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Copy number analysis', 'Pathway analysis']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper mentions using various databases for expression validation, prognostic significance, and mutational analysis of CDCA genes in GBM. While cBioPortal is likely among the databases used for mutation, CNV, and methylation analyses of CDCA genes, the specific details of cBioPortal usage are not explicitly described in the provided abstract and introduction sections.",['TCGA'],['Citation only'],"['CDCA2', 'CDCA3', 'CDCA7', 'CDCA8']",['Not specified'],Unclear,low,4.0,40114265,"Mechanistic insights into CDCA gene family-mediated glioblastoma progression: implications for diagnosis, prognosis, and therapeutic targeting.",2025,pdf,2025-12-19T04:12:03.431914,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration']","['Pan-cancer', 'Lung cancer']","['Biomarker discovery', 'Immunotherapy']",['Original research'],['Multiple sources'],"The paper mentions utilizing data retrieved from multiple databases for analyzing PLIN3 mRNA and protein expression across normal and cancerous tissues, and for assessing PLIN3 as a diagnostic and prognostic biomarker. While cBioPortal is cited as one of the databases, the specific details of how it was used are not explicitly described in the abstract and introduction. The study appears to have integrated data from multiple sources for pan-cancer analysis.",[],['Citation only'],['PLIN3'],['Not specified'],Unclear,low,4.0,40098998,The Role of PLIN3 in Prognosis and Tumor-Associated Macrophage Infiltration: A Pan-Cancer Analysis.,2025,abstract,2025-12-19T04:12:03.465891,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used in this pan-cancer study to analyze NSUN7 genetic alterations and mutations across multiple cancer types from TCGA data. The authors likely used cBioPortal to query mutation data and potentially visualize genomic alterations of NSUN7, though specific details of the analysis workflow are not provided in the abstract and introduction sections.",['TCGA'],"['Web-based analysis', 'Data download/export']",['NSUN7'],['Not specified'],Unclear,medium,4.0,40100478,Pan-cancer analysis of the prognosis and immune infiltration of NSUN7 and its potential function in renal clear cell carcinoma.,2025,pdf,2025-12-19T04:12:05.108312,,,,
"['Mutation analysis', 'Survival analysis']","['Breast cancer', 'Pan-cancer']","['Biomarker discovery', 'Methods/Tools development', 'Precision medicine']","['Original research', 'Methods/Software']","['TCGA', 'Multiple sources']","The paper mentions retrospective analysis of patient outcomes from the Genomic Data Commons (GDC) to predict survival with newly identified HER2 gain-of-function variants. While cBioPortal is cited, the specific usage details are not clearly described in the abstract/introduction. The study appears to primarily focus on the GigaAssay method for testing HER2 mutations, with cBioPortal potentially used for validation or comparison of mutation data.",[],['Citation only'],"['ERBB2', 'EGFR']",['Not specified'],Unclear,low,4.0,40093211,New Gain-of-Function Mutations Prioritize Mechanisms of HER2 Activation.,2025,abstract,2025-12-19T04:12:05.759739,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],['Biomarker discovery'],['Original research'],['Multiple sources'],"cBioPortal was used to perform mutational and copy number variation (CNV) analysis of the four hub genes (COL3A1, COL4A1, COL5A2, and CXCL8) in ESCA samples. The analysis revealed that COL3A1 was altered in 67% of ESCA samples primarily through missense mutations, while COL5A2 exhibited alterations in 50% of samples including splice site and missense mutations. Gene amplification patterns were also observed through cBioPortal analysis.",[],"['Web-based analysis', 'Web-based visualization']","['COL3A1', 'COL4A1', 'COL5A2', 'CXCL8']",['Query interface'],cBioPortal platform,high,4.0,40087784,Integrative bioinformatics analysis of high-throughput sequencing and in vitro functional analysis leads to uncovering key hub genes in esophageal squamous cell carcinoma.,2025,pdf,2025-12-19T04:12:07.785832,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Mutation analysis']",['Breast cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, the paper appears to use cBioPortal to access breast cancer genomic data, likely including TCGA datasets, to analyze FAT1 expression patterns and their correlation with patient outcomes in different breast cancer subtypes. The study performed subtype-specific survival analysis showing that high FAT1 expression correlates with poor outcomes in TNBC but improved prognosis in luminal A/ER-positive breast cancers. While cBioPortal is likely used for data access and preliminary analysis, the specific usage details are not explicitly described in the provided text.",['TCGA'],"['Web-based analysis', 'Data download/export']",['FAT1'],"['Expression analysis', 'Survival analysis']","[""Mixed""]",medium,4.0,40083689,FAT1 functions as an oncogenic driver in triple negative breast cancer through AKT pathway-driven effects on the matrisome.,2025,abstract,2025-12-19T04:12:08.799274,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Copy number analysis', 'Pathway analysis']","['Pan-cancer', 'Lung cancer']","['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used as one of multiple bioinformatics platforms to analyze BUB1B in pan-cancer and lung adenocarcinoma using TCGA data. The platform was employed alongside other tools (HPA, TIMER, TISIDB, GEPIA, GDC, LinkedOmics, and CancerSEA) to investigate BUB1B's role in cancer progression, likely including mutation analysis, expression analysis, and correlation with clinical outcomes. The specific features used are not detailed in the abstract, but cBioPortal appears to be part of a comprehensive multi-platform analysis approach.",['TCGA'],"['Web-based analysis', 'Web-based visualization']",['BUB1B'],['Not specified'],"[""Unclear""]",medium,4.0,40076684,A Comprehensive Analysis Revealing BUB1B as a Potential Prognostic and Immunological Biomarker in Lung Adenocarcinoma.,2025,abstract,2025-12-19T04:12:08.819121,,,,
"['Gene expression analysis', 'Mutation analysis']","['Lung cancer', 'Pan-cancer']","['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis']",['Original research'],['Not specified'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on experimental investigation of LDHB's role in mitochondria-associated ferroptosis in cancer cells, particularly lung cancer. While the paper cites cBioPortal (as indicated by the user), the specific usage details are not described in the provided text sections.",[],['Citation only'],"['LDHB', 'LDHA', 'GPX4', 'DHODH', 'SLC7A11', 'KRAS']",['Not specified'],Unclear,low,4.0,40090955,Ubiquinol-mediated suppression of mitochondria-associated ferroptosis is a targetable function of lactate dehydrogenase B in cancer.,2025,pdf,2025-12-19T04:12:09.118733,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The study analyzed TCGA-HNSC data to investigate the molecular basis of tumor budding in head and neck squamous cell carcinoma. The authors examined mutation data, miRNA expression, whole transcriptome data, and RPPA protein data from the TCGA cohort. Additionally, they used CPTAC-HNSCC cohort as a validation dataset, analyzing multi-omics data to identify molecular correlates of tumor budding.","['TCGA-HNSC', 'CPTAC-HNSCC']",['Data download/export'],"['NSD1', 'SNAIL', 'SLUG', 'VIM', 'PDPN', 'CAV1', 'MMP14']",['Download data'],External (downloaded data),medium,4.0,40082664,Multi-omics analysis to uncover the molecular basis of tumor budding in head and neck squamous cell carcinoma.,2025,pdf,2025-12-19T04:12:10.068543,,,,
['Mutation analysis'],['Other solid tumor'],"['Methods/Tools development', 'Precision medicine', 'Biomarker discovery']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on comparing the Idylla™ IDH1-2 Mutation Assay Kit (a FastTrack method) with NGS panels for detecting IDH1/2 mutations in cholangiocarcinoma patients. The study appears to use custom clinical samples from 25 patients and does not describe any use of cBioPortal for data access, analysis, or visualization.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40075667,Evaluation of an <i>IDH1/2</i> Mutation FastTrack Assay for Patients with Cholangiocarcinoma.,2025,abstract,2025-12-19T04:12:10.094065,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Mutation analysis']",['Prostate cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","The paper mentions cBioPortal in the context of analyzing genetic alterations and mutation data for prostate cancer. However, the abstract and introduction provided do not contain explicit details about how cBioPortal was specifically used. Based on the methodology described, the authors primarily used TCGA and GEO databases for RNA-sequencing data analysis, with cBioPortal likely used for querying genetic alterations and mutation information related to RBIS in prostate cancer.",['TCGA'],['Citation only'],['RBIS'],['Not specified'],Unclear,low,4.0,40069535,RBIS as a prognostic biomarker for progression-free survival in prostate cancer: insights from bioinformatics and immune infiltration analysis.,2025,pdf,2025-12-19T04:12:10.543283,,,,
['Gene expression analysis'],['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],['TCGA'],"The paper used cBioPortal to analyze VDAC2 and Bak expression levels in human liver cancers. The authors queried gene expression data to demonstrate that VDAC2 and Bak are upregulated in hepatocellular carcinoma compared to normal liver tissue, which forms a key part of their rationale for selective tumor targeting.",[],['Web-based analysis'],"['VDAC2', 'BAK1']",['Expression analysis'],cBioPortal platform,medium,4.0,40069152,VDAC2 and Bak scarcity in liver mitochondria enables targeting hepatocarcinoma while sparing hepatocytes.,2025,pdf,2025-12-19T04:12:12.602788,,,,
"['Gene expression analysis', 'Mutation analysis', 'Copy number analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the methods or abstract. The authors obtained data from TCGA database directly and used various other bioinformatic tools including GEPIA, TIMER2.0, and HPA for their analyses. While cBioPortal is cited, there is no clear description of how it was used in this study.",['TCGA'],['Citation only'],"['SPATA2', 'CYLD', 'DVL1', 'TNFA', 'BRCA1']",['Not specified'],Unclear,low,4.0,40069269,Clinical and functional significance of SPATA2 in cancer particularly in LIHC.,2025,pdf,2025-12-19T04:12:12.712606,,,,
['Gene expression analysis'],"['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy', 'Drug response/resistance']",['Original research'],['TCGA'],"Based on the paper abstract and introduction provided, cBioPortal appears to have been used to analyze HLA-G expression across different cancer types, likely using TCGA data. The study describes JNJ-78306358 as a bispecific antibody targeting HLA-G, which is expressed in several tumor types, suggesting the authors may have used cBioPortal to characterize HLA-G expression patterns across cancers. However, specific details about cBioPortal usage are not explicitly mentioned in the provided abstract and introduction sections.",['TCGA'],['Citation only'],['HLA-G'],['Not specified'],Unclear,low,4.0,40060890,"JNJ-78306358, a first-in-class bispecific T cell engaging antibody targeting CD3 and HLA-G.",2025,abstract,2025-12-19T04:12:14.912021,,,,
"['Mutation analysis', 'Other']",['Pan-cancer'],"['Methods/Tools development', 'Database/Resource', 'Precision medicine']","['Methods/Software', 'Original research']",['Multiple sources'],"Based on the abstract and introduction provided, cBioPortal appears to be used as one of multiple data sources for human genetic variation data that was integrated into the H2M computational pipeline. The paper focuses on developing a tool to model human genetic variants in mice, and likely used cBioPortal to access cancer-related mutation data. However, specific details about how cBioPortal was used are not explicitly described in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40060429,Computational modeling of human genetic variants in mice.,2025,abstract,2025-12-19T04:12:15.013082,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, the paper does not explicitly mention cBioPortal usage. The study focuses on analyzing tumor-stroma proportion (TSP) in breast cancer using multiple public and in-house patient cohorts, including RNA-seq data and HE staining. While TCGA data may have been accessed (a common source available through cBioPortal), no specific mention of cBioPortal platform, tools, or data download is made in the provided text.",['TCGA'],['Citation only'],"['AEBP1', 'COL6A3', 'CTSK', 'PLAC9']",['Not specified'],Unclear,low,4.0,40068383,Tumor-stroma proportion is associated with increased M2 macrophage abundance and predicts the resistance to immune checkpoint blockade in breast cancer.,2025,abstract,2025-12-19T04:12:15.062213,,,,
"['Gene expression analysis', 'Mutation analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Breast cancer']","['Drug response/resistance', 'Biomarker discovery', 'Pathway analysis', 'Precision medicine']",['Original research'],"['TCGA', 'METABRIC', 'Multiple sources']","Based on the paper content provided, cBioPortal is cited as a cancer genomics data portal, but the abstract and introduction do not provide explicit details about how cBioPortal was specifically used in this study. The paper focuses on transcriptional regulation of alternative end-joining (alt-EJ) DNA repair pathway and its relationship with hypoxia and MYC activity in cancer treatment prediction. Given the research involves analysis of cancer genomics data including gene expression (PARP1, POLQ, HIF1A) and mutations, cBioPortal was likely used to access and analyze cancer genomics datasets, but specific usage details are not provided in the excerpts given.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40061566,Harnessing transcriptional regulation of alternative end-joining to predict cancer treatment.,2025,abstract,2025-12-19T04:12:16.190917,,,,
"['Multi-omics integration', 'Mutation analysis']",['Other solid tumor'],"['Methods/Tools development', 'Review/Commentary', 'Immunotherapy']","['Review', 'Methods/Software']",['Custom/Private data'],"This paper is a survey/review on proteomics methods for cancer neoantigen discovery. cBioPortal is likely cited as a reference resource in the context of cancer genomics databases, but no specific usage of cBioPortal for data analysis or visualization is described in the abstract or introduction. The study focuses on proteomics approaches using HepG2 cell line and hepatocellular carcinoma samples.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40052441,Integration of proteomics profiling data to facilitate discovery of cancer neoantigens: a survey.,2025,abstract,2025-12-19T04:12:16.224017,,,,
"['Gene expression analysis', 'Pathway analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['Custom/Private data'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal being used in this study. The paper describes using the Galaxy platform for RNA-Seq analysis of GEO dataset GSE137327 to identify differentially expressed genes and lncRNAs in colorectal cancer. The analysis workflow involved FastQC, Trim Galore, HISAT2, and HTseq-count tools within Galaxy. cBioPortal may only be cited in the references or not mentioned at all in the provided text.",['GSE137327'],['Citation only'],"['CCN1', 'CCL2', 'FLNC', 'MYH11', 'CEMIP', 'MMP7', 'DPEP1']",['Not specified'],Unclear,low,4.0,40056245,Comprehensive identification of hub mRNAs and lncRNAs in colorectal cancer using galaxy: an in silico transcriptome analysis.,2025,pdf,2025-12-19T04:12:16.759139,,,,
"['Mutation analysis', 'Survival analysis']",['Leukemia/Lymphoma'],"['Biomarker discovery', 'Precision medicine']",['Original research'],['Multiple sources'],"The authors used cBioPortal to access data from 399 CMML patients in the myelodysplastic syndromes (MDS IWG, IPS SM, NEJM Evidence 2022) dataset. They extracted clinical parameters (age, sex, WBC, hemoglobin, platelets, bone marrow blasts, circulating blasts, cytogenetics) and gene mutation data to analyze overall survival, AML-free survival, and phenotypic differences between TP53-mutated and wildtype patients. This cBioPortal cohort was used to validate findings from their national Austrian ABCMML database.","['MDS IWG, IPS SM, NEJM Evidence 2022']","['Data download/export', 'Web-based analysis']",['TP53'],"['Survival analysis', 'Group comparison', 'Download data']",External (downloaded data),high,4.0,40042734,Features of TP53-mutated patients with chronic myelomonocytic leukemia in a national (ABCMML) and international cohort (cBIOPORTAL).,2025,pdf,2025-12-19T04:12:19.424670,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Pathway analysis', 'Multi-omics integration']",['Colorectal cancer'],"['Biomarker discovery', 'Pathway analysis', 'Precision medicine']",['Original research'],"['Custom/Private data', 'Multiple sources']","The paper mentions comparing findings from Hispanic/Latino early-onset CRC patients with publicly available data from Non-Hispanic White cohorts, suggesting cBioPortal may have been used to access comparative data. However, the abstract and introduction do not provide explicit details about how cBioPortal was specifically utilized in the study methodology. The primary analysis appears to be performed on custom samples from Hispanic/Latino patients using multi-omics approaches.",[],['Citation only'],"['MYC', 'APC', 'TCF7L2', 'DKK1', 'DKK2', 'FZD10', 'LRP5', 'RSPO3', 'MYCBP2', 'FBXW7']",['Not specified'],Unclear,low,4.0,40034762,Assessment of MYC Gene and WNT Pathway Alterations in Early-Onset Colorectal Cancer Among Hispanic/Latino Patients Using Integrated Multi-Omics Approaches.,2025,pdf,2025-12-19T04:12:19.984381,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The study used cBioPortal to analyze FOXM1 gene expression and its correlations with various molecular factors in glioblastoma multiforme (GBM). The authors examined FOXM1 expression patterns, survival associations, and relationships with stemness factors, metabolic genes, and immune cell infiltration. The analysis included investigation of DNA methylation patterns and identification of FOXM1-targeting miRNAs using bioinformatics approaches.",['TCGA-GBM'],"['Web-based analysis', 'Web-based visualization']","['FOXM1', 'SOX2', 'SOX9']","['Expression analysis', 'Survival analysis', 'Query interface']",Mixed,medium,4.0,40032774,Deciphering FOXM1 regulation: implications for stemness and metabolic adaptations in glioblastoma.,2025,abstract,2025-12-19T04:12:20.705674,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy', 'Precision medicine']",['Original research'],['TCGA'],"The cBioPortal database was used to examine CDH18 mutations in uterine corpus endometrial carcinoma (UCEC). The study identified thirteen mutation sites in CDH18 through cBioPortal analysis. The mutation data was integrated with other analyses including expression, survival, and immune infiltration studies to comprehensively characterize CDH18's role in UCEC.",['TCGA-UCEC'],['Web-based analysis'],['CDH18'],['Query interface'],Unclear,medium,4.0,40017628,"Calcium-dependent adhesion protein CDH18, a potential biomarker for prognosis in uterine corpus endometrial carcinoma.",2025,abstract,2025-12-19T04:12:20.834393,,,,
"['Gene expression analysis', 'Mutation analysis', 'Survival analysis']",['Lung cancer'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, the paper appears to cite cBioPortal as a data source for validating findings related to EGFR-driven non-small cell lung cancer. The study likely used cBioPortal to access TCGA or other lung cancer datasets to examine expression patterns of TRIDENT, TRIM28, and EGFR mutations. However, specific details about how cBioPortal was used are not provided in the abstract/introduction sections given.",[],['Citation only'],"['EGFR', 'TRIM28']",['Not specified'],Unclear,low,4.0,40030013,EGFR-induced lncRNA <i>TRIDENT</i> promotes drug resistance in non-small cell lung cancer via phospho-TRIM28-mediated DNA damage repair.,2025,abstract,2025-12-19T04:12:20.922263,,,,
['Mutation analysis'],['Other solid tumor'],"['Pathway analysis', 'Other']",['Original research'],['Not specified'],"The paper mentions that ERK2 is recurrently mutated in human squamous cell carcinomas and other tumors, with mutations clustering in a docking recruitment site. While cBioPortal is likely cited as a reference for cancer mutation data (identifying ERK2 as a cancer hotspot), the paper focuses on experimental structural biology and biochemical characterization of ERK2 mutants rather than computational analysis of genomic data. The specific usage of cBioPortal is not explicitly described in the abstract or introduction.",[],['Citation only'],"['ERK2', 'MAPK1']",['Not specified'],Unclear,low,4.0,40015635,Cancer hotspot mutations rewire ERK2 specificity by selective exclusion of docking interactions.,2025,abstract,2025-12-19T04:12:22.186463,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']",The paper used cBioPortal to analyze ITGA4 alterations (mutations and copy number variations) across 22 cancer types in a pan-cancer analysis. The study examined the relationship between ITGA4 genetic alterations and its expression patterns across multiple tumor types. cBioPortal served as one of several data sources for the comprehensive multi-omics evaluation of ITGA4's role in cancer.,[],"['Web-based analysis', 'Web-based visualization']",['ITGA4'],"['Query interface', 'Expression analysis']",Mixed,medium,4.0,40012546,ITGA4 as a potential prognostic and immunotherapeutic biomarker in human cancer and its clinical significance in gastric cancer: an integrated analysis and validation.,2025,abstract,2025-12-19T04:12:22.247114,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to explore genetic alterations in TMEM9 across multiple cancer types, including mutation types and copy number alterations. The platform was specifically mentioned in the Methods section as the tool for analyzing genetic alterations. The study identified that genetic alterations, predominantly amplifications, were frequent in BRCA, LIHC, and UCEC.","['TCGA-BRCA', 'TCGA-LIHC', 'TCGA-UCEC', 'TCGA-ACC', 'TCGA-BLCA', 'TCGA-CHOL', 'TCGA-COAD', 'TCGA-GBM', 'TCGA-CESC', 'TCGA-KICH', 'TCGA-UVM', 'TCGA-THYM', 'TCGA-HNSC', 'TCGA-KIRC']",['Web-based analysis'],['TMEM9'],['Query interface'],cBioPortal platform,medium,4.0,40053281,Comprehensive analysis of TMEM9 in human tumors.,2025,pdf,2025-12-19T04:12:22.399645,,,,
"['Gene expression analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Drug response/resistance', 'Pathway analysis', 'Biomarker discovery']",['Original research'],['Multiple sources'],"cBioPortal was used as one of multiple databases for core target validation at the transcriptional, translational, and immune infiltration levels in laryngeal cancer. The study integrated cBioPortal data with other databases (GEPIA, HPA, TIMER) to validate the 15 core targets identified through network pharmacology analysis. Specific details about how cBioPortal was used or what features were accessed are not provided in the abstract.",[],['Citation only'],"['MAPK1', 'GSK3B', 'MAPK14']",['Not specified'],Unclear,low,4.0,40009149,"Integrating network pharmacology, molecular docking, and bioinformatics to explore the mechanism of sparganii rhizoma in the treatment of laryngeal cancer.",2025,abstract,2025-12-19T04:12:23.092386,,,,
"['Mutation analysis', 'Other']","['Lung cancer', 'Other solid tumor']",['Methods/Tools development'],"['Original research', 'Methods/Software']",['Not specified'],"This paper describes the development of Cas12a knock-in mice for multiplexed genome editing and disease modeling. While the paper cites cBioPortal in the references, there is no explicit description in the provided abstract and introduction of how cBioPortal was used for data analysis, visualization, or data download. The focus is on developing a new mouse model tool rather than analyzing cancer genomics data from cBioPortal.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40114032,"Cas12a-knock-in mice for multiplexed genome editing, disease modelling and immune-cell engineering.",2025,pdf,2025-12-19T04:12:23.436098,,,,
['Other'],['Pan-cancer'],['Review/Commentary'],['Other'],['Not specified'],"This is an editorial for a special issue on bioinformatics and computational biology for cancer prediction and prognosis. cBioPortal is likely mentioned as a relevant resource or tool in the field, but no specific analysis or data usage from cBioPortal is described in this editorial piece. The paper serves as an introduction to the special issue rather than presenting original research using cBioPortal.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40004496,Editorial for the Special Issue: Bioinformatics and Computational Biology for Cancer Prediction and Prognosis.,2025,abstract,2025-12-19T04:12:26.418123,,,,
"['Gene expression analysis', 'Survival analysis']",['Lung cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine']","['Original research', 'Clinical study']","['TCGA', 'Custom/Private data']",The authors used cBioPortal to access and analyze HGF mRNA expression levels in EGFR-mutated lung adenocarcinoma from TCGA and Singapore Oncology Data Portal (SODP) cohorts. They investigated whether solid predominant histology or high-podoplanin expression was associated with higher HGF expression levels in these publicly available datasets. The analysis was used to validate findings from their primary clinical cohort regarding mechanisms of osimertinib resistance.,"['TCGA', 'Singapore Oncology Data Portal']","['Web-based analysis', 'Expression analysis']","['EGFR', 'HGF']","['Expression analysis', 'Query interface']","[""cBioPortal platform""]",medium,4.0,40007550,Solid Predominant Histology and High Podoplanin Expression in Cancer-Associated Fibroblast Predict Primary Resistance to Osimertinib in <i>EGFR</i>-Mutated Lung Adenocarcinoma.,2025,abstract,2025-12-19T04:12:26.449618,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Pathway analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Pathway analysis', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","The paper conducted a pan-cancer analysis of RBP4 using data from public databases including TCGA across 33 tumor types. The study examined RBP4 expression levels, correlations with clinical outcomes (OS, DSS, PFI), immune cell infiltration, DNA methylation, and gene mutations. While cBioPortal is cited as a potential data source for cancer genomics data, the specific details of how cBioPortal was used are not explicitly described in the abstract and introduction provided.",[],['Citation only'],['RBP4'],['Not specified'],Unclear,low,4.0,40004479,"Retinol-Binding Protein 4 as a Biomarker in Cancer: Insights from a Pan-Cancer Analysis of Expression, Immune Infiltration, and Methylation.",2025,abstract,2025-12-19T04:12:26.631939,,,,
['Other'],['Pan-cancer'],"['Review/Commentary', 'Drug response/resistance', 'Precision medicine']",['Review'],['Not specified'],"This is a review paper that discusses therapeutic targeting of ubiquitin ligases to stabilize tumor suppressor proteins. Based on the abstract and introduction provided, there is no explicit description of cBioPortal usage for data analysis or visualization. The paper appears to cite cBioPortal as a reference resource in the context of discussing cancer genomics and E3 ligase inhibitors, but does not describe any specific analysis performed using the platform.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,40002221,A Perspective on Therapeutic Targeting Against Ubiquitin Ligases to Stabilize Tumor Suppressor Proteins.,2025,abstract,2025-12-19T04:12:26.998412,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Mutation analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['Multiple sources'],"cBioPortal was used to analyze genetic alterations in the five core hub genes (COL6A1, MMP2, POSTN, TAGLN, and THY1) identified from the differential expression analysis. The platform was likely used to query mutation and copy number alteration data for these genes in osteosarcoma samples. The specific details of how cBioPortal was accessed or which features were used are not explicitly described in the abstract.",[],['Web-based analysis'],"['COL6A1', 'MMP2', 'POSTN', 'TAGLN', 'THY1']",['Not specified'],Unclear,medium,4.0,40000579,Identification of potential genes associated with metastasis in osteosarcoma: an integrated bioinformatics analysis.,2025,abstract,2025-12-19T04:12:28.370579,,,,
"['Gene expression analysis', 'Pathway analysis', 'Survival analysis']",['Prostate cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction, the paper appears to analyze prostate cancer subtypes (CRPC-adeno and NEPC) using gene expression data and survival analysis. While cBioPortal is cited, the specific details of how it was used are not explicitly described in the provided text. The study likely used cBioPortal to access TCGA prostate cancer data for differential gene expression analysis and prognostic evaluation of hub genes like CHST1, MPPED2, and RIPPLY3.",['TCGA'],['Citation only'],"['CHST1', 'MPPED2', 'RIPPLY3']",['Not specified'],Unclear,low,4.0,39999729,"Identification of the specific characteristics of neuroendocrine prostate cancer: Immune status, hub genes and treatment.",2025,abstract,2025-12-19T04:12:28.401122,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis']","['Pan-cancer', 'Leukemia/Lymphoma', 'Breast cancer']","['Biomarker discovery', 'Drug response/resistance']",['Original research'],['Multiple sources'],"The authors used cBioPortal to analyze PPRC1 expression levels across multiple cancer types compared to normal tissues, and to examine correlations between PPRC1 expression/mutations and patient survival outcomes. They analyzed data from 23,456 cancer patients to assess the correlation between PPRC1 mutations and overall survival across various cancer types. The analysis included expression data from blood, breast, and other cancer types to establish PPRC1 as a potential oncogenic target.",[],"['Web-based analysis', 'Web-based visualization']",['PPRC1'],"['Expression analysis', 'Survival analysis', 'Query interface']",cBioPortal platform,medium,4.0,39996733,Eugenol Promotes Apoptosis in Leukemia Cells via Targeting the Mitochondrial Biogenesis PPRC1 Gene.,2025,abstract,2025-12-19T04:12:28.518495,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Glioma/Brain cancer', 'Lung cancer']","['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The cBioPortal database was used to acquire SMARCAL1 gene alteration profiles across 32 cancer types from a cohort of 10,953 patients encompassing 10,967 samples. The alterations analyzed included mutations, amplifications, and deep deletions of the SMARCAL1 gene across pan-cancer samples.",[],['Data download/export'],['SMARCAL1'],"['Download data', 'Query interface']",External (downloaded data),high,4.0,39994264,Pan-cancer analysis reveals SMARCAL1 expression is associated with immune cell infiltration and poor prognosis in various cancers.,2025,pdf,2025-12-19T04:12:29.088724,,,,
"['Gene expression analysis', 'Mutation analysis', 'Survival analysis']",['Breast cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, the paper appears to cite cBioPortal as a data source for validating findings from their CRISPR screen. The authors likely used cBioPortal to access TCGA breast cancer data to examine SMARCA4 expression, mutation status, and potentially survival correlations in breast cancer patients. However, specific details about cBioPortal usage are not explicitly described in the provided text.",['TCGA'],['Citation only'],"['SMARCA4', 'ARHGAP29', 'RHOA']",['Not specified'],Unclear,low,4.0,39992701,SMARCA4 Inhibits Breast Cancer Progression and Metastasis through RHOA Suppression.,2025,abstract,2025-12-19T04:12:29.882220,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Pan-cancer'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the methods or results. The study utilized multiple databases including TIMER, Sanger box, Genomic Cancer Analysis database, and STRING database, along with TCGA and GTEx data analyzed using R software. While cBioPortal is cited, there is no clear description of how it was specifically used in this study.",[],['Citation only'],['MATN3'],['Not specified'],Unclear,low,4.0,39991588,The Role of MATN3 in Cancer Prognosis and Immune Infiltration Across Multiple Tumor Types.,2025,abstract,2025-12-19T04:12:32.748337,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Mutation analysis']",['Breast cancer'],['Biomarker discovery'],['Original research'],['Multiple sources'],"cBioPortal was used to examine the correlations and alterations of three key genes (RACGAP1, SPAG5, and KIF20A) in breast cancer. The analysis revealed that alterations in these genes co-occurred. The platform was used after initial identification of hub genes through other bioinformatics tools to further characterize the genetic alterations and relationships among the key biomarkers.",[],"['Web-based analysis', 'Web-based visualization']","['RACGAP1', 'SPAG5', 'KIF20A']",['Query interface'],cBioPortal platform,medium,4.0,39988630,Identification of key biomarkers in breast cancer based on bioinformatics analysis and experimental verification.,2025,pdf,2025-12-19T04:12:32.775206,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']","['Pan-cancer', 'Lung cancer']","['Biomarker discovery', 'Drug response/resistance', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly describe how cBioPortal was used in the methodology. While the abstract mentions using ""public databases such as TCGA and the R language"" for pan-cancer analyses, there is no specific mention of cBioPortal in the provided abstract and introduction. The citation of cBioPortal may be for reference purposes or the actual usage details may be in the methods section not provided.",[],['Citation only'],"['HOXB7', 'HOXC6']",['Not specified'],Unclear,low,4.0,39980564,A pan-cancer analysis of homeobox family: expression characteristics and latent significance in prognosis and immune microenvironment.,2025,abstract,2025-12-19T04:12:33.063639,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The cBioPortal database (www.cbioportal.org) was used to analyze genomic alterations of CBX1-8 genes in 15 breast cancer sequencing studies conducted between 2012 and 2022. The analysis included examination of gene mutations, copy number variations, and other genomic discrepancies in these chromobox family members. The study integrated cBioPortal data with other databases (TCGA, Human Protein Atlas, Kaplan-Meier Plotter) for comprehensive analysis of CBX family expression and clinical significance in breast cancer.",[],"['Web-based analysis', 'Web-based visualization']","['CBX1', 'CBX2', 'CBX3', 'CBX4', 'CBX5', 'CBX6', 'CBX7', 'CBX8']",['Query interface'],Mixed,medium,4.0,39987187,Integrated bioinformatics investigation and experimental validation reveals the clinical and biological significance of chromobox family in breast cancer.,2025,pdf,2025-12-19T04:12:33.223148,,,,
['Other'],['Not specified'],['Other'],"['Original research', 'Clinical study']",['Custom/Private data'],"This paper does not appear to use cBioPortal. The study focuses on SPG7 gene variants in patients with spastic paraplegia and mitochondrial dysfunction, which is a neurological/neuromuscular disorder, not cancer. The paper analyzes a Hungarian patient cohort for SPG7 pathogenic variants using ACMG criteria. There is no mention of cBioPortal usage in the abstract or introduction provided.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39978794,Expanding the Phenotypic Spectrum of SPG7 Rare Damaging Variants: Insights From a Hungarian Cohort.,2025,abstract,2025-12-19T04:12:33.779012,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Tumor evolution', 'Immunotherapy', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, the paper appears to study MLL3 mutations in upper aerodigestive squamous cell carcinoma (UASCC). While cBioPortal is cited, the specific usage details are not explicitly described in the provided text. The study likely used cBioPortal to access TCGA or other genomic datasets to analyze MLL3 mutation frequencies and their clinical correlations in squamous cancers.",[],['Citation only'],"['MLL3', 'GRHL2', 'IRF1']",['Not specified'],Unclear,low,4.0,39964485,The MLL3/GRHL2 complex regulates malignant transformation and anti-tumor immunity in squamous cancer.,2025,abstract,2025-12-19T04:12:34.692983,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']",['Original research'],['TCGA'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal being used in this study. The paper describes using TCGA HNSCC cohort data with R package DESeq2 for differential gene expression analysis, Cox regression, and prognostic modeling. While cBioPortal is cited (as indicated by the paper being identified as citing cBioPortal), the specific usage details are not described in the provided text.",['TCGA-HNSCC'],['Citation only'],"['FADD', 'H2AZ1', 'PYGL', 'JAK3', 'ZBP1']",['Not specified'],Unclear,low,4.0,39974401,Deciphering the prognostic potential of a necroptosis-related gene signature in head and neck squamous cell carcinoma: a bioinformatic analysis.,2025,abstract,2025-12-19T04:12:35.269721,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis']",['Original research'],['Multiple sources'],"The paper mentions using publicly available bulk and single cell RNA-seq datasets to assess T-type calcium channel expression in medulloblastoma. While cBioPortal is cited as a potential source for such publicly available cancer genomics data, the abstract and introduction do not provide explicit details about specific cBioPortal usage, datasets accessed, or features utilized. The study primarily focuses on experimental validation using cell lines, RPPA proteomics, and xenograft models.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39961940,T-type calcium channels regulate medulloblastoma and can be targeted for therapy.,2025,abstract,2025-12-19T04:12:35.561172,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, the paper appears to analyze HCC datasets including RNA-sequencing, microarray, single-cell RNA-sequencing data to study TACE refractoriness and tumor stemness. While cBioPortal is cited, the specific usage details are not explicitly described in the provided text. The study likely used cBioPortal to access TCGA HCC data for genomic alterations and multi-omics analysis, but the exact features and mode of usage cannot be determined from the abstract alone.",['TCGA'],['Citation only'],[],['Not specified'],Unclear,low,4.0,39961903,Molecular subtyping combined with multiomics analysis to study correlation between TACE refractoriness and tumor stemness in hepatocellular carcinoma.,2025,abstract,2025-12-19T04:12:35.927274,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Lung cancer'],"['Biomarker discovery', 'Precision medicine', 'Drug response/resistance']","['Original research', 'Clinical study']","['Custom/Private data', 'Multiple sources']","Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper describes a comprehensive analysis of early-onset lung cancer using a cohort of 421 NSCLC patients from ten medical centers in China, with targeted DNA sequencing of 808 cancer-related genes and transcriptome profiling. While cBioPortal is cited (as indicated by the paper being in the analysis queue), the specific usage details are not described in the provided text sections.",[],['Citation only'],"['EGFR', 'TP53', 'ERBB2', 'HER2', 'ALK', 'NQO1', 'MTHFR', 'KMT2B', 'BRCA1', 'BRCA2', 'XRCC1', 'ROS1']",['Not specified'],Unclear,low,4.0,40000630,"Comprehensive characterization of early-onset lung cancer, in Chinese young adults.",2025,pdf,2025-12-19T04:12:37.938073,,,,
"['Mutation analysis', 'Drug response/resistance']",['Not specified'],"['Drug response/resistance', 'Precision medicine', 'Methods/Tools development']","['Original research', 'Methods/Software']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on deep mutational scanning (DMS) of MET kinase domain variants to profile resistance mutations against various inhibitors. This appears to be a primarily experimental study using custom data generated through DMS rather than analysis of existing cancer genomics databases through cBioPortal.",[],['Citation only'],['MET'],['Not specified'],Unclear,low,4.0,39960754,Mapping kinase domain resistance mechanisms for the MET receptor tyrosine kinase via deep mutational scanning.,2025,abstract,2025-12-19T04:12:38.144947,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Liver hepatocellular carcinoma', 'Kidney renal clear cell carcinoma', 'Cholangiocarcinoma', 'Breast cancer', 'Uterine corpus endometrial carcinoma']","['Biomarker discovery', 'Precision medicine', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to assess genetic alterations in GAS5 across different cancer types and to evaluate the relationship between GAS5 alterations and radiation therapy response. The tool was applied as part of a comprehensive pan-cancer analysis that integrated multiple bioinformatics platforms to characterize GAS5 expression, regulation, and clinical significance.",[],['Web-based analysis'],['GAS5'],['Not specified'],Mixed,medium,4.0,39958058,"The Multifaceted Role of lncRNA GAS5: A Pan-Cancer Analysis of Its Diagnostic, Prognostic, and Therapeutic Potential.",2025,pdf,2025-12-19T04:12:38.985879,,,,
"['Gene expression analysis', 'Survival analysis']",['Melanoma'],"['Biomarker discovery', 'Other']",['Original research'],['Multiple sources'],"The study used cBioPortal to perform bioinformatic analyses of published melanoma datasets to examine MCAM expression patterns in primary and metastatic melanomas. The authors likely queried gene expression data and potentially performed survival analyses to investigate the association between MCAM expression and disease progression. The analyses were conducted as part of a broader investigation combining immunohistochemistry, bioinformatics, and experimental approaches to understand MCAM's role in melanoma metastasis.",[],"['Web-based analysis', 'Web-based visualization']",['MCAM'],"['Expression analysis', 'Not specified']",Unclear,medium,4.0,39945026,MCAM Expression Facilitates Melanoma-Endothelial Interactions and Promotes Metastatic Disease Progression.,2025,abstract,2025-12-19T04:12:39.436322,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Other solid tumor']",['Biomarker discovery'],['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the abstract or introduction provided. The study primarily used TCGA and GTEx data to analyze HSPG2 expression across 33 cancers, performing survival analysis, immune infiltration analysis, DNA methylation analysis, and pathway enrichment. While cBioPortal is cited, there is no clear description of how it was specifically used in the methodology based on the provided text.",[],['Citation only'],['HSPG2'],['Not specified'],Unclear,low,4.0,39956899,Comprehensive pan-cancer analysis of HSPG2 as a marker for prognosis.,2025,abstract,2025-12-19T04:12:39.610727,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Leukemia/Lymphoma'],"['Biomarker discovery', 'Precision medicine']",['Original research'],['Multiple sources'],"The paper mentions using the GEPIA database (Gene Expression Profiling Interactive Analysis) to screen RIPK family members and identify RIPK3 overexpression associated with poor prognosis in AML. While GEPIA is mentioned rather than cBioPortal directly, the paper appears to have used public databases for initial expression and prognostic analysis before validating findings in their own research cohort. The specific role of cBioPortal in this study is not explicitly detailed in the abstract.",[],['Citation only'],['RIPK3'],['Not specified'],Unclear,low,4.0,39948488,Overexpression and oncogenic role of RIPK3 in acute myeloid leukemia associated with specific subtypes and treatment outcome.,2025,abstract,2025-12-19T04:12:40.774491,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Colorectal cancer'],"['Drug response/resistance', 'Immunotherapy', 'Biomarker discovery']",['Original research'],"['TCGA', 'Multiple sources']","The study utilized TCGA database data, likely accessed through cBioPortal, to analyze MYOF expression patterns and their correlation with immune cell infiltration and checkpoint expression in colorectal cancer. The TCGA data was used alongside CPTAC database information to support the integrative analysis of MYOF's role in CRC. The specific mode of cBioPortal usage (web-based vs. data download) is not explicitly detailed in the abstract.",['TCGA'],['Citation only'],"['MYOF', 'CD274']",['Not specified'],"[""Unclear""]","[""low""]",4.0,39941891,Apatinib Degrades PD-L1 and Reconstitutes Colon Cancer Microenvironment via the Regulation of Myoferlin.,2025,abstract,2025-12-19T04:12:41.033077,,,,
['Other'],['Breast cancer'],"['Drug response/resistance', 'Other']",['Original research'],['Not specified'],"This paper does not appear to use cBioPortal for any analysis. The study focuses on rheumatoid arthritis (RA) and synovial fibroblast proliferation using in vitro cell culture experiments and collagen-induced arthritis mouse models. While palbociclib (a CDK4/6 inhibitor used for breast cancer) is mentioned in the context of exploring it as a treatment for RA, there is no indication that cBioPortal was accessed or utilized for data analysis, visualization, or data download.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39940918,"CDK6-Dependent, CDK4-Independent Synovial Hyperplasia in Arthritic Mice and Tumor Necrosis Factor-α-Induced Proliferation of Synovial Fibroblasts.",2025,abstract,2025-12-19T04:12:41.142144,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis', 'Precision medicine']","['Original research', 'Clinical study']","['TCGA', 'Custom/Private data']",The study used TCGA epithelioid pleural mesothelioma data to validate their molecular stratification findings. They accessed mutation and copy number alteration data from TCGA through cBioPortal to investigate genomic alterations associated with the two molecular subgroups (HP1 and HP2) they identified. The cBioPortal data was used to examine homodeletions in Hippo core suppressors and other genomic alterations in the Hippo pathway genes.,['TCGA'],['Data download/export'],"['YAP1', 'WWTR1', 'VSIR']",['Download data'],External (downloaded data),medium,4.0,39941836,Prognostic Stratification of Epithelioid Pleural Mesothelioma Based on the Hippo-TEADs Network.,2025,abstract,2025-12-19T04:12:41.415300,,,,
['Mutation analysis'],['Pan-cancer'],"['Biomarker discovery', 'Methods/Tools development']",['Original research'],['Multiple sources'],The study used cBioPortal to identify and select cancer-associated missense variants in the retinoblastoma (Rb) protein pocket domain for functional characterization. The authors queried cBioPortal databases to compile a list of 75 cancer-associated missense mutations in the RB1 gene that were then experimentally tested using biophysical and structural methods. cBioPortal served as the primary source for identifying clinically relevant mutations across multiple cancer types.,[],"['Data download/export', 'Web-based analysis']",['RB1'],"['Query interface', 'Mutation Mapper']","[""External (downloaded data)""]",medium,4.0,39938803,Structural and functional analysis of cancer-associated missense variants in the retinoblastoma protein pocket domain.,2025,abstract,2025-12-19T04:12:42.235019,,,,
"['Mutation analysis', 'Gene expression analysis']",['Other solid tumor'],"['Biomarker discovery', 'Other']",['Original research'],"['TCGA', 'Multiple sources']",cBioPortal was used to identify and analyze somatic nonstop mutations in BAP1 and VHL genes in renal cell carcinoma patients. The authors queried cBioPortal databases to find these specific mutation types enriched in kidney cancer. The platform served as a data source for identifying clinically relevant nonstop mutations in tumor suppressor genes.,[],"['Data download/export', 'Web-based analysis']","['BAP1', 'VHL', 'SMAD4']",['Query interface'],"[""External (downloaded data)""]",medium,4.0,39937911,Nonstop mutations cause loss of renal tumor suppressor proteins <i>VHL</i> and <i>BAP1</i> and affect multiple stages of protein translation.,2025,abstract,2025-12-19T04:12:43.489949,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],['TCGA'],"The paper analyzed gene expression data from 257 ER-positive invasive ductal carcinoma patients from The Cancer Genome Atlas (TCGA) accessed through cBioPortal. The study examined FGFR2 expression and 12 stromal genes (FAP, CXCL12, PDGFRA, COL1A1, HSPG2, CCL2, MMP14, S100A4, MMP9, PDGFA, MCAM, IL6) to assess their prognostic value in relation to overall survival. The data was downloaded from cBioPortal for external analysis including k-means clustering and Cox proportional hazards regression modeling.",['TCGA'],['Data download/export'],"['FGFR2', 'FGFR1', 'FGFR3', 'FGFR4', 'FAP', 'CXCL12', 'PDGFRA', 'COL1A1', 'HSPG2', 'CCL2', 'MMP14', 'S100A4', 'MMP9', 'PDGFA', 'MCAM', 'IL6']",['Download data'],External (downloaded data),high,4.0,39935756,Prognostic value of <i>FGFR2</i> in ER-positive breast cancer is influenced by the profile of stromal gene expression: an <i>in silico</i> analysis based on TCGA data.,2024,abstract,2025-12-19T04:12:44.251595,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Pathway analysis', 'Multi-omics integration']","['Lung cancer', 'Other solid tumor']","['Review/Commentary', 'Drug response/resistance', 'Biomarker discovery', 'Precision medicine', 'Immunotherapy']",['Review'],['Not specified'],"This is a comprehensive review article on squamous cell cancers of the head and neck, esophagus, and lung. cBioPortal appears to be cited as a reference resource for cancer genomics data, but the abstract and introduction do not provide specific details about how cBioPortal was used or what analyses were performed using the platform. The paper focuses on synthesizing knowledge about shared genetic alterations, model systems, and therapeutic approaches across these cancer types.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39933897,"Squamous cell cancers of the aero-upper digestive tract: A unified perspective on biology, genetics, and therapy.",2025,abstract,2025-12-19T04:12:44.696567,,,,
"['Mutation analysis', 'Multi-omics integration']",['Lung cancer'],"['Tumor evolution', 'Methods/Tools development']",['Original research'],"['TCGA', 'Custom/Private data']","The paper used cBioPortal to access lung cancer mutation data from TCGA to compare with their experimental BPDE-induced mutagenesis patterns. The authors integrated publicly available lung cancer sequencing data with their high-resolution genomic measurements of BPDE damage formation, repair, and mutagenesis in human cell lines. This allowed them to validate their experimental findings against real-world smoking-associated mutational signatures in lung cancer patients.",['TCGA'],['Data download/export'],[],['Download data'],External (downloaded data),medium,4.0,39933696,The epigenetic landscape shapes smoking-induced mutagenesis by modulating DNA damage susceptibility and repair efficiency.,2025,abstract,2025-12-19T04:12:45.233440,,,,
"['Gene expression analysis', 'Mutation analysis']",['Lung cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],"Based on the abstract and introduction provided, the paper appears to focus on experimental validation of the RAS-POU3F3-ATP5PF axis in NSCLC using cell lines and molecular biology techniques. While cBioPortal is cited, the abstract does not explicitly describe how cBioPortal was used. It is likely that cBioPortal was used to query TCGA data for validation of gene expression patterns or mutation status in NSCLC, but specific usage details are not provided in the excerpts given.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39932442,Phosphorylation of POU3F3 Mediated Nuclear Translocation Promotes Proliferation in Non-Small Cell Lung Cancer through Accelerating ATP5PF Transcription and ATP Production.,2025,abstract,2025-12-19T04:12:45.674669,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Immunotherapy', 'Drug response/resistance']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the methods or results. The data analysis was performed using R programming language on bulk sequencing data obtained from UCSC datasets (TCGA data). While cBioPortal is cited, there is no clear description of how it was used for data access, analysis, or visualization in this study.",['TCGA'],['Citation only'],['UCK2'],['Not specified'],Unclear,low,4.0,39931080,"Uridine-cytidine kinase 2 is correlated with immune, DNA damage repair and promotion of cancer stemness in pan-cancer.",2025,abstract,2025-12-19T04:12:46.231742,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Immunotherapy', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to assess somatic mutations and copy number variations (CNVs) of ACSL family genes in low-grade gliomas. The platform was utilized to analyze genomic alterations in ACSL1, ACSL3, ACSL5, and ACSL6 genes and their associations with immune cell infiltration. The analysis focused on understanding the relationship between somatic CNVs and immune function in LGG patients.",['TCGA'],['Web-based analysis'],"['ACSL1', 'ACSL3', 'ACSL5', 'ACSL6']",['Query interface'],External (downloaded data),medium,4.0,39924494,Bioinformatics insights into ACSL1 and ACSL5: prognostic and immune roles in low-grade glioma.,2025,abstract,2025-12-19T04:12:47.117713,,,,
"['Mutation analysis', 'Other']",['Other solid tumor'],"['Review/Commentary', 'Precision medicine', 'Biomarker discovery']",['Review'],['Not specified'],"This is a review paper on pediatric differentiated thyroid carcinoma that discusses molecular landscape and therapeutic strategies. Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage. The paper appears to cite cBioPortal as a reference resource but does not describe specific analyses or data queries performed using the platform.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39921216,Molecular Landscape and Therapeutic Strategies in Pediatric Differentiated Thyroid Carcinoma.,2025,abstract,2025-12-19T04:12:47.450624,,,,
"['Gene expression analysis', 'Survival analysis', 'Other']",['Pan-cancer'],"['Review/Commentary', 'Biomarker discovery']",['Review'],['Not specified'],"This is a comprehensive review paper about PA2G4 (EBP1) protein in health and disease. cBioPortal appears to be cited as a reference or data source in the context of discussing PA2G4's role in cancer, but no specific details about how cBioPortal was used are provided in the abstract or introduction. The paper focuses on summarizing existing knowledge about PA2G4's molecular structure, functions, and relevance to tumorigenesis rather than presenting original cBioPortal-based analyses.",[],['Citation only'],['PA2G4'],['Not specified'],Unclear,low,4.0,39923993,PA2G4 in health and disease: An underestimated multifunctional regulator.,2025,abstract,2025-12-19T04:12:47.522511,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Colorectal cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The paper mentions using cBioPortal in the context of analyzing TCGA datasets for CDCA gene expression in colorectal adenocarcinoma (COAD). However, the abstract and introduction do not provide explicit details about how cBioPortal was specifically used - whether for data download, web-based analysis, or visualization. The study primarily focuses on TCGA data analysis along with in vitro experiments, suggesting cBioPortal may have been used for accessing or analyzing TCGA COAD data.",['TCGA'],['Citation only'],"['CDCA2', 'CDCA3', 'CDCA4', 'CDCA5', 'CDCA7', 'CDCA8']",['Not specified'],Unclear,low,4.0,39924497,CDCA genes as prognostic and therapeutic targets in Colon adenocarcinoma.,2025,abstract,2025-12-19T04:12:48.573832,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Leukemia/Lymphoma'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']","['TCGA', 'Custom/Private data']","The paper does not explicitly mention using cBioPortal in the abstract or introduction provided. The study primarily describes using TCGA datasets to screen for prognostic value of HOXA cluster gene methylation in AML, followed by validation in an independent cohort. While TCGA data was used, there is no clear indication that cBioPortal was the platform used to access or analyze this data.",['TCGA'],['Citation only'],"['HOXA9', 'FLT3', 'NPM1', 'DNMT3A', 'SOSTDC1', 'MEG3']",['Not specified'],Unclear,low,4.0,39920624,Identification of HOXA9 methylation as an epigenetic biomarker predicting prognosis and guiding treatment choice in acute myeloid leukemia.,2025,abstract,2025-12-19T04:12:49.473656,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis', 'Multi-omics integration']",['Glioma/Brain cancer'],"['Drug response/resistance', 'Pathway analysis', 'Biomarker discovery']",['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper describes an integrative multi-omics approach using patient-derived glioblastoma cancer stem cells with targeted proteomics, transcriptomics, genomics, and DNA methylation profiling. If cBioPortal was used, it may have been for reference data or validation purposes, but this is not stated in the provided text.",[],['Citation only'],['TP53'],['Not specified'],Unclear,low,4.0,39919036,"Impact of developmental state, p53 status, and interferon signaling on glioblastoma cell response to radiation and temozolomide treatment.",2025,abstract,2025-12-19T04:12:50.557523,,,,
"['Gene expression analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine']",['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on multi-omics analyses (transcriptomics, proteomics, and phosphoproteomics) to identify CD66c as an ADC target for GEJ cancer, but does not describe using cBioPortal for data access, analysis, or visualization. If cBioPortal is cited, it appears to be a reference citation only without direct usage described in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39918687,Identification of CD66c as a potential target in gastroesophageal junction cancer for antibody-drug conjugate development.,2025,abstract,2025-12-19T04:12:51.018663,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Breast cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],['TCGA'],"The paper analyzed 696 breast cancer patients from TCGA database to compare AJCC seventh and eighth edition staging systems. The study examined multiple biological features including cell proliferation, intratumor heterogeneity, homologous recombination deficiency, neoantigen load, immune cell infiltration, and gene expression of immune checkpoints (PDCD1, PDL1, CTLA4, LAG3, TIGIT, IDO1, IDO2). While cBioPortal is cited as a potential data source for TCGA data, the specific usage details are not explicitly described in the abstract.",['TCGA'],['Citation only'],"['PDCD1', 'CD274', 'CTLA4', 'LAG3', 'TIGIT', 'IDO1', 'IDO2']",['Not specified'],Unclear,low,4.0,39918749,"The American Joint Committee on Cancer (AJCC) Breast Cancer Staging, Eighth Edition, is more Reflective of Cancer Biology than the Seventh Edition.",2025,abstract,2025-12-19T04:12:51.030240,,,,
"['Gene expression analysis', 'Survival analysis', 'Copy number analysis']","['Pan-cancer', 'Colorectal cancer']","['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was not explicitly mentioned in the abstract or introduction. The study used databases including TIMER, GEPIA, and UALCAN to analyze SREBF1 expression in pan-cancers and COAD. While cBioPortal may have been cited in the paper, the specific usage details are not provided in the abstract/introduction sections provided.",[],['Citation only'],['SREBF1'],['Not specified'],Unclear,low,4.0,39917010,Sterol regulatory element binding transcription factor 1 is an important prognostic factor for colon adenocarcinoma and closely related to immune infiltration.,2024,abstract,2025-12-19T04:12:51.087934,,,,
"['Gene expression analysis', 'Other']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Methods/Tools development']",['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on circulating miRNA profiles from serum samples analyzed using weighted miRNA co-expression network analysis and machine learning techniques. cBioPortal may only be cited in the references without direct usage in the methodology.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39915853,Circulating microRNA panels for multi-cancer detection and gastric cancer screening: leveraging a network biology approach.,2025,abstract,2025-12-19T04:12:51.391702,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Glioma/Brain cancer'],['Biomarker discovery'],"['Original research', 'Clinical study']","['TCGA', 'Custom/Private data']","The paper does not explicitly mention using cBioPortal in the abstract or introduction provided. The study primarily used GEPIA tool for bioinformatics analysis of DDIT4 mRNA expression and prognostic significance in gliomas, followed by validation using immunohistochemistry on tissue microarrays. While cBioPortal is cited, the actual usage details are not described in the provided text.",[],['Citation only'],['DDIT4'],['Not specified'],Unclear,low,4.0,39915428,Increased nuclear expression of DNA damage inducible transcript 4 can serve as a potential prognostic biomarker in patients with gliomas: a study based on data mining and experimental tools.,2025,abstract,2025-12-19T04:12:52.795517,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis']",['Pan-cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper appears to use cBioPortal primarily for accessing cancer genomics data to validate findings related to 9p21.3 deletions and MSI-H status across different cancer types. Based on the abstract and introduction, the study likely queried cBioPortal for mutation, copy number, and microsatellite instability data to identify patient populations with FOCAD deletions or TTC37 mutations. The specific details of cBioPortal usage are not explicitly described in the provided abstract and introduction sections.",[],['Citation only'],"['FOCAD', 'TTC37', 'PELO']",['Not specified'],Unclear,low,4.0,39910293,SKI complex loss renders 9p21.3-deleted or MSI-H cancers dependent on PELO.,2025,abstract,2025-12-19T04:12:53.537849,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Prostate cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, the paper appears to use cBioPortal to analyze ATAD2 expression patterns and its association with MYC pathway activation in patient datasets. The study likely queried multiple independent human cohorts through cBioPortal to validate findings about ATAD2 enrichment in metastatic prostate cancer and its correlation with patient outcomes. However, specific details about cBioPortal usage are not explicitly mentioned in the provided text.",[],['Citation only'],"['ATAD2', 'MYC']",['Not specified'],Unclear,low,4.0,39907729,ATAD2 Drives Prostate Cancer Progression to Metastasis.,2025,abstract,2025-12-19T04:12:53.931128,,,,
"['Mutation analysis', 'Survival analysis']","['Colorectal cancer', 'Lung cancer']","['Tumor evolution', 'Methods/Tools development', 'Biomarker discovery']","['Original research', 'Methods/Software']","['Custom/Private data', 'Multiple sources']","Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on developing a novel framework to count cell divisions using DNA replication-related mutations in polyguanine homopolymers, analyzing custom patient samples from colorectal and lung cancers. cBioPortal may be cited in the references but does not appear to be directly used for data acquisition or analysis in this work.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39905260,Quantifying cell divisions along evolutionary lineages in cancer.,2025,abstract,2025-12-19T04:12:54.031411,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Other']",['Original research'],['TCGA'],The authors used cBioPortal to analyze RBM42 expression levels in pancreatic ductal adenocarcinoma (PDAC) patients from TCGA datasets. They examined the correlation between RBM42 expression and patient survival outcomes to demonstrate that high RBM42 expression predicts poor survival in PDAC patients. This analysis supported their functional findings that RBM42 is a key mediator of oncogenic translation in PDAC.,['TCGA-PAAD'],"['Web-based analysis', 'Web-based visualization']",['RBM42'],"['Expression analysis', 'Survival analysis']",cBioPortal platform,medium,4.0,39905246,Functional screen identifies RBM42 as a mediator of oncogenic mRNA translation specificity.,2025,abstract,2025-12-19T04:12:55.042402,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration', 'Copy number analysis', 'Mutation analysis']","['Pan-cancer', 'Other solid tumor']","['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used as one of multiple web platforms to analyze the role of CDC6 in cancer. The study performed comprehensive multi-omics analysis of CDC6 across multiple cancer types, examining expression patterns, prognostic value, and associations with immune features. The specific features or data extracted from cBioPortal are not detailed in the abstract, but it was listed among the analytical tools used alongside R, UALCAN, and SangerBox.",[],['Web-based analysis'],['CDC6'],['Not specified'],Unclear,medium,4.0,39904279,Comprehensive multi-omics analysis showed that CDC6 is a potential prognostic and immunotherapy biomarker for multiple cancer types including HCC.,2025,abstract,2025-12-19T04:12:56.536562,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly describe how cBioPortal was used in the study. While TCGA data was analyzed for gastric cancer and the paper mentions validation in bulk cohorts, there is no specific mention of cBioPortal in the abstract or introduction provided. The citation of cBioPortal may be in the references or methods section not included in this excerpt.",['TCGA'],['Citation only'],"['VWF', 'EPAS1', 'HIF1A']",['Not specified'],Unclear,low,4.0,39901877,Hypoxia signature derived from tumor-associated endothelial cells predict prognosis in gastric cancer.,2025,pdf,2025-12-19T04:12:57.060805,,,,
['Other'],['Not specified'],"['Review/Commentary', 'Database/Resource']",['Review'],['Not specified'],"This is a review paper providing a practical guide to FAIR (Findable, Accessible, Interoperable, Reusable) data management principles for multi-omics and AI applications in biomedical research. cBioPortal is likely cited as an example of a public data repository or resource that embodies FAIR principles, but no specific usage, analysis, or data extraction from cBioPortal is described in the provided abstract and introduction. The paper focuses on data stewardship practices rather than conducting original cancer genomics research.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39902035,A practical guide to FAIR data management in the age of multi-OMICS and AI.,2024,pdf,2025-12-19T04:12:57.244451,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis']",['Pan-cancer'],"['Biomarker discovery', 'Other']",['Original research'],"['TCGA', 'GENIE', 'Multiple sources']",cBioPortal was used to query and identify H3E50K mutations in human patient tumors across multiple cancer genomics databases. The authors used cBioPortal to examine the co-occurrence of H3E50K mutations with BRAF mutations in patient tumors. This analysis helped establish the clinical relevance of H3E50K mutations in cancer.,"['TCGA', 'GENIE']","['Web-based analysis', 'Web-based visualization']","['HIST1H3B', 'HIST1H3C', 'HIST1H3D', 'HIST1H3E', 'HIST1H3F', 'HIST1H3G', 'HIST1H3H', 'HIST1H3I', 'HIST1H3J', 'BRAF']","['Query interface', 'Mutation Mapper']",cBioPortal platform,medium,4.0,39901931,Histone H3E50K remodels chromatin to confer oncogenic activity and support an EMT phenotype.,2025,abstract,2025-12-19T04:12:58.144965,,,,
"['Gene expression analysis', 'Survival analysis']",['Colorectal cancer'],"['Methods/Tools development', 'Biomarker discovery']","['Methods/Software', 'Original research']",['TCGA'],The authors applied their proposed ensemble feature selection approach to a colorectal cancer dataset from The Cancer Genome Atlas (TCGA). The data was likely obtained through cBioPortal to access TCGA gene expression data for their survival analysis. The approach was used to select genes and generate a composite score to distinguish different subtypes of colorectal cancer patients.,['TCGA colorectal cancer'],['Data download/export'],[],['Download data'],External (downloaded data),medium,4.0,39897528,A robust ensemble feature selection approach to prioritize genes associated with survival outcome in high-dimensional gene expression data.,2024,abstract,2025-12-19T04:12:58.447087,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],"['TCGA', 'Multiple sources']","The paper appears to have used cBioPortal to access and analyze gastric cancer data, likely including gene expression, survival, and methylation data for MAP3K genes. The study integrated multiple data types including transcriptomic, proteomic, and methylation profiling to characterize MAP3K gene family members in gastric cancer. However, the abstract and introduction do not provide explicit details about specific cBioPortal features or usage methods.",['TCGA'],"['Web-based analysis', 'Data download/export']","['MAP3K1', 'MAP3K2', 'MAP3K3', 'MAP3K4', 'MAP3K5', 'MAP3K6', 'MAP3K7', 'MAP3K8', 'MAP3K9', 'MAP3K10', 'MAP3K11', 'MAP3K12', 'MAP3K13', 'MAP3K14', 'MAP3K15']","['Expression analysis', 'Survival analysis', 'Not specified']","[""Unclear""]",medium,4.0,39901302,"Exploring MAP3K genes in gastric cancer: biomarkers, tumor microenvironment dynamics, and chemotherapy resistance.",2025,abstract,2025-12-19T04:12:59.163699,,,,
['Mutation analysis'],['Not specified'],"['Methods/Tools development', 'Other']","['Original research', 'Methods/Software']",['Not specified'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. This paper focuses on experimental characterization of STIM1 EF-hand variants through functional assays in cultured human cells. If cBioPortal is cited, it appears to be a reference citation only without direct usage for data analysis or visualization in this particular study.",[],['Citation only'],['STIM1'],['Not specified'],"[""Unclear""]","[""low""]",4.0,39896620,Comprehensive mutational characterization of the calcium-sensing STIM1 EF-hand reveals residues essential for structure and function.,2025,abstract,2025-12-19T04:12:59.200541,,,,
"['Gene expression analysis', 'Multi-omics integration', 'Pathway analysis']",['Leukemia/Lymphoma'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine']",['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on transcriptomic profiling of blast phase chronic myelomonocytic leukemia (BP-CMML) samples using RNA sequencing and integrative multiparametric approaches. While cBioPortal is cited, the specific usage details are not described in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39892394,An integrative multiparametric approach stratifies putative distinct phenotypes of blast phase chronic myelomonocytic leukemia.,2025,abstract,2025-12-19T04:12:59.416007,,,,
"['Gene expression analysis', 'Other']",['Breast cancer'],['Biomarker discovery'],['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The research focuses on proteomics analysis of a CTC cell line (CTC-ITB-01) and validation of SUSD2 expression in clinical blood samples from metastatic breast cancer patients. The study appears to use custom experimental data from cell lines and patient samples rather than cBioPortal data resources.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39890941,Discovery of a sushi domain-containing protein 2-positive phenotype in circulating tumor cells of metastatic breast cancer patients.,2025,abstract,2025-12-19T04:12:59.899180,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],['Biomarker discovery'],['Original research'],['TCGA'],cBioPortal was used to access gene expression data from TCGA endometrial cancer datasets to investigate selected cancer stem cell markers. The gene expression data was used to analyze CD44 expression patterns and its association with patient prognosis. This analysis complemented the primary imaging mass cytometry experiments performed on patient tumor biopsies and organoids.,['TCGA'],['Data download/export'],"['CD44', 'ALDH1', 'SOX9', 'SOX2', 'CD133', 'CD15']","['Expression analysis', 'Download data']",External (downloaded data),medium,4.0,39888143,"Multiplex single-cell profiling of putative cancer stem cell markers ALDH1, SOX9, SOX2, CD44, CD133 and CD15 in endometrial cancer.",2025,abstract,2025-12-19T04:13:00.656833,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Breast cancer'],"['Biomarker discovery', 'Precision medicine']",['Original research'],['TCGA'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage. The study focuses on characterizing a high-risk breast cancer subgroup using hypoxia signatures, immune cell composition analysis (CIBERSORT), and tumor-infiltrating lymphocytes assessment. While the study uses multi-omic data integration and likely TCGA data, cBioPortal is not specifically mentioned in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39875417,Biological correlates associated with high-risk breast cancer patients identified using a computational method.,2025,abstract,2025-12-19T04:13:02.713481,,,,
"['Mutation analysis', 'Copy number analysis', 'Survival analysis', 'Gene expression analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy', 'Precision medicine']","['Original research', 'Clinical study']",['Multiple sources'],"The study enrolled 2438 patients with urothelial carcinoma from seven independent real-world cohorts with comprehensive clinical and genomic data. The paper analyzed KDM6A mutations (point mutations and homozygous deletions) and their correlation with clinical outcomes, genomic profiles, and immunological characteristics across gender. While cBioPortal is cited and the study uses publicly available cancer genomics data, the specific details of how cBioPortal was used for data access or analysis are not explicitly described in the abstract and introduction.",[],['Citation only'],['KDM6A'],['Not specified'],Unclear,low,4.0,39886491,Gender disparities in clinical outcomes of urothelial carcinoma linked to X chromosome gene <i>KDM6A</i> mutation.,2023,abstract,2025-12-19T04:13:02.716945,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']","['Pan-cancer', 'Lung cancer']","['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to explore MARCH8 genetic alterations and expression patterns across multiple cancer types. The platform was utilized alongside GTEx and TCGA databases to investigate MARCH8 in a pan-cancer context. The study examined mutation patterns, copy number alterations, and expression data for MARCH8 across various cancer types.",['TCGA'],"['Web-based analysis', 'Web-based visualization']",['MARCH8'],"['Expression analysis', 'Query interface']",Mixed,medium,4.0,39881438,"A pan-cancer analysis of MARCH8: molecular characteristics, clinical relevance, and immuno-oncology features.",2025,abstract,2025-12-19T04:13:03.264611,,,,
"['Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']",['Original research'],['TCGA'],"The paper utilized TCGA data to analyze genome-wide CpG methylation patterns across 245 endometrial cancer tumor samples. While the abstract mentions using ""the most recent data within the Cancer Genome Atlas (TCGA),"" there is no explicit mention of cBioPortal in the provided abstract and introduction. The study focused on DNA methylation analysis, molecular subtypes, and survival outcomes with race-specific patterns, but the specific role of cBioPortal (if any) is not described in the provided text.",['TCGA'],['Citation only'],"['HIF3A', 'MLH1', 'GNB1', 'IL37']",['Not specified'],Unclear,low,4.0,39873457,Epigenetic mechanisms underlying endometrial cancer outcomes: race-specific patterns of DNA methylation associated with molecular subtypes and survival.,2025,abstract,2025-12-19T04:13:03.987616,,,,
"['Gene expression analysis', 'Mutation analysis', 'Survival analysis']","['Breast cancer', 'Lung cancer', 'Pan-cancer']","['Drug response/resistance', 'Pathway analysis']",['Original research'],"['TCGA', 'GENIE', 'Multiple sources']","Based on the abstract and title, this paper investigates ARAF condensates in RAS-related cancer drug resistance. While cBioPortal is cited, the abstract does not provide specific details about how cBioPortal was used. The study likely accessed genomic and clinical data from TCGA or other databases through cBioPortal to analyze ARAF expression, mutations, or correlations with drug resistance in cancer patients.",[],['Citation only'],"['ARAF', 'RAS', 'NF1']",['Not specified'],Unclear,low,4.0,39870764,Plasma membrane-associated ARAF condensates fuel RAS-related cancer drug resistance.,2025,abstract,2025-12-19T04:13:04.172627,,,,
"['Gene expression analysis', 'Pathway analysis']",['Pan-cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],['TCGA'],"The authors performed comparative analysis of TCGA datasets from tumor databases to examine the expression patterns of CEBPZ, NOC2L, and NOC3L across different tumor types. They used Gene Ontology and bioinformatic analyses to correlate the expression of these genes with processes regulating rRNA processing and ribosomal maturation in tumors. The analysis revealed context-dependent expression patterns of these genes across tumor types, suggesting complex regulatory roles in cancer.",[],"['Web-based analysis', 'Citation only']","['CEBPZ', 'NOC2L', 'NOC3L']","['Expression analysis', 'Not specified']",Unclear,medium,4.0,39868138,"From Flies to Humans: A Conserved Role of CEBPZ, NOC2L, and NOC3L in rRNA Processing and Tumorigenesis.",2025,abstract,2025-12-19T04:13:04.233039,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Meta-analysis']",['Multiple sources'],"The study utilized cBioPortal to analyze sequencing data from 135 male breast cancer patients. The authors examined HER2 pathway alterations, gene mutations, and copy number variations in HER2+ versus HER2- male breast cancer patients. Genomic analysis through cBioPortal revealed differences in altered genes (ERBB2, AGO2, RECQL4, CLTC) between HER2+ male breast cancer and HER2+ female breast cancer patients.",[],"['Web-based analysis', 'Web-based visualization']","['ERBB2', 'AGO2', 'RECQL4', 'CLTC']","['Query interface', 'Expression analysis']","[""cBioPortal platform""]",medium,4.0,39870698,"HER2 expression and pathway status in male breast cancer patients: results of an integrated analysis among 6,150 patients.",2025,abstract,2025-12-19T04:13:04.988251,,,,
"['Mutation analysis', 'Gene expression analysis']","['Melanoma', 'Pan-cancer']","['Biomarker discovery', 'Tumor evolution', 'Other']",['Original research'],['Multiple sources'],"The study utilized the Cancer Cell Line Encyclopedia (CCLE) data, which is accessible through cBioPortal, to analyze ZC3H18 mutations and ERV RNA expression levels in human cancer cell lines. The authors examined Z18 mutant human cell lines from CCLE and found they expressed higher levels of ERV RNA. The specific usage mode and features of cBioPortal are not explicitly detailed in the abstract.",['Cancer Cell Line Encyclopedia'],['Citation only'],['ZC3H18'],['Not specified'],Unclear,low,4.0,39868094,Recurrent oncogenic ZC3H18 mutations stabilize endogenous retroviral RNA.,2025,abstract,2025-12-19T04:13:05.768708,,,,
"['Gene expression analysis', 'Survival analysis', 'Other']",['Other solid tumor'],['Biomarker discovery'],['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, the paper does not explicitly mention cBioPortal usage. The study utilized TCGA and GEO databases for expression and survival analysis of thyroid hormone receptors (TRs) in hepatocellular carcinoma, analyzed with R software. While TCGA data was used, there is no clear indication that cBioPortal was the source or platform for accessing this data.",['TCGA'],['Citation only'],"['THRA', 'THRB']",['Not specified'],"[""Unclear""]",low,4.0,39866810,The Prognostic Significance of TRs in Hepatocellular Carcinoma: Insights from TCGA and GEO Databases.,2025,abstract,2025-12-19T04:13:06.186998,,,,
"['Gene expression analysis', 'Copy number analysis', 'Survival analysis', 'Pathway analysis']","['Pan-cancer', 'Lung cancer']","['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the abstract or introduction. The study analyzed data from TCGA and GTEx databases, along with TCPA, TIMER2.0, CellMiner, GDSC, and CTRP databases for various analyses. While cBioPortal is cited, the specific usage details are not provided in the available text, suggesting it may have been used for data access or cited as a reference resource.",['TCGA'],['Citation only'],"['ARPC1A', 'ARPC1B', 'ARPC2', 'ARPC3', 'ARPC4', 'ARPC5', 'ARPC5L', 'ACTR2', 'ACTR3', 'MYC', 'ASNS']",['Not specified'],Unclear,low,4.0,39867911,Pan-cancer analysis of Arp2/3 complex subunits: focusing on ARPC1A's role and validating the ARPC1A/c-Myc axis in non-small cell lung cancer.,2024,abstract,2025-12-19T04:13:06.499999,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis']",['Leukemia/Lymphoma'],"['Biomarker discovery', 'Precision medicine', 'Methods/Tools development']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction, this study appears to have used cBioPortal as a data source for AML genomic data, likely downloading mutation and clinical data to validate their findings. The paper focuses on single-cell RNA-seq analysis and develops a novel workflow (sciNMF) to characterize cellular heterogeneity in AML, with validation using public RNA-seq cohorts that may include TCGA data accessed through cBioPortal. The specific details of cBioPortal usage are not explicitly described in the provided abstract and introduction.",[],['Data download/export'],[],['Download data'],External (downloaded data),low,4.0,39865982,Deciphering cell states and the cellular ecosystem to improve risk stratification in acute myeloid leukemia.,2024,abstract,2025-12-19T04:13:08.876273,,,,
['Gene expression analysis'],"['Glioma/Brain cancer', 'Pan-cancer']","['Immunotherapy', 'Biomarker discovery']",['Original research'],"['TCGA', 'Multiple sources']","The study used RNA-seq data from TCGA, TARGET, and GTEx datasets to evaluate B7-H3 expression across various solid tumors. This expression analysis was performed to identify B7-H3 as a promising target for CAR T cell therapy development. The data appears to have been accessed and analyzed externally rather than using cBioPortal's web-based analysis tools.",[],['Data download/export'],"['B7-H3', 'CD276']",['Download data'],External (downloaded data),medium,4.0,39863300,Novel B7-H3 CAR T cells show potent antitumor effects in glioblastoma: a preclinical study.,2025,abstract,2025-12-19T04:13:09.174706,,,,
"['Gene expression analysis', 'Survival analysis']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Drug response/resistance', 'Review/Commentary']","['Review', 'Original research']","['TCGA', 'Multiple sources']","The study used TCGA data to analyze ABC transporter gene expression and survival outcomes in glioblastoma patients. The authors performed univariate and multivariate survival analyses to identify ABC transporters (ABCA1, ABCA13, ABCB9, ABCD4, ABCB5) that negatively impact patient survival. The analysis identified ABCA13, ABCB9, and ABCB5 as independent prognostic factors in GBM patients treated with alkylating agents.",['TCGA'],['Citation only'],"['ABCA1', 'ABCA13', 'ABCB9', 'ABCD4', 'ABCB5', 'ABCB1']",['Not specified'],Unclear,low,4.0,39861164,Revisiting ABC Transporters and Their Clinical Significance in Glioblastoma.,2025,abstract,2025-12-19T04:13:09.948910,,,,
"['Gene expression analysis', 'Copy number analysis']",['Other solid tumor'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],['TCGA'],"Based on the abstract and introduction provided, cBioPortal appears to have been used to analyze metallothionein gene expression and copy number alterations in ovarian cancer, particularly high-grade serous ovarian cancer (HGSC). The study mentions that chromosome 16q13, where all 11 metallothionein genes are clustered, is commonly lost in solid tumors, suggesting cBioPortal may have been used to examine the frequency of this chromosomal loss. However, specific details about cBioPortal usage are not explicitly mentioned in the provided text.",[],['Citation only'],['MT2A'],['Not specified'],Unclear,low,4.0,39858588,Screening Methods to Discover the FDA-Approved Cancer Drug Encorafenib as Optimally Selective for Metallothionein Gene Loss Ovarian Cancer.,2025,abstract,2025-12-19T04:13:10.464720,,,,
['Other'],['Not specified'],['Methods/Tools development'],['Methods/Software'],['Not specified'],"This paper does not appear to use cBioPortal for any analysis. The study focuses on developing a new site-directed mutagenesis method (P3 method) for efficient plasmid engineering. The paper tests this method on expression vectors encoding epigenetic regulators linked to cancer and neurodevelopmental disorders, but does not involve any cancer genomics data analysis or use of cBioPortal resources.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39863101,P3 site-directed mutagenesis: An efficient method based on primer pairs with 3'-overhangs.,2025,abstract,2025-12-19T04:13:10.599908,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Melanoma']","['Biomarker discovery', 'Immunotherapy', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to perform mutation and copy number alteration (CNA) analyses of NTN1 across multiple cancer types. The study examined NTN1 genetic alterations including deep deletions, amplifications, and mutations, and investigated the correlation between NTN1 CNAs and expression levels. The platform was specifically mentioned alongside the SMART database for conducting mutation and methylation analyses.",['TCGA'],"['Web-based analysis', 'Web-based visualization']",['NTN1'],"['Query interface', 'Expression analysis']",cBioPortal platform,medium,4.0,39863609,Comprehensive pan-cancer analysis reveals NTN1 as an immune infiltrate risk factor and its potential prognostic value in SKCM.,2025,pdf,2025-12-19T04:13:10.721840,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis']",['Other solid tumor'],"['Immunotherapy', 'Biomarker discovery', 'Review/Commentary']",['Review'],['Not specified'],"This is a comprehensive review paper on the immune-genomics of cholangiocarcinoma (CCA) and immunotherapy development. The paper discusses genomic alterations and immune profiling in CCA but does not explicitly describe direct usage of cBioPortal for original analysis. cBioPortal may be cited as a reference resource for genomic data on CCA, but no specific analysis, data download, or visualization using the platform is described in the abstract or introduction.",[],['Citation only'],"['FGFR2', 'IDH1', 'HER2']",['Not specified'],Unclear,low,4.0,39858054,The Immune-Genomics of Cholangiocarcinoma: A Biological Footprint to Develop Novel Immunotherapies.,2025,abstract,2025-12-19T04:13:10.900671,,,,
"['Gene expression analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Methods/Tools development']",['Original research'],"['TCGA', 'Custom/Private data']","The authors used TCGA data from cBioPortal to validate their findings from spatial analysis of ccRCC H&E images. They used the top differentially expressed genes (with fold change > 3) identified from their spatial analysis to stratify a larger cohort of 352 ccRCC patients from The Cancer Genome Atlas, examining differences in survival and TNM disease stage. The cBioPortal data served as an independent validation cohort for their matrisome gene expression signature.",['TCGA'],['Data download/export'],[],['Download data'],External (downloaded data),medium,4.0,39858031,Spatial Distribution of Tumor Cells in Clear Cell Renal Cell Carcinoma Is Associated with Metastasis and a Matrisome Gene Expression Signature.,2025,abstract,2025-12-19T04:13:11.579312,,,,
['Gene expression analysis'],['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance', 'Precision medicine']",['Original research'],['Multiple sources'],"The study used a public dataset (likely cBioPortal) to evaluate SSTR2 expression in hepatocellular carcinoma clinical samples. This was part of a broader investigation combining in vitro cell line studies, clinical sample analysis, and animal model experiments to assess SSTR2-targeted theranostics in HCC. The public dataset analysis complemented their experimental validation of SSTR2 expression using qRT-PCR and Western blot.",[],['Web-based analysis'],['SSTR2'],['Expression analysis'],Unclear,medium,4.0,39857944,SSTR2-Targeted Theranostics in Hepatocellular Carcinoma.,2025,abstract,2025-12-19T04:13:11.930230,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Pan-cancer'],"['Biomarker discovery', 'Tumor evolution', 'Other']",['Original research'],"['TCGA', 'Multiple sources']","Based on the provided abstract and introduction, cBioPortal usage is not explicitly described in these sections. The study focuses on a mouse model (Trim28+/D9) investigating developmental heterogeneity and cancer susceptibility through epigenetic mechanisms. While the paper likely uses cBioPortal to validate findings in human cancer datasets (given it cites cBioPortal), the specific usage details are not present in the provided text. The study appears to use human cancer data to correlate differentially methylated loci with oncogenic potential and prognosis.",[],['Citation only'],['TP53'],['Not specified'],Unclear,low,4.0,39856421,TRIM28-dependent developmental heterogeneity determines cancer susceptibility through distinct epigenetic states.,2025,pdf,2025-12-19T04:13:14.175455,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],['Biomarker discovery'],['Original research'],['Multiple sources'],"Based on the abstract and introduction provided, cBioPortal is not explicitly mentioned in the text. The study focuses on RNA-Seq datasets, differential gene expression analysis, protein-protein interaction networks, WGCNA, and overall survival analysis for gastric cancer biomarker discovery. Without explicit mention of cBioPortal usage in the provided text, it appears cBioPortal may only be cited as a reference or used minimally for data access.",[],['Citation only'],"['THY1', 'CDH17', 'TGIF1', 'AEBP1', 'ITGA5', 'COL1A1', 'FN1', 'MMP2', 'IGFBP2']",['Not specified'],Unclear,low,4.0,39854135,Integration of Gastric Cancer RNA-Seq Datasets Along With PPI Network Suggests That Nonhub Nodes Have the Potential to Become Biomarkers.,2025,abstract,2025-12-19T04:13:14.951352,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Breast cancer'],"['Biomarker discovery', 'Other']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, the paper does not explicitly mention cBioPortal usage in these sections. The study focuses on investigating miR-1307 in breast cancer using xenograft models, cell line experiments, and analysis of human breast tumor samples. If cBioPortal was used, it would likely be for accessing TCGA breast cancer data for expression or survival analysis, but this is not clearly stated in the provided text.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39849498,Selective arm-usage of pre-miR-1307 dysregulates angiogenesis and affects breast cancer aggressiveness.,2025,pdf,2025-12-19T04:13:15.261581,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],['Biomarker discovery'],['Original research'],['TCGA'],The authors used cBioPortal to analyze PDAC tissue profiles from 177 patients from The Cancer Genome Atlas (TCGA). They performed Gene Set Enrichment Analysis (GSEA) comparing high versus low AHNAK2 mRNA expression data from TCGA to identify positively and negatively correlated genes and group them into Gene Set Ontologies. The analysis was performed in silico to explore AHNAK2 as a potential diagnostic biomarker for pancreatic cancer.,['TCGA'],['Web-based analysis'],['AHNAK2'],"['Expression analysis', 'Enrichment analysis']",cBioPortal platform,high,4.0,39849106,AHNAK2: a potential diagnostic biomarker for pancreatic cancer related to cellular motility.,2025,pdf,2025-12-19T04:13:15.869490,,,,
"['Mutation analysis', 'Multi-omics integration']",['Lung cancer'],"['Biomarker discovery', 'Tumor evolution']",['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper describes original research using custom patient samples (tumor and BALF) with next-generation sequencing and whole exome sequencing performed by the authors. The bioinformatics analysis used Kraken2, MEGAHIT, and custom R scripts, with no reference to cBioPortal tools or data. If cBioPortal is cited, it appears to be citation only without direct usage in the methodology.",[],['Citation only'],['PTPRZ1'],['Not specified'],"[""Unclear""]",low,4.0,39845316,Characterizing microbial communities and their correlation with genetic mutations in early-stage lung adenocarcinoma: implications for disease progression and therapeutic targets.,2024,abstract,2025-12-19T04:13:16.342507,,,,
"['Mutation analysis', 'Gene expression analysis']","['Lung cancer', 'Colorectal cancer', 'Pancreatic cancer']","['Drug response/resistance', 'Biomarker discovery']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to query and analyze KRAS mutation data across multiple cancer types. The authors likely used the platform to identify and characterize KRAS mutations, particularly focusing on the C118 position and common oncogenic KRAS mutations (G12, G13, Q61) in various cancer datasets. The platform served as a resource for accessing genomic data to support their experimental findings on KRAS oxidation-based inhibition.",[],"['Web-based analysis', 'Citation only']",['KRAS'],['Not specified'],Unclear,low,4.0,39838816,Oncogenic mutant KRAS inhibition through oxidation at cysteine 118.,2025,abstract,2025-12-19T04:13:16.681501,,,,
"['Gene expression analysis', 'Survival analysis']",['Leukemia/Lymphoma'],"['Biomarker discovery', 'Precision medicine']",['Original research'],['Multiple sources'],"The paper mentions using two publicly available AML RNA-Seq datasets to analyze FLT3 and NPM1 transcript levels and their association with overall survival. While cBioPortal is cited, the abstract and introduction do not provide explicit details about how cBioPortal was specifically used, whether for data download, web-based analysis, or visualization. The study appears to have analyzed RNA expression data from public sources, which may have included cBioPortal as one of the data repositories.",[],['Citation only'],"['FLT3', 'NPM1']",['Not specified'],Unclear,low,4.0,39834628,<i>FLT3</i> and <i>NPM1</i> mRNA expression-based risk stratification of <i>de novo</i> acute Myeloid Leukemia.,2025,abstract,2025-12-19T04:13:17.233994,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],['Biomarker discovery'],['Original research'],['TCGA'],"The paper used cBioPortal to analyze TCGA-UCEC data for validation of hub genes. The platform was utilized to examine gene expression levels, promoter methylation patterns, genetic alterations (mutations), and their correlations with survival outcomes in uterine corpus endometrial carcinoma. The analysis complemented in vitro experimental validation of six hub genes (CD44, FGF2, FGF10, KDM6A, FN1, and MMP2).",['TCGA-UCEC'],"['Web-based analysis', 'Web-based visualization']","['CD44', 'FGF2', 'FGF10', 'KDM6A', 'FN1', 'MMP2']","['Expression analysis', 'Survival analysis', 'Query interface']",Mixed,medium,4.0,39833941,Key wound healing genes as diagnostic biomarkers and therapeutic targets in uterine corpus endometrial carcinoma: an integrated in silico and in vitro study.,2025,pdf,2025-12-19T04:13:17.766257,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis']",['Breast cancer'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],"['TCGA', 'Custom/Private data']","Based on the abstract and title provided, cBioPortal appears to have been used to analyze SCRN2 expression and potentially mutation data in breast cancer, particularly triple-negative breast cancer (TNBC). The study likely queried TCGA breast cancer datasets through cBioPortal to examine SCRN2 downregulation patterns and correlate them with patient prognosis. The platform was probably used for survival analysis and gene expression analysis to validate the clinical relevance of SCRN2 in TNBC patients.",['TCGA-BRCA'],"['Web-based analysis', 'Web-based visualization']","['SCRN2', 'KMT2C']","['Expression analysis', 'Survival analysis']",Unclear,medium,4.0,39836524,Secernin-2 Stabilizes Histone Methyltransferase KMT2C to Suppress Progression and Confer Therapeutic Sensitivity to PARP Inhibition in Triple-Negative Breast Cancer.,2025,abstract,2025-12-19T04:13:17.893611,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Lung cancer'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used as one of multiple databases to estimate gene mutations in the four key prognostic genes (CENPH, SLC35F4, TESMIN, and TERT) identified in lung adenocarcinoma. The study integrated cBioPortal with other tools including GEPIA2, UALCAN, TIMER, and Kaplan-Meier plotter to comprehensively analyze gene expression, patient prognosis, and mutations. The specific details of how cBioPortal was used are not extensively described in the abstract.",['TCGA-LUAD'],['Web-based analysis'],"['CENPH', 'SLC35F4', 'TESMIN', 'TERT']",['Not specified'],"[""Unclear""]",medium,4.0,39831256,Comprehensive bioinformatics analysis of prognosis and immunotherapy in lung adenocarcinoma.,2024,abstract,2025-12-19T04:13:18.076895,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Multi-omics integration']",['Breast cancer'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']","['TCGA', 'METABRIC', 'Custom/Private data', 'Multiple sources']","The paper analyzed transcriptomic and genomic data from METABRIC (Molecular Taxonomy of BC International Consortium) as the discovery cohort and TCGA as the validation cohort. The study examined HER2-negative breast cancers stratified by ERBB2 mRNA levels, analyzing mutations, copy number alterations (including 17q12 deletions), and gene expression patterns. Additional validation was performed using two real-world cohorts from Dana-Farber Cancer Institute and Memorial Sloan Kettering.","['TCGA', 'METABRIC', 'MSK-MetTropism']",['Data download/export'],"['ERBB2', 'PIK3CA', 'TP53']",['Download data'],External (downloaded data),medium,4.0,39826477,Molecular characterization of HER2-negative breast cancers reveals a distinct patient subgroup with 17q12 deletion and heterozygous loss of ERBB2.,2025,abstract,2025-12-19T04:13:20.079888,,,,
"['Mutation analysis', 'Copy number analysis']",['Melanoma'],"['Precision medicine', 'Biomarker discovery']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper describes a retrospective analysis of comprehensive genome profiling (CGP) data from 569 Japanese melanoma patients registered in a national database. The study focuses on identifying actionable gene alterations in BRAF, NRAS, NF1, and KIT genes, but does not indicate that cBioPortal was used for data analysis, visualization, or as a data source.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39823560,Actionable Gene Alterations Identified in Patients With Malignant Melanoma by Targeted Sequencing in Japan.,2025,abstract,2025-12-19T04:13:20.595175,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance']",['Original research'],['Multiple sources'],The study used cBioPortal to analyze survival outcomes (overall survival and progression-free survival) in ovarian cancer patients based on MFAP4 and EFEMP1 expression levels. The authors examined the correlation between high expression of these genes and patient survival in all cases and specifically in platinum-treated cases. cBioPortal was likely used for accessing ovarian cancer datasets and performing survival analysis with visualization.,[],"['Web-based analysis', 'Web-based visualization']","['MFAP4', 'EFEMP1']","['Survival analysis', 'Expression analysis']",cBioPortal platform,medium,4.0,39822989,Unveiling novel biomarkers for platinum chemoresistance in ovarian cancer.,2025,abstract,2025-12-19T04:13:21.308398,,,,
"['Gene expression analysis', 'Mutation analysis']",['Other solid tumor'],"['Tumor evolution', 'Biomarker discovery']",['Original research'],['TCGA'],"The paper appears to use cBioPortal to access TCGA pancreatic cancer data for validation purposes. Based on the abstract and introduction, the study focuses on KRAS-mutated pancreatic cancer and mentions that KRAS mutations are present in approximately 90% of PDAC. While cBioPortal is likely used to query KRAS mutation status and potentially validate findings in TCGA datasets, the specific details of cBioPortal usage are not explicitly described in the provided text.",['TCGA'],['Citation only'],['KRAS'],['Not specified'],Unclear,low,4.0,39825392,Intercellular TIMP-1-CD63 signaling directs the evolution of immune escape and metastasis in KRAS-mutated pancreatic cancer cells.,2025,pdf,2025-12-19T04:13:21.434768,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],['Biomarker discovery'],['Original research'],['Multiple sources'],"cBioPortal was used to perform promoter methylation and mutational analyses of the identified hub genes (AURKA, BUB1B, CCNA2, and PTTG1) in hepatocellular carcinoma. The platform was utilized to assess the methylation status and mutation patterns of these genes to understand their role in LIHC pathogenesis. The analysis complemented other validation approaches including expression analysis and survival analysis performed using other databases.",[],['Web-based analysis'],"['AURKA', 'BUB1B', 'CCNA2', 'PTTG1']",['Not specified'],"[""cBioPortal platform""]",medium,4.0,39822558,"Exploring potential key genes and pathways associatedwith hepatocellular carcinoma prognosis through bioinformatics analysis, followed by experimental validation.",2024,pdf,2025-12-19T04:13:22.376145,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']","['TCGA', 'Custom/Private data']","The study mentions using The Cancer Genome Atlas (TCGA) data to explore the rarity of BRCA1/2 mutations in gastric cancer and to corroborate findings from their NGS analysis. TCGA data was used for frequency analysis and to emphasize the distinctive nature of the identified mutations. However, the paper does not explicitly mention cBioPortal as the platform used to access or analyze TCGA data.",['TCGA'],['Citation only'],"['BRCA1', 'BRCA2']",['Not specified'],Unclear,low,4.0,39822496,Detection of genomic variants in BRCA1 and BRCA2 across gastric cancer patients using next generation sequencing.,2024,pdf,2025-12-19T04:13:22.825050,,,,
"['Gene expression analysis', 'Pathway analysis', 'Multi-omics integration']",['Pan-cancer'],"['Methods/Tools development', 'Database/Resource', 'Pathway analysis']","['Methods/Software', 'Original research']",['Multiple sources'],"cBioPortal is used as one of several data sources integrated into the APPIC webtool. The tool compiles biological and clinical information from various databases including cBioPortal, along with the Human Protein Atlas, Hugo Gene Nomenclature Committee, g:Profiler, and Clue.io. cBioPortal appears to provide clinical and genomic data that is incorporated into the APPIC platform for visualization and analysis of protein-protein interactions across cancer subtypes.",[],['Data download/export'],[],['Download data'],External (downloaded data),medium,4.0,39822275,The Atlas of Protein-Protein Interactions in Cancer (APPIC)-a webtool to visualize and analyze cancer subtypes.,2025,abstract,2025-12-19T04:13:23.838327,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Pathway analysis', 'Multi-omics integration']",['Glioma/Brain cancer'],"['Biomarker discovery', 'Pathway analysis', 'Tumor evolution']",['Original research'],"['TCGA', 'Custom/Private data']","Based on the abstract and introduction provided, the paper investigates genetic alterations in high-grade gliomas with primitive neuronal components, focusing on RB1, TP53, CDK4, MDM2/4, and MYC pathways. While cBioPortal is cited, the specific usage details are not explicitly described in the provided text. The study likely used cBioPortal to query mutation and copy number data for glioblastoma samples, particularly focusing on cell cycle and p53 pathway alterations.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39821672,Concurrent RB1 and P53 pathway disruption predisposes to the development of a primitive neuronal component in high-grade gliomas depending on MYC-driven EBF3 transcription.,2025,abstract,2025-12-19T04:13:24.119719,,,,
"['Gene expression analysis', 'Mutation analysis', 'Copy number analysis', 'Survival analysis', 'Pathway analysis']","['Pan-cancer', 'Glioma/Brain cancer', 'Ovarian cancer', 'Colorectal cancer', 'Breast cancer', 'Lung cancer', 'Liver cancer', 'Prostate cancer']","['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'ICGC', 'Multiple sources']","The study used cBioPortal (referenced as part of TCGA database access) to obtain mRNA sequencing data and clinical information across multiple cancer types for pan-cancer analysis of CENPA. The authors analyzed CENPA's genetic alterations, mRNA expression, and clinical correlations using data retrieved from TCGA, GTEx, CGGA, and ICGC databases to evaluate CENPA as a potential biomarker and therapeutic target.","['TCGA', 'GTEx', 'CGGA', 'ICGC']",['Data download/export'],['CENPA'],['Download data'],External (downloaded data),medium,4.0,39820192,Single-cell and bulk RNA sequencing analysis reveals CENPA as a potential biomarker and therapeutic target in cancers.,2025,pdf,2025-12-19T04:13:27.315021,,,,
"['Multi-omics integration', 'Other']",['Pan-cancer'],"['Precision medicine', 'Methods/Tools development']","['Original research', 'Methods/Software']",['Custom/Private data'],"cBioPortal was selected as a platform to visualize data generated from NGS analysis for molecular tumor boards (MTBs). The study evaluated cBioPortal as a digital support and visualization tool to assist in case preparation, discussion, and documentation for personalized oncology. The research focused on understanding user requirements and the evolution of digital tools for MTBs, with cBioPortal being one of the key platforms assessed for supporting clinical decision-making in precision medicine.",[],"['Web-based visualization', 'Citation only']",[],['Not specified'],Unclear,medium,4.0,39819625,Empowering personalized oncology: evolution of digital support and visualization tools for molecular tumor boards.,2025,pdf,2025-12-19T04:13:27.316278,,,,
"['Mutation analysis', 'Gene expression analysis', 'Pathway analysis', 'Multi-omics integration']",['Leukemia/Lymphoma'],"['Biomarker discovery', 'Drug response/resistance', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The paper mentions comparing hotspot mutations in sAML to de novo leukemia cohorts including TCGA LAML and BeatAML2, noting differences in prevalence of mutations in ASXL1, TP53, SF3B1, DNMT3A, FLT3, and NPM1. However, the paper does not explicitly state that cBioPortal was used to access or analyze these data. The reference to TCGA LAML suggests potential use of publicly available data, but the specific method of data access or analysis through cBioPortal is not described.",['TCGA LAML'],['Citation only'],"['ASXL1', 'TP53', 'SF3B1', 'DNMT3A', 'FLT3', 'NPM1', 'TET2', 'SRSF2', 'ZRSR2', 'JAK2', 'CALR', 'MPL']",['Not specified'],Unclear,low,4.0,39820365,RSK1 is an exploitable dependency in myeloproliferative neoplasms and secondary acute myeloid leukemia.,2025,pdf,2025-12-19T04:13:27.913554,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Pan-cancer'],"['Methods/Tools development', 'Database/Resource']",['Methods/Software'],['Not specified'],"cBioPortal is mentioned only as a reference or comparison point in this methods paper. The paper describes Sherlock-Genome, a new R Shiny application for WGS data analysis and visualization. There is no explicit description of cBioPortal being used for data download, analysis, or visualization in this study.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39819269,Sherlock-Genome: an R Shiny application for genomic analysis and visualization.,2025,abstract,2025-12-19T04:13:28.224064,,,,
"['Mutation analysis', 'Copy number analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to analyze genetic alterations (mutations, amplifications, deletions) in gasdermin family members (GSDMs) in HNSC patients. The study found that 18.65% (94/504) of HNSC patients harbored GSDM alterations, with amplification being the most dominant type. The platform was likely used to query and visualize these alterations across the GSDM gene family members (GSDMA, GSDMB, GSDMC, GSDMD, GSDME, and PJVK).",['TCGA-HNSC'],"['Web-based analysis', 'Web-based visualization']","['GSDMA', 'GSDMB', 'GSDMC', 'GSDMD', 'GSDME', 'PJVK']","['Query interface', 'OncoPrint']",Mixed,medium,4.0,39807507,Comprehensive analyses reveal the promising value of gasdermins as prognostic biomarkers and immunotherapeutic targets in head and neck squamous cell carcinoma.,2025,abstract,2025-12-19T04:13:28.422082,,,,
"['Gene expression analysis', 'Survival analysis', 'Copy number analysis']",['Breast cancer'],['Biomarker discovery'],['Original research'],['Multiple sources'],"The paper does not explicitly mention cBioPortal in the abstract or introduction provided. The study uses multiple databases including GEPIA, CancerSEA, TIMER, and GeneMANIA for analyzing CDCA gene family expression, survival, immune infiltration, and interactions in breast cancer. While cBioPortal may have been cited in the references, there is no clear description of its specific usage in the methodology described.",[],['Citation only'],"['CDCA1', 'CDCA2', 'CDCA3', 'CDCA5', 'CDCA6', 'CDCA7', 'CDCA8', 'FOXP3', 'YY1', 'CD38', 'IL12RB2']",['Not specified'],Unclear,low,4.0,39814554,Roles of the CDCA gene family in breast carcinoma.,2025,abstract,2025-12-19T04:13:29.294850,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Mutation analysis']",['Pan-cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, cBioPortal is not explicitly mentioned in the text. The study uses TCGA and GTEx databases for pan-cancer analysis of RNF187, examining expression patterns, survival, mutations, and pathway analysis. While cBioPortal may have been cited in the references or used for data access, no specific usage details are provided in the available text.","['TCGA', 'GTEx', 'CPTAC', 'GEPIA2']",['Citation only'],"['RNF187', 'ALKBH4', 'FAM134A', 'MLST8', 'SANP47', 'TMEM9']",['Not specified'],Unclear,low,4.0,39804497,A comprehensive pan-cancer analysis of RNF187 in human tumors.,2025,pdf,2025-12-19T04:13:29.395633,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The paper used cBioPortal to analyze the expression and prognostic efficacy of migrasome-related genes (TSPAN4, PIGK, NDST1, CPQ, TSPAN7) in hepatocellular carcinoma. The authors likely queried gene expression data and survival information from TCGA liver hepatocellular carcinoma (LIHC) dataset through cBioPortal. The analysis was complemented with validation in clinical samples and functional experiments.",['TCGA-LIHC'],"['Web-based analysis', 'Data download/export']","['TSPAN4', 'PIGK', 'NDST1', 'CPQ', 'TSPAN7']","['Expression analysis', 'Survival analysis', 'Query interface']",Mixed,medium,4.0,39799524,Migrasome-related prognostic signature TSPAN4 correlates with immune infiltrates and metabolic disturbances in hepatocellular carcinoma.,2025,abstract,2025-12-19T04:13:29.840502,,,,
"['Mutation analysis', 'Gene expression analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Drug response/resistance', 'Methods/Tools development']",['Original research'],['Custom/Private data'],"The paper does not explicitly describe using cBioPortal for any analysis. The study focuses on establishing and characterizing a new mouse gastric carcinoma cell line (MCC) through primary culture, genomic and proteomic analyses. While mutations in genes like Kras, Egfr, and Ccnd3 are identified and compared to clinical gastric cancer patients, there is no mention of cBioPortal being used for data retrieval, analysis, or visualization in the abstract or introduction provided.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39800685,"Establishment and characterization of a new mouse gastric carcinoma cell line, MCC.",2025,abstract,2025-12-19T04:13:29.870735,,,,
"['Gene expression analysis', 'Survival analysis', 'Mutation analysis', 'Copy number analysis']",['Melanoma'],"['Biomarker discovery', 'Precision medicine']",['Original research'],"['TCGA', 'Multiple sources']","cBioPortal was used to analyze MMP gene expression, mutations, and copy number alterations in SKCM patients. The platform was utilized to investigate the relationship between MMP alterations and clinical outcomes in melanoma. The study appears to have used cBioPortal primarily for querying and analyzing genomic data related to matrix metalloproteinases in skin cutaneous melanoma cohorts.",['TCGA-SKCM'],"['Web-based analysis', 'Web-based visualization']","['MMP1', 'MMP2', 'MMP3', 'MMP7', 'MMP9', 'MMP10', 'MMP11', 'MMP12', 'MMP13', 'MMP14', 'MMP21', 'MMP25']","['Expression analysis', 'Query interface']",Mixed,medium,4.0,39820824,"Comprehensive investigation of matrix metalloproteinases in skin cutaneous melanoma: diagnostic, prognostic, and therapeutic insights.",2025,pdf,2025-12-19T04:13:30.026568,,,,
['Gene expression analysis'],['Breast cancer'],['Biomarker discovery'],['Original research'],['TCGA'],"The paper mentions that MYBL1 and VCPIP1 genes are co-expressed and dysregulated in some of the same triple negative breast cancer patient samples, suggesting the authors examined gene expression data. Based on the abstract and introduction, cBioPortal appears to have been used to examine co-expression patterns of MYBL1 and VCPIP1 genes in TNBC patient samples. However, specific details about how cBioPortal was used are not provided in the abstract and introduction.",[],['Citation only'],"['MYBL1', 'VCPIP1']",['Not specified'],Unclear,low,4.0,39796135,Analyses of the <i>MYBL1</i> Gene in Triple Negative Breast Cancer: Evidence of Regulation of the <i>VCPIP1</i> Gene and Identification of a Specific Exon Overexpressed in Tumor Cell Lines.,2024,abstract,2025-12-19T04:13:32.973822,,,,
"['Gene expression analysis', 'Other']",['Lung cancer'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],['Not specified'],"Based on the provided abstract and introduction, there is no explicit mention of cBioPortal usage in this study. The paper focuses on discovering a tribenzophenazine analog (MBD) that targets KRAS mRNA G-quadruplex structures in cisplatin-resistant NSCLC cells. The study appears to be primarily experimental, involving in vitro and in vivo validation of the compound's antitumor efficacy, without clear indication of cBioPortal data analysis or visualization.",[],['Citation only'],['KRAS'],['Not specified'],"[""Unclear""]","[""low""]",4.0,39793888,Discovery of a tribenzophenazine analog for binding to the KRAS mRNA G-quadruplex structures in the cisplatin-resistant non-small cell lung cancer.,2025,abstract,2025-12-19T04:13:33.595100,,,,
['Mutation analysis'],['Pan-cancer'],"['Drug response/resistance', 'Methods/Tools development']",['Original research'],['Not specified'],"The paper mentions that recurrent missense mutations in HER2 have been identified across various human cancers, with specific focus on the S310F mutation. However, the abstract and introduction do not provide explicit details about how cBioPortal was used in this study. The paper appears to focus on computational-aided rational design of antibody variants rather than detailed genomic data analysis from cBioPortal. Usage details are unclear from the provided text.",[],['Citation only'],['HER2'],['Not specified'],"[""Unclear""]",low,4.0,39793038,Computational-aided rational mutation design of pertuzumab to overcome active HER2 mutation S310F through antibody-drug conjugates.,2025,abstract,2025-12-19T04:13:33.660899,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The paper appears to have used cBioPortal to access multi-omics data for ccRCC, including gene expression and methylation data. The study investigated MAZ transcription factor regulation of TYMP and UPP1 genes, and examined correlations between TYMP promoter methylation and clinicopathological features and survival outcomes. However, the abstract and introduction do not provide explicit details about how cBioPortal was specifically utilized in the analysis workflow.",['TCGA-KIRC'],['Data download/export'],"['MAZ', 'TYMP', 'UPP1']",['Not specified'],"[""External (downloaded data)""]",medium,4.0,39797954,Transcription factor MAZ activates the transcription of hypomethylated TYMP in ccRCC.,2025,abstract,2025-12-19T04:13:34.378274,,,,
"['Gene expression analysis', 'Other']",['Other solid tumor'],"['Drug response/resistance', 'Biomarker discovery']",['Original research'],['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper focuses on experimental evaluation of selpercatinib in a RET-negative tumor model (HT1080) and retrospective analysis of patient weight gain data. The study appears to be primarily laboratory-based with animal models and transcriptome analysis, without clear indication of cBioPortal data or tools being utilized.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39778760,Selpercatinib mitigates cancer cachexia independent of anti-tumor activity in the HT1080 tumor model.,2025,abstract,2025-12-19T04:13:34.682349,,,,
"['Mutation analysis', 'Copy number analysis', 'Survival analysis']",['Other solid tumor'],"['Biomarker discovery', 'Precision medicine']","['Original research', 'Clinical study']",['Custom/Private data'],"Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in this study. The paper describes a targeted NGS analysis of 40 salivary gland cancer patients using archival tissue samples to identify mutations, copy number variations, and their association with clinical outcomes. The study appears to have used custom/private patient data analyzed with their own NGS panel. cBioPortal may only be cited in the references or methods section not provided here.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39780157,Potentially actionable molecular alterations in particular related to poor oncologic outcomes in salivary gland carcinomas.,2025,pdf,2025-12-19T04:13:35.773194,,,,
"['Mutation analysis', 'Gene expression analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Pan-cancer', 'Lung cancer']","['Biomarker discovery', 'Pathway analysis', 'Immunotherapy']",['Original research'],"['TCGA', 'Multiple sources']","The paper performed a comprehensive pan-cancer analysis of MRPL21 using multiple online data platforms including TCGA. The analysis covered expression levels, survival analysis, gene mutations, immune-correlation analysis, tumor heterogeneity, and cancer-associated signaling pathways. While cBioPortal is likely one of the platforms used for accessing TCGA data and performing these analyses, the abstract does not provide specific details about how cBioPortal was utilized.",[],['Citation only'],['MRPL21'],['Not specified'],Unclear,low,4.0,39775548,Integrative Analysis of the Role of MRPL21 in Human Pan-Cancer and Its Relationship with the Progression of Lung Adenocarcinoma.,2025,abstract,2025-12-19T04:13:36.536827,,,,
"['Mutation analysis', 'Multi-omics integration', 'Gene expression analysis']",['Leukemia/Lymphoma'],"['Biomarker discovery', 'Precision medicine', 'Other']",['Original research'],"['TCGA', 'Multiple sources']","Based on the abstract and introduction provided, cBioPortal usage is not explicitly mentioned in these sections. The study focuses on analyzing DNA methylation patterns in AML patients with DNMT3A-destabilizing variants using publicly available methylation profiles and their own RRBS data. If cBioPortal was used, it would likely be for accessing TCGA AML mutation data or patient cohort information, but this is not clearly stated in the provided text.",['TCGA'],['Citation only'],['DNMT3A'],['Not specified'],Unclear,low,4.0,39794314,Increased local DNA methylation disorder in AMLs with DNMT3A-destabilizing variants and its clinical implication.,2025,pdf,2025-12-19T04:13:37.126242,,,,
"['Gene expression analysis', 'Mutation analysis', 'Copy number analysis', 'Survival analysis', 'Pathway analysis']",['Colorectal cancer'],"['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The study used cBioPortal (C-Bio portal) as one of several public databases to investigate exportins in colon adenocarcinoma (COAD) patients. The authors performed mutation analysis using cBioPortal, which revealed amplifications and missense mutations in XPO2 and XPO4, as well as deep deletions in XPO7 genes. cBioPortal was used alongside other databases including UALCAN, Human Protein Atlas, DAVID, Kaplan-Meier plotter, TIMER, STRING, and KEGG for comprehensive analysis of exportins expression and their prognostic significance.",['TCGA-COAD'],"['Web-based analysis', 'Web-based visualization']","['XPO1', 'XPO2', 'XPO4', 'XPO5', 'XPO6', 'XPO7', 'XPOT']","['Mutation analysis', 'Expression analysis', 'Query interface']",Mixed,medium,4.0,39776001,Analysis of exportins expression unveils their prognostic significance in colon adenocarcinoma: insights from public databases.,2025,pdf,2025-12-19T04:13:37.750541,,,,
"['Copy number analysis', 'Mutation analysis', 'Gene expression analysis', 'Pathway analysis']",['Other solid tumor'],"['Biomarker discovery', 'Pathway analysis', 'Tumor evolution']",['Original research'],['Multiple sources'],"The paper conducted a pooled analysis of 1094 primary papillary thyroid carcinoma tumors from four published PTC genomic studies to investigate chromosome 22q deletions. The study analyzed somatic copy number alterations, particularly 22qDEL, and their association with driver mutations (especially RAS mutations) and differential RNA expression patterns. While cBioPortal is cited, the specific usage details are not explicitly described in the abstract and introduction provided.",[],['Citation only'],"['RAS', 'HRAS']",['Not specified'],Unclear,low,4.0,39773491,Somatic copy number deletion of chromosome 22q in papillary thyroid carcinoma.,2025,abstract,2025-12-19T04:13:39.676034,,,,
['Other'],['Pan-cancer'],"['Review/Commentary', 'Drug response/resistance']",['Review'],['Not specified'],"This is a review paper on nanocarriers for anticancer drug delivery. Based on the abstract and introduction provided, there is no explicit mention of cBioPortal usage in the study. The paper focuses on discussing nanobased carriers, their properties, polymers for drug delivery, and recent advances in cancer therapy formulations rather than genomic data analysis.",[],['Citation only'],[],['Not specified'],Unclear,low,4.0,39771506,"Nanocarriers for Delivery of Anticancer Drugs: Current Developments, Challenges, and Perspectives.",2024,abstract,2025-12-19T04:13:39.703351,,,,
"['Gene expression analysis', 'Survival analysis', 'Pathway analysis']","['Pan-cancer', 'Breast cancer']",['Biomarker discovery'],['Original research'],"['TCGA', 'Multiple sources']","The paper does not explicitly mention using cBioPortal in the methods or results. The authors used multiple databases including TIMER2.0, Kaplan-Meier Plotter, GEPIA, UALCAN, HPA, and XIANTAO platform for their pan-cancer and breast cancer analysis of PRAF2. While cBioPortal is cited in the references, there is no clear description of how it was used in this study.",['TCGA'],['Citation only'],"['PRAF2', 'TP53']",['Not specified'],Unclear,low,4.0,39773456,PRAF2 as a novel biomarker for breast cancer with machine learning and experimentation validation.,2025,pdf,2025-12-19T04:13:40.031987,,,,
"['Mutation analysis', 'Other']",['Pan-cancer'],"['Methods/Tools development', 'Precision medicine', 'Biomarker discovery']","['Original research', 'Methods/Software']",['Multiple sources'],"Based on the abstract and introduction provided, cBioPortal appears to have been used as a reference source for cancer-associated TP53 missense mutations. The study conducted a deep mutational scan covering 94.5% of all cancer-associated TP53 missense mutations, suggesting cBioPortal data was likely used to identify and catalog the known TP53 mutations found in cancer. However, the specific details of cBioPortal usage are not explicitly described in the provided text.",[],['Citation only'],['TP53'],['Not specified'],Unclear,low,4.0,39774325,Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations.,2025,abstract,2025-12-19T04:13:40.138482,,,,
"['Gene expression analysis', 'Mutation analysis', 'Copy number analysis', 'Survival analysis', 'Pathway analysis', 'Multi-omics integration']","['Colorectal cancer', 'Other solid tumor']","['Biomarker discovery', 'Pathway analysis']",['Original research'],"['TCGA', 'Multiple sources']","The paper mentions cBioPortal in the context of analyzing INHBA alterations (mutations and amplifications) across gastrointestinal tract cancers, particularly noting higher frequencies in mucinous adenocarcinoma, esophageal squamous cell carcinoma, and stomach adenocarcinoma. However, the abstract and introduction do not provide detailed information about specific cBioPortal features used or the exact methodology. The primary analysis appears to have been conducted using GEPIA2 for expression analysis, with cBioPortal likely used for mutation and copy number alteration data.","['TCGA-CHOL', 'TCGA-COAD', 'TCGA-ESCA', 'TCGA-LIHC', 'TCGA-PAAD', 'TCGA-READ', 'TCGA-STAD']","['Web-based analysis', 'Web-based visualization']",['INHBA'],['Query interface'],Mixed,medium,4.0,39774945,Comprehensive analysis of inhibin-β A as a potential biomarker for gastrointestinal tract cancers through bioinformatics approaches.,2025,pdf,2025-12-19T04:13:40.167389,,,,
